<SEC-DOCUMENT>0001193125-17-085372.txt : 20170316
<SEC-HEADER>0001193125-17-085372.hdr.sgml : 20170316
<ACCEPTANCE-DATETIME>20170316160715
ACCESSION NUMBER:		0001193125-17-085372
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		90
CONFORMED PERIOD OF REPORT:	20161231
FILED AS OF DATE:		20170316
DATE AS OF CHANGE:		20170316

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			HISTOGENICS CORP
		CENTRAL INDEX KEY:			0001372299
		STANDARD INDUSTRIAL CLASSIFICATION:	ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36751
		FILM NUMBER:		17694535

	BUSINESS ADDRESS:	
		STREET 1:		830 WINTER STREET
		CITY:			WALTHAM
		STATE:			MA
		ZIP:			02451
		BUSINESS PHONE:		781-457-7900

	MAIL ADDRESS:	
		STREET 1:		830 WINTER STREET
		CITY:			WALTHAM
		STATE:			MA
		ZIP:			02451
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>d293850d10k.htm
<DESCRIPTION>FORM 10-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 10-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:4.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>FORM 10-K
</B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:4.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman"><B>(Mark One) </B></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B></B>&#9746;</TD>
<TD ALIGN="left" VALIGN="top"><B>ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </B></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>For the fiscal year ended December&nbsp;31, 2016 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>or </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B></B>&#9744;</TD>
<TD ALIGN="left" VALIGN="top"><B>TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </B></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>For the transition period from
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> to
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </U> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>Commission file number: 001-36751 </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:4.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:21pt; font-family:Times New Roman" ALIGN="center"><B>Histogenics
Corporation </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:4.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="49%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>04-3522315</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>incorporation or organization)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification Number)</B></P></TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8.5pt" ALIGN="center">


<TR>
<TD WIDTH="49%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>830 Winter Street, 3rd Floor</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>Waltham, Massachusetts</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>02451</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>(Address of principal executive offices)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(Zip Code)</B></TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>(781) 547-7900 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Registrant&#146;s telephone number, including area code) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>Securities registered pursuant to Section&nbsp;12(b) of the Act: </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8.5pt" ALIGN="center">


<TR>
<TD WIDTH="49%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top" ALIGN="center"><B>Common Stock, $0.01 par value per share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>The NASDAQ Stock Market LLC</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>(Title of each class)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(Name of each exchange on which registered)</B></TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>Securities registered pursuant to Section&nbsp;12(g) of the Act: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>None </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:4.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:8.5pt; font-family:Times New Roman">Indicate by
check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;&#9744;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&#9746; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:8.5pt; font-family:Times New Roman">Indicate by check mark if the registrant is not required to file reports pursuant to Section&nbsp;13 or Section&nbsp;15(d) of the
Act.&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;&#9744;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&#9746; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:8.5pt; font-family:Times New Roman">Indicate by check mark whether the
registrant (1)&nbsp;has filed all reports required to be filed by Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and
(2)&nbsp;has been subject to such filing requirements for the past 90 days.&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;&#9746;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&#9744; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:8.5pt; font-family:Times New Roman">Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Website, if any, every Interactive Data
File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12&nbsp;months (or for such shorter period that the registrant was required to submit and post such
files).&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;&#9746;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:8.5pt; font-family:Times New Roman">Indicate by check mark if disclosure
of delinquent filers pursuant to Item&nbsp;405 of Regulation S-K (&#167; 229.405 of this chapter) is not contained herein, and will not be contained, to the best of registrant&#146;s knowledge, in definitive proxy or information statements
incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K.&nbsp;&nbsp; &#9744; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:8.5pt; font-family:Times New Roman">Indicate by check mark
whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of &#147;large accelerated filer,&#148; &#147;accelerated filer&#148; and &#147;smaller reporting
company&#148; in Rule 12b-2 of the Exchange Act. (Check one): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8.5pt" ALIGN="center">


<TR>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="60%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="20%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="1%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="bottom">Large&nbsp;accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="bottom">Non-accelerated filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;&nbsp;&nbsp;(Do not check if a smaller reporting company)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Smaller&nbsp;reporting&nbsp;company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9746;</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:8.5pt; font-family:Times New Roman">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the
Act).&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;&#9744;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&#9746; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:8.5pt; font-family:Times New Roman">As of June&nbsp;30, 2016, the last
business day of the registrant&#146;s last completed second quarter, the aggregate market value of the Common Stock held by non-affiliates of the registrant was approximately $14.9 million, based on the closing price of the registrant&#146;s Common
Stock, as reported by the NASDAQ Global Market. For purposes of this disclosure, shares of Common Stock held by each executive officer, director, stockholders known by the registrant to be affiliates of such executive officers and directors based on
public filings and stockholders known by the registrant to own 20% or more of the outstanding stock based on public filings and other information known to the registrant have been excluded since such persons may be deemed affiliates. This
determination of affiliate status is not necessarily a conclusive determination for other purposes. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:3%; font-size:8.5pt; font-family:Times New Roman">As of March&nbsp;14, 2017 there were
22,168,090 shares of the registrant&#146;s Common Stock issued and outstanding. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8.5pt; font-family:Times New Roman" ALIGN="center"><B>DOCUMENTS INCORPORATED BY REFERENCE </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Specified portions of the registrant&#146;s proxy statement with respect to the registrant&#146;s 2017 Annual Meeting of Stockholders, which is to be filed
pursuant to Regulation 14A within 120 days after the end of the registrant&#146;s fiscal year ended December&nbsp;31, 2016, are incorporated by reference into Part III of this Form 10-K. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Histogenics Corporation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>Form 10-K </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Table of Contents </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="9%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="84%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Part I</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#tx293850_1">Special Note Regarding Forward-Looking Statements</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#tx293850_2">Industry and Market Data</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item 1.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#tx293850_3">Business</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item 1A.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#tx293850_4">Risk Factors</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item 1B.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#tx293850_5">Unresolved Staff Comments</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item 2.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#tx293850_6">Properties</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item 3.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#tx293850_7">Legal Proceedings</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item 4.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#tx293850_8">Mine Safety Disclosures</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Part II</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item 5.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#tx293850_9">Market for Registrant&#146;s Common Equity, Related Shareholder Matters and Issuer Purchases of Equity Securities</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">78</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item 6.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#tx293850_10">Selected Consolidated Financial Data</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item 7.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#tx293850_11">Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item 7A.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#tx293850_12">Qualitative and Quantitative Disclosures about Market Risk</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">92</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item 8.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#tx293850_13">Financial Statements and Supplementary Data</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">92</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item 9.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#tx293850_14">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">92</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item 9A.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#tx293850_15">Controls and Procedures</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">92</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item 9B.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#tx293850_16">Other Information</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">93</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Part III</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item 10.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#tx293850_17">Directors, Executive Officers and Corporate Governance</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item 11.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#tx293850_18">Executive Compensation</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item 12.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#tx293850_19">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item 13.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#tx293850_20">Certain Relationships and Related Transactions, and Director Independence</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item 14.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#tx293850_21">Principal Accountant Fees and Services</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Part IV</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item 15.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#tx293850_22">Exhibits and Financial Statements Schedules</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Item 16.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><A HREF="#tx293850_23">Form 10-K Summary</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" COLSPAN="3"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx293850_24">Signatures </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">96</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" COLSPAN="3"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx293850_25">Index to Financial Statements </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">97</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5" COLSPAN="3"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx293850_26">Exhibit Index </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">131</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">HISTOGENICS (and design), our logo design and NEOCART are our registered trademarks, and BIOCART is our trademark. Any other
trademarks, registered marks and trade names appearing in this annual report on Form 10-K are the property of their respective holders. All other trademarks, trade names and service marks appearing in this annual report are the property of their
respective owners. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PART I </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx293850_1"></A>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Various statements in this report are &#147;forward-looking statements&#148; within the meaning of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this report regarding our strategy, future operations, future financial position, future revenues,
projected costs, prospects, plans and objectives of management are forward-looking statements. These statements are subject to risks and uncertainties and are based on information currently available to our management. Words such as, but not limited
to, &#147;anticipate,&#148; &#147;believe,&#148; &#147;contemplates,&#148; &#147;continue,&#148; &#147;could,&#148; &#147;design,&#148; &#147;estimate,&#148; &#147;expect,&#148; &#147;intend,&#148; &#147;likely,&#148; &#147;may,&#148;
&#147;ongoing,&#148; &#147;plan,&#148; &#147;potential,&#148; &#147;predict,&#148; &#147;project,&#148; &#147;will,&#148; &#147;would,&#148; &#147;seek,&#148; &#147;should,&#148; &#147;target,&#148; or the negative of these terms and similar
expressions or words, identify forward-looking statements. The events and circumstances reflected in our forward-looking statements may not occur and actual results could differ materially from those projected in our forward-looking statements.
Meaningful factors which could cause actual results to differ include, but are not limited to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the timing of enrollment commencement and completion of our clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the timing and success of preclinical studies and clinical trials conducted by us and our development partners; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our securities&#146; or industry analysts&#146; expectations regarding the timing and success of enrollment in our clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the scope, progress and expansion and costs of developing and commercializing our product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our expectations regarding our expenses and revenues, the sufficiency of our cash resources, and the timing of future profitability, if at all; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our need for additional financing and our ability to raise additional funds on commercially reasonable terms; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to establish and maintain development and commercialization partnerships; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our technology manufacturing location and partners; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to adequately manufacture our product candidates for our clinical trials and the raw materials utilized therein; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the ability to obtain and maintain regulatory approval of our product candidates and the labeling for any approved products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to obtain and maintain intellectual property protection for our product candidates and our regenerative medicine platform; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our expectations regarding competition, including the actions of competitors and the perceived relative performance in the marketplace of NeoCart as compared to competitive products; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the size and growth of the potential markets for our product candidates and the ability to serve those markets; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to manufacture our product candidates at a commercial scale to serve those markets, if approved; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the rate and degree of reimbursement and market acceptance of any of our product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our anticipated growth strategies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the anticipated trends and challenges in our business and the market in which we operate; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to attract or retain key personnel; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to operate our business in compliance with the covenants and restrictions that we are subject to under our loan and security agreement; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">regulatory developments in the United States and foreign countries; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our plans for the use of our cash and cash equivalents. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All written and verbal forward-looking statements
attributable to us or any person acting on our behalf are expressly qualified in their entirety by the cautionary statements contained or referred to in this section. We caution investors not to rely too heavily on the forward-looking statements we
make or that are made on our behalf. We undertake no obligation, and specifically decline any obligation, to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise. You are
advised, however, to consult any further disclosures we make on related subjects in any annual, quarterly or current reports that we may file with the Securities and Exchange Commission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We encourage you to read the discussion and analysis of our financial condition and our consolidated financial statements contained in this annual report on
Form 10-K. We also encourage you to read Item&nbsp;1A of Part 1 of this annual report on Form 10-K, entitled &#147;Risk Factors,&#148; which contains a more complete discussion of the risks and uncertainties associated with our business. In addition
to the risks described above and in Item&nbsp;1A of this report, other unknown or unpredictable factors also could affect our results. There can be no assurance that the actual results or developments anticipated by us will be realized or, even if
substantially realized, that they will have the expected consequences to, or effects on, us. Therefore no assurance can be given that the outcomes stated in such forward-looking statements and estimates will be achieved. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As used in this annual report on Form 10-K, the terms &#147;Histogenics,&#148; &#147;Company,&#148; &#147;registrant,&#148; &#147;we,&#148; &#147;us,&#148;
and &#147;our&#148; mean Histogenics Corporation and its subsidiaries unless the context indicates otherwise. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx293850_2"></A>INDUSTRY AND MARKET DATA </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We obtained the industry, market and competitive position data used throughout this annual report on Form 10-K from our own internal estimates and research,
as well as from industry and general publications, in addition to research, surveys and studies conducted by third parties in certain instances. Internal estimates are derived from publicly-available information released by industry analysts and
third-party sources, our internal research and our industry experience, and are based on assumptions made by us based on such data and our knowledge of our industry and market, which we believe to be reasonable. In addition, while we believe the
industry, market and competitive position data included in this annual report on Form 10-K are reliable and are based on reasonable assumptions, such data involves risks and uncertainties and are subject to change based on various factors, including
those discussed in &#147;Risk Factors.&#148; These and other factors could cause results to differ materially from those expressed in the estimates made by the independent parties and by us. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B><A NAME="tx293850_3"></A>ITEM&nbsp;1.</B></TD>
<TD ALIGN="left" VALIGN="top"><B></B><B><I>BUSINESS</I></B><B> </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are a regenerative medicine company focused on developing and commercializing products in the musculoskeletal segment of the marketplace. Our first product
candidate, NeoCart<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, is an innovative tissue implant that utilizes various aspects of our regenerative medicine platform to treat tissue injury in the field of orthopedics, specifically
cartilage damage in the knee. We are currently investigating NeoCart in a 245 patient, Phase 3 clinical trial. Joint, or articular, cartilage covers the ends of bones and allows for joints to glide smoothly with minimal friction. Cartilage damage,
or chondral defects, can be caused by acute trauma, such as a bad fall or sports-related injury, or by repetitive trauma, such as general wear over time. Unlike other tissues in the body, joint cartilage has no innate ability to repair itself,
making any injury permanent. Left untreated, even a small defect can expand in size and progress to debilitating osteoarthritis, ultimately necessitating a joint replacement procedure. An estimated 27 million people in the United States and 630
million people worldwide suffer from osteoarthritis. Compelling demographic trends, such as the growing population of aging yet active individuals and rising rates of obesity, are expected to be key drivers in the continued growth of osteoarthritis
occurrence. Osteoarthritis is more common in adults over the age of 50, but the condition and precursors of the condition can be observed much earlier, and cartilage damage is believed to be one of the leading contributors of this disease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have no products that are approved for sale in the United States and currently we are not selling any other products that may be approved for sale in other
jurisdictions. NeoCart is based on our regenerative medicine platform, which combines expertise in the following areas: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Cell therapy and processing: the handling of a tissue biopsy and the extraction, isolation and expansion of the cells; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Biomaterials and Scaffold: three-dimensional biomaterials structures that enable the proper distribution of cells and organize cells in their natural environment to support tissue formation; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Tissue engineering: the use of a combination of cells, engineering and biomaterials to improve or replace biological functions; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Bioadhesives: natural, biocompatible materials that act as adhesives for biological tissue and allow for natural cell and tissue infiltration and integration with native cells. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">NeoCart is a cartilage-like implant created using a patient&#146;s own cartilage cells through a series of tissue engineering processes. First, the
patient&#146;s cells are separated from a tissue biopsy specimen extracted from the patient and multiplied in our laboratory. The cells are then infused into our proprietary scaffold that provides structure for the developing implant. Before NeoCart
is implanted in a patient, the cell- and scaffold construct undergoes a bioengineering process in our Tissue Engineering Processor (TEP). Our TEP is designed to mimic the conditions found in a joint so that the implant is prepared to begin
functioning like normal healthy cartilage prior to implantation. When NeoCart is implanted, a bioadhesive is used to anchor NeoCart in the cartilage injury and seal the implant to the surrounding native cartilage interface. The use of our
proprietary bioadhesive eliminates the need for complicated suturing, results in a rapid, controllable set-time, and enables the cartilage implant to integrate with the surrounding native cartilage. We believe that our completed Phase 1 and Phase 2
clinical trials provide preliminary evidence of the safety of the NeoCart implant and improvement in pain and function in patients treated with NeoCart. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are currently enrolling a Phase 3 clinical trial for NeoCart in the United States to provide evidence of the safety and effectiveness of NeoCart, studying
cartilage defects in the knees of 245 patients under a Special Protocol Assessment (SPA) with the United States Food and Drug Administration (FDA). Pursuant to the SPA, we formally and prospectively reached agreement with the FDA on key elements of
the Phase 3 clinical trial protocol, including design, endpoints and statistical analyses of the resulting study data. The SPA is binding on the FDA review division with limited exceptions. If the clinical trial is successful, the data may be used
to support efficacy claims for NeoCart approval and demonstrate clinical superiority over the current standard of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
care, microfracture. Microfracture consists of the creation of tiny holes or &#147;fractures&#148; in the bone underneath the injured cartilage leading to formation of a blood clot in the
affected area. The blood and bone marrow that form the clot contain stem cells, which are thought to grow into cartilage-building cells, as well as growth factors to support cell function and development of replacement cartilage matrix. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2016, we had enrolled 196 patients into the Phase 3 clinical trial. We expect to complete enrollment of our NeoCart Phase 3 clinical
trial by the end of the first half of 2017, but we may encounter difficulties enrolling patients in our Phase 3 clinical trial, which could delay or otherwise adversely affect our clinical development activities for NeoCart. As of December&nbsp;31,
2016, we had 34 sites (out of a maximum of 40) eligible including two sites in Canada to enroll patients. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Musculoskeletal-related conditions, including
cartilage damage, are one of the most prevalent health problems in the United States. Based on recent publications, we estimate that more than 1,200,000 knee arthroscopies are performed each year in the United States and we believe cartilage damage
is likely to be identified and treated in over 60% of those knee arthroscopies. Furthermore, cartilage damage is a leading cause of osteoarthritis, a chronic condition in which cartilage breaks down, and the condition most responsible for the
estimated 750,000 knee replacements performed in the United States annually. We believe the current alternatives available to treat cartilage damage in the knee, including microfracture, the most frequently used procedure for severe cartilage
damage, inadequately address this condition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe NeoCart would represent a superior solution to treat cartilage damage in the knee because it has
the potential to solve for the limitations of the current treatment alternatives. In addition, NeoCart has the potential to provide accelerated patient recovery, improved efficacy, long-term patient benefits such as improved durability, and
predictable patient outcomes through a technically straightforward surgical procedure. If we are able to successfully complete our Phase 3 clinical trial, we believe these advantages may assist in securing approval to sell NeoCart in the United
States and may enable us to become a market leader in cartilage repair and regeneration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To date, we have completed two FDA-regulated human clinical
trials in the United States. Specifically, we conducted a Phase 1 safety study of eight patients and a Phase 2 randomized controlled exploratory study of 30 patients. The objective of the Phase 1 clinical trial was to demonstrate the safety of
NeoCart for use when implanted into cartilage defects in the knee. The objectives of the Phase 2 clinical trial were to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">continue the safety evaluation of NeoCart; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">gather additional efficacy data compared to microfracture; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">identify validated endpoints that are clinically meaningful to patients and physicians; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">identify appropriate patient populations to receive NeoCart; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">obtain additional data to be used in the design of future clinical studies. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Data from these trials has been
presented at leading scientific forums and published in peer-reviewed journals. For example, two-year data from the Phase 1 clinical trial was published in <I>The American Journal of Sports Medicine</I> in 2009 and two-year data from the Phase 2
clinical trial was published in <I>The Journal of Bone and Joint Surgery</I> in 2012. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In January 2017, five-year clinical and magnetic resonance imaging
(MRI) data from the combined Phase 1 and 2 NeoCart clinical trials was published in the <I>American Journal of Sports Medicine</I>. The 2017 publication, included data from a total of 29 patients with symptomatic full thickness cartilage lesions of
the distal femoral condyle that were treated with NeoCart in the Phase 1 and 2 clinical trials. Safety and efficacy were evaluated prospectively by MRI and patient reported outcomes (PROs) through a 60-month follow-up period, with 21 of 29 patients
evaluable at the final time point. MRI analysis demonstrated NeoCart repair tissue to be durable and evolve over time. Changes in imaging measures over time corresponded with improvement in clinical measures,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
with maximum benefits experienced at 24-months. The Phase 1 and 2 NeoCart PROs when compared to baseline also demonstrated statistically significant improvements on virtually all of the pain and
functional endpoints, as early as 3 to 6 months, with sustained outcomes through five years. The results from these two prior studies indicate that NeoCart is a safe and effective treatment for articular cartilage lesions through five years. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our objective is to publish additional data supporting the commercial use of NeoCart, if approved, and we anticipate that additional long-term data from the
Phase 2 trial will be published in 2017. In the Phase 2 clinical trial, NeoCart demonstrated a clinically meaningful and statistically significant improvement in clinical efficacy based on pain and function measures as compared to microfracture one
year after treatment. We believe these elements, specifically the one-year superiority primary endpoint based on a dual threshold responder analysis of both pain and function for each individual patient are unique to the NeoCart Phase 3 clinical
trial. We also believe our Phase 3 clinical trial will confirm the positive Phase 1 and Phase 2 clinical data generated by NeoCart. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In anticipation of
potential approval of NeoCart, we have continued the process of scaling our internal current Good Manufacturing Practices (cGMP) manufacturing capabilities and transitioning the manufacture of the critical components (raw materials) of NeoCart,
including collagen, the proprietary scaffold and surgical adhesive in-house to our facilities located in the greater Boston area. The transition commenced in March 2014 with the communication of our plans to the FDA for the internal manufacture of
NeoCart and the critical components of NeoCart, in the event NeoCart is approved. In December 2014, we received preliminary feedback and general acceptance of our raw material transition strategy and future commercial readiness upgrades from the
FDA. In 2016, we reached agreement with the FDA on the data package for internally produced collagen, and in the second quarter of 2016 we incorporated this collagen into the ongoing, NeoCart Phase 3 clinical trial. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We also reached agreement with the FDA on the qualification and comparability plan for the NeoCart collagen scaffold in the third quarter of 2016, and we
expect to complete the scaffold transition in 2017. Once the scaffold comparability work is complete we will work towards qualifying the components of the proprietary adhesive, which we also believe will be completed in 2017. Following completion of
the transition, and as part of our BLA application for NeoCart, we will be required to obtain final FDA approval of the comparability of the critical NeoCart raw materials manufactured in-house. If we fail to obtain, or if we experience a delay in
obtaining such approval, our business, operating results and prospects will be adversely affected. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe our regenerative medicine platform may
provide us with the ability to develop a strong pipeline and that the positive clinical data we have seen in treating cartilage damage of the knee with NeoCart will be applicable to other joints such as the ankle, hip and shoulder. We also believe
our regenerative medicine platform has the ability to translate the fundamental science relating to tissue engineering to allow us to develop additional product candidates to treat other soft tissue damage throughout the body such as tendon,
ligament and meniscus tears and complex joint degeneration. Although not utilized in connection with our current NeoCart development, our portfolio of proprietary fibroblast growth factors may be explored for their use in optimizing manufacturing
yields and we believe they could also have various therapeutic applications including wound healing and fracture healing. We plan to continue to invest in our intellectual property portfolio in order to expand and protect the components of our
regenerative medicine platform and future product candidates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Regenerative Medicine </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Regenerative medicine is a rapidly developing, interdisciplinary field that is transforming healthcare by translating fundamental science into a variety of
products and solutions aimed at repairing, regenerating or replacing function loss caused by injury, disease or aging. Regenerative medicine technologies encompass a variety of therapeutic approaches, including tissue engineering, cell-based
therapies, gene therapy, small molecules and biologics, stem cells and biobanking. Any combination of these technologies may be used to harness or stimulate the body&#146;s innate healing ability in order to treat a wide range of ailments, including
musculoskeletal-related conditions, cardio- and peripheral vascular diseases, neurological disorders, stroke, non-healing wounds and ocular diseases. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Musculoskeletal conditions, comprised of injuries to or diseases of bones, cartilage, joints, ligaments, muscles,
nerves, skin or tendons, are the most common health problem in the United States and are a leading cause of disability and healthcare expenditures according to <I>The Burden of Musculoskeletal Diseases in the United States</I>, a 2011 publication of
a coalition of professional organizations including the American Academy of Orthopaedic Surgeons. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Limitations of Current Alternatives for Treating
Cartilage Damage </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We estimate, based on internal research, that over 500,000 knee cartilage procedures are performed annually in the United States,
primarily in the form of debridement, microfracture, conventional autologous chondrocyte implantation (ACI) and osteochondral grafting. Debridement and microfracture procedures are the most frequently performed surgical procedures for the treatment
of cartilage damage, accounting for an estimated 90% of all such procedures according to materials from a 2009 meeting of the Cellular Tissue and Gene Therapies Advisory Committee of the FDA. Debridement is an arthroscopic procedure that involves
removal of injured or loose tissue debris by shaving, cutting or scraping it. Debridement does not attempt to repair cartilage damage. The surgeon&#146;s only goal when performing debridement is to improve a patient&#146;s symptoms of pain or loss
of function. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Microfracture is considered the current standard of care for chondral defects due to its ability to improve symptoms in specific types of
patients, its simplicity, its safety profile and the lack of other viable alternatives. The procedure consists of perforations, or microfractures, made to the bone plate at the location of cartilage damage in order to allow stem cells from the bone
marrow to access the injured area. Microfracture surgery, a procedure pioneered in the 1980s, was developed to exploit the ability of stem cells to differentiate into mature cells and tissue types. If bone marrow stem cells are able to access the
injured area and stay in place by forming a blood clot, then they may differentiate into cartilage cells, or chondrocytes, that would potentially go on to form cartilage. However, microfracture has been unsuccessful in reliably solving the
underlying problem of cartilage damage because the repair tissue formed by the procedure, which has often been found to be a mix of tissue types, is incapable of withstanding the normal shock and shear forces that joint cartilage sustains and may
not provide the appropriate level of lubrication to the joint. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to its inability to solve the underlying problem&#151;damage to the articular
cartilage&#151;microfracture is associated with numerous other drawbacks and limitations, including the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Modest and Variable Efficacy: </I></B>The results of microfracture vary based on patient-specific characteristics and individual healing responses. Studies have shown the benefits of microfracture are negatively
influenced by advanced age, higher body weight or body mass index, larger chondral defect size and limited amount of repair tissue formed. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Limited Long-Term Patient Benefits: </I></B>Positive clinical response to microfracture has been shown to wane over time. A systematic review summarizing multiple articles on microfracture and published in the
<I>American Journal of Sports Medicine</I> in 2009 revealed that up to 80% of microfracture patients report deterioration in their postoperative functional improvement after two years. Based on our interpretation of a 2013 article in
<I>Cartilage</I> and the 2009 systematic review in the <I>American Journal of Sports Medicine</I>, we believe over 30% of microfracture patients require subsequent additional cartilage procedures after two years and up to 50% of all microfracture
patients eventually require unplanned knee procedures due to persistent or recurrent symptoms. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Extended Patient Recovery: </I></B>Microfracture patients are typically not allowed to resume any vigorous activities for six months after surgery. During this time, patients must avoid weight-bearing activities
for the first six weeks and use continuous passive motion machines for several hours per day. Prolonged physical therapy is often recommended. Such requirements and restrictions are believed necessary to optimize the anatomic and clinical results of
microfracture, but come at the cost of muscle weakening, quality of life and delayed resumption of activities. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ACI and osteochondral grafting are procedures generally reserved either for patients who have failed prior
cartilage procedures or those with very large cartilage defects. While studies indicate beneficial outcomes for patients receiving these treatments, both have drawbacks and limitations similar to those affecting debridement and microfracture, and
also are associated with the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Technically Demanding Surgeries: </I></B>ACI is a slurry of autologous cartilage cells formed from a biopsy of a patient&#146;s cartilage and grown over six to eight weeks. A patch or cover is sometimes sutured
into the surrounding healthy cartilage to hold the slurry in place or cells are delivered on a scaffold and affixed with an adhesive. Osteochondral grafting, whether using the patient&#146;s own cells or using another person&#146;s tissue, consists
of a circular plug of bone and cartilage press-fit into the defect and can be challenging to perform because of the difficulty of achieving an exact match, fit and placement of the graft. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Negative Safety Profile: </I></B>ACI techniques are associated with graft failure, delamination (loss of cartilage layering), tissue overgrowth and knee stiffness. According to a 2006 report in the <I>Journal of
Bone and Joint Surgery</I>, 48% of ACI patients underwent reoperation as a result of problems directly related to the graft. Osteochondral grafting, if performed with the patient&#146;s own cells, is associated with limitations in treatable defect
sizes because of associated donor site morbidity. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Regenerative Medicine Platform and Initial Product Candidate </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our Regenerative Medicine Platform </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our
regenerative medicine platform is comprised of innovative bioengineering, advanced proprietary materials sciences as well as molecular and cellular biology technologies that can be utilized individually or in a variety of combinations to treat
musculoskeletal-related conditions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Cell Processing: </I></B>As part of our process of implant production, our cell processing technologies involve the handling of a biopsy specimen in our own cGMP facilities, cell extraction from the biopsy and the
isolation and expansion of cells in our segregated cell culture facility. These steps effectively return such cells to their juvenile phenotype where they may once again grow into mature cartilage cells. Our proprietary process is currently
optimized for, but not limited to, cartilage cell culturing. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Scaffolds: </I></B>Scaffolds are structures capable of supporting three-dimensional tissue formation and providing an environment for the cells that are needed to form the tissue. Our proprietary,
three-dimensional scaffold structures, including our honeycomb collagen scaffolds, are designed to produce a cartilage-like implant. The scaffold for NeoCart is shaped like a disk, with diameter of 34 mm and thickness of approximately 1.5 mm. The
term &#147;honeycomb&#148; describes the shape of the pores inside of the scaffold as they are shaped like a honeycomb. The honeycomb structure is important because it allows cartilage cells to line up vertically throughout the scaffold so that they
organize as they normally would in native cartilage. Competing scaffolds only accommodate cells on their surface or in layers. Our proprietary three-dimensional scaffolds can support and deliver a variety of cell types and are biocompatible,
biodegradable and non-toxic. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Tissue Engineering: </I></B>Tissue engineering refers to applications that repair or replace portions of or whole tissues such as cartilage, bone, blood vessels and skin. We use a combination of cells, engineering
and materials methods to produce our tissue implant for the purpose of repairing cartilage tissue. Our proprietary TEPs incubate our cell- and scaffold-based implants under conditions designed to mimic the conditions found in the knee, including
pressure changes and low oxygen levels. We believe our proprietary TEP technology is unique to the tissue repair market and is one of the reasons patients receiving a NeoCart implant in our Phase 1 and Phase 2 clinical trials recovered more quickly
and realized positive long-term outcomes as compared to patients receiving microfracture surgery. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Bioadhesive: </I></B>Our proprietary bioadhesive, CT3, secures the NeoCart implant in the defect and
eliminates the need for complicated suturing that may be required during certain other cartilage repair </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
treatments. CT3 is biodegradable, non-toxic and comprised of three components: methylated collagen, activated polyethylene glycol (PEG) and a simple salt buffering solution that acts as a curing
component. The curing component enables the physician to control the adhesive set-time which, we believe both simplifies and expedites the procedure relative to other autologous cartilage repair treatments. We believe CT3 also contributes to the
quick recovery and the positive long-term outcomes seen in our Phase 1 and Phase 2 clinical trials. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>NeoCart: Our Initial Product
Candidate </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">NeoCart, our Phase 3 product candidate, utilizes many aspects of our regenerative medicine platform to repair knee cartilage damage. We
believe NeoCart has the potential to provide several benefits not provided by current treatment alternatives for knee cartilage damage, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Improved Efficacy: </I></B>In our Phase 2 clinical trial of 30 patients, NeoCart showed better clinical outcomes when compared to baseline and/or microfracture on multiple measures of pain and function throughout
the duration of the study. In addition, patients treated with NeoCart experienced statistically significant and clinically meaningful improvements in the Knee Injury and Osteoarthritis Outcome Score (KOOS) pain and function subscales when compared
to baseline as early as three months and continuing through five years after surgery, with similar results for the mean International Knee Documentation Committee Subjective (IKDC Subjective) scores. The difference in improvement between patients
treated with NeoCart and those receiving microfracture started as early as three months in certain subscales and lasted up to five years. We believe efficacy seen in our clinical trials to date is a result of NeoCart&#146;s ability to function like
cartilage upon implantation and integrate with the surrounding native tissue, features that distinguish it from current treatment alternatives. Based on biomarker release testing we conduct in our laboratories, there is evidence that NeoCart is
comprised of maturing hyaline cartilage prior to implantation into a patient. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Accelerated Patient Recovery: </I></B>Our CT3 bioadhesive anchors NeoCart in the defect bed and seals it to the surrounding native cartilage. The cartilage-like NeoCart implant coupled with the secure CT3 fixation
may allow for earlier weight-bearing and accelerated recovery of function than is typical with alternative therapies, which would be distinctly advantageous for any cartilage repair solution. In our Phase 3 clinical trial, patients may be allowed to
begin weight-bearing activities as soon as two weeks following implantation versus six weeks for the current standard of care, microfracture. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Long-Term Patient Benefits: </I></B>In contrast to microfracture&#146;s well-documented deterioration of results after two years, NeoCart&#146;s positive outcomes have been sustained for up to five years in our
Phase 1 and 2 clinical trials. We believe that all of the biologic and mechanical attributes of NeoCart provide the potential for a durable clinical response and give it the potential to prevent the evolution of osteoarthritis and subsequent need
for knee replacement surgery. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Technically Straightforward Surgery: </I></B>The cartilage-like NeoCart implant has certain biomechanical competence and handling characteristics that allow the surgeon to easily trim the implant to the size of
the defect. Furthermore, the use of our CT3 bioadhesive eliminates the need for complicated suturing associated with some ACI techniques. Unlike osteochondral grafting procedures, the NeoCart implant is tailored to the shape of the defect so that
all normal host tissue is left in place. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Positive Safety Profile: </I></B>To date, NeoCart has shown no evidence of tissue overgrowth or knee stiffness often associated with ACI techniques. Reoperation rates to address problems directly related to the
cartilage procedure or other persistent general knee symptoms, associated with all cartilage techniques and particularly high with ACI techniques, have been very low in NeoCart patients followed for five years in our Phase 1 and Phase 2 clinical
trials. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Favorable Reimbursement Profile: </I></B>We are developing NeoCart to be used as a first-line therapy for
the treatment of cartilage damage in the knee. We believe that the data we have generated to date, when </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
combined with the data from the ongoing Phase 3 clinical trial, may enable us to secure favorable reimbursement without the prior-authorization hurdles associated with the some of the currently
available ACI therapies. </P></TD></TR></TABLE> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>THE NEOCART PROCESS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g293850g91i69.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Business Strategy </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our goal is to leverage our regenerative medicine platform to develop and commercialize innovative, next generation products to treat patients suffering from
musculoskeletal-related conditions. The overarching strategies that support these goals are as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Complete the Phase 3 Clinical Trial and Apply for Regulatory Approval of NeoCart in the United States.</I></B> We are currently enrolling our Phase 3 clinical trial. As of December&nbsp;31, 2016, we had enrolled
196 patients and had 34 sites participating in the clinical trial. In 2016, we enrolled 82 patients as compared to 59 patients in 2015, representing an increase of approximately 40%. We believe this increase was largely due to a change in our
approach to managing and recruiting patients into the clinical trial. We expect to complete enrollment in the Phase 3 clinical trial by the end of the second quarter of 2017 with 12-month data available in the middle of 2018. Assuming positive
results of the NeoCart Phase 3 clinical trial, we plan to submit a Biologics License Application (BLA) to the FDA in the second half of 2018. Upon receiving approval from the FDA, if at all, which we anticipate would be in 2019 if a BLA is submitted
in the second half of 2018, we then intend to launch and commercially market NeoCart in the United States for the treatment of cartilage defects in the knee. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><I>Continue to Develop Our Manufacturing Capabilities.</I></B> We own and operate our own cGMP manufacturing
operations for NeoCart and are in the process of transferring the production of the critical raw materials and components used in the NeoCart production process to our manufacturing facility in Lexington, Massachusetts. Our goal is to gain full
control over quality, process, supply and costs. In 2016, we incorporated internally produced collagen into the ongoing, NeoCart Phase 3 clinical trial and reached agreement with the FDA on the qualification and comparability plan for the NeoCart
collagen scaffold. We expect to complete the scaffold transition and comparability work and to begin and complete the qualification of the components of the proprietary adhesive in 2017. This transition to
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
our own manufacturing facilities will also enable us to expand production capacity for clinical and commercial supply of NeoCart in the future in the event we receive FDA approval, subject to
comparability verification and confirmation by the FDA. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Maximize Commercial Opportunity of NeoCart.</I></B> We expect to invest strategically in a U.S. commercial infrastructure to support the successful launch, commercialization and post-marketing support for NeoCart,
in the event NeoCart should receive FDA approval. As part of this investment, we intend to build a highly experienced medical affairs, sales and marketing organization to target orthopedic surgeons in the United States as the primary point of
contact. In preparation for a potential launch of NeoCart, if ever, we are developing a reimbursement dossier to facilitate the introduction of NeoCart into the marketplace and are collecting Health Economics Outcomes Research data per a January
2015 protocol amendment to the ongoing NeoCart Phase 3 clinical trial. The additional data include key economic data and outcomes associated with quality of life, productivity and return to work status, as well as healthcare resource utilization
related to direct and indirect costs. We believe the recovery advantages of NeoCart over other treatments may be substantial, and expect these data to be critical to the reimbursement and adoption of NeoCart, if approved. Furthermore, we intend to
leverage these data and our manufacturing expertise to develop potential commercial and product collaborations in markets outside of the United States, such as Japan and Asia, in order to maximize the commercialization of NeoCart in those markets.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Leverage Our Regenerative Medicine Platform and Exclusive Channel Collaboration Agreement with Intrexon to Expand Our Pipeline.</I></B> We believe the strength of our regenerative medicine platform provides us
with a significant opportunity to enhance and expand our product pipeline. In addition, we believe we can leverage our technology and reduce our manufacturing costs by using Intrexon&#146;s synthetic biology technology platform to develop and
commercialize genetically modified chondrocyte cell therapeutics for the treatment or repair of damaged articular hyaline cartilage in humans. Initially we are focused on using Intrexon&#146;s technology to develop induced pluripotent stem cell
derived (IPSC) source materials in our NeoCart manufacturing process. In 2016, we generated positive proof-of-concept data for IPSC derived NeoCart implants and are working with Intrexon to define the most appropriate development and regulatory
plans to move this program forward. We also believe there is a significant unmet market need and commercial opportunity to treat cartilage defects in other joints such as ankles, shoulders and hips and intend to explore these areas both alone and in
conjunction with Intrexon. Examples of such initiatives may include one-step, off-the&#150;shelf and/or next-generation NeoCart products as well as products designed to treat additional soft tissue and musculoskeletal-related disorders.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B><I>Continue to Invest in Our Intellectual Property and Selectively Evaluate Business Development Opportunities. </I></B>Our intellectual property estate includes more than 55 licensed or owned patents worldwide as
well as trade secrets and know-how around the manufacturing of cell therapies. We intend to continue to expand our intellectual property portfolio to further protect both NeoCart and our future product candidates by filing patent applications in the
United States, the European Economic Area (EEA, which is comprised of the 28 Member States of the European Union, Iceland, Liechtenstein and Norway) and other jurisdictions. In addition, we believe there may be opportunities to generate additional
value from our intellectual property portfolio and intend to explore and evaluate various business development opportunities, both domestically and internationally, including collaborations around rights to NeoCart outside the United States.
Furthermore, we believe there are opportunities to bring in complementary technologies and or product candidates that will leverage the commercial infrastructure we intend to build for the potential launch of NeoCart, if approved, and we intend to
pursue such opportunities in the future. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Phase 3 Product Candidate: NeoCart </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">NeoCart data for the Phase 1 and 2 clinical trials have been published in leading medical journals including the<I> Journal of Bone and Joint Surgery</I> and
the <I>American Journal of Sports Medicine</I>. The results from these two </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
prior studies indicate that NeoCart may be a safe and effective treatment for articular cartilage lesions through five years of follow-up. We believe the <I>Journal of Bone and Joint Surgery</I>,
accepted the initial Phase 2 data because of the high degree of rigor and quality of the design and analysis of the data. Please see the sections below entitled &#147;Phase 2 Clinical Trial&#148; and &#147;Phase 1 Clinical Trial&#148; for a
discussion of the data from our Phase 1 and Phase 2 clinical trials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the first quarter of 2017, five-year clinical and MRI data from 29 patients with
symptomatic full thickness cartilage lesions of the distal femoral condyle that were treated with NeoCart in the combined Phase 1 and 2 clinical trials were published in the <I>American Journal of Sports Medicine</I>. The publication contained an
analysis and evaluation of safety and efficacy based on prospective MRI analyses and PROs through a 60-month follow-up period with 21 of 29 patients evaluable at the final time point. NeoCart patients in the publication were followed over a median
of 60 months. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Qualitative MRI metrics were quantified according to modified magnetic resonance observation of cartilage repair tissue (MOCART) criteria,
with an additional evaluation of repair tissue signal intensity. MOCART analyses indicated significant improvement (p&lt;0.001) in cartilage quality from three 3 to 24 months, with stabilization and maturation from 24 to 60 months. P-values are an
indication of statistical significance reflecting the probability of an observation occurring due to chance alone. A p-value&lt;0.001 means that the probability of the event measured occurring by chance is less than 1 in 1,000. In addition, MRI
analysis demonstrated NeoCart repair tissue to be durable and evolve over time. Changes in imaging measures over time corresponded with improvement in clinical measures, with maximum benefits experienced at 24-months. The Phase 1 and 2 NeoCart PROs
when compared to baseline also demonstrated statistically significant improvements on virtually all of the pain and functional endpoints, as early as 3 to 6 months, with sustained outcomes through 5 years. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Specifically, there were significant improvement in PROs from baseline measurements (mean &plusmn; standard deviation at baseline to mean &plusmn; standard
deviation at follow-up points) that are summarized in the table below. </P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g293850g01z41.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The results from these two prior studies, as further set forth in the 2017 publication in the <I>American Journal of Sports
Medicine</I> indicate that NeoCart may be a safe and effective treatment for articular cartilage lesions through five years. Furthermore, the demonstrated rapid maturation of cartilage as evidenced by the MRI data from the Phase 1 and Phase 2
clinical trials is consistent with biomechanical data generated and presented by Histogenics and Cornell University that showed that <I>in vitro</I> cartilage constructs, or tissue implants, produced
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
using a process that is designed to mimic that of NeoCart exhibited mechanical properties prior to implantation that were similar to that of native cartilage. The biomechanical data were
initially presented at Orthopedic Research Society 2016 annual meeting and are published in <I>the Journal of Orthopaedic Research</I>. Taken together, these results suggest that the maturation of tissue-engineered cartilage implants, such as
NeoCart, leads to improved mechanical properties prior to implantation and may result in a more rapid recovery and return to function for patients suffering from cartilage defects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We consider the data observed thus far to be a direct result of NeoCart&#146;s distinct attributes that combine to form a sophisticated and unique biologic
implant with evidence of cartilage growth prior to implantation and the ability to function like normal cartilage upon implantation. Further, we believe the data reflects that, after implantation, NeoCart continues to mature and integrate with the
native cartilage as it is exposed to the natural environment of the joint. We believe these attributes and the clinical data we have accumulated to date differentiate NeoCart from other treatment alternatives, including microfracture. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Phase 3 Clinical Trial </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are pursuing FDA
approval via a BLA pathway with a clinical trial designed to show superiority against the current standard of care, microfracture. Our NeoCart Phase 3 clinical trial is being performed under an SPA with the FDA and was initiated as a confirmatory
study based on the promising safety and efficacy findings from our Phase 2 clinical trial. The Phase 3 clinical trial design, based on our Phase 2 clinical trial, is a prospective, controlled, multi-center trial of 245 adults between the ages of 18
and 59 years who have symptomatic focal full-thickness chondral knee defects randomized between NeoCart and microfracture on a two-to-one basis. Randomization is done at arthroscopy, at which time final patient eligibility is determined. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As agreed to with the FDA under our SPA, the primary endpoint for approval is superiority at one year in the proportion of responders in the NeoCart patient
group compared to the proportion of responders in the microfracture patient group in a dual-threshold responder analysis. We believe that both the one year primary endpoint and the dual threshold responder analysis are unique to the NeoCart
Phase&nbsp;3 clinical trial. Specifically, the one year endpoint may be a result of our ability to make cartilage tissue <I>ex vivo</I><I> </I>which has the potential to result in a more rapid recovery. We believe the dual threshold responder
analysis represents a high hurdle endpoint that requires patients to have clinically meaningful responses on both pain and function scales&#151;results that may be difficult for other procedures to achieve. The dual-threshold responder analysis
utilizes the KOOS pain subscale and IKDC Subjective assessments. Both the KOOS pain and the IKDC Subjective assessments are validated, patient-centered and self-administered outcome instruments intended to assess patient-relevant outcomes. The KOOS
separately assesses and scores five dimensions of outcomes from the patient&#146;s perspective: pain, symptoms, activities of daily living, sport and recreation function and knee-related quality of life. Similarly, the IKDC Subjective assesses and
scores three dimensions of outcomes from the patient&#146;s perspective: symptoms, function during activities of daily living and sports. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The scores are
tabulated and transformed to a 100-point scale, where 100 represents the best outcome for either pain or function and zero represents the worst outcome. A one-year superiority endpoint was deemed appropriate for our Phase 3 clinical trial under our
SPA based on the magnitude of difference between the responder rates at one year for patients receiving NeoCart implants and patients receiving microfracture surgery in our Phase 2 clinical trial. We believe that, should our Phase 3 clinical trial
show a comparable magnitude of difference in responder rates between NeoCart and microfracture, NeoCart&#146;s ability to function like cartilage upon implantation and integrate with the surrounding native tissue (attributes of NeoCart we believe
are responsible for our Phase 2 clinical trial results) will be a principal reason for the one-year Phase 3 clinical trial outcome and the presumed resultant durability. However, there is no guarantee that our Phase 3 clinical trial results will
demonstrate the same results as our Phase 2 or Phase 1 clinical trials and NeoCart may not be approved for sale in the United States by the FDA after the FDA reviews the results of the Phase 3 clinical trial. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Similar to our Phase 2 clinical trial, discussed below in &#147;Phase 2 Clinical Trial,&#148; in the Phase 3
clinical trial, a patient is considered a responder if he or she achieves both of the following patient-reported outcomes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">improvement of at least 12 points compared to the patient&#146;s baseline score in KOOS pain subscore assessment; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">improvement of at least 20 points compared to the patient&#146;s baseline score on the IKDC Subjective assessment. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the schematic below, the area in the upper right-hand quadrant of the graph, shaded in gray, is the zone reflecting those patients who achieved improvement
of both at least 12 points on the KOOS pain scale and at least 20 points on the IKDC Subjective. The horizontal axis, or x-axis, is the KOOS pain scale and the vertical axis, or y-axis, is the IKDC Subjective. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHEMATIC REPRESENTATION OF RESPONDER RATE ANALYSIS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g293850g36l77.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following additional endpoints will be evaluated in secondary superiority testing at one year comparing the NeoCart
patient group to the microfracture patient group: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">time to full weight-bearing; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">&#147;treatment failure,&#148; defined as a greater than an 8-point deterioration in KOOS pain score at one year compared to baseline and/or a reoperation; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">presence of mature collagen layering as assessed by magnetic resonance imaging cartilage mapping at one year. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Patients will be followed for a total of three years for safety and additional efficacy data. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Phase 3 Status </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2016, we
had enrolled 196 patients into the Phase 3 clinical trial, an increase of approximately 72% over total enrollment at December&nbsp;31, 2015. We expect to complete enrollment of our NeoCart Phase 3 clinical trial by the end of the second quarter of
2017, but we may encounter difficulties enrolling patients in our clinical trials, which could delay or otherwise adversely affect our clinical development activities. In November 2015, we filed an amendment to the NeoCart Phase 3 clinical trial
protocol under the SPA to expand the eligible patient population. In December 2015, the FDA accepted the amendment which allows for, among other things, the inclusion of patients with trochlear lesions and the inclusion of patients up to age 59 into
the trial. As of December&nbsp;31, 2016, we had 34 sites eligible (out of a maximum of 40) to enroll patients. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In late 2009, pursuant to our SPA, we
initiated our Phase 3 clinical trial and our first patient was randomized in June 2010. In September 2010, after nine patients had been randomized, active enrollment was postponed until the completion of a convertible debt financing in late 2011.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In November 2012, we voluntarily suspended manufacturing operations and paused enrollment of the NeoCart Phase 3
clinical trial upon discovery of discrepancies in the testing procedures used to assess one of the raw materials (bovine-derived type I collagen) utilized in the manufacture of NeoCart implants. All participating clinical trial sites, including
Institutional Review Boards (IRB), and the FDA were notified of our decision. After an in-depth review of all available information, we concluded that the observed discrepancies did not impact product quality or patient safety, but we chose to
continue our self-imposed pause to improve and upgrade certain of our existing manufacturing and quality control systems processes to meet or exceed cGMP standards. This transition was completed in December 2013. Prior to our November 2012 voluntary
election to pause enrollment, 30 patients had been randomized into the NeoCart Phase 3 clinical trial. Twenty-one of these patients were randomized to receive a NeoCart implant and nine were randomized to undergo a microfracture procedure. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Phase 2 Clinical Trial </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our NeoCart Phase 2
clinical trial was initiated in 2007 to evaluate further the positive safety and early efficacy signals demonstrated in our Phase 1 clinical trial of NeoCart for articular cartilage damage in the knee. We also sought to identify clinically
meaningful endpoints and appropriate patient populations to be studied in the design of future clinical studies. The trial was a five-year prospective, controlled, randomized, clinical study of 30 patients conducted at six U.S. centers and completed
its enrollment in 2008. Twenty-one patients were randomized to receive a NeoCart implant and nine patients were randomized to undergo a microfracture procedure. The trial was completed in 2013 with final data collection and analysis in 2014 and
2015. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the Phase 2 clinical trial, baseline (preoperative) pain and function assessments were obtained and included, among other measurement
instruments, the KOOS pain and symptoms subscales, the IKDC Subjective assessment and a visual analog pain scale. At every measurement interval between three months and three years, the same pain and function assessments were measured. The data were
analyzed using descriptive statistics (mean and standard deviation), paired t testing and analysis of covariance with significance levels (p-values) set at less than 0.05 (two-sided). According to the results of the analysis, those patients
receiving a NeoCart implant achieved statistically significant improvement (all p-values &lt;0.05) compared to their baseline assessments on the KOOS pain and symptoms subscales, the IKDC Subjective assessment and a visual analog pain scale, meaning
that sufficient data exist to indicate the improvement on each measure is unlikely to have occurred by chance. Furthermore, when this improvement from baseline was compared to the improvement of microfracture from baseline, NeoCart&#146;s
improvement was statistically significantly better (all p-values &lt;0.05) than microfracture&#146;s improvement on a meaningful number of the measurements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additional comparison of the two groups was performed with the previously described dual-threshold responder analysis we are utilizing in our Phase 3 clinical
trial. To be considered a responder in the Phase 2 clinical trial, a patient must have achieved a minimum improvement on the KOOS pain subscale and the IKDC Subjective assessment compared to his or her baseline scores. The minimum required
improvement for pain was 12 points and the minimum required improvement for function was 20 points. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The selected thresholds have been validated in the
literature as clinically meaningful to patients. In some cases, patients entered the Phase 2 clinical trial with pain scores at a level such that they could not have improved a great deal (for example, a baseline of 91 points on a scale of 100). In
those cases, patients were considered responders if their function scores improved a minimum of 20 points even if their pain scores did not improve the required 12 points. Compared to the microfracture group, NeoCart-treated patients had superior
responses to treatment as early as three months in certain subscales with such responses lasting up to five years. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RESPONDER RATE ANALYSIS AT YEAR 1 </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g293850g45n27.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As shown in the graphic above, at Year 1, the number of NeoCart patients (represented by an &#147;O&#148;) who achieved
responder status was greater than the number of microfracture patients (represented by an &#147;X&#148;) who achieved responder status. Many patients far exceeded the minimum dual thresholds required to be considered a responder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As explained more fully above, some patients entered the Phase 2 clinical trial with minimal pain indicated by a high baseline KOOS pain score. A score of 100
on the KOOS pain scale indicates the patient is reporting no pain. In those few cases, only the change in IKDC Subjective score was used to determine if the patients responded to therapy. In those cases, patients were deemed responders if their
function scores improved a minimum of 20 points even if their pain scores did not improve the required 12 points. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In November 2013, the five-year
observation period for the Phase 2 clinical trial concluded. Initial preliminary results were presented at the May 2015 Annual Meeting of the International Cartilage Repair Society demonstrating continued positive results of NeoCart. A subsequent
analysis and validation of the data was performed in the second half of 2015 in connection with the submission of the data to the FDA and for peer-reviewed publication. The data from the trial are now final, and are currently under review for a
future peer-reviewed publication, which is expected in 2017. Based on the initial analysis and consistent with already published initial data, NeoCart generally demonstrated a lasting improvement over baseline through five years after implant.
During the course of the trial, no serious adverse events (expected or unexpected) were considered to be product- or implant-related. We believe the data demonstrate the advantage of NeoCart relative to Microfracture through five years after
surgery. Importantly, the difference in responders at the end of the first year (the primary endpoint on our current Phase 3 clinical trial) was statistically significant (p &lt; 0.05). Two-year results of this trial were published in the<I> Journal
of Bone and Joint Surgery</I> in 2012. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Phase 1 Clinical Trial </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A Phase 1 clinical trial was conducted to demonstrate the safety of NeoCart for use when implanted into cartilage defects in the knee with the intention of
repairing the articular cartilage defects. The two-year results of our Phase 1 clinical trial were published in the <I>American Journal of Sports Medicine</I> in 2009. Among the eight </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
patients studied, all of whom enrolled in 2005 and completed five years of observation, a highly favorable safety profile of NeoCart was documented. The trial was completed in 2010 and final data
collection was completed in 2011. Specifically, few reported complications occurred and no serious adverse events (expected or unexpected) were deemed treatment-related. No cases of infection, implant rejection or immune reaction were documented.
Additionally, joint stiffness and implant overgrowth did not occur in any patient. Efficacy signals in the form of significant improvement in pain and function, measured with patient-reported outcome surveys such as the visual analog pain scale and
the IKDC Subjective score, compared to each patient&#146;s baseline scores were also noted. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Pipeline and NeoCart Indication Expansion </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We intend to build a robust development pipeline by leveraging our regenerative medicine platform and intellectual property portfolio as well as expanding the
applications of NeoCart into additional indications. Although our initial focus for NeoCart is for the treatment of knee cartilage damage, we plan to leverage our regenerative medicine platform to explore the treatment of chondral defects in other
joints, such as the ankle, hip and shoulder. Furthermore, we believe our platform can be utilized to address more extensive cartilage damage associated with significant bone loss and generalized arthritis as well. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our acellular scaffolds are capable of hosting cells of any type, which allows us the flexibility to tailor their use for other regenerative medicine
opportunities beyond cartilage repair, including ligament, tendon and meniscus repair. In addition to the potential use of our growth factor variants to optimize our manufacturing process, our proprietary growth factor variants may be of use in
therapeutic applications such as fracture healing, osteoporosis, generalized osteoarthritis, orphan diseases involving genetically-based bone growth disruption and wound healing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In September 2014, we entered into our ECC with Intrexon that governs a &#147;channel collaboration&#148; arrangement. Pursuant to the ECC we are working with
Intrexon to utilize their synthetic biology technology platform for the development and commercialization of allogeneic, genetically modified, chondrocyte cell therapeutics for the treatment or repair of damaged articular hyaline cartilage in
humans. We believe an allogeneic therapy may offer advantages to both the patient and Histogenics including the elimination of the need for a biopsy and the ability to significantly streamline and thereby reduce the costs of manufacturing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Together with Intrexon, we reached a number of important objectives in 2016. After evaluating a number of different cell sources we decided to focus our
development efforts on the use of IPSC source materials to make a next-generation NeoCart. In 2016, we generated positive proof-of-concept data for IPSC derived NeoCart implants and are working with Intrexon to define the most appropriate
development and regulatory plans to move this program forward. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Commercialization </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If NeoCart is approved by the FDA, we plan to build our own commercial organization in the United States to support the launch and commercialization of
NeoCart. The organization will be designed for scalability to support other potential future products as well. For NeoCart, we initially plan to launch with a small sales force and scale up to approximately 40 sales representatives and management
after FDA approval. The NeoCart sales force will target the estimated 4,000 to 5,000 orthopedic surgeons in the United States who may use NeoCart, including a core group of physicians focused on the care of cartilage injuries. We expect this core
commercial team to be comprised of experienced sales representatives with relevant industry experience in the areas of orthopedic surgery and biologics sales. We may also selectively evaluate commercialization strategies, including partnering, for
NeoCart outside of the United States due to the cost and complexity of building an international infrastructure and, in some regions the challenging economic and reimbursement environments. For example, we believe that Asia, specifically Japan, may
be an attractive market opportunity. The Japanese market for cartilage repair is estimated to represent more than 200,000 procedures annually and is growing due to favorable demographic trends and a greater general acceptance of regenerative
medicine products relative to other parts of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the world. Furthermore, the Japanese Regenerative Medicine Law was passed in 2014 to potentially expedite the clinical development and commercialization pathways for innovative regenerative
cell-based medicines that have demonstrated safety and probable efficacy. To date, two new products have received full and conditional approval since the law went into effect with favorable reimbursement profiles. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In 2016, we initiated discussions with the Japan Pharmaceuticals and Medical Devices Agency (PMDA) regarding the development of NeoCart for the Japanese
market. To date we have held both informal and formal meetings to discuss the data from the NeoCart Phase 1 and Phase 2 clinical trials, the ongoing Phase 3 trial design and the proposed development program and the required regulatory submission
package for potential conditional approval. In the first half of 2017, we intend to conduct formal meetings with the PMDA to define and agree upon the regulatory pathway and development requirements for the potential conditional approval of NeoCart
in Japan. Once we have completed this process, we will seek to find a commercial and manufacturing partner for the Japan or Asia Pacific market. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Manufacturing </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We operate our own cGMP manufacturing
facility in Waltham, Massachusetts for the end-to-end production of NeoCart. We currently have adequate capacity in our Waltham, Massachusetts facility to meet NeoCart clinical demand and we believe we have adequate capacity to meet initial
commercial demand if we are successful in receiving regulatory approval for NeoCart in the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our manufacturing strategy is to own and
operate fully integrated cGMP manufacturing operations for the commercial production of NeoCart in the event NeoCart receives FDA approval. We have historically manufactured the NeoCart implants for our clinical trials and are in the process of
transitioning the production of the NeoCart components, or critical raw materials, to our facility in Lexington, Massachusetts in order to gain full control over quality, process, supply and costs. We intend to demonstrate the comparability of
NeoCart implants made with the new raw materials to the prior implants that we produced with the critical raw materials from third-parties and are in the process of conducting the work necessary to support comparability. Please see the sections
below entitled &#147;NeoCart Technology and Materials Transfer&#148; for additional information. Please see &#147;Risk Factors&#151;Risks Related to Our Business and Commercialization of Our Product Candidates&#151;Failure to obtain, or any delay in
obtaining, FDA approval regarding the comparability of critical NeoCart raw materials following our technology transfer and manufacturing location transition may have an adverse effect on our business, operating results and prospects&#148; for
additional information on the risks associated with our intellectual property strategy and portfolio. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have also entered into a supply agreement with
Collagen Solutions (UK) Limited (Collagen Solutions) pursuant to which we may seek to establish them as a secondary source of additional collagen for use in our manufacture of NeoCart in the U.S. We may also seek to collaborate with Collagen
Solutions for potential future European manufacturing capabilities for future clinical trials of NeoCart and commercialization, if approved. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>NeoCart Manufacturing Process </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our manufacturing
process for NeoCart is systematic and organized with specific steps that are tightly controlled. The first step includes receiving a biopsy from the patient&#146;s own cartilage from which cartilage cells can be isolated and expanded in number using
segregated cell culture technology at our cGMP manufacturing facility in Waltham, Massachusetts. Once we have achieved an adequate number of cartilage cells, these cartilage cells are placed into a sterile collagen solution provided to us in vials
after sterile filtration by a third-party contract manufacturer, and then applied to the three-dimensional collagen scaffold. The scaffold, which is currently provided to us by a third-party supplier, provides an environment for the NeoCart implant
to grow and develop into the form ultimately implanted. The development of the NeoCart implant occurs under controlled conditions in our TEP system which exposes the implant to pressure cycles designed to simulate the pressure cycles that cartilage
is exposed to in the knee. After development in the TEP system, the implant is placed into a solution </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
that allows further maturation prior to implantation. Once the implant is mature and has met the appropriate manufacturing and quality control specifications, which include certain biomarkers of
native, articular, hyaline cartilage, it is shipped by a third-party to the clinical site for implantation in the patient. This typically occurs within three to five days after the completion of the manufacturing process. The manufacturing cycle
time, from receipt of biopsy to delivery of the implant, is approximately six to eight weeks. The range in cycle time is dependent upon the variability in the growth rates of the cells obtained from individual patients. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The quality control laboratory, located within our main Waltham, Massachusetts facility, handles cGMP release testing for the raw materials, CT3 components
and adhesive, the collagen scaffold and final NeoCart implant. Further, our quality control group handles all in-process and finished product environmental monitoring related to the manufacturing process. Testing is performed pursuant to validated
test methods using qualified equipment. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>NeoCart Technology and Materials Transfer </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Manufacturing of raw materials and components used in the NeoCart supply chain is undergoing a technology transfer from outsourced contract manufacturers,
which we used for clinical manufacturing, to our manufacturing facility in Lexington, Massachusetts, which we will use for commercial manufacturing in the event NeoCart is approved by the FDA. This technology transfer extends to the base collagen,
the collagen honeycomb scaffold and the three components of the CT3 bioadhesive&#151;methylated collagen, curing solution and activated PEG. Sterile filtration and aseptic filling of our sterile collagen solution used in NeoCart production will
continue to be performed by a third-party contract manufacturer until after commercialization. We do not anticipate any material changes to raw materials, components, formulations or properties, nor do we anticipate material changes to the NeoCart
manufacturing process or finished product specifications as a result of the transfer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Because we are transitioning production of critical raw material
and components to our own manufacturing facility for future commercial production, we will be required to demonstrate to the FDA that the raw collagen material and the components manufactured in our facility are comparable to those that were used
previously in clinical studies. In December 2014, we obtained FDA feedback and general agreement with our plans via a formal FDA-Sponsor Type C meeting, where we presented technology transfer and comparability plans that included our product test
methods, and manufacturing process summaries. Based on internal review, guidance from FDA and a response from the FDA to our type C meeting received in January 2015, we believe our current strategy to generate and provide comparability data to the
FDA for review should be sufficient. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In 2016, we reached agreement with the FDA on the data package for internally produced collagen, and in the second
quarter of 2016 we incorporated internally produced collagen into the ongoing, NeoCart Phase 3 clinical trial. After the base collagen material, we focused on the remaining critical raw materials including the collagen scaffold and the adhesive,
both of which have collagen as a component. We reached agreement with the FDA on the qualification and comparability plan for the NeoCart collagen scaffold in the third quarter of 2016 and expect to complete the scaffold transition in 2017. Once the
scaffold transition is complete we will work towards qualifying the components of the proprietary adhesive, which we also believe will be completed in 2017. We believe we will be able to complete the transition without any additional clinical
studies. However, as part of our BLA application for NeoCart, we will be required to obtain FDA approval of the comparability of the critical NeoCart raw materials manufactured in-house. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Intellectual Property </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Patent and trade secret protection
is critical to our business. Our success will depend in large part on our ability to continue to protect our cell processing technology, materials science and products for tissue repair through a variety of methods, including seeking, maintaining
and defending patents and other intellectual property intended to cover our products and compositions, their methods of use and processes for their manufacture, our platform technologies, our trade secrets and any other inventions that are
commercially important to the development of our business. We actively seek patent protection in the United States and select foreign countries. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our intellectual property portfolio is currently composed of 15 issued patents and 8 patent applications in the
United States that we own, and 27 issued patents and six patent applications in the United States that we license from academic institutions and business entities. We also have over 100 counterpart patent and patent applications owned or licensed in
certain foreign jurisdictions. This portfolio of owned and in-licensed patents and patent applications covers aspects of: our implants, including NeoCart and our protein implants; our tissue engineering processor; our adhesives; our growth factors,
methods of delivery of therapeutic agents and promoters for increased expression of protein; our method for treatment of ligament and tendon injuries; surgical tools for placing our implants; and our bone composites. The patents that cover the
listed technologies have statutory expiration dates between 2020 and 2031. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have entered into license agreements with various academic institutions and
business entities to obtain the rights to use certain patents and patent applications for the development and commercialization of our technology and products. We also rely on know-how and continuing technological innovation to develop and maintain
our proprietary position. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We license from Purpose Co., Ltd. (f/k/a Takagi Sangyo Co. Ltd. and f/k/a Takagi Industrial Co., Ltd.) (Purpose) an exclusive
right to 39 issued patents and 10 pending patent applications worldwide relating to an exogenous tissue processor. Through this agreement, we have a sublicense to three issued U.S. patents and six issued foreign patents owned by Brigham and
Women&#146;s Hospital, Inc. (BWH) and Purpose that relate to compositions and methods for preparing multi-layered tissue constructs that include a cellular support matrix seeded with living cells derived from a native tissue and tissue culture
protocols to promote the in vitro growth of tissues and tissue constructs. We also have an exclusive license to two issued U.S. patents and one pending U.S. patent application for restoration of articular cartilage matrix from the Board of Trustees
of The Leland Stanford Junior University. The patents that have issued or may yet issue that have been licensed to us under these agreements will have statutory expiration dates between 2021 and 2031. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have an exclusive license to a portfolio consisting of four families of issued patents and pending patent applications owned by Angiotech Pharmaceuticals
(US), Inc. and Angiodevice International GmbH. This exclusivity is for CT3 for use in combination with intellectual property for the repair of articular cartilage, ligament, meniscus or tendon damage. The patents relate to a method of introducing
rapidly gelling biodegradable collagen-PEG hydrogel to the site of injury, methods of inducing meniscal regeneration by introducing a strong adhesive to a site of injury and methods for in situ repair in which the meniscal injury is filled with an
adhesive hydrogel complex consisting of methylated PEG and in which the injury is filled with the adhesive hydrogel complex and a collagen matrix. Any patents within this portfolio that have issued or may yet issue will have statutory expiration
dates between 2014 and 2019. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have an exclusive license to a portfolio of three patent families relating to growth factors and high level expression of
heterologous proteins owned by Yeda Research and Development Co., Ltd. Any patents within this portfolio that have issued or may yet issue will have statutory expiration dates between 2016 and 2023. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We continually assess and refine our intellectual property strategy in order to fortify our position in our target markets. We cannot ensure that patents will
be granted with respect to any of our pending owned or in-licensed patent applications or with respect to any patent applications we may own or license in the future, nor can we be sure that any of our existing owned or in-licensed patents or any
patents we may own or license in the future will be useful in protecting our technology. Please see &#147;Risk Factors&#151;Risks Related to Our Intellectual Property&#148; for additional information on the risks associated with our intellectual
property strategy and portfolio. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Material Technology License Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Purpose Co., Ltd. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On May&nbsp;10, 2016, we amended
our license agreement (the &#147;Amendment&#148;) with Purpose whereby we acquired the development and commercialization rights to NeoCart in Japan. Under the Amendment, we assume sole </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
responsibility for the development and commercialization of all or any portion our products in Japan. In addition, the amended agreement provides us with an exclusive, perpetual (with respect to
patent rights, for the full term of each patent licensed) and sublicensable license, under Purpose&#146;s patent rights and technology relating to their tissue processor, in Japan, to make, use, sell, import and otherwise exploit products or
services covered by claims of such Purpose patents or Purpose&#146;s technology, in connection with articular cartilage, ligaments, tendons and meniscus. The Amendment also terminates the license that Purpose held under the original license
agreement to develop and commercialize Histogenics&#146; patents and technology in Japan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the Amendment, we are obligated to pay Purpose
payments of up to $10 million in the event certain milestones are satisfied as well as a royalty payment in the low single digits on the net sales in Japan for Histogenics products that rely on a Purpose patent or incorporate or necessarily rely
upon any Purpose technology. Such royalty payment shall be reduced if the applicable Histogenics products do not rely on an outstanding Purpose patent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The other terms of the agreement with Purpose remain in effect including our ability outside of Japan to (1)&nbsp;make, use and sell products or services
covered by claims of Purpose&#146;s patents and (2)&nbsp;use and create derivative works of Purpose&#146;s technology for the design, development, manufacture, testing, support and commercialization of any product or service that incorporates or
builds upon Purpose&#146;s technology, in each case, only in connection with articular cartilage, ligaments, tendons and meniscus. Purpose reserves the right to sell its single unit exogenous tissue processer machines to research institutes for
general but noncommercial use anywhere in the world. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As part of our agreement with Purpose, they continue to manufacture and sell single unit exogenous
tissue processor machines to us. In addition, Purpose exclusively sublicensed to us its rights and obligations under the BWH-Purpose license, as amended from time to time. Under the Purpose-BWH license agreement, BWH granted Purpose an exclusive,
royalty-bearing, worldwide, sublicensable license, under its rights in licensed patents and patent applications co-owned by BWH and Purpose, to make, use and sell (1)&nbsp;apparatuses for cultivating a cell or tissue, (2)&nbsp;tissue or cell
products made using such apparatuses, (3)&nbsp;tissue or cell products made using processes for cultivating a cell or tissue as disclosed in the licensed patents and patent applications and (4)&nbsp;any apparatus that cultivates cells or tissues
using such processes, in each case, whose manufacture, use, or sale is covered by the claims of the licensed patents and patent applications, only for therapeutic use. BWH may terminate this agreement if Purpose, itself or through its sublicensees,
does not achieve commercial distribution and sale of the licensed products in the United States by December&nbsp;31, 2019. In return for extending the termination period through December&nbsp;31, 2019 pursuant to an amendment effective November
2015, we agreed to pay BWH $50,000 in November 2015 and three annual payments of $30,000 on the anniversary of the effective date of such amendment for the three years thereafter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to our sublicense from Purpose, we are obligated to pay royalties and milestone payments and sublicense payments due on the BWH-Purpose license
agreement. We have paid minimum royalty amounts of $200,000 and sublicense payments of $175,000 through December&nbsp;31, 2016. Purpose agreed to pay BWH a royalty rate in the low single digits of our net sales of licensed products, subject to a
minimum of $20,000 annually, until the license agreement terminates or until royalty payments no longer have to be made. Purpose is obligated to make one additional sublicense payment of $25,000 and milestone payments to BWH of (1)&nbsp;$75,000 upon
the first patient treated in Phase 3 clinical trials for each licensed product or licensed process and (2)&nbsp;$75,000 upon final FDA approval for each licensed product or licensed process. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The agreement remains in effect for the life of the licensed patents, expected to be until October&nbsp;19, 2028. Purpose may terminate the agreement by
providing written notice to BWH at least 60 days in advance. BWH has the right to terminate the agreement if Purpose fails to make minimum royalty payments or other payments or otherwise breaches the agreement and such breach is not cured within 30
days of BWH providing notice to Purpose. Upon termination of the BWH-Purpose license agreement, our sublicense will convert to a nonexclusive </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
license to Purpose&#146;s interest in the licensed products or processes. Upon written notice to Purpose of our intent to stop using the technology sublicensed to us in the BWH-Purpose license,
Purpose will reassume all responsibility under the BWH-Purpose license. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Angiotech Pharmaceuticals (US), Inc. and Angiodevice International GmbH
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In May 2005, we entered into a worldwide license agreement with Angiotech Pharmaceuticals (US), Inc. and Angiodevice International GmbH
(collectively, Angiotech) for the right, under Angiotech&#146;s licensed patents and patent applications and technical information, to make, use and sell any product that includes both our intellectual property and CT3 for the repair of articular
cartilage, ligament, meniscus or tendon damage, including related osteochrondal defects. The license excludes any product in which one nonliving ingredient is included in CT3 for the primary purpose of producing a physiological, metabolic or
biological effect in mammals. The license grant was made exclusive under the fifth amendment to the license agreement that came into effect in August 2010 after we paid $1.0 million to Angiotech. We have obligations to supply CT3 to Angiotech under
certain terms and conditions, and Angiotech is entitled to use any data and results obtained from any clinical studies conducted by us with respect to CT3. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a license fee, we issued to Angiotech certain warrants to purchase from us shares of common stock, subject to certain anti-dilution protections. These
warrants are no longer outstanding. We paid $1.0 million to Angiotech to make the license grant under the agreement exclusive. In addition, we paid four annual patent fees of $50,000 each as of December&nbsp;31, 2016. We are also obligated to pay an
additional fee of $3.0 million within 30 days after we receive regulatory approval from the FDA for a licensed product. As further consideration for the license, we also agreed to pay royalties at percentage rates of single digits of net sales of
NeoCart and certain other products. We were able to reduce royalties from percentage rates of net sales in the double digits to this rate after making revenue share reduction payments that totaled $2.0 million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The agreement terminates on the earlier of May&nbsp;12, 2035 and expiration of all royalty payment obligations under the agreement. Either party has the right
to terminate the agreement if the other party materially breaches the agreement and fails to cure such breach within 30 days from the date of notice of such breach (ten days in the case of non-payment). We may also terminate the agreement by giving
at least one year&#146;s notice. Angiotech may also terminate the agreement if we or any of our affiliates or sublicensees challenge the validity of Angiotech&#146;s patents rights or rights to improvements (or directly or indirectly support any
such challenge), or if we are acquired by or merge with a third party that has developed or is marketing, or has an affiliate that has developed or is marketing, a competitive product prior to such acquisition or merger and the resulting or
surviving entity post-acquisition or merger fails to either continue to develop or sell licensed product at a level reasonably similar to the development or sale that was occurring prior to the acquisition or merger, during the six-month period
following the acquisition or merger. Competitive product means, in a given country, (1)&nbsp;a drug or biologic approved for marketing or in Phase 3 clinical development, (2)&nbsp;a 510(k), or foreign equivalent, device approved for marketing, or
(3)&nbsp;an FDA Premarket Approval, or foreign equivalent, device approved for marketing or in pivotal study clinical development, other than a licensed product, that acts (or is being developed to act) for one or more target label indications
substantially similar to one or more approved or target label indications for a licensed product. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Koken Co., Ltd. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In March 2013, we entered into a license agreement with Koken Co., Ltd. (Koken) for a non-exclusive, non-transferable and non-sublicensable right to use its
know-how related to the process for manufacturing atelocollagen honeycomb sponge materials, which we use in our scaffolds. Pursuant to the agreement, we paid Koken a fee in March 2013 for such right. Koken may terminate this agreement if we fail to
perform any obligation under the agreement and such failure remains uncured for more than 30 days, if we become insolvent, bankrupt, go into liquidation or receivership, or if we file for bankruptcy or a petition in bankruptcy is filed against us.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The Board of Trustees of The Leland Stanford Junior University </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In April 2001, we entered into a license agreement with The Board of Trustees of The Leland Stanford Junior University (Stanford) for patent rights relating to
the restoration of articular cartilage. Our agreement with Stanford provides us with a worldwide license to make and sell products covered by claims of the licensed patents for growth, ontogenesis, and regeneration of cartilaginous tissues and
collagen. Under the agreement, Stanford agreed not to grant further licenses to such rights in such field. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We paid Stanford $30,000 upon execution of the
agreement and, as of December&nbsp;31, 2016, $421,000 as reimbursement for patent-related costs incurred by Stanford. We are required to pay Stanford a yearly royalty fee of $10,000, which is creditable against earned royalty payments due on net
sales of that year. We have paid $140,000 in yearly royalty fees through December&nbsp;31, 2016. Stanford is also entitled to a low single digit percentage rate of our net sales in royalties. We paid Stanford milestone payments of $35,000 upon
issuance of the first licensed patent and $50,000 upon initiation of Phase 1 clinical trials of the licensed product in the first field that requires separate regulatory authority clinical approval. We have paid Stanford a milestone payment of
$50,000 upon initiation of Phase 1 clinical trials of the licensed product in other fields that requires separate regulatory authority clinical approval, and are obligated to pay an additional milestone payment of $300,000 upon FDA marketing
approval of the first licensed product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The agreement terminates on the date that the last of the licensed patents expire, expected to be
January&nbsp;25, 2021. We may terminate the agreement by giving Stanford notice in writing at least 30 days in advance of the date of termination. Stanford has the right to terminate the agreement if we are in default in payment of royalty or
providing of reports, if we are in breach of any other provisions of the agreement, or if we provide a false report to Stanford, and in each case, we fail to remedy such default, breach or false report within 30 days after written notice thereof. We
are obligated to have licensed products relating to growth, ontogenesis and regeneration of cartilaginous tissue available for commercial sale by December&nbsp;31, 2015. If we fail to fulfill such obligation, Stanford may terminate our rights with
respect to the applicable part of the field of use. Stanford may also terminate the agreement if we or our sublicensees have not sold licensed products for a continuous period of one year after the first commercial sale of licensed products. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Advanced BioMatrix, Inc. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In April 2014, we
entered into an agreement with Advanced BioMatrix, Inc. (ABM) for a nonexclusive, nontransferable (except as expressly provided in the agreement), non-sublicensable (except as provided in the agreement), perpetual, irrevocable, worldwide,
royalty-free right and license to use its technology related to certain collagen solutions and to make, use, sell and otherwise exploit collagen solutions produced using such technology, solely for the development and commercialization, including
generation, implantation and use, of engineered tissue and biomaterials in the field of orthopedics. Pursuant to the agreement, we paid fees in April and November 2014 and will reimburse ABM for mutually agreed upon expenses for such rights and
services to be performed by ABM for us in connection with such technology. This agreement will remain in effect until we or ABM provides written notice to terminate the agreement. Either party may terminate the agreement if the other party
materially breaches any material term of the agreement and fails to cure such breach within 45 days after receiving notice of such breach. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Intrexon
Corporation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In September 2014, we entered into our ECC with Intrexon governing a &#147;channel collaboration&#148; arrangement in which we will
use Intrexon&#146;s current and future proprietary technology directed towards the design, identification, culturing and/or production of genetically modified cells (Technology). The ECC grants us an exclusive worldwide license to utilize
Intrexon&#146;s Technology to develop and commercialize allogeneic genetically modified chondrocyte cell therapeutics for the treatment or repair of damaged articular hyaline cartilage in humans. Under the ECC, we agreed that we would not pursue,
outside of our relationship with Intrexon, the utilization of any synthetic biology platform in conjunction with a universal cell line for the development or commercialization of any products for the purpose of treating and/or repairing damaged
articular </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
hyaline cartilage in humans where such products would compete with commercial products resulting from our collaboration with Intrexon. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Contemporaneously with entering into the ECC, we issued a 6% convertible promissory note (the Note) in the principal amount of $10.0 million as partial
consideration for the execution and delivery of our ECC with Intrexon. The Note converted into 918,206 shares of our common stock in connection with our initial public offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The ECC provides for the establishment of committees comprised of equal numbers of representatives from Intrexon and our company that will govern activities
in the areas of project establishment, chemistry, manufacturing and controls, clinical and regulatory matters, commercialization efforts and intellectual property. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the ECC, we are responsible for the research and development costs incurred by Intrexon associated with the development of product candidates
developed under our collaboration, the effect of which may increase the level of our overall research and development expenses. Subject to certain exceptions, we will be responsible for, among other things, funding the further anticipated
development of cell lines toward the goal of commercialization, conducting preclinical and clinical development of candidate product(s), as well as for other aspects of manufacturing and the commercialization of the product(s). Among other things,
Intrexon will be responsible for technology discovery efforts and cell line development. We will reimburse Intrexon for 50% of the costs it incurs under the ECC pursuant to a jointly agreed upon work plan prior to the acceptance by the FDA or
equivalent regulatory agency in an applicable jurisdiction of an IND or equivalent regulatory filing for a collaboration product, and the remaining 50% of such costs after such filing acceptance by the FDA or equivalent regulatory authority. As of
December&nbsp;31, 2016, we have paid Intrexon $2.7 million in research and development expenses and have an additional $3.4 million payable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will pay
Intrexon a royalty fee of a low double digit percentage of the gross profit derived from the sale of products developed from ECC. We will also pay Intrexon an intermediate double digit percentage of sublicensing revenue we may receive pursuant to
certain conditions set forth in the ECC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have also agreed to make certain payments to Intrexon upon our achievement of designated commercialization
and sales milestones in the form of shares of our common stock (based upon the fair market value of the shares otherwise required to be issued) or, at our option, a cash payment including up to $12 million of development and regulatory milestones
and up to $22.5 million of commercialization milestones. In the event that we consummate an acquisition of our company prior to paying to Intrexon any one or more of the milestone payments and the ECC is transferred or assigned to the buyer in
connection with such acquisition, then all subsequent milestone payments will thereafter each be payable only in cash to Intrexon. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The ECC shall continue
until it is terminated pursuant to certain triggering events, as specified in the ECC. We may voluntarily terminate the ECC at any time upon 90 days&#146; written notice to Intrexon. Either party may terminate the ECC upon 60 days&#146; written
notice following a material breach, and failure to cure such breach by the other party. Intrexon may also terminate the ECC if: we fail to pursue therapies demonstrably superior to existing therapies and those under development by us using the
Technology to commercialize products under the ECC; or we attempt to assign the ECC, other than as permitted under the ECC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon termination of the ECC,
we may continue to develop and commercialize any product developed under the ECC that, at the time of termination satisfies at least one of the following criteria: (i)&nbsp;the product is being sold by us triggering profit sharing payments under the
ECC to Intrexon; (ii)&nbsp;the product has received regulatory approval; (iii)&nbsp;the product is a subject of an application for regulatory approval in the field covered by the ECC that is pending before the applicable regulatory authority; and
(iv)&nbsp;the particular product is the subject of at least an ongoing or completed human clinical trial wherein the product was implanted into at least one patient. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Competition </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The regenerative medicine industry is
characterized by innovative science, rapidly advancing technologies and a strong emphasis on proprietary products. While we believe that our technology, development experience, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
scientific knowledge and intellectual property portfolio provide us with competitive advantages, we face potential competition from many different sources, including major pharmaceutical,
specialty pharmaceutical, biotechnology and regenerative medicine companies, academic institutions, governmental agencies and public and private research institutions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The competitive landscape in the field of articular cartilage repair is emerging and has stimulated a substantial amount of interest from companies developing
tissue repair solutions. Companies have employed a variety of approaches to meet the goals of cartilage repair. The approaches, which represent the scientific evolution of the field, can be generally categorized in five ways:
(1)&nbsp;non-cell-based, such as Arthrosurface&#146;s HemiCAP and Anika&#146;s Hyalofast; (2)&nbsp;uncultured cell-based (with or without scaffold), such as Zimmer&#146;s DeNovo NT, Arthrex&#146;s BioCartilage and Osiris&#146; Cartiform, distributed
exclusively with Arthrex; (3)&nbsp;cultured cell-based (without scaffold), such as Vericel&#146;s Carticel and ISTO&#146;s RevaFlex; (4)&nbsp;cultured cell- and scaffold-based, such as Vericel&#146;s MACI and the Aesculap division of B. Braun
Medical&#146;s NovoCart 3D; and (5)&nbsp;cultured cell- and scaffold-based incorporating tissue engineering, such as NeoCart. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For knee cartilage repair
and regeneration, the market is large and growing, driven by more knee injuries in an increasingly active population. Worldwide, many additional products are commercially available, but the majority of these products were historically only available
in the EEA. Carticel and MACI are currently the only two biologic products approved by the FDA, with MACI having been approved in December 2016. Carticel was approved by the FDA in 1997 and has a restrictive label that limits its use in salvage
cases. However, we believe based on public statements made by Vericel, that MACI currently does not have similar label restrictions and will replace Carticel in the market. RevaFlex and NovoCart 3D are in U.S. clinical development, and based on our
internal analysis of publicly available information, we believe may be approved in 2023 and 2021, respectively. However, their early clinical data have not been published in highly regarded peer-reviewed journals and the results of their clinical
development program in the U.S. are unknown. Although minimally-modified cells such as DeNovo NT, which launched in the United States in 2007, and acellular cartilage matrix products such as Cartiform and Arthrex&#146;s BioCartilage and are
available in the United States, their path to market did not require a rigorous regulatory path and their clinical data to date has been sparse and commercial uptake limited. Product-less procedures such as debridement and microfracture continue to
dominate the U.S. market. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any product candidates that we successfully develop and commercialize will compete with existing therapies and new therapies
that may become available in the future. Our competitors may move faster and have substantially greater financial, technical and human resources that could put them at an advantage in the development of safe and efficacious products and may help
them obtain regulatory approval for their products more rapidly, as well as achieve more widespread market acceptance. We believe, however, the competitive benefits of NeoCart will allow us to position NeoCart effectively as a strong contender in
the tissue repair market. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Outside the United States, many procedures and products for cartilage repair are available. However, we anticipate that many of
these are unlikely to seek approval in the United States because of the rigorous and lengthy regulatory path a sponsor must pursue in order to access the market and the high-quality superiority data that must be produced. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Government Regulation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Regulatory Background on
Autologous Cellular Products </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The FDA does not apply a single regulatory scheme to human tissues and the products derived from human tissue. On a
product-by-product basis, the FDA may regulate such products as drugs, biologics, or medical devices, in addition to regulating them as human cells, tissues, or cellular or tissue-based products (HCT/Ps), depending on whether or not the particular
product triggers any of an enumerated list of regulatory factors. A fundamental difference in the treatment of products under these classifications is that the FDA generally permits HCT/Ps that do not trigger any of those regulatory factors to be
commercially distributed without marketing approval. In contrast, products that trigger those factors, such as if they are more than minimally manipulated </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
when processed or manufactured, are regulated as drugs, biologics, or medical devices and require FDA approval. The FDA has designated NeoCart as a biologic under the jurisdiction of the Center
for Biologics Evaluation and Research and market access or approval will require BLA approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In 1997, the FDA began requiring BLA filing for autologous
cellular products and approved the already-marketed Carticel contingent on further clinical trials. In 2000, Carticel&#146;s indication narrowed to second-line therapy for patients with inadequate response to prior treatment. As of December 2011,
the FDA requires evidence of clinical efficacy against approved and validated endpoints and standard of care control arm as outlined in their final guidance on the subject of cartilage repair. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The grant of marketing authorization in the EEA for products containing viable human tissues or cells such as NeoCart is governed by Regulation 1394/2007/EC
on advanced therapy medicinal products, read in combination with Directive 2001/83/EC of the European Parliament and of the Council, commonly known and the Community code on medicinal products. Regulation 1394/2007/EC lays down specific rules
concerning the authorization, supervision and pharmacovigilance of gene therapy medicinal products, somatic cell therapy medicinal products and tissue engineered products. Manufacturers of advanced therapy medicinal products must demonstrate the
quality, safety and efficacy of their products to the European Medicines Agency (EMA), which is required to provide an opinion regarding the application for marketing authorization. The European Commission grants or refuses marketing authorization
in light of the opinion delivered by the EMA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Applicants for marketing authorization for medicinal products in the EEA are required to submit
applications for marketing authorization based on the ICH Common Technical Document and must demonstrate the safety, quality and efficacy of the medicinal product for which the marketing authorization is sought. The application must include the
results of pre-clinical tests and clinical trials conducted with the medicinal product. The conduct of clinical trials in the EEA is governed by Directive 2001/20/EC which imposes obligations and procedures that are similar to those provided in
applicable U.S. laws. The obligations provided in the European Union (EU) Good Clinical Practice rules and EU Good Laboratory Practice must also be respected during conduct of the trials. Clinical trials must be approved by the competent regulatory
authorities and the competent Ethics Committees in the EU Member States in which the clinical trials take place. Moreover, applicants are required to demonstrate that studies have been conducted with the medicinal product in the pediatric population
as provided by a Pediatric Investigation Plan approved by the Pediatric Committee of the EMA. Alternatively, confirmation that the applicant has obtained a waiver or deferral for the conduct of these studies must be provided. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Anticipated FDA Regulatory and Approval Process for NeoCart </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We anticipate NeoCart, if approved, to be the first autologous cell- and scaffold-based product in the U.S. market to have been studied in a randomized
controlled trial with a rigorous responder analysis under an approved SPA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The FDA approved the NeoCart Phase 3 study design under the SPA process and
concluded that the trial &#147;design and planned analyses &#133; sufficiently address the studies&#146; objectives &#133; these studies are adequately designed to provide the necessary data that &#133; could support a license application
submission.&#148; We anticipate the SPA to be binding on the FDA review division, with limited exceptions provided by FDA guidance, such as the FDA &#147;determines that a substantial issue essential to determining the safety or efficacy of the
[product] has been identified after the testing has begun,&#148; or if we fail to follow the agreed-upon protocol. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Reimbursement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In both domestic and foreign markets, sales of any regulatory-approved products depend in part upon the availability of reimbursement from third-party payors.
Third-party payors include government health programs, such as Medicare and Medicaid, private health insurers and managed care providers, and other organizations. Reimbursement policy involves coding, coverage and payment decisions and our business
strategy is to produce the necessary information for optimal decision-making by payors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Coding</I></B>: While reimbursement policy for NeoCart is uncertain at this point, we believe that the
existing Current Procedural Terminology, Healthcare Commission Procedure Coding System and International Classification of Diseases, Ninth Edition coding options for ACI are sufficiently broad that they could apply to NeoCart. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Coverage</I></B>: Our goal is to demonstrate improved health outcomes (e.g., improved patient outcomes and quality of life on several parameters, lower
total costs including lower overall utilization of healthcare services and faster return to work) for patients receiving NeoCart compared to microfracture, an important element in securing coverage decisions by payors (Medicare and private payors).
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Payment</I></B>: Analysis of recent trends in ACI coverage (discharge data) suggest that patients between 18 and 64 years of age constitute the
majority of the market for ACI, resulting in a market dominated by private payors. Only 10% to 20% of ACI patients are estimated to be 65 years of age and older. While limited data is available for private payor reimbursement of ACI, these payors
typically reimburse inpatient procedures with bundling mechanisms similar to Medicare Severity Diagnosis Related Groups. In addition, some private payors also tend to use Medicare rates as benchmarks when setting their own fee schedules. In
preparation for the potential launch of NeoCart, if ever, we are developing a reimbursement dossier to facilitate the introduction of NeoCart into the marketplace. In November 2014, we submitted a protocol amendment to the FDA to augment additional
Health Economics Outcomes Research data to further support our future reimbursement initiatives. These data would collect additional key economic data and outcomes associated with quality of life, productivity and return to work status, and
healthcare resource utilization related to direct and indirect costs. Upon receipt of this data we plan to provide objective clinical data, patient-reported quality of life data and health economic data demonstrating NeoCart&#146;s value to assist
in optimizing payment decisions for NeoCart. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Government Regulation Overview </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>United States </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><U>Overview </U></I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the United States, the FDA regulates biological products under the Federal Food, Drug, and Cosmetic Act and the Public Health Service Act and related
regulations. Biological products are also subject to other federal, state, local, and foreign statutes and regulations. The FDA and comparable regulatory agencies in state and local jurisdictions and in foreign countries impose substantial
requirements upon the clinical development, manufacture and marketing of biological products. These agencies and other federal, state, local, and foreign entities regulate research and development activities and the testing, manufacture, quality
control, safety, effectiveness, packaging, labeling, storage, distribution, record keeping, reporting, approval, advertising and promotion of our products. Failure to comply with the applicable U.S. regulatory requirements at any time during the
product development process, including clinical testing, approval process or after approval may subject an applicant to administrative or judicial sanctions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Government regulation may delay or prevent marketing of product candidates for a considerable period of time and impose costly procedures upon our activities.
The testing and approval process requires substantial time, effort, and financial resources, and we cannot be certain that the FDA or any other regulatory agency will grant approvals for NeoCart or any future product candidates on a timely basis, if
at all. The FDA&#146;s policies may change and additional government regulations may be enacted that could prevent or delay regulatory approval of NeoCart or any future product candidates or approval of new disease indications or label changes. We
cannot predict the likelihood, nature or extent of adverse governmental regulation that might arise from future legislative, judicial, or administrative action, either in the United States or abroad. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><U>Marketing Approval </U></I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The process required by the FDA before biological products may be marketed in the United States generally involves the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">completion of nonclinical laboratory and animal tests according to good laboratory practices, and applicable requirements for the humane use of laboratory animals or other applicable regulations; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">submission to the FDA of an IND application which must become effective before human clinical trials may begin; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">performance of adequate and well-controlled human clinical trials according to the FDA&#146;s regulations commonly referred to as good clinical practices (GCP), and any additional requirements for the protection of
human research patients and their health information, to establish the safety and efficacy of the proposed biological product for its intended use or uses; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">submission to the FDA of a BLA for marketing approval that includes substantive evidence of safety, purity, and potency from results of nonclinical testing and clinical trials; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">satisfactory completion of an FDA pre-approval inspection of manufacturing facilities where the biological product is produced to assess compliance with good manufacturing practices (GMP) to assure that the facilities,
methods and controls are adequate to preserve the biological product&#146;s identity, strength, quality and purity and, if applicable, the FDA&#146;s current good tissue practices (GTP) for the use of human cellular and tissue products to prevent
the introduction, transmission or spread of communicable diseases; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">potential FDA audit of the nonclinical study sites and clinical trial sites that generated the data in support of the BLA; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">FDA review and approval, or licensure, of the BLA, which must occur before a biological product can be marketed or sold. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><U>U.S. Biological Products Development Process </U></I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Before testing any biological product candidate in humans, the product candidate enters the nonclinical testing stage. Nonclinical tests include laboratory
evaluations of product chemistry, toxicity and formulation, as well as animal studies to assess the potential safety and activity of the product candidate. The conduct of the nonclinical tests must comply with federal regulations and requirements
including good laboratory practices. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prior to commencing the first clinical trial, the clinical trial sponsor must submit the results of the nonclinical
tests, together with manufacturing information, analytical data, any available clinical data or literature and a proposed clinical protocol, to the FDA as part of an initial IND application. Some nonclinical testing may continue even after the IND
application is submitted. The IND application automatically becomes effective 30 days after receipt by the FDA unless the FDA, within the 30-day time period, raises concerns or questions about the conduct of the clinical trial and places the
clinical trial on a clinical hold. In such case, the IND application sponsor must resolve any outstanding concerns with the FDA before the clinical trial may begin. Further, an IRB for each site proposing to conduct the clinical trial must review
and approve the plan for any clinical trial before it commences at that site. An IRB is charged with protecting the welfare and rights of study subjects and considers such items as whether the risks to individuals participating in the clinical
trials are minimized and are reasonable in relation to anticipated benefits. The IRB also approves the form and content of the informed consent that must be signed by each clinical trial subject or his or her legal representative and must monitor
the clinical trial until completed. The FDA or IRB may impose clinical holds on a biological product candidate at any time before or during clinical trials due to safety concerns or non-compliance. If the FDA imposes a clinical hold, trials may not
recommence without FDA or IRB authorization and then only under terms authorized by the FDA and IRB. Accordingly, we cannot be sure that submission of an IND application will result in the FDA allowing clinical trials to begin or that, once begun,
issues will not arise that will result in the suspension or termination of such trials. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Clinical trials involve the administration of the biological product candidate to healthy volunteers or patients
under the supervision of qualified investigators, generally physicians not employed by or under the trial sponsor&#146;s control. Clinical trials are conducted under protocols detailing, among other things, the objectives of the clinical trial,
dosing procedures, subject selection and exclusion criteria, and the parameters to be used to monitor subject safety, including stopping rules that assure a clinical trial will be stopped if certain adverse events should occur. Each protocol and any
amendments to the protocol must be submitted to the FDA as part of the IND application and to the IRB. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For purposes of BLA approval, human clinical
trials are typically conducted in three sequential phases that may overlap: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Phase 1&#151;The biological product is initially introduced into healthy human patients and tested for safety. In the case of some products for severe or life-threatening diseases, especially when the product may be too
inherently toxic to ethically administer to healthy volunteers, the initial human testing is conducted in patients. These trials may also provide early evidence on effectiveness. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Phase 2&#151;These trials are conducted in a limited number of patients in the target population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific
targeted diseases and to determine dosage tolerance and optimal dosage. Multiple Phase 2 clinical trials may be conducted by the sponsor to obtain information prior to beginning larger and more expensive Phase 3 clinical trials. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Phase 3&#151;Phase 3 trials are undertaken to provide statistically significant evidence of clinical efficacy and to further evaluate dosage, potency and safety in an expanded patient population at multiple clinical
trial sites. They are performed after preliminary evidence suggesting effectiveness of the product has been obtained, and are intended to establish the overall benefit-risk relationship of the investigational product and to provide an adequate basis
for product approval and labeling. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Post-approval clinical trials, sometimes referred to as Phase 4 clinical trials, may be conducted after
initial marketing approval. These trials may be required by the FDA as a condition of approval and are used to gain additional experience from the treatment of patients in the intended therapeutic indication, particularly for long-term safety
follow-up. The FDA now has express statutory authority to require post-market clinical trials to address safety issues. All of these trials must be conducted in accordance with GCP requirements in order for the data to be considered reliable for
regulatory purposes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During all phases of clinical development, regulatory agencies require extensive monitoring and auditing of all clinical activities,
clinical data and clinical trial investigators. Annual progress reports detailing the results of the clinical trials must be submitted to the FDA. Written IND safety reports must be promptly submitted to the FDA and the investigators for serious and
unexpected adverse events; any findings from other studies, tests in laboratory animals or in vitro testing that suggest a significant risk for human patients; or any clinically important increase in the rate of a serious suspected adverse reaction
over that listed in the protocol or investigator brochure. The sponsor must submit an IND safety report within 15 calendar days after the sponsor determines that the information qualifies for reporting. The sponsor also must notify the FDA of any
unexpected fatal or life-threatening suspected adverse reaction within seven calendar days after the sponsor&#146;s initial receipt of the information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Phase 1, Phase 2 and Phase 3 clinical trials may not be completed successfully within any specified period, if at all. Regulatory authorities, a data safety
monitoring board or the sponsor may suspend a clinical trial at any time on various grounds, including a finding that the participants are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a
clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#146;s requirements or if the biological product has been associated with unexpected serious harm to patients. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our ongoing and planned clinical trials for our product candidates may not begin or be completed on schedule, if
at all. Clinical trials can be delayed for a variety of reasons, including delays in: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">obtaining regulatory approval to commence a trial; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reaching agreement with third-party clinical trial sites and their subsequent performance in conducting accurate and reliable trials on a timely basis; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">obtaining IRB approval to conduct a trial at a prospective site; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">recruiting patients to participate in a trial; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">supply of the biological product. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Typically, if a biological product is intended to treat a chronic disease,
as is the case with NeoCart, safety and efficacy data must be gathered over an extended period of time, which can range from six months to three years or more. Success in early stage clinical trials does not ensure success in later stage clinical
trials. Data obtained from clinical activities is not always conclusive and may be susceptible to varying interpretations, which could delay, limit or prevent regulatory approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Concurrent with clinical trials, companies usually complete additional animal studies and must also develop additional information about the physical
characteristics of the biological product as well as finalize a process for manufacturing the product in commercial quantities in accordance with GMP requirements. To help reduce the risk of the introduction of adventitious agents with the use of
biological products, the Public Health Service Act emphasizes the importance of manufacturing control for products whose attributes cannot be precisely defined. The manufacturing process must be capable of consistently producing quality batches of
the product candidate and, among other things, the sponsor must develop methods for testing the identity, strength, quality, potency and purity of the final biological product. Additionally, appropriate packaging must be selected and tested and
stability studies must be conducted to demonstrate that the biological product candidate does not undergo unacceptable deterioration over its shelf life. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><U>U.S. Review and Approval Processes </U></I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In
order to obtain approval to market a biological product in the United States, a BLA must be submitted to the FDA that provides data establishing to the FDA&#146;s satisfaction the safety, purity and potency of the investigational biological product
for the proposed indication. The application includes all data available from nonclinical studies and clinical trials, including negative or ambiguous results as well as positive findings, together with detailed information relating to the
product&#146;s manufacture and composition, and proposed labeling, among other things. The testing and approval processes require substantial time and effort, and there can be no assurance that the FDA will accept the BLA for filing and, even if
filed, that any approval will be granted on a timely basis, if at all. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the Prescription Drug User Fee Act (PDUFA), each BLA must be accompanied by
a user fee. The FDA adjusts the PDUFA user fees on an annual basis. According to the FDA&#146;s fee schedule, the user fee for an application requiring clinical data, such as a BLA, will be $2.4 million for 2016. PDUFA also imposes an annual product
fee for biologics ($114,450 for 2016), and an annual establishment fee ($585,200 for 2016) on facilities used to manufacture prescription biologics. Fee waivers or reductions are available in certain circumstances, including a waiver of the
application fee for the first application filed by a small business. Additionally, no user fees are assessed on BLAs for products designated as orphan drugs, unless the product also includes a non-orphan indication. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The FDA has 60 days from its receipt of a BLA to determine whether the application will be accepted for filing based on the FDA&#146;s threshold determination
that the application is sufficiently complete to permit substantive review. The FDA may refuse to file any BLA that it deems incomplete or not properly reviewable at the time of submission and may request additional information. In this event, the
BLA must be resubmitted with the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
additional information. The resubmitted application also is subject to review before the FDA accepts it for filing. After the BLA submission is accepted for filing, the FDA reviews the BLA to
determine, among other things, whether the proposed product is safe and potent, or effective, for its intended use, and has an acceptable purity profile, and whether the product is being manufactured in accordance with GMPs to assure and preserve
the product&#146;s identity, safety, strength, quality, potency, and purity, and biological product standards. The FDA may refer applications for novel biological products or biological products that present difficult questions of safety or efficacy
to an advisory committee, typically a panel that includes clinicians and other experts, for review, evaluation and a recommendation as to whether the application should be approved and, if so, under what conditions. The FDA is not bound by the
recommendations of an advisory committee, but it considers such recommendations carefully when making decisions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Before approving a BLA, the FDA will
inspect the facilities at which the product is manufactured. The FDA will not approve the product unless it determines that the manufacturing processes and facilities are in compliance with GMP requirements and adequate to assure consistent
production of the product within required specifications. For a human cellular or tissue product, the FDA also will not approve the product if the manufacturer is not in compliance with the GTP. These are FDA regulations that govern the methods used
in, and the facilities and controls used for, the manufacture of HCT/Ps, which are human cells or tissue intended for implantation, transplant, infusion, or transfer into a human recipient. The primary intent of the GTP requirements is to ensure
that cell and tissue based products are manufactured in a manner designed to prevent the introduction, transmission and spread of communicable disease. FDA regulations also require tissue establishments to register and list their HCT/Ps with the FDA
and, when applicable, to evaluate donors through screening and testing. Additionally, before approving a BLA, the FDA may inspect one or more clinical sites to assure that the clinical trials were conducted in compliance with IND application study
requirements and GCP. To assure GMP, GTP and GCP compliance, an applicant must incur significant expenditure of time, money and effort. If the FDA determines the manufacturing process or manufacturing facilities are not acceptable, it typically will
outline the deficiencies and often will require the facility to take corrective action and provide documentation evidencing the implementation of such corrective action. This may significantly delay further review of the application. If the FDA
finds that a clinical site did not conduct the clinical trial in accordance with GCP, the FDA may determine the data generated by the clinical site should be excluded from the primary efficacy analyses provided in the BLA and request additional
testing or data. Additionally, notwithstanding the submission of any requested additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The FDA also has authority to require a Risk Evaluation and Mitigation Strategy (REMS) from manufacturers to ensure that the benefits of a biological product
outweigh its risks. A sponsor may also voluntarily propose a REMS as part of the BLA submission. The need for a REMS is determined as part of the review of the BLA. Based on statutory standards, elements of a REMS may include &#147;dear doctor
letters,&#148; a medication guide, more elaborate targeted educational programs, and in some cases restrictions on distribution. These elements are negotiated as part of the BLA approval, and in some cases may delay the approval date. Once adopted,
REMS are subject to periodic assessment and modification. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">After the FDA completes its initial review of a BLA, it will communicate to the sponsor that
the biological product will either be approved, or it will issue a complete response letter to communicate that the BLA will not be approved in its current form. The complete response letter usually describes all of the specific deficiencies in the
BLA identified by the FDA. The deficiencies identified may be minor, for example, requiring labeling changes, or major, for example, requiring additional clinical trials. Additionally, the complete response letter may include recommended actions
that the applicant might take to place the applicant in a condition for approval. If a complete response letter is issued, the applicant may either resubmit the BLA, addressing all of the deficiencies identified in the letter, or withdraw the
application. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The FDA may not grant approval on a timely basis, or at all. We may encounter difficulties or unanticipated costs
in our efforts to secure necessary governmental approvals, which could delay or preclude us from marketing our products. The testing and approval process for a biological product usually takes several years to complete. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">One of the performance goals agreed to by the FDA under PDUFA is to review 90% of standard BLAs within ten months of the 60-day filing date and 90% of
priority BLAs within six months of the 60-day filing date, whereupon a review decision is to be made. The FDA does not always meet its PDUFA goal dates for standard and priority BLAs and its review goals are subject to change from time to time. The
review process and the PDUFA goal data may be extended by three months if the FDA requests or the BLA applicant otherwise provides additional information or clarification regarding information already provided in the submission within the last three
months before the PDUFA goal date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Even if a product candidate receives regulatory approval, the approval may be limited to specific disease states,
patient populations and dosages, or the indications for use may otherwise be limited, which could restrict the commercial value of the product. Further, the FDA may require that certain contraindications, warnings, or precautions be included in the
product labeling. The FDA may impose restrictions and conditions on product distribution, prescribing or dispensing in the form of a risk management plan, or otherwise limit the scope of any approval. In addition, the FDA may require Phase 4
post-marketing clinical trials, designed to further assess a biological product&#146;s safety and effectiveness, and testing and surveillance programs to monitor the safety of approved products that have been commercialized. Further, even after
regulatory approval is obtained, later discovery of previously unknown problems with a product may result in the imposition of new restrictions on the product or even complete withdrawal of the product from the market. Delay in obtaining, or failure
to obtain and maintain, regulatory approval for NeoCart, or obtaining approval but for significantly limited use, would harm our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><U>FDA
Post-Approval Requirements </U></I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Maintaining substantial compliance with applicable federal, state, local and foreign statutes and regulations
requires the expenditure of substantial time and financial resources. Rigorous and extensive FDA regulation of biological products continues after approval, particularly with respect to GMP. We may rely, in the future, on third parties for the
production of clinical and commercial quantities of any future products that we may commercialize. Manufacturers of our products are required to comply with applicable requirements in the GMP regulations, including quality control and quality
assurance and maintenance of records and documentation. We cannot be certain that we or our present or future suppliers will be able to comply with the GMP and other FDA regulatory requirements. Other post-approval requirements applicable to
biological products include reporting of GMP deviations that may affect the identity, potency, purity and overall safety of a distributed product, record-keeping requirements, reporting of adverse effects, reporting updated safety and efficacy
information and complying with electronic record and signature requirements. After a BLA is approved, the product also may be subject to official lot release. As part of the manufacturing process, the manufacturer is required to perform certain
tests on each lot of the product before it is released for distribution. If the product is subject to official release by the FDA, the manufacturer submits samples of each lot of product to the FDA together with a release protocol showing a summary
of the history of manufacture of the lot and the results of all of the manufacturer&#146;s tests performed on the lot. The FDA also may perform certain confirmatory tests on lots of some products, such as viral vaccines, before releasing the lots
for distribution by the manufacturer. In addition, the FDA conducts laboratory research related to the regulatory standards on the safety, purity, potency and effectiveness of biological products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Discovery of previously unknown problems or the failure to comply with the applicable regulatory requirements, by us or our suppliers, may result in
restrictions on the marketing of a product or withdrawal of the product from the market as well as possible civil or criminal sanctions and adverse publicity. FDA sanctions could include refusal to approve pending applications, suspension or
revocation of an approval, clinical hold, warning or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
untitled letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, mandated corrective
advertising or communications with doctors, debarment, restitution, disgorgement of profits or civil or criminal penalties. Any agency or judicial enforcement action could have a material adverse effect on us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Biological product manufacturers and other entities involved in the manufacture and distribution of approved biological products are required to register
their facilities with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with GMPs and other laws. In addition, changes to the manufacturing process or
facility generally require prior FDA approval before being implemented and other types of changes to the approved product, such as adding new indications and additional labeling claims, are also subject to further FDA review and approval. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><U>Labeling, Marketing and Promotion </U></I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The FDA
closely regulates the labeling, marketing and promotion of biological products, including direct-to-consumer advertising, promotional activities involving the internet, and industry-sponsored scientific and educational activities. While doctors are
free to prescribe any product approved by the FDA for any use, a company can only make claims relating to safety and efficacy of a biological product that are consistent with FDA approval, and the company is allowed to market a biological product
only for the particular use and treatment approved by the FDA. In addition, any claims we make for our products in advertising or promotion must be appropriately balanced with important safety and risk information and otherwise be adequately
substantiated. Failure to comply with these requirements can result in adverse publicity, warning letters, corrective advertising, injunctions, seizures, potential civil and criminal penalties and exclusion from government healthcare programs. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><U>Anti-Kickback and False Claims Laws </U></I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the
United States, the research, manufacture, distribution, sale and promotion of biological products are potentially subject to regulation by various federal, state and local authorities in addition to the FDA, including the Centers for
Medicare&nbsp;&amp; Medicaid Services, other divisions of the U.S. Department of Health and Human Services (for example, the Office of Inspector General), the U.S. Department of Justice, state Attorneys General, and other federal, state and local
government agencies. For example, sales, marketing and scientific/educational grant programs must comply with the Anti-Kickback Statute, the False Claims Act, the privacy regulations promulgated under the Health Insurance Portability and
Accountability Act and similar state laws. Pricing and rebate programs must comply with the Medicaid Drug Rebate Program requirements of the Omnibus Budget Reconciliation Act, and the Veterans Health Care Act. If products are made available to
authorized users of the Federal Supply Schedule of the General Services Administration, additional laws and requirements apply. All of these activities are also potentially subject to federal and state consumer protection and unfair competition
laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As noted above, in the United States, we are subject to complex laws and regulations pertaining to healthcare &#147;fraud and abuse,&#148;
including the Anti-Kickback Statute, the False Claims Act and other state and federal laws and regulations. The Anti-Kickback Statute makes it illegal for any person, including a biological product manufacturer (or a party acting on its behalf), to
knowingly and willfully solicit, receive, offer, or pay any remuneration that is intended to induce the referral of business, including the purchase or order of an item for which payment may be made under a federal healthcare program, such as
Medicare or Medicaid. Violations of this law are punishable by up to five years in prison, criminal fines, administrative civil money penalties and exclusion from participation in federal healthcare programs. In addition, many states have adopted
laws similar to the Anti-Kickback Statute. Some of these state prohibitions apply to the referral of patients for healthcare services reimbursed by any insurer, not just federal healthcare programs such as Medicare and Medicaid. Due to the breadth
of these federal and state anti-kickback laws and the potential for additional legal or regulatory change in this area, it is possible that our future sales and marketing practices or our future relationships with physicians might be challenged
under anti-kickback laws, which could harm us. Because we intend to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
commercialize products that could be reimbursed under a federal healthcare program and other governmental healthcare programs, we plan to develop a comprehensive compliance program that
establishes internal controls to facilitate adherence to the rules and program requirements to which we will or may become subject. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The False Claims Act
prohibits anyone from, among other things, knowingly presenting, or causing to be presented, for payment to federal programs (including Medicare and Medicaid) claims for items or services, including biological products, that are false or fraudulent.
Although we likely would not submit claims directly to payers, manufacturers can be held liable under these laws if they are deemed to &#147;cause&#148; the submission of false or fraudulent claims by, for example, providing inaccurate billing or
coding information to customers or promoting a product off-label. In addition, our future activities relating to the reporting of wholesaler or estimated retail prices for our products, the reporting of prices used to calculate Medicaid rebate
information and other information affecting federal, state and third-party coverage and reimbursement for our products and the sale and marketing of our products, are subject to scrutiny under this law. For example, pharmaceutical companies have
been prosecuted under the False Claims Act in connection with their off-label promotion of drugs. Penalties for a False Claims Act violation include three times the actual damages sustained by the government, plus mandatory civil penalties of
between $5,500 and $11,000 for each separate false claim, the potential for exclusion from participation in federal healthcare programs, and, although the federal False Claims Act is a civil statute, conduct that results in a False Claims Act
violation may also implicate various federal criminal statutes. If the government were to allege that we were, or convict us of, violating these false claims laws, we could be subject to a substantial fine and may suffer a decline in our stock
price. In addition, private individuals have the ability to bring actions under the False Claims Act and certain states have enacted laws modeled after the False Claims Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There are also an increasing number of state laws that require manufacturers to make reports to states on pricing and marketing information. Many of these
laws contain ambiguities as to what is required to comply with the laws. In addition, beginning in August 2013, a similar federal requirement requires manufacturers to track and report to the federal government certain payments made to physicians
and teaching hospitals made in the previous calendar year. These laws may affect our sales, marketing, and other promotional activities by imposing administrative and compliance burdens on us. In addition, given the lack of clarity with respect to
these laws and their implementation, our reporting actions could be subject to the penalty provisions of the pertinent state, and soon federal, authorities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><U>Other Regulations </U></I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are also subject to
numerous federal, state and local laws relating to such matters as safe working conditions, manufacturing practices, environmental protection, fire hazard control and disposal of hazardous or potentially hazardous substances. We may incur
significant costs to comply with such laws and regulations now or in the future. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>EU and EEA </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Marketing authorization in the EU for products containing viable human tissues or cells such as NeoCart is governed by Regulation 1394/2007/EC on advanced
therapy medicinal products, read in combination with Directive 2001/83/EC of the European parliament and of the Council, commonly known as the Community code on medicinal products. Regulation 1394/2007/EC establishes specific rules concerning the
authorization, supervision and pharmacovigilance of gene therapy medicinal products, somatic cell therapy medicinal products and tissue engineered products. Manufacturers of advanced therapy medicinal products must demonstrate the quality, safety
and efficacy of their products to the EMA which is required to provide an opinion regarding the application for marketing authorization. The European Commission grants or refuses marketing authorization in light of the opinion delivered by the EMA.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Applicants for marketing authorizations for medicinal products in the EEA are required to submit applications for
marketing authorization in a form that is based on the ICH Common Technical Document, and must demonstrate the safety, quality and efficacy of the medicinal product for which the marketing authorization is sought. The application must include the
results of pre-clinical tests and clinical trials conducted with the medicinal product. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The conduct of clinical trials in the EEA is governed by
Directive 2001/20/EC which imposes obligations and procedures that are similar to those provided in applicable U.S. laws. The EU Good Clinical Practice rules and EU Good Laboratory Practice obligations must also be respected during conduct of the
trials. Clinical trials must be approved by the competent regulatory authorities and the competent Ethics Committees in the EU Member States in which the clinical trials take place. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Moreover, applicants are required to provide evidence that studies have been conducted with the medicinal product in the pediatric population as provided by a
Pediatric Investigation Plan approved by the Pediatric Committee of the EMA. Alternatively, confirmation that the applicant has obtained a waiver or deferral for the conduct of these studies must be provided. Cell-based products must also comply
with Directive 2004/23/EC of the European Parliament and of the Council of March&nbsp;31, 2004 on setting standards of quality and safety for the donation, procurement, testing, processing, preservation, storage and distribution of human tissues and
cells (Tissues and Cells Directive). This Directive describes the conditions and quality requirements which must be applied when sourcing the cells intended for manufacturing of the cell-based medicinal product. The EU Member States have transposed
the Tissues and Cells Directive into their national laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Locally different interpretations of the Tissue and Cells Directive have occurred during
adoption of the national legal implementations by individual EU Member States. This has led to some inconsistency of approach leading to additional complexity in complying with the all-over requirements in this already difficult regulatory field.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Given the specific nature of cell-based products, the clinical development paths are less standardized than for classic pharmaceutical or biological
products. Phase 1 studies are often not relevant, in particular for autologous cell-based products, since cells often need to be directly implanted into a tissue defect only present in patients. As cellular therapy Phase 3 studies are very complex
to organize, often limited numbers of patients can be enrolled and follow up times can be very long, so that the design and execution of these large confirmatory trials might not always be possible to the classical extent. Upfront discussions and
agreement with the regulatory authorities are an important criterion to success. It is also expected that new regulatory guidance will become available in the near future, more clearly describing the regulatory expectations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Employees </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2016, we employed 47
full-time employees, including seven in research and development, nine in clinical development, 25 in manufacturing and quality control and assurance, and six in executive, general and administrative. We have never had a work stoppage, and none of
our employees is represented by a labor organization or under any collective bargaining arrangements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We were originally incorporated as a Massachusetts corporation in 2000. In 2006, we underwent a corporate reorganization pursuant to which we were incorporated
as a Delaware corporation. Our principal offices are located at 830 Winter Street, 3rd Floor, Waltham, Massachusetts 02451, and our telephone number is (781)&nbsp;547-7900. Our website address is www.histogenics.com. Our website and the information
contained on, or that can be accessed through, our website shall not be deemed to be incorporated by reference in, and are not considered part of, this annual report. You should not rely on any such information in making your decision whether to
purchase our common stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Available Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We file annual, quarterly, and current reports, proxy statements, and other documents with the Securities and Exchange Commission (SEC) under the Securities
Exchange Act of 1934, as amended (the Exchange Act). The public may read and copy any materials that we file with the SEC at the SEC&#146;s Public Reference Room at 100 F Street, NE, Washington, DC 20549. The public may obtain information on the
operation of the Public Reference Room by calling the SEC at 1-800-SEC-0330. Also, the SEC maintains an Internet website that contains reports, proxy and information statements, and other information regarding issuers, including us, that file
electronically with the SEC. The public can obtain any documents that we file with the SEC at www.sec.gov. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Copies of each of our filings with the SEC on
Form 10-K, Form 10-Q and Form 8-K and all amendments to those reports, can be viewed and downloaded free of charge at our website, www.histogenics.com as soon as reasonably practicable after the reports and amendments are electronically filed with
or furnished to the SEC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our code of ethics, other corporate policies and procedures, and the charters of our Audit Committee, Compensation Committee and
Nominating/Corporate Governance Committee are available through our website at www.histogenics.com. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B><A NAME="tx293850_4"></A>ITEM&nbsp;1A.</B></TD>
<TD ALIGN="left" VALIGN="top"><B></B><B><I>RISK FACTORS</I></B><B> </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Investing in our common stock involves risk. You should carefully
consider the risks described below as well as all the other information in this report, including the consolidated financial statements and the related notes appearing at the end of this annual report on Form 10-K, before making an investment
decision. The risks and uncertainties described below are not the only risks and uncertainties we face. Additional risks and uncertainties not presently known to us or that we currently deem immaterial also may impair our business operations. If any
of the following risks actually occur, our business, results of operations and financial condition could suffer. In that event the trading price of our common stock could decline, and you may lose all or part of your investment. The risks discussed
below also include forward-looking statements and our actual results may differ substantially from those discussed in these forward-looking statements. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Business and Commercialization of Our Product Candidates </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are a clinical-stage regenerative medicine company with a limited operating history of developing late-stage product candidates. There is a limited
amount of information about us upon which to evaluate our product candidates and business prospects, making an investment in our common stock unsuitable for many investors. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are a clinical-stage regenerative medicine company, formed in 2000, with a limited operating history. Since inception we have devoted substantially all of
our resources to the development of our regenerative medicine platform, the clinical and preclinical advancement of our product candidates, the creation, licensing and protection of related intellectual property rights and the provision of general
and administrative support for these operations. We have not yet obtained regulatory approval for any product candidates in any jurisdiction or generated any significant revenues from product sales. If NeoCart or any of our future product candidates
fails in clinical trials or preclinical development, or does not gain regulatory approval, or if our product candidates following regulatory approval, if any, do not achieve market acceptance, we may never become profitable or sustain profitability.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We commenced our first clinical trial in 2005, and we have a limited operating history developing clinical-stage regenerative medicine products upon
which you can evaluate our business and prospects. In addition, besides our current ongoing Phase 3 clinical trial we have never conducted clinical trials of a size required for regulatory approvals. Further, we have not yet demonstrated an ability
to successfully overcome many of the risks and uncertainties frequently encountered by companies in new and rapidly evolving fields, such as regenerative medicine. For example, to execute our current business plan we will need to successfully: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">execute our research and development strategies, including successfully enrolling and completing our clinical trial program for NeoCart; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">manufacture NeoCart and constituent products contained in NeoCart for our ongoing Phase 3 clinical trial of NeoCart; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">complete the transition of the NeoCart raw material manufacturing process to our in-house facilities and satisfy the United States Food and Drug Administration (the FDA) as to the comparability of such raw materials to
those manufactured by third parties for use in our NeoCart clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">secure additional funding as may be needed, including, without limitation, in order to complete our NeoCart Phase 3 clinical trial, and file a BLA with the FDA; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">obtain required regulatory approvals for the manufacturing and commercialization of NeoCart; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">manage our spending as costs and expenses increase due to clinical trials, regulatory approvals, manufacturing and commercialization; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">continue to build and maintain a strong intellectual property portfolio; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">recruit and retain qualified executive management and other personnel; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">build and maintain appropriate research and development, clinical, sales, manufacturing, financial reporting, distribution and marketing capabilities on our own or through third parties; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">expand potential indications of NeoCart and our regenerative medicine platform; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">gain broad market acceptance for our product candidates; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">develop and maintain successful strategic relationships. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we are unsuccessful in accomplishing any of these
objectives, we may not be able to develop product candidates, raise capital, expand our business or continue our operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we encounter
difficulties enrolling patients in our clinical trials, including our NeoCart Phase 3 clinical trial, our clinical development activities could be delayed or otherwise adversely affected. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are required to identify and enroll a sufficient number of patients that meet inclusion criteria under investigation for NeoCart. We will need to enroll the
remaining patients in a timely manner in order to complete the trial. There is a limited patient population from which to draw participants in clinical trials. Due to the need to find patients with few or no concomitant joint disease, we may not be
able to identify and enroll a sufficient number of patients, or those with required or desired characteristics and criteria, in a timely manner. In addition, there are a limited number of specialized orthopedic surgeons that perform cartilage repair
implantation procedures and among physicians who perform such procedures, some may not choose to perform these procedures under conditions that fall within our protocols, which would have an adverse effect on our development of NeoCart. For example,
in November 2015 we changed our guidance for the completion of patient enrollment in the NeoCart Phase 3 clinical trial from June 2016 to June 2017 based on enrollment trends in November 2015 not meeting our expectations. Our ability to enroll
patients in our clinical trials is affected by a number of factors including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the size and nature of the patient population; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the design of the trial protocol for our NeoCart Phase 3 clinical trial; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the eligibility and exclusion criteria for the trial in question; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the availability of competing therapies and competing clinical trials, and physician and patient perception of NeoCart and our other product candidates being studied in relation to these other potential options;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the efforts to facilitate timely enrollment in our NeoCart Phase 3 clinical trial; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the ability to identify, and recruit a sufficient number of patients; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the ability to obtain and maintain patient consent; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the number and location of clinical sites in our NeoCart Phase 3 clinical trial; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the proximity and availability of clinical trial sites for prospective patients; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the availability of time and resources at the institutions where clinical trials are and will be conducted; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the availability of raw materials and the possibility of raw materials expiring prior to their use; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the availability of adequate financing to fund ongoing clinical trial expenses; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the presence of concomitant joint disease in patients under investigation; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the study endpoints such as pain that rely on subjective patient reported outcomes. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we have difficulty
enrolling a sufficient number of patients to conduct our clinical trials as planned, we may need to delay or terminate ongoing or planned clinical trials, either of which would have an adverse effect on our business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A number of companies in the regenerative medicine industry have suffered significant setbacks or difficulty
enrolling patients in later stage clinical trials even after achieving promising results in earlier stages of development. Success in preclinical testing and early clinical trials does not ensure that later clinical trials will be successful, and
initial results from a clinical trial do not necessarily predict final results. Even if early stage clinical trials are successful, we may need to conduct additional clinical trials for product candidates in additional patient populations or under
different treatment conditions before we are able to seek approvals from the FDA and regulatory authorities outside the United States to market and sell these product candidates. Our failure to demonstrate the required characteristics to support
marketing approval for NeoCart and our product candidates in our current and future clinical trials would substantially harm our business and prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Failure to obtain, or any delay in obtaining, FDA approval regarding the comparability of critical NeoCart raw materials following our technology
transfer and manufacturing location transition may have an adverse effect on our business, operating results and prospects. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are in the process
of completing a technology transfer to transition the manufacturing of certain raw materials and components in the NeoCart supply chain from outsourced contract manufacturers to in-house manufacturing facilities. This technology transfer extends to
our source collagen and collagen honeycomb scaffold, as well as the three components of the CT3 bioadhesive&#151;methylated collagen, curing component and activated polyethylene glycol. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have also entered into a supply agreement with Collagen Solutions (UK) Limited (Collagen Solutions) pursuant to which we may oversee the manufacture of
additional collagen used in our manufacture of NeoCart. We currently do not anticipate using any collagen produced by Collagen Solutions during our NeoCart Phase 3 clinical trial, but anticipate needing additional supplies of collagen above those we
anticipate being able to produce in-house upon commercialization, if ever. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Although we do not anticipate changes to the raw materials, formulations or
properties, nor do we anticipate changes to the NeoCart manufacturing process or finished product specifications as a result of the transfer, we are required to demonstrate to the FDA that the raw materials manufactured in our facility, and which
may be manufactured under our direction in third party facilities (including, without limitation, facilities operated by Collagen Solutions) are comparable to the raw materials that were manufactured in the previous contract manufacturers&#146;
facilities. Demonstrating comparability requires evidence that the product is consistent with that produced for the clinical trial to assure that the technology transfer does not affect safety, identity, purity or efficacy during the expansion from
pilot scale to full scale production. For example, in April 2016, the FDA approved our submission which provided equivalence data for the collagen manufactured at our Lexington, Massachusetts facility, meaning that the collagen manufactured at such
facility will require no further additional data or actual patient equivalence studies. Similarly, in August 2016, the FDA notified us that it approved our collagen scaffold equivalence strategy, which we previously submitted in May 2016. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the future, the FDA may determine that such analytical data is not sufficient to prove comparability of the raw materials produced at our in-house
manufacturing sites, or the sites of third parties under our direction, to the raw materials sourced from external vendors for earlier clinical trial work, including the NeoCart Phase 3 clinical trial. If this is the case, the FDA may require that
we provide additional preclinical or clinical data to provide evidence to support the comparability of the raw materials. The size, scope, length and costs of any new or supplemental clinical trials that may be required by the FDA to provide such
data are not known at this time. Failure or delay in obtaining FDA approval of the comparability of our NeoCart raw materials or the FDA requiring us to provide clinical data may result in delays to our current projected timelines and could have an
adverse effect on our business, operating results and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, our manufacturing sites, or those of third party sites under our
direction, may not receive FDA approval to operate at all, resulting in delays while we implement improvements necessary to receive approval </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
which would lead to delays in the initiation of commercial production. In addition, we could encounter difficulties involving production yields, quality control and quality assurance, as well as
shortages of qualified personnel, leading to additional delays. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are heavily dependent on the success of our lead product candidate NeoCart,
which is still under development in a Phase 3 clinical trial. If we are unable to commercialize NeoCart in the future, or experience significant delays due to manufacturing or otherwise in doing so, our business will be materially harmed.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have invested a significant portion of our time and financial resources in the development of NeoCart, our product candidate in clinical
development. We anticipate that in the near term our ability to generate revenues will depend solely on the successful development and commercialization of NeoCart. We may not complete our registration filings in our anticipated time frame. Even
after we complete our Biologics License Application (BLA) filing, the FDA may not accept our submission, may request additional information from us, including data from additional clinical trials, and, ultimately, may not grant marketing approval
for NeoCart. In addition, the clinical data we have generated to date is susceptible to varying interpretations and many companies that have believed that their products performed satisfactorily in clinical trials have nonetheless failed to obtain
FDA approval for their products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we are not successful in commercializing NeoCart, or are significantly delayed in doing so, our business will be
materially harmed and we may need to curtail or cease operations. Our ability to successfully commercialize NeoCart will depend, among other things, on our ability to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">complete the enrollment, data analysis and BLA submission for our NeoCart Phase 3 clinical trial; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">successfully monitor patients during and after treatment and minimize the risk that enrolled subjects will drop out of the NeoCart Phase 3 clinical trial before they are evaluated for the primary endpoint;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">successfully complete and produce NeoCart implants for our clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">produce, through a validated process, NeoCart in quantities sufficiently large to permit successful commercialization; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">receive marketing approvals from the FDA and similar foreign regulatory authorities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">build a commercial infrastructure and launch commercial sales of NeoCart; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">maintain adequate capital resources to fund operations through commercialization; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">secure acceptance of NeoCart in the medical community and with third-party payors. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have incurred
significant losses since our inception and anticipate that we will continue to incur substantial losses for the next several years. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have
incurred net losses in each year since our inception, including net losses of $15.8 million in 2016 and $32.0 million in 2015. As of December&nbsp;31, 2016 and December&nbsp;31, 2015 we had an accumulated deficit of $181.8 million and $165.5
million, respectively. We expect to continue to incur substantial losses for the next several years, and we expect these losses to increase as we continue our development of and seek regulatory approval for, NeoCart and our future product
candidates. In addition, if we receive regulatory approval to market NeoCart or any of our future product candidates, we will incur additional losses as we scale our manufacturing operations and build an internal sales and marketing organization to
commercialize any approved products. In addition, we expect our expenditures to increase as we add infrastructure and personnel to support our expanding operations in connection with the commercialization of NeoCart, if approved. We anticipate that
our net losses and accumulated deficit for the next several years will be significant as we conduct our planned operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Because of the numerous risks
and uncertainties associated with regenerative medicine product development, we are unable to accurately predict the timing or amount of the development and clinical expenses or when, or if we </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
will be able to achieve, or maintain, profitability. In addition, our expenses could increase if we are required by the FDA or comparable foreign regulatory authorities to perform preclinical or
clinical studies or trials in addition to those currently expected, or if there are any delays in completing the technology transfer and manufacturing location transition of our NeoCart raw material manufacturing process or completing our clinical
trials or the development of NeoCart or our future product candidates. The amount of our future net losses will depend, in part, on the amount and timing of our expenses, our ability to generate revenue and our ability to raise additional capital.
These net losses have had, and will continue to have, an adverse effect on our stockholders&#146; equity and working capital. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We will require
substantial additional funding, which may not be available to us on acceptable terms, or at all, and, if not available, may require us to delay, reduce or cease our product development activities and operations. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are currently advancing our lead product candidate NeoCart through clinical development. Developing regenerative medicine products, including conducting
preclinical studies and clinical trials, is expensive. We will require substantial additional capital in order to file a BLA for NeoCart with the FDA, create additional manufacturing capacity for and to commercialize NeoCart and to conduct the
research and development and clinical and regulatory activities necessary to bring other product candidates to market. If the FDA or comparable foreign regulatory authorities require that we perform additional preclinical studies or clinical trials
at any point or expand or extend our current trials, our expenses would further increase beyond what we currently expect, and the anticipated timing of any future clinical development activities and potential regulatory approvals may be delayed
depending upon our allocation of resources and available funding. Raising funds currently or in the then-current economic environment may be difficult and additional funding may not be available on acceptable terms, or at all. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The global economic downturn and market instability has made the business climate more volatile and more costly. These economic conditions, and uncertainty as
to the general direction of the macroeconomic environment, are beyond our control and may make any necessary debt or equity financing more difficult, more costly, and more dilutive. Additional funds may not be available when we need them on terms
that are acceptable to us, or at all. If adequate funds are not available to us on a timely basis, or on acceptable terms, we may be required to delay, limit, reduce or terminate preclinical studies, clinical trials or other development activities
for one or more of our product candidates or delay, limit, reduce or terminate our establishment of sales and marketing capabilities or other activities that may be necessary to commercialize our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The amount and timing of our funding requirements will depend on many factors, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the scope, progress, expansion, costs and results of our NeoCart clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the scope, timing and costs of manufacturing NeoCart implants for use in our NeoCart clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the timing of and costs associated with obtaining FDA approval of the comparability of the NeoCart raw materials manufactured in our facilities, or in third party facilities at our direction, with the raw materials that
were manufactured by third parties for the use in our NeoCart clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the timing of and costs involved in obtaining NeoCart regulatory approvals; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">market acceptance of NeoCart following the receipt of regulatory approval, if any; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the resources we devote to marketing and commercializing NeoCart, if approved; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the scope, progress, expansion and costs of manufacturing NeoCart; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the costs of maintaining, expanding and protecting our intellectual property portfolio, including potential litigation costs and liabilities associated therewith; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our need to implement additional internal systems and infrastructure, including financial and reporting systems, related to our status as a public company and the potential commercialization of NeoCart, if approved.
</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Many of these factors are outside of our control. Based upon our currently expected level of operating
expenditures, we believe that we will be able to fund our operations and sustain currently projected cash needs into the middle of 2018. Our expectations are based on management&#146;s current assumptions and clinical development plans, which may
prove to be wrong, and we could spend our available financial resources much faster than we currently expect. This period could be shortened if there are any unanticipated increases in spending on development programs or other unanticipated
increases in spending related to circumstances outside of our control, including, without limitation, costs associated with litigation or other legal proceedings, hiring of additional consultants and personnel or procurement of additional raw
materials. Our existing cash and cash equivalents will not be sufficient to complete a BLA filing for NeoCart or complete any clinical development of any future product candidates that would be necessary to support an application for regulatory
approval. Accordingly, we will continue to require substantial additional capital. In order to fund our future needs, we may seek additional funding through equity or debt financings, development partnering arrangements, lines of credit or other
sources. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our fundraising efforts in the future to secure additional financing will divert our management from our day-to-day activities, which may
adversely affect our ability to develop and commercialize our product candidates. In addition, we cannot guarantee that future financing will be available in sufficient amounts or on terms acceptable to us, if at all. If we are unable to raise
additional capital when required or on acceptable terms, we may be required to significantly delay, reduce or discontinue the development or commercialization of one or more of our product candidates or curtail our operations, which will have an
adverse effect on our business, operating results and prospects. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>NeoCart and our future product candidates are subject to extensive regulation,
compliance with which is costly and time consuming, may cause unanticipated delays or prevent the receipt of the approvals required to commercialize NeoCart and our future product candidates. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The clinical development, manufacturing, labeling, storage, record-keeping, advertising, promotion, import, export, marketing and distribution of NeoCart and
our future product candidates are subject to extensive regulation by the FDA in the United States and by comparable authorities in foreign markets. In the United States, we are not permitted to market our product candidates until we receive
regulatory approval from the FDA. The process of obtaining regulatory approval is expensive, often takes many years, and can vary substantially based upon the type, complexity, and novelty of the products involved, as well as the target indications.
Approval policies or regulations may change and the FDA has substantial discretion in the tissue regeneration approval process, including the ability to delay, limit or deny approval of a product candidate for many reasons. Despite the time and
expense invested in clinical development of product candidates, regulatory approval is never guaranteed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The FDA or comparable foreign regulatory
authorities can delay, limit or deny approval of a product candidate for many reasons, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">such authorities may disagree with the design or implementation of our current NeoCart Phase 3 clinical trial or any of our future development partners&#146; clinical trials; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we or any of our future development partners may be unable to demonstrate to the satisfaction of the FDA or other regulatory authorities that a product candidate is safe and effective for any indication;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">such authorities may not accept clinical data from trials which are conducted at clinical facilities or in countries where the standard of care is potentially different from the United States; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the results of clinical trials may not demonstrate the safety or efficacy required by such authorities for approval; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we or any of our future development partners may be unable to demonstrate that a product candidate&#146;s clinical and other benefits outweigh its safety risks; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">such authorities may disagree with our interpretation of data from preclinical studies or clinical trials or the use of results from studies that served as precursors to our current or future product candidates;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">such authorities may find deficiencies in our manufacturing processes or facilities or those of third-party manufacturers with which we or any of our future development partners contract for clinical and commercial
supplies; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the approval policies or regulations of such authorities may significantly change in a manner rendering our or any of our future development partners&#146; clinical data insufficient for approval. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">With respect to foreign markets, approval procedures vary among countries and, in addition to the risks described above, can involve additional product
testing, administrative review periods, and agreements with pricing authorities. In addition, events raising questions about the safety of certain marketed pharmaceuticals or biologics may result in increased cautiousness by the FDA and comparable
foreign regulatory authorities in reviewing new tissue regeneration products based on safety, efficacy or other regulatory considerations and may result in significant delays in obtaining regulatory approvals. Any delay in obtaining, or inability to
obtain, applicable regulatory approvals would prevent us or any of our future development partners from commercializing our product candidates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We
are subject to a multitude of manufacturing risks, any of which could substantially increase our costs and limit supply of our products. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
process of manufacturing NeoCart is complex, highly regulated and subject to several risks, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The process of manufacturing NeoCart, including the use of autologous cells, is susceptible to product loss due to contamination, equipment failure or improper installation or operation of equipment, or surgeon or
laboratory technician error. Even minor deviations from normal manufacturing processes could result in lost NeoCart production runs, product defects and other supply disruptions. If microbial, viral or other contaminations are discovered in our
products or in the manufacturing process or facilities in which our products are made, such manufacturing facilities may need to be closed for an extended period of time to investigate and remedy the contamination. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The manufacturing facilities in which NeoCart is made could be adversely affected by equipment failures, labor shortages, natural disasters, power failures and numerous other factors. For instance, in 2012, we
voluntarily suspended manufacturing operations and paused enrollment of the NeoCart Phase 3 clinical trial upon discovery of discrepancies in the testing procedures used to assess one of the raw materials utilized in the manufacture of NeoCart
implants and we could be required in the future to suspend manufacturing due to circumstances out of our control. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We and our contract manufacturers must comply with the current Good Manufacturing Practices (cGMP) regulations
and guidelines promulgated by the FDA. We and our contract manufacturers may encounter difficulties in achieving quality control and quality assurance and may experience shortages in qualified personnel. We and our contract manufacturers are subject
to inspections by the FDA and comparable agencies in other jurisdictions to confirm compliance with applicable regulatory requirements. Any failure to follow cGMP or other regulatory requirements or delay, interruption or other issues that arise in
the manufacture, packaging, storage or shipping of our products as a result of a failure of our facilities or operations, or the facilities or operations of third parties, to comply with regulatory requirements or pass any regulatory authority
inspection could significantly impair our ability to develop and commercialize our products, including leading to significant delays in the availability of products for our clinical studies or the termination or hold on a clinical study, or the
delay or prevention of a filing or approval of marketing applications for our product candidates. Significant noncompliance could also result in the imposition of sanctions, including fines, injunctions,
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
civil penalties, failure of regulatory authorities to grant marketing approvals for our product candidates, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls
of products, operating restrictions and criminal prosecutions, any of which could damage our reputation. If we are not able to maintain regulatory compliance, we may not be permitted to market our products or may be subject to product recalls,
seizures, injunctions, or criminal prosecution. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Any adverse developments affecting manufacturing operations for our products may result in shipment delays, clinical enrollment delays, inventory shortages, lot failures, product withdrawals or recalls, or other
interruptions in the supply of our products. We may also have to take inventory write-offs and incur other charges and expenses for products that fail to meet specifications, undertake costly remediation efforts or seek more costly manufacturing
alternatives. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In order to manufacture NeoCart, we operate our own cGMP manufacturing facility in Waltham, Massachusetts for production of
NeoCart. In 2015, we completed a facility for our cGMP manufacturing in Lexington, Massachusetts which we plan to further build out to produce key NeoCart raw materials, including the CT3 components, source collagen and collagen scaffold. While we
own the manufacturing process, unforeseen issues or outside influences could impact potential supply. For example: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Our facility in Waltham may not meet FDA cGMP standards during the pre-approval inspection necessary for BLA approval, delaying BLA approval and resulting in added cost to mitigate issues identified during inspection.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Our Lexington, Massachusetts facility for production of key raw materials may not receive FDA approval to operate, resulting in delays while we implement improvements necessary to receive approval, leading to delays in
the initiation of commercial production. We met with the FDA in December 2014 to obtain preliminary feedback and general acceptance of our raw material transition strategy.&nbsp;In April 2016, the FDA approved our production of collagen and the use
of collagen in the current NeoCart phase 3 clinical trial and in August 2016, the FDA also approved our collagen scaffold equivalence strategy. Additionally, we have entered into a supply agreement with Collagen Solutions pursuant to which we will
oversee the manufacture of additional collagen used in our manufacture of NeoCart. Any raw materials manufactured or handled at facilities operated by Collagen Solutions will similarly need to be approved by the FDA for comparability, and the FDA
may delay approval of the new raw material source or require additional studies to show comparability. We currently do not anticipate using any collagen produced by Collagen Solutions during our Phase 3 clinical trial, but anticipate needing
additional supplies of collagen above those we anticipate being able to produce in-house upon commercialization, if ever. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The raw material to be produced at our facilities may not be comparable to the raw materials sourced from external vendors for earlier clinical trial work, including the ongoing NeoCart Phase 3 clinical trial, according
to our current projected timelines, and the FDA may delay approval of the new raw material source or require additional studies to show comparability. Such delays may impact enrollment of our NeoCart Phase 3 clinical trial and FDA approval, if
granted at all. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We may not achieve our anticipated production throughput targets, resulting in lower than anticipated capacity, limiting supply of our products, lowering revenue and increasing costs. We may not hit our production cost
target for a variety of reasons including increased raw material cost, underestimate of labor requirements, underestimate of capital requirement and other facility, personnel or materials issues that we have not anticipated. Increased costs will
adversely impact gross margin achieved by our products. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We may not be able to fund future expansions of additional clean rooms and associated equipment and validations to support NeoCart production, or the FDA may require additional data that may delay our ability to supply
anticipated market needs. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The FDA may not approve implementation of the multi-unit NeoCart reactor or approval may be delayed, which could result in capacity limitation and high unit costs, depending upon the length of the delay.
</TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>NeoCart or any future product candidate we or any of our future development partners advance into clinical trials may cause
unacceptable adverse events or have other properties that may delay or prevent its regulatory approval or limit its commercial potential. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unacceptable adverse events caused by NeoCart or any of our future product candidates that we advance into clinical trials could cause us or regulatory
authorities to interrupt, delay or halt clinical trials and could result in the denial of regulatory approval by the FDA or other regulatory authorities for any or all targeted indications and markets. This in turn could prevent us from completing
development or commercializing the affected product candidate and generating revenue from its sale. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have not yet completed clinical testing of any of
our product candidates for the treatment of the indications for which we intend to seek approval, and we currently do not know the extent of adverse events, if any, that will be observed in individuals who receive any of our product candidates. If
any of our product candidates cause unacceptable adverse events in clinical trials, we may not be able to obtain regulatory approval or commercialize such product candidate. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The results of preclinical studies and early clinical trials are not always predictive of future results. Any product candidate we or any of our future
development partners advance into clinical trials may not have favorable results in later clinical trials, if any, or receive regulatory approval. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Regenerative medicine product development has inherent risk. We or any of our future development partners will be required to demonstrate through adequate and
well-controlled clinical trials that our product candidates are effective, with a favorable benefit-risk profile, for use in their target indications before we can seek regulatory approvals for their commercial sale. Regenerative medicine product
development is a long, expensive and uncertain process, and delay or failure can occur at any stage of development, including after commencement of any of our clinical trials. In addition, success in early clinical trials does not mean that later
clinical trials will be successful because product candidates in later-stage clinical trials may fail to demonstrate sufficient safety or efficacy despite having progressed through initial clinical testing. Furthermore, our future trials will need
to demonstrate sufficient safety and efficacy for approval by regulatory authorities in larger patient populations. Companies frequently suffer significant setbacks in advanced clinical trials, even after earlier clinical trials have shown promising
results. In addition, only a small percentage of biologics under development result in the submission of a BLA to the FDA and even fewer are approved for commercialization. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Development of regenerative medicine products is inherently expensive and risky and may not be understood by or accepted in the marketplace, which could
adversely affect our future value. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The clinical development, commercialization and marketing of regenerative medicine products are at an
early-stage, substantially research-oriented, and financially speculative. To date, very few companies have been successful in their efforts to develop and commercialize regenerative medicine products. In general, regenerative medicine products may
be susceptible to various risks, including undesirable and unintended side effects, unintended immune system responses, inadequate therapeutic efficacy, potentially prohibitive costs or other characteristics that may prevent or limit their approval
or commercial use. Furthermore, the number of people who may use cell- or tissue-based regenerative medicine therapies is difficult to forecast with accuracy. Our future success is dependent on the establishment of a large global market for
regenerative medicine products and our ability to capture a share of this market with NeoCart and our future product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our development efforts
with our regenerative medicine platform are susceptible to the same risks of failure inherent in the development and commercialization of product candidates based on new technologies. The novel </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
nature of regenerative medicine products creates significant challenges in the areas of product development and optimization, manufacturing, government regulation, third-party reimbursement and
market acceptance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Even if we successfully develop and obtain regulatory approval for NeoCart and our future product candidates, the market may not
understand or accept them. NeoCart and our future product candidates represent novel treatments and are expected to compete with a number of surgical options and more conventional products and therapies manufactured and marketed by others, including
major pharmaceutical and biotechnology companies. The degree of market acceptance of any of our developed and potential product candidates will depend on a number of factors, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the clinical safety and effectiveness of NeoCart and our future product candidates and their perceived advantage over alternative treatment methods, if any; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the design of the trial protocol for our NeoCart Phase 3 clinical trial; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">adverse events involving NeoCart and our future product candidates or the products or product candidates of others; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the performance of competitive products in the market; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the cost of manufacturing our products, the selling price of our products, and the reimbursement policies of government and private third-party payors. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the healthcare community does not accept NeoCart or our future product candidates for any of the foregoing reasons, or for any other reason, it could
affect our sales, having an adverse effect on our business, financial condition and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have a limited manufacturing capacity
for NeoCart and our future product candidates, which could inhibit our revenues and the long-term growth prospects of our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We currently
produce materials for clinical trials, including production of NeoCart, at our existing manufacturing facilities in Waltham, Massachusetts, which we have designed and operated to be compliant with FDA, cGMP and the current Good Tissue Practice as
and if applicable, requirements. While we believe these facilities provide us with sufficient capacity to meet our expected clinical demand and possibly our initial commercial launch demand, it is possible that the demand for products could exceed
our existing manufacturing capacity. It will become necessary or desirable for us to expand our manufacturing capabilities for our regenerative medicine platform in the future, which may require us to invest significant amounts of capital and to
obtain regulatory approvals. If we are unable to meet rising demand for products on a timely basis or unable to maintain cGMP compliance standards, then it is likely that our clients and potential clients will elect to obtain the products from
competitors, which could materially and adversely affect the level of our revenues and our prospects for growth. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The current tissue engineering processor
(TEP) in our Waltham facility is resource dependent due to the single-unit capacity. We are developing a multi-unit NeoCart reactor design which we believe would alleviate the capacity restraints currently resulting from our single-unit processors.
We may begin implementation of a multi-reactor unit during the first year of product commercialization, thus providing adequate capacity to meet expected demand through the first two years of commercialization from our internal facilities. The FDA
may not, however, approve implementation of the multi-unit NeoCart reactor or approval may be delayed which could result in capacity limitation or high unit costs depending upon the length of the delay. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may not be able to fund future expansions of additional clean rooms and associated equipment and validations to support NeoCart production, or the FDA may
require additional data that may delay our ability to supply anticipated market needs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Components of regenerative medicine products approved for
commercial sale or used in late-stage clinical trials must be manufactured in accordance with cGMP. In addition, the manufacturing process of regenerative </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
medicine products may be required to be modified from time to time in response to FDA requests. Manufacture of cell- or tissue-based regenerative medicine products is complex and subjects
companies to significant regulatory burdens that may change over time. We may encounter difficulties in the production of our product candidates due to our limited manufacturing experience. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Significant developments arising from the United States presidential election or the U.K.s referendum on membership in the EU could have a material
adverse effect on us. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In January of 2017, a new presidential administration and Congress took power in the United States. The new president has
expressed antipathy towards existing trade agreements, like the North American Free Trade Agreement, greater restrictions on free trade generally and significant increases on tariffs on goods imported into the United States, particularly from China
and Mexico. Changes in United States social, political, regulatory and economic conditions or in laws and policies governing foreign trade, manufacturing, development and investment, and any negative sentiments towards the United States as a result
of such changes, could adversely affect our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, the new presidential administration and Congress have indicated that they will repeal
and replace the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act of 2010 (the ACA) and the president, in January of 2017, signed an executive order that mandated that all
executive agencies to the maximum extent of the law waive, defer, grant exemptions from, or delay implementation of any provision or requirement of the ACA. The provisions of the ACA became effective beginning in 2010, although the new presidential
administration and Congress is actively working to repeal it and replace it with a different health care law. While we cannot predict what impact on federal reimbursement policies this law or any replacement law will have in general or specifically
on any product we may commercialize in the future, the ACA or any replacement may result in downward pressure on reimbursement, which could negatively affect market acceptance of new products. Any rebates, discounts, taxes costs or regulatory or
systematic changes on healthcare resulting from the ACA or its replacement may have a significant effect on our profitability in the future. We cannot predict whether the ACA will continue or what other laws or proposals will be made or adopted, or
what impact these efforts may have on us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&nbsp;23, 2016, the United Kingdom held a referendum and voted in favor of leaving the European Union.
On February&nbsp;1, 2017, the United Kingdom parliament voted to allow the United Kingdom to exit the European Union by passing a bill that gives the prime minister of the United Kingdom the authority to invoke Article 50 of the Lisbon Treaty. This
referendum has created political and economic uncertainty, particularly in the United Kingdom and the European Union, and this uncertainty may last for years. There are many ways in which our business could be affected, only some of which we can
identify. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The referendum, and the likely withdrawal of the United Kingdom from the European it triggers, has caused and, along with events that could
occur in the future as a consequence of the United Kingdom&#146;s withdrawal, including the possible breakup of the United Kingdom, may continue to cause significant volatility in global financial markets, including in global currency and debt
markets. This volatility could cause a slowdown in economic activity in the United Kingdom, Europe or globally, which could adversely affect our operating results and growth prospects. In addition, our business could be negatively affected by new
trade agreements between the United Kingdom and other countries, including the United States, and by the possible imposition of trade or other regulatory barriers in the United Kingdom. These possible negative impacts, and others resulting from the
United Kingdom&#146;s actual or threatened withdrawal from the European Union, may adversely affect our operating results and growth prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Changes in government funding for the FDA and other government agencies could hinder their ability to hire and retain key leadership and other
personnel, properly administer drug innovation, or prevent new products </I></B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>
and services from being developed or commercialized by our life science tenants, which could negatively impact our business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The ability of the FDA to review and approve new products can be affected by a variety of factors, including budget and funding levels, ability to hire and
retain key personnel, and statutory, regulatory, and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research and development
activities is subject to the political process, which is inherently fluid and unpredictable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The ability of the FDA and other government agencies to
properly administer their functions is highly dependent on the levels of government funding and the ability to fill key leadership appointments, among various factors. Currently, the FDA Commissioner position is vacant, pending the appointment of a
new Commissioner by the new presidential administration. The confirmation process for a new commissioner may not occur efficiently. Delays in filling or replacing key positions could significantly impact the ability of the FDA and other agencies to
fulfill their functions and could greatly impact healthcare and the biologics industry. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In December 2016, the 21<SUP
STYLE="font-size:85%; vertical-align:top">st</SUP> Century Cures Act was signed into law. This new legislation is designed to advance medical innovation and empower the FDA with the authority to directly hire positions related to drug and device
development and review. In the past, the FDA was often unable to offer key leadership candidates (including scientists) competitive compensation packages as compared to those offered by private industry. The 21<SUP
STYLE="font-size:85%; vertical-align:top">st</SUP> Century Cures Act is designed to streamline the agency&#146;s hiring process and enable the FDA to compete for leadership talent by expanding the narrow ranges that are provided in the existing
compensation structures. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the first week of the new presidential administration, it issued executive orders to freeze government hiring of new
employees with the exception of military, national security and public safety personnel. This hiring freeze could impede current or future operations at the FDA and other agencies. It is unknown at this time what the impact of the hiring freeze will
have on the FDA and on programs such as the 21<SUP STYLE="font-size:85%; vertical-align:top">st</SUP> Century Cures Act. Furthermore, future government proposals to reduce or eliminate budgetary deficits may include reduced allocations to the FDA
and other related government agencies. These budgetary pressures may result in a reduced ability by the FDA to perform their respective roles; including the related impact to academic institutions and research laboratories whose funding is fully or
partially dependent on both the level and timing of funding from government sources. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Disruptions at the FDA and other agencies may also slow the time
necessary for new drugs, biologics and devices to be reviewed and/or approved by necessary government agencies and the healthcare and drug industries&#146; ability to deliver new products to the market in a timely manner, which would adversely
affect our tenants&#146; operating results and business. Interruptions to the function of the FDA and other government agencies could adversely affect the demand for office/laboratory space and significantly impact our operating results and our
business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If our competitors develop treatments for the target indications of NeoCart or our future product candidates that are approved more
quickly, marketed more successfully or demonstrated to be safer or more effective than our product candidates, our commercial opportunity will be reduced or eliminated. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The regenerative medicine industry is intensely competitive and subject to rapid and significant technological change. We face competition from major
multinational companies, established and early-stage biotechnology companies, and universities and other research institutions. Many of our competitors have greater financial and other resources, such as larger research and development staff and
more experienced marketing and manufacturing organizations. Large pharmaceutical companies, in particular, have extensive experience in clinical testing, obtaining regulatory approvals, recruiting patients and manufacturing products. These companies
also have significantly greater research, sales and marketing capabilities and collaborative arrangements in our target markets with leading companies and research institutions. Established companies may also invest heavily to accelerate discovery
and development of novel therapeutics or to in-license novel therapeutics that could make </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the product candidates that we develop obsolete. As a result of all of these factors, our competitors may succeed in obtaining patent protection or FDA approval or discovering, developing and
commercializing treatments in the regenerative medicine indications that we are targeting before we do. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large,
established companies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There are several clinical-stage development programs in various stages of development that seek to regenerate soft tissue and
repair cartilage. Our competitors may succeed in developing, acquiring or licensing on an exclusive basis, technologies and products that are more effective, including a one-step alternative to NeoCart, or less costly than NeoCart or any future
product candidates that we may develop, which could render our products obsolete and noncompetitive. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe that our ability to successfully compete
will depend on, among other things: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the results of our and our collaborative partners&#146; preclinical studies and clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the relative prices and perceived value of competitive products as compared to NeoCart; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to recruit and enroll patients for our clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the relative efficacy, safety, ease of use, reliability and durability of our product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the speed at which we and our competitors develop our respective product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to design and successfully execute appropriate clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to manufacture raw materials for use in our clinical trials, including our Phase&nbsp;3 clinical trial of NeoCart; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to protect and develop intellectual property rights related to our products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to maintain a good relationship with regulatory authorities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the timing and scope of regulatory approvals, if any; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to commercialize and market any of our product candidates that receive regulatory approval; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">market perception and acceptance of regenerative medicine products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">acceptance of our product candidates by physicians, patients and institutions; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the cost to manufacture and price of our products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">adequate levels of reimbursement under private and governmental health insurance plans, including Medicare; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to manufacture and sell commercial quantities of any approved products to the market. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If our
competitors market products that are more effective, safer or less expensive than our future products or that reach the market sooner than our future products, we may not achieve commercial success. In addition, poor market reception to the recently
launched MACI product by a competitor could negatively impact the future launch of NeoCart. Any inability to compete effectively will adversely impact our business and financial prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we are not successful in discovering, developing, acquiring and commercializing additional product candidates, our ability to expand our business
will be limited. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A substantial amount of our effort is focused on the continued clinical testing and potential approval of NeoCart and our future
product candidates and expanding our product candidates to serve other indications of high unmet medical needs. Research programs to identify other indications require substantial technical, financial and human resources, whether or not any product
candidates for other indications are ultimately identified. Our research programs may initially show promise in identifying potential product candidates, yet fail to yield product candidates for clinical development for many reasons, including the
following: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">48 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the research methodology used may not be successful in identifying potential product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">competitors may develop alternatives that render our product candidates obsolete or less attractive; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">product candidates we develop may nevertheless be covered by third parties&#146; patents or other exclusive rights; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a product candidate may on further study be shown to have harmful side effects or other characteristics that indicate it is unlikely to be effective or otherwise does not meet applicable regulatory criteria;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a product candidate may not be capable of being produced in commercial quantities at an acceptable cost, or at all; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a product candidate may not be accepted as safe and effective by patients, the medical community or third-party payors, if applicable. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we do not successfully develop and commercialize product candidates for other indications, our business and future prospects may be limited and our
business will be more vulnerable to problems that we encounter in developing and commercializing our current product candidates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may fail to
comply with any of our obligations under existing agreements pursuant to which we license rights or technology, which could result in the loss of rights or technology that are material to our business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are a party to technology licenses that are important to our business and we may enter into additional licenses in the future. We currently hold material
licenses from Purpose Co., Ltd., Angiotech Pharmaceuticals (US), Inc., Angiodevice International GmbH, the Board of Trustees of The Leland Stanford Junior University, Koken Co., Ltd., Intrexon and Advanced BioMatrix, Inc. The rights licensed under
these agreements, including rights relating to our scaffolds, tissue processor, bioadhesives and growth factors, are material to our regenerative medicine platform and the continued development of NeoCart and our future product candidates. These
licenses impose various commercial, contingent payment, royalty, insurance, indemnification and other obligations on us. If we fail to comply with these obligations, the licensor may have the right to terminate the license, in which event we would
lose valuable rights under our license agreements and our ability to develop or commercialize product candidates. Any termination or reversion of our rights to under the foregoing agreements may have a material adverse effect on our business,
prospects and results of operations. Our Exclusive Channel Collaboration Agreement (the ECC) with Intrexon Corporation (Intrexon) provides that Intrexon may terminate such agreement if we do not perform certain specified requirements, including
developing therapies considered demonstrably superior to existing therapies and those under development by us. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The technologies on which our
channel partnering agreement with Intrexon is based are currently in preclinical and clinical stages of development. The intellectual property of Intrexon underlying the ECC may be subject to infringement or other challenges, similar to those we
face, as set forth elsewhere in these risk factors. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our ECC with Intrexon that provides for the worldwide exclusive use of Intrexon&#146;s
proprietary synthetic biology technology platform for the development and commercialization of allogeneic genetically modified chondrocyte cell therapeutics for the treatment or repair of damaged articular hyaline cartilage in humans. Such
technologies have a limited history of use in the design and development of human therapeutic product candidates and may therefore involve unanticipated risks or delays. We cannot assure that any product candidates developed from this collaboration
will result in nonclinical results sufficient to warrant the advancement of such product candidates into human clinical trials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the extent the
intellectual property protection of any of the assets owned or licensed by Intrexon utilized under our ECC with Intrexon are successfully challenged or encounter problems, including, without limitation, restrictions on freedom to operate, with the
United States Patent and Trademark Office or other comparable agencies throughout the world, the future development or commercialization, if any, of these potential products </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">49 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
could be delayed or prevented. Any challenge to the intellectual property protection of intellectual property owned or licensed by Intrexon of a potential development asset arising from our ECC
with Intrexon could harm our business have an adverse effect on our financial condition and results of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We will incur additional
expenses in connection with our exclusive channel collaboration arrangement with Intrexon. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to our ECC with Intrexon, we are responsible
for future research and development expenses of product candidates developed under each such collaboration, the effect of which may increase the level of our overall research and development expenses going forward. We have incurred $3.0 million and
$3.1 million for the years ended December&nbsp;31, 2016 and 2015, respectively, in connection with our collaboration with Intrexon. In addition, because development activities are determined pursuant to a joint steering committee comprised of
representatives of Intrexon and us, future development costs associated this program may be difficult to anticipate and may exceed our expectations. Our actual cash requirements may vary materially from our current expectations for a number of other
factors that may include, but are not limited to, unanticipated technical challenges, changes in the focus and direction of our development activities or adjustments necessitated by changes in the competitive landscape in which we operate. If we are
unable to continue to financially support such collaborations due to our own working capital constraints, we may be forced to delay our activities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may experience delays in commencing or conducting our clinical trials or in receiving data from third parties or in the completion of clinical
testing, which could result in increased costs to us and delay our ability to generate product candidate revenue. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Before we can initiate clinical
trials in the United States for our product candidates, we need to submit the results of preclinical testing to the FDA as part of an IND application, along with other information including information about product candidate chemistry,
manufacturing and controls and our proposed clinical trial protocol. We may rely in part on preclinical, clinical and quality data generated by contract research organization and other third parties for regulatory submissions for our product
candidates. If these third parties do not make timely regulatory submissions for our product candidates, it will delay our plans for our clinical trials. If those third parties do not make this data available to us, we will likely have to develop
all necessary preclinical and clinical data on our own, which will lead to significant delays and increase development costs of the product candidate. In addition, the FDA may require us to conduct additional preclinical testing for any product
candidate before it allows us to initiate clinical testing under any IND application, which may lead to additional delays and increase the costs of our preclinical development. Despite the presence of an active IND application for a product
candidate, clinical trials can be delayed for a variety of reasons including delays in: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">identifying, recruiting and training suitable clinical investigators; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reaching agreement on acceptable terms with prospective contract research organizations and trial sites, the terms of which can be subject to extensive negotiation, may be subject to modification from time to time, and
may vary significantly among different contract research organizations and trial sites; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">manufacturing and obtaining sufficient quantities of a product candidate for use in clinical trials, including as a result of transferring the manufacturing of a product candidate to another site or manufacturer or the
procurement of critical raw materials required for manufacturing a product candidate; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">obtaining and maintaining institutional review board or ethics committee approval to conduct a clinical trial at an existing or prospective site; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">identifying, recruiting and enrolling subjects to participate in a clinical trial; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">retaining or replacing participants who have initiated a clinical trial but may withdraw due to adverse events from the therapy, insufficient efficacy, fatigue with the clinical trial process, or personal issues.
</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">50 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The FDA may also put a clinical trial on clinical hold at any time during product candidate development. In
addition, we may voluntarily pause a clinical trial for a variety of reasons. For instance, in 2012 we voluntarily suspended manufacturing operations and paused enrollment of the NeoCart Phase 3 clinical trial upon discovery of discrepancies in the
testing procedures used to assess one of the raw materials utilized in the manufacture of NeoCart implants and we could be required in the future to suspend manufacturing due to circumstances out of our control. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Once a clinical trial has begun, it may also be delayed as a result of ambiguous or negative interim results. Further, a clinical trial may be suspended or
terminated by us, an institutional review board, an ethics committee or a data safety monitoring committee overseeing the clinical trial, any of our clinical trial sites with respect to that site or the FDA or other regulatory authorities due to a
number of factors, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">inspection of the clinical trial operations or clinical trial site by the FDA or other regulatory authorities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">unforeseen safety issues, known safety issues that occur at a greater frequency or severity than we anticipate, or any determination that the clinical trial presents unacceptable health risks; or </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">lack of adequate funding to continue the clinical trial. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any delays in the commencement of our clinical
trials will delay our ability to pursue regulatory approval for our product candidates. Changes in U.S. and foreign regulatory requirements and guidance also may occur and we may need to amend clinical trial protocols to reflect these changes.
Amendments may require us to resubmit our clinical trial protocols to institutional review boards for re-examination, which may affect the costs, timing and likelihood of a successful completion of a clinical trial. If we or any of our future
development partners experience delays in the completion of, or if we or any of our future development partners must terminate, any clinical trial of any product candidate our ability to obtain regulatory approval for that product candidate will be
delayed and the commercial prospects, if any, for the product candidate may suffer as a result. In addition, many of these factors may also ultimately lead to the denial of regulatory approval of a product candidate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Regulatory authorities, including the FDA, PMDA and the European Medicines Agency, may disagree with our interpretations of data from pre-clinical studies and
clinical trials. Regulatory authorities also may approve a product for narrower indications than requested or may grant approval subject to the performance of post-marketing studies for a product. There can be no guarantee that such post-approval
studies, if required, will corroborate the results of earlier trials. Furthermore, the market use of such products may show different safety and efficacy profiles to those demonstrated in the trials on which marketing approval was based. Such
circumstances could lead to the withdrawal or suspension of marketing approval for the product, which could have a material adverse effect on our business, financial condition, operating results or cash flows. In addition, regulatory authorities may
not approve or agree with the labeling claims that are necessary or desirable for the successful commercialization of our products. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If NeoCart or
any future product candidate that we successfully develop does not achieve broad market acceptance among physicians, patients, healthcare payors and the medical community, the revenue that it generates may be limited. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Even if NeoCart or our future product candidates receive regulatory approval, they may not gain market acceptance among physicians, patients, healthcare payors
and the medical community. Coverage and reimbursement of our product candidates by third-party payors, including government payors, generally is also necessary for commercial success. The degree of market acceptance of any approved product
candidates will depend on a number of factors, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the efficacy and safety as demonstrated in clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the clinical indications for which our product candidate is approved; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">51 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">acceptance by physicians, major operators of hospitals and clinics and patients of our product candidate as a safe and effective treatment; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the number of alternative treatments on the market and the potential and perceived advantages of our product candidates over such alternative treatments; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the safety of product candidates seen in a broader patient group, including their use outside the approved indications; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the cost of treatment in relation to alternative treatments; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the availability of adequate reimbursement and pricing by third parties and government authorities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">relative convenience and ease of administration; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the prevalence and severity of adverse events; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the effectiveness of our sales and marketing efforts; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">unfavorable publicity relating to the product candidate or regenerative medicine products, in general. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If any
product candidate is approved but does not achieve an adequate level of acceptance by physicians, hospitals, healthcare payors and patients, we may not generate sufficient revenue from that product candidate and may not become or remain profitable.
Ethical, social and legal concerns about regenerative medicine products could result in additional regulations restricting or prohibiting the use of our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, if any of our competitors&#146; products are approved and are unable to gain market acceptance for any reason, there could be a market
perception that products like NeoCart are not able to adequately meet an unmet medical need. If we are unable to demonstrate to physicians, hospitals, healthcare payors and patients that our products are better alternatives, we may not be able to
gain market acceptance for our products at the levels we anticipate and our business may be materially harmed as a result. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Insurance coverage and
reimbursement may be limited or unavailable in certain market segments for our product candidates, which could make it difficult for us to sell our product candidates profitably. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Market acceptance and sales of NeoCart and our future product candidates will depend significantly on the availability of adequate insurance coverage and
reimbursement from third-party payors for any of our product candidates and may be affected by existing and future health care reform measures. Government authorities and third-party payors, such as private health insurers and health maintenance
organizations, decide which medical treatments they will pay for and establish reimbursement levels. Reimbursement by a third-party payor may depend upon a number of factors including the third-party payor&#146;s determination that use of a product
candidate is: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a covered benefit under its health plan; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">safe, effective and medically necessary; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">appropriate for the specific patient; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">cost effective; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">neither experimental nor investigational. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Obtaining coverage and reimbursement approval for a product
candidate from a government or other third-party payor is a time-consuming and costly process that could require us to provide supporting scientific, clinical and cost effectiveness data for the use of our product candidates to the payor. We may not
be able to provide data sufficient to gain acceptance with respect to coverage and reimbursement. We cannot be sure that coverage or adequate reimbursement will be available for any of our product candidates. Also, we cannot be sure that
reimbursement amounts will not reduce the demand for, or the price of, NeoCart or our future product candidates. If reimbursement is not available or is available only to limited levels, we may not be able to commercialize certain of our product
candidates profitably, or at all, even if approved. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">52 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the United States and certain foreign jurisdictions, there have been a number of legislative and regulatory
changes to health care systems that could affect our ability to sell our product candidates profitably. In particular, in 2003 the Medicare Modernization Act revised the payment methods for many product candidates under Medicare. This has resulted
in lower rates of reimbursement. There have been numerous other federal and state initiatives designed to reduce payment for products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a result of
legislative proposals and the trend toward managed health care in the United States, third-party payors are increasingly attempting to contain healthcare costs by limiting both coverage and the level of reimbursement of new tissue regenerative
medicine products. They may also refuse to provide coverage of approved product candidates for medical indications other than those for which the FDA has granted market approvals. As a result, significant uncertainty exists as to whether and how
much third-party payors will reimburse patients for their use of newly approved regenerative medicine products, which in turn will put pressure on the pricing of such products. We expect to experience pricing pressures in connection with the sale of
our product candidates due to the trend toward managed health care, the increasing influence of health maintenance organizations, and additional legislative proposals as well as country, regional, or local healthcare budget limitations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, reimbursement agencies in foreign jurisdictions may be more conservative than those in the United States. Accordingly, in markets outside the
United States, the reimbursement for our products may be more limited than in the United States and may be insufficient to generate commercially reasonable revenues and profits. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Failure to obtain or maintain adequate reimbursement for any products for which we receive marketing approval will adversely impact our ability to achieve
commercial success. See also the risk factor entitled &#147;Significant developments arising from the United States presidential election or the U.K.s referendum on membership in the EU could have a material adverse effect on us&#148; located
elsewhere in these risk factors for further risks associated with reimbursement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may face product liability claims and, if successful claims are
brought against us, we may incur substantial liability and costs. If the use of our product candidates harms patients, or is perceived to harm patients even when such harm is unrelated to our product candidates, our regulatory approvals could be
revoked or otherwise negatively impacted and we could be subject to costly and damaging product liability claims. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The use of NeoCart and our
future product candidates in clinical trials and the sale of any products for which we obtain marketing approval exposes us to the risk of product liability claims. Product liability claims might be brought against us by participants in clinical
trials, consumers, healthcare providers, pharmaceutical companies or others selling or otherwise coming into contact with our product candidates and any products for which we obtain marketing approval. There is a risk that our product candidates may
induce adverse events, and that such adverse events may not be detected for a long period of time. If we cannot successfully defend against product liability claims, we could incur substantial liability and costs. In addition, regardless of merit or
eventual outcome, product liability claims may result in: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">impairment of our business reputation; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">withdrawal of clinical trial participants; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">termination of clinical trial sites or entire trial programs; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">increased costs due to related litigation; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">distraction of management&#146;s attention from our primary business; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">substantial monetary awards to patients or other claimants; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the inability to commercialize our product candidates; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">decreased demand for our product candidates, if approved for commercial sale. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">53 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We carry product liability insurance that we believe is sufficient in light of our current clinical programs;
however, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability. If and when we obtain marketing approval for product candidates, we intend to expand our
insurance coverage to include the sale of commercial products; however, we may be unable to obtain product liability insurance on commercially reasonable terms or in adequate amounts. On occasion, large judgments have been awarded in class action
lawsuits based on regenerative medicine products or medical treatments that had unanticipated adverse effects. In addition, under some of our agreements with clinical trial sites, we are required to indemnify the sites and their personnel against
product liability and other claims. A successful product liability claim or series of claims brought against us or any third parties whom we are required to indemnify could cause our stock price to decline and, if judgments exceed our insurance
coverage, could adversely affect our results of operations and business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the course of treatment, patients may suffer adverse events for reasons
that may be related to our product candidates. Such events could subject us to costly litigation, require us to pay substantial amounts of money to injured patients, delay, negatively impact or end our opportunity to receive or maintain regulatory
approval to market our products, or require us to suspend or abandon our commercialization efforts. Even in a circumstance in which we do not believe that an adverse event is related to our products, the investigation into the circumstance may be
time-consuming or inconclusive. These investigations may interrupt our development and commercialization efforts, delay our regulatory approval process, or impact and limit the type of regulatory approvals our product candidates receive or maintain.
As a result of these factors, a product liability claim, even if successfully defended, could have a material adverse effect on our business, financial condition or results of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We do not carry insurance for all categories of risk that our business may encounter and we may not be able to maintain insurance with adequate levels of
coverage. Any significant uninsured liability may require us to pay substantial amounts, which would adversely affect our financial position and results of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we are unable to establish sales and marketing capabilities or fail to enter into agreements with third parties to market and sell any product
candidates we may successfully develop, we may not be able to effectively market and sell any such product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have no experience
selling and marketing any products. We do not currently have any infrastructure for the sale, marketing and distribution of any of our product candidates once approved, if at all, and we must build this infrastructure in order to commercialize any
product candidates for which we may obtain approval in the United States or make arrangements with third parties to perform these functions for us outside of the United States. To successfully commercialize any products that may result from our
development programs, we will need to develop these capabilities, either on our own or with others. The establishment and development of a sales force, either by us or jointly with a development partner, or the establishment of a contract sales
force to market any product candidates we may develop will be expensive and time consuming and could delay any commercial launch. If we or any of our future development partners are unable to establish sales and marketing capabilities or any other
nontechnical capabilities necessary to commercialize any product candidates we may successfully develop, we will need to contract with third parties to market and sell such product candidates. We may not be able to establish arrangements with third
parties on acceptable terms, if at all. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Legislative or regulatory healthcare reforms in the United States and abroad may make it more difficult and
costly for us to obtain regulatory approval of our product candidates and to produce, market and distribute our products after approval is obtained. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">From time to time, legislation is drafted and introduced in Congress that could significantly change the statutory provisions governing the regulatory
approval, manufacture and marketing of regulated products or the reimbursement thereof. In addition, FDA regulations and guidance are often revised or reinterpreted by the FDA in ways that may significantly affect our business and our products. Any
new regulations or revisions or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">54 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
reinterpretations of existing regulations may impose additional costs or lengthen review times of NeoCart or any future product candidates. We cannot determine what effect changes in regulations,
statutes, legal interpretation or policies, when and if promulgated, enacted or adopted may have on our business in the future. Such changes could, among other things, require: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">changes to manufacturing methods; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">additional studies, including clinical studies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">recall, replacement, or discontinuance of one or more of our products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the payment of additional taxes; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">additional record keeping. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each of these requirements would likely entail substantial time and cost and could
adversely harm our business and our financial results. In addition, delays in receipt of or failure to receive regulatory approvals for any future products would harm our business, financial condition and results of operations. We intend to seek
approval to market our product candidates in both the United States and in foreign jurisdictions. If we obtain approval in one or more foreign jurisdictions, we will be subject to rules and regulations in those jurisdictions relating to such product
candidate. If reimbursement of our future products is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, we may be unable to achieve or sustain profitability. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We currently rely on third parties in order to perform certain aspects of our business, including to support certain aspects of our clinical trials and
to supply the NeoCart tissue engineering processor. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize our product
candidates and our business could be substantially harmed. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have relied upon and plan to continue to rely upon third parties to monitor and
manage data for our ongoing clinical programs. We rely on these parties for execution of our clinical trials, and control only certain aspects of their activities. Nevertheless, we are responsible for ensuring that each of our studies is conducted
in accordance with the applicable protocol and legal, regulatory and scientific standards, and our reliance on third parties does not relieve us of our regulatory responsibilities. We also rely on third parties to assist in conducting our
nonclinical studies in accordance with good laboratory practices. We and our third-party service providers are required to comply with good clinical practices, which are regulations and guidelines enforced by the FDA, as well as comparable foreign
regulations and guidelines, for all of our product candidates in clinical development. Regulatory authorities enforce these good clinical practices through periodic inspections of trial sponsors, principal investigators and trial sites. If we or any
of our third-party service providers or clinical trial sites fail to comply with applicable good clinical practices, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities
may require us to perform additional clinical trials before approving our marketing applications. We cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials
comply with good clinical practices requirements. In addition, our clinical trials must be conducted with product produced under applicable good manufacturing practices requirements. Failure to comply with these regulations may require us to repeat
nonclinical and clinical trials, which would delay the regulatory approval process. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our third-party service providers are not our employees, and except
for remedies available to us under our agreements with such third parties, we cannot control whether or not they devote sufficient time and resources to our on-going clinical and nonclinical programs. If third-party service providers do not
successfully carry out their contractual duties or obligations or meet expected deadlines or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols, regulatory requirements
or for other reasons, our clinical trials may be extended, delayed or terminated and we may not be able to obtain regulatory approval for or successfully commercialize our product candidates. As a result, our results of operations and the commercial
prospects for our product candidates would be harmed, our costs could increase and our ability to generate revenues could be delayed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">55 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Because we have relied on third parties, our internal capacity to perform these functions is limited. Outsourcing
these functions involves risk that third parties may not perform to our standards, may not produce results in a timely manner or may fail to perform at all. In addition, the use of third-party service providers requires us to disclose our
proprietary information to these parties, which could increase the risk that this information will be misappropriated. We currently have a small number of employees, which limits the internal resources we have available to identify and monitor our
third-party service providers. To the extent we are unable to identify and successfully manage the performance of third-party service providers in the future, our business may be adversely affected. Although we carefully manage our relationships
with our third-party service providers, there can be no assurance that we will not encounter similar challenges or delays in the future or that these delays or challenges will not have a material adverse impact on our business, financial condition
and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are also dependent on third-party suppliers, most of which are sole source suppliers of the components used to manufacture our TEP. If
these third-party suppliers do not supply sufficient quantities to us on a timely basis and in accordance with applicable specifications and other regulatory requirements, there could be a significant interruption of our ability to supply, which
would adversely affect clinical development or commercial production of the product candidate. Furthermore, if any of these third parties cannot successfully supply TEPs that we require for our production that conforms to our specifications and with
regulatory requirements, we will not be able to meet demand, for our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We do not expect to have the resources or capacity to
commercially manufacture TEPs required to manufacture our proposed product candidates if approved, and will likely continue to be dependent on third-party suppliers. Our dependence on third parties to manufacture and supply us with these TEPs may
adversely affect our ability to develop and commercialize our product candidates on a timely basis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have also entered into a supply agreement with
Collagen Solutions pursuant to which we may oversee the manufacture of additional collagen used in our manufacture of NeoCart. We currently do not anticipate using any collagen produced by Collagen Solutions during our Phase 3 clinical trial, but
anticipate needing additional supplies of collagen above those we anticipate being able to produce in-house upon commercialization, if ever. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may
not be successful in establishing and maintaining development or other strategic partnerships, which could adversely affect our ability to develop and commercialize product candidates. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As part of our strategy, we intend to enter into development or other strategic partnerships in the future, including collaborations with major biotechnology
or pharmaceutical companies. We face significant competition in seeking appropriate partners and the negotiation process is time consuming and complex. Moreover, we may not be successful in our efforts to establish a development partnership or other
alternative arrangements for any of our other existing or future product candidates and programs because our research and development pipeline may be insufficient, our product candidates and programs may be deemed to be at too early a stage of
development for collaborative effort or third parties may not view our product candidates and programs as having the requisite potential to demonstrate safety and efficacy. Even if we are successful in our efforts to establish development
partnerships, the terms that we agree upon may not be favorable to us and we may not be able to maintain such development partnerships if, for example, development or approval of a product candidate is delayed or sales of an approved product
candidate are disappointing. Any delay in entering into development partnership agreements related to our product candidates could delay the development and commercialization of our product candidates and reduce their competitiveness if they reach
the market. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Moreover, if we fail to establish and maintain development or other strategic partnerships related to our product candidates: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the development of certain of our current or future product candidates may be terminated or delayed; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our cash expenditures related to development of certain of our current or future product candidates would increase significantly and we may need to seek additional financing; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">56 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we may be required to hire additional employees or otherwise develop expertise, such as sales and marketing expertise, for which we have not budgeted; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we will bear all of the risk related to the development of any such product candidates. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We will need to
expand our operations and increase the size of our company and we may experience difficulties in managing any such growth. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As we continue to
advance NeoCart towards potential commercialization, increase the number of ongoing product development programs and advance our future product candidates through preclinical studies and clinical trials, we will need to expand our development,
regulatory, manufacturing, marketing and sales capabilities and, in some cases, collaborate and contract with third parties to provide these capabilities for us. Our management, personnel and systems currently in place may not be adequate to support
this future growth. Our need to effectively manage our operations, growth and various projects requires that we: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">successfully attract and recruit new employees or consultants with the requisite expertise and experience; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">manage our preclinical and clinical programs effectively; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">develop a marketing and sales infrastructure if we receive regulatory approval for any product candidate; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">continue to improve our operational, financial and management controls, reporting systems and procedures, including those related to being a public company; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">construct, validate and effectively operate new and expanded manufacturing facilities. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we are unable to
successfully manage this growth and increased complexity of operations, our business may be adversely affected. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we fail to attract and keep
senior management and key scientific personnel, the future development and commercialization of our product candidates may suffer, harming future regulatory approvals, sales of our product candidates or our results of operations. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are highly dependent on members of our management and scientific teams, including Adam Gridley, our Chief Executive Officer and President; Jonathan Lieber,
our Chief Financial Officer; Gloria Matthews, DVM, Ph.D., DACVS, our Chief Medical Officer; and Stephen Kennedy, our Chief Technology Officer. The loss of the services of any of these persons could impede the achievement of our research, development
and commercialization objectives. We do not maintain &#147;key person&#148; insurance for any of our executives or other employees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Recruiting and
retaining qualified scientific, clinical, manufacturing, sales and marketing personnel will also be critical to our success. We may not be able to attract and retain these personnel on acceptable terms given the competition among numerous
pharmaceutical and biotechnology companies for similar personnel. We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions. In addition, we rely on consultants and advisors,
including scientific and clinical advisors, to assist us in formulating our research and development and commercialization strategy. Our consultants and advisors may be employed by employers other than us and may have commitments under consulting or
advisory contracts with other entities that may limit their availability to us. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may not be able to manage our business effectively if we are
unable to attract and retain key personnel and consultants. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Given the specialized nature of regenerative cell therapy and that it is a relatively
new field, there is an inherent scarcity of experienced personnel in the field. We may not be able to attract or retain qualified management (including a new chief executive officer), finance, scientific and clinical personnel and consultants due to
the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">57 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
intense competition for qualified personnel and consultants among biotechnology, pharmaceutical and other businesses. If we are not able to attract and retain necessary personnel and consultants
to accomplish our business objectives, we may experience constraints that will significantly impede the achievement of our development objectives, our ability to raise additional capital and our ability to implement our business strategy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our industry has experienced high turnover of management personnel in recent years. We are highly dependent on the development, regulatory, commercialization
and business development expertise of our senior management team. The loss of Mr.&nbsp;Gridley or one or more additional executive officers or key employees, could seriously harm our ability to implement our business strategy successfully. While we
have entered into employment contracts with each of our executive officers, any of them could leave our employment at any time, as all of our employees are at-will employees. Replacing key personnel and consultants may be difficult and may take an
extended period of time because of the limited number of individuals in our industry with the breadth of skills and experience required to develop, gain regulatory approval of and commercialize products successfully. Competition to hire and retain
employees and consultants from this limited pool is intense, and we may be unable to hire, train, retain or motivate these additional key personnel and consultants. Our failure to retain key personnel or consultants could materially harm our
business, and the transition to any replacement personnel, particularly at the chief executive officer position, may cause or result in: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">speculation and uncertainty about our business and future direction; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">distraction of our employees and management; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">difficulty in recruiting, hiring, motivating and retaining talented and skilled personnel; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">volatility in our stock price; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">difficulty in negotiating, maintaining or consummating business or strategic relationships or transactions. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We rely on our scientific and clinical advisors and consultants to assist us in formulating our research, development and clinical strategies. These advisors
and consultants are not our employees and may have commitments to, or consulting or advisory contracts with, other entities that may limit their availability to us. In addition, these advisors and consultants typically will not enter into
non-compete agreements with us. If a conflict of interest arises between their work for us and their work for another entity, we may lose their services. Furthermore, our advisors may have arrangements with other companies to assist them in
developing products or technologies that may compete with ours. If we are unable to maintain consulting relationships with our key advisors or consultants or if they provide services to our competitors, our development and commercialization efforts
will be impaired, and our business will be significantly harmed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Failure to build our finance infrastructure and improve our accounting systems and
controls could impair our ability to comply with the financial reporting and internal control requirements for publicly traded companies. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a
public company, we operate in an increasingly demanding regulatory environment, which requires us to comply with the Sarbanes-Oxley Act and the related rules and regulations of the SEC, expanded disclosure requirements, accelerated reporting
requirements and more complex accounting rules. Company responsibilities required by the Sarbanes-Oxley Act include establishing corporate oversight and adequate internal control over financial reporting and disclosure controls and procedures.
Effective internal controls are necessary for us to produce reliable financial reports and are important to help prevent financial fraud. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to
Section&nbsp;404 of the Sarbanes-Oxley Act and related rules, our management will be required to report upon the effectiveness of our internal control over financial reporting when we are no longer a &#147;smaller reporting company&#148; or an
&#147;emerging growth company,&#148; each as defined under the Exchange Act. When and if we are a &#147;large accelerated filer&#148; or an &#147;accelerated filer&#148; and are no longer an &#147;emerging growth company,&#148; each as defined in
the Exchange Act, our independent registered public accounting firm will be required to attest to the effectiveness of our internal control over financial reporting. However, for so long as we remain an emerging
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">58 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
growth company, we intend to take advantage of certain exemptions from various reporting requirements that are applicable to public companies that are not emerging growth companies, including not
being required to comply with the auditor attestation requirements of Section&nbsp;404 for a period of no more than five years. Once we are no longer an emerging growth company or, if prior to such date, we opt to no longer take advantage of the
applicable exemption, we will be required to include an opinion from our independent registered public accounting firm on the effectiveness of our internal control over financial reporting. The rules governing the standards that must be met for
management to assess our internal control over financial reporting are complex and require significant documentation, testing, and possible remediation. To comply with the requirements of being a reporting company under the Exchange Act, we need to:
upgrade our systems, including information technology; implement additional financial and management controls, reporting systems and procedures; and hire additional accounting and finance staff. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are also subject to complex tax laws, regulations, accounting principles and interpretations thereof. The preparation of our financial statements requires
us to interpret accounting principles and guidance and make estimates and judgments that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well
as the reported revenue generated and expenses incurred during the reporting periods. Our interpretations, estimates and judgments are based on our historical experience and on various other factors that we believe are reasonable under the
circumstances, the results of which form the basis for the preparation of our financial statements. U.S. generally accepted accounting principles presentation is subject to interpretation by the SEC, the Financial Accounting Standards Board and
various other bodies formed to interpret and create appropriate accounting principles and guidance. In the event that one of these bodies disagrees with our accounting recognition, measurement or disclosure or any of our accounting interpretations,
estimates or assumptions, it may have a significant effect on our reported results and may retroactively affect previously reported results. The need to restate our financial results could, among other potential adverse effects, result in us
incurring substantial costs, affect our ability to timely file our periodic reports until such restatement is completed, divert the attention of our management and employees from managing our business, result in material changes to our historical
and future financial results, result in investors losing confidence in our operating results, subject us to securities class action litigation, and cause our stock price to decline. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may identify material weaknesses in the future that may cause us to fail to meet our reporting obligations or result in material misstatements of our
financial statements. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our management team is responsible for establishing and maintaining adequate internal control over financial reporting.
Internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements in accordance with U.S. generally accepted accounting
principles. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of annual or interim financial statements will
not be prevented or detected on a timely basis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We cannot assure you that we will not have material weaknesses or significant deficiencies in our
internal control over financial reporting. If we identify any material weaknesses or significant deficiencies that may exist, the accuracy and timing of our financial reporting may be adversely affected, we may be unable to maintain compliance with
securities law requirements regarding timely filing of periodic reports in addition to applicable stock exchange listing requirements, and our stock price may decline materially as a result. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we engage in an acquisition, reorganization or business combination, we will incur a variety of risks that could adversely affect our business
operations or our stockholders. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">From time to time we have considered, and we will continue to consider in the future, strategic business
initiatives intended to further the expansion and development of our business. These initiatives may include acquiring businesses, technologies or products or entering into a business combination with another company.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">59 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
For instance, in 2011, we acquired ProChon Biotech Ltd. Although we intend to evaluate and consider acquisitions, reorganizations and business combinations in the future, we have no agreements or
understandings with respect to any acquisition, reorganization or business combination at this time. Any acquisitions we undertake, including our prior acquisition of ProChon Biotech Ltd., will likely be accompanied by business risks which may
include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the effect of the acquisition on our financial and strategic position and reputation; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the need to reprioritize our development programs and even cease development and commercialization of our product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the failure of an acquisition to result in expected benefits, which may include benefits relating to enhanced revenues, technology, human resources, costs savings, operating efficiencies, goodwill and other synergies;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the difficulty, cost and management effort required to integrate the acquired businesses, including costs and delays in implementing common systems and procedures and costs and delays caused by communication
difficulties; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the assumption of certain known or unknown liabilities of the acquired business, including litigation-related liabilities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the reduction of our cash available for operations and other uses, the increase in amortization expense related to identifiable assets acquired, potentially dilutive issuances of equity securities or the incurrence of
debt; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a lack of experience in new markets, new business culture, products or technologies or an initial dependence on unfamiliar distribution partners; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the possibility that we will pay more than the value we derive from the acquisition; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the impairment of relationships with customers, partners or suppliers of the acquired business; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the potential loss of key employees of the acquired company. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These factors could harm our business, results
of operations or financial condition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to the risks commonly encountered in the acquisition of a business or assets as described above, we may
also experience risks relating to the challenges and costs of evaluating or closing a transaction, including distraction of our management team from normal business operations. The risks described above may be exacerbated as a result of managing
multiple acquisitions at once. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our ability to utilize our net operating loss carryforwards and certain other tax attributes may be limited.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have incurred substantial losses during our history and do not expect to become profitable in the foreseeable future and may never achieve
profitability. To the extent that we continue to generate taxable losses, unused losses will carry forward to offset future taxable income, if any, until such unused losses expire. We may be unable to use these losses to offset income before such
unused losses expire. Under Sections&nbsp;382 and 383 of the Internal Revenue Code (Code), utilization of net operating losses and research and development credit carryforwards may be subject to a substantial annual limitation due to ownership
change limitations that have occurred or that could occur in the future. In general, an &#147;ownership change&#148; as defined by Section 382 of the Code results from a transaction or series of transactions over a three year period resulting in an
ownership change of more than 50 percentage points of the outstanding stock of a company by certain stockholders. We have in the past experienced ownership changes that have resulted in limitations on the use of a portion of our net operating loss
carryforwards. We have completed a study to assess whether an ownership change has occurred or whether there have been multiple ownership changes since our formation. The results of this study indicated we experienced ownership changes, as defined
by Section&nbsp;382 of the Code, in each of 2006, 2011, 2012, 2013 and 2016. If we experience further ownership changes, our ability to utilize our net operating loss carryforwards could be further limited. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">60 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our internal computer systems, or those of our development partners, third-party clinical research
organizations or other contractors or consultants, may fail or suffer security breaches, which could result in a material disruption of our product development programs. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Despite the implementation of security measures, our internal computer systems and those of our development partners, third-party clinical research
organizations and other contractors and consultants are vulnerable to damage from computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. While we have not experienced any such system
failure, accident or security breach to date, if such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our programs. For example, the loss of clinical trial data for any of our product
candidates could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach results in a loss of or damage to our data or
applications or other data or applications relating to our technology or product candidates, or inappropriate disclosure of confidential or proprietary information, we could incur liabilities and the further development of our product candidates
could be delayed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We use hazardous chemicals and biological materials in our business. Any claims relating to improper handling, storage or
disposal of these materials could be time consuming and costly. We may incur significant costs complying with environmental laws and regulations. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our research and development and manufacturing processes involve the controlled use of hazardous materials, including chemicals and biological materials. Our
operations produce hazardous waste products. We cannot eliminate the risk of accidental contamination or discharge and any resultant injury from these materials. We may be sued for any injury or contamination that results from our use or the use by
third parties of these materials, and our liability may exceed our insurance coverage and our total assets. Federal, state and local laws and regulations govern the use, manufacture, storage, handling and disposal of these hazardous materials and
specified waste products, as well as the discharge of pollutants into the environment and human health and safety matters. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Compliance with environmental
laws and regulations may be expensive and may impair our research, development and production efforts. If we fail to comply with these requirements, we could incur substantial costs, including civil or criminal fines and penalties, clean-up costs or
capital expenditures for control equipment or operational changes necessary to achieve and maintain compliance. In addition, we cannot predict the impact on our business of new or amended environmental laws or regulations or any changes in the way
existing and future laws and regulations are interpreted and enforced. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our employees may engage in misconduct or other improper activities,
including noncompliance with regulatory standards and requirements and insider trading. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are exposed to the risk of employee fraud or other
misconduct. Misconduct by employees could include intentional failures to comply with the regulations of the FDA or foreign regulators, failure to provide accurate information to regulatory authorities, failure to comply with manufacturing standards
we have established, failure to comply with federal and state health care fraud and abuse laws and regulations in the United States and abroad, failure to report financial information or data accurately or disclose unauthorized activities to us. In
particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations
may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Employee misconduct could also involve the improper use of information obtained in
the course of clinical trials, which could result in regulatory sanctions and cause harm to our reputation. We have adopted a code of business conduct and ethics, but it is not always possible to identify and deter employee misconduct, and the
precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with
these laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">61 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
asserting our rights, those actions could have a significant impact on our business, including the imposition of significant fines or other sanctions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, during the course of our operations our directors, executives and employees may have access to material, nonpublic information regarding our
business, our results of operations or potential transactions we are considering. We may not be able to prevent a director, executive or employee from trading in our common stock on the basis of, or while having access to, material, nonpublic
information. If a director, executive or employee was to be investigated or an action was to be brought against a director, executive or employee for insider trading, it could have a negative impact on our reputation and our stock price. Such a
claim, with or without merit, could also result in substantial expenditures of time and money and divert attention of our management team from other tasks important to the success of our business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Costs associated with being a public reporting company are significant, and public reporting requirements divert significant company resources and
management attention. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are subject to the reporting requirements of the Exchange Act and the other rules and regulations of the SEC. We are
working with our legal, independent accounting and financial advisors to identify those areas in which changes should be made to our financial and management control systems to manage our growth and our obligations as a public reporting company
including preparing for the commercialization of NeoCart, if approved. These areas include corporate governance, corporate control, disclosure controls and procedures, and financial reporting and accounting systems. We have made, and will continue
to make, changes in these and other areas. Compliance with the various reporting and other requirements applicable to public reporting companies will require considerable time, attention of management and financial resources. In addition, the
changes we make may not be sufficient to allow us to satisfy our obligations as a public reporting company on a timely basis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further, the listing
requirements of NASDAQ require that we satisfy certain corporate governance requirements relating to director independence, distributing annual and interim reports, stockholder meetings, approvals and voting, soliciting proxies, conflicts of
interest and a code of conduct. Our management and other personnel will need to devote a substantial amount of time to ensure that we comply with all of these requirements. Moreover, the reporting requirements, rules and regulations will increase
our legal and financial compliance costs and will make some activities more time-consuming and costly. These reporting requirements, rules and regulations, coupled with the increase in potential litigation exposure associated with being a public
company, could also make it more difficult for us to attract and retain qualified persons to serve as our directors or executive officers, or to obtain certain types of insurance, including directors&#146; and officers&#146; insurance, on acceptable
terms. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our business is subject to the risks of earthquakes, fire, power outages, floods and other catastrophic events, and to interruption by
manmade problems such as terrorism. If any of our manufacturing, processing or storage facilities are damaged or destroyed, our business and prospects would be adversely affected. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A significant natural disaster, such as an earthquake, fire or flood, or a significant power outage, could have a material adverse impact on our business,
operating results and financial condition. If any of our manufacturing, processing or storage facilities, or any of the equipment in such facilities were to be damaged or destroyed, this would force us to delay or halt our clinical trial or
commercial production processes. We currently produce materials for our clinical trials at our manufacturing facilities located in Waltham, Massachusetts. If these facilities or the equipment in them are significantly damaged or destroyed, we may
not be able to quickly or inexpensively replace our manufacturing capacity. In addition, natural disasters could affect our third-party service providers&#146; and manufacturers ability to perform services and provide materials for us on a timely
basis. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, our efforts to obtain regulatory approvals for, and to commercialize, our product candidates may be delayed or prevented. For example,
if a central laboratory holding all of our clinical product supply were to suffer a catastrophic loss of their facility, we would be required to delay our clinical trials. In addition, acts of terrorism could cause
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">62 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
disruptions in our business or the business of our third-party service providers, partners, customers or the economy as a whole. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our loan and security agreement contains operating covenants and restrictions that may restrict our business and financing activities. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are party to a loan and security agreement with Silicon Valley Bank, which provides for a line of credit of up to $1.75 million in the aggregate to finance
certain equipment purchases. Borrowings under this agreement are secured by a first priority lien over all equipment purchased using the line of credit. This agreement restricts our ability to, among other things: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">sell assets; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">engage in any business other than our current business; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">merge or consolidate with other entities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">incur additional indebtedness; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">create liens on our assets; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">make investments; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">pay or declare dividends, or, in certain cases, repurchase our stock; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">enter into transactions with affiliates; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">make any payment on subordinated indebtedness. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The operating covenants and restrictions in the loan and
security agreement, as well as covenants and restrictions in any future financing agreements that we may enter into, may restrict our ability to finance our operations, engage in business activities or expand or fully pursue our business strategies.
Our ability to comply with these covenants may be affected by events beyond our control, and we may not be able to meet those covenants. A breach of any of these covenants could result in a default under the loan and security agreement or any future
financing agreement, which could cause all of the outstanding indebtedness under the facility to become immediately due and payable and terminate all commitments to extend further credit. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We cannot assure you that we will continue to maintain sufficient cash reserves or that our business will ever generate cash flow from operations at levels
sufficient to permit us to pay principal, premium, if any, and interest on our indebtedness, or that our cash needs will not increase. If we are unable to generate sufficient cash flow or otherwise obtain funds necessary to make required payments,
or if we fail to comply with the various requirements of our loan and security agreement with Silicon Valley Bank, or any indebtedness which we may incur in the future, we would be in default under our agreement with Silicon Valley Bank or other
indebtedness we may incur in the future. Any default under our agreement with Silicon Valley Bank, or any indebtedness that we may incur in the future, could have a material adverse effect on our business, results of operations and financial
condition. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are increasingly dependent on information technology systems, infrastructure and data. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are increasingly dependent upon information technology systems, infrastructure and data. Our computer systems may be vulnerable to service interruption or
destruction, malicious intrusion and random attack. Security breaches pose a risk that sensitive data, including intellectual property, clinical data, trade secrets or personal information may be exposed to unauthorized persons or to the public.
Cyber-attacks are increasing in their frequency, sophistication and intensity, and have become increasingly difficult to detect. Cyber-attacks could include the deployment of harmful malware, denial-of service, social engineering and other means to
affect service reliability and threaten data confidentiality, integrity and availability. Our key business partners face similar risks, and a security breach of their systems could adversely affect our security posture. While we
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">63 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
continue to invest data protection and information technology, there can be no assurance that our efforts will prevent service interruptions, or identify breaches in our systems, that could
adversely affect our business and operations and/or result in the loss of critical or sensitive information, which could result in financial, legal, business or reputational harm. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Regulatory Approval </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we fail to
complete clinical trials and obtain regulatory approval for NeoCart, our business would be significantly harmed. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have not completed clinical
development for any of our product candidates and will only obtain regulatory approval to commercialize a product candidate if we can demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities in well-designed and
conducted clinical trials that the product candidate is safe, effective, and otherwise meets the appropriate standards required for approval for a particular class of products or indication. Clinical trials are lengthy, complex and extremely
expensive processes with uncertain results. A failure of one or more clinical trials may occur at any stage. Of the large number of products in development, only a small percentage successfully complete the FDA regulatory approval process and are
commercialized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have never obtained marketing approval from the FDA or any comparable foreign regulatory authority for any product candidate. Our
ability to obtain regulatory approval of our product candidates depends on, among other things, whether our clinical trials demonstrate statistically significant efficacy with safety issues that do not potentially outweigh the therapeutic benefit of
the product candidates, and whether the regulatory agencies agree that the data from our future clinical trials is sufficient to support approval for any of our product candidates. The final results of our current and future clinical trials may not
meet the FDA&#146;s or other regulatory agencies&#146; requirements to approve a product candidate for marketing, and the regulatory agencies may otherwise determine that our manufacturing processes or facilities are insufficient to support
approval. We may need to conduct more clinical trials than we currently anticipate. Even if we do receive FDA or other regulatory agency approval, we may not be successful in commercializing approved product candidates. If any of these events occur,
our business could be materially harmed and the value of our common stock would likely decline. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our clinical development of NeoCart could be
substantially delayed if the FDA requires us to conduct additional studies or trials or imposes other requirements or restrictions. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will need
to generate and provide the FDA with comparability data from our new raw material production for the collagen critical raw materials used in our manufacturing process and intended for clinical use. The FDA may also require us to generate additional
preclinical or clinical data to support the use of these new critical raw material suppliers in our NeoCart trial. Additionally, the FDA may impose other requirements on the protocol for our NeoCart trial. These additional requirements may cause
further delays in our NeoCart trial which could require us to incur additional development costs, seek funding for these increased costs or delay or cease our clinical development activities for NeoCart. Any inability to advance NeoCart or any other
product candidate through clinical development would have a material adverse effect on our business. For example, the recently enacted Food and Drug Administration Safety and Innovation Act made permanent the Pediatric Research Equity Act, which
requires a sponsor to conduct pediatric studies for most tissue regeneration products for a new active ingredient, new indication, new dosage form, new dosing regimen or new route of administration. Under the Pediatric Research Equity Act, original
NDAs and BLAs and supplements thereto must contain a pediatric assessment unless the sponsor has received a deferral or waiver. The required assessment must evaluate the safety and effectiveness of the product for the claimed indications in all
relevant pediatric subpopulations and support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The sponsor or FDA may request a deferral of pediatric studies for some or all of the pediatric
subpopulations, and it is likely that we will request such a deferral. A deferral may be granted for several reasons, including a finding that the tissue regeneration products is ready for approval for use in adults before pediatric studies are
complete or that additional safety or effectiveness data needs to be collected before the pediatric studies begin. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">64 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
The FDA must send a non-compliance letter to any sponsor that fails to submit the required assessment, keep a deferral current or fails to submit a request for approval of a pediatric
formulation. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are subject to numerous U.S. federal and state laws pertaining to health care fraud and abuse, including anti-kickback,
self-referral, false claims and fraud laws, and any violation by us of such laws could result in fines or other penalties. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If one or more of our
product candidates is approved, we will be subject to U.S. federal and state laws intended to prevent health care fraud and abuse. The federal anti-kickback statute prohibits the offer, receipt, or payment of remuneration in exchange for or to
induce the referral of patients or the use of products or services that would be paid for in whole or part by Medicare, Medicaid or other federal health care programs. Remuneration has been broadly defined to include anything of value, including
cash, improper discounts, and free or reduced price items and services. Many states have similar laws that apply to their state health care programs as well as private payors. Violations of the anti-kickback laws can result in exclusion from federal
health care programs and substantial civil and criminal penalties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The False Claims Act imposes liability on persons who, among other things, present or
cause to be presented false or fraudulent claims for payment by a federal health care program. The False Claims Act has been used to prosecute persons submitting claims for payment that are inaccurate or fraudulent, that are for services not
provided as claimed, or for services that are not medically necessary. The False Claims Act includes a whistleblower provision that allows individuals to bring actions on behalf of the federal government and share a portion of the recovery of
successful claims. If our marketing or other arrangements were determined to violate the False Claims Act or anti-kickback or related laws, then our revenue could be adversely affected, which would likely harm our business, financial condition and
results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">State and federal authorities have aggressively targeted medical technology companies for alleged violations of these anti-fraud
statutes, based on improper research or consulting contracts with doctors, certain marketing arrangements that rely on volume-based pricing, off-label marketing schemes and other improper promotional practices. Companies targeted in such
prosecutions have paid substantial fines in the hundreds of millions of dollars or more, have been forced to implement extensive corrective action plans or Corporate Integrity </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Agreements, and have often become subject to consent decrees severely restricting the manner in which they conduct their business. If we become the target of
such an investigation or prosecution based on our contractual relationships with providers or institutions, or our marketing and promotional practices, we could face similar sanctions, which would materially harm our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Foreign Corrupt Practices Act and similar worldwide anti-bribery laws generally prohibit companies and their intermediaries from making improper payments
to non-U.S. officials for the purpose of obtaining or retaining business. We cannot assure you that our internal control policies and procedures will protect us from reckless or negligent acts committed by our employees, future distributors,
partners, collaborators or agents. Violations of these laws, or allegations of such violations, could result in fines, penalties or prosecution and have a negative impact on our business, results of operations and reputation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Also, the Physician Payment Sunshine Act imposes new reporting and disclosure requirements on drug, device, biologic and medical supply manufacturers for any
&#147;transfer of value&#148; made or distributed to prescribers and other healthcare providers. In addition, device and drug manufacturers will also be required to report and disclose any investment interests held by physicians and their immediate
family members during the preceding calendar year. Failure to submit required information may result in significant civil monetary penalties. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our
failure to comply with extensive governmental regulation may significantly affect our operating results. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Even if we obtain regulatory approval for
some or all of our product candidates, we will continue to be subject to extensive ongoing requirements by the FDA, as well as by a number of foreign, national, state and local agencies. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">65 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These regulations will impact many aspects of our operations, including testing, research and development,
manufacturing, safety, efficacy, labeling, storage, quality control, adverse event reporting, import and export, record keeping, approval, distribution, advertising and promotion of our future products. We must also submit new or supplemental
applications and obtain FDA approval for certain changes to an approved product, product labeling or manufacturing process. Application holders must also submit advertising and other promotional material to the FDA and report on ongoing clinical
trials. The FDA enforces post-marketing regulatory requirements, including cGMP requirements, through periodic unannounced inspections. We do not know whether we will pass any future FDA inspections. Failure to pass an inspection could disrupt,
delay or shut down our manufacturing operations. Failure to comply with applicable regulatory requirements could, among other things, result in: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">administrative or judicial enforcement actions; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">changes to advertising; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">failure to obtain marketing approvals for our product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">revocation or suspension of regulatory approvals of products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">product seizures or recalls; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">court-ordered injunctions; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">import detentions; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">delay, interruption or suspension of product manufacturing, distribution, marketing and sales; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">civil or criminal sanctions. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The discovery of previously unknown problems with our product candidates or
future products may result in restrictions of the products, including withdrawal from the market. In addition, the FDA may revisit and change its prior determinations with regard to the safety or efficacy of our future products. If the FDA&#146;s
position changes, we may be required to change our labeling or cease to manufacture and market our future products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Even prior to any formal regulatory
action, we could voluntarily decide to cease the distribution and sale or recall any of our future products if concerns about their safety or efficacy develop. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In their regulation of advertising and other promotion, the FDA and the U.S. Federal Trade Commission may issue correspondence alleging that some advertising
or promotional practices are false, misleading or deceptive. The FDA and the U.S. Federal Trade Commission are authorized to impose a wide array of sanctions on companies for such advertising and promotion practices, which could result in any of the
following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our incurrence of substantial expenses, including fines, penalties, legal fees and costs to comply with the FDA&#146;s requirements; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our being required to change in the methods of marketing and selling products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our being required to take FDA mandated corrective action, which may include placing advertisements or sending letters to physicians rescinding previous advertisements or promotions; or </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a disruption in the distribution of products and loss of sales until compliance with the FDA&#146;s position is obtained. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Improper promotional activities may also lead to investigations by federal or state prosecutors, and result in criminal and civil penalties. If we become
subject to any of the above requirements, it could be damaging to our reputation and restrict our ability to sell or market our future products, and our business condition could be adversely affected. We may also incur significant expenses in
defending ourselves. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Physicians may prescribe pharmaceutical or biologic products for uses that are not described in a product&#146;s labeling or differ
from those tested by us and approved by the FDA. While such &#147;off-label&#148; uses are common and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">66 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the FDA does not regulate physicians&#146; choice of treatments, the FDA does restrict a manufacturer&#146;s communications on the subject of off-label use. Companies cannot promote FDA-approved
pharmaceutical or biologic products for off-label uses, but under certain limited circumstances they may disseminate to practitioners&#146; articles published in peer-reviewed journals. To the extent allowed by the FDA, we intend to disseminate
peer-reviewed articles on our future products to practitioners. If, however, our activities fail to comply with the FDA&#146;s regulations or guidelines, we may be subject to warnings from, or enforcement action by, the FDA or other regulatory or
law enforcement authorities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Depending on the circumstances, failure to meet post-approval requirements can result in criminal prosecution, fines or
other penalties, injunctions, recall or seizure of products, total or partial suspension of production, denial or withdrawal of pre-marketing product approvals, or refusal to allow us to enter into supply contracts, including government contracts.
Any government investigation of alleged violations of law could require us to expend significant time and resources in response, and could generate negative publicity. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Even if we obtain regulatory approval for a product candidate, our products will remain subject to regulatory scrutiny. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any product candidate for which we obtain marketing approval, along with the manufacturing processes, qualification testing, post-approval clinical data,
labeling and promotional activities for such product, will be subject to continuing and additional requirements of the FDA and other regulatory authorities. These requirements include submissions of safety and other post-marketing information,
reports, registration and listing requirements, cGMP requirements relating to quality control, quality assurance and corresponding maintenance of records and documents, and recordkeeping. Even if marketing approval of a product candidate is granted,
the approval may be subject to limitations on the indicated uses for which the product may be marketed or to conditions of approval, or contain requirements for costly post-marketing testing and surveillance to monitor the safety or efficacy of the
product. The FDA closely regulates the post-approval marketing and promotion of pharmaceutical and biological products to ensure such products are marketed only for the approved indications and in accordance with the provisions of the approved
labeling. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, later discovery of previously unknown problems with our products, manufacturing processes, or failure to comply with regulatory
requirements, may lead to various adverse results, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">restrictions on such products, manufacturers or manufacturing processes; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">restrictions on the labeling or marketing of a product; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">restrictions on product distribution or use; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">requirements to conduct post-marketing clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">requirements to institute a risk evaluation and mitigation strategy to monitor safety of the product post-approval; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">warning letters issued by the FDA or other regulatory authorities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">withdrawal of the products from the market; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">refusal to approve pending applications or supplements to approved applications that we submit; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">recalls of products, fines, restitution or disgorgement of profits or revenue; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">suspension, revocation or withdrawal of marketing approvals; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">refusal to permit the import or export of our products; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">injunctions or the imposition of civil or criminal penalties. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The FDA&#146;s policies may change and
additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. If we are slow or unable to adapt to changes in existing </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">67 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained, which would
adversely affect our business, prospects and ability to achieve or sustain profitability. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Intellectual Property </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our success depends on our ability to protect our intellectual property and our proprietary technologies. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our commercial success depends in part on our ability to obtain and maintain patent protection and trade secret protection for our product candidates,
proprietary technologies and their uses as well as our ability to operate without infringing upon the proprietary rights of others. There can be no assurance that our patent applications or those of our licensors will result in additional patents
being issued or that issued patents will afford sufficient protection against competitors with similar technology, nor can there be any assurance that the patents issued will not be infringed, designed around, or invalidated by third parties. Even
issued patents may later be found unenforceable or may be modified or revoked in proceedings instituted by third parties before various patent offices or in courts. The degree of future protection for our proprietary rights is uncertain. Only
limited protection may be available and may not adequately protect our rights or permit us to gain or keep any competitive advantage. This failure to properly protect the intellectual property rights relating to these product candidates could have a
material adverse effect on our financial condition and results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Composition-of-matter patents are generally considered to be the strongest
form of intellectual property protection as such patents provide protection without regard to any method of use. We cannot be certain that the claims in our patent applications covering composition-of-matter of our product candidates will be
considered patentable by the U.S. Patent and Trademark Office and courts in the United States or by the patent offices and courts in foreign countries, nor can we be certain that the claims in our issued composition-of-matter patents will not be
found invalid or unenforceable if challenged. Method-of-use patents protect the use of a product for the specified method. This type of patent does not prevent a competitor from making and marketing a product that is identical to our product for a
use that is outside the scope of the patented method. Moreover, even if competitors do not actively promote their product for our targeted indications, physicians may prescribe these products &#147;off-label.&#148; Although off-label prescriptions
may infringe or contribute to the infringement of method-of-use patents, the practice is common and such infringement is difficult to prevent or prosecute. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The patent application process is subject to numerous risks and uncertainties, and there can be no assurance that we or any of our future development partners
will be successful in protecting our product candidates by obtaining and defending patents. These risks and uncertainties include the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The U.S. Patent and Trademark Office and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other provisions during the patent process. There are
situations in which noncompliance can result in abandonment or lapse of a patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, competitors might be able to enter the
market earlier than would otherwise have been the case. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Patent applications may not result in any patents being issued. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Patents that may be issued or in-licensed may be challenged, invalidated, modified, revoked, circumvented, found to be unenforceable, or otherwise may not provide any competitive advantage. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Our competitors, many of whom have substantially greater resources than we do and many of whom have made significant investments in competing technologies, may seek or may have already obtained patents that will limit,
interfere with, or eliminate our ability to make, use and sell our potential product candidates. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">There may be significant pressure on the U.S. government and international governmental bodies to limit the scope of patent protection both inside and outside the United States for treatments that prove successful, as a
matter of public policy regarding worldwide health concerns. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">68 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Countries other than the United States may have patent laws less favorable to patentees than those upheld by U.S. courts, allowing foreign competitors a better opportunity to create, develop, and market competing
product candidates. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, we rely on the protection of our trade secrets and proprietary know-how. Although we have taken steps to
protect our trade secrets and unpatented know-how, including entering into confidentiality agreements with third parties, and confidential information and inventions agreements with employees, consultants and advisors, third parties may still obtain
this information or may come upon this or similar information independently. If any of these events occurs or if we otherwise lose protection for our trade secrets or proprietary know-how, the value of this information may be greatly reduced. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we or any of our future development or collaborative partners are sued for infringing intellectual property rights of third parties, it will be
costly and time consuming, and an unfavorable outcome in that litigation could have a material adverse effect on our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our success also
depends on our ability and the ability of our current or future development or collaborative partners to develop, manufacture, market and sell our product candidates without infringing upon the proprietary rights of third parties. Numerous U.S. and
foreign-issued patents and pending patent applications owned by third parties exist in the fields in which we are developing product candidates, some of which may contain claims that overlap with the subject matter of our intellectual property or
are directed at our product candidates. When we become aware of patents held by third parties that may implicate the manufacture, development or commercialization of our product candidates, we evaluate our need to license rights to such patents. If
we need to license rights from third parties to manufacture, develop or commercialize our product candidates, there can be no assurance that we will be able to obtain a license on commercially reasonable terms or at all. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Because patent applications can take many years to issue there may be currently pending applications, unknown to us, that may later result in issued patents
upon which our product candidates or proprietary technologies may infringe. Similarly, there may be issued patents relevant to our product candidates of which we are not aware. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There is a substantial amount of litigation involving patent and other intellectual property rights in the biologics industry generally. If a third-party
claims that we or any of our licensors, suppliers or development partners infringe upon a third-party&#146;s intellectual property rights, we may have to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">seek to obtain licenses that may not be available on commercially reasonable terms, if at all; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">abandon an infringing product candidate or redesign our products or processes to avoid infringement; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">pay substantial damages including, in an exceptional case, treble damages and attorneys&#146; fees, which we may have to pay if a court decides that the product candidate or proprietary technology at issue infringes
upon or violates the third-party&#146;s rights; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">pay substantial royalties or fees or grant cross-licenses to our technology; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">defend litigation or administrative proceedings that may be costly whether we win or lose, and which could result in a substantial diversion of our financial and management resources. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, which could be expensive, time consuming and
unsuccessful. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Competitors may infringe upon our patents or the patents of our licensors. To counter infringement or unauthorized use, we may be
required to file infringement claims, which can be expensive and time consuming. An adverse result in any litigation or defense proceedings could put one or more of our patents at risk of being invalidated, found to be unenforceable or interpreted
narrowly and could put our patent applications at risk of not issuing. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential
information could be compromised by disclosure during this type of litigation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">69 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Most of our competitors are larger than we are and have substantially greater resources. They are, therefore,
likely to be able to sustain the costs of complex patent litigation longer than we could. In addition, the uncertainties associated with litigation could have a material adverse effect on our ability to raise the funds necessary to continue our
clinical trials, continue our internal research programs, in-license needed technology, or enter into development partnerships that would help us bring our product candidates to market. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, any future patent litigation, interference or other administrative proceedings will result in additional expense and distraction of our
personnel. An adverse outcome in such litigation or proceedings may expose us, or any of our future development partners to loss of our proprietary position, expose us to significant liabilities or require us to seek licenses that may not be
available on commercially acceptable terms, if at all. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our issued patents could be found invalid or unenforceable if challenged in court which
could have a material adverse effect on our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we or any of our future development partners were to initiate legal proceedings against a
third party to enforce a patent covering one of our product candidates or one of our future product candidates, the defendant could counterclaim that our patent is invalid or unenforceable. In patent litigation in the United States, defendant
counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness or non- enablement. Grounds for
an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the U.S. Patent and Trademark Office, or made a misleading statement, during prosecution. Third parties may
also raise similar claims before the U.S. Patent and Trademark Office even outside the context of litigation. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity question, for
example, we cannot be certain that there is no invalidating prior art, of which we and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity or unenforceability, we would lose at least
part, and perhaps all, of the patent protection on such product candidate. Such a loss of patent protection would have a material adverse impact on our business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be subject to claims that our consultants or independent contractors have wrongfully used or disclosed alleged trade secrets of their other
clients or former employers to us, which could subject us to costly litigation. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As is common in the biotechnology industry, we engage the services
of consultants to assist us in the development of our product candidates. Many of these consultants were previously employed at, or may have previously or may be currently providing consulting services to, other biotechnology or pharmaceutical
companies, including our competitors or potential competitors. We may become subject to claims that our company or a consultant inadvertently or otherwise used or disclosed trade secrets or other information proprietary to their former employers or
their former or current clients. Litigation may be necessary to defend against these claims. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to our management team. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Changes in U.S. patent law could diminish the value of patents in general, which could materially impair our ability to protect our product candidates.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As is the case with other biotechnology companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and
enforcing patents in the biotechnology industry involve technological and legal complexity. Therefore, obtaining and enforcing biotechnology patents is costly, time consuming and inherently uncertain. In addition, Congress recently passed patent
reform legislation. The Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. In addition
to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">70 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
respect to the value of patents, once obtained. Depending on decisions by the U.S. Congress, the federal courts and the U.S. Patent and Trademark Office, the laws and regulations governing
patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents we might obtain in the future. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may not be able to protect our intellectual property rights throughout the world which could materially, negatively affect our business. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Filing, prosecuting and defending patents on product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual
property rights in some countries outside the United States can be less extensive than those in the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state
laws in the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United
States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and further, may export otherwise infringing products to territories where we have patent
protection, but enforcement is not as strong as that in the United States. These products may compete with our product candidates and our patents or other intellectual property rights may not be effective or sufficient to prevent them from
competing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The
legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents and other intellectual property protection, particularly those relating to biotechnology, which could make it difficult for us to
stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and
attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not
prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a
significant commercial advantage from the intellectual property that we develop or license and may adversely affect our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If our trademarks
and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our registered or unregistered trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other
marks. We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition by potential partners or customers in our markets of interest. Over the long term, if we are unable to establish name
recognition based on our trademarks and trade names, then we may not be able to compete effectively and our business may be adversely affected. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks
Related to Our Common Stock </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The trading price of our common stock has been, and is likely to continue to be, volatile, and you might not be able
to sell your shares at or above the price you paid. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We completed our initial public offering in December 2014 at an initial price to the public of
$11.00 per share. Subsequently, as of March&nbsp;8, 2017 our common stock has traded as low as $1.39 per share. The realization of any of the risks described in these risk factors or other unforeseen risks could have a dramatic and adverse effect on
the market price of our common stock. The trading price of our common stock is likely to continue to be highly volatile and could be subject to wide fluctuations in response to various factors, some of which are beyond our control. These factors
include those discussed elsewhere in this &#147;Risk Factors&#148; section and others such as: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">71 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the delay or failure in initiating, enrolling or completing preclinical studies or clinical trials, or unsatisfactory results of these trials; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">announcements about us or about our competitors including clinical trial results, regulatory approvals, or new product candidate introductions and the revenue and growth potential of such new products;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">developments concerning our current or future development partner, licensors or product candidate manufacturers; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">litigation and other developments relating to our patents or other proprietary rights or those of our competitors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">conditions in the pharmaceutical or biotechnology industries and the economy as a whole; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">governmental regulation and legislation; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the recruitment or departure of members of our board of directors, management team or other key personnel; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">changes in our operating results; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any changes in the financial projections we may provide to the public, our failure to meet these projections, or changes in recommendations by any securities analysts that elect to follow our common stock;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any change in securities analysts&#146; estimates of our performance, or our failure to meet analysts&#146; expectations; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the expiration of market standoff or contractual lock-up agreements; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">sales or potential sales of substantial amounts of our common stock; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">price and volume fluctuations in the overall stock market or resulting from inconsistent trading volume levels of our shares. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In recent months and years, the stock market in general, and the market for pharmaceutical and biotechnological companies in particular, has experienced
extreme price and volume fluctuations that have often been unrelated or disproportionate to changes in the operating performance of the companies whose stock is experiencing those price and volume fluctuations. In addition, Brexit or actions taken
by the new presidential administration and Congress could adversely affect United States, European or worldwide economic or market conditions and could contribute to instability and volatility in global financial markets. Broad market and industry
factors may seriously affect the market price of our common stock, regardless of our actual operating performance. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our quarterly operating results
may fluctuate substantially, which may cause the price of our common stock to fluctuate substantially. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect our quarterly operating results
to be subject to fluctuations. Our net income or loss and other operating results may be affected by numerous factors, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any variations in the level of expenses related to our development and expected commercialization of NeoCart; </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">derivative instruments recorded at fair value; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the addition or termination of any clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any regulatory or clinical developments affecting NeoCart; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the nature and terms of any stock-based compensation grants and any intellectual property infringement lawsuits in which we may become involved. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If our quarterly operating results fall below the expectations of investors or securities analysts, the price of our common stock could decline substantially.
Furthermore, any quarterly fluctuations in our operating results may, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">72 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
in turn, cause the price of our stock to fluctuate substantially. We believe that quarterly comparisons of our financial results are not necessarily meaningful and should not be relied upon as an
indication of our future performance. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our stock price may be volatile, and securities class action litigation has often been instituted against
companies following periods of volatility of their stock price. Any such litigation, if instituted against us, could result in substantial costs and a diversion of our management&#146;s attention and resources. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the past, following periods of volatility in the overall market and the market price of a particular company&#146;s securities, securities class action
litigation has often been instituted against these companies. This litigation, if instituted against us, could result in substantial costs and a diversion of our management&#146;s attention and resources. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If securities analysts do not publish research or publish unfavorable research about our business, our stock price and trading volume could decline.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The trading market for our common stock will depend in part on the research and reports that securities and industry analysts publish about us or
our business. We currently have limited research coverage by securities analysts. If no additional securities or industry analysts commence coverage of our company, the trading price for our stock could suffer. In the event we obtain additional
securities or industry analyst coverage, if one or more of the analysts who covers us downgrades our stock or publishes unfavorable research about our business, or if our clinical trials or operating results fail to meet the analysts&#146;
expectations, our stock price would likely decline. If one or more of these analysts ceases coverage of our company or fails to publish reports on us regularly, demand for our stock could decrease, which could cause our stock price and trading
volume to decline. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Raising additional funds by issuing securities or through licensing or lending arrangements may cause dilution to our existing
stockholders, restrict our operations or require us to relinquish proprietary rights. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will need to raise additional funding in order to file a
BLA for NeoCart, create additional manufacturing capacity and to commercialize NeoCart and to conduct the research and development and clinical and regulatory activities necessary to bring other product candidates to market. To the extent that we
raise additional capital by issuing equity securities, the share ownership of existing stockholders will be diluted. Any future debt financing may involve covenants that restrict our operations, including limitations on our ability to incur liens or
additional debt, pay dividends, redeem our stock, make certain investments, and engage in certain merger, consolidation, or asset sale transactions. In addition, if we seek funds through arrangements with collaborative partners, these arrangements
may require us to relinquish rights to some of our technologies or product candidates or otherwise agree to terms unfavorable to us. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have never
paid and do not intend to pay cash dividends and, consequently, your ability to achieve a return on your investment will depend on appreciation in the price of our common stock. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have never paid cash dividends on any of our capital stock, and we currently intend to retain future earnings, if any, to fund the development and growth of
our business. Therefore, you are not likely to receive any dividends on our common stock for the foreseeable future or at all. Since we do not intend to pay dividends, your ability to receive a return on your investment will depend on any future
appreciation in the market value of our common stock. There is no guarantee that our common stock will appreciate or even maintain the price at which you have purchased it. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our principal stockholders and management own a significant percentage of our stock and will be able to exert significant control over matters subject
to stockholder approval. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of March&nbsp;8, 2017, our executive officers, directors, holders of more than 5% of our capital stock and their
respective affiliates beneficially owned 58% of our outstanding capital stock. These stockholders have the ability </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">73 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to influence us through their ownership position. These stockholders are able to determine all matters requiring stockholder approval. For example, these stockholders are able to control
elections of directors, amendments of our organizational documents, or approval of any merger, sale of assets, or other major corporate transaction. This may prevent or discourage unsolicited acquisition proposals or offers for our common stock that
you may feel are in your best interest as one of our stockholders. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Substantial future sales of shares by existing stockholders, including pursuant
to our equity incentive plans, or the perception that such sales may occur, could cause our stock price to decline. </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A small number of
institutional investors and private equity funds hold a significant number of shares of our common stock and all of our shares of Series A Convertible Preferred Stock and warrants to purchase our common stock issued in our September 2016 private
placement. If these existing stockholders, particularly our directors and executive officers and the venture capital funds affiliated with our current and former directors, sell substantial amounts of our common stock in the public market, or are
perceived by the public market as intending to sell substantial amounts of our common stock, the trading price of our common stock could decline. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Some of
pre-IPO existing security holders have demand and piggyback rights to require us to register with the SEC up to 4,479,418 shares of our common stock. If we register these shares of common stock, the stockholders would be able to sell those shares
freely in the public market, subject to Rule 144 transfer restrictions applicable to affiliates. In November 2016, we registered 26,800,001 shares of common stock for resale by selling stockholders, including 10,737,275 shares of common stock
underlying our outstanding Series A Convertible Preferred Stock and 13,466,667 shares of common stock underlying outstanding warrants issued in connection with our September 2016 private placement. The selling stockholders in the private placement
are able to freely trade such shares of common stock, subject to Rule 144 transfer restrictions applicable to affiliates. We have registered an additional 2,436,666 shares of our common stock that we may issue under our equity plans. Once we issue
these shares, they can be freely sold in the public market upon issuance, contractual lock-up agreements, or Rule 144 transfer restrictions applicable to affiliates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our stock price does not meet the minimum continued listing requirements for Market Value of Listed Securities on The NASDAQ Global Market. Our ability
to publicly or privately sell equity securities and the liquidity of our common stock could be adversely affected if we are delisted from The NASDAQ Global Market or if we are unable to transfer our listing to another stock market. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As previously reported on our Current Report on Form 8-K filed on November&nbsp;21, 2016, on November&nbsp;18, 2016, we received a notice (the Notice) from The
NASDAQ Stock Market LLC (NASDAQ) stating that, because we did not maintain a minimum Market Value of Listed Securities (MVLS) of $50,000,000 for the last 30 consecutive business days prior to November&nbsp;18, 2016, we were no longer in compliance
with NASDAQ Listing Rule 5450(b)(2)(A). The Notice had no immediate effect on the listing or trading of our common stock on The NASDAQ Global Market and the common stock continues to trade under the symbol &#147;HSGX&#148;. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Notice stated that, in accordance with NASDAQ Listing Rule 5810(c)(3)(C), we have been provided a period of 180 calendar days, or until May&nbsp;17, 2017,
to regain compliance with the minimum MVLS listing requirement. The Notice also states that if, at any time on or before May&nbsp;17, 2017, the MVLS of our common stock closes at $50,000,000 or more for a minimum of 10 consecutive business days,
NASDAQ will provide the Company with written confirmation that we have achieved compliance with the minimum MVLS listing requirement and the matter will be closed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event that we do not regain compliance with the minimum MVLS listing requirement on or before May&nbsp;17, 2017, NASDAQ will provide us with written
notification that our securities are subject to delisting. At that time, we would be permitted to appeal the delisting determination to a NASDAQ Hearings Panel or apply to transfer our common stock to The NASDAQ Capital Market (provided that we
satisfy the requirements for continued listing on that market at such time). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">74 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Provisions in our amended and restated certificate of incorporation and amended and restated bylaws and
Delaware law might discourage, delay or prevent a change in control of our company or changes in our management and, therefore, depress the market price of our common stock. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our certificate of incorporation and bylaws contain provisions that could depress the market price of our common stock by acting to discourage, delay or
prevent a change in control of our company or changes in our management that the stockholders of our company may deem advantageous. These provisions among other things: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">establish a classified board of directors so that not all members of our board are elected at one time; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">permit the board of directors to establish the number of directors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">provide that directors may only be removed &#147;for cause&#148;; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">require super-majority voting to amend some provisions in our certificate of incorporation and bylaws; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">authorize the issuance of &#147;blank check&#148; preferred stock that our board of directors could use to implement a stockholder rights plan; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">eliminate the ability of our stockholders to call special meetings of stockholders; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">prohibit stockholder action by written consent, which requires all stockholder actions to be taken at a meeting of our stockholders; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">provide that the board of directors is expressly authorized to make, alter or repeal our bylaws; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">establish advance notice requirements for nominations for election to our board of directors or for proposing matters that can be acted upon by stockholders at annual stockholder meetings. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, Section&nbsp;203 of the Delaware General Corporation Law may discourage, delay or prevent a change in control of our company. Section&nbsp;203
imposes certain restrictions on merger, business combinations and other transactions between us and holders of 15% or more of our common stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We
are an emerging growth company and the extended transition period for complying with new or revised financial accounting standards and reduced disclosure and governance requirements applicable to emerging growth companies could make our common stock
less attractive to investors. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are an emerging growth company. Under the Jumpstart Our Business Startups Act, emerging growth companies can
delay adopting new or revised accounting standards until such time as those standards apply to private companies. We plan to avail ourselves of this exemption from new or revised accounting standards and, therefore, we may not be subject to the same
new or revised accounting standards as other public companies that are not emerging growth companies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For as long as we continue to be an emerging growth
company, we also intend to take advantage of certain other exemptions from various reporting requirements that are applicable to other public companies, including reduced disclosure obligations regarding executive compensation in our periodic
reports and proxy statements, exemptions from the requirements of holding a nonbinding advisory stockholder vote on executive compensation and any golden parachute payments not previously approved, exemption from the requirement of auditor
attestation on our internal control over financial reporting and exemption from any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor&#146;s report
providing additional information about the audit and the financial statements (auditor discussion and analysis). If we do, the information that we provide stockholders may be different than what is available with respect to other public companies.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Investors could find our common stock less attractive because we will rely on these exemptions, which may make it more difficult for investors to compare
our business with other companies in our industry. If some </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">75 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile. In addition, it may be
difficult for us to raise additional capital as and when we need it. If we are unable to do so, our financial condition and results of operations could be materially and adversely affected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will remain an emerging growth company until the earliest of: (1)&nbsp;the end of the fiscal year in which the market value of our common stock that is
held by non-affiliates exceeds $700.0 million as of the end of the second fiscal quarter; (2)&nbsp;the end of the fiscal year in which we have total annual gross revenue of $1.0 billion or more during such fiscal year; (3)&nbsp;the date on which we
issue more than $1.0 billion in non-convertible debt in a three-year period or (4)&nbsp;December&nbsp;31, 2019, the end of the fiscal year following the fifth anniversary of the completion of our initial public offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">76 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B><A NAME="tx293850_5"></A>ITEM&nbsp;1B.</B></TD>
<TD ALIGN="left" VALIGN="top"><B></B><B><I>UNRESOLVED STAFF COMMENTS</I></B><B> </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Not applicable. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B><A NAME="tx293850_6"></A>ITEM&nbsp;2.</B></TD>
<TD ALIGN="left" VALIGN="top"><B></B><B><I>PROPERTIES</I></B><B> </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our corporate headquarters are currently located in Waltham,
Massachusetts, for which we have a lease until December 2017, renewable for two additional five-year terms. We lease approximately 25,472 square feet of office, manufacturing and laboratory space, including 5,700 square feet of cGMP clean room space
that is outfitted for NeoCart manufacturing. This facility also houses our quality staff, including quality control testing, necessary to support NeoCart manufacturing. We subleased approximately 7,310 square feet of our facility to a tenant through
May 2015, at which time this space was returned for our use. The Waltham facility is expected to be adequate for a potential initial commercial launch of NeoCart in 2019. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, we lease approximately 16,601 square feet of laboratory and manufacturing space, along with related office space, in Lexington, Massachusetts.
The term of the Lexington lease expires October&nbsp;1, 2022 and can be extended for one additional five year period thereafter. This facility includes clean room space that will be utilized for production of our CT3 adhesive components, our
collagen scaffold and the collagen raw material used to produce the scaffold and components of the CT3 adhesive. This facility also includes necessary space for quality operations, including necessary quality control testing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, as part of the acquisition of ProChon Biotech Ltd., we leased approximately 807 square feet of office space in Tel Aviv, Israel. The term of the
lease expired on March&nbsp;31, 2015 and was not renewed. As part of the acquisition, we also assumed approximately 1,641 square feet of office space in Woburn, Massachusetts. This lease expired on May&nbsp;30, 2016 and was not renewed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Management believes that the leased facilities are suitable and adequate to meet our anticipated near-term needs. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B><A NAME="tx293850_7"></A>ITEM&nbsp;3.</B></TD>
<TD ALIGN="left" VALIGN="top"><B></B><B><I>LEGAL PROCEEDINGS</I></B><B> </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">From time to time, we may become subject to legal proceedings,
claims and litigation arising in the ordinary course of business. We currently are not a party to any threatened or pending litigation and do not have contingency reserves established for any litigation liabilities. However, third parties might
allege that we are infringing their patent rights or that we are otherwise violating their intellectual property rights, including trade names and trademarks. Such third parties may resort to litigation. We accrue contingent liabilities when it is
probable that future expenditures will be made and such expenditures can be reasonably estimated. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B><A NAME="tx293850_8"></A>ITEM&nbsp;4.</B></TD>
<TD ALIGN="left" VALIGN="top"><B></B><B><I>MINE SAFETY DISCLOSURES</I></B><B> </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Not applicable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">77 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PART II </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B><A NAME="tx293850_9"></A>ITEM&nbsp;5.</B></TD>
<TD ALIGN="left" VALIGN="top"><B></B><B><I>MARKET FOR REGISTRANT&#146;S COMMON EQUITY, RELATED SHAREHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</I></B><B> </B></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our common stock has been trading on The NASDAQ Global Market (NASDAQ) under the symbol &#147;HSGX&#148; since our initial public offering on December&nbsp;3,
2014. Prior to that time, there was no established public trading market for our common stock. The following table sets forth, for the periods indicated, the range of high and low sale prices of our common stock as reported by NASDAQ. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="78%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:108.65pt; font-size:8pt; font-family:Times New Roman"><B>Year ending December&nbsp;31, 2015</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>High</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Low</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">First Quarter:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12.47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7.04</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Second Quarter:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.92</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Third Quarter:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.91</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fourth Quarter:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.97</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:108.65pt; font-size:8pt; font-family:Times New Roman"><B>Year ending December 31, 2016</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>High</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Low</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">First Quarter:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Second Quarter:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Third Quarter:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fourth Quarter:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Holders </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of
March&nbsp;14, 2017, there were 14 holders of record of our common stock. The number of holders of record of our common stock does not reflect the number of beneficial holders whose shares are held by depositors, brokers or other nominees. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Dividends </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have not declared or paid any cash
dividends on our common stock since our inception. We do not plan to pay dividends in the foreseeable future. Under our credit facility, we have agreed not to pay any dividends so long as it has any outstanding obligations thereunder. We currently
intend to retain earnings, if any, to finance our growth. Consequently, stockholders will need to sell shares of our common stock to realize a return on their investment, if any. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Securities Authorized for Issuance under Equity Incentive Plans </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Information regarding securities authorized for issuance under equity incentive plans will be contained in our Proxy Statement for the 2017 Annual Meeting of
Stockholders to be filed with the SEC within 120 days after the end of the fiscal year ended December&nbsp;31, 2016, under the captions &#147;Equity Compensation Plan Information&#148; and &#147;Security Ownership of Certain Beneficial Owners and
Management&#148; and is incorporated herein by reference pursuant to General Instruction G(3) to Form 10-K. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Use of Proceeds </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&nbsp;8, 2014, we closed our IPO whereby 5,909,091 shares of common stock were sold at a public offering price of $11.00 per share for an aggregate
offering price of $65.0 million. On January&nbsp;6, 2015, an additional 465,000 shares of common stock were sold at the IPO price of $11.00 per share following the underwriters&#146; exercise in part of their overallotment option (Underwriters&#146;
Option). The offer and sale of all of the shares in the IPO and pursuant to the Underwriters&#146; Option were registered under the Securities Act pursuant to a registration statement on Form S-1 (File No.&nbsp;333- 199202), which was declared
effective by the SEC on </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">78 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
December&nbsp;2, 2014. The offering commenced as of December&nbsp;2, 2014 and did not terminate before all of the securities registered in the registration statement were sold. The syndicate of
underwriters was led by Cowen and Company, Needham&nbsp;&amp; Company and Canaccord Genuity as joint book-running managers and BTIG, LLC as co-manager. We raised approximately $61.3 million in net proceeds after deducting underwriting discounts and
commissions and other offering expenses. No payments were made by us to directors, officers or persons owning ten percent or more of our common stock or to their associates, or to our affiliates, other than payments in the ordinary course of
business to officers for salaries and to non-employee directors as compensation for board committee service. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There has been no material change in the
planned use of proceeds from our IPO as described in our prospectus dated December&nbsp;2, 2014, filed with the SEC pursuant to Rule 424(b)(4) under the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September&nbsp;29, 2016, we closed a private placement of common stock Series A Preferred Stock and warrants. H.C. Wainwright&nbsp;&amp; Co. LLC served as
the sole placement agent for the private placement. No payments were made by us to directors, officers or persons owning ten percent or more of our common stock or to their associates, or to our affiliates, other than payments in the ordinary course
of business to officers for salaries and to non-employee directors as compensation for board committee service. We raised approximately $27.6 million in net proceeds after deducting placement agent and legal fees from the private placement. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B><A NAME="tx293850_10"></A>ITEM&nbsp;6.</B></TD>
<TD ALIGN="left" VALIGN="top"><B></B><I></I><B><I>SELECTED CONSOLIDATED FINANCIAL DATA</I></B><I></I><B> </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a smaller reporting company,
we are not required to provide this information. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">79 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B><A NAME="tx293850_11"></A>ITEM&nbsp;7.</B></TD>
<TD ALIGN="left" VALIGN="top"><B></B><B><I>MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</I></B><B> </B></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The following discussion and analysis should be read in conjunction with our audited annual consolidated financial statements and the related notes that
appear elsewhere in this annual report on Form 10-K. This discussion contains forward-looking statements reflecting our current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these
forward-looking statements due to a number of factors, including those set forth in the section entitled &#147;Risk Factors&#148; and elsewhere in this annual report on Form 10-K. For further information regarding forward-looking statements, please
refer to the &#147;Special Note Regarding Forward-Looking Statements&#148; at the beginning of Part I of this annual report on Form&nbsp;10-K. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are a regenerative medicine company focused
on developing and commercializing products in the musculoskeletal segment of the marketplace. Our first product candidate, NeoCart<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, is an innovative tissue implant that utilizes various
aspects of our regenerative medicine platform to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee. We are currently investigating NeoCart in a 245 patient, Phase 3 clinical trial. We have no products that
are approved for sale in the United States and currently we are not selling any other products that may be approved for sale in other jurisdictions. Our regenerative medicine platform; combines expertise in the following areas: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Cell therapy and processing: the handling of a tissue biopsy and the extraction, isolation and expansion of the cells; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Biomaterials and Scaffold: three-dimensional biomaterials structures that enable the proper distribution of cells and organize cells in their natural environment to support tissue formation; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Tissue engineering: the use of a combination of cells, engineering and biomaterials to improve or replace biological functions; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Bioadhesives: natural, biocompatible materials that act as adhesives for biological tissue and allow for natural cell and tissue infiltration and integration with native cells. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">NeoCart is a cartilage-like implant created using a patient&#146;s own cartilage cells through a series of tissue engineering processes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have devoted substantially all of our resources to the development of our regenerative medicine platform, the preclinical and clinical advancement of our
product candidates, the creation and protection of related intellectual property and the provision of general and administrative support for these operations. Prior to 2014, we generated revenue from product sales, collaboration activities and
grants. We have funded our operations primarily through the private placement of preferred stock and convertible promissory notes, through commercial bank debt and the proceeds from our initial public offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have never been profitable and incurred net losses in each year since inception. Our accumulated deficit was $181.8 million as of December&nbsp;31, 2016.
Substantially all of our net losses resulted from costs incurred in connection with our research and development programs and from general and administrative costs associated with our operations. Our net losses may fluctuate significantly from
quarter to quarter and year to year. We expect to continue to incur significant expenses and operating losses in connection with our ongoing activities as we: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">conduct clinical trials of our product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">continue scale up and improvement of our manufacturing processes; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">continue with the transition of our manufacturing technology transfer; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">80 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">continue our research and development efforts; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">manufacture preclinical study and clinical trial materials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">seek regulatory approvals for our product candidates that successfully complete clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">prepare to commercialize NeoCart, if approved; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">hire additional clinical, quality control and technical personnel to conduct our clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">hire additional scientific personnel to support our product development efforts; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">maintain, expand and protect our intellectual property portfolio; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">implement operational, financial and management systems associated with the potential commercialization of NeoCart, if approved; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">hire additional general and administrative personnel to operate as a public company. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We do not expect to
generate any future revenue from therapeutic product sales until we successfully complete development and obtain regulatory approval for one or more of our product candidates, which we expect will take a number of years. If we obtain regulatory
approval for any of our product candidates, we expect to incur significant commercialization expenses related to product sales, marketing, manufacturing and distribution. Accordingly, we will seek to fund our operations through public or private
equity or debt financings or other sources. However, we may be unable to raise additional funds or enter into such other arrangements when needed on favorable terms or at all. Our failure to raise capital or enter into such other arrangements when
needed would have a negative impact on our financial condition and ability to develop our product candidates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Financial Operations Overview </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We conduct operations in two geographic regions: Histogenics Corporation, a Delaware corporation, at our facilities in Waltham and Lexington, Massachusetts,
and ProChon Biotech Ltd. (ProChon) in Tel Aviv, Israel. We own 100% of the voting shares of ProChon. As the nature of the products, customers and methods to distribute products are the same and the nature of the regulatory environment, the
production processes and historical and estimated future margins are similar, the two operations have been aggregated into one reporting segment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On
May&nbsp;13, 2011, we acquired ProChon, a privately held biotechnology company focused on modulating the fibroblast growth factor system to enable it to create more effective solutions for tissue regeneration. The acquisition of ProChon provided us
with access to a portfolio of intellectual property, including proprietary cell growth factors, in addition to furthering opportunities for the use of biomaterials to create more effective solutions for regenerating human tissue. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The ProChon acquisition was accounted for as a business combination. The results of operations of ProChon have been included in our consolidated statements of
operations since May&nbsp;13, 2011, the date we obtained control of ProChon. Following the completion of the acquisition, ProChon became our wholly owned subsidiary and was integrated into our operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September&nbsp;29, 2016, we completed a private placement (the Private Placement) where we issued 2,596,059 shares of our common stock at a per share price
of $2.25 and 24,158.8693 shares of our newly-created Series A Convertible Preferred Stock, which shares of preferred stock are convertible into approximately 10,737,275 shares of common stock. The Series A Convertible Preferred Stock became
convertible into shares of our common stock following approval of the private placement by our stockholders in the fourth quarter of 2016. The net proceeds after deduction of placement agent fees and other transaction-related expenses was $27.6
million. As part of the Private Placement, the investors received warrants to purchase up to 13,333,334 shares of our common stock at an exercise price of $2.25 per share. The warrants include a cashless-exercise feature that may
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">81 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
be exercised solely in the event there is no effective registration statement registering, or no current prospectus available for, the resale of the shares of common stock underlying the warrants
as of the six-month anniversary of the closing of the Private Placement. The warrants became exercisable following approval of the Private Placement by our stockholders in the fourth quarter of 2016 and expire five years after the date of such
stockholder approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The consolidated financial statements and the following information include the accounts of Histogenics, ProChon and Histogenics
Securities Corporation. All intercompany accounts and transactions have been eliminated in consolidation. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Revenue </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We did not generate any revenue in 2016 or 2015 and do not expect to generate any revenue in the future until we have successfully completed the development of
NeoCart and received approval from the FDA to market NeoCart or any future product candidates. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development Expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Research and development expenses consist of development costs associated with our regenerative medicine platform and development programs. These costs are
expensed as incurred and include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">compensation and employee-related costs; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">costs incurred under clinical trial agreements with investigative sites; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">costs to acquire, develop and manufacture preclinical study and clinical trial materials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">costs associated with conducting our preclinical, clinical and regulatory activities, including fees paid to third-party professional consultants and service providers; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">costs for laboratory supplies and laboratory equipment; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">charges associated with the achievement of certain preclinical and financial milestones pursuant to our licenses for our bioadhesive, and our tissue engineering processor; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">facilities, depreciation and other expenses including allocated expenses for rent and maintenance of facilities. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We plan to maintain our current level of research and development expenses for the foreseeable future as we continue the development of our regenerative
medicine platform and our initial therapeutic product candidates. Our current planned research and development activities include the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">advancing NeoCart in the Phase 3 clinical trial; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">continued development work with Intrexon per the terms of the exclusive collaboration agreement; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">leveraging our regenerative medicine platform to expand into additional therapeutic applications; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">expanding and protecting our intellectual property platform. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We cannot determine with certainty the timing
and costs of initiation, the duration and the completion of current or future preclinical studies and clinical trials of our product candidates. At this time, due to the inherently unpredictable nature of preclinical and clinical development, we are
unable to estimate with any certainty the costs we will incur and the timelines we will require in the continued development of our product candidates, including NeoCart. Clinical and preclinical development timelines, the probability of success and
related development costs can differ materially from expectations. In addition, we cannot forecast which product candidates may be subject to future collaborations, when such arrangements will be secured, if at all, and to what degree such
arrangements would affect our development plans and capital requirements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">82 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We do not track research and development expenses by product. We do not allocate general equipment and supply
costs, facilities, depreciation and other miscellaneous expenses to specific products as these expenses are deployed across all of our products. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>General and Administrative Expenses </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">General and
administrative expenses consist primarily of salaries and employee-related costs, including stock-based compensation and travel expenses for our employees in the executive, finance and human resource functions. Other general and administrative
expenses include facility-related costs and professional fees for directors, accounting and legal services, and expenses associated with obtaining and maintaining patents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We anticipate that our general and administrative expenses will increase in the future to support the continued research and development and potential
commercialization of our product development programs as well as to maintain compliance with SEC requirements and related costs associated with being a public company. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Total Other Income (Expense), Net </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Total other
income (expense), net consists primarily of warrant expense for fees paid in our Private Placement; interest income earned on cash and cash equivalents; interest expense on our equipment loan; and changes in liabilities that are held at fair value.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Critical Accounting Policies and Significant Judgments and Estimates </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our management&#146;s discussion and analysis of our consolidated financial condition and results of operations are based on our consolidated financial
statements, which have been prepared in accordance with U.S. generally accepted accounting principles. The preparation of these consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets,
liabilities, revenue and expenses and the disclosure of contingent assets and liabilities in our consolidated financial statements. On an ongoing basis, we evaluate our estimates and judgments, including those related to accrued expenses and
stock-based compensation. We base our estimates on historical experience, known trends and events, and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about
the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">While our significant accounting policies are described in more detail in the notes to our consolidated financial statements appearing elsewhere in this
annual report on Form 10-K, we believe the following accounting policies to be most critical to the significant judgments and estimates used in the preparation of our consolidated financial statements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Income Taxes </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We utilize the asset and liability
method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement carrying amounts and tax basis of assets and liabilities using enacted tax rates in
effect for years in which temporary differences are expected to reverse. We provide a valuation allowance when it is more likely than not that deferred tax assets will not be realized. We recognize the benefit of an uncertain tax position that has
been taken or we expect to take on income tax returns if such tax position is more likely than not to be sustained. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We follow the authoritative guidance
regarding accounting for uncertainty in income taxes, which prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. These
unrecognized tax benefits relate primarily to issues related to the timing of certain income and deductions for federal income tax purposes. We apply a variety of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">83 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
methodologies in making these estimates which include advice and studies performed by independent subject matter experts, evaluation of public actions taken by the U.S. Internal Revenue Service
and other taxing authorities, as well as our own industry experience. We provide estimates for unrecognized tax benefits which may be subject to material adjustments until matters are resolved with taxing authorities or statutes expire. If our
estimates are not representative of actual outcomes, our results of operations could be materially impacted. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We continue to maintain a valuation
allowance against our deferred tax assets due to our assessment that their realization is not certain. We periodically evaluate the likelihood of the realization of deferred tax assets and reduce the carrying amounts of these deferred tax assets by
a valuation allowance to the extent we believe a portion will not be realized. We consider many factors when assessing the likelihood of future realization of deferred tax assets, including our recent cumulative earnings experience by taxing
jurisdiction, expectations of future taxable income, carryforward periods available to us for tax reporting purposes, various income tax strategies and other relevant factors. Significant judgment is required in making this assessment and, to the
extent future expectations change, we would assess the recoverability of our deferred tax assets at that time. If we determine that the deferred tax assets become realizable in a future period, we would record material adjustments to income tax
expense that period. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Uncertain Income Tax Positions </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We record uncertain tax positions on the basis of a two-step process whereby (1)&nbsp;we determine whether it is more likely than not that the tax positions
will be sustained on the basis of the technical merits of the positions and (2)&nbsp;for those tax positions that meet the more-likely-than-not recognition threshold, we recognize the largest amount of tax benefit that is more than 50% likely to be
realized upon ultimate settlement with the related tax authority. We recognize interest and penalties related to unrecognized tax benefits within income tax expense. Any accrued interest and penalties are included within the related tax liability. A
reconciliation of the beginning and ending pre-tax amounts of uncertain tax positions is as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="79%"></TD>
<TD VALIGN="bottom" WIDTH="16%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Tax&nbsp;Positions</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(in&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at December&nbsp;31, 2014</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(812</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Reductions based on tax positions related to the period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at December&nbsp;31, 2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(687</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Reductions based on tax positions related to the period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at December&nbsp;31, 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(562</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The uncertain tax positions giving rise to the unrecognized tax benefits of $0.6 million at December&nbsp;31, 2016 relate to
the timing of certain income and deductions for federal income tax purposes. The reversal of unrecognized tax benefits would not have any impact on the effective tax rate in future periods and are not expected to create cash tax liability upon
settlement due to our ability to utilize both pre-change and post-change NOLs to offset their impact. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Accrued Expenses </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As part of the process of preparing our consolidated financial statements, we are required to estimate our accrued expenses. This process involves reviewing
open contracts and purchase orders, communicating with our personnel to identify services that have been performed on our behalf and estimating the level of service performed and the associated cost incurred for the service when we have not yet been
invoiced or otherwise notified of the actual cost. The majority of our service providers invoice us monthly in arrears for services performed or when contractual milestones are met. We make estimates of our accrued expenses as of each balance sheet
date in our consolidated financial statements based on facts and circumstances known to us at that </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">84 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
time. We periodically confirm the accuracy of our estimates with the service providers and make adjustments if necessary. Examples of estimated accrued research and development expenses include
fees payable to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">clinical research organizations and investigative sites in connection with clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">vendors in connection with preclinical development activities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">vendors related to product manufacturing, development, and distribution of clinical materials; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">professional service fees for consulting and related services. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We base our expense accruals related to
clinical trials on our estimates of the services received and efforts expended pursuant to our contract arrangements. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment
flows and expense recognition. Payments under some of these contracts depend on factors such as the successful enrollment of patients and the completion of clinical trial milestones. In accruing service fees, we estimate the time period over which
services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from our estimate, we adjust the accrual or prepaid accordingly. Our understanding of
the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in our reporting changes in estimates in any particular period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Although we do not expect our estimates to be materially different from amounts actually incurred, if our estimates of the status and timing of services
performed differs from the actual status and timing of services performed, we may report amounts that are too high or too low in any particular period. To date, there have been no material differences from our estimates to the amount actually
incurred. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Impairment of Long-Lived Assets </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Long-lived assets consist primarily of property and equipment. We test long-lived assets for impairment at year end or whenever events or circumstances present
an indication of impairment. If the sum of expected future cash flows (undiscounted and without interest charges) of the long-lived assets is less than the carrying amount of such assets, an impairment loss would be recognized in earnings. The
long-lived asset would be written down to the estimated fair value, calculated based on the present value of expected future cash flows. While our current negative cash flows are indicators of impairment, we believe that future cash flows to be
received support the carrying value of our long-lived assets. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Impairment of Intangible Assets </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We test intangible assets for impairment at year end or whenever events or circumstances present an indication of impairment. If the sum of expected future
cash flows (undiscounted and without interest charges) of the intangible assets is less than the carrying amount of such assets, an impairment loss would be recognized in earnings in &#147;impairment of goodwill and intangible assets.&#148; The
intangible assets would be written down to the estimated fair value, calculated based on the present value of expected future cash flows. Our intangible assets consisted of in-process research and development (IPR&amp;D) obtained through the
acquisition of ProChon and the AT Grade license. The results of our annual impairment test as of December&nbsp;31, 2015, indicated a decline in the fair market value of the IPR&amp;D, resulting in an impairment charge of $0.3 million for 2015. For
year ended December&nbsp;31, 2016, we deemed the value of the IPR&amp;D to be zero as we have no plans to advance the technology or use it in any future clinical development activities. The result was a write-off of $0.2 million. IPR&amp;D is now
fully impaired. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock-Based Compensation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We
account for grants of stock options and restricted stock based on their grant date fair value and recognize compensation expense over their vesting period. We estimate the fair value of stock options as of the date of
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">85 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
grant using the Black-Scholes option pricing model and, if issued, restricted stock based on the fair value of the underlying common stock as determined by management or the value of the services
provided, whichever is more readily determinable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stock-based compensation expense represents the cost of the grant date fair value of employee stock
option grants recognized over the requisite service period of the awards (usually the vesting period) on a straight-line basis, net of estimated forfeitures. The expense is adjusted for actual forfeitures at year end. Stock-based compensation
expense recognized in the financial statements is based on awards that are ultimately expected to vest. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Black-Scholes option pricing model requires
us to make certain assumptions and estimates concerning our stock price volatility, the rate of return of risk-free investments, the expected term of the awards, and our anticipated dividends. We utilize the volatility from an analysis of peer group
companies used in the Black-Scholes model, as we do not believe we have sufficient historical data to support this assumption. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We account for stock
options and restricted stock awards to non-employees using the fair value approach. Stock options and restricted stock awards granted to non-employees are subject to periodic revaluation over their vesting terms. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Other Company Information </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>JOBS Act </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On April&nbsp;5, 2012, the Jumpstart Our Business Startups Act (JOBS Act) was enacted. Section&nbsp;107 of the JOBS Act permits an &#147;emerging growth
company&#148; to delay the adoption of new or revised accounting standards until those standards would otherwise apply to private companies. We plan to avail ourselves of this exemption from new or revised accounting standards and, therefore, we may
not be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For so long as we are an
&#147;emerging growth company,&#148; we intend to rely on exemptions relating to: (1)&nbsp;providing an auditor&#146;s attestation report on our system of internal control over financial reporting pursuant to Section&nbsp;404(b) of the
Sarbanes-Oxley Act and (2)&nbsp;complying with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor&#146;s report providing additional information
about the audit and the financial statements, known as the auditor discussion and analysis. We will remain an emerging growth company until the earliest of (a)&nbsp;the last day of the fiscal year in which we have total annual gross revenue of $1.0
billion or more, (b)&nbsp;December&nbsp;31, 2019, the last day of our fiscal year following the fifth anniversary of the date of the completion of our initial public offering, (c)&nbsp;the date on which we have issued more than $1.0 billion in
non-convertible debt during the previous three years and (d)&nbsp;the date on which we are deemed to be a large accelerated filer under the rules of the SEC. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Net Operating Loss Carryforwards </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Utilization of
the net operating loss (NOL) and research and development credit carryforwards may be subject to a substantial annual limitation due to ownership change limitations that have occurred or that could occur in the future, as required by
Section&nbsp;382 and 383 of the Internal Revenue Code (Code), as well as similar state and foreign provisions. These ownership changes may limit the amount of NOL and research and development credit carryforwards that can be utilized annually to
offset future taxable income and tax, respectively. In general, an &#147;ownership change&#148; as defined by Section&nbsp;382 of the Code results from a transaction or series of transactions over a three-year period resulting in an ownership change
of more than 50% of the outstanding stock of a company by certain stockholders. We have completed a study to assess whether an ownership change has occurred or whether there have been multiple ownership changes since our formation. The results of
this study indicated we experienced ownership changes, as defined by Section&nbsp;382 of the Code, in each of 2006, 2011, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">86 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
2012, 2013 and 2016. We have not recorded NOLs that as a result of these restrictions will expire unused. The limitations are $3.9 million, $30.5 million, $36.7 million, $47.2 million, $47.2
million, $47.2 million and $100.1 million in 2010, 2011, 2012, 2013, 2014, 2015 and 2016 respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2016, and 2015, we had
U.S. federal NOL carryforwards of $24.5 million and $55.5 million respectively, which may be available to offset future income tax liabilities and expire at various dates through 2036. As of December&nbsp;31, 2016, and 2015, we also had U.S. state
NOL carryforwards of $24.3 million and $55.4 million, respectively, which may be available to offset future income tax liabilities and expire at various dates through 2036. At December&nbsp;31, 2016 and 2015, we also had $26.1 million and $25.6
million, respectively, of foreign NOL carryforwards which may be available to offset future income tax liabilities, which carryforwards do not expire. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As
of December&nbsp;31, 2016, we have provided a full valuation allowance for deferred tax assets. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recently Adopted Accounting Pronouncements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In November 2015, the Financial Accounting Standards Board (the FASB) issued Accounting Standards Update (ASU) No.&nbsp;2015-17, Income Taxes (Topic 740):
Balance Sheet Classification of Deferred Taxes. The new standard requires that deferred tax assets and liabilities be classified as noncurrent in a classified statement of financial position. We adopted this standard as of December&nbsp;31, 2015,
with prospective application. As a result, we reclassified our deferred tax assets classified as current to noncurrent and our deferred tax liabilities classified as current to noncurrent in our December&nbsp;31, 2015 consolidated balance sheet.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In November 2014, the FASB issued ASU 2014-16, Derivatives and Hedging (Topic 815): Determining Whether the Host Contract in a Hybrid Financial
Instrument Issued in the Form of a Share Is More Akin to Debt or to Equity. This standard provides guidance to eliminate the existing diversity in practice in accounting for hybrid financial instruments issued in the form of a share. A hybrid
financial instrument consists of a &#147;host contract&#148; into which one or more derivative terms have been embedded. This guidance requires an entity to consider the terms and features of the entire financial instrument, including the embedded
derivative features, in order to determine whether the nature of the host contract is more akin to debt or to equity. This guidance is effective for fiscal years and interim periods beginning after December&nbsp;15, 2015, with early adoption
permitted. A reporting entity should apply this guidance using a modified retrospective approach by recording a cumulative-effect adjustment to equity as of the beginning of the annual period of adoption. Retrospective application is permitted to
all relevant prior periods. We have concluded that this guidance has no impact on the presentation of our results of operations, financial position and disclosures. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In August 2014, the FASB issued ASU No. 2014-15, Presentation of Financial Statements&#151;Going Concern (Subtopic 2015-40): Disclosure of Uncertainties about
an Entity&#146;s Ability to Continue as a Going Concern. This guidance addresses management&#146;s responsibility in evaluating whether there is substantial doubt about a company&#146;s ability to continue as a going concern and to provide related
footnote disclosures. The guidance is effective for fiscal years ending after December&nbsp;15, 2016 and for interim periods within those fiscal years. The adoption of this standard did not have a material impact on our consolidated financial
statements and related disclosures. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In June 2014, the FASB issued ASU No.&nbsp;2014-12, Compensation-Stock Compensation (Topic 718): Accounting for
Share-Based Payments When the Terms of an Award Provide That a Performance Target Could be Achieved after the Requisite Service Period. This standard provides guidance requiring when there is a performance target that affects vesting of equity
awards granted and could be achieved after the requisite service period to be treated as a performance condition. A reporting entity should apply existing guidance on stock-based compensation, as it relates to such awards. This guidance is effective
for annual periods and interim periods within those annual periods beginning after December&nbsp;15, 2015 with early adoption permitted using either of two methods: (i)&nbsp;prospective to all awards granted or modified after the effective date; or
(ii)&nbsp;retrospective to all awards with </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">87 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
performance targets that are outstanding as of the beginning of the earliest annual period presented in the financial statements and to all new or modified awards thereafter, with the cumulative
effect of applying this guidance as an adjustment to the opening retained earnings balance as of the beginning of the earliest annual period presented in the financial statements. We issued performance-based awards during the year ended
December&nbsp;31, 2015. We adopted this guidance on a prospective basis and there have not been any performance-based awards since the effective date of the guidance. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recently Issued Accounting Pronouncements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In November
2016, the FASB issued guidance that requires restricted cash and restricted cash equivalents be included with cash and cash equivalents when reconciling the total beginning and ending amounts for the periods shown on the statement of cash flows. The
new standard is effective for us on January&nbsp;1, 2018 using a retrospective transition method to each period presented. Early adoption is permitted. We are currently evaluating the timing of our adoption and the expected impact that this standard
could have on our consolidated financial statements and related disclosures. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In March 2016, the FASB issued ASU No.&nbsp;2016-09, Compensation-Stock
Compensation (Topic 718): Improvements to Employee Shared-Based Payment Accounting. This standard provides guidance on accounting for employee share-based payments. This guidance addresses several aspects of the accounting for share-based payment
award transactions, including: (a)&nbsp;income tax consequences; (b)&nbsp;classification of awards as either equity or liabilities; and (c)&nbsp;classification on the statement of cash flows.&nbsp;This standard will be effective for fiscal years
beginning after December&nbsp;15, 2016, including interim periods within those fiscal years.&nbsp;We are evaluating the impact of this guidance on the presentation of our results of operations, financial position and disclosures. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In February 2016, the FASB, issued ASU No.&nbsp;2016-02-&nbsp;<I>Leases (Topic 842)</I>. This requires companies to recognize on the balance sheet the assets
and liabilities for the rights and obligations created by leased assets. ASU 2016-02 will be effective for us in the first quarter of 2019, with early adoption permitted. We are currently evaluating the impact that the adoption of ASU 2016-02 will
have on our consolidated financial statements or related disclosures. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In May 2014, the FASB issued guidance that affect any entity that either enters
into contracts with customers to transfer goods or services or enters into contracts for the transfer of nonfinancial assets unless those contracts are within the scope of other standards (e.g., insurance contracts or lease contracts). The core
principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those
goods or services. The amendments are effective for annual reporting periods beginning after December&nbsp;15, 2016, including interim periods within that reporting period. Early application is not permitted. We have not had any revenue from
contracts with customers through December&nbsp;31, 2016. Our adoption of this guidance is not expected to have a material impact on our consolidated financial statements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Results of Operations </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Years Ended
December&nbsp;31, 2016 and 2015 </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes the results of our operations for the years ended December&nbsp;31, 2016 and 2015:
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="60%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="6" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">21,577</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">23,243</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1,666</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,530</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,266</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">264</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Impairment of goodwill and intangible assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">310</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(110</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(35</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,099</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(205</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,304</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,978</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">88 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Revenue</I></B>. We did not record any revenue for the years ended December&nbsp;31, 2016 and 2015. We do
not expect to generate any revenue in the future until we have successfully completed the development of NeoCart and received approval from the FDA to market NeoCart or any future product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development Expenses</I></B>. Research and development expenses were $21.6 million for the year ended December&nbsp;31, 2016 as compared to
$23.2 million for the year ended December&nbsp;31, 2015. The decrease in research and development expenses of $1.7 million was primarily due to a reduction in consulting expenses of $1.6 million, a reduction in raw materials expense of $0.8 million
due to purchases made in 2015 of raw materials to support our ongoing Phase 3 clinical trial that were not repeated in 2016, and a reduction in patient recruitment costs of $0.6 million, and was partially offset by an increase of approximately $1.2
million due to higher patient enrollment in the NeoCart Phase 3 clinical trial. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General and Administrative Expenses</B>. General and administrative
expenses were $8.5 million for the year ended December&nbsp;31, 2016 as compared to $8.3 million for the year ended December&nbsp;31, 2015. The increase in expense of $0.3 million was primarily due to an increase in personnel related costs of
approximately $0.5 million, an increase of approximately $0.3 million related to stock-based compensation expense from new option grants and an increase of $0.2 million of facility-related expenses, partially offset by a decrease of $0.7 million in
professional and consulting expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Impairment of Intangible Assets</B>. Impairment of intangible assets was $0.2 million and $0.3 million for the
years ended December&nbsp;31, 2016 and 2015, respectively. Impairments of IPR&amp;D were identified during our annual impairment testing for the years ended December&nbsp;31, 2016 and 2015, respectively. The underlying IPR&amp;D is a secondary asset
to our core product NeoCart, which receives virtually all of our development and commercialization efforts. As a result, we recorded the necessary reduction in the value IPR&amp;D resulting in the complete write-off of the asset. During the fourth
quarter of 2016, we deemed the value of the IPR&amp;D to be zero for the year ended December&nbsp;31, 2016 as we have no plans to advance the technology or use it in any future clinical development activities. The result was a write-off of $0.2
million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Other Income (Expense), Net</B>. Other income (expense), net was $14.1 million for the year ended December&nbsp;31, 2016, compared to ($0.2)
million for the year ended December&nbsp;31, 2015. The $14.3 million change from other (expense) to other income was primarily due to the periodic fair value adjustment of warrant liability of $17.5 million partially offset by costs incurred of $3.1
million in conjunction with the Private Placement in September 2016. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Liquidity and Capital Resources </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Through December&nbsp;31, 2016, we had an accumulated deficit of $181.8 million and anticipate that we will continue to incur net losses for the next several
years. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Through December&nbsp;31, 2016, we have funded our consolidated operations primarily through the proceeds of our initial public offering, private
placement of preferred stock and convertible notes and commercial bank debt. As of December&nbsp;31, 2016, we had cash and cash equivalents of $31.9 million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe our existing cash and cash equivalents will be sufficient to fund our projected cash needs into the middle of 2018 and we have the ability to
reduce or defer operating expenses as may be needed to fund our operations into the middle of the third quarter of 2018. We will require additional capital for the further development and commercialization activities of our existing product
candidates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">89 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth a summary of the net cash flow activity for each of the periods indicated: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="60%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>$</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(25,736</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(30,034</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,298</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(320</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,949</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,629</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(84</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,049</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,371</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,678</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">519</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net increase (decrease) in cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">993</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(27,612</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">28,605</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(104</TD>
<TD NOWRAP VALIGN="bottom">)%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Operating Capital Requirements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We anticipate that we will continue to incur losses for the next several years, and we expect the losses to increase as we continue the development of, and
seek regulatory approvals for NeoCart and our future product candidates, and begin to commercialize any approved products. We are subject to all risks incident to the development of new therapeutic products, and we may encounter unforeseen expenses,
difficulties, complications, delays and other unknown factors that may adversely affect our business. We have incurred additional costs associated with operating as a public company. We anticipate that we will need substantial additional funding in
connection with our continuing operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Until we can generate a sufficient amount of revenue from our regenerative medicine products, if ever, we
expect to finance future cash needs through public or private equity or debt offerings. Additional capital may not be available on reasonable terms, if at all. If we are unable to raise additional capital in sufficient amounts or on terms acceptable
to us, we may have to significantly delay, scale back or discontinue the development or commercialization of one or more of our product candidates. If we raise additional funds through the issuance of additional debt or equity securities, it could
result in dilution to our existing stockholders, increased fixed payment obligations and the existence of securities with rights that may be senior to those of our common stock. If we incur indebtedness, we could become subject to covenants that
would restrict our operations and potentially impair our competitiveness, such as limitations on our ability to incur additional debt, limitations on our ability to acquire, sell or license intellectual property rights and other operating
restrictions that could adversely impact our ability to conduct our business. Any of these events could significantly harm our business, financial condition and prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our forecast of the period of time through which our financial resources will be adequate to support our operations is a forward-looking statement and
involves risks and uncertainties, and actual results could vary as a result of a number of factors. We have based this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently
expect. The amount and timing of future funding requirements, both near- and long-term, will depend on many factors, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the design, initiation, progress, size, timing, costs and results of preclinical studies and clinical trials for our product candidates; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the outcome, timing and cost of regulatory approvals by the U.S. Food and Drug Administration (FDA) and comparable foreign regulatory authorities, including the potential for the FDA or comparable foreign regulatory
authorities to require that we perform more studies than, or evaluate clinical endpoints other than those that we currently expect; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the timing and costs associated with our manufacturing technology transfer; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the timing and costs associated with manufacturing NeoCart and our future product candidates for clinical trials, preclinical studies and, if approved, for commercial sale; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the cost of establishing sales, marketing and distribution capabilities for NeoCart, or any products for which we may receive regulatory approval; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">90 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the number and characteristics of product candidates that we pursue; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the extent to which we are required to pay milestone or other payments under our in-license agreements and the timing of such payments; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the cost of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our need to expand our research and development activities, including our need and ability to hire additional employees; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our need to implement additional infrastructure and internal systems and hire additional employees to operate as a public company and prepare to support the commercialization of NeoCart, if approved; and
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the effect of competing technological and market developments. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we cannot expand our operations or
otherwise capitalize on our business opportunities because we lack sufficient capital, our business, financial condition and results of operations could be materially adversely affected. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Operating Activities </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cash used in operating
activities decreased $4.3 million to $25.7 million for the year ended December&nbsp;31, 2016 from $30.0 million for the year ended December&nbsp;31, 2015. During the year ended December&nbsp;31, 2016, the net cash used for operating activities of
$25.7 million consisted primarily of our net loss of $16.0 million adjusted for non-cash items including: the decrease in fair value of warrants of $17.5 million, $3.1 million in warrant expense, $1.7 million in depreciation expense, a $2.0 million
increase in operating assets and liabilities, $1.5 million in stock-based compensation expense, a $0.5 million decrease in deferred rent and lease incentive, and $0.2 million related to the impairment of intangible assets. During the year ended
December&nbsp;31, 2015, the net cash used for operating activities of $30.0 million consisted primarily of our net loss of $32.0 million adjusted for non-cash items including: $1.6 million in depreciation expense, $1.2 million in stock-based
compensation expense, a $0.8 million decrease in operating assets and liabilities, a $0.3 million decrease in deferred rent and lease incentive and $0.3 million related to the impairment of intangible assets. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Investing Activities </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cash used in investing
activities decreased $1.6 million to $0.3 million for the year ended December&nbsp;31, 2016 from $1.9 million for the year ended December&nbsp;31, 2015. The difference was primarily related to a reduction in purchases of property and equipment. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Financing Activities </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cash provided by financing
activities increased $22.7 million to $27.0 million for the year ended December&nbsp;31, 2016 from $4.4 million for the year ended December&nbsp;31, 2015. During the year ended December&nbsp;31, 2016, we received net proceeds of $27.6 million from
the Private Placement, partially offset by the payment on our equipment term loan of $0.6 million. During the year ended December&nbsp;31, 2015, we received net proceeds of $4.7 million from the partial exercise of the underwriters&#146;
overallotment option as part of our initial public offering, partially offset by the payment on our equipment line of credit of $0.4 million. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Loan and
Security Agreements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Equipment Loan </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In
July 2014, we entered into a loan and security agreement with Silicon Valley Bank, which provides for a line of credit to finance certain equipment purchases up to an aggregate of $1.75 million through March&nbsp;31, 2015.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">91 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
The line has been fully drawn and is payable in 36 monthly installments of principal and interest commencing six months following the date of the draw with an annual interest rate of 2.75% plus
the greater of 3.25% and the prime rate in effect at the time of each draw, as published in the Wall Street Journal. The outstanding balance on the line of credit is secured by a first priority lien over all equipment purchased using the line of
credit. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In accordance with the terms of the equipment line of credit, we issued a warrant to Silicon Valley Bank in July 2014 to purchase 6,566 shares of
our common stock at an exercise price per share of $7.99. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The equipment line of credit includes customary operating but non-financial covenants,
including limitations on our ability to incur additional indebtedness, issue dividends, sell assets, engage in any business other than our current business, merge or consolidate with other entities, create liens on our assets, make investments,
repurchase our stock in certain instances, enter into transactions with affiliates, make payments on subordinated indebtedness and transfer or encumber any collateral securing the debt. As of December&nbsp;31, 2016 and 2015, $0.8 million and $1.3
million, respectively, of borrowings were outstanding under the line of credit and we were in compliance with all required covenants. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Off-Balance
Sheet Arrangements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We did not have any off-balance sheet arrangements during the periods presented, and we do not currently have, any off-balance
sheet arrangements, as defined in the rules and regulations of the SEC. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B><A NAME="tx293850_12"></A>ITEM&nbsp;7A.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>QUALITATIVE AND QUANTITATIVE DISCLOSURES ABOUT MARKET RISK </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Not applicable. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B><A NAME="tx293850_13"></A>ITEM&nbsp;8.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The consolidated financial statements and related
consolidated financial statement schedules required to be filed are indexed on page&nbsp;97 and are incorporated herein. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B><A NAME="tx293850_14"></A>ITEM&nbsp;9.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Not applicable.
</P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B><A NAME="tx293850_15"></A>ITEM&nbsp;9A.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>CONTROLS AND PROCEDURES </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Conclusion Regarding the Effectiveness of Disclosure Controls and Procedures
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our management, with the participation of our Chief Executive Officer and our Chief Financial Officer, evaluated the effectiveness of our disclosure
controls and procedures as of December&nbsp;31, 2016. The term &#147;disclosure controls and procedures,&#148; as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to
ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC&#146;s rules and forms.
Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and
communicated to the company&#146;s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no
matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the
evaluation of our disclosure controls and procedures as of December&nbsp;31, 2016, our Chief Executive Officer and Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable
assurance level. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">92 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Management&#146;s Report on Internal Control over Financial Reporting </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our management is responsible for establishing and maintaining adequate &#147;internal control over financial reporting&#148; for the Company, as that term is
defined in Rule 13a-15(f) and Rule 15d-15(f) under the Exchange Act. Our internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of our
consolidated financial statements for external purposes in accordance with U.S. generally accepted accounting principles. Internal control over financial reporting includes those policies and procedures that (i)&nbsp;pertain to the maintenance of
records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets of the company; (ii)&nbsp;provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial
statements in accordance with U.S. generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (iii)&nbsp;provide
reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the company&#146;s assets that could have a material effect on the financial statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, we have conducted an
evaluation of the effectiveness of our internal control over financial reporting based upon the criteria established in <I>Internal Control&#151;Integrated Framework (2013)</I>&nbsp;issued by the Committee of Sponsoring Organizations of the Treadway
Commission. Based on this evaluation, our management has concluded that our internal control over financial reporting was effective as of December&nbsp;31, 2016 to provide reasonable assurance regarding the reliability of financial reporting and the
preparation of financial statements for external reporting purposes in accordance with U.S. generally accepted accounting principles. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Because of its
inherent limitations, a system of internal control over financial reporting can provide only reasonable assurances and may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the
risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with policies and procedures may deteriorate. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Changes in Internal Control over Financial Reporting </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There has been no change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) during the fourth
quarter of 2016 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Limitations
on the Effectiveness of Controls </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Control systems, no matter how well conceived and operated, are designed to provide a reasonable, but not an
absolute, level of assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their
costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected. Because of the inherent limitations in any
control system, misstatements due to error or fraud may occur and not be detected. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B><A NAME="tx293850_16"></A>ITEM&nbsp;9B.</B></TD>
<TD ALIGN="left" VALIGN="top"><B></B><B><I>OTHER INFORMATION</I></B><B> </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">None. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">93 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PART III </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B><A NAME="tx293850_17"></A>ITEM&nbsp;10.</B></TD>
<TD ALIGN="left" VALIGN="top"><B></B><B><I>DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</I></B><B> </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The information required by
this item regarding our directors, including the audit committee and audit committee financial experts, and executive officers corporate governance, our code of conduct and compliance with Section&nbsp;16(a) of the Exchange Act will be included in
our Proxy Statement for the 2017 Annual Meeting of Stockholders to be filed with the Securities and Exchange Commission within 120 days of fiscal year ended December&nbsp;31, 2016 (2017 Proxy Statement) and is incorporated herein by reference. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B><A NAME="tx293850_18"></A>ITEM&nbsp;11.</B></TD>
<TD ALIGN="left" VALIGN="top"><B></B><B><I>EXECUTIVE COMPENSATION</I></B><B> </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The information required by this item regarding executive
compensation will be included in our 2017 Proxy Statement and is incorporated herein by reference. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B><A NAME="tx293850_19"></A>ITEM&nbsp;12.</B></TD>
<TD ALIGN="left" VALIGN="top"><B></B><B><I>SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</I></B><B> </B></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Information required by this item regarding security ownership of certain beneficial owners and management will be included in our 2017 Proxy Statement and is
incorporated herein by reference. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B><A NAME="tx293850_20"></A>ITEM&nbsp;13.</B></TD>
<TD ALIGN="left" VALIGN="top"><B></B><B><I>CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</I></B><B> </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
information required by this item regarding certain relationships and related transactions and directors independence will be included in our 2017 Proxy Statement and is incorporated herein by reference. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B><A NAME="tx293850_21"></A>ITEM&nbsp;14.</B></TD>
<TD ALIGN="left" VALIGN="top"><B></B><B><I>PRINCIPAL ACCOUNTANT FEES AND SERVICES</I></B><B> </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The information required by this item
regarding principal accounting fees and services will be included in our 2017 Proxy Statement and is incorporated herein by reference. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">94 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PART IV </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B><A NAME="tx293850_22"></A>ITEM&nbsp;15.</B></TD>
<TD ALIGN="left" VALIGN="top"><B></B><B><I>EXHIBITS AND FINANCIAL STATEMENTS SCHEDULES</I></B><B> </B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">The following documents are filed as part of, or incorporated by reference into, this annual report on Form&nbsp;10-K: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"><I>Financial Statements</I>. See Index to Consolidated Financial Statements under Item&nbsp;8 of this annual report on Form 10-K. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"><I>Financial Statement Schedules</I>. All schedules have been omitted because the information required to be presented in them is not applicable or is shown in the consolidated financial statements or related notes.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"><I>Exhibits</I>. We have filed, or incorporated into this annual report on Form 10-K by reference, the exhibits listed on the accompanying Exhibit Index immediately following the consolidated financial statements of
this annual report on Form 10-K. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"><I>Exhibits</I>. See Item&nbsp;15(a)(3) above. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"><I>Financial Statement Schedules</I>.<I> </I>See Item&nbsp;15(a)(2) above. <I></I> </TD></TR></TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B><A NAME="tx293850_23"></A>ITEM&nbsp;16.</B></TD>
<TD ALIGN="left" VALIGN="top"><B></B><B><I>FORM 10-K SUMMARY</I></B><B> </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Not applicable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">95 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx293850_24"></A>Signatures </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of Section&nbsp;13 and 15(d) of the Securities Exchange Act of 1934, as amended, the registrant has duly caused
this annual report on Form 10-K to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Waltham, Commonwealth of Massachusetts, on March 16, 2017. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>HISTOGENICS CORPORATION</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/ Adam Gridley</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Adam Gridley,</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>President and Chief Executive Officer</B></P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act of 1934, this annual report on Form 10-K has been
signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="15%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:33.30pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Signature</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:15.95pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Title</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:16.00pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Date</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/ Adam Gridley</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Adam Gridley</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Chief Executive Officer, President and Director<BR>(Principal Executive Officer)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">March&nbsp;16, 2017</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/ Jonathan Lieber</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Jonathan Lieber</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Chief Financial Officer<BR>(Principal Financial and Accounting Officer)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">March&nbsp;16, 2017</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/ Garheng Kong, M.D., Ph.D.</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Garheng Kong, M.D., Ph.D.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Chairman of the Board of Directors</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">March&nbsp;16, 2017</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/ Joshua Baltzell</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Joshua Baltzell</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">March&nbsp;16, 2017</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/ David Gill</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>David Gill</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">March&nbsp;16, 2017</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/ John H. Johnson</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>John H. Johnson</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">March&nbsp;16, 2017</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/ Michael Lewis</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Michael Lewis</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">March&nbsp;16, 2017</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman" ALIGN="center">/s/ Kevin Rakin</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Kevin Rakin</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">March&nbsp;16, 2017</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">96 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx293850_25"></A>Histogenics Corporation </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="index"></A>Index to the Consolidated Financial Statements </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="95%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin293850_1">Report of Independent Registered Public Accounting Firm</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">98</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin293850_2">Consolidated Balance Sheets as of December&nbsp;31, 2016 and
2015</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">99</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin293850_3">Consolidated Statements of Operations for the Years Ended December&nbsp;
31, 2016 and 2015</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin293850_4">Consolidated Statements of Convertible Preferred Stock and Stockholders&#146;
 Equity for the Years Ended December&nbsp;31, 2016 and 2015</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">101</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin293850_5">Consolidated Statements of Cash Flows for the Years Ended December&nbsp;
31, 2016 and 2015</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">102</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#fin293850_6">Notes to Consolidated Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">103</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">97 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin293850_1"></A>Report of Independent Registered Public Accounting Firm </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Board of Directors and Shareholders </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Histogenics Corporation
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have audited the accompanying consolidated balance sheets of Histogenics Corporation (a&nbsp;Delaware corporation) and subsidiaries (the
&#147;Company&#148;) as of December&nbsp;31, 2016 and 2015, and the related consolidated statements of operations, convertible preferred stock and stockholders&#146; equity, and cash flows for each of the two years in the period ended
December&nbsp;31, 2016. These financial statements are the responsibility of the Company&#146;s management. Our responsibility is to express an opinion on these financial statements based on our audits. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we
plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. We were not engaged to perform an audit of the Company&#146;s internal control over financial reporting. Our audits
included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company&#146;s
internal control over financial reporting. Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles
used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of Histogenics
Corporation and subsidiaries as of December&nbsp;31, 2016 and 2015, and the results of their operations and their cash flows for each of the two years in the period ended December&nbsp;31, 2016 in conformity with accounting principles generally
accepted in the United States of America. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ GRANT THORNTON LLP </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Boston, Massachusetts </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">March&nbsp;16, 2017 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">98 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin293850_2"></A>Histogenics Corporation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Consolidated Balance Sheets </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(In thousands, except share and per share data) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>ASSETS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">31,908</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">30,915</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">173</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">321</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,081</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,236</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,860</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,213</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Intangible asset, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">137</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">137</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">36,078</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">36,786</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>LIABILITIES AND STOCKHOLDERS&#146; EQUITY</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,588</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable due to Intrexon Corporation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">360</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">229</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,097</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,444</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses due to Intrexon Corporation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,546</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current portion of deferred rent</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">136</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">126</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current portion of deferred lease incentive</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">407</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">407</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current portion of equipment loan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">583</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">583</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,171</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,359</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses due to Intrexon Corporation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,040</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred rent, long-term</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">315</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">451</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred lease incentive, long-term</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">610</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equipment loan, long-term</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">178</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">761</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Warrant liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,197</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,511</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,588</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Commitments and contingencies (Note 7)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible preferred stock and stockholders&#146; equity:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible preferred stock, $0.01 par value; 30,000,000 shares authorized, 13,416.4734 and 0
shares issued and outstanding at December&nbsp;31, 2016 and 2015, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock, $0.01 par value; 100,000,000 shares authorized, 20,647,612 and 13,273,470 shares
issued and outstanding at December&nbsp;31, 2016 and 2015, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">159</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">132</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional paid-in capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">195,181</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">193,631</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(181,773</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(165,565</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,567</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,198</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities and stockholders&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">36,078</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">36,786</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:48pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral part of these consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">99 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin293850_3"></A>Histogenics Corporation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Consolidated Statements of Operations </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(In thousands, except share and per share data) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="76%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,577</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,243</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,530</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,266</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Impairment of intangible asset</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">310</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,307</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,819</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(30,307</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(31,819</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(60</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(133</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other expense, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(248</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(72</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Warrant expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,100</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of warrant liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,507</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,099</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(205</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(16,208</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(32,024</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="4"></TD>
<TD HEIGHT="24" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss attributable to common stockholders&#151;basic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(13,863</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(32,024</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss attributable to common stockholders&#151;diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(31,370</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(32,024</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss per common share&#151;basic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.97</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2.42</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss per common share&#151;diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2.18</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2.42</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average shares used to compute loss per common share&#151;basic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,256,954</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,231,126</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average shares used to compute loss per common share&#151;diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,389,192</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,231,126</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:200pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral part of these consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">100 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin293850_4"></A>Histogenics Corporation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Consolidated Statements of Convertible Preferred Stock and Stockholders&#146; Equity </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(In thousands, except share and per share data) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="47%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series A</B><br><B>Convertible</B><br><B>Preferred Stock</B><br><B>$0.01 Par Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common Stock<BR>$0.01 Par Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Restricted</B><br><B>Stock $0.01 Par</B><br><B>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Additional</B><br><B>Paid-In</B><br><B>Capital</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated</B><br><B>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B><br><B>Stockholders</B><br><B>Equity</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Balance at December&nbsp;31, 2014</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,746,519</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">127</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,493</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">187,620</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(133,541</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">54,206</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Issuance of common stock</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">from overallotment, net of underwriting</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">fees and issuance costs of $377</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">465,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,733</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,738</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Issuance of warrant as part of the</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">consideration for the consulting related</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">to financial support services in March 2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Vesting of restricted stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,303</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,303</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,228</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,228</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Exercise of common stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,458</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(32,024</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(32,024</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Balance at December&nbsp;31, 2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,268,280</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">132</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,190</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">193,631</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(165,565</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,198</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,548</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,548</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Exercise of common stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,685</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Vesting of restricted stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,301</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,301</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Issuance of common stock related to private placement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,596,059</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Issuance of Series A convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,159</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Conversion of Series A convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,743</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,774,398</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,208</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(16,208</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Balance at December&nbsp;31, 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,416</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,645,723</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">159</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,889</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">195,181</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(181,773</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13,567</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:110pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral part of these consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">101 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin293850_5"></A>Histogenics Corporation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Consolidated Statements of Cash Flows </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(In thousands, except share and per share data) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8.5pt" ALIGN="center">


<TR>
<TD WIDTH="84%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">CASH FLOWS FROM OPERATING ACTIVITIES:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(16,208</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(32,024</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Adjustments to reconcile net loss to net cash used in operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,673</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,614</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Deferred rent and lease incentive</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(533</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(322</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Impairment of intangible asset</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">310</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,548</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,228</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Change in fair value of warrant</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,507</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Warrant expense in connection with private placement</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Changes in operating assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">148</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">475</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Accrued expenses due to Intrexon Corporation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,494</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,539</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(435</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,844</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Accounts payable due to Intrexon Corporation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">131</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">211</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">653</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(232</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(25,736</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(30,034</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">CASH FLOWS FROM INVESTING ACTIVITIES:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Purchases of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(320</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,949</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(320</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,949</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">CASH FLOWS FROM FINANCING ACTIVITIES:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Proceeds from issuance of common stock, preferred stock, and warrants in connection with private
placement, net of issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,630</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Proceeds from overallotment, net of issuance costs of $377</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,738</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Repayments on equipment term loan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(583</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(406</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Proceeds from exercise of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,049</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,371</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Net increase (decrease) in cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">993</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(27,612</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Cash and cash equivalents&#151;Beginning of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,915</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58,527</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Cash and cash equivalents&#151;End of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">31,908</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">30,915</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman"><B>Supplemental Disclosure of Non-Cash Items:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Fair market value of private placement warrants at issuance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">30,704</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman"><B>Supplemental Disclosure of Cash Flow information:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Cash paid for taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">257</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8.5pt; font-family:Times New Roman">Cash paid for interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:150pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">The accompanying notes are an integral part of these consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">102 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="fin293850_6"></A>Histogenics Corporation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>NATURE OF BUSINESS </B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>Organization</B></TD>
<TD ALIGN="left" VALIGN="top"><B></B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Histogenics Corporation (the &#147;Company&#148;) was incorporated under the laws of the Commonwealth
of Massachusetts on June&nbsp;28, 2000 and has its principal operations in Waltham, Massachusetts. In 2006, the Company&#146;s board of directors approved a corporate reorganization pursuant to which the Company incorporated as a Delaware
corporation. The Company is a regenerative medicine company engaged in developing and commercializing products in the musculoskeletal segment of the marketplace. The Company combines cell therapy and tissue engineering technologies to develop
products for tissue repair and regeneration and is initially focused on patients suffering from cartilage-derived pain and immobility. The Company&#146;s most advanced product, NeoCart, is currently in a Phase 3 clinical trial in the United States
(the &#147;U.S.&#148;) under a special protocol assessment with the U.S. Food and Drug Administration (&#147;FDA&#148;) for the treatment of knee cartilage damage. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On May&nbsp;13, 2011, the Company completed the acquisition of ProChon Biotech Ltd. (&#147;ProChon&#148;), a privately-held biotechnology company focused on
modulating the fibroblast growth factor system for consideration of $2.2 million to enable it to create more effective solutions for tissue regeneration. ProChon&#146;s products combine cell regeneration technologies with proprietary growth factors
and biocompatible scaffolds to restore injured or chronically damaged tissues. The acquisition of ProChon provided the Company with access to a significant portfolio of intellectual property, including proprietary cell growth factors, in addition to
furthering opportunities for the use of biomaterials to create more effective solutions for regenerating human tissue. The acquisition led to the initial recognition of goodwill, which was subsequently written off in 2011, and intangible assets
including IPR&amp;D and a licensing agreement which have been impaired as discussed in Note 2. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&nbsp;18, 2014, the Company formed a wholly
owned subsidiary, Histogenics Securities Corporation, under the laws of the Commonwealth of Massachusetts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September&nbsp;29, 2016, the Company closed
a private placement of common stock, preferred stock and warrants, contemplated by a securities purchase agreement dated September&nbsp;15, 2016, with certain institutional and accredited investors. The net proceeds after deducting placement agent
fees and other transaction-related expenses was $27.6 million. See Note 8, Capital Stock, for further discussion of the private placement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Since its
inception, the Company has devoted substantially all of its efforts to product development, recruiting management and technical staff, raising capital, starting up production and building infrastructure and has not yet generated revenues from its
planned principal operations. Expenses have primarily been for research and development and related administrative costs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company is subject to a
number of risks. The developmental nature of its activities is such that significant inherent risks exist in the Company&#146;s operations. Principal among these risks are the successful development of therapeutics, successfully enrolling patients
in its clinical trials in a timely manner, obtaining regulatory approval for any of its product candidates in any jurisdiction, compliance with government regulations, ability to obtain adequate financing, protection of proprietary therapeutics,
fluctuations in operating results, dependence on key personnel and collaborative partners, adoption of the Company&#146;s products by the physician community, rapid technological changes inherent in the markets targeted, and substitute products and
competition from larger companies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The consolidated financial statements have been prepared on a going-concern basis, which contemplates the realization
of assets and the satisfaction of liabilities in the normal course of business. As shown in the accompanying consolidated financial statements, the Company has incurred losses and cash flow deficits from
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">103 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Histogenics Corporation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
operations for the years ended December&nbsp;31, 2016 and 2015. The Company has financed operations to date primarily through private placements of equity securities, including the sale of common
stock and preferred stock, and the related issuance of warrants in September 2016, the issuance of common stock in the initial public offering completed in December 2014, and borrowings under debt agreements. The Company has incurred losses and
negative cash flows from operations since inception resulting in an accumulated deficit at December&nbsp;31, 2016 of $181.8 million. The Company anticipates that it will continue to incur net losses for the next several years. The Company believes
that its existing cash and cash equivalents will be sufficient to fund its projected cash needs into the middle of 2018, and it has the ability to reduce or defer operating expenses as may be needed to fund its operations into the middle of the
third quarter of 2018. The Company will require additional capital to complete the filing of a biologics license application with the FDA and commercialize NeoCart, if approved, and for the future development of its existing product candidates.
However, the terms of such financing may not be on favorable terms or available to the Company. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Initial public offering </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December&nbsp;3, 2014, the Company completed its initial public offering (&#147;IPO&#148;) whereby the Company sold 5,909,091 shares of common stock at a
price of $11.00 per share. The shares began trading on the Nasdaq Global Market on December&nbsp;3, 2014. Gross proceeds from the offering were $65 million. In January 2015, the underwriters exercised a portion of their overallotment option and
purchased an additional 465,000 shares of the Company&#146;s common stock at $11.00 per share, resulting in an additional $5.1 million in gross proceeds. After giving effect to underwriting discounts and commissions and offering expenses payable by
the Company, net proceeds were $61.3 million. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Basis of Accounting </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The consolidated financial statements are prepared in conformity with accounting principles generally accepted in the United States of America (&#147;U.S.
GAAP&#148;). The consolidated financial statements include the accounts of Histogenics Corporation and its wholly-owned subsidiaries, ProChon and Histogenics Securities Corporation. All significant intercompany accounts and transactions are
eliminated in consolidation. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Reclassifications </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
Company has reclassified certain prior period amounts to conform to the current period presentation. The amounts reclassified impact Accounts Payable and Accounts Payable due to Intrexon Corporation (&#147;Intrexon&#148;) for the year ended
December&nbsp;31, 2015. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Use of Estimates </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
preparation of the Company&#146;s consolidated financial statements requires it to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities
in the Company&#146;s consolidated financial statements and accompanying notes. The most significant estimates in the Company&#146;s consolidated financial statements relate to the valuation of equity awards, warrant liability, recoverability of
deferred tax assets, estimated useful lives of fixed assets and intangible assets. The Company bases estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances.
The Company evaluates its estimates and assumptions on an ongoing basis. The Company&#146;s actual results may differ from these estimates under different assumptions or conditions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">104 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Histogenics Corporation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Foreign Currency Translation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s consolidated financial statements are prepared in U.S. dollars. The Company&#146;s foreign subsidiary uses the U.S. dollar as its functional
and reporting currency, as management determined that the U.S. dollar is the primary currency of the economic environment in which the subsidiary operates. When transactions are required to be paid in the local currency of the foreign subsidiary,
any resulting foreign currency transaction gain or loss is recorded as a component of &#147;Other income (expense), net&#148; in the consolidated statements of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Segment and Geographic Information </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Operating segments
are defined as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker (&#147;CODM&#148;) or decision-making group in making decisions regarding resource
allocation and assessing performance. The Company operates in two geographic regions: the United States (Massachusetts) and Israel (Tel Aviv) and views its operations as two operating segments: Histogenics Corporation (United States) and ProChon
(Israel) as the CODM reviews separate discrete financial information in making decisions regarding resource allocations and assessing performance. Operating segments that have similar economic characteristics can be aggregated. As the nature of the
products, customers, and methods to distribute products are the same and the nature of the regulatory environment, the production processes and historical and estimated future margins are similar, the two operating segments have been aggregated into
one reporting segment as they have similar economic characteristics. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Information about the Company&#146;s operations in different geographic regions is
presented in the tables below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="66%"></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Long-lived assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">United States</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,860</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,204</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Israel</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total long-lived assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,860</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,213</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Fair Value Measurements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The carrying amounts reported in the Company&#146;s consolidated financial statements for cash and cash equivalents, accounts payable, equipment loan, and
accrued liabilities approximate their respective fair values because of the short-term nature of these accounts. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Fair value is defined as the price that
would be received if selling an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Fair value should be based on the assumptions that market participants would use when pricing an asset or liability and is based on a fair value hierarchy
that prioritizes the information used to develop those assumptions. The fair value hierarchy gives the highest priority to quoted prices in active markets (observable inputs) and the lowest priority to the Company&#146;s assumptions (unobservable
inputs). Fair value measurements should be disclosed separately by level within the fair value hierarchy. For assets and liabilities recorded at fair value, it is the Company&#146;s policy to maximize the use of observable inputs and minimize the
use of unobservable inputs when developing fair value measurements, in accordance with established fair value hierarchy. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">105 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Histogenics Corporation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Fair value measurements for assets and liabilities where there exists limited or no observable market data
are based primarily upon estimates, and often are calculated based on the economic and competitive environment, the characteristics of the asset or liability and other factors. Therefore, the results cannot be determined with precision and may not
be realized in an actual sale or immediate settlement of the asset or liability. Additionally, there may be inherent weaknesses in any valuation technique, and changes in the underlying assumptions used, including discount rates and estimates of
future cash flows, could significantly affect the results of current or future values. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, from time to time, the Company may be required to
record at fair value other assets on a nonrecurring basis, such as assets held for sale and certain other assets. These nonrecurring fair value adjustments typically involve application of lower-of-cost-or-market accounting or write-downs of
individual assets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The fair value hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets (Level 1), and
the lowest priority to unobservable inputs (Level 3). The Company&#146;s financial assets are classified within the fair value hierarchy based on the lowest level of inputs that is significant to the fair value measurement. The three levels of the
fair value hierarchy, and its applicability to the Company&#146;s financial assets, are described below. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Level 1</I>: Unadjusted quoted
prices in active markets that are accessible at the measurement date of identical, unrestricted assets. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Level 2</I>: Quoted prices for
similar assets, or inputs that are observable, either directly or indirectly, for substantially the full term through corroboration with observable market data. Level 2 includes investments valued at quoted prices adjusted for legal or contractual
restrictions specific to the security. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Level 3</I>: Pricing inputs are unobservable for the assets, that is, inputs that reflect the
reporting entity&#146;s own assumptions about the assumptions market participants would use in pricing the assets. Level 3 includes private investments that are supported by little or no market activity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Level 3 valuations are for instruments that are not traded in active markets or are subject to transfer restrictions and may be adjusted to reflect
illiquidity and/or non-transferability, with such adjustment generally based on available market evidence. In the absence of such evidence, management&#146;s best estimate is used. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">An adjustment to the pricing method used within either Level 1 or Level 2 inputs could generate a fair value measurement that effectively falls in a lower
level in the hierarchy. The Company had no assets or liabilities classified as Level 1 or Level 2 as of December&nbsp;31, 2016 and 2015 other than the money market fund described in the &#147;Cash and Cash Equivalents&#148; section below and there
were no material re-measurements of fair value with respect to financial assets and liabilities, during the periods presented, other than those assets and liabilities that are measured at fair value on a recurring basis. Other than the warrants
issued in connection with the private placement transaction which closed on September&nbsp;29, 2016, the Company had no assets or liabilities classified as Level 3 as of December&nbsp;31, 2016 and 2015.&nbsp;Transfers are calculated on values as of
the transfer date. There were no transfers between Levels 1, 2 and 3 during the twelve months ended December&nbsp;31, 2016 and 2015. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">106 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Histogenics Corporation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The fair value of the warrants was determined using a Monte Carlo simulation model.&nbsp;This model
incorporated several assumptions at each valuation date including: the price of the Company&#146;s common stock on the date of valuation, the historical volatility of the price of the Company&#146;s common stock, the remaining contractual term of
the warrant and estimates of the probability of a fundamental transaction occurring. See Note 8, Capital Stock, for further discussion of the private placement. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:39.50pt; font-size:8pt; font-family:Times New Roman"><B>Description</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Quoted</B><br><B>prices in</B><br><B>active&nbsp;markets</B><br><B>(Level 1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Significant</B><br><B>other</B><br><B>observable&nbsp;inputs</B><br><B>(Level 2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Significant</B><br><B>unobservable</B><br><B>inputs</B><br><B>(Level 3)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>December&nbsp;31, 2016</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Money market funds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">30,318</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">30,318</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Liabilities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Warrant liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,197</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,197</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>December&nbsp;31, 2015</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Money market funds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,764</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,764</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table provides a reconciliation of all liabilities measured at fair value using Level 3 significant unobservable
inputs: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="67%"></TD>
<TD VALIGN="bottom" WIDTH="25%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;December&nbsp;31,&nbsp;2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Beginning balance, January&nbsp;1, 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Issuance of warrants,</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,704</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of warrant liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,507</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ending balance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13,197</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Cash and Cash Equivalents </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents include cash in readily available checking and savings accounts and money market funds. The Company considers all highly liquid
investments with an original maturity of three months or less from the date of purchase to be cash equivalents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s cash equivalents,
which consist of money market funds, are measured at fair value on a recurring basis. As of December&nbsp;31, 2016 and 2015, the carrying amount of cash and cash equivalents was $31.9 million and $30.9 million, respectively, which approximates fair
value and was determined based upon Level 1 inputs. Money market funds are valued using quoted market prices with no valuation adjustments applied. Accordingly, these securities are categorized as Level 1 and had a balance of $30.3 million and $25.8
million as of December&nbsp;31, 2016 and 2015, respectively, shown in the table above. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Concentration of Credit Risk </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Financial instruments, which potentially subject the Company to significant concentration of credit risk, consist primarily of cash and cash equivalents. The
Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and management believes that the Company is not exposed to significant credit
risk due to the financial position of the depository institutions in which those deposits are held. The Company has no financial instruments with off-balance sheet risk of loss. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">107 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Histogenics Corporation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Property and Equipment </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Property and equipment are recorded at historical cost. Costs for capital assets not yet placed into service are capitalized as construction in progress, and
will be depreciated in accordance with the below guidelines once placed into service. Maintenance and repair costs are expensed as incurred. Costs which materially improve or extend the lives of existing assets are capitalized. The Company provides
for depreciation and amortization using the straight-line method over the estimated useful lives of the assets, which are as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="63%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman">Asset Category</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman">Estimated Useful Lives</P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Office equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">3 to 5 years</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Laboratory equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">3 to 5 years</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leasehold improvements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Shorter of the remaining lease term or useful life</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon retirement or sale, the cost of assets disposed and the related accumulated depreciation are removed from the accounts
and any resulting gain or loss is recorded in the consolidated statements of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Impairment of Long-Lived Assets </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Long-lived assets consist primarily of property and equipment and identifiable intangible assets. When impairment indicators exist, the Company&#146;s
management evaluates long-lived assets for potential impairment. An impairment loss is recorded if and when events and circumstances indicate that assets might be impaired and the undiscounted cash flows estimated to be generated by those assets are
less than the carrying amount of those assets. While the Company&#146;s current and historical operating losses and negative cash flows are indicators of impairment, management believes that future cash flows to be received support the carrying
value of its long-lived assets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Impairments, if any, are recognized in earnings. An impairment loss would be recognized in an amount equal to the excess
of the carrying amount over the undiscounted expected future cash flows. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Intangible Asset </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s intangible asset consists of acquired in-process research and development (&#147;IPR&amp;D&#148;) obtained through the acquisition of
ProChon. IPR&amp;D represents the fair value assigned to research and development assets that have not been completed at the date of acquisition. The value assigned to acquired IPR&amp;D is determined by estimating the costs to develop the acquired
technology into commercially viable products, estimating the resulting revenue from the projects, and discounting the net cash flows to present value. The revenue and costs projections used to value acquired IPR&amp;D were adjusted based on the
probability of success of developing a new product. Additionally, the projections considered the relevant market sizes and growth factors, expected trends in technology and the nature and expected timing of new product introductions by the Company
and its competitors. The rates utilized to discount the net cash flows to their present value were commensurate with the stage of development of the projects and uncertainties in the economic estimates used in the projections described above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">IPR&amp;D is considered an indefinite-lived intangible asset and is assessed for impairment annually or more frequently if impairment indicators exist. When
performing the impairment assessment, the Company first assesses qualitative factors to determine whether it is necessary to recalculate the fair value of its acquired IPR&amp;D. If the Company believes, as a result of the qualitative assessment,
that it is more likely than not that the fair value of acquired IPR&amp;D is less than its carrying amount, it calculates the fair value using the same methodology as described above. If the carrying value of the Company&#146;s acquired IPR&amp;D
exceeds its fair value, then an impairment charge is taken and the intangible asset is written-down to its fair value. During the fourth </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">108 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Histogenics Corporation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
quarter the Company deemed the value of the IPR&amp;D to be zero for the year ended December&nbsp;31, 2016 as it has no plans to advance the technology or use it in any future clinical
development activities. The result was a write-off of $0.2 million. For the year ended December&nbsp;31, 2015, the Company determined that there was impairment of its IPR&amp;D of $0.3 million. The Company performed its annual impairment test of its
IPR&amp;D as of December&nbsp;31, 2015 using an income approach, including a discount rate of 13%, applied to probability-adjusted after-tax cash flows. The Company believes that the assumptions are representative of those a market participant would
use in estimating the fair value of the IPR&amp;D. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Intangible asset, net of accumulated impairment charges, are summarized as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December&nbsp;31,&nbsp;2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December&nbsp;31, 2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Cost</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated</B><br><B>Impairment</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Net&nbsp;Book</B><br><B>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Cost</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated</B><br><B>Impairment</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Net&nbsp;Book</B><br><B>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">IPR&amp;D</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">630</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(630</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">630</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(430</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">630</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(630</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">630</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(430</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Initial Public Offering Costs </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company deferred direct incremental costs attributable with the IPO of its common stock prior to the closing of the IPO. These costs represent legal,
accounting and other direct costs related to the Company&#146;s efforts to raise capital through a public sale of its common stock. Upon completion of the IPO, $3.9 million of IPO costs were reclassified to additional paid-in capital as a reduction
of the IPO proceeds. As of December&nbsp;31, 2014, the Company had paid $2.9 million with the remaining $1.0 million included in accounts payable in the consolidated balance sheet. This amount was subsequently paid in 2015. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Restricted Cash </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Restricted cash represents cash held in
a depository account at a financial institution to collateralize a conditional stand-by letter of credit related to the Company&#146;s Lexington, Massachusetts facility lease agreement. Restricted cash is reported as non-current unless the
restrictions are expected to be released in the next twelve months. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Deferred Rent </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Deferred rent consists of the difference between cash payments and the recognition of rent expense on a straight-line basis for the facilities the Company
occupies. The Company&#146;s leases for its Waltham, Massachusetts facility and its Lexington, Massachusetts facility provide for fixed increases in minimum annual rental payments. The total amount of rental payments due over each lease term is
being charged to rent expense ratably over the life of each lease, respectively. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Financial Instruments Indexed to and Potentially Settled in the
Company&#146;s Common Stock </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company evaluates all financial instruments issued in connection with its equity offerings when determining the proper
accounting treatment for such instruments in the Company&#146;s financial statements. The Company considers a number of generally accepted accounting principles under U.S. GAAP to determine such treatment and evaluates the features of the instrument
to determine the appropriate accounting treatment. The Company utilizes the Probability Weighted Expected Return Method (&#147;PWERM&#148;), Option Pricing Model (&#147;OM&#148;) or other appropriate methods to determine the fair value of its
derivative financial instruments. For financial instruments </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">109 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Histogenics Corporation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
indexed to and potentially settled in the Company&#146;s common stock that are determined to be classified as liabilities on the consolidated balance sheet, changes in fair value are recorded as
a gain or loss in the Company&#146;s consolidated statement of operations with the corresponding amount recorded as an adjustment to the liability on its consolidated balance sheet. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Revenue Recognition </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the future, if we generate
revenue, it may be through license agreements, collaborations and product sales. The Company recognizes revenue when all four of the following criteria are met: (1)&nbsp;persuasive evidence that an agreement exists; (2)&nbsp;delivery of the products
and/or services has occurred; (3)&nbsp;the selling price is fixed or determinable; and (4)&nbsp;collectability is reasonably assured. The Company did not recognize any revenue for the years ended December&nbsp;31, 2016 and 2015. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Research and Development Costs </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Research and development
costs are charged to expense as incurred. These costs include, but are not limited to: license fees related to the acquisition of in-licensed products; employee-related expenses, including salaries, benefits and travel; expenses incurred under
agreements with contract research organizations and investigative sites that conduct clinical trials and preclinical studies; the cost of acquiring, developing and manufacturing clinical trial materials; facilities, depreciation and other expenses,
which include direct and allocated expenses for rent and maintenance of facilities; insurance and other supplies; and costs associated with preclinical activities and regulatory operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Costs for certain development activities, such as clinical trials, are recognized based on an evaluation of the progress to completion of specific tasks using
data such as patient enrollment, clinical site activations, or information provided to the Company by its vendors with respect to their actual costs incurred. Payments for these activities are based on the terms of the individual arrangements, which
may differ from the pattern of costs incurred, and are reflected in the consolidated financial statements as prepaid or accrued research and development expense. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Collaboration Arrangements </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Costs reimbursed to a
collaborator for work that it performs are recorded as research and development expenses. These reimbursements can include payments for work performed, or a milestone for which a payment is due, the reimbursements or development milestone
achievement are recorded as research and development expense. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In September 2014, the Company entered into a collaboration agreement with Intrexon
Corporation (&#147;Intrexon&#148;) for the development and commercialization of allogeneic cell therapeutics for the treatment or repair of damaged articular hyaline cartilage in humans, utilizing Intrexon&#146;s proprietary technology (the
&#147;Collaboration Agreement&#148;). Under the terms of the Collaboration Agreement, the Company is responsible for the costs of development and commercialization, with some exceptions. Refer to Note 14, <I>Related Parties</I> for further details
on all terms, conditions and exceptions of this collaboration. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>License Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Costs associated with licenses of technology are expensed as incurred and are included in research and development expenses. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">110 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Histogenics Corporation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Patent Costs </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Costs related to filing and pursuing patent applications are recorded as general and administrative expense as incurred since the recoverability of such
expenditures is uncertain. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Stock-Based Compensation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company accounts for grants of stock options and restricted stock based on their grant date fair value and recognizes compensation expense over their
vesting period. The Company estimates the fair value of stock options as of the date of grant using the Black-Scholes option pricing model and restricted stock based on the fair value of the underlying common stock as determined by management or the
value of the services provided, whichever is more readily determinable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stock-based compensation expense represents the cost of the grant date fair value
of employee stock option grants recognized over the requisite service period of the awards (usually the vesting period) on a straight-line basis, net of estimated forfeitures. The expense is adjusted for actual forfeitures at year end. Stock-based
compensation expense recognized in the consolidated financial statements is based on awards that are ultimately expected to vest. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For stock option grants
with performance-based milestones, the expense is recorded over the remaining service period after the point when the achievement of the milestone is probable or the performance condition has been achieved. For stock option grants with both
performance-based milestones and market conditions, expense is recorded over the derived service period after the point when the achievement of the performance-based milestone is probable or the performance condition has been achieved. The Company
issued performance-based awards in 2015, but not in 2016. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company accounts for stock options and restricted stock awards to non-employees using the
fair value approach. Stock options and restricted stock awards to non-employees are subject to periodic revaluation over their vesting terms. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Income
Taxes </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company accounts for income taxes under the liability method, which requires the recognition of deferred tax assets and liabilities for the
expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of
assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes
the enactment date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company recognizes net deferred tax assets to the extent that the Company believes these assets are more likely than not to be
realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results
of recent operations. If management determines that the Company would be able to realize its deferred tax assets in the future, in excess of its net recorded amount, management would make an adjustment to the deferred tax asset valuation allowance,
which would reduce the provision for income taxes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company records uncertain tax positions on the basis of a two-step process whereby
(1)&nbsp;management determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">111 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Histogenics Corporation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
merits of the position and (2)&nbsp;for those tax positions that meet the more likely than not recognition threshold, management recognizes the largest amount of tax benefit that is more than 50
percent likely to be realized upon ultimate settlement with the related tax authority. The Company recognizes interest and penalties related to unrecognized tax benefits within income tax expense. Any accrued interest and penalties are included
within the related tax liability. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Earnings (Loss) per Common Share </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Earnings (loss) per common share is calculated using the two-class method, which is an earnings allocation formula that determines earnings (loss) per share
for the holders of the Company&#146;s common shares and participating securities. All series of preferred stock contain participation rights in any dividend paid by the Company and are deemed to be participating securities. Earnings available to
common stockholders and participating convertible redeemable preferred shares are allocated to each share on an as-converted basis as if all of the earnings for the period had been distributed. The participating securities include a contractual
obligation to share in losses of the Company and are included in the calculation of net loss per share in the periods that have a net loss. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Diluted
earnings per share is computed using the more dilutive of (a)&nbsp;the two-class method, or (b)&nbsp;the if-converted method. The Company allocates earnings first to preferred stockholders based on dividend rights and then to common and preferred
stockholders based on ownership interests. The weighted-average number of common shares included in the computation of diluted earnings (loss) gives effect to all potentially dilutive common equivalent shares, including outstanding stock options,
warrants, convertible redeemable preferred stock and the potential issuance of stock upon the conversion of the Company&#146;s convertible notes. Common stock equivalent shares are excluded from the computation of diluted earnings (loss) per share
if their effect is antidilutive. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Warrant Accounting </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As noted in Note 9, the Company classifies warrants to purchase shares of its common stock as a liability on its consolidated balance sheet if the warrant is a
free-standing financial instrument that may require the Company to transfer consideration upon exercise. Each warrant of this type is initially recorded at fair value on date of grant using the Monte Carlo simulation model and net of issuance costs,
and is subsequently re-measured to fair value at each subsequent balance sheet date. Changes in fair value of the warrants are recognized as a component of other income (expense), net in the consolidated statement of operations. The Company will
continue to adjust the liability for changes in fair value until the earlier of the exercise or expiration of the warrants. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recently Adopted
Accounting Pronouncements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In November 2015, Financial Accounting Standards Board (&#147;the FASB&#148;) issued Accounting Standard Update
(&#147;ASU&#148;) No.&nbsp;2015-17, Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes. The new standard requires that deferred tax assets and liabilities be classified as noncurrent in a classified statement of financial
position. The Company prospectively adopted this guidance in the fourth quarter of 2015, which resulted in the removal of gross deferred tax assets and liabilities from the Company&#146;s consolidated balance sheet. The net impact was zero and the
prior period was not retrospectively adjusted. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In November 2014, the FASB issued ASU No.&nbsp;2014-16, Derivatives and Hedging (Topic 815): Determining
Whether the Host Contract in a Hybrid Financial Instrument Issued in the Form of a Share Is More Akin to Debt or to Equity. This standard provides guidance to eliminate the existing diversity in practice in accounting for
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">112 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Histogenics Corporation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
hybrid financial instruments issued in the form of a share. A hybrid financial instrument consists of a &#147;host contract&#148; into which one or more derivative terms have been embedded. This
guidance requires an entity to consider the terms and features of the entire financial instrument, including the embedded derivative features, in order to determine whether the nature of the host contract is more akin to debt or to equity. This
guidance is effective for fiscal years and interim periods beginning after December&nbsp;15, 2015, with early adoption permitted. A reporting entity should apply this guidance using a modified retrospective approach by recording a cumulative-effect
adjustment to equity as of the beginning of the annual period of adoption. Retrospective application is permitted to all relevant prior periods. The Company has concluded that this guidance has no impact on the presentation of its results of
operations, financial position and disclosures. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In August 2014, the FASB issued ASU No.&nbsp;2014-15, Presentation of Financial Statements&#151;Going
Concern (Subtopic 2015-40): Disclosure of Uncertainties about an Entity&#146;s Ability to Continue as a Going Concern. This guidance addresses management&#146;s responsibility in evaluating whether there is substantial doubt about a company&#146;s
ability to continue as a going concern and to provide related footnote disclosures. The guidance is effective for fiscal years ending after December&nbsp;15, 2016 and for interim periods within those fiscal years. The adoption of this standard did
not have a material impact on our consolidated financial statements and related disclosures. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In June 2014, the FASB issued ASU No.&nbsp;2014-12,
Compensation-Stock Compensation (Topic 718): Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could be Achieved after the Requisite Service Period. This standard provides guidance requiring when there
is a performance target that affects vesting of equity awards granted and could be achieved after the requisite service period to be treated as a performance condition. A reporting entity should apply existing guidance on stock-based compensation,
as it relates to such awards. This guidance is effective for annual periods and interim periods within those annual periods beginning after December&nbsp;15, 2015 with early adoption permitted using either of two methods: (i)&nbsp;prospective to all
awards granted or modified after the effective date; or (ii)&nbsp;retrospective to all awards with performance targets that are outstanding as of the beginning of the earliest annual period presented in the financial statements and to all new or
modified awards thereafter, with the cumulative effect of applying this guidance as an adjustment to the opening retained earnings balance as of the beginning of the earliest annual period presented in the financial statements. The Company issued
performance-based awards during the year ended December&nbsp;31, 2015. The Company adopted this guidance on a prospective basis and there have not been any performance-based awards since the effective date of the guidance. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recently Issued Accounting Pronouncements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In November
2016, the FASB issued guidance that requires restricted cash and restricted cash equivalents be included with cash and cash equivalents when reconciling the total beginning and ending amounts for the periods shown on the statement of cash flows. The
new standard is effective for us on January&nbsp;1, 2018 using a retrospective transition method to each period presented. Early adoption is permitted. We are currently evaluating the timing of our adoption and the expected impact that this standard
could have on our consolidated financial statements and related disclosures. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In March 2016, the FASB issued ASU No.&nbsp;2016-09, Compensation-Stock
Compensation (Topic 718): Improvements to Employee Shared-Based Payment Accounting. This standard provides guidance on accounting for employee share-based payments. This guidance addresses several aspects of the accounting for share-based payment
award transactions, including: (a)&nbsp;income tax consequences; (b)&nbsp;classification of awards as either equity or liabilities; and (c)&nbsp;classification on the statement of cash flows.&nbsp;This standard will be effective for fiscal years
beginning after December&nbsp;15, 2016, including interim periods within those fiscal years.&nbsp;The Company is </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">113 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Histogenics Corporation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
evaluating the impact of this guidance on the presentation of its results of operations, financial position and disclosures. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In February 2016, the FASB, issued ASU No.&nbsp;2016-02, Leases (Topic 842). The ASU requires companies to recognize on the balance sheet the assets and
liabilities for the rights and obligations created by leased assets. ASU 2016-02 will be effective for the Company in the first quarter of 2019, with early adoption permitted. The Company is currently evaluating the impact that the adoption of ASU
2016-02 will have on the Company&#146;s consolidated financial statements or related disclosures. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In May 2014, the FASB issued ASU No.&nbsp;2014-09,
Revenue from Contracts with Customers (Topic 606), which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. ASU 2014-09 will replace most existing
revenue recognition guidance in U.S. GAAP when it becomes effective. In July 2015, the FASB issued a one-year deferral of the effective date of the new revenue recognition standard. The new guidance will be effective for the Company&#146;s first
quarter of fiscal year 2018 and early application for fiscal year 2017 would be permitted. The Company is evaluating the impact of this guidance on the presentation of its results of operations, financial position and disclosures. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>LOSS PER COMMON SHARE </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Basic and diluted loss per common share are calculated as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="76%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For the Year Ended</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(In thousands, except share and<BR>per share data</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Numerator:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(16,208</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(32,024</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net Loss attributable to Series A Preferred Stock (a)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,345</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Numerator for basic EPS&#151;Earnings (loss) attributable to common stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,863</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(32,024</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effect of dilutive securities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deduct change in fair value of warrant liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,507</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Numerator for diluted EPS&#151;Earnings (loss) attributable to common stockholders after assumed
conversions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(31,370</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(32,024</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Denominator:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average number of common shares used in earnings (loss) per<BR>share&#151;basic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,256,954</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,231,126</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effect of dilutive securities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nonparticipating warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">132,238</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Denominator for diluted EPS&#151;adjusted weighted average shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,389,192</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,231,126</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Earnings (loss) per share&#151;basic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.97</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2.42</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Earnings (loss) per share&#151;diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2.18</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2.42</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">The Series A Preferred Stock participates in income and losses </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">114 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Histogenics Corporation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following potentially dilutive securities have been excluded from the computation of diluted
weighted-average shares outstanding, as they would be anti-dilutive (in common stock equivalent shares): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="70%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unvested restricted stock and options to purchase common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,578,905</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,227,957</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series A preferred stock unconverted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,962,817</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Warrants exercisable into common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">166,403</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">166,403</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4. PREPAID EXPENSES AND OTHER CURRENT ASSETS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current assets consisted of the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="82%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deposits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Undelivered laboratory and office equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Insurance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">195</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">173</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">321</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5. PROPERTY AND EQUIPMENT </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Property and equipment consisted of the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="65%"></TD>
<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Office equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">266</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">539</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Laboratory equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,443</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,337</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leasehold improvements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,683</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,683</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Construction in progress</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">759</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">547</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">96</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">96</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,247</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,202</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: accumulated depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,387</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,989</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,860</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,213</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Depreciation expense related to property and equipment amounted to $1.7 million and $1.6 million for the years ended
December&nbsp;31, 2016 and 2015, respectively. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">115 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Histogenics Corporation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>6.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>ACCRUED EXPENSES </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Accrued expenses consisted of the following: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="76%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,402</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">758</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued clinical expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">187</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">138</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">508</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">548</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,097</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,444</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>7.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>COMMITMENTS AND CONTINGENCIES </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Operating Leases </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company leases office and research facilities in Waltham, Massachusetts under a non-cancellable operating lease, which expires in December 2017, with two
additional five-year renewal options. Terms of the agreement provide for an initial rent-free period and future rent escalation, and provide that in addition to minimum lease rental payments, the Company is responsible for a pro-rata share of common
area operating expenses. In June 2014, the Company entered into a lease agreement to rent a facility in Lexington, Massachusetts. The commencement date of the lease was July&nbsp;9, 2014 with a term that extends through June&nbsp;1, 2023, with one
additional five-year renewal option. Terms of the lease agreement provide for an initial rent-free period and future rent escalation, and provide that in addition to minimum lease rental payments, the Company is responsible for a pro-rata share of
operating expenses. The Company&#146;s wholly-owned subsidiary, ProChon, leased a facility in Woburn, Massachusetts which expired in 2016 and was not renewed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Aggregate minimum annual lease commitments of the Company under its non-cancellable operating leases as of December&nbsp;31, 2016, are as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="79%"></TD>
<TD VALIGN="bottom" WIDTH="15%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" COLSPAN="4" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:116.90pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>For the Year Ended
December&nbsp;31,</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(in&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,266</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">754</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">586</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">596</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">605</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Thereafter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">926</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total minimum lease payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,733</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Rent expense under operating lease agreements amounted to $1.0 million and $1.1 million for the years ended December&nbsp;31,
2016 and 2015, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As an inducement to enter into its Waltham facility lease, the lessor agreed to provide the Company with a construction
allowance of up to $3.2 million towards the total cost of tenant improvements. As an inducement to enter into its Lexington facility lease, the lessor agreed to provide the Company with a construction allowance of up to $1.0 million towards the
total cost of tenant improvements. The Company has recorded these costs in the consolidated balance sheet as leasehold improvements, with the corresponding liability as deferred lease incentive. These liabilities are amortized on a straight-line
basis over the term of the lease as a reduction of rent expense. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">116 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Histogenics Corporation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>License Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">From time to time, the Company enters into various licensing agreements whereby the Company may use certain technologies in conjunction with its product
research and development. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Licensing agreements and the Company&#146;s commitments under the agreements are as follows: </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Hydrogel License </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In May 2005, the Company entered into
an exclusive license agreement with Angiotech Pharmaceuticals (US), Inc. for the use of certain patents, patent applications, and knowledge related to the manufacture and use of a hydrogel material in conjunction with NeoCart and certain other
products (&#147;Hydrogel License Agreement&#148;). As of December&nbsp;31, 2016, the Company has paid an aggregate $3.2 million in commercialization milestones under the terms of the Hydrogel License Agreement, which has been expensed to research
and development. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the terms of the Hydrogel License Agreement, the Company&#146;s future commitments include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">A one-time $3.0 million payment upon approval of an eligible product by the FDA; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Single digit royalties on the net sales of NeoCart and certain other future products. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Tissue Regeneration
License </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In April 2001, the Company entered into an exclusive license agreement with The Board of Trustees of the Leland Stanford Junior University
(&#147;Stanford University&#148;) for the use of certain technology to develop, manufacture and sell licensed products in the field of growth and regeneration of cartilage (&#147;Tissue Regeneration License Agreement&#148;). The term of the Tissue
Regeneration License Agreement extends to the expiration date of Stanford University&#146;s last to expire domestic or foreign patents. As of December&nbsp;31, 2016, the Company has paid an aggregate $0.7 million in patent reimbursement costs,
royalty fees, and commercialization milestone payments under the terms of the Tissue Regeneration License Agreement, which have been recorded to research and development expense. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the terms of the Tissue Regeneration License Agreement, the Company&#146;s future commitments include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">A one-time $0.3 million payment upon approval of an eligible product by the FDA; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">An annual minimum non-refundable royalty fee of $10 thousand for the life of the license that may be used to offset up to 50% of each earned royalty described below; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Low single digit royalties on net sales. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Honeycomb License </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In March 2013, the Company entered into a license agreement with Koken Co., Ltd. (&#147;Koken&#148;) and paid a fee for a non-exclusive, non-transferable and
non-sublicensable right to use its know-how related to the process for manufacturing atelocollagen honeycomb sponge materials, which is used in scaffolds (the &#147;Honeycomb License Agreement&#148;). Under the terms of the Honeycomb License
Agreement, future commitments will be based on the amount of materials supplied to the Company and may vary from period to period over the term of the agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">117 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Histogenics Corporation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Tissue Processor Sub-License </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In December 2005, the Company entered into an exclusive agreement to sub-license certain technology from Purpose, Co. (&#147;Purpose&#148;), which is owned by
a stockholder of the Company (&#147;Sub-License Agreement&#148;). Purpose entered into the original license agreement (&#147;Original Agreement&#148;) with Brigham and Women&#146;s Hospital, Inc. (&#147;Brigham and Women&#146;s&#148;) in August
2001. The Original Agreement shall remain in effect for the licensed patents owned by Brigham and Women&#146;s unless extended or terminated as provided for in the agreement. The technology is to be used to develop, manufacture, use and sell
licensed products that cultivate cell or tissue development. The Sub-License Agreement extends to the expiration date of the last to expire domestic or foreign patents covered by the agreement. As of December&nbsp;31, 2016, the Company has paid an
aggregate $1.0 million in royalty and sub-license payments under the terms of the Sub-License Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Sub-License Agreement was amended and
restated in June 2012. Under the amended and restated agreement, the Company made Purpose the sole supplier of equipment the Company uses in its manufacturing processes, and granted Purpose distribution rights of the Company&#146;s products for
certain territories. In exchange, Purpose allowed for the use of its technology (owned or licensed) and manufactured and serviced exogenous tissue processors used by the Company. Under the terms of the agreement, as amended, Purpose granted the
Company:&nbsp;(a)&nbsp;exclusive rights to all of Purpose&#146;s technology (owned or licensed) related to the exogenous tissue processors, (b)&nbsp;continued supply of exogenous tissue processors during the Company&#146;s clinical trials, and
(c)&nbsp;rights to manufacture the exogenous tissue processors at any location the Company chooses. In exchange for such consideration, the Company granted Purpose an exclusive license in Japan for the use of all of the Company&#146;s technology and
made a payment of $0.3 million to reimburse Purpose for development costs on a next generation tissue processor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In May 2016, the Original Agreement was
amended whereby the Company acquired the development and commercialization rights to NeoCart for the Japanese market from Purpose. Under the terms of the amended agreement, the Company assumes sole responsibility for and rights to the development
and commercialization of NeoCart in Japan. In exchange for the transfer of development and commercialization rights, the Company will pay a success-based milestone to Purpose upon conditional approval of NeoCart in Japan, as well as commercial
milestones and a low single digit royalty on Japanese sales of NeoCart, upon full approval, if any, in Japan </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to the above, the Company&#146;s
future commitments under the terms of the Original Agreement and Sub-License Agreement include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">A minimum non-refundable annual royalty fee of $20 thousand, for the life of the license; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">An additional, non-refundable annual royalty fee of $30 thousand from 2016 through 2019; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">$10.2 million in potential milestone payments; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Low single digit royalties on net sales of a licensed product. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The OCS Agreement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with its research and development, the Company received grants from the Office of Chief Scientist of the Ministry of Industry and Trade in Israel
(&#147;OCS&#148;) in the aggregate of $1.1 million for funding the fibroblast growth factor (&#147;FGF&#148;) program. In consideration for this grant, the Company is committed to pay royalties at a rate of 3% to 5% of the sales of sponsored
products developed using the grant money, up to the amount of the participation payments received. The Company committed to pay up to 100% of grants received plus interest according to the LIBOR interest rate if the sponsored product is produced in
Israel. If the manufacturing of the sponsored product takes place outside of Israel, the royalties can increase up to, but no more than, 300% of grants </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">118 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Histogenics Corporation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
received plus interest based on the LIBOR interest rate, depending on the percentage of the manufacturing of sponsored product that takes place outside of Israel. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Engineering Agreement </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company entered into an
agreement with a development corporation to purchase a multi-unit bioreactor system. Pursuant to the agreement, as of December&nbsp;31, 2016, the Company made total payments in an aggregate amount of $0.6 million of which $0.2 million was made in
2016 after acceptance of the final product. There are no additional payments due under this agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Collagen Supply Agreement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In September 2015, the Company entered into an agreement with Collagen Solutions (UK) Limited (the &#147;Supplier&#148;) to purchase soluble collagen that
meets specifications provided by the Company. The initial term of the agreement is three years and will automatically renew from year to year thereafter unless otherwise terminated with at least 180 days&#146; notice by either party. Pursuant to the
agreement, starting 12 months after entering into the agreement, the Company will be required to order a minimum amount of material and/or services totaling $0.2 million from the Supplier in each calendar year until the expiration of the initial
term of the agreement. The Company also committed to pay a non-refundable payment totaling $0.1 million by the end of 2015. This expense was recorded to research and development expense as of December&nbsp;31, 2015. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>8.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>CAPITAL STOCK </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September&nbsp;29, 2016, the Company closed the private placement contemplated by the
securities purchase agreement (the &#147;Purchase Agreement&#148;), dated September&nbsp;15, 2016, between the Company and certain institutional and accredited investors in which the Company received gross proceeds of $30.0 million (the
&#147;Private Placement&#148;). The net proceeds after deducting placement agent fees and other transaction-related expenses was $27.6 million. At the closing, the Company issued 2,596,059 shares of the Company&#146;s common stock at a per share
price of $2.25 and 24,158.8693 shares of the Company&#146;s newly-created Series A Convertible Preferred Stock (&#147;Series A Preferred Stock&#148;), which are convertible into approximately 10,737,275 shares of common stock. As part of the Private
Placement, the investors received warrants to purchase up to 13,333,334 shares of the Company&#146;s common stock at an exercise price of $2.25 per share.&nbsp;The placement agent for the Private Placement, H.C. Wainwright&nbsp;&amp; Co. LLC
(&#147;HCW&#148;), and certain of its affiliates were also granted warrants to purchase 133,333 shares of the Company&#146;s common stock at an exercise price of $2.25 per share in exchange for the services provided by HCW. The placement agent
warrants were considered a financing cost of the Company and included in warrant expense within the consolidated statements of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The warrants
include a cashless-exercise feature that may be exercised solely in the event there is no effective registration statement, or no current prospectus available for, the resale of the shares of common stock underlying the warrants as of the six-month
anniversary of the closing of the Private Placement. Upon a fundamental transaction, the holders of the warrant may require the Company to purchase any unexercised warrants in an amount equal to the Black-Scholes value of the option. A fundamental
transaction is defined as a merger, sale of assets, sale of the Company, recapitalization of stock and a sale of stock whereby any owner after the transaction would own greater than 50% of the outstanding common stock in the Company. The warrants
became exercisable following approval of the Private Placement by our stockholders in the fourth quarter of 2016 and expire five years after the date of such stockholder approval.&nbsp;The Company determined the warrants are classified as a
liability on the consolidated balance sheet because they contain a provision whereby in a fundamental transaction (as described above), the holder can elect to receive either the amount they are entitled
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">119 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Histogenics Corporation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to on an as-if-exercised basis or an amount based on the Black-Scholes value of the warrants at the time of the fundamental transaction.&nbsp;At the issuance date, the warrants were recorded at
the fair value of $30.7 million and approximately $0.4 million excess of the fair value of the liability recorded for these warrants over the proceeds received was recorded as a charge to earnings in the third quarter of 2016 and is included in
warrant expense within the consolidated statement of operations. In connection with the Private Placement, the Company incurred expenses of $3.1 million in warrant expense within the consolidated statements of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Concurrent with the closing of the Private Placement, the Company&#146;s&nbsp;Certificate of Incorporation was amended by the filing of a Certificate of
Designation to create the Series A Preferred Stock.&nbsp;The Series A Preferred Stock has a par value of $0.01 and each share is convertible into 444.44 shares of common stock, at a conversion price of $2.25 per share, at the option of the
holder.&nbsp;The Series A Preferred Stock has no voting rights and is only entitled to dividends as declared on an as-converted basis.&nbsp;The Series A Preferred Stock contains no liquidation preferences or redemption rights and shares in
distributions of the Company on an as-converted basis with the common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As part of the Private Placement, affiliates of certain members of the
Company&#146;s Board of Directors purchased an aggregate of 283,046 shares of common stock, an aggregate of 2,563.1439 shares of Series A Preferred Stock and received warrants to purchase up to 1,422,221 shares of common stock at an exercise price
of $2.25 per share in the Private Placement.&nbsp;These amounts are included in the amounts noted above. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Common Stock-100,000,000 shares authorized
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The holders of shares of common stock are entitled to one vote per share. The holders of shares of common stock are not entitled to receive dividends,
unless declared by the Company&#146;s board of directors out of legally available funds, if ever. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Reserved for future issuance </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has reserved for future issuance the following number of shares of common stock: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="64%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vesting of restricted stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,889</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,190</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Options to purchase common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,577,016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,222,767</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock warrants</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,633,070</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">166,403</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,211,975</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,394,360</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Preferred Stock-30,000,000 shares authorized </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B></B>S<B>eries A Convertible Preferred Stock </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On
September&nbsp;29, 2016, the Company issued 24,158.8693 shares of newly-created Series A Convertible Preferred Stock, which were convertible into approximately 10,737,275 shares of common stock at an initial conversion price of $2.25. The Series A
Preferred Stock has a par value of $0.01 and each share is convertible into 444.44 shares of common stock at the option of the holder. The holders of Series A Preferred Stock have no voting rights, share in both income and losses and are only
entitled to dividends as declared on an as-converted basis. The Series A Preferred Stock contains no liquidation preferences or redemption rights and shares in the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">120 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Histogenics Corporation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
distribution of the Company on an as-converted basis with the common stock. The Series A Preferred Stock shall not be converted if, after giving effect to the conversion, the holder and its
affiliated persons would own beneficially more than 4.99% of our common stock (subject to adjustment up to 9.99% solely at the holder&#146;s discretion upon 61 days&#146; prior notice to us or, solely as to a holder, if such limitation is waived by
such holder upon execution of the private placement agreement). </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>9.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>WARRANTS </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investor Warrants </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In September 2016, in connection with the Private Placement, the Company issued common stock warrants to the investors to purchase up to 13,333,334 shares of
our common stock at an exercise price of $2.25 per share. The warrants include a cashless-exercise feature that may be exercised solely in the event there is no effective registration statement registering, or no current prospectus available for,
the resale of the shares of common stock underlying the warrants as of the six-month anniversary of the closing of the Private Placement. The warrants became exercisable following approval of the Private Placement by our stockholders in the fourth
quarter of 2016 and expire five years after the date of such stockholder approval. The warrants were valued at $2.28 per share using a Monte Carlo simulation and are marked-to-market on a quarterly basis with the change in value recorded as warrant
expense or income on the consolidated statements of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Placement Agent Warrants </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In September 2016, in connection with the Private Placement, the Company issued HCW and certain of its affiliates warrants for the purchase of 133,333 shares
of common stock at an exercise price of $2.25 per share. The HCW warrants became exercisable following approval of the Private Placement by our stockholders in the fourth quarter of 2016 and expire five years after the date of such stockholder
approval. The warrants were valued at $2.28 per share using a Monte Carlo simulation and are marked-to-market on a quarterly basis with the change in value recorded as warrant expense or income on the consolidated statements of operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Affiliates of an Advisor Warrant </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July&nbsp;20, 2012,
the Company issued a warrant to purchase its common stock to affiliates of an advisor. The warrant provides the holders with the right to purchase an aggregate of 161,977 shares of the Company&#146;s common stock at a per share exercise price of
$0.01. The warrants are exercisable, in whole or in part, immediately upon issuance and may be exercised on a cashless basis. The warrants expire on the tenth anniversary of issuance. The fair value of the warrants as of July&nbsp;20, 2012 was
estimated using the OM with the following inputs: (a)&nbsp;risk-free interest rate of 0.22%; (b)&nbsp;implied volatility of the Company&#146;s common stock of 99%; and (c)&nbsp;the expected term to a liquidity event of 1.7 years. On December&nbsp;3,
2014, the Company completed its IPO and warrants for 5,839 shares of common stock were surrendered and common stock was issued by the Company to Purpose, Co. for the warrant shares surrendered. As of December&nbsp;31, 2016 and 2015, warrants to
purchase an aggregate of 156,138 shares of the Company&#146;s common stock at an exercise price of $0.01 are outstanding. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Consulting Agreement Warrant
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In March 2015, in connection with a consulting agreement entered into for an interim chief financial officer, the Company issued a common stock
warrant as compensation to the consulting firm. The warrant provides the holder with the right to purchase an aggregate of 7,398 shares of the Company&#146;s common stock at a per share exercise price of $9.75, the closing price of the
Company&#146;s common stock on the date of issuance. The warrant </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">121 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Histogenics Corporation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
vested and became exercisable in monthly installments over 24 months beginning September&nbsp;30, 2015 and expires on the tenth anniversary of issuance. The warrant is equity classified and
accounted for using the fair value approach. The fair value of the warrant is estimated using the Black-Scholes option pricing model and is subject to re-measurement at each reporting period until the measurement date is reached. On
December&nbsp;21, 2015, the Company terminated the consulting agreement resulting in the forfeiture of 50% (3,699)&nbsp;of the shares eligible for exercise under the warrant. The remaining 3,699 shares were vested and exercisable on
December&nbsp;31, 2016 and December&nbsp;31, 2015. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>10.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>EQUIPMENT LOAN PAYABLE </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2016 and 2015, the Company had the following outstanding
borrowing obligations: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="66%"></TD>
<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Silicon Valley Bank Equipment Loan Payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">761</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,344</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(583</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(583</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Long-term debt, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">178</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">761</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In July 2014, the Company entered into a loan and security agreement with Silicon Valley Bank, which provides for a line of
credit to finance certain equipment purchases up to an aggregate of $1.8 million through March&nbsp;31, 2015. The line has been fully drawn and is payable in 36 monthly installments of principal and interest, with an annual interest rate of 2.75%
plus the greater of 3.25% and the prime rate in effect at the time of each draw, as published in the Wall Street Journal. The outstanding balance on the line of credit is secured by a first priority lien over all equipment purchased using the line
of credit. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In accordance with the terms of the equipment line of credit, the Company issued a warrant to Silicon Valley Bank in July 2014 to purchase
6,566 shares of our common stock at an exercise price per share of $7.99. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The equipment line of credit includes customary operating but non-financial
covenants, including limitations on the Company&#146;s ability to incur additional indebtedness, issue dividends, sell assets, engage in any business other than its current business, merge or consolidate with other entities, create liens on our
assets, make investments, repurchase stock in certain instances, enter into transactions with affiliates, make payments on subordinated indebtedness and transfer or encumber any collateral securing the debt. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2016 and 2015, $0.8 and $1.3 million respectively, of borrowings were outstanding under the line of credit and the Company was in
compliance with all required covenants. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>11.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>STOCK-BASED COMPENSATION </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Restricted Stock Awards and Stock Options </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company adopted the 2012 Equity Incentive Plan, as amended (&#147;2012 Plan&#148;) in July 2012 pursuant to which 609,389 shares of common stock were
authorized for issuance to employees, officers, directors, consultants and advisors of the Company as of December&nbsp;31, 2014. Upon the closing of the IPO on December&nbsp;3, 2014, no further grants will be made under the 2012 Plan as the 2013
Equity Incentive Plan (&#147;2013 Plan&#148;) replaced the 2012 Plan on this date. The 2012 Plan provided for the grant of incentive stock options, non-statutory stock options, rights to purchase restricted stock, stock appreciation rights, phantom
stock awards and stock units. In connection with </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">122 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Histogenics Corporation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the issuance of restricted common stock, the Company maintains a repurchase right and shares of restricted common stock are released from such repurchase right over a period of time of continued
service by the recipient. Recipients of incentive stock options shall be eligible to purchase shares of the Company&#146;s common stock at an exercise price equal to no less than the estimated fair value of such stock on the date of grant. Stock
options generally vest 25% on the first anniversary of the original vesting date, with the balance vesting monthly over the remaining three years, unless they contain specific performance and/or market-based vesting provisions. The maximum term of
stock options granted under the 2012 Plan is ten years. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In determining the exercise prices for options granted, the board of directors considered the
fair value of the common stock as of the measurement date. The fair value of the common stock was determined by the board of directors based on a variety of different factors, including valuations prepared by third party valuation specialists,
Company&#146;s financial position, the status of development efforts within the Company, the composition and ability of the current scientific and management teams, the current climate in the marketplace, the illiquid nature of the Company&#146;s
common stock, arm&#146;s length sale of the Company&#146;s preferred stock, the effect of the rights and preferences of the preferred stockholders, and the prospects of a liquidity event, among others. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2013 Equity Incentive Plan </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s board of
directors adopted the 2013 Plan in November 2013 which the stockholders approved in October 2014. The 2013 Plan provides for the grant of incentive stock options, non-statutory stock options, rights to purchase restricted stock, stock appreciation
rights and stock units. In connection with the issuance of restricted common stock, the Company maintains a repurchase right and shares of restricted common stock are released from such repurchase right over a period of time of continued service by
the recipient. Recipients of stock options shall be eligible to purchase shares of the Company&#146;s common stock at an exercise price equal to no less than the estimated fair value of such stock on the date of grant. Stock options generally vest
25% on the first anniversary of the original vesting date, with the balance vesting monthly over the remaining three years, unless they contain specific performance and/or market-based vesting provisions. The maximum term of stock options granted
under the 2013 Plan is ten years. In June 2016, the Company&#146;s stockholders approved an amendment to the EIP to increase the number of shares of common stock available for issuance under the 2013 Plan by 300,000 shares and increase the number of
shares of common stock automatically added to the 2013 Plan on January&nbsp;1 of each year during the term of the 2013 Plan, starting with January&nbsp;1, 2017 (the &#147;EIP Amendment&#148;). Following adoption of the EIP Amendment, the number of
shares of common stock available for issuance under the 2013 Plan is subject to an automatic annual increase on the first day of the Company&#146;s calendar year beginning in 2017 equal to the lesser of (a)&nbsp;4.0% of the total number of shares of
common stock outstanding on December&nbsp;31 of the prior year or, (b)&nbsp;the number determined by the Company&#146;s Board of Directors Accordingly, the number of shares of common stock available for issuance under the EIP was increased by
825,904 shares effective January&nbsp;1, 2017. To the extent any awards under the 2013 Plan are forfeited, terminate, expire, lapse without the issuance of shares, or if the Company repurchases shares subject to awards under the 2013 Plan, those
shares will again become available for issuance under the 2013 Plan. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2013 Employee Stock Purchase Plan </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#146;s board of directors adopted the 2013 Employee Stock Purchase Plan (&#147;2013 ESPP&#148;) in November 2013 which the stockholders approved in
October 2014. The 2013 ESPP became effective upon the closing of the IPO on December&nbsp;3, 2014. The Company&#146;s 2013 ESPP qualifies under Section&nbsp;423 of the Internal Revenue Code of 1986, as amended (the &#147;Code&#148;). Under the 2013
ESPP, 103,665 shares of the Company&#146;s common stock are authorized for issuance to eligible employees. The number of shares reserved for issuance under the 2013 ESPP is automatically increased on the first business day of each of the
Company&#146;s fiscal years, commencing in 2015, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">123 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Histogenics Corporation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
by a number equal to the lowest of (a)&nbsp;51,832 shares of common stock,(b) 1% of the shares of common stock outstanding on the last business day of the prior fiscal year; or (c)&nbsp;the
number of shares determined by the Company&#146;s Board of Directors. Accordingly, the number of authorized shares of the Company&#146;s common stock authorized for issuance to eligible employees under the 2013 ESPP was increased by 206,476 shares
effective January&nbsp;1, 2017. The number of shares reserved under the 2013 ESPP will automatically be adjusted in the event of a stock split, stock dividend or a reverse stock split (including an adjustment to the per-purchase period share limit).
The Company&#146;s 2013 ESPP permits each eligible employee to purchase common stock through payroll deductions. There was no activity under the Plan in 2016 and 2015. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stock option activity under the 2012 and 2013 plans is summarized as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="61%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number</B><br><B>of Options</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted-</B><br><B>Average</B><br><B>Exercise</B><br><B>Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted-</B><br><B>Average</B><br><B>Remaining</B><br><B>Contractual</B><br><B>Term</B><br><B>(in years)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate</B><br><B>Intrinsic</B><br><B>Value</B><br><B>(in&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding at December&nbsp;31, 2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,229,339</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7.32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(4,679</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">464,240</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.02</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,685</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.76</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cancelled</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(112,878</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.97</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding at December&nbsp;31, 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,577,016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5.95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vested and expected to vest at December&nbsp;31, 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,492,341</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5.97</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercisable at December&nbsp;31, 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">561,693</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6.79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2016 and 2015, the unrecognized compensation cost related to outstanding options was $2.6 million and
$3.9 million, respectively, and is expected to be recognized as expense over approximately 2.01 years and 2.68 years, respectively. The intrinsic value of options exercised during the years ended December&nbsp;31, 2016 and 2015 was $10 thousand and
$0.3 million, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2016, the weighted average grant date fair value of vested options was $4.71 and the weighted average
grant date fair value of options outstanding was $3.67. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additional information about the Company&#146;s stock option activity is as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="82%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted-average grant date fair value per share of employee option grants within the
year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.08</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash received upon exercise of options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Restricted stock awards under the 2012 and 2013 plans are summarized as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="64%"></TD>
<TD VALIGN="bottom" WIDTH="13%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of</B><br><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted&nbsp;Average</B><br><B>Grant Date&nbsp;Fair</B><br><B>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unvested at December&nbsp;31, 2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,190</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.07</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vesting of restricted stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,301</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unvested at December&nbsp;31, 2016</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,889</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">124 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Histogenics Corporation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2016 and 2015, the unrecognized compensation cost related to restricted stock awards
was $1 thousand and $4 thousand respectively, and is expected to be recognized as expense over approximately 0.3 years and 1.2 years, respectively. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Stock-Based Compensation Expense </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company granted
stock options to employees for the years ended December&nbsp;31, 2016 and 2015. The Company estimates the fair value of stock options as of the date of grant using the Black-Scholes option pricing model and restricted stock based on the fair value
of the award. Stock options and restricted stock issued to non-board member, non-employees are accounted for using the fair value approach and are subject to periodic revaluation over their vesting terms. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For all periods from inception to date, stock-based compensation for all options granted and restricted stock awards are classified as research and
development expense and general and administrative expense. Stock compensation expense amounted to approximately $1.5 million and $1.2 million for the years ended December&nbsp;31, 2016 and 2015, respectively. Included in the table below is
restricted stock-based compensation expense of $2 thousand and $4 thousand, respectively, recorded in general and administrative expense during the years ended December&nbsp;31, 2016 and 2015. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stock-based compensation is as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="76%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">491</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">451</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,057</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">777</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,548</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,228</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The weighted-average assumptions used in the Black-Scholes option pricing model to determine the fair value of the employee
stock option grants were as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="83%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.73</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.68</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">72.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected term (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.08</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.04</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The weighted-average assumptions used in the Black-Scholes option pricing model to determine the fair value of the
non-employee stock option grants were as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="83%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.57</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.79</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected term (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">125 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Histogenics Corporation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Risk-free Interest Rate</I></B>. The risk-free interest rate assumption is based on observed interest
rates appropriate for the expected term of the stock option grants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Expected Volatility</I></B>. Due to the Company&#146;s limited operating
history and lack of company-specific historical or implied volatility, the expected volatility assumption is based on historical volatilities of a peer group of similar companies whose share prices are publicly available. The peer group was
developed based on companies in the biotechnology and medical device industries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Expected Term</I></B>. The expected term represents the period of
time that options are expected to be outstanding. Because the Company does not have historical exercise behavior, through December&nbsp;31, 2016 it determined the expected life assumption using the simplified method, which is an average of the
contractual term of the option and its vesting period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Expected Dividend Yield</I></B>. The expected dividend yield assumption is based on the fact
that the Company has never paid cash dividends and has no present intention to pay cash dividends. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>12.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>INCOME TAXES </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the years ended December&nbsp;31, 2016 and 2015, the Company did not record a current
or deferred income tax expense or benefit due to current and historical losses incurred by the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The components of loss before income taxes were
as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="71%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">U.S.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(15,838</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(31,382</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Foreign</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(369</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(691</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(16,208</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(32,073</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A reconciliation of income tax expense (benefit) computed at the statutory federal income tax rate to income taxes as
reflected in the financial statements is as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="79%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Federal income tax (benefit) at statutory rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(Increase) decrease income tax benefit resulting from:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Permanent differences</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1.2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net Operating Loss Limitation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(111.1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">R&amp;D Credit Limitation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1.5</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(31.7</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1.2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income tax expense (benefit)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">126 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Histogenics Corporation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Deferred taxes are recognized for temporary differences between the basis of assets and liabilities for
financial statement and income tax purposes. The significant components of the Company&#146;s deferred tax assets and liabilities are comprised of the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="71%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net operating loss carryforwards</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16,146</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">28,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,229</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,688</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,082</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,183</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Capitalized start-up costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,037</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,531</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">259</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax assets before valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,569</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44,861</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(34,569</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(43,751</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,110</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred tax liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">IPR&amp;D</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(36</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in accounting method</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,074</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,110</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has evaluated the positive and negative evidence bearing upon the realizability of its deferred tax assets. As of
December&nbsp;31, 2016 and 2015, based on the Company&#146;s history of operating losses, the Company has concluded that it is not more likely than not that the benefit of its deferred tax assets will be realized. Accordingly, the Company has
provided a full valuation allowance for deferred tax assets as of December&nbsp;31, 2016 and 2015. The valuation allowance decreased $9.2 million during the year ended December&nbsp;31, 2016, due primarily to a reduction of net operating losses
generated. The valuation allowance increased by $11.8 million during the year ended December&nbsp;31, 2015, due primarily to net operating losses generated and capitalized expenses. In addition, the reduction in net operating losses were related to
Section 382 limits as a result in a change in ownership. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During November 2015, the FASB issued ASU 2015-17, &#147;Balance Sheet Classification of
Deferred Taxes&#148;, which simplifies the presentation of deferred income taxes. This ASU requires that deferred tax assets and liabilities be classified as non-current in a statement of financial position. We early adopted ASU 2015-17 effective
December&nbsp;31, 2015 on a prospective basis. Adoption of this ASU resulted in the removal of gross deferred tax assets and liabilities from the Company&#146;s Consolidated Balance Sheet at December&nbsp;31, 2015. The impact was zero. No prior
periods were retrospectively adjusted. As of December&nbsp;31, 2016 and 2015, the Company had U.S. federal NOL carryforwards of $24.5 million, and $55.5 million, respectively, which may be available to offset future income tax liabilities and expire
at various dates through 2036. As of December&nbsp;31, 2016 and 2015, the Company also had U.S. state NOL carryforwards of $24.3 million and $55.4 million, respectively, which may be available to offset future income tax liabilities and expire at
various dates through 2036. At December&nbsp;31, 2016 and 2015, the Company also had $26.1 million and $25.6 million, respectively, of foreign NOL carryforwards which may be available to offset future income tax liabilities, which carryforwards do
not expire. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Utilization of the NOL and research and development credit carryforwards may be subject to a substantial annual limitation due to ownership
change limitations that have occurred or that could occur in the future, as required by Section&nbsp;382 and Section&nbsp;383 of the Code, as well as similar state and foreign provisions. These ownership
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">127 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Histogenics Corporation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
changes may limit the amount of NOL and research and development credit carryforwards that can be utilized annually to offset future taxable income and tax, respectively. In general, an
&#147;ownership change&#148; as defined by Section&nbsp;382 of the Code results from a transaction or series of transactions over a three-year period resulting in an ownership change of more than 50 percentage points of the outstanding stock of a
company by certain stockholders. The Company has completed a study to assess whether an ownership change has occurred or whether there have been multiple ownership changes since its formation. The results of this study indicated we experienced
ownership changes, as defined by Section&nbsp;382 of the Code, in each of 2006, 2011, 2012, 2013, and 2016. The Company has not recorded NOLs that, as a result of these restrictions, will expire unused. The limitations were approximately $47.1
million in 2015 and $100.1 million in 2016. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The changes in the Company&#146;s unrecognized tax benefits are summarized as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="79%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unrecognized tax benefit, beginning of year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">687</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">811</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase (decrease) related to current year positions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(125</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(124</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Settlements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Unrecognized tax benefit, end of year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">562</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">687</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2016 and 2015, the total amount of unrecognized tax benefits was $0.6 million and $0.7 million,
respectively which, if recognized, would favorably affect the effective income tax rate in future periods. Note that liabilities for unrecognized tax benefits have been recorded to the extent that they do not exceed the Company&#146;s available
losses that are not limited as a result of ownership changes that have occurred under Section&nbsp;382 of the Code. Reductions to unrecognized tax benefits for limitations on the utilization of net operating losses due to ownership changes occurring
during the year has been reflected in the table as reductions based on tax positions related to the current year. Histogenics accrues interest and penalties related to unrecognized tax benefits as a component of its provision for income taxes. No
accrued interest and penalties related to the Company&#146;s unrecognized tax benefits has been accrued as of December&nbsp;31, 2016 and 2015. The Company believes that it is reasonably possible that none of its unrecognized tax benefits, may be
recognized at the end of 2016. The Company or one of its subsidiaries files income tax returns in the United States and various states and Israel. The Company is subject to U.S. federal, state and local income tax examinations by tax authorities for
years 2001 through present. Carryforward attributes that were generated in earlier periods remain subject to examination to the extent the year in which they were used or will be used remains open for examination. The tax years which remain subject
to examination by tax authorities in Israel, as of December&nbsp;31, 2016, include years 2013 through the present. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>13.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>EMPLOYEE BENEFITS </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has a defined contribution 401(k) plan for employees who are at least 21
years of age. Employees are eligible to participate in the plan beginning on the first day of the calendar quarter following their date of hire. Under the terms of the plan, employees may make voluntary contributions as a percent of compensation. No
matching contributions have been made by the Company since the adoption of the 401(k) plan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">128 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Histogenics Corporation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>14.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>RELATED PARTIES </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Intrexon Corporation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In September 2014, the Company entered into an Exclusive Channel Collaboration agreement with Intrexon (the &#147;Collaboration Agreement&#148;) to use
Intrexon&#146;s proprietary technology for the development and commercialization of allogeneic cell therapeutics (the &#147;Collaboration Products&#148;) to treat or repair damaged articular hyaline cartilage in humans. The term of the Collaboration
Agreement commenced upon the effective date, September&nbsp;30, 2014, and continues until either written notice of termination is given by the Company within ninety days, or if either party creates a material breach that cannot be remedied within
sixty days. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the terms of the Collaboration Agreement, the Company is solely responsible for the costs to develop and commercialize any
Collaboration Products with the following exceptions: (i)&nbsp;the establishment of certain manufacturing capabilities and facilities; (ii)&nbsp;the cost of basic research related to Intrexon&#146;s proprietary technology outside of costs related to
the Collaboration Products; (iii)&nbsp;payments related to certain in-licensed third party IP; (iv)&nbsp;the costs of filing, prosecution and maintenance of Intrexon patents; and (v)&nbsp;any other costs mutually agreed upon as being the
responsibility of Intrexon. As partial consideration, the Company will pay commercialization milestones totaling $12 million, if and when achieved, and sales milestones totaling $22.5 million, if and when achieved. The milestone payments are payable
in cash or shares of the Company&#146;s common stock at the option of the Company. In the event the Company is sold prior to making any of these milestone payments and the Collaboration Agreement is transferred in the sale, the milestone payments
would be payable in cash. The Company is also required to make low double digit royalty payments to Intrexon on any gross profit arising from the sale of Collaboration Products and to pay an intermediate double digit percentage of any sublicensing
revenue it receives. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the terms of the Collaboration Agreement, the Company reimburses Intrexon for 50% of the product research and development
costs with the remaining 50% due after acceptance by the FDA or equivalent regulatory authority of an Investigational New Drug Application or equivalent regulatory filing of a collaboration product or upon 90 day written notice of cancellation by
the Company. Total incurred expenses were $3.0 million and $3.1 million for the year ended December&nbsp;31, 2016 and 2015, respectively. The total accrued expenses due Intrexon at December&nbsp;31, 2016 and December&nbsp;31, 2015 was $3.0 million
and $1.5 million, respectively. Amounts are reflected as current liabilities in the consolidated balance sheet as of December&nbsp;31, 2015. Amounts have been reclassified to long term liabilities in the consolidated balance sheet as of
December&nbsp;31, 2016, as a result of a change in circumstances, including the plans for products that we are developing as a part of the Exclusive Channel Collaboration with Intrexon. These expenses were included in research and development in the
consolidated statement of operations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Purpose, Co. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In June 2012, the Company entered into an agreement with Purpose, Co. to amend its previous agreements. In the previous agreements, Purpose, Co. granted the
Company a perpetual license to its patents related to its exogenous tissue processor which is used in the development of the Company&#146;s products. In exchange, the Company granted Purpose, Co. a perpetual license to all of the Company&#146;s
biotechnology and biomaterial for use in Japan. The agreement provides for Purpose, Co. to manufacture and sell machinery to the Company for cost until the Company&#146;s products become commercially viable. The Company has also agreed to pay
royalties on any third-party revenue generated using Purpose, Co.&#146;s licensed technology. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the June 2012 amendment, the Company received
exclusive rights to all of Purpose, Co.&#146;s technology related to the exogenous tissue processor, continued supply of exogenous tissue processors during the Company&#146;s clinical trials, and rights to manufacture the exogenous tissue processors
at any location the Company chooses. In </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">129 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Histogenics Corporation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Notes to Consolidated Financial Statements </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
exchange for such consideration, the Company named Purpose, Co. the sole manufacturer of equipment and also clarified the geographic territories of the exclusive license that Purpose Co. was
granted for use of the Company&#146;s technology. Also, the Company agreed to reimburse Purpose, Co. for $0.3 million of development costs on a next generation tissue processer. Refer to the discussion under Note 7, <I>Tissue Processor
Sub-License</I>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In May 2016, the Company acquired the development and commercialization rights to NeoCart for the Japanese market from Purpose, Co.
Under the terms of the amended agreement, the Company assumes sole responsibility for and rights to the development and commercialization of NeoCart in Japan. In exchange for the transfer of development and commercialization rights, the Company will
pay a success-based milestone to Purpose upon conditional approval of NeoCart in Japan, as well as commercial milestones and a low single digit royalty on Japanese sales of NeoCart, upon full approval, if any, in Japan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The amounts that have been paid to Purpose, Co. under this agreement were $0.1 and $0.2 million for the years ended December&nbsp;31, 2016 and 2015,
respectively. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board of Director Affiliates </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Affiliates of certain members of the Company&#146;s Board of Directors participated in the Private Placement as described in Note 8. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>15.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>SUBSEQUENT EVENTS </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On February&nbsp;22, 2017, the Company entered into an amendment with Collagen
Solutions (UK) LTD (the &#147;Supplier&#148;). The original agreement was entered into on September&nbsp;15, 2015. Pursuant to the amendment, the Company agrees to pay the Supplier approximately $0.1 million in exchange for eliminating the minimum
annual order of material and/or services and any other amounts due Supplier. The payment of $0.1 million will be made over the 18 months following the date of the amendment. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">130 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx293850_26"></A>EXHIBIT INDEX </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD WIDTH="88%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:25.30pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:39.50pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;3.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Sixth Amended and Restated Certificate of Incorporation (filed as Exhibit 3.1 to the Registrant&#146;s Current Report on Form 8-K as filed on December 8, 2014, and incorporated herein by reference)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;3.2<BR></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Amended and Restated Bylaws (filed as Exhibit 3.2 to the Registrant&#146;s Current Report on
<FONT STYLE="white-space:nowrap">Form&nbsp;8-K</FONT> as filed on December 8, 2014, and incorporated herein by reference)</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;3.3<BR></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Preferred Stock of Histogenics Corporation (filed as Exhibit 3.3 to the Registrant&#146;s Current Report on Form&nbsp;8-K as filed on
September&nbsp;16, 2016, and incorporated herein by reference)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;4.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Specimen stock certificate evidencing the shares of common stock (filed as Exhibit 4.1 to Amendment No. 3 to the Registrant&#146;s Registration Statement on Form S-1 (SEC File
<FONT STYLE="white-space:nowrap">No.&nbsp;333-199202),</FONT> as filed on November 26, 2014, and incorporated herein by reference)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;4.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Second Amended and Restated Investors&#146; Rights Agreement dated as of December 18, 2013 (filed as Exhibit 4.2 to the Registrant&#146;s Registration Statement on Form S-1 (SEC File No. 333-199202), as filed on October 7, 2014, and
incorporated herein by reference)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;4.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Second Amended and Restated Stockholders&#146; Agreement dated as of December 18, 2013 (filed as Exhibit 4.3 to the Registrant&#146;s Registration Statement on Form S-1 (SEC File No. 333-199202), as filed on October 7, 2014, and
incorporated herein by reference)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;4.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Warrant to Purchase Common Stock dated July 9, 2014 issued to Silicon Valley Bank (filed as Exhibit 4.4 to the Registrant&#146;s Registration Statement on Form S-1 (SEC File No. 333-199202), as filed on October 7, 2014, and
incorporated herein by reference)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;4.5<BR></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Amended and Restated Royalty Agreement dated as of October 14, 2014 (filed as Exhibit 4.5 to Amendment No. 1 to the Registrant&#146;s
Registration Statement on Form S-1 (SEC File No. <FONT STYLE="white-space:nowrap">333-199202),</FONT> as filed on November 7, 2014, and incorporated herein by reference)</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;4.6</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Securities Purchase Agreement dated September 15, 2016 (filed as Exhibit 10.34 to the Registrant&#146;s Current Report on Form 8-K as filed on September 16, 2016, and incorporated herein by reference)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;4.7<BR></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Registration Rights Agreement dated September&nbsp;29, 2016 (filed as Exhibit 10.35 to the Registrant&#146;s Current Report on Form 8-K as filed on September&nbsp;29, 2016, and incorporated herein by reference)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;4.8<BR></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Warrant to Purchase Common Stock (filed as Exhibit 4.6 to the Registrant&#146;s Current Report on Form 8-K as filed on September 29, 2016, and incorporated herein by reference)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;4.9<BR></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Warrant to Purchase Common Stock of Histogenics Corporation issued to H.C. Wainwright &amp; Co., LLC dated September 29, 2016 (filed as Exhibit 4.7 to the Registrant&#146;s Current Report on Form
<FONT STYLE="white-space:nowrap">8-K</FONT> as filed on September 29, 2016, and incorporated herein by reference)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Indemnity Agreement for directors and officers (filed as Exhibit 10.1 to the Registrant&#146;s Registration Statement on Form S-1 (SEC File No. 333-199202), as filed on October 7, 2014, and incorporated herein by
reference)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.2+</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">2012 Equity Incentive Plan, as amended, and form of option agreement thereunder (filed as Exhibit 10.6 to the Registrant&#146;s Registration Statement on Form S-1 (SEC File No. 333-199202), as filed on October 7, 2014, and
incorporated herein by reference)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.3+</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">2013 Equity Incentive Plan (filed as Exhibit 10.3 to the Registrant&#146;s Current Report on Form 8-K as filed on May 4, 2016, and incorporated herein by reference)</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">131 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="88%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:25.30pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:39.50pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.3A+<BR></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Amendment No. 1 to 2013 Equity Incentive Plan (filed as Exhibit 10.3A to the Registrant&#146;s Registration Statement on Form S-8 (SEC File
No.&nbsp;333-212358), as filed on June&nbsp;30, 2016, and incorporated herein by reference)</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.4+<BR></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">2013 Employee Stock Purchase Plan (filed as Exhibit 10.4 to the Registrant&#146;s Current Report on Form 8-K as filed on May&nbsp;4, 2016,
and incorporated herein by reference)</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.5&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">License Agreement dated as of May 12, 2005 among the Registrant and Angiotech Pharmaceuticals (US), Inc. and Angiodevice International GmbH (filed as Exhibit 10.10 to the Registrant&#146;s Registration Statement on Form S-1 (SEC
File No. 333-199202), as filed on October&nbsp;7, 2014, and incorporated herein by reference)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.6&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Amendment to License Agreement dated as of August 31, 2007 among the Registrant and Angiotech Pharmaceuticals (US), Inc. and Angiodevice International GmbH (filed as Exhibit 10.11 to the Registrant&#146;s Registration Statement on
Form S-1 (SEC File No. 333-199202), as filed on October 7, 2014, and incorporated herein by reference)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.7&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Second Amendment to License Agreement dated as of January 1, 2008 among the Registrant and Angiotech Pharmaceuticals (US), Inc. and Angiodevice International GmbH (filed as Exhibit 10.12 to the Registrant&#146;s Registration
Statement on Form S-1 (SEC File No. 333-199202), as filed on October 7, 2014, and incorporated herein by reference)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.8&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Third Amendment to License Agreement dated as of April 15, 2008 among the Registrant and Angiotech Pharmaceuticals (US), Inc. and Angiodevice International GmbH (filed as Exhibit 10.13 to the Registrant&#146;s Registration Statement
on Form S-1 (SEC File No. 333-199202), as filed on October 7, 2014, and incorporated herein by reference)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.9&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Fourth Amendment to License Agreement dated as of November&nbsp;1, 2008 among the Registrant and Angiotech Pharmaceuticals (US), Inc. and Angiodevice International GmbH (filed as Exhibit 10.14 to the Registrant&#146;s Registration
Statement on Form S-1 (SEC File No. 333-199202), as filed on October&nbsp;7, 2014, and incorporated herein by reference)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.10&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Fifth Amendment to License Agreement dated as of August 6, 2010 among the Registrant and Angiotech Pharmaceuticals (US), Inc. and Angiodevice International GmbH (filed as Exhibit 10.15 to the Registrant&#146;s Registration Statement
on Form S-1 (SEC File No. 333-199202), as filed on October 7, 2014, and incorporated herein by reference)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.11&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Reinstatement Agreement and Sixth Amendment to License Agreement dated as of February 8, 2011 among the Registrant and Angiotech Pharmaceuticals (US), Inc. and Angiodevice International GmbH (filed as Exhibit 10.16 to the
Registrant&#146;s Registration Statement on Form S-1 (SEC File No.&nbsp;333-199202), as filed on October 7, 2014, and incorporated herein by reference)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.12&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Seventh Amendment to License Agreement dated as of March 31, 2011 among the Registrant and Angiotech Pharmaceuticals (US), Inc. and Angiodevice International GmbH (filed as Exhibit 10.17 to the Registrant&#146;s Registration
Statement on Form S-1 (SEC File No. 333-199202), as filed on October 7, 2014, and incorporated herein by reference)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.13&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Eighth Amendment to License Agreement dated as of June 29, 2012 among the Registrant and Angiotech Pharmaceuticals (US), Inc. and Angiodevice International GmbH (filed as Exhibit 10.18 to the Registrant&#146;s Registration Statement
on Form S-1 (SEC File No. 333-199202), as filed on October 7, 2014, and incorporated herein by reference)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.14&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Paid-up License Agreement dated as of March 6, 2013 between the Registrant and Koken Co., Ltd. (filed as Exhibit 10.19 to the Registrant&#146;s Registration Statement on Form S-1 (SEC File
<FONT STYLE="white-space:nowrap">No.&nbsp;333-199202),</FONT> as filed on October 7, 2014, and incorporated herein by reference)</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">132 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="88%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:25.30pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:39.50pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.15&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Agreement dated as of June 22, 2012 between the Registrant and Purpose Co., Ltd. f/k/a Takagi Sangyo Co. Ltd. and f/k/a Takagi Industrial Co., Ltd. (filed as Exhibit 10.20 to the Registrant&#146;s Registration Statement on Form S-1
(SEC File No. 333-199202), as filed on October 7, 2014, and incorporated herein by reference)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.16&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Exclusive Agreement dated as of April 15, 2001 between the Registrant and The Board of Trustees of The Leland Stanford Junior University (filed as Exhibit 10.21 to the Registrant&#146;s Registration Statement on Form S-1 (SEC File
No. 333-199202), as filed on October 7, 2014, and incorporated herein by reference)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.17</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">First Amendment to Exclusive Agreement dated as of October 26, 2005 between the Registrant and The Board of Trustees of The Leland Stanford Junior University (filed as Exhibit 10.22 to the Registrant&#146;s Registration Statement on
Form S-1 (SEC File No. 333-199202), as filed on October&nbsp;7, 2014, and incorporated herein by reference)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.18&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Second Amendment to Exclusive Agreement dated as of January 15, 2006 between the Registrant and The Board of Trustees of The Leland Stanford Junior University (filed as Exhibit 10.23 to the Registrant&#146;s Registration Statement
on Form S-1 (SEC File No. 333-199202), as filed on October&nbsp;7, 2014, and incorporated herein by reference)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.19&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Amendment No. 3 to the License Agreement Effective 4/15/2001 dated as of May 1, 2009 between the Registrant and The Board of Trustees of The Leland Stanford Junior University (filed as Exhibit 10.24 to the Registrant&#146;s
Registration Statement on Form S-1 (SEC File No.&nbsp;333-199202), as filed on October 7, 2014, and incorporated herein by reference)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.20</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Amendment No. 4 to the License Agreement Effective 4/15/2001 dated as of April 29, 2010 between the Registrant and The Board of Trustees of The Leland Stanford Junior University (filed as Exhibit 10.25 to the Registrant&#146;s
Registration Statement on Form S-1 (SEC File No.&nbsp;333-199202), as filed on October 7, 2014, and incorporated herein by reference)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.21</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Lease Agreement dated of June&nbsp;9, 2006 between the Registrant and Intercontinental Fund III 830 Winter Street LLC (filed as Exhibit 10.28 to the Registrant&#146;s Registration Statement on Form S-1 (SEC File No. 333-199202), as
filed on October&nbsp;7, 2014, and incorporated herein by reference)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.22</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">First Amendment to Lease dated as of October 1, 2009 between the Registrant and Intercontinental Fund III 830 Winter Street LLC (filed as Exhibit 10.29 to the Registrant&#146;s Registration Statement on Form S-1 (SEC File No.
333-199202), as filed on October 7, 2014, and incorporated herein by reference)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.23&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Collagen Technology Transfer Agreement dated as of April 15, 2014 between the Registrant and Advanced BioMatrix, Inc. (filed as Exhibit 10.31 to the Registrant&#146;s Registration Statement on Form S-1 (SEC File No. 333-199202), as
filed on October 7, 2014, and incorporated herein by reference)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.24+</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Employment Agreement dated April 26, 2014 between the Registrant and Adam Gridley (filed as Exhibit 10.32 to the Registrant&#146;s Registration Statement on Form S-1 (SEC File No. 333-199202), as filed on October 7, 2014, and
incorporated herein by reference)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.25</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Lease Agreement dated as of June 2, 2014 between the Registrant and ARE-60 Westview, LLC (filed as Exhibit 10.33 to the Registrant&#146;s Registration Statement on Form S-1 (SEC File
<FONT STYLE="white-space:nowrap">No.&nbsp;333-199202),</FONT> as filed on October 7, 2014, and incorporated herein by reference)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.26</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Loan and Security Agreement dated as of July 9, 2014 between the Registrant and Silicon Valley Bank (filed as Exhibit 10.34 to the Registrant&#146;s Registration Statement on Form S-1 (SEC File No. 333-199202), as filed on October
7, 2014, and incorporated herein by reference)</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">133 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="88%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:25.30pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:39.50pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.27&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Exclusive Channel Collaboration Agreement dated as of September 30, 2014 between the Registrant and Intrexon Corporation (filed as Exhibit 10.35 to the Registrant&#146;s Registration Statement on Form S-1 (SEC File No. 333-199202),
as filed on October 7, 2014, and incorporated herein by reference)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.28+</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Employment Agreement by and between the Registrant and Jonathan Lieber, entered into as of June 17, 2015 (filed as Exhibit 10.38 to the Registration&#146;s Current Report on Form 8-K as filed on June 22, 2015, and incorporated
herein by reference)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.29+</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Amended and Restated Employment Agreement by and between Histogenics Corporation and Stephen Kennedy dated July 29, 2015 (filed as Exhibit 10.39 to the Registration&#146;s Current Report on Form 8-K as filed on July 30, 2015, and
incorporated herein by reference)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.30+<BR></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Amended and Restated Compensation Program for Non-Employee Directors adopted on June 24, 2015 (filed as Exhibit 10.32 to the
Registrant&#146;s Annual Report on Form 10-K as filed on March 10, 2016, and incorporated herein by reference)</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.31&#134;<BR></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">First Amendment to License Agreement, dated May 9, 2016, between the Registrant and Purpose Co., Ltd., f/k/a Takagi Sangyo Co. Ltd. (filed as Exhibit 10.33 to the Registrant&#146;s Quarterly Report on Form 10-Q as filed on August
11, 2016, and incorporated herein by reference)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.32+*<BR></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Employment Agreement by and between the Registrant and Gloria Matthews, DVM, Ph.D., DACVS, entered into as of July 14, 2015</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;21.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">List of Subsidiaries (filed as Exhibit 21.1 to the Registrant&#146;s Annual Report on Form 10-K as filed on March 27, 2015, and incorporated herein by reference)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;23.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Consent of Grant Thornton LLP, independent registered public accounting firm</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;31.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Certification of the Chief Executive Officer, as required by Section 302 of the Sarbanes-Oxley Act of 2002</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;31.2*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Certification of the Chief Financial Officer as required by Section 302 of the Sarbanes-Oxley Act of 2002</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;32.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Certifications of the Chief Executive Officer and Chief Financial Officer as required by 18 U.S.C. 1350</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.INS*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">XBRL Instance Document</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.SCH*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">XBRL Taxonomy Extension Schema Document</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.CAL*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">XBRL Taxonomy Extension Calculation Linkbase Document</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.DEF*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">XBRL Taxonomy Extension Definition Linkbase Document</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.LAB*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">XBRL Taxonomy Extension Label Linkbase Document</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.PRE*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">XBRL Taxonomy Extension Presentation Linkbase Document</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">+</TD>
<TD ALIGN="left" VALIGN="top">Indicates management contract or compensatory plan. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#134;</TD>
<TD ALIGN="left" VALIGN="top">Confidential treatment has been granted with respect to certain portions of this document. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top">Filed herewith </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">134 </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.32
<SEQUENCE>2
<FILENAME>d293850dex1032.htm
<DESCRIPTION>EX-10.32
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.32</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.32 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>E<SMALL>MPLOYMENT</SMALL> A<SMALL>GREEMENT</SMALL> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">This Employment Agreement (this &#147;Agreement&#148;) is entered into as of July&nbsp;14, 2015, by and between Gloria Matthews (the
&#147;Employee&#148;) and Histogenics Corporation, a Delaware corporation (the &#147;Company&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1. Duties and Scope of
Employment. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) <B>Position</B>. For the term of the Employee&#146;s employment under this Agreement (the &#147;Employment&#148;),
the Company agrees to employ the Employee in the position of Chief Medical Officer. The Employee shall report to the Company&#146;s Chief Executive Officer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) <B>Obligations to the Company</B>. During the Employee&#146;s Employment, the Employee (i)&nbsp;shall devote her full business efforts and
time to the Company, (ii)&nbsp;shall not engage in any other employment, consulting or other business activity that would create a conflict of interest with the Company, (iii)&nbsp;shall not assist any person or entity in competing with the Company
or in preparing to compete with the Company and (iv)&nbsp;shall comply with the Company&#146;s policies and rules, as they may be in effect from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) <B>No Conflicting Obligations</B>. The Employee represents and warrants to the Company that the Employee is under no obligations or
commitments, whether contractual or otherwise, that are inconsistent with the Employee&#146;s obligations under this Agreement. The Employee represents and warrants that the Employee will not use or disclose, in connection with his Employment, any
trade secrets or other proprietary information or intellectual property in which the Employee or any other person has any right, title or interest and that her Employment will not infringe or violate the rights of any other person. The Employee
represents and warrants to the Company that the Employee has returned all property and confidential information belonging to any prior employer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d) <B>Commencement Date</B>. The Employee shall commence full-time Employment on July15, 2015 (the &#147;Commencement Date&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(e) <B>Definitions</B>. Certain capitalized terms are defined in Section&nbsp;10. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <B>Cash and Incentive Compensation</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) <B>Salary</B>. The Company shall pay the Employee as compensation a base salary at a gross annual rate of not less than $330,000. Such
salary shall be payable in accordance with the Company&#146;s standard payroll procedures. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) <B>Incentive Bonuses</B>. The Employee
shall be eligible for an annual incentive bonus with a target amount equal to 35% of the Employee&#146;s Base Salary. Such bonus (if any) shall be awarded based on objective or subjective criteria established in advance by the Board or the
Compensation Committee of the Board. The determinations of the Board or its Compensation Committee with respect to such bonus shall be final and binding. Any incentive bonus for a fiscal year shall in no event be paid later than 90 days after the
close of such fiscal year. The Employee shall not be entitled to an incentive bonus if he is not employed by the </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Company on the date when such bonus is payable. The amount of any incentive bonus for the fiscal year in which the Employee&#146;s Employment begins shall be prorated, based on the number of days
of Employment during such fiscal year. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) <B>Stock Options</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Subject to the approval of the Board or the Compensation Committee of the Board, the Company shall grant the Employee an option to purchase
120,000 shares of the Company&#146;s Common Stock (the &#147;Option&#148;). The Option shall be granted as soon as reasonably practicable after the date of this Agreement, but in any event, no later than 90 days after the execution of this agreement
by Employee. The <FONT STYLE="white-space:nowrap">per-share</FONT> exercise price of the Option shall be equal to the fair market value per share of the Company&#146;s Common Stock on the date the Option is granted, as determined by the Board or its
Compensation Committee. The term of the Option shall be 10 years, subject to earlier expiration in the event of the termination of the Employee&#146;s Employment. The grant of the Option shall be subject to the terms and conditions set forth in the
Plan and in the Company&#146;s standard form of Stock Option Agreement. The Employee shall vest in 25% of the Option shares after the first 12 months of continuous service and shall vest in the remaining Option shares in equal monthly installments
over the next three years of continuous service. Vesting of the Option shall accelerate in full if (i)&nbsp;the Company is subject to a Change in Control before the Employee&#146;s service with the Company terminates and (ii)&nbsp;the Employee is
subject to an Involuntary Termination within 12 months after such Change in Control. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Subject to the approval of the Board or the
Compensation Committee of the Board, the Company shall also grant the Employee an option to purchase 30,000 shares of the Company&#146;s Common Stock (the &#147;Performance Option&#148;). The Performance Option shall be granted as soon as reasonably
practicable after the date of this Agreement. The <FONT STYLE="white-space:nowrap">per-share</FONT> exercise price of the Performance Option shall be equal to the fair market value per share of the Company&#146;s Common Stock on the date the
Performance Option is granted, as determined by the Board or its Compensation Committee. The term of the Performance Option shall be 10 years, subject to earlier expiration in the event of the termination of the Employee&#146;s Employment. The grant
of the Performance Option shall be subject to the terms and conditions set forth in the Plan and in the Company&#146;s standard form of Stock Option Agreement. The Performance Option shall vest in full if the Company&#146;s stock price is at or
above $19.92 for any consecutive 60 day period within 4 years of the Vesting Commencement Date. If the Performance Option is exercised within one year of earning the award, the executive must hold shares, issued on exercise, net of taxes until the <FONT
STYLE="white-space:nowrap">one-year</FONT> anniversary of earning the award is reached. Additionally, the shares subject to such Performance Option shall become fully vested and exercisable upon a Change in Control if the per share transaction price
for such Change in Control is at or above $19.92; the post-vesting holding period described above shall be waived if the Performance Option is accelerated upon a Change in Control. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <B>Vacation and Employee Benefits</B>. During her Employment, the Employee shall be eligible for paid vacations in accordance with the
Company&#146;s vacation policy, as it may be amended from time to time; provided, however, that in no event will the Employee be entitled to fewer than three weeks&#146; paid vacation per year. During her Employment, the Employee shall also be
eligible to participate in the employee benefit plans maintained by the Company, subject in each case to the generally applicable terms and conditions of the plan in question and to the determinations of any person or committee administering such
plan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <B>Business Expenses</B>. During her Employment, the Employee shall be authorized to incur
necessary and reasonable travel, entertainment and other business expenses in connection with the Employee&#146;s duties hereunder. The Company shall reimburse the Employee for such expenses upon presentation of an itemized account and appropriate
supporting documentation, all in accordance with the Company&#146;s generally applicable policies. Any reimbursement shall (a)&nbsp;be paid promptly but not later than 30 days after the month in which the expense was incurred, (b)&nbsp;not be
affected by any other expenses that are eligible for reimbursement in any calendar year and (c)&nbsp;not be subject to liquidation or exchange for another benefit. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <B>Term of Employment</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) <B>Employment at Will</B>. The Employee&#146;s Employment with the Company shall be &#147;at will,&#148; meaning that either the Employee
or the Company shall be entitled to terminate the Employee&#146;s Employment at any time and for any reason, with or without Cause. Any contrary representations that may have been made to the Employee shall be superseded by this Agreement. This
Agreement shall constitute the full and complete agreement between the Employee and the Company on the &#147;at will&#148; nature of the Employee&#146;s Employment, which may only be changed in an express written agreement signed by the Employee and
a duly authorized officer of the Company. The termination of the Employee&#146;s Employment shall not limit or otherwise affect her obligations under Section&nbsp;7 below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) <B>Rights upon Termination</B>. Except as expressly provided in Section&nbsp;6 below, upon the termination of the Employee&#146;s
Employment, the Employee shall be entitled only to the compensation, benefits and expense reimbursements that the Employee has earned under this Agreement before the effective date of the termination. The payments under this Agreement shall fully
discharge all responsibilities of the Company to the Employee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <B>Termination Benefits</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) <B>Preconditions</B>. Any other provision of this Agreement notwithstanding, the remaining Subsections of this Section&nbsp;6 shall not
apply unless each of the following requirements is satisfied: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) The Employee has executed a general release of all
claims in a form prescribed by the Company. The Employee shall execute and return the release on or before the date specified by the Company in the prescribed form (the &#147;Release Deadline&#148;). The Release Deadline shall in no event be later
than 50 days after the Employee&#146;s Separation. If the Employee fails to return the release on or before the Release Deadline, or if the Employee revokes the release, then the Employee shall not be entitled to the benefits described in this
Section&nbsp;6. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) The Employee has returned all property of the Company in the Employee&#146;s possession. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) If requested by the Board, the Employee has resigned as a member of the Board and as a member of the boards of directors
of all subsidiaries of the Company, to the extent applicable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) <B>Severance Pay</B>. If, during the term of this Agreement, the Employee is subject to an
Involuntary Termination, then the Company shall pay the Employee an amount equal to the Employee&#146;s Base Salary for a period of six months following the Separation (the &#147;Continuation Period&#148;). Such severance payments shall be paid at
the Base Salary rate in effect at the time of the Separation and in accordance with the Company&#146;s standard payroll procedures. The severance payments shall commence on the first payroll period following expiration of any legally required
revocation period and in no event later than 60 days after the Employee&#146;s Separation and, once they commence, shall include any unpaid amounts accrued from the date of the Employee&#146;s Separation. However, if the <FONT
STYLE="white-space:nowrap">60-day</FONT> period described in the preceding sentence spans two calendar years, then the payments shall in any event begin on the first payroll period following expiration of the 60 day period in the second calendar
year. In addition, The Company shall pay the Employee any accrued benefits, including earned but unpaid salary, earned but unpaid incentive bonuses, accrued and unused vacation time, unreimbursed business expenses, and any vested benefits under the
Company&#146;s benefit plans. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) <B>Health Insurance</B>. If, during the period of Employment, the Employee is subject to an Involuntary
Termination, and if the Employee elects to continue health insurance coverage under the Consolidated Omnibus Budget Reconciliation Act (&#147;COBRA&#148;) for the Employee and, if applicable, her dependents following the Separation, then the Company
shall pay the employer portion of the monthly premium under COBRA for the Employee and, if applicable, such dependents until the earliest of (i)&nbsp;the close of the Continuation Period, (ii)&nbsp;the expiration of the Employee&#146;s continuation
coverage under COBRA or (iii)&nbsp;the date when the Employee receives substantially equivalent health insurance coverage in connection with new employment or self-employment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <B>Confidential Information and Intellectual Property Assignment Agreement</B>. The Employee shall enter into the Company&#146;s standard
form of Confidential Information and Intellectual Property Assignment Agreement, which is incorporated herein by this reference. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.
<B>Successors</B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) <B>Company&#146;s Successors</B>. This Agreement shall be binding upon any successor (whether direct or indirect
and whether by purchase, lease, merger, consolidation, liquidation or otherwise) to all or substantially all of the Company&#146;s business and/or assets. For all purposes under this Agreement, the term &#147;Company&#148; shall include any
successor to the Company&#146;s business and/or assets which becomes bound by this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) <B>Employee&#146;s Successors</B>. This
Agreement and all rights of the Employee hereunder shall inure to the benefit of, and be enforceable by, the Employee&#146;s personal or legal representatives, executors, administrators, successors, heirs, distributees, devisees and legatees. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. <B>Definitions</B>. The following terms shall have the meaning set forth below wherever they
are used in this Agreement: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) <B>Base Salary</B>. The term &#147;Base Salary&#148; shall mean the annual compensation specified in
Section&nbsp;2(a), together with any increases in such compensation that the Company may grant from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) <B>Cause</B>. The
term &#147;Cause&#148; shall mean a good faith determination by the Board of any of the following: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) An unauthorized use
or disclosure by the Employee of the Company&#146;s confidential information or trade secrets, which use or disclosure causes material harm to the Company; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) A material breach by the Employee of any agreement between the Employee and the Company after receiving written
notification of such failure from the Board specifying such breach and after the expiration of a 45 day opportunity to cure; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) A material failure by the Employee to comply with the Company&#146;s written policies or rules after receiving written
notification of such failure from the Board specifying such failure and after the expiration of a 45 day opportunity to cure; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) The sale, possession or use of illegal drugs by the Employee or habitual intoxication of the Employee on the premises of
the Company or a customer or business partner of the Company or while conducting Company business; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) The Employee&#146;s
conviction of, or plea of &#147;guilty&#148; or &#147;no contest&#148; to, a felony under the laws of the United States or any State thereof; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vi) The Employee&#146;s gross negligence or willful misconduct in the course of performing service to the Company; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vii) A continuing failure by the Employee to perform reasonably assigned duties after receiving written notification of such
failure from the Board specifying such failure and after the expiration of a <FONT STYLE="white-space:nowrap">45-day</FONT> opportunity to cure ; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(viii) A failure by the Employee to cooperate in good faith with a governmental or internal investigation of the Company or its
directors, officers or employees, if the Company has requested the Employee&#146;s cooperation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) <B>Change in Control</B>. The term
&#147;Change in Control&#148; shall have the meaning ascribed to it in the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d) <B>Code</B>. The term &#147;Code&#148; shall mean
the Internal Revenue Code of 1986, as amended. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(e) <B>Involuntary Termination</B>. The term &#147;Involuntary Termination&#148; shall mean
either (a)&nbsp;the Employee&#146;s Termination Without Cause or (b)&nbsp;the Employee&#146;s Resignation for Good Reason. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(f)
<B>Plan</B>. The term &#147;Plan&#148; shall mean the Histogenics Corporation 2012 Equity Incentive Plan or the Histogenics Corporation 2013 Equity Incentive Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(g) &#147;<B>Resignation for Good Reason</B>&#148; means a Separation as a result of the Employee&#146;s resignation after one of the
following conditions has come into existence without the Employee&#146;s consent: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) A material reduction in the
Employee&#146;s Base Salary or incentive compensation; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) A change in the Employee&#146;s title or position with the
Company or reporting structure that materially reduces the Employee&#146;s level of authority or responsibility; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii)
A relocation of the Employee&#146;s principal workplace by more than 40 miles. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A Resignation for Good Reason shall not be deemed to have occurred unless
the Employee gives the Company written notice of the condition within 15 days after the condition comes into existence and the Company fails to remedy the condition within 15 days after receiving the Employee&#146;s written notice. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(h) <B>Separation</B>. The term &#147;Separation&#148; shall mean a &#147;separation from service,&#148; as defined in the regulations under
Section&nbsp;409A of the Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(i) &#147;<B>Termination Without Cause</B>&#148; means a Separation as a result of a termination of the
Employee&#146;s employment by the Company without Cause, provided the Employee is willing and able to continue performing services within the meaning of Treasury Regulation <FONT STYLE="white-space:nowrap">1.409A-1(n)(1).</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10. <B>Indemnification and D&amp;O Insurance.</B> The Employee shall enter into the Company&#146;s standard Indemnification Agreement for its
directors and officers. During the term of the Employee&#146;s Employment, the Employee will be named as an insured on the directors&#146; and officers&#146; liability insurance policy currently maintained, or as may be maintained by the Company
from time to time, at the same level of coverage applicable to active directors and officers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11. <B>Miscellaneous Provisions</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(a) <B>Notice</B>. Notices and all other communications contemplated by this Agreement shall be in writing and shall be deemed to have been
duly given when personally delivered, when delivered by FedEx with delivery charges prepaid, or when mailed by U.S. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
registered or certified mail, return receipt requested and postage prepaid. In the case of the Employee, mailed notices shall be addressed to the Employee at the home address that he most
recently communicated to the Company in writing. In the case of the Company, mailed notices shall be addressed to its corporate headquarters, and all notices shall be directed to the attention of its Secretary. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(b) <B>Modifications and Waivers</B>. No provision of this Agreement shall be modified, waived or discharged unless the modification, waiver
or discharge is agreed to in writing and signed by the Employee and by an authorized officer or director of the Company (other than the Employee). No waiver by either party of any breach of, or of compliance with, any condition or provision of this
Agreement by the other party shall be considered a waiver of any other condition or provision or of the same condition or provision at another time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(c) <B>Whole Agreement</B>. This Agreement supersedes all other agreements, representations or understandings (whether oral or written and
whether express or implied) that are not expressly set forth in this Agreement have been made or entered into by either party with respect to the subject matter hereof. This Agreement and the Confidential Information and Intellectual Property
Assignment Agreement contain the entire understanding of the parties with respect to the subject matter hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(d) <B>Tax Matters</B>.
All payments made under this Agreement shall be subject to reduction to reflect taxes or other charges required to be withheld by law. For purposes of Section&nbsp;409A of the Code, each periodic salary continuation payment under Section&nbsp;6(b)
is hereby designated as a separate payment. If the Company determines that the Employee is a &#147;specified employee&#148; under Section&nbsp;409A(a)(2)(B)(i) of the Code and the regulations thereunder at the time of her Separation, then
(i)&nbsp;the salary continuation payments under Section&nbsp;6(b), to the extent that they are subject to Section&nbsp;409A of the Code, shall commence on the first business day following (A)&nbsp;expiration of the
<FONT STYLE="white-space:nowrap">six-month</FONT> period measured from the Employee&#146;s Separation or (B)&nbsp;the date of the Employee&#146;s death and (ii)&nbsp;the installments that otherwise would have been paid prior to such date shall be
paid in a lump sum when such salary continuation payments commence. The Company shall not have a duty to design its compensation policies in a manner that minimizes the Employee&#146;s tax liabilities, and the Employee shall not make any claim
against the Company or the Board related to tax liabilities arising from the Employee&#146;s compensation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(e) <B>Choice of Law and
Severability</B>. This Agreement shall be interpreted in accordance with the laws of the Commonwealth of Massachusetts (except their provisions governing the choice of law). If any provision of this Agreement becomes or is deemed invalid, illegal or
unenforceable in any applicable jurisdiction by reason of the scope, extent or duration of its coverage or any other reason, then such provision shall be deemed amended to the minimum extent necessary to conform to applicable law so as to be valid
and enforceable or, if such provision cannot be so amended without materially altering the intention of the parties, then such provision shall be stricken and the remainder of this Agreement shall continue in full force and effect. If any provision
of this Agreement is rendered illegal by any present or future statute, law, ordinance or regulation (collectively the &#147;Law&#148;), then such provision shall be curtailed or limited only to the minimum extent necessary to bring such provision
into compliance with the Law. All the other terms and provisions of this Agreement shall continue in full force and effect without impairment or limitation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(f) <B>No Assignment</B>. This Agreement and all rights and obligations of the Employee hereunder
are personal to the Employee and may not be transferred or assigned by the Employee at any time. The Company may assign its rights under this Agreement to any entity that assumes the Company&#146;s obligations hereunder in connection with any sale
or transfer of all or a substantial portion of the Company&#146;s assets to such entity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(g) <B>Counterparts</B>. This Agreement may be
executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Remainder of page left blank intentionally.] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, each of the parties has executed this Agreement, in the case of the Company
by its duly authorized officer, as of the day and year first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="10%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="89%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Gloria Matthews</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Gloria Matthews</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">H<SMALL>ISTOGENICS</SMALL> C<SMALL>ORPORATION</SMALL></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Adam Gridley</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">CEO</P></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>d293850dex231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-23.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 23.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>CONSENT OF INDEPENDENT REGISTERED PUBLIC </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have issued
our report dated March&nbsp;16, 2017, with respect to the consolidated financial statements included in the Annual Report of Histogenics Corporation on Form 10-K for the year ended December&nbsp;31, 2016. We consent to the incorporation by reference
of said report in the Registration Statements of Histogenics Corporation on Form S-3 (File No.&nbsp;333-213980) and on Forms S-8 (File No.&nbsp;333-201552, File No.&nbsp;333-210075, and File No.&nbsp;333-212358). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ GRANT THORNTON LLP </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Boston, Massachusetts </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">March&nbsp;16, 2017 </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>d293850dex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-31.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">EXHIBIT 31.1 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CERTIFICATION </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">I, Adam Gridley,
certify that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">I have reviewed this annual report on Form 10-K of Histogenics Corporation; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">Based on my knowledge, this report does not contain any untrue statements of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such
statements were made, not misleading with respect to the period covered by this report; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top">Based on my knowledge, the consolidated financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash
flows of the registrant as of, and for, the periods presented in this report; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top">The registrant&#146;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control
over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its
consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of
financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">c.</TD>
<TD ALIGN="left" VALIGN="top">evaluated the effectiveness of the registrant&#146;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of
the period covered by this report based on such evaluation; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">d.</TD>
<TD ALIGN="left" VALIGN="top">disclosed in this report any change in the registrant&#146;s internal control over financial reporting that occurred during the registrant&#146;s most recent fiscal quarter (the registrant&#146;s fourth fiscal quarter
in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#146;s internal control over financial reporting. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top">The registrant&#146;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#146;s auditors and the audit committee of the
registrant&#146;s board of directors (or persons performing the equivalent functions): </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#146;s ability to record,
process, summarize and report financial information; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#146;s internal control over financial reporting. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="47%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: March&nbsp;16, 2017</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Adam Gridley</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Adam Gridley</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>President and Chief
Executive Officer</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>(Principal Executive Officer)</B></P></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>d293850dex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-31.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">EXHIBIT 31.2 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CERTIFICATION </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">I, Jonathan
Lieber, certify that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">I have reviewed this annual report on Form 10-K of Histogenics Corporation; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">Based on my knowledge, this report does not contain any untrue statements of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such
statements were made, not misleading with respect to the period covered by this report; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top">Based on my knowledge, the consolidated financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash
flows of the registrant as of, and for, the periods presented in this report; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top">The registrant&#146;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control
over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its
consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of
financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">c.</TD>
<TD ALIGN="left" VALIGN="top">evaluated the effectiveness of the registrant&#146;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of
the period covered by this report based on such evaluation; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">d.</TD>
<TD ALIGN="left" VALIGN="top">disclosed in this report any change in the registrant&#146;s internal control over financial reporting that occurred during the registrant&#146;s most recent fiscal quarter (the registrant&#146;s fourth fiscal quarter
in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#146;s internal control over financial reporting. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top">The registrant&#146;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#146;s auditors and the audit committee of the
registrant&#146;s board of directors (or persons performing the equivalent functions): </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#146;s ability to record,
process, summarize and report financial information; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#146;s internal control over financial reporting. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="47%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: March&nbsp;16, 2017</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Jonathan Lieber</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Jonathan Lieber</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Chief Financial
Officer</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>(Principal Financial and Accounting Officer)</B></P></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>d293850dex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-32.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">EXHIBIT 32.1 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CERTIFICATION </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with the Annual
Report of Histogenics Corporation (the &#147;Registrant&#148;) on Form 10-K for the annual period ended December&nbsp;31, 2016 as filed with the Securities and Exchange Commission on the date hereof (the &#147;Report&#148;), the undersigned, Adam
Gridley, President, Chief Executive Officer and Director of the Registrant, and Jonathan Lieber, Chief Financial Officer of the Registrant, certify, pursuant to 18 U.S.C. Section&nbsp;1350, as adopted pursuant to Section&nbsp;906 of the
Sarbanes-Oxley Act of 2002, that to their respective knowledge: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="47%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: March&nbsp;16, 2017</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;/s/ Adam Gridley</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>&nbsp;&nbsp;Adam Gridley</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>&nbsp;&nbsp;President and Chief Executive Officer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>&nbsp;&nbsp;(Principal Executive Officer)</B></P></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="47%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: March&nbsp;16, 2017</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;/s/ Jonathan Lieber</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>&nbsp;&nbsp;Jonathan Lieber</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>&nbsp;&nbsp;Chief Financial Officer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>&nbsp;&nbsp;(Principal Financial and Accounting Officer)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>This certification is made solely for the purposes of 18 U.S.C. Section&nbsp;1350, subject to the knowledge standard
contained therein, and not for any other purpose. A signed original of this written statement required by Section&nbsp;906 has been provided to the Registrant and will be retained by the Registrant and furnished to the United States Securities and
Exchange Commission or its staff upon request. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>This certification accompanies the Form 10-K to which it relates, is not deemed filed with the
Securities and Exchange Commission and is not to be incorporated by reference into any filing of the Registrant under the Securities Act of 1933 or the Securities Exchange Act of 1934, each as amended (whether made before or after the date of the
Form 10-K), irrespective of any general incorporation language contained in such filing. </I></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>7
<FILENAME>hsgx-20161231.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- RR Donnelley Xcelerate Instance Document, based on XBRL 2.1  http://www.rrdonnelley.com/ -->
<!-- Version:  6.23.6 -->
<!-- Round: 5 -->
<!-- Creation date: 2017-03-15T19:04:29Z -->
<!-- Copyright (c) 2005-2013 R.R. Donnelley & Sons Company All Rights Reserved. -->
<xbrl xmlns="http://www.xbrl.org/2003/instance" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-gaap="http://fasb.org/us-gaap/2016-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:hsgx="http://www.histogenics.com/20161231" xmlns:us-types="http://fasb.org/us-types/2016-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:country="http://xbrl.sec.gov/country/2016-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2016-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2016-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:utr="http://www.xbrl.org/2009/utr">
  <xbrll:schemaRef xlink:type="simple" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xlink:href="hsgx-20161231.xsd" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" />
  <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="eol_PE717962--1610-K0012_STD_0_20140731_0_2033330x2361826" unitRef="pure" decimals="INF" id="id_11655837_A251A8CE-F5C0-4315-B48A-09D533A291E2_3001_2">0.0325</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="eol_PE717962--1610-K0012_STD_0_20140731_0_2033330x2361826" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_11655837_6BE8E696-1148-4BE9-813D-615DC8B901C6_1001_1">7.99</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="eol_PE717962--1610-K0012_STD_0_20140731_0_2033330x2361826" unitRef="shares" decimals="INF" id="id_11655837_6BE8E696-1148-4BE9-813D-615DC8B901C6_1001_0">6566</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="eol_PE717962--1610-K0012_STD_0_20140731_0_2033330x2361826" unitRef="iso4217_USD" decimals="INF" id="id_11655837_A251A8CE-F5C0-4315-B48A-09D533A291E2_3001_0">1800000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="eol_PE717962--1610-K0012_STD_0_20141203_0_2029102x2377267" unitRef="shares" decimals="INF" id="id_11655837_E46D1C6D-90B6-403D-B13F-C661F3E7206B_2001_0">103665</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
  <us-gaap:SaleOfStockPricePerShare contextRef="eol_PE717962--1610-K0012_STD_0_20141203_0_2040137x2029877" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_11655837_E8F250E2-5279-4840-BE96-3F4C8B48850F_1001_1">11.00</us-gaap:SaleOfStockPricePerShare>
  <us-gaap:SaleOfStockPricePerShare contextRef="eol_PE717962--1610-K0012_STD_0_20150131_0_2040137x2030849" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_11655837_E8F250E2-5279-4840-BE96-3F4C8B48850F_1003_1">11.00</us-gaap:SaleOfStockPricePerShare>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="eol_PE717962--1610-K0012_STD_0_20150331_0_2027723x2068134" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_11655837_BE8C7A74-1E78-400A-9F65-806A419A74D3_1001_1">9.75</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="eol_PE717962--1610-K0012_STD_0_20150331_0_2027723x2068134" unitRef="shares" decimals="INF" id="id_11655837_BE8C7A74-1E78-400A-9F65-806A419A74D3_1001_0">7398</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <dei:EntityCommonStockSharesOutstanding contextRef="eol_PE717962--1610-K0012_STD_0_20170314_0" unitRef="shares" decimals="INF" id="id_11655837_4376F2C2-CCA2-43BC-BD83-928C14BA3491_2_500008">22168090</dei:EntityCommonStockSharesOutstanding>
  <hsgx:DevelopmentCostReimbursementCommitment contextRef="eol_PE717962--1610-K0012_STD_0_20120630_0_2038452x2128515" unitRef="iso4217_USD" decimals="-5" id="id_11655837_29A8865E-CFB3-43C5-BB75-1BA4EE81C7D5_1001_0">300000</hsgx:DevelopmentCostReimbursementCommitment>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="eol_PE717962--1610-K0012_STD_0_20120720_0_2027723x2424282" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_11655837_695D3B3B-82B7-4956-A797-AEFD74B2A4AF_2001_1">0.01</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="eol_PE717962--1610-K0012_STD_0_20120720_0_2027723x2424282" unitRef="shares" decimals="INF" id="id_11655837_695D3B3B-82B7-4956-A797-AEFD74B2A4AF_2001_0">161977</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <dei:EntityPublicFloat contextRef="eol_PE717962--1610-K0012_STD_0_20160630_0" unitRef="iso4217_USD" decimals="-5" id="id_11655837_4376F2C2-CCA2-43BC-BD83-928C14BA3491_3_600009">14900000</dei:EntityPublicFloat>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="eol_PE717962--1610-K0012_STD_0_20160929_0_2039549x2037928" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_11655837_BA55390A-7F6A-4E74-AD37-FCFA4868621B_2001_2">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesIssued contextRef="eol_PE717962--1610-K0012_STD_0_20160929_0_2039549x2037928" unitRef="shares" decimals="INF" id="id_11655837_BA55390A-7F6A-4E74-AD37-FCFA4868621B_2001_0">24158.8693</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockSharesIssued contextRef="eol_PE717962--1610-K0012_STD_0_20160929_0_2039549x2037928_2040137x2032595" unitRef="shares" decimals="INF" id="id_11655837_0C4D853D-8EDE-44A2-8648-C64AEF8502EB_2001_3">24158.8693</us-gaap:PreferredStockSharesIssued>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="eol_PE717962--1610-K0012_STD_0_20160929_0_2040137x2032595" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_11655837_0C4D853D-8EDE-44A2-8648-C64AEF8502EB_3001_2">2.25</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockSharesIssued contextRef="eol_PE717962--1610-K0012_STD_0_20160929_0_2040137x2032595" unitRef="shares" decimals="INF" id="id_11655837_0C4D853D-8EDE-44A2-8648-C64AEF8502EB_3001_1">2596059</us-gaap:CommonStockSharesIssued>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="eol_PE717962--1610-K0012_STD_0_20160929_0_2040137x2032595" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_11655837_0C4D853D-8EDE-44A2-8648-C64AEF8502EB_3001_6">2.25</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="eol_PE717962--1610-K0012_STD_0_20160929_0_2040137x2032595" unitRef="shares" decimals="INF" id="id_11655837_0C4D853D-8EDE-44A2-8648-C64AEF8502EB_3001_5">13333334</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <hsgx:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsIssuedForService contextRef="eol_PE717962--1610-K0012_STD_0_20160929_0_2040137x2032595" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_11655837_0C4D853D-8EDE-44A2-8648-C64AEF8502EB_3001_9">2.25</hsgx:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsIssuedForService>
  <hsgx:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsIssuedForService contextRef="eol_PE717962--1610-K0012_STD_0_20160929_0_2040137x2032595" unitRef="shares" decimals="INF" id="id_11655837_0C4D853D-8EDE-44A2-8648-C64AEF8502EB_3001_7">133333</hsgx:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsIssuedForService>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="eol_PE717962--1610-K0012_STD_0_20160930_0_2027723x2283059" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_11655837_6C944E68-201D-497B-9EE4-BBB539A7CF8A_2001_1">2.25</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="eol_PE717962--1610-K0012_STD_0_20160930_0_2027723x2283059" unitRef="shares" decimals="INF" id="id_11655837_6C944E68-201D-497B-9EE4-BBB539A7CF8A_2001_0">13333334</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="eol_PE717962--1610-K0012_STD_0_20160930_0_2027723x2394050" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_11655837_B5EF8294-DA1A-4946-9F7E-C56AF2DB0E10_2001_1">2.25</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="eol_PE717962--1610-K0012_STD_0_20160930_0_2027723x2394050" unitRef="shares" decimals="INF" id="id_11655837_B5EF8294-DA1A-4946-9F7E-C56AF2DB0E10_2001_0">133333</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE717962--1610-K0012_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_F517A3E7-CD09-482E-A458-78C5E43ED953_2001_27">58527000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:StockholdersEquity contextRef="eol_PE717962--1610-K0012_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_5A0DEAA9-8FA8-403D-B739-D326D818EDBC_1007_1000001">54206000</us-gaap:StockholdersEquity>
  <us-gaap:UnrecognizedTaxBenefits contextRef="eol_PE717962--1610-K0012_STD_0_20141231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_6C26F4B4-0D62-4BDF-8A8C-63D664124B3A_2001_0">811000</us-gaap:UnrecognizedTaxBenefits>
  <us-gaap:SharesOutstanding contextRef="eol_PE717962--1610-K0012_STD_0_20141231_0_2025317x2041099" unitRef="shares" decimals="INF" id="id_11655837_5A0DEAA9-8FA8-403D-B739-D326D818EDBC_1003_600002">8493</us-gaap:SharesOutstanding>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="eol_PE717962--1610-K0012_STD_0_20141231_0_2029102x2176993" unitRef="shares" decimals="INF" id="id_11655837_ABCD2E8A-6979-497E-8ECB-04F5599D6C50_3001_0">609389</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
  <hsgx:RemainingOfferingCostsIncludedInAccountsPayable contextRef="eol_PE717962--1610-K0012_STD_0_20141231_0_2040137x2029877" unitRef="iso4217_USD" decimals="-5" id="id_11655837_7D08BE0B-1F46-4071-905D-4814923C00EC_1002_2">1000000</hsgx:RemainingOfferingCostsIncludedInAccountsPayable>
  <us-gaap:StockholdersEquity contextRef="eol_PE717962--1610-K0012_STD_0_20141231_0_2040323x2025075" unitRef="iso4217_USD" decimals="-3" id="id_11655837_5A0DEAA9-8FA8-403D-B739-D326D818EDBC_1005_800001">187620000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="eol_PE717962--1610-K0012_STD_0_20141231_0_2040323x2027302" unitRef="iso4217_USD" decimals="-3" id="id_11655837_5A0DEAA9-8FA8-403D-B739-D326D818EDBC_1001_500001">127000</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding contextRef="eol_PE717962--1610-K0012_STD_0_20141231_0_2040323x2027302" unitRef="shares" decimals="INF" id="id_11655837_5A0DEAA9-8FA8-403D-B739-D326D818EDBC_1001_400002">12746519</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity contextRef="eol_PE717962--1610-K0012_STD_0_20141231_0_2040323x2037658" unitRef="iso4217_USD" decimals="-3" id="id_11655837_5A0DEAA9-8FA8-403D-B739-D326D818EDBC_1006_900001">-133541000</us-gaap:StockholdersEquity>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="eol_PE717962--1610-K0012_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_3CB85D34-5D5F-482C-9359-359FBEED229A_1002_0">758000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="eol_PE717962--1610-K0012_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_DA046FE2-45EA-4061-9B96-ECBFB4F53FD8_1002_4">630000</us-gaap:FiniteLivedIntangibleAssetsGross>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="eol_PE717962--1610-K0012_STD_0_20151231_0" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_11655837_B3B68C79-A4E2-4679-8303-E543A568839E_2_31">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="eol_PE717962--1610-K0012_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_790A0593-5588-47C6-B63B-510E6890BA00_2_6">7989000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts contextRef="eol_PE717962--1610-K0012_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_08D6FE89-CA70-4EAE-89FE-D5ACF76B77DE_1002_10">36000</us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts>
  <us-gaap:CommitmentsAndContingencies contextRef="eol_PE717962--1610-K0012_STD_0_20151231_0" unitRef="iso4217_USD" xsi:nil="true" id="id_11655837_B3B68C79-A4E2-4679-8303-E543A568839E_2_23" />
  <us-gaap:CommonStockSharesOutstanding contextRef="eol_PE717962--1610-K0012_STD_0_20151231_0" unitRef="shares" decimals="INF" id="id_11655837_B3B68C79-A4E2-4679-8303-E543A568839E_2_34">13273470</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockSharesIssued contextRef="eol_PE717962--1610-K0012_STD_0_20151231_0" unitRef="shares" decimals="INF" id="id_11655837_B3B68C79-A4E2-4679-8303-E543A568839E_2_33">13273470</us-gaap:CommonStockSharesIssued>
  <us-gaap:Assets contextRef="eol_PE717962--1610-K0012_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_B3B68C79-A4E2-4679-8303-E543A568839E_2_7">36786000</us-gaap:Assets>
  <us-gaap:DeferredIncomeTaxLiabilities contextRef="eol_PE717962--1610-K0012_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_08D6FE89-CA70-4EAE-89FE-D5ACF76B77DE_1002_12">1110000</us-gaap:DeferredIncomeTaxLiabilities>
  <us-gaap:DeferredRentCreditNoncurrent contextRef="eol_PE717962--1610-K0012_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_B3B68C79-A4E2-4679-8303-E543A568839E_2_18">451000</us-gaap:DeferredRentCreditNoncurrent>
  <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="eol_PE717962--1610-K0012_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_08D6FE89-CA70-4EAE-89FE-D5ACF76B77DE_1002_13">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
  <us-gaap:DeferredRentCreditCurrent contextRef="eol_PE717962--1610-K0012_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_B3B68C79-A4E2-4679-8303-E543A568839E_2_13">126000</us-gaap:DeferredRentCreditCurrent>
  <us-gaap:DeferredTaxAssetsOther contextRef="eol_PE717962--1610-K0012_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_08D6FE89-CA70-4EAE-89FE-D5ACF76B77DE_1002_5">259000</us-gaap:DeferredTaxAssetsOther>
  <us-gaap:AssetsCurrent contextRef="eol_PE717962--1610-K0012_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_B3B68C79-A4E2-4679-8303-E543A568839E_2_3">31236000</us-gaap:AssetsCurrent>
  <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="eol_PE717962--1610-K0012_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_08D6FE89-CA70-4EAE-89FE-D5ACF76B77DE_1002_7">43751000</us-gaap:DeferredTaxAssetsValuationAllowance>
  <us-gaap:CommonStockSharesAuthorized contextRef="eol_PE717962--1610-K0012_STD_0_20151231_0" unitRef="shares" decimals="INF" id="id_11655837_B3B68C79-A4E2-4679-8303-E543A568839E_2_32">100000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:DeferredRevenueLeasesCurrent contextRef="eol_PE717962--1610-K0012_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_B3B68C79-A4E2-4679-8303-E543A568839E_2_14">407000</us-gaap:DeferredRevenueLeasesCurrent>
  <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="eol_PE717962--1610-K0012_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_B3B68C79-A4E2-4679-8303-E543A568839E_2_35">193631000</us-gaap:AdditionalPaidInCapitalCommonStock>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE717962--1610-K0012_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_B3B68C79-A4E2-4679-8303-E543A568839E_2_1">30915000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities contextRef="eol_PE717962--1610-K0012_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_08D6FE89-CA70-4EAE-89FE-D5ACF76B77DE_1002_3">1183000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
  <us-gaap:CommonStockValue contextRef="eol_PE717962--1610-K0012_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_B3B68C79-A4E2-4679-8303-E543A568839E_2_30">132000</us-gaap:CommonStockValue>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="eol_PE717962--1610-K0012_STD_0_20151231_0" unitRef="shares" decimals="INF" id="id_11655837_B24AD55E-55B0-45FC-ACAD-5A912A6B3450_2_3">1394360</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:AccountsPayableCurrent contextRef="eol_PE717962--1610-K0012_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_B3B68C79-A4E2-4679-8303-E543A568839E_2_9">2024000</us-gaap:AccountsPayableCurrent>
  <us-gaap:DeferredTaxAssetsNet contextRef="eol_PE717962--1610-K0012_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_08D6FE89-CA70-4EAE-89FE-D5ACF76B77DE_1002_8">1110000</us-gaap:DeferredTaxAssetsNet>
  <us-gaap:AccountsPayableRelatedPartiesCurrent contextRef="eol_PE717962--1610-K0012_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_B3B68C79-A4E2-4679-8303-E543A568839E_2_10">229000</us-gaap:AccountsPayableRelatedPartiesCurrent>
  <us-gaap:DepositAssets contextRef="eol_PE717962--1610-K0012_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_18335864-285B-4D09-8D40-2546591AED88_2_0">67000</us-gaap:DepositAssets>
  <us-gaap:DeferredTaxAssetsGross contextRef="eol_PE717962--1610-K0012_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_08D6FE89-CA70-4EAE-89FE-D5ACF76B77DE_1002_6">44861000</us-gaap:DeferredTaxAssetsGross>
  <us-gaap:DueToRelatedPartiesCurrent contextRef="eol_PE717962--1610-K0012_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_B3B68C79-A4E2-4679-8303-E543A568839E_2_12">1546000</us-gaap:DueToRelatedPartiesCurrent>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="eol_PE717962--1610-K0012_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_08D6FE89-CA70-4EAE-89FE-D5ACF76B77DE_1002_1">28200000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
  <us-gaap:AccruedLiabilitiesCurrent contextRef="eol_PE717962--1610-K0012_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_B3B68C79-A4E2-4679-8303-E543A568839E_2_11">1444000</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:LoansPayableCurrent contextRef="eol_PE717962--1610-K0012_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_B3B68C79-A4E2-4679-8303-E543A568839E_2_15">583000</us-gaap:LoansPayableCurrent>
  <us-gaap:PrepaidInsurance contextRef="eol_PE717962--1610-K0012_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_18335864-285B-4D09-8D40-2546591AED88_2_2">42000</us-gaap:PrepaidInsurance>
  <us-gaap:NoncurrentAssets contextRef="eol_PE717962--1610-K0012_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_8D7B7024-1C27-4427-AF4F-2B916D0BBDE3_1002_2">5213000</us-gaap:NoncurrentAssets>
  <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="eol_PE717962--1610-K0012_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_DA046FE2-45EA-4061-9B96-ECBFB4F53FD8_1002_5">430000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
  <us-gaap:OtherAssetsCurrent contextRef="eol_PE717962--1610-K0012_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_18335864-285B-4D09-8D40-2546591AED88_2_3">195000</us-gaap:OtherAssetsCurrent>
  <us-gaap:Liabilities contextRef="eol_PE717962--1610-K0012_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_B3B68C79-A4E2-4679-8303-E543A568839E_2_22">8588000</us-gaap:Liabilities>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="eol_PE717962--1610-K0012_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_B3B68C79-A4E2-4679-8303-E543A568839E_2_38">36786000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="eol_PE717962--1610-K0012_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_B3B68C79-A4E2-4679-8303-E543A568839E_2_5">200000</us-gaap:FiniteLivedIntangibleAssetsNet>
  <us-gaap:LiabilitiesCurrent contextRef="eol_PE717962--1610-K0012_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_B3B68C79-A4E2-4679-8303-E543A568839E_2_16">6359000</us-gaap:LiabilitiesCurrent>
  <us-gaap:IncentiveFromLessor contextRef="eol_PE717962--1610-K0012_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_B3B68C79-A4E2-4679-8303-E543A568839E_2_19">1017000</us-gaap:IncentiveFromLessor>
  <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="eol_PE717962--1610-K0012_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_3CB85D34-5D5F-482C-9359-359FBEED229A_1002_2">548000</us-gaap:OtherAccruedLiabilitiesCurrent>
  <us-gaap:PreferredStockValue contextRef="eol_PE717962--1610-K0012_STD_0_20151231_0" unitRef="iso4217_USD" xsi:nil="true" id="id_11655837_B3B68C79-A4E2-4679-8303-E543A568839E_2_25" />
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="eol_PE717962--1610-K0012_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_9C467F66-5F6B-466C-B000-70054CF38384_1001_1">4679000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
  <us-gaap:LongTermLoansPayable contextRef="eol_PE717962--1610-K0012_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_B3B68C79-A4E2-4679-8303-E543A568839E_2_20">761000</us-gaap:LongTermLoansPayable>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="eol_PE717962--1610-K0012_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_B3B68C79-A4E2-4679-8303-E543A568839E_2_4">5213000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE717962--1610-K0012_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_790A0593-5588-47C6-B63B-510E6890BA00_2_5">13202000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:StockholdersEquity contextRef="eol_PE717962--1610-K0012_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_B3B68C79-A4E2-4679-8303-E543A568839E_2_37">28198000</us-gaap:StockholdersEquity>
  <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment contextRef="eol_PE717962--1610-K0012_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_08D6FE89-CA70-4EAE-89FE-D5ACF76B77DE_1002_2">6688000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="eol_PE717962--1610-K0012_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-5" id="id_11655837_9D59D34B-448C-4FAF-A6E9-512FD74E0A44_2002_0">3900000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="eol_PE717962--1610-K0012_STD_0_20151231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_11655837_D773A7C3-9EBB-45B3-BC43-D1082FBCD371_1001_1">7.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:Supplies contextRef="eol_PE717962--1610-K0012_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_18335864-285B-4D09-8D40-2546591AED88_2_1">17000</us-gaap:Supplies>
  <us-gaap:UnrecognizedTaxBenefits contextRef="eol_PE717962--1610-K0012_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_6C26F4B4-0D62-4BDF-8A8C-63D664124B3A_1002_0">687000</us-gaap:UnrecognizedTaxBenefits>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="eol_PE717962--1610-K0012_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_B3B68C79-A4E2-4679-8303-E543A568839E_2_36">-165565000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="eol_PE717962--1610-K0012_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_B3B68C79-A4E2-4679-8303-E543A568839E_2_2">321000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued contextRef="eol_PE717962--1610-K0012_STD_0_20151231_0" unitRef="iso4217_USD" decimals="INF" id="id_11655837_A79DB659-8B27-4A30-9A9C-35C1D5680E0D_1002_0">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
  <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent contextRef="eol_PE717962--1610-K0012_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_B3B68C79-A4E2-4679-8303-E543A568839E_2_6">137000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="eol_PE717962--1610-K0012_STD_0_20151231_0" unitRef="shares" decimals="INF" id="id_11655837_4EA76CC8-F5DB-4BEE-8639-4745B518B6F3_1001_1">1229339</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <hsgx:DeferredTaxLiabilitiesChangeInAccountingMethod contextRef="eol_PE717962--1610-K0012_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_08D6FE89-CA70-4EAE-89FE-D5ACF76B77DE_1002_11">1074000</hsgx:DeferredTaxLiabilitiesChangeInAccountingMethod>
  <hsgx:DeferredTaxAssetsCapitalizedStartUpCosts contextRef="eol_PE717962--1610-K0012_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_08D6FE89-CA70-4EAE-89FE-D5ACF76B77DE_1002_4">8531000</hsgx:DeferredTaxAssetsCapitalizedStartUpCosts>
  <hsgx:OperatingLossCarryforwardsNetOfLimitations contextRef="eol_PE717962--1610-K0012_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-5" id="id_11655837_C8B89248-F510-4BF4-9B1E-29587AFCAE5B_1001_0">47100000</hsgx:OperatingLossCarryforwardsNetOfLimitations>
  <hsgx:FairValueInputAmountTransferBetweenLevels contextRef="eol_PE717962--1610-K0012_STD_0_20151231_0" unitRef="iso4217_USD" decimals="INF" id="id_11655837_5D32150D-6080-4582-BB4F-2EE14E5E5F1C_1008_2">0</hsgx:FairValueInputAmountTransferBetweenLevels>
  <hsgx:AccruedClinicalExpensesCurrent contextRef="eol_PE717962--1610-K0012_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_3CB85D34-5D5F-482C-9359-359FBEED229A_1002_1">138000</hsgx:AccruedClinicalExpensesCurrent>
  <us-gaap:AssetsFairValueDisclosureRecurring contextRef="eol_PE717962--1610-K0012_STD_0_20151231_0_2022410x2021995" unitRef="iso4217_USD" decimals="INF" id="id_11655837_5D32150D-6080-4582-BB4F-2EE14E5E5F1C_1004_0">0</us-gaap:AssetsFairValueDisclosureRecurring>
  <us-gaap:LiabilitiesFairValueDisclosureRecurring contextRef="eol_PE717962--1610-K0012_STD_0_20151231_0_2022410x2021995" unitRef="iso4217_USD" decimals="INF" id="id_11655837_5D32150D-6080-4582-BB4F-2EE14E5E5F1C_1004_1">0</us-gaap:LiabilitiesFairValueDisclosureRecurring>
  <us-gaap:AssetsFairValueDisclosureRecurring contextRef="eol_PE717962--1610-K0012_STD_0_20151231_0_2022410x2022419" unitRef="iso4217_USD" decimals="INF" id="id_11655837_5D32150D-6080-4582-BB4F-2EE14E5E5F1C_1006_0">0</us-gaap:AssetsFairValueDisclosureRecurring>
  <us-gaap:LiabilitiesFairValueDisclosureRecurring contextRef="eol_PE717962--1610-K0012_STD_0_20151231_0_2022410x2022419" unitRef="iso4217_USD" decimals="INF" id="id_11655837_5D32150D-6080-4582-BB4F-2EE14E5E5F1C_1006_1">0</us-gaap:LiabilitiesFairValueDisclosureRecurring>
  <us-gaap:AssetsFairValueDisclosureRecurring contextRef="eol_PE717962--1610-K0012_STD_0_20151231_0_2022410x2026970" unitRef="iso4217_USD" decimals="INF" id="id_11655837_5D32150D-6080-4582-BB4F-2EE14E5E5F1C_1002_0">0</us-gaap:AssetsFairValueDisclosureRecurring>
  <us-gaap:LiabilitiesFairValueDisclosureRecurring contextRef="eol_PE717962--1610-K0012_STD_0_20151231_0_2022410x2026970" unitRef="iso4217_USD" decimals="INF" id="id_11655837_5D32150D-6080-4582-BB4F-2EE14E5E5F1C_1002_1">0</us-gaap:LiabilitiesFairValueDisclosureRecurring>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="eol_PE717962--1610-K0012_STD_0_20151231_0_2022410x2026970_2025340x2029281" unitRef="iso4217_USD" decimals="-5" id="id_11655837_197548DF-ABA8-45B1-AC01-2065A0C7AA2F_1004_1">25800000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE717962--1610-K0012_STD_0_20151231_0_2022410x2026970_2026315x2029281" unitRef="iso4217_USD" decimals="-3" id="id_11655837_68432C6A-CA97-439A-BB2D-FF62D53525B6_1002_6">25764000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="eol_PE717962--1610-K0012_STD_0_20151231_0_2025317x2022619" unitRef="shares" decimals="INF" id="id_11655837_B24AD55E-55B0-45FC-ACAD-5A912A6B3450_1002_1">1222767</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="eol_PE717962--1610-K0012_STD_0_20151231_0_2025317x2041099" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_11655837_D01666D7-512E-4DEB-BE05-8E7949A33DBA_1003_4">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions contextRef="eol_PE717962--1610-K0012_STD_0_20151231_0_2025317x2041099" unitRef="iso4217_USD" decimals="-3" id="id_11655837_221B4776-CDDF-4F75-8802-3671377CDC93_2002_0">4000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="eol_PE717962--1610-K0012_STD_0_20151231_0_2025317x2041099" unitRef="shares" decimals="INF" id="id_11655837_B24AD55E-55B0-45FC-ACAD-5A912A6B3450_2002_0">5190</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="eol_PE717962--1610-K0012_STD_0_20151231_0_2025317x2041099" unitRef="shares" decimals="INF" id="id_11655837_942CD0BF-A20C-4D47-824E-ACE757FC85CE_1001_1">5190</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="eol_PE717962--1610-K0012_STD_0_20151231_0_2025317x2041099" unitRef="iso4217_USD_per_shares" decimals="2" id="id_11655837_A53E2444-FE4F-4F74-815C-FA924807C41A_1001_1">1.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
  <us-gaap:SharesOutstanding contextRef="eol_PE717962--1610-K0012_STD_0_20151231_0_2025317x2041099" unitRef="shares" decimals="INF" id="id_11655837_5A0DEAA9-8FA8-403D-B739-D326D818EDBC_3003_600014">5190</us-gaap:SharesOutstanding>
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE717962--1610-K0012_STD_0_20151231_0_2026315x2029281" unitRef="iso4217_USD" decimals="-3" id="id_11655837_68432C6A-CA97-439A-BB2D-FF62D53525B6_1001_6">25764000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="eol_PE717962--1610-K0012_STD_0_20151231_0_2027723x2424282" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_11655837_695D3B3B-82B7-4956-A797-AEFD74B2A4AF_1003_8">0.01</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="eol_PE717962--1610-K0012_STD_0_20151231_0_2027723x2424282" unitRef="shares" decimals="INF" id="id_11655837_695D3B3B-82B7-4956-A797-AEFD74B2A4AF_1003_7">156138</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE717962--1610-K0012_STD_0_20151231_0_2030037x2023509" unitRef="iso4217_USD" decimals="-3" id="id_11655837_790A0593-5588-47C6-B63B-510E6890BA00_1002_1">4337000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE717962--1610-K0012_STD_0_20151231_0_2030037x2024062" unitRef="iso4217_USD" decimals="-3" id="id_11655837_790A0593-5588-47C6-B63B-510E6890BA00_2002_3">547000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE717962--1610-K0012_STD_0_20151231_0_2030037x2028633" unitRef="iso4217_USD" decimals="-3" id="id_11655837_790A0593-5588-47C6-B63B-510E6890BA00_3002_2">7683000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE717962--1610-K0012_STD_0_20151231_0_2030037x2031893" unitRef="iso4217_USD" decimals="-3" id="id_11655837_790A0593-5588-47C6-B63B-510E6890BA00_4002_0">539000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE717962--1610-K0012_STD_0_20151231_0_2030037x2037949" unitRef="iso4217_USD" decimals="-3" id="id_11655837_790A0593-5588-47C6-B63B-510E6890BA00_5002_4">96000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:OperatingLossCarryforwards contextRef="eol_PE717962--1610-K0012_STD_0_20151231_0_2031777x2024390" unitRef="iso4217_USD" decimals="-5" id="id_11655837_F58303BF-A32D-4120-87E5-203E27551ADE_3002_4">25600000</us-gaap:OperatingLossCarryforwards>
  <us-gaap:OperatingLossCarryforwards contextRef="eol_PE717962--1610-K0012_STD_0_20151231_0_2031777x2024782" unitRef="iso4217_USD" decimals="-5" id="id_11655837_F58303BF-A32D-4120-87E5-203E27551ADE_4002_0">55500000</us-gaap:OperatingLossCarryforwards>
  <us-gaap:OperatingLossCarryforwards contextRef="eol_PE717962--1610-K0012_STD_0_20151231_0_2031777x2037951" unitRef="iso4217_USD" decimals="-5" id="id_11655837_F58303BF-A32D-4120-87E5-203E27551ADE_5002_2">55400000</us-gaap:OperatingLossCarryforwards>
  <us-gaap:LoansPayable contextRef="eol_PE717962--1610-K0012_STD_0_20151231_0_2033330x2361826" unitRef="iso4217_USD" decimals="-3" id="id_11655837_5FC72CC3-338E-4CE3-8F67-3925C6D5F99B_2002_0">1344000</us-gaap:LoansPayable>
  <us-gaap:LineOfCredit contextRef="eol_PE717962--1610-K0012_STD_0_20151231_0_2033330x2361826" unitRef="iso4217_USD" decimals="-5" id="id_11655837_9DDCE00E-794F-4CAA-89CB-4239C158D36E_1002_0">1300000</us-gaap:LineOfCredit>
  <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="eol_PE717962--1610-K0012_STD_0_20151231_0_2035448x2031417" unitRef="iso4217_USD" decimals="-3" id="id_11655837_DA046FE2-45EA-4061-9B96-ECBFB4F53FD8_1001_4">630000</us-gaap:FiniteLivedIntangibleAssetsGross>
  <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="eol_PE717962--1610-K0012_STD_0_20151231_0_2035448x2031417" unitRef="iso4217_USD" decimals="-3" id="id_11655837_DA046FE2-45EA-4061-9B96-ECBFB4F53FD8_1001_5">430000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
  <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="eol_PE717962--1610-K0012_STD_0_20151231_0_2035448x2031417" unitRef="iso4217_USD" decimals="-3" id="id_11655837_DA046FE2-45EA-4061-9B96-ECBFB4F53FD8_1001_6">200000</us-gaap:FiniteLivedIntangibleAssetsNet>
  <us-gaap:DueToRelatedPartiesCurrent contextRef="eol_PE717962--1610-K0012_STD_0_20151231_0_2038452x2183197" unitRef="iso4217_USD" decimals="-5" id="id_11655837_7442F8D7-2D4D-4BC2-86FB-09636C3F6B44_2002_3">1500000</us-gaap:DueToRelatedPartiesCurrent>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="eol_PE717962--1610-K0012_STD_0_20151231_0_2039549x2159266" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_11655837_B3B68C79-A4E2-4679-8303-E543A568839E_1002_26">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesAuthorized contextRef="eol_PE717962--1610-K0012_STD_0_20151231_0_2039549x2159266" unitRef="shares" decimals="INF" id="id_11655837_B3B68C79-A4E2-4679-8303-E543A568839E_1002_27">30000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesOutstanding contextRef="eol_PE717962--1610-K0012_STD_0_20151231_0_2039549x2159266" unitRef="shares" decimals="INF" id="id_11655837_B3B68C79-A4E2-4679-8303-E543A568839E_1002_29">0.0000</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="eol_PE717962--1610-K0012_STD_0_20151231_0_2039549x2159266" unitRef="iso4217_USD" decimals="-3" id="id_11655837_7EE727ED-2B5B-4314-A01B-2ACB6184A985_1001_1">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
  <us-gaap:TemporaryEquityParOrStatedValuePerShare contextRef="eol_PE717962--1610-K0012_STD_0_20151231_0_2039549x2159266" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_11655837_D01666D7-512E-4DEB-BE05-8E7949A33DBA_1001_2">0.01</us-gaap:TemporaryEquityParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesIssued contextRef="eol_PE717962--1610-K0012_STD_0_20151231_0_2039549x2159266" unitRef="shares" decimals="INF" id="id_11655837_B3B68C79-A4E2-4679-8303-E543A568839E_1002_28">0.0000</us-gaap:PreferredStockSharesIssued>
  <us-gaap:NoncurrentAssets contextRef="eol_PE717962--1610-K0012_STD_0_20151231_0_2039550x2032405" unitRef="iso4217_USD" decimals="-3" id="id_11655837_8D7B7024-1C27-4427-AF4F-2B916D0BBDE3_2002_1">9000</us-gaap:NoncurrentAssets>
  <us-gaap:NoncurrentAssets contextRef="eol_PE717962--1610-K0012_STD_0_20151231_0_2039550x2037985" unitRef="iso4217_USD" decimals="-3" id="id_11655837_8D7B7024-1C27-4427-AF4F-2B916D0BBDE3_3002_0">5204000</us-gaap:NoncurrentAssets>
  <us-gaap:StockholdersEquity contextRef="eol_PE717962--1610-K0012_STD_0_20151231_0_2040323x2025075" unitRef="iso4217_USD" decimals="-3" id="id_11655837_5A0DEAA9-8FA8-403D-B739-D326D818EDBC_3005_800013">193631000</us-gaap:StockholdersEquity>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="eol_PE717962--1610-K0012_STD_0_20151231_0_2040323x2027302" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_11655837_D01666D7-512E-4DEB-BE05-8E7949A33DBA_1002_4">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:StockholdersEquity contextRef="eol_PE717962--1610-K0012_STD_0_20151231_0_2040323x2027302" unitRef="iso4217_USD" decimals="-3" id="id_11655837_5A0DEAA9-8FA8-403D-B739-D326D818EDBC_3001_500013">132000</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding contextRef="eol_PE717962--1610-K0012_STD_0_20151231_0_2040323x2027302" unitRef="shares" decimals="INF" id="id_11655837_5A0DEAA9-8FA8-403D-B739-D326D818EDBC_3001_400014">13268280</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity contextRef="eol_PE717962--1610-K0012_STD_0_20151231_0_2040323x2037658" unitRef="iso4217_USD" decimals="-3" id="id_11655837_5A0DEAA9-8FA8-403D-B739-D326D818EDBC_3006_900013">-165565000</us-gaap:StockholdersEquity>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="eol_PE717962--1610-K0012_STD_0_20151231_0_2040323x2039180" unitRef="shares" decimals="INF" id="id_11655837_B24AD55E-55B0-45FC-ACAD-5A912A6B3450_3002_2">166403</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="eol_PE717962--1610-K0012_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_3CB85D34-5D5F-482C-9359-359FBEED229A_1001_0">1402000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="eol_PE717962--1610-K0012_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_DA046FE2-45EA-4061-9B96-ECBFB4F53FD8_2002_1">630000</us-gaap:FiniteLivedIntangibleAssetsGross>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="eol_PE717962--1610-K0012_STD_0_20161231_0" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_11655837_B3B68C79-A4E2-4679-8303-E543A568839E_1_31">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="eol_PE717962--1610-K0012_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_790A0593-5588-47C6-B63B-510E6890BA00_1_6">9387000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <us-gaap:CommitmentsAndContingencies contextRef="eol_PE717962--1610-K0012_STD_0_20161231_0" unitRef="iso4217_USD" xsi:nil="true" id="id_11655837_B3B68C79-A4E2-4679-8303-E543A568839E_1_23" />
  <us-gaap:CommonStockSharesOutstanding contextRef="eol_PE717962--1610-K0012_STD_0_20161231_0" unitRef="shares" decimals="INF" id="id_11655837_B3B68C79-A4E2-4679-8303-E543A568839E_1_34">20647612</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockSharesIssued contextRef="eol_PE717962--1610-K0012_STD_0_20161231_0" unitRef="shares" decimals="INF" id="id_11655837_B3B68C79-A4E2-4679-8303-E543A568839E_1_33">20647612</us-gaap:CommonStockSharesIssued>
  <us-gaap:Assets contextRef="eol_PE717962--1610-K0012_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_B3B68C79-A4E2-4679-8303-E543A568839E_1_7">36078000</us-gaap:Assets>
  <us-gaap:DeferredRentCreditNoncurrent contextRef="eol_PE717962--1610-K0012_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_B3B68C79-A4E2-4679-8303-E543A568839E_1_18">315000</us-gaap:DeferredRentCreditNoncurrent>
  <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="eol_PE717962--1610-K0012_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_08D6FE89-CA70-4EAE-89FE-D5ACF76B77DE_1001_13">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
  <us-gaap:DeferredRentCreditCurrent contextRef="eol_PE717962--1610-K0012_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_B3B68C79-A4E2-4679-8303-E543A568839E_1_13">136000</us-gaap:DeferredRentCreditCurrent>
  <us-gaap:DeferredTaxAssetsOther contextRef="eol_PE717962--1610-K0012_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_08D6FE89-CA70-4EAE-89FE-D5ACF76B77DE_1001_5">75000</us-gaap:DeferredTaxAssetsOther>
  <us-gaap:AssetsCurrent contextRef="eol_PE717962--1610-K0012_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_B3B68C79-A4E2-4679-8303-E543A568839E_1_3">32081000</us-gaap:AssetsCurrent>
  <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="eol_PE717962--1610-K0012_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_08D6FE89-CA70-4EAE-89FE-D5ACF76B77DE_1001_7">34569000</us-gaap:DeferredTaxAssetsValuationAllowance>
  <us-gaap:CommonStockSharesAuthorized contextRef="eol_PE717962--1610-K0012_STD_0_20161231_0" unitRef="shares" decimals="INF" id="id_11655837_B3B68C79-A4E2-4679-8303-E543A568839E_1_32">100000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:DeferredRevenueLeasesCurrent contextRef="eol_PE717962--1610-K0012_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_B3B68C79-A4E2-4679-8303-E543A568839E_1_14">407000</us-gaap:DeferredRevenueLeasesCurrent>
  <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="eol_PE717962--1610-K0012_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_B3B68C79-A4E2-4679-8303-E543A568839E_1_35">195181000</us-gaap:AdditionalPaidInCapitalCommonStock>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE717962--1610-K0012_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_B3B68C79-A4E2-4679-8303-E543A568839E_1_1">31908000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:DueToRelatedPartiesNoncurrent contextRef="eol_PE717962--1610-K0012_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_B3B68C79-A4E2-4679-8303-E543A568839E_1_17">3040000</us-gaap:DueToRelatedPartiesNoncurrent>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities contextRef="eol_PE717962--1610-K0012_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_08D6FE89-CA70-4EAE-89FE-D5ACF76B77DE_1001_3">2082000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
  <us-gaap:CommonStockValue contextRef="eol_PE717962--1610-K0012_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_B3B68C79-A4E2-4679-8303-E543A568839E_1_30">159000</us-gaap:CommonStockValue>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="eol_PE717962--1610-K0012_STD_0_20161231_0" unitRef="shares" decimals="INF" id="id_11655837_B24AD55E-55B0-45FC-ACAD-5A912A6B3450_1_3">15211975</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:AccountsPayableCurrent contextRef="eol_PE717962--1610-K0012_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_B3B68C79-A4E2-4679-8303-E543A568839E_1_9">1588000</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccountsPayableRelatedPartiesCurrent contextRef="eol_PE717962--1610-K0012_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_B3B68C79-A4E2-4679-8303-E543A568839E_1_10">360000</us-gaap:AccountsPayableRelatedPartiesCurrent>
  <us-gaap:DepositAssets contextRef="eol_PE717962--1610-K0012_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_18335864-285B-4D09-8D40-2546591AED88_1_0">10000</us-gaap:DepositAssets>
  <us-gaap:DeferredTaxAssetsGross contextRef="eol_PE717962--1610-K0012_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_08D6FE89-CA70-4EAE-89FE-D5ACF76B77DE_1001_6">34569000</us-gaap:DeferredTaxAssetsGross>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="eol_PE717962--1610-K0012_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_08D6FE89-CA70-4EAE-89FE-D5ACF76B77DE_1001_1">16146000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
  <us-gaap:AccruedLiabilitiesCurrent contextRef="eol_PE717962--1610-K0012_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_B3B68C79-A4E2-4679-8303-E543A568839E_1_11">2097000</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDue contextRef="eol_PE717962--1610-K0012_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_5619731E-EA32-4441-8661-B6442390C042_1001_6">5733000</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
  <us-gaap:LoansPayableCurrent contextRef="eol_PE717962--1610-K0012_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_B3B68C79-A4E2-4679-8303-E543A568839E_1_15">583000</us-gaap:LoansPayableCurrent>
  <us-gaap:PreferredStockSharesAuthorized contextRef="eol_PE717962--1610-K0012_STD_0_20161231_0" unitRef="shares" decimals="INF" id="id_11655837_1B3736E2-001C-4699-AE31-1DABD15AF2AB_1_0">30000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears contextRef="eol_PE717962--1610-K0012_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_5619731E-EA32-4441-8661-B6442390C042_1001_4">605000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears contextRef="eol_PE717962--1610-K0012_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_5619731E-EA32-4441-8661-B6442390C042_1001_3">596000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears>
  <us-gaap:PrepaidInsurance contextRef="eol_PE717962--1610-K0012_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_18335864-285B-4D09-8D40-2546591AED88_1_2">95000</us-gaap:PrepaidInsurance>
  <us-gaap:NoncurrentAssets contextRef="eol_PE717962--1610-K0012_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_8D7B7024-1C27-4427-AF4F-2B916D0BBDE3_1001_2">3860000</us-gaap:NoncurrentAssets>
  <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="eol_PE717962--1610-K0012_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_DA046FE2-45EA-4061-9B96-ECBFB4F53FD8_2002_2">630000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
  <us-gaap:OtherAssetsCurrent contextRef="eol_PE717962--1610-K0012_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_18335864-285B-4D09-8D40-2546591AED88_1_3">68000</us-gaap:OtherAssetsCurrent>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent contextRef="eol_PE717962--1610-K0012_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_5619731E-EA32-4441-8661-B6442390C042_1001_0">2266000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
  <us-gaap:Liabilities contextRef="eol_PE717962--1610-K0012_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_B3B68C79-A4E2-4679-8303-E543A568839E_1_22">22511000</us-gaap:Liabilities>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="eol_PE717962--1610-K0012_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_B3B68C79-A4E2-4679-8303-E543A568839E_1_38">36078000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesCurrent contextRef="eol_PE717962--1610-K0012_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_B3B68C79-A4E2-4679-8303-E543A568839E_1_16">5171000</us-gaap:LiabilitiesCurrent>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter contextRef="eol_PE717962--1610-K0012_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_5619731E-EA32-4441-8661-B6442390C042_1001_5">926000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter>
  <us-gaap:IncentiveFromLessor contextRef="eol_PE717962--1610-K0012_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_B3B68C79-A4E2-4679-8303-E543A568839E_1_19">610000</us-gaap:IncentiveFromLessor>
  <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="eol_PE717962--1610-K0012_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_3CB85D34-5D5F-482C-9359-359FBEED229A_1001_2">508000</us-gaap:OtherAccruedLiabilitiesCurrent>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears contextRef="eol_PE717962--1610-K0012_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_5619731E-EA32-4441-8661-B6442390C042_1001_2">586000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
  <us-gaap:ProductWarrantyAccrualNoncurrent contextRef="eol_PE717962--1610-K0012_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_B3B68C79-A4E2-4679-8303-E543A568839E_1_21">13197000</us-gaap:ProductWarrantyAccrualNoncurrent>
  <us-gaap:PreferredStockValue contextRef="eol_PE717962--1610-K0012_STD_0_20161231_0" unitRef="iso4217_USD" xsi:nil="true" id="id_11655837_B3B68C79-A4E2-4679-8303-E543A568839E_1_25" />
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="eol_PE717962--1610-K0012_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_9C467F66-5F6B-466C-B000-70054CF38384_3001_2">71000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears contextRef="eol_PE717962--1610-K0012_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_5619731E-EA32-4441-8661-B6442390C042_1001_1">754000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
  <us-gaap:LongTermLoansPayable contextRef="eol_PE717962--1610-K0012_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_B3B68C79-A4E2-4679-8303-E543A568839E_1_20">178000</us-gaap:LongTermLoansPayable>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="eol_PE717962--1610-K0012_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_B3B68C79-A4E2-4679-8303-E543A568839E_1_4">3860000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE717962--1610-K0012_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_790A0593-5588-47C6-B63B-510E6890BA00_1_5">13247000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="eol_PE717962--1610-K0012_STD_0_20161231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_11655837_D773A7C3-9EBB-45B3-BC43-D1082FBCD371_3001_7">6.79</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
  <us-gaap:StockholdersEquity contextRef="eol_PE717962--1610-K0012_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_B3B68C79-A4E2-4679-8303-E543A568839E_1_37">13567000</us-gaap:StockholdersEquity>
  <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment contextRef="eol_PE717962--1610-K0012_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_08D6FE89-CA70-4EAE-89FE-D5ACF76B77DE_1001_2">6229000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="eol_PE717962--1610-K0012_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-5" id="id_11655837_9D59D34B-448C-4FAF-A6E9-512FD74E0A44_2001_0">2600000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="eol_PE717962--1610-K0012_STD_0_20161231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_11655837_D773A7C3-9EBB-45B3-BC43-D1082FBCD371_3001_5">5.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="eol_PE717962--1610-K0012_STD_0_20161231_0" unitRef="shares" decimals="INF" id="id_11655837_4EA76CC8-F5DB-4BEE-8639-4745B518B6F3_3001_7">561693</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
  <us-gaap:SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit contextRef="eol_PE717962--1610-K0012_STD_0_20161231_0" unitRef="iso4217_USD" decimals="INF" id="id_11655837_A79DB659-8B27-4A30-9A9C-35C1D5680E0D_1001_2">0</us-gaap:SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit>
  <us-gaap:UnrecognizedTaxBenefits contextRef="eol_PE717962--1610-K0012_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_6C26F4B4-0D62-4BDF-8A8C-63D664124B3A_1001_3">562000</us-gaap:UnrecognizedTaxBenefits>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="eol_PE717962--1610-K0012_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_B3B68C79-A4E2-4679-8303-E543A568839E_1_36">-181773000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="eol_PE717962--1610-K0012_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_B3B68C79-A4E2-4679-8303-E543A568839E_1_2">173000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued contextRef="eol_PE717962--1610-K0012_STD_0_20161231_0" unitRef="iso4217_USD" decimals="INF" id="id_11655837_A79DB659-8B27-4A30-9A9C-35C1D5680E0D_1001_0">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue contextRef="eol_PE717962--1610-K0012_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_9C467F66-5F6B-466C-B000-70054CF38384_3001_3">69000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="eol_PE717962--1610-K0012_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_9C467F66-5F6B-466C-B000-70054CF38384_3001_4">52000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="eol_PE717962--1610-K0012_STD_0_20161231_0" unitRef="shares" decimals="INF" id="id_11655837_4EA76CC8-F5DB-4BEE-8639-4745B518B6F3_3001_6">1492341</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
  <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent contextRef="eol_PE717962--1610-K0012_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_B3B68C79-A4E2-4679-8303-E543A568839E_1_6">137000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice contextRef="eol_PE717962--1610-K0012_STD_0_20161231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_11655837_D773A7C3-9EBB-45B3-BC43-D1082FBCD371_3001_6">5.97</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="eol_PE717962--1610-K0012_STD_0_20161231_0" unitRef="shares" decimals="INF" id="id_11655837_4EA76CC8-F5DB-4BEE-8639-4745B518B6F3_3001_5">1577016</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <hsgx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue contextRef="eol_PE717962--1610-K0012_STD_0_20161231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_11655837_9D59D34B-448C-4FAF-A6E9-512FD74E0A44_2001_5">3.67</hsgx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue>
  <hsgx:DeferredTaxAssetsCapitalizedStartUpCosts contextRef="eol_PE717962--1610-K0012_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_08D6FE89-CA70-4EAE-89FE-D5ACF76B77DE_1001_4">10037000</hsgx:DeferredTaxAssetsCapitalizedStartUpCosts>
  <hsgx:OperatingLossCarryforwardsNetOfLimitations contextRef="eol_PE717962--1610-K0012_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-5" id="id_11655837_C8B89248-F510-4BF4-9B1E-29587AFCAE5B_1002_0">100100000</hsgx:OperatingLossCarryforwardsNetOfLimitations>
  <hsgx:FairValueInputAmountTransferBetweenLevels contextRef="eol_PE717962--1610-K0012_STD_0_20161231_0" unitRef="iso4217_USD" decimals="INF" id="id_11655837_5D32150D-6080-4582-BB4F-2EE14E5E5F1C_1007_2">0</hsgx:FairValueInputAmountTransferBetweenLevels>
  <hsgx:AccruedClinicalExpensesCurrent contextRef="eol_PE717962--1610-K0012_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_3CB85D34-5D5F-482C-9359-359FBEED229A_1001_1">187000</hsgx:AccruedClinicalExpensesCurrent>
  <us-gaap:AssetsFairValueDisclosureRecurring contextRef="eol_PE717962--1610-K0012_STD_0_20161231_0_2022410x2021995" unitRef="iso4217_USD" decimals="INF" id="id_11655837_5D32150D-6080-4582-BB4F-2EE14E5E5F1C_1003_0">0</us-gaap:AssetsFairValueDisclosureRecurring>
  <us-gaap:LiabilitiesFairValueDisclosureRecurring contextRef="eol_PE717962--1610-K0012_STD_0_20161231_0_2022410x2021995" unitRef="iso4217_USD" decimals="INF" id="id_11655837_5D32150D-6080-4582-BB4F-2EE14E5E5F1C_1003_1">0</us-gaap:LiabilitiesFairValueDisclosureRecurring>
  <us-gaap:AssetsFairValueDisclosureRecurring contextRef="eol_PE717962--1610-K0012_STD_0_20161231_0_2022410x2022419" unitRef="iso4217_USD" decimals="INF" id="id_11655837_5D32150D-6080-4582-BB4F-2EE14E5E5F1C_1005_0">0</us-gaap:AssetsFairValueDisclosureRecurring>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="eol_PE717962--1610-K0012_STD_0_20161231_0_2022410x2022419" unitRef="iso4217_USD" decimals="-3" id="id_11655837_C8CDBCD2-A7E8-4C56-A079-BCD9A063E3D8_2001_3">13197000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
  <us-gaap:LiabilitiesFairValueDisclosureRecurring contextRef="eol_PE717962--1610-K0012_STD_0_20161231_0_2022410x2022419" unitRef="iso4217_USD" decimals="INF" id="id_11655837_5D32150D-6080-4582-BB4F-2EE14E5E5F1C_1005_1">0</us-gaap:LiabilitiesFairValueDisclosureRecurring>
  <us-gaap:LiabilitiesFairValueDisclosure contextRef="eol_PE717962--1610-K0012_STD_0_20161231_0_2022410x2022419_2027829x2103098" unitRef="iso4217_USD" decimals="-3" id="id_11655837_68432C6A-CA97-439A-BB2D-FF62D53525B6_5004_4">13197000</us-gaap:LiabilitiesFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosureRecurring contextRef="eol_PE717962--1610-K0012_STD_0_20161231_0_2022410x2026970" unitRef="iso4217_USD" decimals="INF" id="id_11655837_5D32150D-6080-4582-BB4F-2EE14E5E5F1C_1001_0">0</us-gaap:AssetsFairValueDisclosureRecurring>
  <us-gaap:LiabilitiesFairValueDisclosureRecurring contextRef="eol_PE717962--1610-K0012_STD_0_20161231_0_2022410x2026970" unitRef="iso4217_USD" decimals="INF" id="id_11655837_5D32150D-6080-4582-BB4F-2EE14E5E5F1C_1001_1">0</us-gaap:LiabilitiesFairValueDisclosureRecurring>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="eol_PE717962--1610-K0012_STD_0_20161231_0_2022410x2026970_2025340x2029281" unitRef="iso4217_USD" decimals="-5" id="id_11655837_197548DF-ABA8-45B1-AC01-2065A0C7AA2F_1003_1">30300000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE717962--1610-K0012_STD_0_20161231_0_2022410x2026970_2026315x2029281" unitRef="iso4217_USD" decimals="-3" id="id_11655837_68432C6A-CA97-439A-BB2D-FF62D53525B6_4002_2">30318000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="eol_PE717962--1610-K0012_STD_0_20161231_0_2025317x2022619" unitRef="shares" decimals="INF" id="id_11655837_B24AD55E-55B0-45FC-ACAD-5A912A6B3450_1001_1">1577016</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="eol_PE717962--1610-K0012_STD_0_20161231_0_2025317x2041099" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_11655837_D01666D7-512E-4DEB-BE05-8E7949A33DBA_3003_3">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions contextRef="eol_PE717962--1610-K0012_STD_0_20161231_0_2025317x2041099" unitRef="iso4217_USD" decimals="-3" id="id_11655837_221B4776-CDDF-4F75-8802-3671377CDC93_2001_0">1000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="eol_PE717962--1610-K0012_STD_0_20161231_0_2025317x2041099" unitRef="shares" decimals="INF" id="id_11655837_B24AD55E-55B0-45FC-ACAD-5A912A6B3450_2001_0">1889</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="eol_PE717962--1610-K0012_STD_0_20161231_0_2025317x2041099" unitRef="shares" decimals="INF" id="id_11655837_942CD0BF-A20C-4D47-824E-ACE757FC85CE_4001_3">1889</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="eol_PE717962--1610-K0012_STD_0_20161231_0_2025317x2041099" unitRef="iso4217_USD_per_shares" decimals="2" id="id_11655837_A53E2444-FE4F-4F74-815C-FA924807C41A_4001_3">0.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
  <us-gaap:SharesOutstanding contextRef="eol_PE717962--1610-K0012_STD_0_20161231_0_2025317x2041099" unitRef="shares" decimals="INF" id="id_11655837_5A0DEAA9-8FA8-403D-B739-D326D818EDBC_5003_600028">1889</us-gaap:SharesOutstanding>
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE717962--1610-K0012_STD_0_20161231_0_2026315x2029281" unitRef="iso4217_USD" decimals="-3" id="id_11655837_68432C6A-CA97-439A-BB2D-FF62D53525B6_4001_2">30318000</us-gaap:AssetsFairValueDisclosure>
  <hsgx:AdjustmentOfWarrantsGrantedForServicesPerShareValue contextRef="eol_PE717962--1610-K0012_STD_0_20161231_0_2027723x2283059" unitRef="iso4217_USD_per_shares" decimals="2" id="id_11655837_6C944E68-201D-497B-9EE4-BBB539A7CF8A_2002_4">2.28</hsgx:AdjustmentOfWarrantsGrantedForServicesPerShareValue>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="eol_PE717962--1610-K0012_STD_0_20161231_0_2027723x2424282" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_11655837_695D3B3B-82B7-4956-A797-AEFD74B2A4AF_1002_8">0.01</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="eol_PE717962--1610-K0012_STD_0_20161231_0_2027723x2424282" unitRef="shares" decimals="INF" id="id_11655837_695D3B3B-82B7-4956-A797-AEFD74B2A4AF_1002_7">156138</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:LiabilitiesFairValueDisclosure contextRef="eol_PE717962--1610-K0012_STD_0_20161231_0_2027829x2103098" unitRef="iso4217_USD" decimals="-3" id="id_11655837_68432C6A-CA97-439A-BB2D-FF62D53525B6_5001_4">13197000</us-gaap:LiabilitiesFairValueDisclosure>
  <us-gaap:ContractualObligation contextRef="eol_PE717962--1610-K0012_STD_0_20161231_0_2029856x2112516" unitRef="iso4217_USD" decimals="-5" id="id_11655837_D1FBF924-00FD-4CA9-9A53-5EE5F21C8E1D_1001_0">3000000</us-gaap:ContractualObligation>
  <us-gaap:ContractualObligation contextRef="eol_PE717962--1610-K0012_STD_0_20161231_0_2029856x2151732" unitRef="iso4217_USD" decimals="-5" id="id_11655837_1FD2A9F2-231B-438A-AC76-8E0016BE46AF_3001_0">300000</us-gaap:ContractualObligation>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE717962--1610-K0012_STD_0_20161231_0_2030037x2023509" unitRef="iso4217_USD" decimals="-3" id="id_11655837_790A0593-5588-47C6-B63B-510E6890BA00_1001_1">4443000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE717962--1610-K0012_STD_0_20161231_0_2030037x2024062" unitRef="iso4217_USD" decimals="-3" id="id_11655837_790A0593-5588-47C6-B63B-510E6890BA00_2001_3">759000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE717962--1610-K0012_STD_0_20161231_0_2030037x2028633" unitRef="iso4217_USD" decimals="-3" id="id_11655837_790A0593-5588-47C6-B63B-510E6890BA00_3001_2">7683000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE717962--1610-K0012_STD_0_20161231_0_2030037x2031893" unitRef="iso4217_USD" decimals="-3" id="id_11655837_790A0593-5588-47C6-B63B-510E6890BA00_4001_0">266000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE717962--1610-K0012_STD_0_20161231_0_2030037x2037949" unitRef="iso4217_USD" decimals="-3" id="id_11655837_790A0593-5588-47C6-B63B-510E6890BA00_5001_4">96000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:OperatingLossCarryforwards contextRef="eol_PE717962--1610-K0012_STD_0_20161231_0_2031777x2024390" unitRef="iso4217_USD" decimals="-5" id="id_11655837_F58303BF-A32D-4120-87E5-203E27551ADE_3001_4">26100000</us-gaap:OperatingLossCarryforwards>
  <us-gaap:OperatingLossCarryforwards contextRef="eol_PE717962--1610-K0012_STD_0_20161231_0_2031777x2024782" unitRef="iso4217_USD" decimals="-5" id="id_11655837_F58303BF-A32D-4120-87E5-203E27551ADE_4001_0">24500000</us-gaap:OperatingLossCarryforwards>
  <us-gaap:OperatingLossCarryforwards contextRef="eol_PE717962--1610-K0012_STD_0_20161231_0_2031777x2037951" unitRef="iso4217_USD" decimals="-5" id="id_11655837_F58303BF-A32D-4120-87E5-203E27551ADE_5001_2">24300000</us-gaap:OperatingLossCarryforwards>
  <us-gaap:LoansPayable contextRef="eol_PE717962--1610-K0012_STD_0_20161231_0_2033330x2361826" unitRef="iso4217_USD" decimals="-3" id="id_11655837_5FC72CC3-338E-4CE3-8F67-3925C6D5F99B_2001_0">761000</us-gaap:LoansPayable>
  <us-gaap:LineOfCredit contextRef="eol_PE717962--1610-K0012_STD_0_20161231_0_2033330x2361826" unitRef="iso4217_USD" decimals="-5" id="id_11655837_9DDCE00E-794F-4CAA-89CB-4239C158D36E_1001_0">800000</us-gaap:LineOfCredit>
  <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="eol_PE717962--1610-K0012_STD_0_20161231_0_2035448x2031417" unitRef="iso4217_USD" decimals="-3" id="id_11655837_DA046FE2-45EA-4061-9B96-ECBFB4F53FD8_2001_1">630000</us-gaap:FiniteLivedIntangibleAssetsGross>
  <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="eol_PE717962--1610-K0012_STD_0_20161231_0_2035448x2031417" unitRef="iso4217_USD" decimals="-3" id="id_11655837_DA046FE2-45EA-4061-9B96-ECBFB4F53FD8_2001_2">630000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
  <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="eol_PE717962--1610-K0012_STD_0_20161231_0_2035448x2031417" unitRef="iso4217_USD" decimals="-3" id="id_11655837_6C55B9EC-B951-4E97-BF6B-4F0E28F0FC4F_1002_2">0</us-gaap:FiniteLivedIntangibleAssetsNet>
  <us-gaap:ContractualObligationFutureMinimumPaymentsDueRemainderOfFiscalYear contextRef="eol_PE717962--1610-K0012_STD_0_20161231_0_2036820x2068097" unitRef="iso4217_USD" decimals="-5" id="id_11655837_3F9291BA-8F81-419C-8DA0-1147BAF206AB_3001_1">10200000</us-gaap:ContractualObligationFutureMinimumPaymentsDueRemainderOfFiscalYear>
  <hsgx:SalesMilestonesPaymentsObligation contextRef="eol_PE717962--1610-K0012_STD_0_20161231_0_2036820x2313845_2038452x2183197" unitRef="iso4217_USD" decimals="-5" id="id_11655837_EBFFE5DC-24AB-471F-9D29-FADBFB640A75_1001_1">22500000</hsgx:SalesMilestonesPaymentsObligation>
  <hsgx:CommercializationMilestonesObligation contextRef="eol_PE717962--1610-K0012_STD_0_20161231_0_2036820x2339473_2038452x2183197" unitRef="iso4217_USD" decimals="-6" id="id_11655837_EBFFE5DC-24AB-471F-9D29-FADBFB640A75_2001_0">12000000</hsgx:CommercializationMilestonesObligation>
  <us-gaap:CommonStockSharesIssued contextRef="eol_PE717962--1610-K0012_STD_0_20161231_0_2037554x2255485_2040137x2032595" unitRef="shares" decimals="INF" id="id_11655837_490B5B91-B1A1-4923-BAF6-C51615809F0C_1001_0">283046</us-gaap:CommonStockSharesIssued>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="eol_PE717962--1610-K0012_STD_0_20161231_0_2037554x2255485_2040137x2032595" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_11655837_490B5B91-B1A1-4923-BAF6-C51615809F0C_1001_3">2.25</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="eol_PE717962--1610-K0012_STD_0_20161231_0_2037554x2255485_2040137x2032595" unitRef="shares" decimals="INF" id="id_11655837_490B5B91-B1A1-4923-BAF6-C51615809F0C_1001_2">1422221</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:PreferredStockSharesIssued contextRef="eol_PE717962--1610-K0012_STD_0_20161231_0_2037554x2255485_2040137x2032595" unitRef="shares" decimals="INF" id="id_11655837_490B5B91-B1A1-4923-BAF6-C51615809F0C_1001_1">2563.1439</us-gaap:PreferredStockSharesIssued>
  <us-gaap:GrantsReceivable contextRef="eol_PE717962--1610-K0012_STD_0_20161231_0_2038064x2336713" unitRef="iso4217_USD" decimals="-5" id="id_11655837_6EF2B0AA-F664-42F1-9105-7D8F60D3AE21_3001_0">1100000</us-gaap:GrantsReceivable>
  <us-gaap:DueToRelatedPartiesCurrent contextRef="eol_PE717962--1610-K0012_STD_0_20161231_0_2038452x2183197" unitRef="iso4217_USD" decimals="-5" id="id_11655837_7442F8D7-2D4D-4BC2-86FB-09636C3F6B44_2001_3">3000000</us-gaap:DueToRelatedPartiesCurrent>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="eol_PE717962--1610-K0012_STD_0_20161231_0_2039549x2159266" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_11655837_B3B68C79-A4E2-4679-8303-E543A568839E_1001_26">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesAuthorized contextRef="eol_PE717962--1610-K0012_STD_0_20161231_0_2039549x2159266" unitRef="shares" decimals="INF" id="id_11655837_B3B68C79-A4E2-4679-8303-E543A568839E_1001_27">30000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesOutstanding contextRef="eol_PE717962--1610-K0012_STD_0_20161231_0_2039549x2159266" unitRef="shares" decimals="INF" id="id_11655837_B3B68C79-A4E2-4679-8303-E543A568839E_1001_29">13416.4734</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="eol_PE717962--1610-K0012_STD_0_20161231_0_2039549x2159266" unitRef="iso4217_USD" decimals="-3" id="id_11655837_7EE727ED-2B5B-4314-A01B-2ACB6184A985_3001_9">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
  <us-gaap:TemporaryEquityParOrStatedValuePerShare contextRef="eol_PE717962--1610-K0012_STD_0_20161231_0_2039549x2159266" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_11655837_D01666D7-512E-4DEB-BE05-8E7949A33DBA_3001_1">0.01</us-gaap:TemporaryEquityParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesIssued contextRef="eol_PE717962--1610-K0012_STD_0_20161231_0_2039549x2159266" unitRef="shares" decimals="INF" id="id_11655837_B3B68C79-A4E2-4679-8303-E543A568839E_1001_28">13416.4734</us-gaap:PreferredStockSharesIssued>
  <us-gaap:TemporaryEquitySharesOutstanding contextRef="eol_PE717962--1610-K0012_STD_0_20161231_0_2039549x2159266" unitRef="shares" decimals="INF" id="id_11655837_7EE727ED-2B5B-4314-A01B-2ACB6184A985_3001_400010">13416</us-gaap:TemporaryEquitySharesOutstanding>
  <us-gaap:NoncurrentAssets contextRef="eol_PE717962--1610-K0012_STD_0_20161231_0_2039550x2037985" unitRef="iso4217_USD" decimals="-3" id="id_11655837_8D7B7024-1C27-4427-AF4F-2B916D0BBDE3_3001_0">3860000</us-gaap:NoncurrentAssets>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="eol_PE717962--1610-K0012_STD_0_20161231_0_2040137x2032595" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_11655837_DD744067-5A4C-4DA1-BFCD-AE0955DF4828_2001_2">2.25</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="eol_PE717962--1610-K0012_STD_0_20161231_0_2040137x2032595" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_11655837_DD744067-5A4C-4DA1-BFCD-AE0955DF4828_2001_0">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:WarrantsNotSettleableInCashFairValueDisclosure contextRef="eol_PE717962--1610-K0012_STD_0_20161231_0_2040137x2032595" unitRef="iso4217_USD" decimals="-5" id="id_11655837_102311C5-EE81-4B25-95D6-D4CD4F86911D_2001_3">30700000</us-gaap:WarrantsNotSettleableInCashFairValueDisclosure>
  <us-gaap:StockholdersEquity contextRef="eol_PE717962--1610-K0012_STD_0_20161231_0_2040323x2025075" unitRef="iso4217_USD" decimals="-3" id="id_11655837_5A0DEAA9-8FA8-403D-B739-D326D818EDBC_5005_800027">195181000</us-gaap:StockholdersEquity>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="eol_PE717962--1610-K0012_STD_0_20161231_0_2040323x2027302" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_11655837_D01666D7-512E-4DEB-BE05-8E7949A33DBA_3002_3">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:StockholdersEquity contextRef="eol_PE717962--1610-K0012_STD_0_20161231_0_2040323x2027302" unitRef="iso4217_USD" decimals="-3" id="id_11655837_5A0DEAA9-8FA8-403D-B739-D326D818EDBC_5001_500027">159000</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding contextRef="eol_PE717962--1610-K0012_STD_0_20161231_0_2040323x2027302" unitRef="shares" decimals="INF" id="id_11655837_5A0DEAA9-8FA8-403D-B739-D326D818EDBC_5001_400028">20645723</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity contextRef="eol_PE717962--1610-K0012_STD_0_20161231_0_2040323x2037658" unitRef="iso4217_USD" decimals="-3" id="id_11655837_5A0DEAA9-8FA8-403D-B739-D326D818EDBC_5006_900027">-181773000</us-gaap:StockholdersEquity>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="eol_PE717962--1610-K0012_STD_0_20161231_0_2040323x2039180" unitRef="shares" decimals="INF" id="id_11655837_B24AD55E-55B0-45FC-ACAD-5A912A6B3450_3001_2">13633070</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted contextRef="eol_PE717962--1610-K0012_STD_0_20161231_0_2040972x2099546" unitRef="iso4217_USD" decimals="INF" id="id_11655837_34EC763B-4AFE-4EDC-AF5F-C96D6CB3EFA5_2001_1">0</us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted>
  <us-gaap:BusinessCombinationConsiderationTransferred1 contextRef="eol_PE717962--1610-K0012_STD_1_20110513_0_2027704x2293940" unitRef="iso4217_USD" decimals="-5" id="id_11655837_82DB38DE-AF84-4E21-A1E4-9F569EFD65C7_1002_1">2200000</us-gaap:BusinessCombinationConsiderationTransferred1>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="eol_PE717962--1610-K0012_STD_1_20141203_0" unitRef="iso4217_USD" decimals="-5" id="id_11655837_7D08BE0B-1F46-4071-905D-4814923C00EC_1_0">3900000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
  <hsgx:ProceedsFromIssuanceInitialPublicOfferingNet contextRef="eol_PE717962--1610-K0012_STD_1_20141203_0" unitRef="iso4217_USD" decimals="-5" id="id_11655837_E8F250E2-5279-4840-BE96-3F4C8B48850F_2_3">61300000</hsgx:ProceedsFromIssuanceInitialPublicOfferingNet>
  <hsgx:ClassOfWarrantOrRightNumberOfSecuritiesSurrendered contextRef="eol_PE717962--1610-K0012_STD_1_20141203_0_2027723x2424282" unitRef="shares" decimals="INF" id="id_11655837_695D3B3B-82B7-4956-A797-AEFD74B2A4AF_1004_6">5839</hsgx:ClassOfWarrantOrRightNumberOfSecuritiesSurrendered>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum contextRef="eol_PE717962--1610-K0012_STD_1_20141203_0_2029102x2377267" unitRef="pure" decimals="INF" id="id_11655837_E46D1C6D-90B6-403D-B13F-C661F3E7206B_1001_2">0.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized contextRef="eol_PE717962--1610-K0012_STD_1_20141203_0_2029102x2377267" unitRef="shares" decimals="INF" id="id_11655837_E46D1C6D-90B6-403D-B13F-C661F3E7206B_1001_1">51832</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
  <us-gaap:ProceedsFromIssuanceInitialPublicOffering contextRef="eol_PE717962--1610-K0012_STD_1_20141203_0_2040137x2029877" unitRef="iso4217_USD" decimals="-5" id="id_11655837_E8F250E2-5279-4840-BE96-3F4C8B48850F_1_2">65000000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="eol_PE717962--1610-K0012_STD_1_20141203_0_2040137x2029877" unitRef="shares" decimals="INF" id="id_11655837_E8F250E2-5279-4840-BE96-3F4C8B48850F_1_0">5909091</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <hsgx:ClassOfWarrantOrRightForfeitureInPeriodPercentage contextRef="eol_PE717962--1610-K0012_STD_1_20151221_0_2027723x2068134" unitRef="pure" decimals="2" id="id_11655837_BE8C7A74-1E78-400A-9F65-806A419A74D3_1004_7">0.50</hsgx:ClassOfWarrantOrRightForfeitureInPeriodPercentage>
  <hsgx:ClassOfWarrantOrRightForfeitureInPeriod contextRef="eol_PE717962--1610-K0012_STD_1_20151221_0_2027723x2068134" unitRef="shares" decimals="0" id="id_11655837_BE8C7A74-1E78-400A-9F65-806A419A74D3_1004_4">3699</hsgx:ClassOfWarrantOrRightForfeitureInPeriod>
  <us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="eol_PE717962--1610-K0012_STD_1_20170222_0_2039338x2038269_2040972x2163139" unitRef="iso4217_USD" decimals="-5" id="id_11655837_A15627CC-77BD-445D-8610-F809C9386E0C_1002_2">100000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
  <hsgx:RepaymentPeriod contextRef="eol_PE717962--1610-K0012_STD_1_20170222_0_2039338x2038269_2040972x2163139" id="id_11655837_A15627CC-77BD-445D-8610-F809C9386E0C_1002_1">P18M</hsgx:RepaymentPeriod>
  <us-gaap:FairValueAssumptionsExpectedTerm contextRef="eol_PE717962--1610-K0012_STD_1_20120720_0_2027723x2424282" id="id_11655837_695D3B3B-82B7-4956-A797-AEFD74B2A4AF_1001_5">P1Y8M12D</us-gaap:FairValueAssumptionsExpectedTerm>
  <us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="eol_PE717962--1610-K0012_STD_1_20120720_0_2027723x2424282" unitRef="pure" decimals="2" id="id_11655837_695D3B3B-82B7-4956-A797-AEFD74B2A4AF_1001_4">0.99</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="eol_PE717962--1610-K0012_STD_1_20120720_0_2027723x2424282" unitRef="pure" decimals="4" id="id_11655837_695D3B3B-82B7-4956-A797-AEFD74B2A4AF_1001_3">0.0022</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
  <hsgx:ClassOfWarrantOrRightExercisableExpirationPeriod contextRef="eol_PE717962--1610-K0012_STD_1_20120720_0_2027723x2424282" id="id_11655837_695D3B3B-82B7-4956-A797-AEFD74B2A4AF_1001_2">P10Y</hsgx:ClassOfWarrantOrRightExercisableExpirationPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized contextRef="eol_PE717962--1610-K0012_STD_1_20160616_0_2027922x2423931_2029102x2253325" unitRef="shares" decimals="INF" id="id_11655837_DB5416B5-BD6F-404E-8465-90EAD32DD211_1002_3">300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
  <us-gaap:ConversionOfStockSharesConverted1 contextRef="eol_PE717962--1610-K0012_STD_1_20160929_0" unitRef="shares" decimals="INF" id="id_11655837_BA55390A-7F6A-4E74-AD37-FCFA4868621B_1_1">10737275</us-gaap:ConversionOfStockSharesConverted1>
  <us-gaap:ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants contextRef="eol_PE717962--1610-K0012_STD_1_20160929_0" unitRef="iso4217_USD" decimals="-5" id="id_11655837_57D19768-5E51-4534-87CC-61419A05ADCF_1_0">27600000</us-gaap:ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants>
  <hsgx:MinimumThresholdPercentageOfBeneficialCommonStockInterest contextRef="eol_PE717962--1610-K0012_STD_1_20160929_0" unitRef="pure" decimals="INF" id="id_11655837_BA55390A-7F6A-4E74-AD37-FCFA4868621B_1_4">0.0499</hsgx:MinimumThresholdPercentageOfBeneficialCommonStockInterest>
  <hsgx:MaximumThresholdPercentageOfBeneficialCommonStockInterestOnHoldersDiscretion contextRef="eol_PE717962--1610-K0012_STD_1_20160929_0" unitRef="pure" decimals="INF" id="id_11655837_BA55390A-7F6A-4E74-AD37-FCFA4868621B_1_5">0.0999</hsgx:MaximumThresholdPercentageOfBeneficialCommonStockInterestOnHoldersDiscretion>
  <us-gaap:ConversionOfStockSharesConverted1 contextRef="eol_PE717962--1610-K0012_STD_1_20160929_0_2039549x2037928_2040137x2032595" unitRef="shares" decimals="INF" id="id_11655837_BA55390A-7F6A-4E74-AD37-FCFA4868621B_1001_3">444.44</us-gaap:ConversionOfStockSharesConverted1>
  <us-gaap:ConversionOfStockSharesConverted1 contextRef="eol_PE717962--1610-K0012_STD_1_20160929_0_2040137x2032595" unitRef="shares" decimals="INF" id="id_11655837_0C4D853D-8EDE-44A2-8648-C64AEF8502EB_1001_4">10737275</us-gaap:ConversionOfStockSharesConverted1>
  <us-gaap:ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants contextRef="eol_PE717962--1610-K0012_STD_1_20160929_0_2040137x2032595" unitRef="iso4217_USD" decimals="-5" id="id_11655837_0C4D853D-8EDE-44A2-8648-C64AEF8502EB_1001_8">27600000</us-gaap:ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants>
  <hsgx:GrossProceedsFromIssuanceOfCommonStockPreferredStockAndWarrants contextRef="eol_PE717962--1610-K0012_STD_1_20160929_0_2040137x2032595" unitRef="iso4217_USD" decimals="-5" id="id_11655837_0C4D853D-8EDE-44A2-8648-C64AEF8502EB_1001_0">30000000</hsgx:GrossProceedsFromIssuanceOfCommonStockPreferredStockAndWarrants>
  <us-gaap:PaymentsOfStockIssuanceCosts contextRef="eol_PE717962--1610-K0012_STD_1_20141231_0_2040137x2029877" unitRef="iso4217_USD" decimals="-5" id="id_11655837_7D08BE0B-1F46-4071-905D-4814923C00EC_2_1">2900000</us-gaap:PaymentsOfStockIssuanceCosts>
  <hsgx:ClassOfWarrantOrRightVestedAndExercisable contextRef="eol_PE717962--1610-K0012_STD_1_20151231_0_2027723x2068134" unitRef="shares" decimals="0" id="id_11655837_BE8C7A74-1E78-400A-9F65-806A419A74D3_1005_5">3699</hsgx:ClassOfWarrantOrRightVestedAndExercisable>
  <hsgx:ClassOfWarrantOrRightVestedAndExercisable contextRef="eol_PE717962--1610-K0012_STD_1_20161231_0_2027723x2068134" unitRef="shares" decimals="0" id="id_11655837_BE8C7A74-1E78-400A-9F65-806A419A74D3_1003_5">3699</hsgx:ClassOfWarrantOrRightVestedAndExercisable>
  <hsgx:ClassOfWarrantOrRightExercisableExpirationPeriod contextRef="eol_PE717962--1610-K0012_STD_273_20150930_0_2027723x2068134" id="id_11655837_BE8C7A74-1E78-400A-9F65-806A419A74D3_1002_3">P10Y</hsgx:ClassOfWarrantOrRightExercisableExpirationPeriod>
  <hsgx:ClassOfWarrantOrRightExercisablePeriod contextRef="eol_PE717962--1610-K0012_STD_273_20150930_0_2027723x2068134" id="id_11655837_BE8C7A74-1E78-400A-9F65-806A419A74D3_1002_2">P24M</hsgx:ClassOfWarrantOrRightExercisablePeriod>
  <hsgx:PaymentForLicenseAgreementReimbursementOfCosts contextRef="eol_PE717962--1610-K0012_STD_30_20120630_0_2036820x2068097" unitRef="iso4217_USD" decimals="-5" id="id_11655837_F736895B-319C-4530-B8A6-2944BAA6D9A6_1001_0">300000</hsgx:PaymentForLicenseAgreementReimbursementOfCosts>
  <us-gaap:LongtermPurchaseCommitmentPeriod contextRef="eol_PE717962--1610-K0012_STD_30_20150930_0_2040972x2163139" id="id_11655837_4F52247A-4CAB-4623-86A5-29FE3949BF1B_1001_2">P3Y</us-gaap:LongtermPurchaseCommitmentPeriod>
  <us-gaap:LongTermPurchaseCommitmentAmount contextRef="eol_PE717962--1610-K0012_STD_30_20150930_0_2040972x2163139" unitRef="iso4217_USD" decimals="-5" id="id_11655837_4F52247A-4CAB-4623-86A5-29FE3949BF1B_1001_0">200000</us-gaap:LongTermPurchaseCommitmentAmount>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="eol_PE717962--1610-K0012_STD_31_20120731_0_2029102x2176993" id="id_11655837_ABCD2E8A-6979-497E-8ECB-04F5599D6C50_1002_2">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="eol_PE717962--1610-K0012_STD_31_20120731_0_2029102x2176993" id="id_11655837_ABCD2E8A-6979-497E-8ECB-04F5599D6C50_1002_3">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="eol_PE717962--1610-K0012_STD_31_20120731_0_2029102x2176993_2037398x2038872" unitRef="pure" decimals="2" id="id_11655837_ABCD2E8A-6979-497E-8ECB-04F5599D6C50_2002_1">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
  <us-gaap:DebtInstrumentTerm contextRef="eol_PE717962--1610-K0012_STD_31_20140731_0_2033330x2361826" id="id_11655837_A251A8CE-F5C0-4315-B48A-09D533A291E2_1001_3">P36M</us-gaap:DebtInstrumentTerm>
  <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1 contextRef="eol_PE717962--1610-K0012_STD_31_20140731_0_2033330x2361826_2039383x2035998" unitRef="pure" decimals="INF" id="id_11655837_A251A8CE-F5C0-4315-B48A-09D533A291E2_2001_1">0.0275</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum contextRef="eol_PE717962--1610-K0012_STD_31_20141031_0_2027922x2423931_2029102x2253325" unitRef="pure" decimals="INF" id="id_11655837_DB5416B5-BD6F-404E-8465-90EAD32DD211_1001_5">0.040</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="eol_PE717962--1610-K0012_STD_31_20141031_0_2029102x2253325" id="id_11655837_DB5416B5-BD6F-404E-8465-90EAD32DD211_2001_1">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="eol_PE717962--1610-K0012_STD_31_20141031_0_2029102x2253325" id="id_11655837_DB5416B5-BD6F-404E-8465-90EAD32DD211_2001_2">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="eol_PE717962--1610-K0012_STD_31_20141031_0_2029102x2253325_2037398x2038872" unitRef="pure" decimals="2" id="id_11655837_DB5416B5-BD6F-404E-8465-90EAD32DD211_3001_0">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
  <us-gaap:ProceedsFromIssuanceInitialPublicOffering contextRef="eol_PE717962--1610-K0012_STD_31_20150131_0_2040137x2030849" unitRef="iso4217_USD" decimals="-5" id="id_11655837_E8F250E2-5279-4840-BE96-3F4C8B48850F_3_2">5100000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="eol_PE717962--1610-K0012_STD_31_20150131_0_2040137x2030849" unitRef="shares" decimals="INF" id="id_11655837_E8F250E2-5279-4840-BE96-3F4C8B48850F_3_0">465000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:AdjustmentOfWarrantsGrantedForServices contextRef="eol_PE717962--1610-K0012_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_F517A3E7-CD09-482E-A458-78C5E43ED953_2_8">11000</us-gaap:AdjustmentOfWarrantsGrantedForServices>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="eol_PE717962--1610-K0012_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_5A0DEAA9-8FA8-403D-B739-D326D818EDBC_4007_1000009">1228000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="eol_PE717962--1610-K0012_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_F517A3E7-CD09-482E-A458-78C5E43ED953_2_26">-27612000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="eol_PE717962--1610-K0012_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_5A0DEAA9-8FA8-403D-B739-D326D818EDBC_4007_1000006">11000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE717962--1610-K0012_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_8FA11797-04AB-46E0-8AAE-AEA61A40519E_2_0">1228000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="eol_PE717962--1610-K0012_STD_365_20151231_0" unitRef="pure" decimals="3" id="id_11655837_9FA36880-6F95-410B-BEC1-B0E0D4FEC8F9_2_5">-0.317</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
  <us-gaap:FairValueInputsDiscountRate contextRef="eol_PE717962--1610-K0012_STD_365_20151231_0" unitRef="pure" decimals="2" id="id_11655837_6C55B9EC-B951-4E97-BF6B-4F0E28F0FC4F_4_1">0.13</us-gaap:FairValueInputsDiscountRate>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE717962--1610-K0012_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_AE354032-1B81-402C-BD47-3E1B7F0C0719_2_3">8266000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:EarningsPerShareBasic contextRef="eol_PE717962--1610-K0012_STD_365_20151231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_11655837_AE354032-1B81-402C-BD47-3E1B7F0C0719_2_16">-2.42</us-gaap:EarningsPerShareBasic>
  <us-gaap:Depreciation contextRef="eol_PE717962--1610-K0012_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_F517A3E7-CD09-482E-A458-78C5E43ED953_2_3">1614000</us-gaap:Depreciation>
  <us-gaap:EarningsPerShareDiluted contextRef="eol_PE717962--1610-K0012_STD_365_20151231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_11655837_AE354032-1B81-402C-BD47-3E1B7F0C0719_2_17">-2.42</us-gaap:EarningsPerShareDiluted>
  <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="eol_PE717962--1610-K0012_STD_365_20151231_0" unitRef="pure" decimals="3" id="id_11655837_9FA36880-6F95-410B-BEC1-B0E0D4FEC8F9_2_6">-0.012</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
  <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="eol_PE717962--1610-K0012_STD_365_20151231_0" unitRef="pure" decimals="3" id="id_11655837_9FA36880-6F95-410B-BEC1-B0E0D4FEC8F9_2_7">0.000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
  <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="eol_PE717962--1610-K0012_STD_365_20151231_0" unitRef="pure" decimals="3" id="id_11655837_9FA36880-6F95-410B-BEC1-B0E0D4FEC8F9_2_0">0.340</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
  <us-gaap:SalesRevenueNet contextRef="eol_PE717962--1610-K0012_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_AE354032-1B81-402C-BD47-3E1B7F0C0719_2_0">0</us-gaap:SalesRevenueNet>
  <us-gaap:OperatingLeasesRentExpenseNet contextRef="eol_PE717962--1610-K0012_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-5" id="id_11655837_D295318A-25D1-40B3-8E85-9F84BBB46A8F_2_0">1100000</us-gaap:OperatingLeasesRentExpenseNet>
  <us-gaap:NonoperatingIncomeExpense contextRef="eol_PE717962--1610-K0012_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_AE354032-1B81-402C-BD47-3E1B7F0C0719_2_12">-205000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="eol_PE717962--1610-K0012_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_AE354032-1B81-402C-BD47-3E1B7F0C0719_2_9">-72000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties contextRef="eol_PE717962--1610-K0012_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_F517A3E7-CD09-482E-A458-78C5E43ED953_2_13">211000</us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties>
  <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="eol_PE717962--1610-K0012_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_F517A3E7-CD09-482E-A458-78C5E43ED953_2_14">-232000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
  <us-gaap:OperatingExpenses contextRef="eol_PE717962--1610-K0012_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_AE354032-1B81-402C-BD47-3E1B7F0C0719_2_5">31819000</us-gaap:OperatingExpenses>
  <us-gaap:NetIncomeLoss contextRef="eol_PE717962--1610-K0012_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_AE354032-1B81-402C-BD47-3E1B7F0C0719_2_13">-32024000</us-gaap:NetIncomeLoss>
  <us-gaap:InterestExpense contextRef="eol_PE717962--1610-K0012_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_AE354032-1B81-402C-BD47-3E1B7F0C0719_2_8">133000</us-gaap:InterestExpense>
  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="eol_PE717962--1610-K0012_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_F517A3E7-CD09-482E-A458-78C5E43ED953_2_18">-1949000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
  <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill contextRef="eol_PE717962--1610-K0012_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_AE354032-1B81-402C-BD47-3E1B7F0C0719_2_4">310000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="eol_PE717962--1610-K0012_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_81818110-2900-437E-A31B-B07988C5A518_2_0">-31382000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="eol_PE717962--1610-K0012_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_81818110-2900-437E-A31B-B07988C5A518_2_1">-691000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted contextRef="eol_PE717962--1610-K0012_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_AE354032-1B81-402C-BD47-3E1B7F0C0719_2_15">-32024000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
  <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="eol_PE717962--1610-K0012_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_F517A3E7-CD09-482E-A458-78C5E43ED953_2_12">-2844000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="eol_PE717962--1610-K0012_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_F517A3E7-CD09-482E-A458-78C5E43ED953_2_10">-475000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="eol_PE717962--1610-K0012_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_AE354032-1B81-402C-BD47-3E1B7F0C0719_2_14">-32024000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE717962--1610-K0012_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_AE354032-1B81-402C-BD47-3E1B7F0C0719_2_6">-31819000</us-gaap:OperatingIncomeLoss>
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="eol_PE717962--1610-K0012_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_F517A3E7-CD09-482E-A458-78C5E43ED953_2_25">4371000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <us-gaap:IncomeTaxesPaidNet contextRef="eol_PE717962--1610-K0012_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_F517A3E7-CD09-482E-A458-78C5E43ED953_2_32">79000</us-gaap:IncomeTaxesPaidNet>
  <us-gaap:IncreaseDecreaseInDueToRelatedPartiesCurrent contextRef="eol_PE717962--1610-K0012_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_F517A3E7-CD09-482E-A458-78C5E43ED953_2_11">1539000</us-gaap:IncreaseDecreaseInDueToRelatedPartiesCurrent>
  <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="eol_PE717962--1610-K0012_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_5A0DEAA9-8FA8-403D-B739-D326D818EDBC_4007_7">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
  <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="eol_PE717962--1610-K0012_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-5" id="id_11655837_D61785A9-8599-4860-92E7-B7BD0AD08130_2_0">11800000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="eol_PE717962--1610-K0012_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_81818110-2900-437E-A31B-B07988C5A518_2_2">-32073000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="eol_PE717962--1610-K0012_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_F517A3E7-CD09-482E-A458-78C5E43ED953_2_15">-30034000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="eol_PE717962--1610-K0012_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_F517A3E7-CD09-482E-A458-78C5E43ED953_2_17">1949000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="eol_PE717962--1610-K0012_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_F517A3E7-CD09-482E-A458-78C5E43ED953_2_21">4738000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:RepaymentsOfDebt contextRef="eol_PE717962--1610-K0012_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_F517A3E7-CD09-482E-A458-78C5E43ED953_2_23">406000</us-gaap:RepaymentsOfDebt>
  <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions contextRef="eol_PE717962--1610-K0012_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_6C26F4B4-0D62-4BDF-8A8C-63D664124B3A_2_1">124000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="eol_PE717962--1610-K0012_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_5A0DEAA9-8FA8-403D-B739-D326D818EDBC_4007_1000005">377000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="eol_PE717962--1610-K0012_STD_365_20151231_0" unitRef="shares" decimals="0" id="id_11655837_AE354032-1B81-402C-BD47-3E1B7F0C0719_2_19">13231126</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1 contextRef="eol_PE717962--1610-K0012_STD_365_20151231_0" id="id_11655837_7D1D2384-E6E7-4C41-8052-1A440B12FCA4_2_2">P6Y1M28D</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="eol_PE717962--1610-K0012_STD_365_20151231_0" id="id_11655837_39D2169F-C53C-4F91-BB9A-DCFB692D93D8_1001_1">P9Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="eol_PE717962--1610-K0012_STD_365_20151231_0" unitRef="pure" decimals="3" id="id_11655837_23624064-F40E-4BAA-AF98-7BDFA20DC6F2_2_3">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate contextRef="eol_PE717962--1610-K0012_STD_365_20151231_0" unitRef="pure" decimals="3" id="id_11655837_7D1D2384-E6E7-4C41-8052-1A440B12FCA4_2_1">0.632</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate>
  <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense contextRef="eol_PE717962--1610-K0012_STD_365_20151231_0" unitRef="iso4217_USD" decimals="INF" id="id_11655837_A79DB659-8B27-4A30-9A9C-35C1D5680E0D_2_1">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="eol_PE717962--1610-K0012_STD_365_20151231_0" unitRef="shares" decimals="0" id="id_11655837_AE354032-1B81-402C-BD47-3E1B7F0C0719_2_18">13231126</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="eol_PE717962--1610-K0012_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_5A0DEAA9-8FA8-403D-B739-D326D818EDBC_4007_1000010">39000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate contextRef="eol_PE717962--1610-K0012_STD_365_20151231_0" unitRef="pure" decimals="4" id="id_11655837_7D1D2384-E6E7-4C41-8052-1A440B12FCA4_2_0">0.0179</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE717962--1610-K0012_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_AE354032-1B81-402C-BD47-3E1B7F0C0719_2_2">23243000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ProceedsFromStockOptionsExercised contextRef="eol_PE717962--1610-K0012_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_F517A3E7-CD09-482E-A458-78C5E43ED953_2_24">39000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="eol_PE717962--1610-K0012_STD_365_20151231_0" unitRef="pure" decimals="3" id="id_11655837_23624064-F40E-4BAA-AF98-7BDFA20DC6F2_2_1">0.626</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="eol_PE717962--1610-K0012_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-5" id="id_11655837_9D59D34B-448C-4FAF-A6E9-512FD74E0A44_2_2">300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="eol_PE717962--1610-K0012_STD_365_20151231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_11655837_27F0019F-7953-4DCE-BCB0-7E24DFF57D91_2_0">4.08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="eol_PE717962--1610-K0012_STD_365_20151231_0" unitRef="pure" decimals="4" id="id_11655837_23624064-F40E-4BAA-AF98-7BDFA20DC6F2_2_0">0.0168</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE717962--1610-K0012_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_F517A3E7-CD09-482E-A458-78C5E43ED953_2_6">1228000</us-gaap:ShareBasedCompensation>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="eol_PE717962--1610-K0012_STD_365_20151231_0" id="id_11655837_23624064-F40E-4BAA-AF98-7BDFA20DC6F2_2_2">P6Y15D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate contextRef="eol_PE717962--1610-K0012_STD_365_20151231_0" unitRef="pure" decimals="3" id="id_11655837_7D1D2384-E6E7-4C41-8052-1A440B12FCA4_2_3">0.000</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate>
  <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities contextRef="eol_PE717962--1610-K0012_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_6C26F4B4-0D62-4BDF-8A8C-63D664124B3A_2_2">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities>
  <us-gaap:InterestPaidNet contextRef="eol_PE717962--1610-K0012_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_F517A3E7-CD09-482E-A458-78C5E43ED953_2_33">94000</us-gaap:InterestPaidNet>
  <hsgx:DeferredRentAndLeaseIncentive contextRef="eol_PE717962--1610-K0012_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_F517A3E7-CD09-482E-A458-78C5E43ED953_2_4">322000</hsgx:DeferredRentAndLeaseIncentive>
  <hsgx:StockIssuedDuringPeriodValueOverallotmentNetOfFeesAndIssuanceCosts contextRef="eol_PE717962--1610-K0012_STD_365_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_5A0DEAA9-8FA8-403D-B739-D326D818EDBC_4007_1000003">4738000</hsgx:StockIssuedDuringPeriodValueOverallotmentNetOfFeesAndIssuanceCosts>
  <hsgx:EffectiveIncomeTaxRateReconciliationPermanentDifferences contextRef="eol_PE717962--1610-K0012_STD_365_20151231_0" unitRef="pure" decimals="3" id="id_11655837_9FA36880-6F95-410B-BEC1-B0E0D4FEC8F9_2_2">-0.012</hsgx:EffectiveIncomeTaxRateReconciliationPermanentDifferences>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE717962--1610-K0012_STD_365_20151231_0_2021628x2039180" unitRef="shares" decimals="INF" id="id_11655837_4AE35B66-6263-4455-8972-B15FC36D4207_1002_2">166403</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE717962--1610-K0012_STD_365_20151231_0_2021628x2039754" unitRef="shares" decimals="INF" id="id_11655837_4AE35B66-6263-4455-8972-B15FC36D4207_2002_0">1227957</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="eol_PE717962--1610-K0012_STD_365_20151231_0_2025317x2022619" id="id_11655837_9D59D34B-448C-4FAF-A6E9-512FD74E0A44_1002_3">P2Y8M5D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="eol_PE717962--1610-K0012_STD_365_20151231_0_2025317x2041099" id="id_11655837_221B4776-CDDF-4F75-8802-3671377CDC93_1002_1">P1Y2M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
  <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="eol_PE717962--1610-K0012_STD_365_20151231_0_2025317x2041099" unitRef="iso4217_USD" decimals="-3" id="id_11655837_5A0DEAA9-8FA8-403D-B739-D326D818EDBC_4003_7">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
  <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures contextRef="eol_PE717962--1610-K0012_STD_365_20151231_0_2025317x2041099" unitRef="shares" decimals="INF" id="id_11655837_5A0DEAA9-8FA8-403D-B739-D326D818EDBC_4003_600008">-3303</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE717962--1610-K0012_STD_365_20151231_0_2029841x2029413" unitRef="iso4217_USD" decimals="-3" id="id_11655837_5BDC6FE6-2849-4B6E-8481-0D6FD0744ED5_1002_1">777000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:RestrictedStockExpense contextRef="eol_PE717962--1610-K0012_STD_365_20151231_0_2029841x2029413" unitRef="iso4217_USD" decimals="-3" id="id_11655837_8FA11797-04AB-46E0-8AAE-AEA61A40519E_1002_1">4000</us-gaap:RestrictedStockExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE717962--1610-K0012_STD_365_20151231_0_2029841x2035076" unitRef="iso4217_USD" decimals="-3" id="id_11655837_5BDC6FE6-2849-4B6E-8481-0D6FD0744ED5_2002_0">451000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty contextRef="eol_PE717962--1610-K0012_STD_365_20151231_0_2029841x2035076_2038452x2183197" unitRef="iso4217_USD" decimals="-5" id="id_11655837_7442F8D7-2D4D-4BC2-86FB-09636C3F6B44_1002_2">3100000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
  <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill contextRef="eol_PE717962--1610-K0012_STD_365_20151231_0_2035448x2031417" unitRef="iso4217_USD" decimals="-5" id="id_11655837_6C55B9EC-B951-4E97-BF6B-4F0E28F0FC4F_1_0">300000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
  <us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="eol_PE717962--1610-K0012_STD_365_20151231_0_2038452x2128515" unitRef="iso4217_USD" decimals="-5" id="id_11655837_4C09E3B2-695D-40E0-83E5-C27E63516AAE_1002_0">200000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="eol_PE717962--1610-K0012_STD_365_20151231_0_2040323x2025075" unitRef="iso4217_USD" decimals="-3" id="id_11655837_5A0DEAA9-8FA8-403D-B739-D326D818EDBC_4005_800009">1228000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="eol_PE717962--1610-K0012_STD_365_20151231_0_2040323x2025075" unitRef="iso4217_USD" decimals="-3" id="id_11655837_5A0DEAA9-8FA8-403D-B739-D326D818EDBC_4005_800006">11000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
  <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="eol_PE717962--1610-K0012_STD_365_20151231_0_2040323x2025075" unitRef="iso4217_USD" decimals="-3" id="id_11655837_5A0DEAA9-8FA8-403D-B739-D326D818EDBC_4005_7">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="eol_PE717962--1610-K0012_STD_365_20151231_0_2040323x2025075" unitRef="iso4217_USD" decimals="-3" id="id_11655837_5A0DEAA9-8FA8-403D-B739-D326D818EDBC_4005_800010">39000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <hsgx:StockIssuedDuringPeriodValueOverallotmentNetOfFeesAndIssuanceCosts contextRef="eol_PE717962--1610-K0012_STD_365_20151231_0_2040323x2025075" unitRef="iso4217_USD" decimals="-3" id="id_11655837_5A0DEAA9-8FA8-403D-B739-D326D818EDBC_4005_800003">4733000</hsgx:StockIssuedDuringPeriodValueOverallotmentNetOfFeesAndIssuanceCosts>
  <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="eol_PE717962--1610-K0012_STD_365_20151231_0_2040323x2027302" unitRef="iso4217_USD" decimals="-3" id="id_11655837_5A0DEAA9-8FA8-403D-B739-D326D818EDBC_4001_7">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="eol_PE717962--1610-K0012_STD_365_20151231_0_2040323x2027302" unitRef="shares" decimals="INF" id="id_11655837_5A0DEAA9-8FA8-403D-B739-D326D818EDBC_4001_400011">53458</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures contextRef="eol_PE717962--1610-K0012_STD_365_20151231_0_2040323x2027302" unitRef="shares" decimals="INF" id="id_11655837_5A0DEAA9-8FA8-403D-B739-D326D818EDBC_4001_400008">3303</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
  <hsgx:StockIssuedDuringPeriodValueOverallotmentNetOfFeesAndIssuanceCosts contextRef="eol_PE717962--1610-K0012_STD_365_20151231_0_2040323x2027302" unitRef="iso4217_USD" decimals="-3" id="id_11655837_5A0DEAA9-8FA8-403D-B739-D326D818EDBC_4001_500003">5000</hsgx:StockIssuedDuringPeriodValueOverallotmentNetOfFeesAndIssuanceCosts>
  <hsgx:StockIssuedDuringPeriodSharesOverallotmentNetOfFeesAndIssuanceCosts contextRef="eol_PE717962--1610-K0012_STD_365_20151231_0_2040323x2027302" unitRef="shares" decimals="INF" id="id_11655837_5A0DEAA9-8FA8-403D-B739-D326D818EDBC_4001_400004">465000</hsgx:StockIssuedDuringPeriodSharesOverallotmentNetOfFeesAndIssuanceCosts>
  <us-gaap:NetIncomeLoss contextRef="eol_PE717962--1610-K0012_STD_365_20151231_0_2040323x2037658" unitRef="iso4217_USD" decimals="-3" id="id_11655837_5A0DEAA9-8FA8-403D-B739-D326D818EDBC_4006_900012">-32024000</us-gaap:NetIncomeLoss>
  <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="eol_PE717962--1610-K0012_STD_365_20151231_0_2040323x2037658" unitRef="iso4217_USD" decimals="-3" id="id_11655837_5A0DEAA9-8FA8-403D-B739-D326D818EDBC_4006_7">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
  <hsgx:PurchaseCommitmentNonrefundablePayment contextRef="eol_PE717962--1610-K0012_STD_365_20151231_0_2040972x2163139" unitRef="iso4217_USD" decimals="-5" id="id_11655837_4F52247A-4CAB-4623-86A5-29FE3949BF1B_1002_1">100000</hsgx:PurchaseCommitmentNonrefundablePayment>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized contextRef="eol_PE717962--1610-K0012_STD_365_20171231_0_2027922x2423931_2029102x2253325_2039338x2038269" unitRef="shares" decimals="INF" id="id_11655837_DB5416B5-BD6F-404E-8465-90EAD32DD211_1003_4">825904</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized contextRef="eol_PE717962--1610-K0012_STD_365_20171231_0_2029102x2377267_2039338x2038269" unitRef="shares" decimals="INF" id="id_11655837_E46D1C6D-90B6-403D-B13F-C661F3E7206B_1002_3">206476</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
  <us-gaap:CompensationRelatedCostsPolicyTextBlock contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" id="id_11655837_EA769644-0DC8-490D-9B71-8B184580C58B_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;Stock-Based Compensation&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 The Company accounts for grants of stock options and restricted
 stock based on their grant date fair value and recognizes
 compensation expense over their vesting period. The Company
 estimates the fair value of stock options as of the date of grant
 using the Black-Scholes option pricing model and restricted stock
 based on the fair value of the underlying common stock as
 determined by management or the value of the services provided,
 whichever is more readily determinable.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 Stock-based compensation expense represents the cost of the grant
 date fair value of employee stock option grants recognized over the
 requisite service period of the awards (usually the vesting period)
 on a straight-line basis, net of estimated forfeitures. The expense
 is adjusted for actual forfeitures at year end. Stock-based
 compensation expense recognized in the consolidated financial
 statements is based on awards that are ultimately expected to
 vest.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 For stock option grants with performance-based milestones, the
 expense is recorded over the remaining service period after the
 point when the achievement of the milestone is probable or the
 performance condition has been achieved. For stock option grants
 with both performance-based milestones and market conditions,
 expense is recorded over the derived service period after the point
 when the achievement of the performance-based milestone is probable
 or the performance condition has been achieved. The Company issued
 performance-based awards in 2015, but not in 2016.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The Company accounts for stock options and restricted stock awards
 to non-employees using the fair value approach. Stock options and
 restricted stock awards to non-employees are subject to periodic
 revaluation over their vesting terms.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:CompensationRelatedCostsPolicyTextBlock>
  <us-gaap:AdjustmentOfWarrantsGrantedForServices contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_AE354032-1B81-402C-BD47-3E1B7F0C0719_1_10">3100000</us-gaap:AdjustmentOfWarrantsGrantedForServices>
  <dei:EntityRegistrantName contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" id="id_11655837_4376F2C2-CCA2-43BC-BD83-928C14BA3491_1_400001">Histogenics Corporation</dei:EntityRegistrantName>
  <us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" id="id_11655837_9A79383D-3001-4A08-89FA-22DD6EC00734_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;Intangible Asset&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 The Company&amp;#x2019;s intangible asset consists of acquired
 in-process research and development (&amp;#x201C;IPR&amp;amp;D&amp;#x201D;)
 obtained through the acquisition of ProChon. IPR&amp;amp;D represents
 the fair value assigned to research and development assets that
 have not been completed at the date of acquisition. The value
 assigned to acquired IPR&amp;amp;D is determined by estimating the
 costs to develop the acquired technology into commercially viable
 products, estimating the resulting revenue from the projects, and
 discounting the net cash flows to present value. The revenue and
 costs projections used to value acquired IPR&amp;amp;D were adjusted
 based on the probability of success of developing a new product.
 Additionally, the projections considered the relevant market sizes
 and growth factors, expected trends in technology and the nature
 and expected timing of new product introductions by the Company and
 its competitors. The rates utilized to discount the net cash flows
 to their present value were commensurate with the stage of
 development of the projects and uncertainties in the economic
 estimates used in the projections described above.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 IPR&amp;amp;D is considered an indefinite-lived intangible asset and is
 assessed for impairment annually or more frequently if impairment
 indicators exist. When performing the impairment assessment, the
 Company first assesses qualitative factors to determine whether it
 is necessary to recalculate the fair value of its acquired
 IPR&amp;amp;D. If the Company believes, as a result of the qualitative
 assessment, that it is more likely than not that the fair value of
 acquired IPR&amp;amp;D is less than its carrying amount, it calculates
 the fair value using the same methodology as described above. If
 the carrying value of the Company&amp;#x2019;s acquired IPR&amp;amp;D
 exceeds its fair value, then an impairment charge is taken and the
 intangible asset is written-down to its fair value. During the
 fourth quarter the Company deemed the value of the IPR&amp;amp;D to be
 zero for the year ended December&amp;#xA0;31, 2016 as it has no plans
 to advance the technology or use it in any future clinical
 development activities. The result was a write-off of $0.2 million.
 For the year ended December&amp;#xA0;31, 2015, the Company determined
 that there was impairment of its IPR&amp;amp;D of $0.3 million. The
 Company performed its annual impairment test of its IPR&amp;amp;D as of
 December&amp;#xA0;31, 2015 using an income approach, including a
 discount rate of 13%, applied to probability-adjusted after-tax
 cash flows. The Company believes that the assumptions are
 representative of those a market participant would use in
 estimating the fair value of the IPR&amp;amp;D.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 Intangible asset, net of accumulated impairment charges, are
 summarized as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="50%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"&gt;&lt;b&gt;As of
 December&amp;#xA0;31,&amp;#xA0;2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"&gt;&lt;b&gt;As of December&amp;#xA0;31,
 2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Cost&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Accumulated&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Impairment&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Net&amp;#xA0;Book&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Value&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Cost&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Accumulated&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Impairment&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Net&amp;#xA0;Book&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Value&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"&gt;&lt;b&gt;(in thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"&gt;&lt;b&gt;(in thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 IPR&amp;amp;D&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;630&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(630&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;630&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(430&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;200&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;630&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(630&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;630&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(430&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;200&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
  <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" id="id_11655837_FDA34CF1-7667-410F-A41D-A25FD9CB9E30_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;Restricted Cash&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 Restricted cash represents cash held in a depository account at a
 financial institution to collateralize a conditional stand-by
 letter of credit related to the Company&amp;#x2019;s Lexington,
 Massachusetts facility lease agreement. Restricted cash is reported
 as non-current unless the restrictions are expected to be released
 in the next twelve months.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
  <dei:DocumentType contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" id="id_11655837_ADDBC638-5679-4BB5-A776-C2BF3404D489_1_0">10-K</dei:DocumentType>
  <dei:EntityCentralIndexKey contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" id="id_11655837_4376F2C2-CCA2-43BC-BD83-928C14BA3491_1_400002">0001372299</dei:EntityCentralIndexKey>
  <us-gaap:DebtDisclosureTextBlock contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" id="id_11655837_B4897369-A852-4B0C-90BB-852D2F5B56A0_1_0">&lt;div&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="break-inside: avoid"&gt;
 &lt;td valign="top" width="4%" align="left"&gt;&lt;b&gt;10.&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;&lt;b&gt;EQUIPMENT LOAN PAYABLE&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 As of December&amp;#xA0;31, 2016 and 2015, the Company had the
 following outstanding borrowing obligations:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="66%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="13%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="12%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;br /&gt;
 2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;br /&gt;
 2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;
 &lt;b&gt;(in&amp;#xA0;thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Silicon Valley Bank Equipment Loan Payable&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;761&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,344&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Less: current portion&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(583&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(583&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Long-term debt, net&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;178&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;761&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 In July 2014, the Company entered into a loan and security
 agreement with Silicon Valley Bank, which provides for a line of
 credit to finance certain equipment purchases up to an aggregate of
 $1.8 million through March&amp;#xA0;31, 2015. The line has been fully
 drawn and is payable in 36 monthly installments of principal and
 interest, with an annual interest rate of 2.75% plus the greater of
 3.25% and the prime rate in effect at the time of each draw, as
 published in the Wall Street Journal. The outstanding balance on
 the line of credit is secured by a first priority lien over all
 equipment purchased using the line of credit.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 In accordance with the terms of the equipment line of credit, the
 Company issued a warrant to Silicon Valley Bank in July 2014 to
 purchase 6,566 shares of our common stock at an exercise price per
 share of $7.99.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 The equipment line of credit includes customary operating but
 non-financial covenants, including limitations on the
 Company&amp;#x2019;s ability to incur additional indebtedness, issue
 dividends, sell assets, engage in any business other than its
 current business, merge or consolidate with other entities, create
 liens on our assets, make investments, repurchase stock in certain
 instances, enter into transactions with affiliates, make payments
 on subordinated indebtedness and transfer or encumber any
 collateral securing the debt.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 As of December&amp;#xA0;31, 2016 and 2015, $0.8 and $1.3 million
 respectively, of borrowings were outstanding under the line of
 credit and the Company was in compliance with all required
 covenants.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_5A0DEAA9-8FA8-403D-B739-D326D818EDBC_7007_1000015">1548000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <dei:DocumentPeriodEndDate contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" id="id_11655837_ADDBC638-5679-4BB5-A776-C2BF3404D489_1_2">2016-12-31</dei:DocumentPeriodEndDate>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_F517A3E7-CD09-482E-A458-78C5E43ED953_1_26">993000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:ConvertiblePreferredStockTermsOfConversion contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" id="id_11655837_BA55390A-7F6A-4E74-AD37-FCFA4868621B_2_6">The  Series A Preferred Stock shall not be converted if, after giving effect to the  conversion, the holder and its affiliated persons would own beneficially more  than 4.99% of our common stock (subject to adjustment up to 9.99% solely at the  holder&apos;s discretion upon 61 days&apos; prior notice to us or, solely as to a holder,  if such limitation is waived by such holder upon execution of the private  placement agreement).</us-gaap:ConvertiblePreferredStockTermsOfConversion>
  <dei:EntityWellKnownSeasonedIssuer contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" id="id_11655837_4376F2C2-CCA2-43BC-BD83-928C14BA3491_1_400004">No</dei:EntityWellKnownSeasonedIssuer>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_8FA11797-04AB-46E0-8AAE-AEA61A40519E_1_0">1548000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" unitRef="pure" decimals="3" id="id_11655837_9FA36880-6F95-410B-BEC1-B0E0D4FEC8F9_1_5">0.487</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
  <dei:DocumentFiscalYearFocus contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" id="id_11655837_ADDBC638-5679-4BB5-A776-C2BF3404D489_1_3">2016</dei:DocumentFiscalYearFocus>
  <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" id="id_11655837_3AA9EC6F-12F7-4E4D-A3D9-C3887C93361D_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The following table provides a reconciliation of all liabilities
 measured at fair value using Level 3 significant unobservable
 inputs:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="67%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="25%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;As&amp;#xA0;of&amp;#xA0;December&amp;#xA0;31,&amp;#xA0;2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;(in thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Beginning balance, January&amp;#xA0;1, 2016&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Issuance of warrants,&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;30,704&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Change in fair value of warrant liability&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(17,507&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Ending balance&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;13,197&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
  <dei:AmendmentFlag contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" id="id_11655837_ADDBC638-5679-4BB5-A776-C2BF3404D489_1_1">false</dei:AmendmentFlag>
  <dei:CurrentFiscalYearEndDate contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" id="id_11655837_4376F2C2-CCA2-43BC-BD83-928C14BA3491_1_400003">--12-31</dei:CurrentFiscalYearEndDate>
  <dei:EntityCurrentReportingStatus contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" id="id_11655837_4376F2C2-CCA2-43BC-BD83-928C14BA3491_1_400005">Yes</dei:EntityCurrentReportingStatus>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_AE354032-1B81-402C-BD47-3E1B7F0C0719_1_3">8530000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:EarningsPerShareBasic contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_11655837_AE354032-1B81-402C-BD47-3E1B7F0C0719_1_16">-0.97</us-gaap:EarningsPerShareBasic>
  <us-gaap:ConcentrationRiskCreditRisk contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" id="id_11655837_9D78657B-A5E5-42EB-8490-8D1825A53E2D_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;Concentration of Credit Risk&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 Financial instruments, which potentially subject the Company to
 significant concentration of credit risk, consist primarily of cash
 and cash equivalents. The Company maintains deposits in federally
 insured financial institutions in excess of federally insured
 limits. The Company has not experienced any losses in such accounts
 and management believes that the Company is not exposed to
 significant credit risk due to the financial position of the
 depository institutions in which those deposits are held. The
 Company has no financial instruments with off-balance sheet risk of
 loss.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
  <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" id="id_11655837_893B37DC-1689-4F2C-B306-EC7A69D1B9BC_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &lt;b&gt;Fair Value Measurements&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 The carrying amounts reported in the Company&amp;#x2019;s consolidated
 financial statements for cash and cash equivalents, accounts
 payable, equipment loan, and accrued liabilities approximate their
 respective fair values because of the short-term nature of these
 accounts.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 Fair value is defined as the price that would be received if
 selling an asset or paid to transfer a liability in the principal
 or most advantageous market for the asset or liability in an
 orderly transaction between market participants on the measurement
 date.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 Fair value should be based on the assumptions that market
 participants would use when pricing an asset or liability and is
 based on a fair value hierarchy that prioritizes the information
 used to develop those assumptions. The fair value hierarchy gives
 the highest priority to quoted prices in active markets (observable
 inputs) and the lowest priority to the Company&amp;#x2019;s assumptions
 (unobservable inputs). Fair value measurements should be disclosed
 separately by level within the fair value hierarchy. For assets and
 liabilities recorded at fair value, it is the Company&amp;#x2019;s
 policy to maximize the use of observable inputs and minimize the
 use of unobservable inputs when developing fair value measurements,
 in accordance with established fair value hierarchy.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 Fair value measurements for assets and liabilities where there
 exists limited or no observable market data are based primarily
 upon estimates, and often are calculated based on the economic and
 competitive environment, the characteristics of the asset or
 liability and other factors. Therefore, the results cannot be
 determined with precision and may not be realized in an actual sale
 or immediate settlement of the asset or liability. Additionally,
 there may be inherent weaknesses in any valuation technique, and
 changes in the underlying assumptions used, including discount
 rates and estimates of future cash flows, could significantly
 affect the results of current or future values.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 Additionally, from time to time, the Company may be required to
 record at fair value other assets on a nonrecurring basis, such as
 assets held for sale and certain other assets. These nonrecurring
 fair value adjustments typically involve application of
 lower-of-cost-or-market accounting or write-downs of individual
 assets.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 The fair value hierarchy gives the highest priority to unadjusted
 quoted prices in active markets for identical assets (Level 1), and
 the lowest priority to unobservable inputs (Level 3). The
 Company&amp;#x2019;s financial assets are classified within the fair
 value hierarchy based on the lowest level of inputs that is
 significant to the fair value measurement. The three levels of the
 fair value hierarchy, and its applicability to the Company&amp;#x2019;s
 financial assets, are described below.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 62px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &lt;i&gt;Level 1&lt;/i&gt;: Unadjusted quoted prices in active markets that are
 accessible at the measurement date of identical, unrestricted
 assets.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 62px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &lt;i&gt;Level 2&lt;/i&gt;: Quoted prices for similar assets, or inputs that
 are observable, either directly or indirectly, for substantially
 the full term through corroboration with observable market data.
 Level 2 includes investments valued at quoted prices adjusted for
 legal or contractual restrictions specific to the security.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 62px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &lt;i&gt;Level 3&lt;/i&gt;: Pricing inputs are unobservable for the assets,
 that is, inputs that reflect the reporting entity&amp;#x2019;s own
 assumptions about the assumptions market participants would use in
 pricing the assets. Level 3 includes private investments that are
 supported by little or no market activity.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 Level 3 valuations are for instruments that are not traded in
 active markets or are subject to transfer restrictions and may be
 adjusted to reflect illiquidity and/or non-transferability, with
 such adjustment generally based on available market evidence. In
 the absence of such evidence, management&amp;#x2019;s best estimate is
 used.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 An adjustment to the pricing method used within either Level 1 or
 Level 2 inputs could generate a fair value measurement that
 effectively falls in a lower level in the hierarchy. The Company
 had no assets or liabilities classified as Level 1 or Level 2 as of
 December&amp;#xA0;31, 2016 and 2015 other than the money market fund
 described in the &amp;#x201C;Cash and Cash Equivalents&amp;#x201D; section
 below and there were no material re-measurements of fair value with
 respect to financial assets and liabilities, during the periods
 presented, other than those assets and liabilities that are
 measured at fair value on a recurring basis. Other than the
 warrants issued in connection with the private placement
 transaction which closed on September&amp;#xA0;29, 2016, the Company
 had no assets or liabilities classified as Level 3 as of
 December&amp;#xA0;31, 2016 and 2015.&amp;#xA0;Transfers are calculated on
 values as of the transfer date. There were no transfers between
 Levels 1, 2 and 3 during the twelve months ended December&amp;#xA0;31,
 2016 and 2015.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 The fair value of the warrants was determined using a Monte Carlo
 simulation model.&amp;#xA0;This model incorporated several assumptions
 at each valuation date including: the price of the Company&amp;#x2019;s
 common stock on the date of valuation, the historical volatility of
 the price of the Company&amp;#x2019;s common stock, the remaining
 contractual term of the warrant and estimates of the probability of
 a fundamental transaction occurring. See Note 8, Capital Stock, for
 further discussion of the private placement.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="46%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WIDTH: 39.5pt; BORDER-BOTTOM: rgb(0,0,0) 1pt solid; MARGIN-TOP: 0pt"&gt;
 &lt;b&gt;Description&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Quoted&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;prices in&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;active&amp;#xA0;markets&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;(Level 1)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Significant&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;other&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;observable&amp;#xA0;inputs&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;(Level 2)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Significant&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;unobservable&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;inputs&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;(Level 3)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="14" align="center"&gt;&lt;b&gt;(in
 thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 &lt;b&gt;December&amp;#xA0;31, 2016&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 &lt;b&gt;Assets:&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Money market funds&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;30,318&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;30,318&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 &lt;b&gt;Liabilities:&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Warrant liability&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;13,197&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;13,197&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 &lt;b&gt;December&amp;#xA0;31, 2015&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Money market funds&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;25,764&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;25,764&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 The following table provides a reconciliation of all liabilities
 measured at fair value using Level 3 significant unobservable
 inputs:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="67%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="25%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;As&amp;#xA0;of&amp;#xA0;December&amp;#xA0;31,&amp;#xA0;2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;(in
 thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Beginning balance, January&amp;#xA0;1, 2016&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Issuance of warrants,&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;30,704&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Change in fair value of warrant liability&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(17,507&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Ending balance&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;13,197&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
  <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" id="id_11655837_3C1CA5BC-401E-46F6-9D35-300420B67CD7_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;Cash and Cash Equivalents&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 Cash and cash equivalents include cash in readily available
 checking and savings accounts and money market funds. The Company
 considers all highly liquid investments with an original maturity
 of three months or less from the date of purchase to be cash
 equivalents.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The Company&amp;#x2019;s cash equivalents, which consist of money market
 funds, are measured at fair value on a recurring basis. As of
 December&amp;#xA0;31, 2016 and 2015, the carrying amount of cash and
 cash equivalents was $31.9 million and $30.9 million, respectively,
 which approximates fair value and was determined based upon Level 1
 inputs. Money market funds are valued using quoted market prices
 with no valuation adjustments applied. Accordingly, these
 securities are categorized as Level 1 and had a balance of $30.3
 million and $25.8 million as of December&amp;#xA0;31, 2016 and 2015,
 respectively, shown in the table above.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
  <us-gaap:Depreciation contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_F517A3E7-CD09-482E-A458-78C5E43ED953_1_3">1673000</us-gaap:Depreciation>
  <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" id="id_11655837_4A3C8315-9635-47FD-87A4-A0A919685533_1_0">&lt;div&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="break-inside: avoid"&gt;
 &lt;td valign="top" width="4%" align="left"&gt;&lt;b&gt;11.&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;&lt;b&gt;STOCK-BASED COMPENSATION&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &lt;b&gt;Restricted Stock Awards and Stock Options&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 The Company adopted the 2012 Equity Incentive Plan, as amended
 (&amp;#x201C;2012 Plan&amp;#x201D;) in July 2012 pursuant to which 609,389
 shares of common stock were authorized for issuance to employees,
 officers, directors, consultants and advisors of the Company as of
 December&amp;#xA0;31, 2014. Upon the closing of the IPO on
 December&amp;#xA0;3, 2014, no further grants will be made under the
 2012 Plan as the 2013 Equity Incentive Plan (&amp;#x201C;2013
 Plan&amp;#x201D;) replaced the 2012 Plan on this date. The 2012 Plan
 provided for the grant of incentive stock options, non-statutory
 stock options, rights to purchase restricted stock, stock
 appreciation rights, phantom stock awards and stock units. In
 connection with the issuance of restricted common stock, the
 Company maintains a repurchase right and shares of restricted
 common stock are released from such repurchase right over a period
 of time of continued service by the recipient. Recipients of
 incentive stock options shall be eligible to purchase shares of the
 Company&amp;#x2019;s common stock at an exercise price equal to no less
 than the estimated fair value of such stock on the date of grant.
 Stock options generally vest 25% on the first anniversary of the
 original vesting date, with the balance vesting monthly over the
 remaining three years, unless they contain specific performance
 and/or market-based vesting provisions. The maximum term of stock
 options granted under the 2012 Plan is ten years.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 In determining the exercise prices for options granted, the board
 of directors considered the fair value of the common stock as of
 the measurement date. The fair value of the common stock was
 determined by the board of directors based on a variety of
 different factors, including valuations prepared by third party
 valuation specialists, Company&amp;#x2019;s financial position, the
 status of development efforts within the Company, the composition
 and ability of the current scientific and management teams, the
 current climate in the marketplace, the illiquid nature of the
 Company&amp;#x2019;s common stock, arm&amp;#x2019;s length sale of the
 Company&amp;#x2019;s preferred stock, the effect of the rights and
 preferences of the preferred stockholders, and the prospects of a
 liquidity event, among others.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &lt;b&gt;2013 Equity Incentive Plan&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 The Company&amp;#x2019;s board of directors adopted the 2013 Plan in
 November 2013 which the stockholders approved in October 2014. The
 2013 Plan provides for the grant of incentive stock options,
 non-statutory stock options, rights to purchase restricted stock,
 stock appreciation rights and stock units. In connection with the
 issuance of restricted common stock, the Company maintains a
 repurchase right and shares of restricted common stock are released
 from such repurchase right over a period of time of continued
 service by the recipient. Recipients of stock options shall be
 eligible to purchase shares of the Company&amp;#x2019;s common stock at
 an exercise price equal to no less than the estimated fair value of
 such stock on the date of grant. Stock options generally vest 25%
 on the first anniversary of the original vesting date, with the
 balance vesting monthly over the remaining three years, unless they
 contain specific performance and/or market-based vesting
 provisions. The maximum term of stock options granted under the
 2013 Plan is ten years. In June 2016, the Company&amp;#x2019;s
 stockholders approved an amendment to the EIP to increase the
 number of shares of common stock available for issuance under the
 2013 Plan by 300,000 shares and increase the number of shares of
 common stock automatically added to the 2013 Plan on January&amp;#xA0;1
 of each year during the term of the 2013 Plan, starting with
 January&amp;#xA0;1, 2017 (the &amp;#x201C;EIP Amendment&amp;#x201D;). Following
 adoption of the EIP Amendment, the number of shares of common stock
 available for issuance under the 2013 Plan is subject to an
 automatic annual increase on the first day of the Company&amp;#x2019;s
 calendar year beginning in 2017 equal to the lesser of
 (a)&amp;#xA0;4.0% of the total number of shares of common stock
 outstanding on December&amp;#xA0;31 of the prior year or, (b)&amp;#xA0;the
 number determined by the Company&amp;#x2019;s Board of Directors
 Accordingly, the number of shares of common stock available for
 issuance under the EIP was increased by 825,904 shares effective
 January&amp;#xA0;1, 2017. To the extent any awards under the 2013 Plan
 are forfeited, terminate, expire, lapse without the issuance of
 shares, or if the Company repurchases shares subject to awards
 under the 2013 Plan, those shares will again become available for
 issuance under the 2013 Plan.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &lt;b&gt;2013 Employee Stock Purchase Plan&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 The Company&amp;#x2019;s board of directors adopted the 2013 Employee
 Stock Purchase Plan (&amp;#x201C;2013 ESPP&amp;#x201D;) in November 2013
 which the stockholders approved in October 2014. The 2013 ESPP
 became effective upon the closing of the IPO on December&amp;#xA0;3,
 2014. The Company&amp;#x2019;s 2013 ESPP qualifies under
 Section&amp;#xA0;423 of the Internal Revenue Code of 1986, as amended
 (the &amp;#x201C;Code&amp;#x201D;). Under the 2013 ESPP, 103,665 shares of
 the Company&amp;#x2019;s common stock are authorized for issuance to
 eligible employees. The number of shares reserved for issuance
 under the 2013 ESPP is automatically increased on the first
 business day of each of the Company&amp;#x2019;s fiscal years,
 commencing in 2015, by a number equal to the lowest of
 (a)&amp;#xA0;51,832 shares of common stock,(b) 1% of the shares of
 common stock outstanding on the last business day of the prior
 fiscal year; or (c)&amp;#xA0;the number of shares determined by the
 Company&amp;#x2019;s Board of Directors. Accordingly, the number of
 authorized shares of the Company&amp;#x2019;s common stock authorized
 for issuance to eligible employees under the 2013 ESPP was
 increased by 206,476 shares effective January&amp;#xA0;1, 2017. The
 number of shares reserved under the 2013 ESPP will automatically be
 adjusted in the event of a stock split, stock dividend or a reverse
 stock split (including an adjustment to the per-purchase period
 share limit). The Company&amp;#x2019;s 2013 ESPP permits each eligible
 employee to purchase common stock through payroll deductions. There
 was no activity under the Plan in 2016 and 2015.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 Stock option activity under the 2012 and 2013 plans is summarized
 as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="61%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Number&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;of Options&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Weighted-&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Average&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Exercise&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Price&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Weighted-&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Average&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Remaining&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Contractual&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Term&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;(in years)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Aggregate&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Intrinsic&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Value&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;(in&amp;#xA0;thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Outstanding at December&amp;#xA0;31, 2015&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,229,339&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7.32&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;9.0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(4,679&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Granted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;464,240&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2.02&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Exercised&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(3,685&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.76&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Cancelled&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(112,878&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4.97&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Outstanding at December&amp;#xA0;31, 2016&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,577,016&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5.95&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8.4&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;71&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Vested and expected to vest at December&amp;#xA0;31, 2016&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,492,341&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5.97&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8.4&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;69&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Exercisable at December&amp;#xA0;31, 2016&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;561,693&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6.79&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7.8&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;52&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 As of December&amp;#xA0;31, 2016 and 2015, the unrecognized
 compensation cost related to outstanding options was $2.6 million
 and $3.9 million, respectively, and is expected to be recognized as
 expense over approximately 2.01 years and 2.68 years, respectively.
 The intrinsic value of options exercised during the years ended
 December&amp;#xA0;31, 2016 and 2015 was $10 thousand and $0.3 million,
 respectively.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 As of December&amp;#xA0;31, 2016, the weighted average grant date fair
 value of vested options was $4.71 and the weighted average grant
 date fair value of options outstanding was $3.67.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 Additional information about the Company&amp;#x2019;s stock option
 activity is as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="82%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"&gt;
 &lt;b&gt;Year&amp;#xA0;Ended&amp;#xA0;December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Weighted-average grant date fair value per share of employee option
 grants within the year&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.26&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4.08&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Cash received upon exercise of options&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;39&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 Restricted stock awards under the 2012 and 2013 plans are
 summarized as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="64%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="13%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="12%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Number&amp;#xA0;of&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Shares&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Weighted&amp;#xA0;Average&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Grant Date&amp;#xA0;Fair&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Value&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Unvested at December&amp;#xA0;31, 2015&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,190&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.07&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Vesting of restricted stock&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(3,301&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Unvested at December&amp;#xA0;31, 2016&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,889&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.83&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 As of December&amp;#xA0;31, 2016 and 2015, the unrecognized
 compensation cost related to restricted stock awards was $1
 thousand and $4 thousand respectively, and is expected to be
 recognized as expense over approximately 0.3 years and 1.2 years,
 respectively.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &lt;b&gt;Stock-Based Compensation Expense&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 The Company granted stock options to employees for the years ended
 December&amp;#xA0;31, 2016 and 2015. The Company estimates the fair
 value of stock options as of the date of grant using the
 Black-Scholes option pricing model and restricted stock based on
 the fair value of the award. Stock options and restricted stock
 issued to non-board member, non-employees are accounted for using
 the fair value approach and are subject to periodic revaluation
 over their vesting terms.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 For all periods from inception to date, stock-based compensation
 for all options granted and restricted stock awards are classified
 as research and development expense and general and administrative
 expense. Stock compensation expense amounted to approximately $1.5
 million and $1.2 million for the years ended December&amp;#xA0;31, 2016
 and 2015, respectively. Included in the table below is restricted
 stock-based compensation expense of $2 thousand and $4 thousand,
 respectively, recorded in general and administrative expense during
 the years ended December&amp;#xA0;31, 2016 and 2015.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 Stock-based compensation is as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="76%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;Year Ended&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;
 &lt;b&gt;(in&amp;#xA0;thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Research and development&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;491&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;451&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 General and administrative&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,057&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;777&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Total stock-based compensation expense&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,548&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,228&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 The weighted-average assumptions used in the Black-Scholes option
 pricing model to determine the fair value of the employee stock
 option grants were as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="83%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;Year Ended&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Risk-free interest rate&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.73&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.68&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Expected volatility&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;72.5&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;62.6&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Expected term (in years)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6.08&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6.04&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Expected dividend yield&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 The weighted-average assumptions used in the Black-Scholes option
 pricing model to determine the fair value of the non-employee stock
 option grants were as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="83%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;Year Ended&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Risk-free interest rate&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.57&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.79&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Expected volatility&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;63.5&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;63.2&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Expected term (in years)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7.00&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6.16&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Expected dividend yield&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &lt;b&gt;&lt;i&gt;Risk-free Interest Rate&lt;/i&gt;&lt;/b&gt;. The risk-free interest rate
 assumption is based on observed interest rates appropriate for the
 expected term of the stock option grants.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &lt;b&gt;&lt;i&gt;Expected Volatility&lt;/i&gt;&lt;/b&gt;. Due to the Company&amp;#x2019;s
 limited operating history and lack of company-specific historical
 or implied volatility, the expected volatility assumption is based
 on historical volatilities of a peer group of similar companies
 whose share prices are publicly available. The peer group was
 developed based on companies in the biotechnology and medical
 device industries.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &lt;b&gt;&lt;i&gt;Expected Term&lt;/i&gt;&lt;/b&gt;. The expected term represents the
 period of time that options are expected to be outstanding. Because
 the Company does not have historical exercise behavior, through
 December&amp;#xA0;31, 2016 it determined the expected life assumption
 using the simplified method, which is an average of the contractual
 term of the option and its vesting period.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &lt;b&gt;&lt;i&gt;Expected Dividend Yield&lt;/i&gt;&lt;/b&gt;. The expected dividend yield
 assumption is based on the fact that the Company has never paid
 cash dividends and has no present intention to pay cash
 dividends.&lt;/p&gt;


 &lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
  <us-gaap:EarningsPerSharePolicyTextBlock contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" id="id_11655837_EFC5DAE5-7CD0-4F78-AB98-7F5AF88111F4_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;Earnings (Loss) per Common Share&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 Earnings (loss) per common share is calculated using the two-class
 method, which is an earnings allocation formula that determines
 earnings (loss) per share for the holders of the Company&amp;#x2019;s
 common shares and participating securities. All series of preferred
 stock contain participation rights in any dividend paid by the
 Company and are deemed to be participating securities. Earnings
 available to common stockholders and participating convertible
 redeemable preferred shares are allocated to each share on an
 as-converted basis as if all of the earnings for the period had
 been distributed. The participating securities include a
 contractual obligation to share in losses of the Company and
 are&amp;#xA0;included in the calculation of net loss per share in the
 periods that have a net loss.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 Diluted earnings per share is computed using the more dilutive of
 (a)&amp;#xA0;the two-class method, or (b)&amp;#xA0;the if-converted method.
 The Company allocates earnings first to preferred stockholders
 based on dividend rights and then to common and preferred
 stockholders based on ownership interests. The weighted-average
 number of common shares included in the computation of diluted
 earnings (loss) gives effect to all potentially dilutive common
 equivalent shares, including outstanding stock options, warrants,
 convertible redeemable preferred stock and the potential issuance
 of stock upon the conversion of the Company&amp;#x2019;s convertible
 notes. Common stock equivalent shares are excluded from the
 computation of diluted earnings (loss) per share if their effect is
 antidilutive.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
  <dei:DocumentFiscalPeriodFocus contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" id="id_11655837_ADDBC638-5679-4BB5-A776-C2BF3404D489_1_4">FY</dei:DocumentFiscalPeriodFocus>
  <us-gaap:EarningsPerShareDiluted contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_11655837_AE354032-1B81-402C-BD47-3E1B7F0C0719_1_17">-2.18</us-gaap:EarningsPerShareDiluted>
  <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" id="id_11655837_BC1C5AD1-D507-4CF6-AA73-68E7375EE703_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 Prepaid expenses and other current assets consisted of the
 following:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="82%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;As of&lt;br /&gt;
 December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;(in
 thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Deposits&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;67&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Undelivered laboratory and office equipment&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;17&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Insurance&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;95&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;42&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Other current assets&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;68&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;195&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Prepaid expenses and other current assets&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;173&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;321&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
  <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" unitRef="pure" decimals="3" id="id_11655837_9FA36880-6F95-410B-BEC1-B0E0D4FEC8F9_1_6">0.009</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
  <dei:EntityFilerCategory contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" id="id_11655837_4376F2C2-CCA2-43BC-BD83-928C14BA3491_1_400007">Smaller Reporting Company</dei:EntityFilerCategory>
  <dei:EntityVoluntaryFilers contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" id="id_11655837_4376F2C2-CCA2-43BC-BD83-928C14BA3491_1_400006">No</dei:EntityVoluntaryFilers>
  <us-gaap:DeferredChargesPolicyTextBlock contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" id="id_11655837_89FF9C8F-16FD-4807-A92D-7FBD2D9981F8_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;Deferred Rent&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 Deferred rent consists of the difference between cash payments and
 the recognition of rent expense on a straight-line basis for the
 facilities the Company occupies. The Company&amp;#x2019;s leases for its
 Waltham, Massachusetts facility and its Lexington, Massachusetts
 facility provide for fixed increases in minimum annual rental
 payments. The total amount of rental payments due over each lease
 term is being charged to rent expense ratably over the life of each
 lease, respectively.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:DeferredChargesPolicyTextBlock>
  <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" id="id_11655837_0118D81A-95B6-4C37-A46B-4037AD60E23B_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 &lt;b&gt;Basis of Accounting&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 The consolidated financial statements are prepared in conformity
 with accounting principles generally accepted in the United States
 of America (&amp;#x201C;U.S. GAAP&amp;#x201D;). The consolidated financial
 statements include the accounts of Histogenics Corporation and its
 wholly-owned subsidiaries, ProChon and Histogenics Securities
 Corporation. All significant intercompany accounts and transactions
 are eliminated in consolidation.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
  <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" id="id_11655837_B1E1B9E3-75E5-4CD2-95EF-F51E1B0C6C0A_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 &lt;b&gt;Foreign Currency Translation&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 The Company&amp;#x2019;s consolidated financial statements are prepared
 in U.S. dollars. The Company&amp;#x2019;s foreign subsidiary uses the
 U.S. dollar as its functional and reporting currency, as management
 determined that the U.S. dollar is the primary currency of the
 economic environment in which the subsidiary operates. When
 transactions are required to be paid in the local currency of the
 foreign subsidiary, any resulting foreign currency transaction gain
 or loss is recorded as a component of &amp;#x201C;Other income
 (expense), net&amp;#x201D; in the consolidated statements of
 operations.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
  <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" id="id_11655837_4CCF1FDC-2B13-4FF0-B922-03653C40DDCB_1_0">&lt;div&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top" width="4%" align="left"&gt;&lt;b&gt;7.&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;&lt;b&gt;COMMITMENTS AND
 CONTINGENCIES&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 &lt;b&gt;Operating Leases&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 The Company leases office and research facilities in Waltham,
 Massachusetts under a non-cancellable operating lease, which
 expires in December 2017, with two additional five-year renewal
 options. Terms of the agreement provide for an initial rent-free
 period and future rent escalation, and provide that in addition to
 minimum lease rental payments, the Company is responsible for a
 pro-rata share of common area operating expenses. In June 2014, the
 Company entered into a lease agreement to rent a facility in
 Lexington, Massachusetts. The commencement date of the lease was
 July&amp;#xA0;9, 2014 with a term that extends through June&amp;#xA0;1,
 2023, with one additional five-year renewal option. Terms of the
 lease agreement provide for an initial rent-free period and future
 rent escalation, and provide that in addition to minimum lease
 rental payments, the Company is responsible for a pro-rata share of
 operating expenses. The Company&amp;#x2019;s wholly-owned subsidiary,
 ProChon, leased a facility in Woburn, Massachusetts which expired
 in 2016 and was not renewed.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 Aggregate minimum annual lease commitments of the Company under its
 non-cancellable operating leases as of December&amp;#xA0;31, 2016, are
 as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="79%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="15%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom" colspan="4" nowrap="nowrap" align="center"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; WIDTH: 116.9pt; BORDER-BOTTOM: #000000 1pt solid; MARGIN-TOP: 0pt" align="center"&gt;&lt;b&gt;For the Year Ended December&amp;#xA0;31,&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;(in&amp;#xA0;thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 2017&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,266&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 2018&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;754&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 2019&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;586&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 2020&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;596&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 2021&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;605&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Thereafter&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;926&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Total minimum lease payments&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,733&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 Rent expense under operating lease agreements amounted to $1.0
 million and $1.1 million for the years ended December&amp;#xA0;31, 2016
 and 2015, respectively.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 As an inducement to enter into its Waltham facility lease, the
 lessor agreed to provide the Company with a construction allowance
 of up to $3.2 million towards the total cost of tenant
 improvements. As an inducement to enter into its Lexington facility
 lease, the lessor agreed to provide the Company with a construction
 allowance of up to $1.0 million towards the total cost of tenant
 improvements. The Company has recorded these costs in the
 consolidated balance sheet as leasehold improvements, with the
 corresponding liability as deferred lease incentive. These
 liabilities are amortized on a straight-line basis over the term of
 the lease as a reduction of rent expense.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 18pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 &lt;b&gt;License Agreements&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 From time to time, the Company enters into various licensing
 agreements whereby the Company may use certain technologies in
 conjunction with its product research and development.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 Licensing agreements and the Company&amp;#x2019;s commitments under the
 agreements are as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;i&gt;Hydrogel License&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 In May 2005, the Company entered into an exclusive license
 agreement with Angiotech Pharmaceuticals (US), Inc. for the use of
 certain patents, patent applications, and knowledge related to the
 manufacture and use of a hydrogel material in conjunction with
 NeoCart and certain other products (&amp;#x201C;Hydrogel License
 Agreement&amp;#x201D;). As of December&amp;#xA0;31, 2016, the Company has
 paid an aggregate $3.2 million in commercialization milestones
 under the terms of the Hydrogel License Agreement, which has been
 expensed to research and development.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 Under the terms of the Hydrogel License Agreement, the
 Company&amp;#x2019;s future commitments include:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td width="5%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="2%" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td valign="top" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;A one-time $3.0 million payment upon
 approval of an eligible product by the FDA; and&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td width="5%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="2%" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td valign="top" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;Single digit royalties on the net
 sales of NeoCart and certain other future products.&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;i&gt;Tissue Regeneration License&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 In April 2001, the Company entered into an exclusive license
 agreement with The Board of Trustees of the Leland Stanford Junior
 University (&amp;#x201C;Stanford University&amp;#x201D;) for the use of
 certain technology to develop, manufacture and sell licensed
 products in the field of growth and regeneration of cartilage
 (&amp;#x201C;Tissue Regeneration License Agreement&amp;#x201D;). The term of
 the Tissue Regeneration License Agreement extends to the expiration
 date of Stanford University&amp;#x2019;s last to expire domestic or
 foreign patents. As of December&amp;#xA0;31, 2016, the Company has paid
 an aggregate $0.7 million in patent reimbursement costs, royalty
 fees, and commercialization milestone payments under the terms of
 the Tissue Regeneration License Agreement, which have been recorded
 to research and development expense.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 Under the terms of the Tissue Regeneration License Agreement, the
 Company&amp;#x2019;s future commitments include:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td width="5%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="2%" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td valign="top" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;A one-time $0.3 million payment upon
 approval of an eligible product by the FDA;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td width="5%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="2%" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td valign="top" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;An annual minimum non-refundable
 royalty fee of $10 thousand for the life of the license that may be
 used to offset up to 50% of each earned royalty described below;
 and&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td width="5%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="2%" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td valign="top" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;Low single digit royalties on net
 sales.&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;i&gt;Honeycomb License&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 In March 2013, the Company entered into a license agreement with
 Koken Co., Ltd. (&amp;#x201C;Koken&amp;#x201D;) and paid a fee for a
 non-exclusive, non-transferable and non-sublicensable right to use
 its know-how related to the process for manufacturing atelocollagen
 honeycomb sponge materials, which is used in scaffolds (the
 &amp;#x201C;Honeycomb License Agreement&amp;#x201D;). Under the terms of the
 Honeycomb License Agreement, future commitments will be based on
 the amount of materials supplied to the Company and may vary from
 period to period over the term of the agreement.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 18pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 &lt;i&gt;Tissue Processor Sub-License&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 In December 2005, the Company entered into an exclusive agreement
 to sub-license certain technology from Purpose, Co.
 (&amp;#x201C;Purpose&amp;#x201D;), which is owned by a stockholder of the
 Company (&amp;#x201C;Sub-License Agreement&amp;#x201D;). Purpose entered into
 the original license agreement (&amp;#x201C;Original Agreement&amp;#x201D;)
 with Brigham and Women&amp;#x2019;s Hospital, Inc. (&amp;#x201C;Brigham and
 Women&amp;#x2019;s&amp;#x201D;) in August 2001. The Original Agreement shall
 remain in effect for the licensed patents owned by Brigham and
 Women&amp;#x2019;s unless extended or terminated as provided for in the
 agreement. The technology is to be used to develop, manufacture,
 use and sell licensed products that cultivate cell or tissue
 development. The Sub-License Agreement extends to the expiration
 date of the last to expire domestic or foreign patents covered by
 the agreement. As of December&amp;#xA0;31, 2016, the Company has paid
 an aggregate $1.0 million in royalty and sub-license payments under
 the terms of the Sub-License Agreement.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The Sub-License Agreement was amended and restated in June 2012.
 Under the amended and restated agreement, the Company made Purpose
 the sole supplier of equipment the Company uses in its
 manufacturing processes, and granted Purpose distribution rights of
 the Company&amp;#x2019;s products for certain territories. In exchange,
 Purpose allowed for the use of its technology (owned or licensed)
 and manufactured and serviced exogenous tissue processors used by
 the Company. Under the terms of the agreement, as amended, Purpose
 granted the Company:&amp;#xA0;(a)&amp;#xA0;exclusive rights to all of
 Purpose&amp;#x2019;s technology (owned or licensed) related to the
 exogenous tissue processors, (b)&amp;#xA0;continued supply of exogenous
 tissue processors during the Company&amp;#x2019;s clinical trials, and
 (c)&amp;#xA0;rights to manufacture the exogenous tissue processors at
 any location the Company chooses. In exchange for such
 consideration, the Company granted Purpose an exclusive license in
 Japan for the use of all of the Company&amp;#x2019;s technology and made
 a payment of $0.3 million to reimburse Purpose for development
 costs on a next generation tissue processor.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 In May 2016, the Original Agreement was amended whereby the Company
 acquired the development and commercialization rights to NeoCart
 for the Japanese market from Purpose. Under the terms of the
 amended agreement, the Company assumes sole responsibility for and
 rights to the development and commercialization of NeoCart in
 Japan. In exchange for the transfer of development and
 commercialization rights, the Company will pay a success-based
 milestone to Purpose upon conditional approval of NeoCart in Japan,
 as well as commercial milestones and a low single digit royalty on
 Japanese sales of NeoCart, upon full approval, if any, in Japan&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 In addition to the above, the Company&amp;#x2019;s future commitments
 under the terms of the Original Agreement and Sub-License Agreement
 include:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td width="5%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="2%" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td valign="top" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;A minimum non-refundable annual
 royalty fee of $20 thousand, for the life of the license;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td width="5%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="2%" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td valign="top" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;An additional, non-refundable annual
 royalty fee of $30 thousand from 2016 through 2019;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td width="5%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="2%" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td valign="top" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;$10.2 million in potential milestone
 payments; and&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td width="5%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="2%" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td valign="top" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;Low single digit royalties on net
 sales of a licensed product.&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;The OCS Agreement&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 In connection with its research and development, the Company
 received grants from the Office of Chief Scientist of the Ministry
 of Industry and Trade in Israel (&amp;#x201C;OCS&amp;#x201D;) in the
 aggregate of $1.1 million for funding the fibroblast growth factor
 (&amp;#x201C;FGF&amp;#x201D;) program. In consideration for this grant, the
 Company is committed to pay royalties at a rate of 3% to 5% of the
 sales of sponsored products developed using the grant money, up to
 the amount of the participation payments received. The Company
 committed to pay up to 100% of grants received plus interest
 according to the LIBOR interest rate if the sponsored product is
 produced in Israel. If the manufacturing of the sponsored product
 takes place outside of Israel, the royalties can increase up to,
 but no more than, 300% of grants received plus interest based on
 the LIBOR interest rate, depending on the percentage of the
 manufacturing of sponsored product that takes place outside of
 Israel.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;Engineering Agreement&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 The Company entered into an agreement with a development
 corporation to purchase a multi-unit bioreactor system. Pursuant to
 the agreement, as of December&amp;#xA0;31, 2016, the Company made total
 payments in an aggregate amount of $0.6 million of which $0.2
 million was made in 2016 after acceptance of the final product.
 There are no additional payments due under this agreement.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;Collagen Supply Agreement&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 In September 2015, the Company entered into an agreement with
 Collagen Solutions (UK) Limited (the &amp;#x201C;Supplier&amp;#x201D;) to
 purchase soluble collagen that meets specifications provided by the
 Company. The initial term of the agreement is three years and will
 automatically renew from year to year thereafter unless otherwise
 terminated with at least 180 days&amp;#x2019; notice by either party.
 Pursuant to the agreement, starting 12 months after entering into
 the agreement, the Company will be required to order a minimum
 amount of material and/or services totaling $0.2 million from the
 Supplier in each calendar year until the expiration of the initial
 term of the agreement. The Company also committed to pay a
 non-refundable payment totaling $0.1 million by the end of 2015.
 This expense was recorded to research and development expense as of
 December&amp;#xA0;31, 2015.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
  <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" unitRef="iso4217_USD" decimals="INF" id="id_11655837_C8097552-D5D9-4EC2-9311-100E7927E976_1_1">0</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
  <us-gaap:FairValueAdjustmentOfWarrants contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_AE354032-1B81-402C-BD47-3E1B7F0C0719_1_11">-17507000</us-gaap:FairValueAdjustmentOfWarrants>
  <us-gaap:EarningsPerShareTextBlock contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" id="id_11655837_F5529AB5-FECA-4C0B-ABEE-8F71E371AE6A_1_0">&lt;div&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="break-inside: avoid"&gt;
 &lt;td valign="top" width="4%" align="left"&gt;&lt;b&gt;3.&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;&lt;b&gt;LOSS PER COMMON SHARE&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 Basic and diluted loss per common share are calculated as
 follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="76%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;For the Year Ended&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;(In thousands,
 except share and&lt;br /&gt;
 per share data&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Numerator:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Net loss&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(16,208&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(32,024&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Net Loss attributable to Series A Preferred Stock (a)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(2,345&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Numerator for basic EPS&amp;#x2014;Earnings (loss) attributable to
 common stockholders&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(13,863&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(32,024&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Effect of dilutive securities:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Deduct change in fair value of warrant liability&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(17,507&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Numerator for diluted EPS&amp;#x2014;Earnings (loss) attributable to
 common stockholders after assumed conversions&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(31,370&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(32,024&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Denominator:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Weighted-average number of common shares used in earnings (loss)
 per&lt;br /&gt;
 share&amp;#x2014;basic&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;14,256,954&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;13,231,126&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Effect of dilutive securities:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Nonparticipating warrants&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;132,238&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Denominator for diluted EPS&amp;#x2014;adjusted weighted average
 shares&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;14,389,192&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;13,231,126&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Earnings (loss) per share&amp;#x2014;basic&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.97&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(2.42&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Earnings (loss) per share&amp;#x2014;diluted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(2.18&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(2.42&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="break-inside: avoid"&gt;
 &lt;td valign="top" width="4%" align="left"&gt;(a)&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;The Series A Preferred Stock
 participates in income and losses&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 The following potentially dilutive securities have been excluded
 from the computation of diluted weighted-average shares
 outstanding, as they would be anti-dilutive (in common stock
 equivalent shares):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="70%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;As of December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Unvested restricted stock and options to purchase common stock&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,578,905&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,227,957&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Series A preferred stock unconverted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,962,817&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Warrants exercisable into common stock&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;166,403&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;166,403&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;br class="Apple-interchange-newline" /&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
  <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" unitRef="pure" decimals="3" id="id_11655837_9FA36880-6F95-410B-BEC1-B0E0D4FEC8F9_1_7">0.000</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
  <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" id="id_11655837_1BFB5BF0-5515-4F7C-9529-58DAB37946C2_1_0">&lt;div&gt;
 &lt;table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" border="0" cellpadding="0" cellspacing="0" width="100%"&gt;
 &lt;tr style="page-break-inside:avoid"&gt;
 &lt;td width="4%" valign="top" align="left"&gt;&lt;b&gt;6.&lt;/b&gt;&lt;/td&gt;
 &lt;td align="left" valign="top"&gt;&lt;b&gt;ACCRUED EXPENSES&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 Accrued expenses consisted of the following:&lt;/p&gt;
 &lt;p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table cellspacing="0" cellpadding="0" width="76%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="76%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;As of
 December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;(in thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Accrued compensation&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,402&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;758&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Accrued clinical expenses&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;187&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;138&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Accrued other&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;508&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;548&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Total accrued expenses&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,097&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,444&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
  <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" unitRef="pure" decimals="3" id="id_11655837_9FA36880-6F95-410B-BEC1-B0E0D4FEC8F9_1_0">0.340</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
  <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" id="id_11655837_A756CFDF-9C4B-4982-8F99-CD919ABC4652_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;Financial Instruments Indexed to and Potentially Settled in the
 Company&amp;#x2019;s Common Stock&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 The Company evaluates all financial instruments issued in
 connection with its equity offerings when determining the proper
 accounting treatment for such instruments in the Company&amp;#x2019;s
 financial statements. The Company considers a number of generally
 accepted accounting principles under U.S. GAAP to determine such
 treatment and evaluates the features of the instrument to determine
 the appropriate accounting treatment. The Company utilizes the
 Probability Weighted Expected Return Method (&amp;#x201C;PWERM&amp;#x201D;),
 Option Pricing Model (&amp;#x201C;OM&amp;#x201D;) or other appropriate
 methods to determine the fair value of its derivative financial
 instruments. For financial instruments indexed to and potentially
 settled in the Company&amp;#x2019;s common stock that are determined to
 be classified as liabilities on the consolidated balance sheet,
 changes in fair value are recorded as a gain or loss in the
 Company&amp;#x2019;s consolidated statement of operations with the
 corresponding amount recorded as an adjustment to the liability on
 its consolidated balance sheet.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
  <us-gaap:SalesRevenueNet contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_AE354032-1B81-402C-BD47-3E1B7F0C0719_1_0">0</us-gaap:SalesRevenueNet>
  <us-gaap:IncomeTaxExaminationDescription contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" id="id_11655837_A79DB659-8B27-4A30-9A9C-35C1D5680E0D_1_3">The  Company is subject to U.S. federal, state and local income tax examinations by  tax authorities for years 2001 through present. Carryforward attributes that  were generated in earlier periods remain subject to examination to the extent  the year in which they were used or will be used remains open for examination.  The tax years which remain subject to examination by tax authorities in Israel,  as of December 31, 2016, include years 2013 through the present.</us-gaap:IncomeTaxExaminationDescription>
  <us-gaap:OperatingLeasesRentExpenseNet contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" unitRef="iso4217_USD" decimals="-5" id="id_11655837_D295318A-25D1-40B3-8E85-9F84BBB46A8F_1_0">1000000</us-gaap:OperatingLeasesRentExpenseNet>
  <us-gaap:NonoperatingIncomeExpense contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_AE354032-1B81-402C-BD47-3E1B7F0C0719_1_12">14099000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_AE354032-1B81-402C-BD47-3E1B7F0C0719_1_9">-248000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" id="id_11655837_BA7EA224-C6F3-4A3B-87A4-996F82564220_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 The fair value of the warrants was determined using a Monte Carlo
 simulation model.&amp;#xA0;This model incorporated several assumptions
 at each valuation date including: the price of the Company&amp;#x2019;s
 common stock on the date of valuation, the historical volatility of
 the price of the Company&amp;#x2019;s common stock, the remaining
 contractual term of the warrant and estimates of the probability of
 a fundamental transaction occurring. See Note 8, Capital Stock, for
 further discussion of the private placement.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="46%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WIDTH: 39.5pt; BORDER-BOTTOM: rgb(0,0,0) 1pt solid; MARGIN-TOP: 0pt"&gt;
 &lt;b&gt;Description&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Quoted&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;prices in&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;active&amp;#xA0;markets&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;(Level 1)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Significant&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;other&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;observable&amp;#xA0;inputs&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;(Level 2)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Significant&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;unobservable&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;inputs&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;(Level 3)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="14" align="center"&gt;&lt;b&gt;(in
 thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 &lt;b&gt;December&amp;#xA0;31, 2016&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 &lt;b&gt;Assets:&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Money market funds&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;30,318&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;30,318&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 &lt;b&gt;Liabilities:&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Warrant liability&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;13,197&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;13,197&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 &lt;b&gt;December&amp;#xA0;31, 2015&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Money market funds&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;25,764&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;25,764&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
  <us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_F517A3E7-CD09-482E-A458-78C5E43ED953_1_13">131000</us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties>
  <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_F517A3E7-CD09-482E-A458-78C5E43ED953_1_14">653000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
  <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" id="id_11655837_95E651E8-E58E-4F64-8987-37D2B80F497E_1_0">&lt;div&gt;
 &lt;p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 &lt;b&gt;5. PROPERTY AND EQUIPMENT&lt;/b&gt;&lt;/p&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 Property and equipment consisted of the following:&lt;/p&gt;
 &lt;p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table cellspacing="0" cellpadding="0" width="76%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="65%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="12%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="11%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;br /&gt;
 2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;br /&gt;
 2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;(in
 thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Office equipment&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;266&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;539&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Laboratory equipment&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,443&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,337&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Leasehold improvements&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7,683&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7,683&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Construction in progress&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;759&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;547&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Software&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;96&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;96&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Total property and equipment&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;13,247&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;13,202&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Less: accumulated depreciation&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(9,387&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(7,989&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Property and equipment, net&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,860&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,213&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 Depreciation expense related to property and equipment amounted to
 $1.7 million and $1.6 million for the years ended December&amp;#xA0;31,
 2016 and 2015, respectively.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
  <us-gaap:IncomeTaxDisclosureTextBlock contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" id="id_11655837_BA161D79-910B-4DB9-8268-0770B4C61A78_1_0">&lt;div&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="break-inside: avoid"&gt;
 &lt;td valign="top" width="4%" align="left"&gt;&lt;b&gt;12.&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;&lt;b&gt;INCOME TAXES&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 For the years ended December&amp;#xA0;31, 2016 and 2015, the Company
 did not record a current or deferred income tax expense or benefit
 due to current and historical losses incurred by the Company.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 The components of loss before income taxes were as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="71%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;As of December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;(in
 thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 U.S.&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(15,838&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(31,382&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Foreign&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(369&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(691&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Total&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(16,208&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(32,073&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 A reconciliation of income tax expense (benefit) computed at the
 statutory federal income tax rate to income taxes as reflected in
 the financial statements is as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="79%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"&gt;
 &lt;b&gt;As&amp;#xA0;of&amp;#xA0;December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Federal income tax (benefit) at statutory rate&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;34.0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;34.0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 (Increase) decrease income tax benefit resulting from:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Permanent differences&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;29.0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(1.2&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Net Operating Loss Limitation&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(111.1&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 R&amp;amp;D Credit Limitation&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(1.5&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Change in valuation allowance&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;48.7&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(31.7&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Other&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.9&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(1.2&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Income tax expense (benefit)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 Deferred taxes are recognized for temporary differences between the
 basis of assets and liabilities for financial statement and income
 tax purposes. The significant components of the Company&amp;#x2019;s
 deferred tax assets and liabilities are comprised of the
 following:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="71%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;As of December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Deferred tax assets:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Net operating loss carryforwards&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;16,146&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;28,200&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Depreciation and amortization&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,229&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,688&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Accrued expenses&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,082&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,183&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Capitalized start-up costs&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10,037&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8,531&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Other&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;75&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;259&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Deferred tax assets before valuation allowance&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;34,569&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;44,861&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Valuation allowance&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(34,569&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(43,751&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,110&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Deferred tax liabilities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 IPR&amp;amp;D&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(36&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Change in accounting method&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(1,074&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(1,110&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Net deferred tax assets&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 The Company has evaluated the positive and negative evidence
 bearing upon the realizability of its deferred tax assets. As of
 December&amp;#xA0;31, 2016 and 2015, based on the Company&amp;#x2019;s
 history of operating losses, the Company has concluded that it is
 not more likely than not that the benefit of its deferred tax
 assets will be realized. Accordingly, the Company has provided a
 full valuation allowance for deferred tax assets as of
 December&amp;#xA0;31, 2016 and 2015. The valuation allowance decreased
 $9.2 million during the year ended December&amp;#xA0;31, 2016, due
 primarily to a reduction of net operating losses generated. The
 valuation allowance increased by $11.8 million during the year
 ended December&amp;#xA0;31, 2015, due primarily to net operating losses
 generated and capitalized expenses. In addition, the reduction in
 net operating losses were related to Section 382 limits as a result
 in a change in ownership.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 During November 2015, the FASB issued ASU 2015-17, &amp;#x201C;Balance
 Sheet Classification of Deferred Taxes&amp;#x201D;, which simplifies the
 presentation of deferred income taxes. This ASU requires that
 deferred tax assets and liabilities be classified as non-current in
 a statement of financial position. We early adopted ASU 2015-17
 effective December&amp;#xA0;31, 2015 on a prospective basis. Adoption
 of this ASU resulted in the removal of gross deferred tax assets
 and liabilities from the Company&amp;#x2019;s Consolidated Balance Sheet
 at December&amp;#xA0;31, 2015. The impact was zero. No prior periods
 were retrospectively adjusted. As of December&amp;#xA0;31, 2016 and
 2015, the Company had U.S. federal NOL carryforwards of $24.5
 million, and $55.5 million, respectively, which may be available to
 offset future income tax liabilities and expire at various dates
 through 2036. As of December&amp;#xA0;31, 2016 and 2015, the Company
 also had U.S. state NOL carryforwards of $24.3 million and $55.4
 million, respectively, which may be available to offset future
 income tax liabilities and expire at various dates through 2036. At
 December&amp;#xA0;31, 2016 and 2015, the Company also had $26.1 million
 and $25.6 million, respectively, of foreign NOL carryforwards which
 may be available to offset future income tax liabilities, which
 carryforwards do not expire.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 Utilization of the NOL and research and development credit
 carryforwards may be subject to a substantial annual limitation due
 to ownership change limitations that have occurred or that could
 occur in the future, as required by Section&amp;#xA0;382 and
 Section&amp;#xA0;383 of the Code, as well as similar state and foreign
 provisions. These ownership changes may limit the amount of NOL and
 research and development credit carryforwards that can be utilized
 annually to offset future taxable income and tax, respectively. In
 general, an &amp;#x201C;ownership change&amp;#x201D; as defined by
 Section&amp;#xA0;382 of the Code results from a transaction or series
 of transactions over a three-year period resulting in an ownership
 change of more than 50 percentage points of the outstanding stock
 of a company by certain stockholders. The Company has completed a
 study to assess whether an ownership change has occurred or whether
 there have been multiple ownership changes since its formation. The
 results of this study indicated we experienced ownership changes,
 as defined by Section&amp;#xA0;382 of the Code, in each of 2006, 2011,
 2012, 2013, and 2016. The Company has not recorded NOLs that, as a
 result of these restrictions, will expire unused. The limitations
 were approximately $47.1 million in 2015 and $100.1 million in
 2016.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 The changes in the Company&amp;#x2019;s unrecognized tax benefits are
 summarized as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="79%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"&gt;
 &lt;b&gt;As&amp;#xA0;of&amp;#xA0;December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;(in
 thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Unrecognized tax benefit, beginning of year&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;687&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;811&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Increase (decrease) related to current year positions&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(125&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(124&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Settlements&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Unrecognized tax benefit, end of year&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;562&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;687&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 As of December&amp;#xA0;31, 2016 and 2015, the total amount of
 unrecognized tax benefits was $0.6 million and $0.7 million,
 respectively which, if recognized, would favorably affect the
 effective income tax rate in future periods. Note that liabilities
 for unrecognized tax benefits have been recorded to the extent that
 they do not exceed the Company&amp;#x2019;s available losses that are
 not limited as a result of ownership changes that have occurred
 under Section&amp;#xA0;382 of the Code. Reductions to unrecognized tax
 benefits for limitations on the utilization of net operating losses
 due to ownership changes occurring during the year has been
 reflected in the table as reductions based on tax positions related
 to the current year. Histogenics accrues interest and penalties
 related to unrecognized tax benefits as a component of its
 provision for income taxes. No accrued interest and penalties
 related to the Company&amp;#x2019;s unrecognized tax benefits has been
 accrued as of December&amp;#xA0;31, 2016 and 2015. The Company believes
 that it is reasonably possible that none of its unrecognized tax
 benefits, may be recognized at the end of 2016. The Company or one
 of its subsidiaries files income tax returns in the United States
 and various states and Israel. The Company is subject to U.S.
 federal, state and local income tax examinations by tax authorities
 for years 2001 through present. Carryforward attributes that were
 generated in earlier periods remain subject to examination to the
 extent the year in which they were used or will be used remains
 open for examination. The tax years which remain subject to
 examination by tax authorities in Israel, as of December&amp;#xA0;31,
 2016, include years 2013 through the present.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
  <us-gaap:OperatingExpenses contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_AE354032-1B81-402C-BD47-3E1B7F0C0719_1_5">30307000</us-gaap:OperatingExpenses>
  <us-gaap:NetIncomeLoss contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_AE354032-1B81-402C-BD47-3E1B7F0C0719_1_13">-16208000</us-gaap:NetIncomeLoss>
  <us-gaap:InterestExpense contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_AE354032-1B81-402C-BD47-3E1B7F0C0719_1_8">60000</us-gaap:InterestExpense>
  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_F517A3E7-CD09-482E-A458-78C5E43ED953_1_18">-320000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
  <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" id="id_11655837_2DCB64D4-91E4-4A98-80DF-30900CE471B1_1_0">&lt;div&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 Property and equipment consisted of the following:&lt;/p&gt;
 &lt;p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table cellspacing="0" cellpadding="0" width="76%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="65%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="12%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="11%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;br /&gt;
 2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;br /&gt;
 2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;(in
 thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Office equipment&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;266&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;539&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Laboratory equipment&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,443&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,337&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Leasehold improvements&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7,683&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7,683&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Construction in progress&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;759&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;547&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Software&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;96&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;96&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Total property and equipment&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;13,247&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;13,202&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Less: accumulated depreciation&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(9,387&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(7,989&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Property and equipment, net&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,860&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,213&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
  <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_AE354032-1B81-402C-BD47-3E1B7F0C0719_1_4">200000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
  <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" id="id_11655837_706A0BFB-DE1D-483F-A050-12CC32CD577D_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;Impairment of Long-Lived Assets&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 Long-lived assets consist primarily of property and equipment and
 identifiable intangible assets. When impairment indicators exist,
 the Company&amp;#x2019;s management evaluates long-lived assets for
 potential impairment. An impairment loss is recorded if and when
 events and circumstances indicate that assets might be impaired and
 the undiscounted cash flows estimated to be generated by those
 assets are less than the carrying amount of those assets. While the
 Company&amp;#x2019;s current and historical operating losses and
 negative cash flows are indicators of impairment, management
 believes that future cash flows to be received support the carrying
 value of its long-lived assets.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 Impairments, if any, are recognized in earnings. An impairment loss
 would be recognized in an amount equal to the excess of the
 carrying amount over the undiscounted expected future cash
 flows.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_81818110-2900-437E-A31B-B07988C5A518_1_0">-15838000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_81818110-2900-437E-A31B-B07988C5A518_1_1">-369000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_AE354032-1B81-402C-BD47-3E1B7F0C0719_1_15">-31370000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
  <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_F517A3E7-CD09-482E-A458-78C5E43ED953_1_12">-435000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_F517A3E7-CD09-482E-A458-78C5E43ED953_1_10">-148000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:PriorPeriodReclassificationAdjustmentDescription contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" id="id_11655837_BD6CBD9A-E6DA-4A42-B774-BDE040CBB8CD_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;Reclassifications&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 The Company has reclassified certain prior period amounts to
 conform to the current period presentation. The amounts
 reclassified impact Accounts Payable and Accounts Payable due to
 Intrexon Corporation (&amp;#x201C;Intrexon&amp;#x201D;) for the year ended
 December&amp;#xA0;31, 2015.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_AE354032-1B81-402C-BD47-3E1B7F0C0719_1_14">-13863000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" id="id_11655837_C6607561-3673-482F-9202-BD3FB43E86BE_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &lt;b&gt;Recently Adopted Accounting Pronouncements&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 In November 2015, Financial Accounting Standards Board (&amp;#x201C;the
 FASB&amp;#x201D;) issued Accounting Standard Update (&amp;#x201C;ASU&amp;#x201D;)
 No.&amp;#xA0;2015-17, Income Taxes (Topic 740): Balance Sheet
 Classification of Deferred Taxes. The new standard requires that
 deferred tax assets and liabilities be classified as noncurrent in
 a classified statement of financial position. The Company
 prospectively adopted this guidance in the fourth quarter of 2015,
 which resulted in the removal of gross deferred tax assets and
 liabilities from the Company&amp;#x2019;s consolidated balance sheet.
 The net impact was zero and the prior period was not
 retrospectively adjusted.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 In November 2014, the FASB issued ASU No.&amp;#xA0;2014-16, Derivatives
 and Hedging (Topic 815): Determining Whether the Host Contract in a
 Hybrid Financial Instrument Issued in the Form of a Share Is More
 Akin to Debt or to Equity. This standard provides guidance to
 eliminate the existing diversity in practice in accounting for
 hybrid financial instruments issued in the form of a share. A
 hybrid financial instrument consists of a &amp;#x201C;host
 contract&amp;#x201D; into which one or more derivative terms have been
 embedded. This guidance requires an entity to consider the terms
 and features of the entire financial instrument, including the
 embedded derivative features, in order to determine whether the
 nature of the host contract is more akin to debt or to equity. This
 guidance is effective for fiscal years and interim periods
 beginning after December&amp;#xA0;15, 2015, with early adoption
 permitted. A reporting entity should apply this guidance using a
 modified retrospective approach by recording a cumulative-effect
 adjustment to equity as of the beginning of the annual period of
 adoption. Retrospective application is permitted to all relevant
 prior periods. The Company has concluded that this guidance has no
 impact on the presentation of its results of operations, financial
 position and disclosures.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 In August 2014, the FASB issued ASU No.&amp;#xA0;2014-15, Presentation
 of Financial Statements&amp;#x2014;Going Concern (Subtopic 2015-40):
 Disclosure of Uncertainties about an Entity&amp;#x2019;s Ability to
 Continue as a Going Concern. This guidance addresses
 management&amp;#x2019;s responsibility in evaluating whether there is
 substantial doubt about a company&amp;#x2019;s ability to continue as a
 going concern and to provide related footnote disclosures. The
 guidance is effective for fiscal years ending after
 December&amp;#xA0;15, 2016 and for interim periods within those fiscal
 years. The adoption of this standard did not have a material impact
 on our consolidated financial statements and related
 disclosures.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 In June 2014, the FASB issued ASU No.&amp;#xA0;2014-12,
 Compensation-Stock Compensation (Topic 718): Accounting for
 Share-Based Payments When the Terms of an Award Provide That a
 Performance Target Could be Achieved after the Requisite Service
 Period. This standard provides guidance requiring when there is a
 performance target that affects vesting of equity awards granted
 and could be achieved after the requisite service period to be
 treated as a performance condition. A reporting entity should apply
 existing guidance on stock-based compensation, as it relates to
 such awards. This guidance is effective for annual periods and
 interim periods within those annual periods beginning after
 December&amp;#xA0;15, 2015 with early adoption permitted using either
 of two methods: (i)&amp;#xA0;prospective to all awards granted or
 modified after the effective date; or (ii)&amp;#xA0;retrospective to
 all awards with performance targets that are outstanding as of the
 beginning of the earliest annual period presented in the financial
 statements and to all new or modified awards thereafter, with the
 cumulative effect of applying this guidance as an adjustment to the
 opening retained earnings balance as of the beginning of the
 earliest annual period presented in the financial statements. The
 Company issued performance-based awards during the year ended
 December&amp;#xA0;31, 2015. The Company adopted this guidance on a
 prospective basis and there have not been any performance-based
 awards since the effective date of the guidance.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &lt;b&gt;Recently Issued Accounting Pronouncements&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 In November 2016, the FASB issued guidance that requires restricted
 cash and restricted cash equivalents be included with cash and cash
 equivalents when reconciling the total beginning and ending amounts
 for the periods shown on the statement of cash flows. The new
 standard is effective for us on January&amp;#xA0;1, 2018 using a
 retrospective transition method to each period presented. Early
 adoption is permitted. We are currently evaluating the timing of
 our adoption and the expected impact that this standard could have
 on our consolidated financial statements and related
 disclosures.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 In March 2016, the FASB issued ASU No.&amp;#xA0;2016-09,
 Compensation-Stock Compensation (Topic 718): Improvements to
 Employee Shared-Based Payment Accounting. This standard provides
 guidance on accounting for employee share-based payments. This
 guidance addresses several aspects of the accounting for
 share-based payment award transactions, including: (a)&amp;#xA0;income
 tax consequences; (b)&amp;#xA0;classification of awards as either
 equity or liabilities; and (c)&amp;#xA0;classification on the statement
 of cash flows.&amp;#xA0;This standard will be effective for fiscal
 years beginning after December&amp;#xA0;15, 2016, including interim
 periods within those fiscal years.&amp;#xA0;The Company is evaluating
 the impact of this guidance on the presentation of its results of
 operations, financial position and disclosures.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 In February 2016, the FASB, issued ASU
 No.&amp;#xA0;2016-02,&amp;#xA0;&lt;i&gt;Leases
 (Topic 842)&lt;/i&gt;. The ASU requires companies to recognize on the
 balance sheet the assets and liabilities for the rights and
 obligations created by leased assets. ASU 2016-02 will be effective
 for the Company in the first quarter of 2019, with early adoption
 permitted. The Company is currently evaluating the impact that the
 adoption of ASU 2016-02 will have on the Company&amp;#x2019;s
 consolidated financial statements or related disclosures.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 In May 2014, the FASB issued ASU No.&amp;#xA0;2014-09, Revenue from
 Contracts with Customers (Topic 606), which requires an entity to
 recognize the amount of revenue to which it expects to be entitled
 for the transfer of promised goods or services to customers. ASU
 2014- 09 will replace most existing revenue recognition guidance in
 U.S. GAAP when it becomes effective. In July 2015, the FASB issued
 a one-year deferral of the effective date of the new revenue
 recognition standard. The new guidance will be effective for the
 Company&amp;#x2019;s first quarter of fiscal year 2018 and early
 application for fiscal year 2017 would be permitted. The Company is
 evaluating the impact of this guidance on the presentation of its
 results of operations, financial position and disclosures.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_AE354032-1B81-402C-BD47-3E1B7F0C0719_1_6">-30307000</us-gaap:OperatingIncomeLoss>
  <us-gaap:ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_F517A3E7-CD09-482E-A458-78C5E43ED953_1_20">27630000</us-gaap:ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants>
  <us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" id="id_11655837_3E9DD967-0841-4237-816A-D373D345C9FD_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 Restricted stock awards under the 2012 and 2013 plans are
 summarized as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="64%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="13%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="12%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Number&amp;#xA0;of&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Shares&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Weighted&amp;#xA0;Average&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Grant Date&amp;#xA0;Fair&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Value&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Unvested at December&amp;#xA0;31, 2015&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,190&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.07&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Vesting of restricted stock&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(3,301&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Unvested at December&amp;#xA0;31, 2016&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,889&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.83&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock>
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_F517A3E7-CD09-482E-A458-78C5E43ED953_1_25">27049000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <us-gaap:IncomeTaxesPaidNet contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_F517A3E7-CD09-482E-A458-78C5E43ED953_1_32">257000</us-gaap:IncomeTaxesPaidNet>
  <us-gaap:IncreaseDecreaseInDueToRelatedPartiesCurrent contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_F517A3E7-CD09-482E-A458-78C5E43ED953_1_11">1494000</us-gaap:IncreaseDecreaseInDueToRelatedPartiesCurrent>
  <us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" id="id_11655837_29303A15-8B4E-4652-8483-0C57EB7AD956_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 Information about the Company&amp;#x2019;s operations in different
 geographic regions is presented in the tables below:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="66%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="11%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="11%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;br /&gt;
 2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;br /&gt;
 2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;(in
 thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Long-lived assets:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 United States&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,860&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,204&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Israel&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;9&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Total long-lived assets&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,860&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,213&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock>
  <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" id="id_11655837_88C8F2AD-90DD-4E93-8E9B-D4044135D622_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 The changes in the Company&amp;#x2019;s unrecognized tax benefits are
 summarized as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="79%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;
 &lt;b&gt;As&amp;#xA0;of&amp;#xA0;December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;(in
 thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Unrecognized tax benefit, beginning of year&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;687&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;811&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Increase (decrease) related to current year positions&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(125&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(124&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Settlements&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Unrecognized tax benefit, end of year&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;562&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;687&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
  <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_5A0DEAA9-8FA8-403D-B739-D326D818EDBC_7007_18">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
  <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" unitRef="iso4217_USD" decimals="-5" id="id_11655837_D61785A9-8599-4860-92E7-B7BD0AD08130_1_0">-9200000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
  <us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" unitRef="shares" decimals="INF" id="id_11655837_9676DC27-A3EF-4B08-B121-A6B6911EBC2F_1_10">132238</us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_81818110-2900-437E-A31B-B07988C5A518_1_2">-16208000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
  <us-gaap:NatureOfOperations contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" id="id_11655837_FA3C031E-CA38-4177-B56F-2F58CE58A512_1_0">&lt;div&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="break-inside: avoid"&gt;
 &lt;td valign="top" width="4%" align="left"&gt;&lt;b&gt;1.&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;&lt;b&gt;NATURE OF BUSINESS&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="break-inside: avoid"&gt;
 &lt;td valign="top" width="4%" align="left"&gt;&lt;b&gt;Organization&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 Histogenics Corporation (the &amp;#x201C;Company&amp;#x201D;) was
 incorporated under the laws of the Commonwealth of Massachusetts on
 June&amp;#xA0;28, 2000 and has its principal operations in Waltham,
 Massachusetts. In 2006, the Company&amp;#x2019;s board of directors
 approved a corporate reorganization pursuant to which the Company
 incorporated as a Delaware corporation. The Company is a
 regenerative medicine company engaged in developing and
 commercializing products in the musculoskeletal segment of the
 marketplace. The Company combines cell therapy and tissue
 engineering technologies to develop products for tissue repair and
 regeneration and is initially focused on patients suffering from
 cartilage-derived pain and immobility. The Company&amp;#x2019;s most
 advanced product, NeoCart, is currently in a Phase 3 clinical trial
 in the United States (the &amp;#x201C;U.S.&amp;#x201D;) under a special
 protocol assessment with the U.S. Food and Drug Administration
 (&amp;#x201C;FDA&amp;#x201D;) for the treatment of knee cartilage damage.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 On May&amp;#xA0;13, 2011, the Company completed the acquisition of
 ProChon Biotech Ltd. (&amp;#x201C;ProChon&amp;#x201D;), a privately-held
 biotechnology company focused on modulating the fibroblast growth
 factor system for consideration of $2.2 million to enable it to
 create more effective solutions for tissue regeneration.
 ProChon&amp;#x2019;s products combine cell regeneration technologies
 with proprietary growth factors and biocompatible scaffolds to
 restore injured or chronically damaged tissues. The acquisition of
 ProChon provided the Company with access to a significant portfolio
 of intellectual property, including proprietary cell growth
 factors, in addition to furthering opportunities for the use of
 biomaterials to create more effective solutions for regenerating
 human tissue. The acquisition led to the initial recognition of
 goodwill, which was subsequently written off in 2011, and
 intangible assets including IPR&amp;amp;D and a licensing agreement
 which have been impaired as discussed in Note 2.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 On December&amp;#xA0;18, 2014, the Company formed a wholly owned
 subsidiary, Histogenics Securities Corporation, under the laws of
 the Commonwealth of Massachusetts.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 On September&amp;#xA0;29, 2016, the Company closed a private placement
 of common stock, preferred stock and warrants, contemplated by a
 securities purchase agreement dated September&amp;#xA0;15, 2016, with
 certain institutional and accredited investors. The net proceeds
 after deducting placement agent fees and other transaction-related
 expenses was $27.6 million. See Note 8, Capital Stock, for further
 discussion of the private placement.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 Since its inception, the Company has devoted substantially all of
 its efforts to product development, recruiting management and
 technical staff, raising capital, starting up production and
 building infrastructure and has not yet generated revenues from its
 planned principal operations. Expenses have primarily been for
 research and development and related administrative costs.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 The Company is subject to a number of risks. The developmental
 nature of its activities is such that significant inherent risks
 exist in the Company&amp;#x2019;s operations. Principal among these
 risks are the successful development of therapeutics, successfully
 enrolling patients in its clinical trials in a timely manner,
 obtaining regulatory approval for any of its product candidates in
 any jurisdiction, compliance with government regulations, ability
 to obtain adequate financing, protection of proprietary
 therapeutics, fluctuations in operating results, dependence on key
 personnel and collaborative partners, adoption of the
 Company&amp;#x2019;s products by the physician community, rapid
 technological changes inherent in the markets targeted, and
 substitute products and competition from larger companies.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;

 The consolidated financial statements have been prepared on a
 going-concern basis, which contemplates the realization of assets
 and the satisfaction of liabilities in the normal course of
 business. As shown in the accompanying consolidated financial
 statements, the Company has incurred losses and cash flow deficits
 from operations for the years ended December&amp;#xA0;31, 2016 and
 2015. The Company has financed operations to date primarily through
 private placements of equity securities, including the sale of
 common stock and preferred stock, and the related issuance of
 warrants in September 2016, the issuance of common stock in the
 initial public offering completed in December 2014, and borrowings
 under debt agreements. The Company has incurred losses and negative
 cash flows from operations since inception resulting in an
 accumulated deficit at December&amp;#xA0;31, 2016 of $181.8 million.
 The Company anticipates that it will continue to incur net losses
 for the next several years. The Company believes that its existing
 cash and cash equivalents will be sufficient to fund its projected
 cash needs into the middle of 2018, and it has the ability to
 reduce or defer operating expenses as may be needed to fund its
 operations into the middle of the third quarter of 2018. The
 Company will require additional capital to complete the filing of a
 biologics license application with the FDA and commercialize
 NeoCart, if approved, and for the future development of its
 existing product candidates. However, the terms of such financing
 may not be on favorable terms or available to the
 Company.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &lt;b&gt;Initial public offering&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 On December&amp;#xA0;3, 2014, the Company completed its initial public
 offering (&amp;#x201C;IPO&amp;#x201D;) whereby the Company sold 5,909,091
 shares of common stock at a price of $11.00 per share. The shares
 began trading on the Nasdaq Global Market on December&amp;#xA0;3, 2014.
 Gross proceeds from the offering were $65 million. In January 2015,
 the underwriters exercised a portion of their overallotment option
 and purchased an additional 465,000 shares of the Company&amp;#x2019;s
 common stock at $11.00 per share, resulting in an additional $5.1
 million in gross proceeds. After giving effect to underwriting
 discounts and commissions and offering expenses payable by the
 Company, net proceeds were $61.3 million.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 18pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/div&gt;</us-gaap:NatureOfOperations>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_F517A3E7-CD09-482E-A458-78C5E43ED953_1_15">-25736000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:IncomeTaxPolicyTextBlock contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" id="id_11655837_18D2DB6A-CB54-40FC-8092-301272D4BAFA_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;Income Taxes&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 The Company accounts for income taxes under the liability method,
 which requires the recognition of deferred tax assets and
 liabilities for the expected future tax consequences of events that
 have been included in the financial statements. Under this method,
 deferred tax assets and liabilities are determined on the basis of
 the differences between the financial statements and tax basis of
 assets and liabilities using enacted tax rates in effect for the
 year in which the differences are expected to reverse. The effect
 of a change in tax rates on deferred tax assets and liabilities is
 recognized in income in the period that includes the enactment
 date.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The Company recognizes net deferred tax assets to the extent that
 the Company believes these assets are more likely than not to be
 realized. In making such a determination, management considers all
 available positive and negative evidence, including future
 reversals of existing taxable temporary differences, projected
 future taxable income, tax-planning strategies, and results of
 recent operations. If management determines that the Company would
 be able to realize its deferred tax assets in the future, in excess
 of its net recorded amount, management would make an adjustment to
 the deferred tax asset valuation allowance, which would reduce the
 provision for income taxes.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The Company records uncertain tax positions on the basis of a
 two-step process whereby (1)&amp;#xA0;management determines whether it
 is more likely than not that the tax positions will be sustained on
 the basis of the technical merits of the position and (2)&amp;#xA0;for
 those tax positions that meet the more likely than not recognition
 threshold, management recognizes the largest amount of tax benefit
 that is more than 50 percent likely to be realized upon ultimate
 settlement with the related tax authority. The Company recognizes
 interest and penalties related to unrecognized tax benefits within
 income tax expense. Any accrued interest and penalties are included
 within the related tax liability.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
  <us-gaap:NumberOfReportableSegments contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" unitRef="Segment" decimals="INF" id="id_11655837_AD19A7AC-7698-44D4-BA28-6830C9FF8D34_1_1">1</us-gaap:NumberOfReportableSegments>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_F517A3E7-CD09-482E-A458-78C5E43ED953_1_17">320000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:RepaymentsOfDebt contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_F517A3E7-CD09-482E-A458-78C5E43ED953_1_23">583000</us-gaap:RepaymentsOfDebt>
  <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" id="id_11655837_2A4489BB-8832-48CE-A1D4-F0935BCFD5DA_1_0">&lt;div&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="break-inside: avoid"&gt;
 &lt;td valign="top" width="4%" align="left"&gt;&lt;b&gt;8.&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;&lt;b&gt;CAPITAL STOCK&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 On September&amp;#xA0;29, 2016, the Company closed the private
 placement contemplated by the securities purchase agreement (the
 &amp;#x201C;Purchase Agreement&amp;#x201D;), dated September&amp;#xA0;15, 2016,
 between the Company and certain institutional and accredited
 investors in which the Company received gross proceeds of $30.0
 million (the &amp;#x201C;Private Placement&amp;#x201D;). The net proceeds
 after deducting placement agent fees and other transaction-related
 expenses was $27.6 million. At the closing, the Company issued
 2,596,059 shares of the Company&amp;#x2019;s common stock at a per share
 price of $2.25 and 24,158.8693 shares of the Company&amp;#x2019;s
 newly-created Series A Convertible Preferred Stock (&amp;#x201C;Series A
 Preferred Stock&amp;#x201D;), which are convertible into approximately
 10,737,275 shares of common stock. As part of the Private
 Placement, the investors received warrants to purchase up to
 13,333,334 shares of the Company&amp;#x2019;s common stock at an
 exercise price of $2.25 per share.&amp;#xA0;The placement agent for the
 Private Placement, H.C. Wainwright&amp;#xA0;&amp;amp; Co. LLC
 (&amp;#x201C;HCW&amp;#x201D;), and certain of its affiliates were also
 granted warrants to purchase 133,333 shares of the Company&amp;#x2019;s
 common stock at an exercise price of $2.25 per share in exchange
 for the services provided by HCW. The placement agent warrants were
 considered a financing cost of the Company and included in warrant
 expense within the consolidated statements of operations.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 The warrants include a cashless-exercise feature that may be
 exercised solely in the event there is no effective registration
 statement, or no current prospectus available for, the resale of
 the shares of common stock underlying the warrants as of the
 six-month anniversary of the closing of the Private Placement. Upon
 a fundamental transaction, the holders of the warrant may require
 the Company to purchase any unexercised warrants in an amount equal
 to the Black-Scholes value of the option. A fundamental transaction
 is defined as a merger, sale of assets, sale of the Company,
 recapitalization of stock and a sale of stock whereby any owner
 after the transaction would own greater than 50% of the outstanding
 common stock in the Company. The warrants became exercisable
 following approval of the Private Placement by our stockholders in
 the fourth quarter of 2016 and expire five years after the date of
 such stockholder approval.&amp;#xA0;The Company determined the warrants
 are classified as a liability on the consolidated balance sheet
 because they contain a provision whereby in a fundamental
 transaction (as described above), the holder can elect to receive
 either the amount they are entitled to on an as-if-exercised basis
 or an amount based on the Black-Scholes value of the warrants at
 the time of the fundamental transaction.&amp;#xA0;At the issuance date,
 the warrants were recorded at the fair value of $30.7 million and
 approximately $0.4 million excess of the fair value of the
 liability recorded for these warrants over the proceeds received
 was recorded as a charge to earnings in the third quarter of 2016
 and is included in warrant expense within the consolidated
 statement of operations. In connection with the Private Placement,
 the Company incurred expenses of $3.1 million in warrant expense
 within the consolidated statements of operations.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 Concurrent with the closing of the Private Placement, the
 Company&amp;#x2019;s&amp;#xA0;Certificate of Incorporation was amended by
 the filing of a Certificate of Designation to create the Series A
 Preferred Stock.&amp;#xA0;The Series A Preferred Stock has a par value
 of $0.01 and each share is convertible into 444.44 shares of common
 stock, at a conversion price of $2.25 per share, at the option of
 the holder.&amp;#xA0;The Series A Preferred Stock has no voting rights
 and is only entitled to dividends as declared on an as-converted
 basis.&amp;#xA0;The Series A Preferred Stock contains no liquidation
 preferences or redemption rights and shares in distributions of the
 Company on an as-converted basis with the common stock.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 As part of the Private Placement, affiliates of certain members of
 the Company&amp;#x2019;s Board of Directors purchased an aggregate of
 283,046 shares of common stock, an aggregate of 2,563.1439 shares
 of Series A Preferred Stock and received warrants to purchase up to
 1,422,221 shares of common stock at an exercise price of $2.25 per
 share in the Private Placement.&amp;#xA0;These amounts are included in
 the amounts noted above.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &lt;b&gt;Common Stock-100,000,000 shares authorized&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 The holders of shares of common stock are entitled to one vote per
 share. The holders of shares of common stock are not entitled to
 receive dividends, unless declared by the Company&amp;#x2019;s board of
 directors out of legally available funds, if ever.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &lt;i&gt;Reserved for future issuance&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 The Company has reserved for future issuance the following number
 of shares of common stock:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="64%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;As of December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Vesting of restricted stock&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,889&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,190&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Options to purchase common stock&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,577,016&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,222,767&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Common stock warrants&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;13,633,070&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;166,403&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Total&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;15,211,975&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,394,360&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &lt;b&gt;Preferred Stock-30,000,000 shares authorized&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 S&lt;b&gt;eries A Convertible Preferred Stock&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 On September&amp;#xA0;29, 2016, the Company issued 24,158.8693 shares
 of newly-created Series A Convertible Preferred Stock, which were
 convertible into approximately 10,737,275 shares of common stock at
 an initial conversion price of $2.25. The Series A Preferred Stock
 has a par value of $0.01 and each share is convertible into 444.44
 shares of common stock at the option of the holder. The holders of
 Series A Preferred Stock have no voting rights, share in both
 income and losses and are only entitled to dividends as declared on
 an as-converted basis. The Series A Preferred Stock contains no
 liquidation preferences or redemption rights and shares in the
 distribution of the Company on an as-converted basis with the
 common stock. The Series A Preferred Stock shall not be converted
 if, after giving effect to the conversion, the holder and its
 affiliated persons would own beneficially more than 4.99% of our
 common stock (subject to adjustment up to 9.99% solely at the
 holder&amp;#x2019;s discretion upon 61 days&amp;#x2019; prior notice to us
 or, solely as to a holder, if such limitation is waived by such
 holder upon execution of the private placement agreement).&lt;/p&gt;


 &lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" unitRef="shares" decimals="INF" id="id_11655837_4EA76CC8-F5DB-4BEE-8639-4745B518B6F3_5001_3">3685</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_6C26F4B4-0D62-4BDF-8A8C-63D664124B3A_1_1">125000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions>
  <us-gaap:UseOfEstimates contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" id="id_11655837_7984ED4E-102A-4311-BF41-75F697402193_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &lt;b&gt;Use of Estimates&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 The preparation of the Company&amp;#x2019;s consolidated financial
 statements requires it to make estimates and assumptions that
 impact the reported amounts of assets, liabilities, revenues and
 expenses and the disclosure of contingent assets and liabilities in
 the Company&amp;#x2019;s consolidated financial statements and
 accompanying notes. The most significant estimates in the
 Company&amp;#x2019;s consolidated financial statements relate to the
 valuation of equity awards, warrant liability, recoverability of
 deferred tax assets, estimated useful lives of fixed assets and
 intangible assets. The Company bases estimates and assumptions on
 historical experience when available and on various factors that it
 believes to be reasonable under the circumstances. The Company
 evaluates its estimates and assumptions on an ongoing basis. The
 Company&amp;#x2019;s actual results may differ from these estimates
 under different assumptions or conditions.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="break-inside: avoid"&gt;
 &lt;td valign="top" width="4%" align="left"&gt;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:UseOfEstimates>
  <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" id="id_11655837_79ADA3AA-2C00-4620-B266-D62A2BED26EC_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;Segment and Geographic Information&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 Operating segments are defined as components of an enterprise about
 which separate discrete financial information is available for
 evaluation by the chief operating decision-maker
 (&amp;#x201C;CODM&amp;#x201D;) or decision-making group in making decisions
 regarding resource allocation and assessing performance. The
 Company operates in two geographic regions: the United States
 (Massachusetts) and Israel (Tel Aviv) and views its operations as
 two operating segments: Histogenics Corporation (United States) and
 ProChon (Israel) as the CODM reviews separate discrete financial
 information in making decisions regarding resource allocations and
 assessing performance. Operating segments that have similar
 economic characteristics can be aggregated. As the nature of the
 products, customers, and methods to distribute products are the
 same and the nature of the regulatory environment, the production
 processes and historical and estimated future margins are similar,
 the two operating segments have been aggregated into one reporting
 segment as they have similar economic characteristics.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 Information about the Company&amp;#x2019;s operations in different
 geographic regions is presented in the tables below:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="66%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="11%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="11%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;br /&gt;
 2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;br /&gt;
 2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;(in
 thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Long-lived assets:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 United States&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,860&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,204&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Israel&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;9&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Total long-lived assets&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,860&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,213&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" unitRef="shares" decimals="0" id="id_11655837_AE354032-1B81-402C-BD47-3E1B7F0C0719_1_19">14389192</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" id="id_11655837_05C156A8-7A72-4C00-A62D-242039C6BBED_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 &lt;b&gt;Property and Equipment&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 Property and equipment are recorded at historical cost. Costs for
 capital assets not yet placed into service are capitalized as
 construction in progress, and will be depreciated in accordance
 with the below guidelines once placed into service. Maintenance and
 repair costs are expensed as incurred. Costs which materially
 improve or extend the lives of existing assets are capitalized. The
 Company provides for depreciation and amortization using the
 straight-line method over the estimated useful lives of the assets,
 which are as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="32%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td width="63%"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" nowrap="nowrap"&gt;
 &lt;p style="MARGIN-BOTTOM: 1pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 Asset Category&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 1pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 Estimated Useful Lives&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Office equipment&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;3 to 5 years&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Laboratory equipment&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;3 to 5 years&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Leasehold improvements&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;Shorter of the remaining lease term or useful
 life&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 Upon retirement or sale, the cost of assets disposed and the
 related accumulated depreciation are removed from the accounts and
 any resulting gain or loss is recorded in the consolidated
 statements of operations.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
  <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1 contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" id="id_11655837_7D1D2384-E6E7-4C41-8052-1A440B12FCA4_1_2">P7Y</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1>
  <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" id="id_11655837_54812108-91ED-45BA-AAF8-53778DD264DB_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The weighted-average assumptions used in the Black-Scholes option
 pricing model to determine the fair value of the employee stock
 option grants were as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="83%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;Year Ended&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Risk-free interest rate&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.73&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.68&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Expected volatility&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;72.5&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;62.6&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Expected term (in years)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6.08&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6.04&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Expected dividend yield&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
  <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" id="id_11655837_6B60D689-A1B0-48B7-9342-36306913B740_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 The following potentially dilutive securities have been excluded
 from the computation of diluted weighted-average shares
 outstanding, as they would be anti-dilutive (in common stock
 equivalent shares):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="70%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;As of December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Unvested restricted stock and options to purchase common stock&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,578,905&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,227,957&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Series A preferred stock unconverted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,962,817&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Warrants exercisable into common stock&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;166,403&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;166,403&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &amp;#xA0;&lt;/p&gt;


 &lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" id="id_11655837_39D2169F-C53C-4F91-BB9A-DCFB692D93D8_3001_2">P8Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" id="id_11655837_C7ACA86F-C554-4BAC-9082-5522B8171D25_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 Basic and diluted loss per common share are calculated as
 follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="76%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;For the Year Ended&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;(In thousands,
 except share and&lt;br /&gt;
 per share data&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Numerator:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Net loss&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(16,208&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(32,024&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Net Loss attributable to Series A Preferred Stock (a)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(2,345&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Numerator for basic EPS&amp;#x2014;Earnings (loss) attributable to
 common stockholders&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(13,863&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(32,024&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Effect of dilutive securities:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Deduct change in fair value of warrant liability&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(17,507&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Numerator for diluted EPS&amp;#x2014;Earnings (loss) attributable to
 common stockholders after assumed conversions&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(31,370&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(32,024&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Denominator:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Weighted-average number of common shares used in earnings (loss)
 per&lt;br /&gt;
 share&amp;#x2014;basic&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;14,256,954&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;13,231,126&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Effect of dilutive securities:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Nonparticipating warrants&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;132,238&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Denominator for diluted EPS&amp;#x2014;adjusted weighted average
 shares&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;14,389,192&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;13,231,126&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Earnings (loss) per share&amp;#x2014;basic&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.97&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(2.42&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Earnings (loss) per share&amp;#x2014;diluted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(2.18&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(2.42&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="break-inside: avoid"&gt;
 &lt;td valign="top" width="4%" align="left"&gt;(a)&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;The Series A Preferred Stock
 participates in income and losses&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" unitRef="pure" decimals="3" id="id_11655837_23624064-F40E-4BAA-AF98-7BDFA20DC6F2_1_3">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_11655837_9D59D34B-448C-4FAF-A6E9-512FD74E0A44_1_4">4.71</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_11655837_D773A7C3-9EBB-45B3-BC43-D1082FBCD371_5001_2">2.02</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_5A0DEAA9-8FA8-403D-B739-D326D818EDBC_7007_24">0</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" id="id_11655837_E1BAF9CD-0C5B-487D-ACB8-465438943AA2_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 Intangible asset, net of accumulated impairment charges, are
 summarized as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="50%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"&gt;&lt;b&gt;As of
 December&amp;#xA0;31,&amp;#xA0;2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"&gt;&lt;b&gt;As of December&amp;#xA0;31,
 2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Cost&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Accumulated&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Impairment&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Net&amp;#xA0;Book&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Value&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Cost&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Accumulated&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Impairment&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Net&amp;#xA0;Book&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Value&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"&gt;&lt;b&gt;(in thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"&gt;&lt;b&gt;(in thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 IPR&amp;amp;D&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;630&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(630&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;630&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(430&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;200&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;630&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(630&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;630&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(430&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;200&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" id="id_11655837_39D2169F-C53C-4F91-BB9A-DCFB692D93D8_3001_4">P7Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_11655837_D773A7C3-9EBB-45B3-BC43-D1082FBCD371_5001_4">4.97</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" unitRef="pure" decimals="3" id="id_11655837_7D1D2384-E6E7-4C41-8052-1A440B12FCA4_1_1">0.635</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate>
  <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" unitRef="iso4217_USD" decimals="INF" id="id_11655837_A79DB659-8B27-4A30-9A9C-35C1D5680E0D_1_1">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
  <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" id="id_11655837_3FB183A1-AB79-4D1A-82B9-74F1A7A16427_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 Deferred taxes are recognized for temporary differences between the
 basis of assets and liabilities for financial statement and income
 tax purposes. The significant components of the Company&amp;#x2019;s
 deferred tax assets and liabilities are comprised of the
 following:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="71%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;As of December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Deferred tax assets:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Net operating loss carryforwards&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;16,146&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;28,200&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Depreciation and amortization&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,229&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,688&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Accrued expenses&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,082&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,183&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Capitalized start-up costs&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10,037&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8,531&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Other&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;75&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;259&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Deferred tax assets before valuation allowance&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;34,569&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;44,861&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Valuation allowance&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(34,569&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(43,751&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,110&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Deferred tax liabilities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 IPR&amp;amp;D&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(36&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Change in accounting method&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(1,074&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(1,110&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Net deferred tax assets&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
  <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" id="id_11655837_4D925A04-0843-4F9F-897E-6451727106D3_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 he components of loss before income taxes were as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="71%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;As of December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;(in
 thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 U.S.&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(15,838&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(31,382&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Foreign&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(369&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(691&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Total&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(16,208&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(32,073&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_11655837_D773A7C3-9EBB-45B3-BC43-D1082FBCD371_5001_3">0.76</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_5A0DEAA9-8FA8-403D-B739-D326D818EDBC_7007_1000020">26000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" unitRef="shares" decimals="0" id="id_11655837_AE354032-1B81-402C-BD47-3E1B7F0C0719_1_18">14256954</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" id="id_11655837_E6055397-6B6C-46A7-AA4B-9370D63F6FF5_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 Aggregate minimum annual lease commitments of the Company under its
 non-cancellable operating leases as of December&amp;#xA0;31, 2016, are
 as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="79%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="15%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom" colspan="4" nowrap="nowrap" align="center"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; WIDTH: 116.9pt; BORDER-BOTTOM: #000000 1pt solid; MARGIN-TOP: 0pt" align="center"&gt;&lt;b&gt;For the Year Ended December&amp;#xA0;31,&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;(in&amp;#xA0;thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 2017&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,266&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 2018&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;754&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 2019&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;586&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 2020&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;596&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 2021&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;605&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Thereafter&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;926&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Total minimum lease payments&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,733&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
  <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" id="id_11655837_5144D0FF-5585-4492-AAD8-837CC3D713B7_1_0">&lt;div&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="break-inside: avoid"&gt;
 &lt;td valign="top" width="4%" align="left"&gt;&lt;b&gt;2.&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;&lt;b&gt;SUMMARY OF SIGNIFICANT ACCOUNTING
 POLICIES&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &lt;b&gt;Basis of Accounting&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 The consolidated financial statements are prepared in conformity
 with accounting principles generally accepted in the United States
 of America (&amp;#x201C;U.S. GAAP&amp;#x201D;). The consolidated financial
 statements include the accounts of Histogenics Corporation and its
 wholly-owned subsidiaries, ProChon and Histogenics Securities
 Corporation. All significant intercompany accounts and transactions
 are eliminated in consolidation.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &lt;b&gt;Reclassifications&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 The Company has reclassified certain prior period amounts to
 conform to the current period presentation. The amounts
 reclassified impact Accounts Payable and Accounts Payable due to
 Intrexon Corporation (&amp;#x201C;Intrexon&amp;#x201D;) for the year ended
 December&amp;#xA0;31, 2015.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &lt;b&gt;Use of Estimates&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 The preparation of the Company&amp;#x2019;s consolidated financial
 statements requires it to make estimates and assumptions that
 impact the reported amounts of assets, liabilities, revenues and
 expenses and the disclosure of contingent assets and liabilities in
 the Company&amp;#x2019;s consolidated financial statements and
 accompanying notes. The most significant estimates in the
 Company&amp;#x2019;s consolidated financial statements relate to the
 valuation of equity awards, warrant liability, recoverability of
 deferred tax assets, estimated useful lives of fixed assets and
 intangible assets. The Company bases estimates and assumptions on
 historical experience when available and on various factors that it
 believes to be reasonable under the circumstances. The Company
 evaluates its estimates and assumptions on an ongoing basis. The
 Company&amp;#x2019;s actual results may differ from these estimates
 under different assumptions or conditions.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 18pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &lt;b&gt;Foreign Currency Translation&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 The Company&amp;#x2019;s consolidated financial statements are prepared
 in U.S. dollars. The Company&amp;#x2019;s foreign subsidiary uses the
 U.S. dollar as its functional and reporting currency, as management
 determined that the U.S. dollar is the primary currency of the
 economic environment in which the subsidiary operates. When
 transactions are required to be paid in the local currency of the
 foreign subsidiary, any resulting foreign currency transaction gain
 or loss is recorded as a component of &amp;#x201C;Other income
 (expense), net&amp;#x201D; in the consolidated statements of
 operations.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &lt;b&gt;Segment and Geographic Information&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 Operating segments are defined as components of an enterprise about
 which separate discrete financial information is available for
 evaluation by the chief operating decision-maker
 (&amp;#x201C;CODM&amp;#x201D;) or decision-making group in making decisions
 regarding resource allocation and assessing performance. The
 Company operates in two geographic regions: the United States
 (Massachusetts) and Israel (Tel Aviv) and views its operations as
 two operating segments: Histogenics Corporation (United States) and
 ProChon (Israel) as the CODM reviews separate discrete financial
 information in making decisions regarding resource allocations and
 assessing performance. Operating segments that have similar
 economic characteristics can be aggregated. As the nature of the
 products, customers, and methods to distribute products are the
 same and the nature of the regulatory environment, the production
 processes and historical and estimated future margins are similar,
 the two operating segments have been aggregated into one reporting
 segment as they have similar economic characteristics.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 Information about the Company&amp;#x2019;s operations in different
 geographic regions is presented in the tables below:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="66%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="11%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="11%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;br /&gt;
 2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;br /&gt;
 2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;(in
 thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Long-lived assets:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 United States&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,860&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,204&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Israel&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;9&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Total long-lived assets&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,860&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,213&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &lt;b&gt;Fair Value Measurements&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 The carrying amounts reported in the Company&amp;#x2019;s consolidated
 financial statements for cash and cash equivalents, accounts
 payable, equipment loan, and accrued liabilities approximate their
 respective fair values because of the short-term nature of these
 accounts.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 Fair value is defined as the price that would be received if
 selling an asset or paid to transfer a liability in the principal
 or most advantageous market for the asset or liability in an
 orderly transaction between market participants on the measurement
 date.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 Fair value should be based on the assumptions that market
 participants would use when pricing an asset or liability and is
 based on a fair value hierarchy that prioritizes the information
 used to develop those assumptions. The fair value hierarchy gives
 the highest priority to quoted prices in active markets (observable
 inputs) and the lowest priority to the Company&amp;#x2019;s assumptions
 (unobservable inputs). Fair value measurements should be disclosed
 separately by level within the fair value hierarchy. For assets and
 liabilities recorded at fair value, it is the Company&amp;#x2019;s
 policy to maximize the use of observable inputs and minimize the
 use of unobservable inputs when developing fair value measurements,
 in accordance with established fair value hierarchy.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 Fair value measurements for assets and liabilities where there
 exists limited or no observable market data are based primarily
 upon estimates, and often are calculated based on the economic and
 competitive environment, the characteristics of the asset or
 liability and other factors. Therefore, the results cannot be
 determined with precision and may not be realized in an actual sale
 or immediate settlement of the asset or liability. Additionally,
 there may be inherent weaknesses in any valuation technique, and
 changes in the underlying assumptions used, including discount
 rates and estimates of future cash flows, could significantly
 affect the results of current or future values.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 Additionally, from time to time, the Company may be required to
 record at fair value other assets on a nonrecurring basis, such as
 assets held for sale and certain other assets. These nonrecurring
 fair value adjustments typically involve application of
 lower-of-cost-or-market accounting or write-downs of individual
 assets.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 The fair value hierarchy gives the highest priority to unadjusted
 quoted prices in active markets for identical assets (Level 1), and
 the lowest priority to unobservable inputs (Level 3). The
 Company&amp;#x2019;s financial assets are classified within the fair
 value hierarchy based on the lowest level of inputs that is
 significant to the fair value measurement. The three levels of the
 fair value hierarchy, and its applicability to the Company&amp;#x2019;s
 financial assets, are described below.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 62px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &lt;i&gt;Level 1&lt;/i&gt;: Unadjusted quoted prices in active markets that are
 accessible at the measurement date of identical, unrestricted
 assets.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 62px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &lt;i&gt;Level 2&lt;/i&gt;: Quoted prices for similar assets, or inputs that
 are observable, either directly or indirectly, for substantially
 the full term through corroboration with observable market data.
 Level 2 includes investments valued at quoted prices adjusted for
 legal or contractual restrictions specific to the security.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 62px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &lt;i&gt;Level 3&lt;/i&gt;: Pricing inputs are unobservable for the assets,
 that is, inputs that reflect the reporting entity&amp;#x2019;s own
 assumptions about the assumptions market participants would use in
 pricing the assets. Level 3 includes private investments that are
 supported by little or no market activity.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 Level 3 valuations are for instruments that are not traded in
 active markets or are subject to transfer restrictions and may be
 adjusted to reflect illiquidity and/or non-transferability, with
 such adjustment generally based on available market evidence. In
 the absence of such evidence, management&amp;#x2019;s best estimate is
 used.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 An adjustment to the pricing method used within either Level 1 or
 Level 2 inputs could generate a fair value measurement that
 effectively falls in a lower level in the hierarchy. The Company
 had no assets or liabilities classified as Level 1 or Level 2 as of
 December&amp;#xA0;31, 2016 and 2015 other than the money market fund
 described in the &amp;#x201C;Cash and Cash Equivalents&amp;#x201D; section
 below and there were no material re-measurements of fair value with
 respect to financial assets and liabilities, during the periods
 presented, other than those assets and liabilities that are
 measured at fair value on a recurring basis. Other than the
 warrants issued in connection with the private placement
 transaction which closed on September&amp;#xA0;29, 2016, the Company
 had no assets or liabilities classified as Level 3 as of
 December&amp;#xA0;31, 2016 and 2015.&amp;#xA0;Transfers are calculated on
 values as of the transfer date. There were no transfers between
 Levels 1, 2 and 3 during the twelve months ended December&amp;#xA0;31,
 2016 and 2015.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 The fair value of the warrants was determined using a Monte Carlo
 simulation model.&amp;#xA0;This model incorporated several assumptions
 at each valuation date including: the price of the Company&amp;#x2019;s
 common stock on the date of valuation, the historical volatility of
 the price of the Company&amp;#x2019;s common stock, the remaining
 contractual term of the warrant and estimates of the probability of
 a fundamental transaction occurring. See Note 8, Capital Stock, for
 further discussion of the private placement.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="46%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WIDTH: 39.5pt; BORDER-BOTTOM: rgb(0,0,0) 1pt solid; MARGIN-TOP: 0pt"&gt;
 &lt;b&gt;Description&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Quoted&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;prices in&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;active&amp;#xA0;markets&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;(Level 1)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Significant&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;other&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;observable&amp;#xA0;inputs&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;(Level 2)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Significant&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;unobservable&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;inputs&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;(Level 3)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="14" align="center"&gt;&lt;b&gt;(in
 thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 &lt;b&gt;December&amp;#xA0;31, 2016&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 &lt;b&gt;Assets:&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Money market funds&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;30,318&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;30,318&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 &lt;b&gt;Liabilities:&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Warrant liability&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;13,197&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;13,197&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 &lt;b&gt;December&amp;#xA0;31, 2015&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Money market funds&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;25,764&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;25,764&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 The following table provides a reconciliation of all liabilities
 measured at fair value using Level 3 significant unobservable
 inputs:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="68%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="67%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="25%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;As&amp;#xA0;of&amp;#xA0;December&amp;#xA0;31,&amp;#xA0;2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;(in
 thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Beginning balance, January&amp;#xA0;1, 2016&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Issuance of warrants,&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;30,704&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Change in fair value of warrant liability&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(17,507&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Ending balance&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;13,197&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &lt;b&gt;Cash and Cash Equivalents&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 Cash and cash equivalents include cash in readily available
 checking and savings accounts and money market funds. The Company
 considers all highly liquid investments with an original maturity
 of three months or less from the date of purchase to be cash
 equivalents.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 The Company&amp;#x2019;s cash equivalents, which consist of money market
 funds, are measured at fair value on a recurring basis. As of
 December&amp;#xA0;31, 2016 and 2015, the carrying amount of cash and
 cash equivalents was $31.9 million and $30.9 million, respectively,
 which approximates fair value and was determined based upon Level 1
 inputs. Money market funds are valued using quoted market prices
 with no valuation adjustments applied. Accordingly, these
 securities are categorized as Level 1 and had a balance of $30.3
 million and $25.8 million as of December&amp;#xA0;31, 2016 and 2015,
 respectively, shown in the table above.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &lt;b&gt;Concentration of Credit Risk&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 Financial instruments, which potentially subject the Company to
 significant concentration of credit risk, consist primarily of cash
 and cash equivalents. The Company maintains deposits in federally
 insured financial institutions in excess of federally insured
 limits. The Company has not experienced any losses in such accounts
 and management believes that the Company is not exposed to
 significant credit risk due to the financial position of the
 depository institutions in which those deposits are held. The
 Company has no financial instruments with off-balance sheet risk of
 loss.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 18pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &lt;b&gt;Property and Equipment&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 Property and equipment are recorded at historical cost. Costs for
 capital assets not yet placed into service are capitalized as
 construction in progress, and will be depreciated in accordance
 with the below guidelines once placed into service. Maintenance and
 repair costs are expensed as incurred. Costs which materially
 improve or extend the lives of existing assets are capitalized. The
 Company provides for depreciation and amortization using the
 straight-line method over the estimated useful lives of the assets,
 which are as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="32%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td width="63%"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" nowrap="nowrap"&gt;
 &lt;p style="MARGIN-BOTTOM: 1pt; FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-TOP: 0pt"&gt;
 Asset Category&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 1pt; FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-TOP: 0pt"&gt;
 Estimated Useful Lives&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Office equipment&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;3 to 5 years&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Laboratory equipment&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;3 to 5 years&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Leasehold improvements&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;Shorter of the remaining lease term or useful
 life&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 Upon retirement or sale, the cost of assets disposed and the
 related accumulated depreciation are removed from the accounts and
 any resulting gain or loss is recorded in the consolidated
 statements of operations.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &lt;b&gt;Impairment of Long-Lived Assets&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 Long-lived assets consist primarily of property and equipment and
 identifiable intangible assets. When impairment indicators exist,
 the Company&amp;#x2019;s management evaluates long-lived assets for
 potential impairment. An impairment loss is recorded if and when
 events and circumstances indicate that assets might be impaired and
 the undiscounted cash flows estimated to be generated by those
 assets are less than the carrying amount of those assets. While the
 Company&amp;#x2019;s current and historical operating losses and
 negative cash flows are indicators of impairment, management
 believes that future cash flows to be received support the carrying
 value of its long-lived assets.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 Impairments, if any, are recognized in earnings. An impairment loss
 would be recognized in an amount equal to the excess of the
 carrying amount over the undiscounted expected future cash
 flows.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &lt;b&gt;Intangible Asset&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 The Company&amp;#x2019;s intangible asset consists of acquired
 in-process research and development (&amp;#x201C;IPR&amp;amp;D&amp;#x201D;)
 obtained through the acquisition of ProChon. IPR&amp;amp;D represents
 the fair value assigned to research and development assets that
 have not been completed at the date of acquisition. The value
 assigned to acquired IPR&amp;amp;D is determined by estimating the
 costs to develop the acquired technology into commercially viable
 products, estimating the resulting revenue from the projects, and
 discounting the net cash flows to present value. The revenue and
 costs projections used to value acquired IPR&amp;amp;D were adjusted
 based on the probability of success of developing a new product.
 Additionally, the projections considered the relevant market sizes
 and growth factors, expected trends in technology and the nature
 and expected timing of new product introductions by the Company and
 its competitors. The rates utilized to discount the net cash flows
 to their present value were commensurate with the stage of
 development of the projects and uncertainties in the economic
 estimates used in the projections described above.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 IPR&amp;amp;D is considered an indefinite-lived intangible asset and is
 assessed for impairment annually or more frequently if impairment
 indicators exist. When performing the impairment assessment, the
 Company first assesses qualitative factors to determine whether it
 is necessary to recalculate the fair value of its acquired
 IPR&amp;amp;D. If the Company believes, as a result of the qualitative
 assessment, that it is more likely than not that the fair value of
 acquired IPR&amp;amp;D is less than its carrying amount, it calculates
 the fair value using the same methodology as described above. If
 the carrying value of the Company&amp;#x2019;s acquired IPR&amp;amp;D
 exceeds its fair value, then an impairment charge is taken and the
 intangible asset is written-down to its fair value. During the
 fourth quarter the Company deemed the value of the IPR&amp;amp;D to be
 zero for the year ended December&amp;#xA0;31, 2016 as it has no plans
 to advance the technology or use it in any future clinical
 development activities. The result was a write-off of $0.2 million.
 For the year ended December&amp;#xA0;31, 2015, the Company determined
 that there was impairment of its IPR&amp;amp;D of $0.3 million. The
 Company performed its annual impairment test of its IPR&amp;amp;D as of
 December&amp;#xA0;31, 2015 using an income approach, including a
 discount rate of 13%, applied to probability-adjusted after-tax
 cash flows. The Company believes that the assumptions are
 representative of those a market participant would use in
 estimating the fair value of the IPR&amp;amp;D.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 Intangible asset, net of accumulated impairment charges, are
 summarized as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="50%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="10" align="center"&gt;&lt;b&gt;As of
 December&amp;#xA0;31,&amp;#xA0;2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="10" align="center"&gt;&lt;b&gt;As of December&amp;#xA0;31,
 2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Cost&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Accumulated&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Impairment&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Net&amp;#xA0;Book&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Value&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Cost&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Accumulated&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Impairment&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Net&amp;#xA0;Book&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Value&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="10" align="center"&gt;&lt;b&gt;(in
 thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="10" align="center"&gt;&lt;b&gt;(in
 thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 IPR&amp;amp;D&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;630&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(630&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;630&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(430&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;200&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;630&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(630&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;630&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(430&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;200&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &lt;b&gt;Initial Public Offering Costs&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 The Company deferred direct incremental costs attributable with the
 IPO of its common stock prior to the closing of the IPO. These
 costs represent legal, accounting and other direct costs related to
 the Company&amp;#x2019;s efforts to raise capital through a public sale
 of its common stock. Upon completion of the IPO, $3.9 million of
 IPO costs were reclassified to additional paid-in capital as a
 reduction of the IPO proceeds. As of December&amp;#xA0;31, 2014, the
 Company had paid $2.9 million with the remaining $1.0 million
 included in accounts payable in the consolidated balance sheet.
 This amount was subsequently paid in 2015.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &lt;b&gt;Restricted Cash&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 Restricted cash represents cash held in a depository account at a
 financial institution to collateralize a conditional stand-by
 letter of credit related to the Company&amp;#x2019;s Lexington,
 Massachusetts facility lease agreement. Restricted cash is reported
 as non-current unless the restrictions are expected to be released
 in the next twelve months.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &lt;b&gt;Deferred Rent&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 Deferred rent consists of the difference between cash payments and
 the recognition of rent expense on a straight-line basis for the
 facilities the Company occupies. The Company&amp;#x2019;s leases for its
 Waltham, Massachusetts facility and its Lexington, Massachusetts
 facility provide for fixed increases in minimum annual rental
 payments. The total amount of rental payments due over each lease
 term is being charged to rent expense ratably over the life of each
 lease, respectively.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &lt;b&gt;Financial Instruments Indexed to and Potentially Settled in the
 Company&amp;#x2019;s Common Stock&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 The Company evaluates all financial instruments issued in
 connection with its equity offerings when determining the proper
 accounting treatment for such instruments in the Company&amp;#x2019;s
 financial statements. The Company considers a number of generally
 accepted accounting principles under U.S. GAAP to determine such
 treatment and evaluates the features of the instrument to determine
 the appropriate accounting treatment. The Company utilizes the
 Probability Weighted Expected Return Method (&amp;#x201C;PWERM&amp;#x201D;),
 Option Pricing Model (&amp;#x201C;OM&amp;#x201D;) or other appropriate
 methods to determine the fair value of its derivative financial
 instruments. For financial instruments indexed to and potentially
 settled in the Company&amp;#x2019;s common stock that are determined to
 be classified as liabilities on the consolidated balance sheet,
 changes in fair value are recorded as a gain or loss in the
 Company&amp;#x2019;s consolidated statement of operations with the
 corresponding amount recorded as an adjustment to the liability on
 its consolidated balance sheet.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &lt;b&gt;Revenue Recognition&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 In the future, if we generate revenue, it may be through license
 agreements, collaborations and product sales. The Company
 recognizes revenue when all four of the following criteria are met:
 (1)&amp;#xA0;persuasive evidence that an agreement exists;
 (2)&amp;#xA0;delivery of the products and/or services has occurred;
 (3)&amp;#xA0;the selling price is fixed or determinable; and
 (4)&amp;#xA0;collectability is reasonably assured. The Company did not
 recognize any revenue for the years ended December&amp;#xA0;31, 2016
 and 2015.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &lt;b&gt;Research and Development Costs&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 Research and development costs are charged to expense as incurred.
 These costs include, but are not limited to: license fees related
 to the acquisition of in-licensed products; employee-related
 expenses, including salaries, benefits and travel; expenses
 incurred under agreements with contract research organizations and
 investigative sites that conduct clinical trials and preclinical
 studies; the cost of acquiring, developing and manufacturing
 clinical trial materials; facilities, depreciation and other
 expenses, which include direct and allocated expenses for rent and
 maintenance of facilities; insurance and other supplies; and costs
 associated with preclinical activities and regulatory
 operations.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 Costs for certain development activities, such as clinical trials,
 are recognized based on an evaluation of the progress to completion
 of specific tasks using data such as patient enrollment, clinical
 site activations, or information provided to the Company by its
 vendors with respect to their actual costs incurred. Payments for
 these activities are based on the terms of the individual
 arrangements, which may differ from the pattern of costs incurred,
 and are reflected in the consolidated financial statements as
 prepaid or accrued research and development expense.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &lt;i&gt;Collaboration Arrangements&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 Costs reimbursed to a collaborator for work that it performs are
 recorded as research and development expenses. These reimbursements
 can include payments for work performed, or a milestone for which a
 payment is due, the reimbursements or development milestone
 achievement are recorded as research and development expense.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 In September 2014, the Company entered into a collaboration
 agreement with Intrexon Corporation (&amp;#x201C;Intrexon&amp;#x201D;) for
 the development and commercialization of allogeneic cell
 therapeutics for the treatment or repair of damaged articular
 hyaline cartilage in humans, utilizing Intrexon&amp;#x2019;s proprietary
 technology (the &amp;#x201C;Collaboration Agreement&amp;#x201D;). Under the
 terms of the Collaboration Agreement, the Company is responsible
 for the costs of development and commercialization, with some
 exceptions. Refer to Note 14,&amp;#xA0;&lt;i&gt;Related
 Parties&lt;/i&gt;&amp;#xA0;for
 further details on all terms, conditions and exceptions of this
 collaboration.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &lt;b&gt;License Agreements&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 Costs associated with licenses of technology are expensed as
 incurred and are included in research and development expenses.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 18pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &lt;b&gt;Patent Costs&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 Costs related to filing and pursuing patent applications are
 recorded as general and administrative expense as incurred since
 the recoverability of such expenditures is uncertain.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &lt;b&gt;Stock-Based Compensation&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 The Company accounts for grants of stock options and restricted
 stock based on their grant date fair value and recognizes
 compensation expense over their vesting period. The Company
 estimates the fair value of stock options as of the date of grant
 using the Black-Scholes option pricing model and restricted stock
 based on the fair value of the underlying common stock as
 determined by management or the value of the services provided,
 whichever is more readily determinable.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 Stock-based compensation expense represents the cost of the grant
 date fair value of employee stock option grants recognized over the
 requisite service period of the awards (usually the vesting period)
 on a straight-line basis, net of estimated forfeitures. The expense
 is adjusted for actual forfeitures at year end. Stock-based
 compensation expense recognized in the consolidated financial
 statements is based on awards that are ultimately expected to
 vest.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 For stock option grants with performance-based milestones, the
 expense is recorded over the remaining service period after the
 point when the achievement of the milestone is probable or the
 performance condition has been achieved. For stock option grants
 with both performance-based milestones and market conditions,
 expense is recorded over the derived service period after the point
 when the achievement of the performance-based milestone is probable
 or the performance condition has been achieved. The Company issued
 performance-based awards in 2015, but not in 2016.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 The Company accounts for stock options and restricted stock awards
 to non-employees using the fair value approach. Stock options and
 restricted stock awards to non-employees are subject to periodic
 revaluation over their vesting terms.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &lt;b&gt;Income Taxes&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 The Company accounts for income taxes under the liability method,
 which requires the recognition of deferred tax assets and
 liabilities for the expected future tax consequences of events that
 have been included in the financial statements. Under this method,
 deferred tax assets and liabilities are determined on the basis of
 the differences between the financial statements and tax basis of
 assets and liabilities using enacted tax rates in effect for the
 year in which the differences are expected to reverse. The effect
 of a change in tax rates on deferred tax assets and liabilities is
 recognized in income in the period that includes the enactment
 date.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 The Company recognizes net deferred tax assets to the extent that
 the Company believes these assets are more likely than not to be
 realized. In making such a determination, management considers all
 available positive and negative evidence, including future
 reversals of existing taxable temporary differences, projected
 future taxable income, tax-planning strategies, and results of
 recent operations. If management determines that the Company would
 be able to realize its deferred tax assets in the future, in excess
 of its net recorded amount, management would make an adjustment to
 the deferred tax asset valuation allowance, which would reduce the
 provision for income taxes.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 The Company records uncertain tax positions on the basis of a
 two-step process whereby (1)&amp;#xA0;management determines whether it
 is more likely than not that the tax positions will be sustained on
 the basis of the technical merits of the position and (2)&amp;#xA0;for
 those tax positions that meet the more likely than not recognition
 threshold, management recognizes the largest amount of tax benefit
 that is more than 50 percent likely to be realized upon ultimate
 settlement with the related tax authority. The Company recognizes
 interest and penalties related to unrecognized tax benefits within
 income tax expense. Any accrued interest and penalties are included
 within the related tax liability.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &lt;b&gt;Earnings (Loss) per Common Share&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 Earnings (loss) per common share is calculated using the two-class
 method, which is an earnings allocation formula that determines
 earnings (loss) per share for the holders of the Company&amp;#x2019;s
 common shares and participating securities. All series of preferred
 stock contain participation rights in any dividend paid by the
 Company and are deemed to be participating securities. Earnings
 available to common stockholders and participating convertible
 redeemable preferred shares are allocated to each share on an
 as-converted basis as if all of the earnings for the period had
 been distributed. The participating securities include a
 contractual obligation to share in losses of the Company and are
 included in the calculation of net loss per share in the periods
 that have a net loss.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 Diluted earnings per share is computed using the more dilutive of
 (a)&amp;#xA0;the two-class method, or (b)&amp;#xA0;the if-converted method.
 The Company allocates earnings first to preferred stockholders
 based on dividend rights and then to common and preferred
 stockholders based on ownership interests. The weighted-average
 number of common shares included in the computation of diluted
 earnings (loss) gives effect to all potentially dilutive common
 equivalent shares, including outstanding stock options, warrants,
 convertible redeemable preferred stock and the potential issuance
 of stock upon the conversion of the Company&amp;#x2019;s convertible
 notes. Common stock equivalent shares are excluded from the
 computation of diluted earnings (loss) per share if their effect is
 antidilutive.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &lt;b&gt;Warrant Accounting&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 As noted in Note 9, the Company classifies warrants to purchase
 shares of its common stock as a liability on its consolidated
 balance sheet if the warrant is a free-standing financial
 instrument that may require the Company to transfer consideration
 upon exercise. Each warrant of this type is initially recorded at
 fair value on date of grant using the Monte Carlo simulation model
 and net of issuance costs, and is subsequently re-measured to fair
 value at each subsequent balance sheet date. Changes in fair value
 of the warrants are recognized as a component of other income
 (expense), net in the consolidated statement of operations. The
 Company will continue to adjust the liability for changes in fair
 value until the earlier of the exercise or expiration of the
 warrants.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &lt;b&gt;Recently Adopted Accounting Pronouncements&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 In November 2015, Financial Accounting Standards Board (&amp;#x201C;the
 FASB&amp;#x201D;) issued Accounting Standard Update (&amp;#x201C;ASU&amp;#x201D;)
 No.&amp;#xA0;2015-17, Income Taxes (Topic 740): Balance Sheet
 Classification of Deferred Taxes. The new standard requires that
 deferred tax assets and liabilities be classified as noncurrent in
 a classified statement of financial position. The Company
 prospectively adopted this guidance in the fourth quarter of 2015,
 which resulted in the removal of gross deferred tax assets and
 liabilities from the Company&amp;#x2019;s consolidated balance sheet.
 The net impact was zero and the prior period was not
 retrospectively adjusted.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 In November 2014, the FASB issued ASU No.&amp;#xA0;2014-16, Derivatives
 and Hedging (Topic 815): Determining Whether the Host Contract in a
 Hybrid Financial Instrument Issued in the Form of a Share Is More
 Akin to Debt or to Equity. This standard provides guidance to
 eliminate the existing diversity in practice in accounting for
 hybrid financial instruments issued in the form of a share. A
 hybrid financial instrument consists of a &amp;#x201C;host
 contract&amp;#x201D; into which one or more derivative terms have been
 embedded. This guidance requires an entity to consider the terms
 and features of the entire financial instrument, including the
 embedded derivative features, in order to determine whether the
 nature of the host contract is more akin to debt or to equity. This
 guidance is effective for fiscal years and interim periods
 beginning after December&amp;#xA0;15, 2015, with early adoption
 permitted. A reporting entity should apply this guidance using a
 modified retrospective approach by recording a cumulative-effect
 adjustment to equity as of the beginning of the annual period of
 adoption. Retrospective application is permitted to all relevant
 prior periods. The Company has concluded that this guidance has no
 impact on the presentation of its results of operations, financial
 position and disclosures.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 In August 2014, the FASB issued ASU No.&amp;#xA0;2014-15, Presentation
 of Financial Statements&amp;#x2014;Going Concern (Subtopic 2015-40):
 Disclosure of Uncertainties about an Entity&amp;#x2019;s Ability to
 Continue as a Going Concern. This guidance addresses
 management&amp;#x2019;s responsibility in evaluating whether there is
 substantial doubt about a company&amp;#x2019;s ability to continue as a
 going concern and to provide related footnote disclosures. The
 guidance is effective for fiscal years ending after
 December&amp;#xA0;15, 2016 and for interim periods within those fiscal
 years. The adoption of this standard did not have a material impact
 on our consolidated financial statements and related
 disclosures.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 In June 2014, the FASB issued ASU No.&amp;#xA0;2014-12,
 Compensation-Stock Compensation (Topic 718): Accounting for
 Share-Based Payments When the Terms of an Award Provide That a
 Performance Target Could be Achieved after the Requisite Service
 Period. This standard provides guidance requiring when there is a
 performance target that affects vesting of equity awards granted
 and could be achieved after the requisite service period to be
 treated as a performance condition. A reporting entity should apply
 existing guidance on stock-based compensation, as it relates to
 such awards. This guidance is effective for annual periods and
 interim periods within those annual periods beginning after
 December&amp;#xA0;15, 2015 with early adoption permitted using either
 of two methods: (i)&amp;#xA0;prospective to all awards granted or
 modified after the effective date; or (ii)&amp;#xA0;retrospective to
 all awards with performance targets that are outstanding as of the
 beginning of the earliest annual period presented in the financial
 statements and to all new or modified awards thereafter, with the
 cumulative effect of applying this guidance as an adjustment to the
 opening retained earnings balance as of the beginning of the
 earliest annual period presented in the financial statements. The
 Company issued performance-based awards during the year ended
 December&amp;#xA0;31, 2015. The Company adopted this guidance on a
 prospective basis and there have not been any performance-based
 awards since the effective date of the guidance.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &lt;b&gt;Recently Issued Accounting Pronouncements&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 In November 2016, the FASB issued guidance that requires restricted
 cash and restricted cash equivalents be included with cash and cash
 equivalents when reconciling the total beginning and ending amounts
 for the periods shown on the statement of cash flows. The new
 standard is effective for us on January&amp;#xA0;1, 2018 using a
 retrospective transition method to each period presented. Early
 adoption is permitted. We are currently evaluating the timing of
 our adoption and the expected impact that this standard could have
 on our consolidated financial statements and related
 disclosures.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 In March 2016, the FASB issued ASU No.&amp;#xA0;2016-09,
 Compensation-Stock Compensation (Topic 718): Improvements to
 Employee Shared-Based Payment Accounting. This standard provides
 guidance on accounting for employee share-based payments. This
 guidance addresses several aspects of the accounting for
 share-based payment award transactions, including: (a)&amp;#xA0;income
 tax consequences; (b)&amp;#xA0;classification of awards as either
 equity or liabilities; and (c)&amp;#xA0;classification on the statement
 of cash flows.&amp;#xA0;This standard will be effective for fiscal
 years beginning after December&amp;#xA0;15, 2016, including interim
 periods within those fiscal years.&amp;#xA0;The Company is evaluating
 the impact of this guidance on the presentation of its results of
 operations, financial position and disclosures.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 In February 2016, the FASB, issued ASU No.&amp;#xA0;2016-02, Leases
 (Topic 842). The ASU requires companies to recognize on the balance
 sheet the assets and liabilities for the rights and obligations
 created by leased assets. ASU 2016-02 will be effective for the
 Company in the first quarter of 2019, with early adoption
 permitted. The Company is currently evaluating the impact that the
 adoption of ASU 2016-02 will have on the Company&amp;#x2019;s
 consolidated financial statements or related disclosures.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 In May 2014, the FASB issued ASU No.&amp;#xA0;2014-09, Revenue from
 Contracts with Customers (Topic 606), which requires an entity to
 recognize the amount of revenue to which it expects to be entitled
 for the transfer of promised goods or services to customers. ASU
 2014-09 will replace most existing revenue recognition guidance in
 U.S. GAAP when it becomes effective. In July 2015, the FASB issued
 a one-year deferral of the effective date of the new revenue
 recognition standard. The new guidance will be effective for the
 Company&amp;#x2019;s first quarter of fiscal year 2018 and early
 application for fiscal year 2017 would be permitted. The Company is
 evaluating the impact of this guidance on the presentation of its
 results of operations, financial position and disclosures.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 18pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_5A0DEAA9-8FA8-403D-B739-D326D818EDBC_7007_1000016">3000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <dei:TradingSymbol contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" id="id_11655837_4376F2C2-CCA2-43BC-BD83-928C14BA3491_1_400000">HSGX</dei:TradingSymbol>
  <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" unitRef="pure" decimals="4" id="id_11655837_7D1D2384-E6E7-4C41-8052-1A440B12FCA4_1_0">0.0157</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_AE354032-1B81-402C-BD47-3E1B7F0C0719_1_2">21577000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" id="id_11655837_08874C3D-3D77-4700-8251-67F494B7924E_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &lt;b&gt;Research and Development Costs&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 Research and development costs are charged to expense as incurred.
 These costs include, but are not limited to: license fees related
 to the acquisition of in-licensed products; employee-related
 expenses, including salaries, benefits and travel; expenses
 incurred under agreements with contract research organizations and
 investigative sites that conduct clinical trials and preclinical
 studies; the cost of acquiring, developing and manufacturing
 clinical trial materials; facilities, depreciation and other
 expenses, which include direct and allocated expenses for rent and
 maintenance of facilities; insurance and other supplies; and costs
 associated with preclinical activities and regulatory
 operations.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 Costs for certain development activities, such as clinical trials,
 are recognized based on an evaluation of the progress to completion
 of specific tasks using data such as patient enrollment, clinical
 site activations, or information provided to the Company by its
 vendors with respect to their actual costs incurred. Payments for
 these activities are based on the terms of the individual
 arrangements, which may differ from the pattern of costs incurred,
 and are reflected in the consolidated financial statements as
 prepaid or accrued research and development expense.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &lt;i&gt;Collaboration Arrangements&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 Costs reimbursed to a collaborator for work that it performs are
 recorded as research and development expenses. These reimbursements
 can include payments for work performed, or a milestone for which a
 payment is due, the reimbursements or development milestone
 achievement are recorded as research and development expense.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 In September 2014, the Company entered into a collaboration
 agreement with Intrexon Corporation (&amp;#x201C;Intrexon&amp;#x201D;) for
 the development and commercialization of allogeneic cell
 therapeutics for the treatment or repair of damaged articular
 hyaline cartilage in humans, utilizing Intrexon&amp;#x2019;s proprietary
 technology (the &amp;#x201C;Collaboration Agreement&amp;#x201D;). Under the
 terms of the Collaboration Agreement, the Company is responsible
 for the costs of development and commercialization, with some
 exceptions. Refer to Note 14,&amp;#xA0;&lt;i&gt;Related
 Parties&lt;/i&gt;&amp;#xA0;for
 further details on all terms, conditions and exceptions of this
 collaboration.&lt;/p&gt;
 &lt;p&gt;&amp;#xA0;&lt;/p&gt;


 &lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
  <us-gaap:ProceedsFromStockOptionsExercised contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_F517A3E7-CD09-482E-A458-78C5E43ED953_1_24">2000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" id="id_11655837_FF52C205-D7FE-47B2-8493-9294487EBF48_1_0">&lt;div&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 Accrued expenses consisted of the following:&lt;/p&gt;
 &lt;p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table cellspacing="0" cellpadding="0" width="76%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="76%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;As of
 December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;(in thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Accrued compensation&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,402&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;758&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Accrued clinical expenses&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;187&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;138&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Accrued other&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;508&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;548&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Total accrued expenses&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,097&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,444&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" unitRef="pure" decimals="3" id="id_11655837_23624064-F40E-4BAA-AF98-7BDFA20DC6F2_1_1">0.725</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:PaymentsOfStockIssuanceCosts contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_F517A3E7-CD09-482E-A458-78C5E43ED953_1_22">377000</us-gaap:PaymentsOfStockIssuanceCosts>
  <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" id="id_11655837_7462AA02-2F93-49B4-898A-7248A6C10E53_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 Stock-based compensation is as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="76%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;Year Ended&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;
 &lt;b&gt;(in&amp;#xA0;thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Research and development&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;491&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;451&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 General and administrative&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,057&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;777&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Total stock-based compensation expense&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,548&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,228&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
  <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" id="id_11655837_E1ED32CB-70F1-4D93-8757-1185B8C3528B_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 A reconciliation of income tax expense (benefit) computed at the
 statutory federal income tax rate to income taxes as reflected in
 the financial statements is as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="79%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"&gt;
 &lt;b&gt;As&amp;#xA0;of&amp;#xA0;December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Federal income tax (benefit) at statutory rate&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;34.0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;34.0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 (Increase) decrease income tax benefit resulting from:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Permanent differences&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;29.0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(1.2&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Net Operating Loss Limitation&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(111.1&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 R&amp;amp;D Credit Limitation&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(1.5&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Change in valuation allowance&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;48.7&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(31.7&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Other&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.9&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(1.2&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Income tax expense (benefit)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &amp;#xA0;&lt;/p&gt;


 &lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
  <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" id="id_11655837_E879BEE9-02F5-4792-8AE7-24A5680AA67E_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 Stock option activity under the 2012 and 2013 plans is summarized
 as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="61%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Number&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;of Options&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Weighted-&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Average&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Exercise&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Price&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Weighted-&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Average&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Remaining&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Contractual&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Term&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;(in years)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Aggregate&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Intrinsic&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Value&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;(in&amp;#xA0;thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Outstanding at December&amp;#xA0;31, 2015&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,229,339&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7.32&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;9.0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(4,679&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Granted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;464,240&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2.02&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Exercised&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(3,685&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.76&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Cancelled&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(112,878&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4.97&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Outstanding at December&amp;#xA0;31, 2016&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,577,016&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5.95&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8.4&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;71&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Vested and expected to vest at December&amp;#xA0;31, 2016&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,492,341&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5.97&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8.4&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;69&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Exercisable at December&amp;#xA0;31, 2016&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;561,693&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6.79&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7.8&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;52&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_9D59D34B-448C-4FAF-A6E9-512FD74E0A44_1_1">10000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" unitRef="shares" decimals="INF" id="id_11655837_4EA76CC8-F5DB-4BEE-8639-4745B518B6F3_5001_2">464240</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" id="id_11655837_40094BD0-BE2E-4FA9-966E-00E8B6175D45_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 Additional information about the Company&amp;#x2019;s stock option
 activity is as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="82%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"&gt;
 &lt;b&gt;Year&amp;#xA0;Ended&amp;#xA0;December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Weighted-average grant date fair value per share of employee option
 grants within the year&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.26&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4.08&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Cash received upon exercise of options&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;39&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;br class="Apple-interchange-newline" /&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_11655837_27F0019F-7953-4DCE-BCB0-7E24DFF57D91_1_0">1.26</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" id="id_11655837_A9E06BE4-F651-441D-A1C4-87A5F084685C_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;Revenue Recognition&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 In the future, if we generate revenue, it may be through license
 agreements, collaborations and product sales. The Company
 recognizes revenue when all four of the following criteria are met:
 (1)&amp;#xA0;persuasive evidence that an agreement exists;
 (2)&amp;#xA0;delivery of the products and/or services has occurred;
 (3)&amp;#xA0;the selling price is fixed or determinable; and
 (4)&amp;#xA0;collectability is reasonably assured. The Company did not
 recognize any revenue for the years ended December&amp;#xA0;31, 2016
 and 2015.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" unitRef="pure" decimals="4" id="id_11655837_23624064-F40E-4BAA-AF98-7BDFA20DC6F2_1_0">0.0173</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" unitRef="shares" decimals="INF" id="id_11655837_4EA76CC8-F5DB-4BEE-8639-4745B518B6F3_5001_4">112878</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
  <us-gaap:ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionBySupplierTextBlock contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" id="id_11655837_A04EABEC-C4AB-4003-B5F3-DDC97E52FDBF_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 The weighted-average assumptions used in the Black-Scholes option
 pricing model to determine the fair value of the non-employee stock
 option grants were as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="83%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;Year Ended&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Risk-free interest rate&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.57&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.79&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Expected volatility&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;63.5&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;63.2&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Expected term (in years)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7.00&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6.16&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Expected dividend yield&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionBySupplierTextBlock>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_F517A3E7-CD09-482E-A458-78C5E43ED953_1_6">1548000</us-gaap:ShareBasedCompensation>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" id="id_11655837_23624064-F40E-4BAA-AF98-7BDFA20DC6F2_1_2">P6Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" unitRef="pure" decimals="3" id="id_11655837_7D1D2384-E6E7-4C41-8052-1A440B12FCA4_1_3">0.000</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate>
  <us-gaap:ScheduleOfDebtTableTextBlock contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" id="id_11655837_8BAA2627-BF84-49B2-AF5D-45CE173A6267_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 As of December&amp;#xA0;31, 2016 and 2015, the Company had the
 following outstanding borrowing obligations:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="66%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="13%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="12%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;br /&gt;
 2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&lt;br /&gt;
 2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;
 &lt;b&gt;(in&amp;#xA0;thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Silicon Valley Bank Equipment Loan Payable&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;761&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,344&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Less: current portion&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(583&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(583&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Long-term debt, net&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;178&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;761&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;


 &lt;/div&gt;</us-gaap:ScheduleOfDebtTableTextBlock>
  <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_6C26F4B4-0D62-4BDF-8A8C-63D664124B3A_1_2">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities>
  <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" id="id_11655837_8F48DBE0-051C-42DF-8CC5-B5B39C42AC3C_1_0">&lt;div&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="break-inside: avoid"&gt;
 &lt;td valign="top" width="4%" align="left"&gt;&lt;b&gt;14.&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;&lt;b&gt;RELATED PARTIES&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &lt;b&gt;Intrexon Corporation&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 In September 2014, the Company entered into an Exclusive Channel
 Collaboration agreement with Intrexon (the &amp;#x201C;Collaboration
 Agreement&amp;#x201D;) to use Intrexon&amp;#x2019;s proprietary technology
 for the development and commercialization of allogeneic cell
 therapeutics (the &amp;#x201C;Collaboration Products&amp;#x201D;) to treat or
 repair damaged articular hyaline cartilage in humans. The term of
 the Collaboration Agreement commenced upon the effective date,
 September&amp;#xA0;30, 2014, and continues until either written notice
 of termination is given by the Company within ninety days, or if
 either party creates a material breach that cannot be remedied
 within sixty days.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 Under the terms of the Collaboration Agreement, the Company is
 solely responsible for the costs to develop and commercialize any
 Collaboration Products with the following exceptions: (i)&amp;#xA0;the
 establishment of certain manufacturing capabilities and facilities;
 (ii)&amp;#xA0;the cost of basic research related to Intrexon&amp;#x2019;s
 proprietary technology outside of costs related to the
 Collaboration Products; (iii)&amp;#xA0;payments related to certain
 in-licensed third party IP; (iv)&amp;#xA0;the costs of filing,
 prosecution and maintenance of Intrexon patents; and (v)&amp;#xA0;any
 other costs mutually agreed upon as being the responsibility of
 Intrexon. As partial consideration, the Company will pay
 commercialization milestones totaling $12 million, if and when
 achieved, and sales milestones totaling $22.5 million, if and when
 achieved. The milestone payments are payable in cash or shares of
 the Company&amp;#x2019;s common stock at the option of the Company. In
 the event the Company is sold prior to making any of these
 milestone payments and the Collaboration Agreement is transferred
 in the sale, the milestone payments would be payable in cash. The
 Company is also required to make low double digit royalty payments
 to Intrexon on any gross profit arising from the sale of
 Collaboration Products and to pay an intermediate double digit
 percentage of any sublicensing revenue it receives.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 Under the terms of the Collaboration Agreement, the Company
 reimburses Intrexon for 50% of the product research and development
 costs with the remaining 50% due after acceptance by the FDA or
 equivalent regulatory authority of an Investigational New Drug
 Application or equivalent regulatory filing of a collaboration
 product or upon 90 day written notice of cancellation by the
 Company. Total incurred expenses were $3.0 million and $3.1 million
 for the year ended December&amp;#xA0;31, 2016 and 2015, respectively.
 The total accrued expenses due Intrexon at December&amp;#xA0;31, 2016
 and December&amp;#xA0;31, 2015 was $3.0 million and $1.5 million,
 respectively. Amounts are reflected as current liabilities in the
 consolidated balance sheet as of December&amp;#xA0;31, 2015. Amounts
 have been reclassified to long term liabilities in the consolidated
 balance sheet as of December&amp;#xA0;31, 2016, as a result of a change
 in circumstances, including the plans for products that we are
 developing as a part of the Exclusive Channel Collaboration with
 Intrexon. These expenses were included in research and development
 in the consolidated statement of operations.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &lt;b&gt;Purpose, Co.&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 In June 2012, the Company entered into an agreement with Purpose,
 Co. to amend its previous agreements. In the previous agreements,
 Purpose, Co. granted the Company a perpetual license to its patents
 related to its exogenous tissue processor which is used in the
 development of the Company&amp;#x2019;s products. In exchange, the
 Company granted Purpose, Co. a perpetual license to all of the
 Company&amp;#x2019;s biotechnology and biomaterial for use in Japan. The
 agreement provides for Purpose, Co. to manufacture and sell
 machinery to the Company for cost until the Company&amp;#x2019;s
 products become commercially viable. The Company has also agreed to
 pay royalties on any third-party revenue generated using Purpose,
 Co.&amp;#x2019;s licensed technology.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 Under the June 2012 amendment, the Company received exclusive
 rights to all of Purpose, Co.&amp;#x2019;s technology related to the
 exogenous tissue processor, continued supply of exogenous tissue
 processors during the Company&amp;#x2019;s clinical trials, and rights
 to manufacture the exogenous tissue processors at any location the
 Company chooses. In exchange for such consideration, the Company
 named Purpose, Co. the sole manufacturer of equipment and also
 clarified the geographic territories of the exclusive license that
 Purpose Co. was granted for use of the Company&amp;#x2019;s technology.
 Also, the Company agreed to reimburse Purpose, Co. for $0.3 million
 of development costs on a next generation tissue processer. Refer
 to the discussion under Note 7,&amp;#xA0;&lt;i&gt;Tissue Processor
 Sub-License&lt;/i&gt;.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 In May 2016, the Company acquired the development and
 commercialization rights to NeoCart for the Japanese market from
 Purpose, Co. Under the terms of the amended agreement, the Company
 assumes sole responsibility for and rights to the development and
 commercialization of NeoCart in Japan. In exchange for the transfer
 of development and commercialization rights, the Company will pay a
 success-based milestone to Purpose upon conditional approval of
 NeoCart in Japan, as well as commercial milestones and a low single
 digit royalty on Japanese sales of NeoCart, upon full approval, if
 any, in Japan.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 The amounts that have been paid to Purpose, Co. under this
 agreement were $0.1 and $0.2 million for the years ended
 December&amp;#xA0;31, 2016 and 2015, respectively.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &lt;b&gt;Board of Director Affiliates&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 Affiliates of certain members of the Company&amp;#x2019;s Board of
 Directors participated in the Private Placement as described in
 Note 8.&lt;/p&gt;


 &lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" id="id_11655837_39D2169F-C53C-4F91-BB9A-DCFB692D93D8_3001_3">P8Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
  <us-gaap:SubsequentEventsTextBlock contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" id="id_11655837_23253712-9E70-4E7C-91FA-7F5412E8934C_1_0">&lt;div&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top" width="4%" align="left"&gt;&lt;b&gt;15.&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;&lt;b&gt;SUBSEQUENT EVENTS&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 On February&amp;#xA0;22, 2017, the Company entered into an amendment
 with Collagen Solutions (UK) LTD (the &amp;#x201C;Supplier&amp;#x201D;). The
 original agreement was entered into on September&amp;#xA0;15, 2015.
 Pursuant to the amendment, the Company agrees to pay the Supplier
 approximately $0.1 million in exchange for eliminating the minimum
 annual order of material and/or services and any other amounts due
 Supplier. The payment of $0.1 million will be made over the 18
 months following the date of the amendment.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
  <us-gaap:InterestPaidNet contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_F517A3E7-CD09-482E-A458-78C5E43ED953_1_33">66000</us-gaap:InterestPaidNet>
  <us-gaap:NumberOfOperatingSegments contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" unitRef="Segment" decimals="INF" id="id_11655837_AD19A7AC-7698-44D4-BA28-6830C9FF8D34_1_0">2</us-gaap:NumberOfOperatingSegments>
  <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" id="id_11655837_95511D73-57F3-4ABB-8290-1D52378317F4_1_0">&lt;div&gt;
 &lt;table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" border="0" cellpadding="0" cellspacing="0" width="100%"&gt;
 &lt;tr style="page-break-inside:avoid"&gt;
 &lt;td width="4%" valign="top" align="left"&gt;&lt;b&gt;13.&lt;/b&gt;&lt;/td&gt;
 &lt;td align="left" valign="top"&gt;&lt;b&gt;EMPLOYEE BENEFITS&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 The Company has a defined contribution 401(k) plan for employees
 who are at least 21 years of age. Employees are eligible to
 participate in the plan beginning on the first day of the calendar
 quarter following their date of hire. Under the terms of the plan,
 employees may make voluntary contributions as a percent of
 compensation. No matching contributions have been made by the
 Company since the adoption of the 401(k) plan.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
  <hsgx:MaximumPercentageOfRecognitionOfTaxBenefitsFromUncertainTaxPositions contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" unitRef="pure" decimals="INF" id="id_11655837_216A5A19-1F91-4D1C-8AC6-EB2165C69FCE_1_0">0.50</hsgx:MaximumPercentageOfRecognitionOfTaxBenefitsFromUncertainTaxPositions>
  <hsgx:ScheduleOfSharesOfCommonStockReservedForFutureIssuanceTableTextBlock contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" id="id_11655837_888BD0E9-67B6-411E-9E97-42166CEBF9EE_1_0">&lt;div&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;
 The Company has reserved for future issuance the following number
 of shares of common stock:&lt;/p&gt;
 &lt;p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table cellspacing="0" cellpadding="0" width="68%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="64%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;As of
 December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Vesting of restricted stock&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,889&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,190&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Options to purchase common stock&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,577,016&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,222,767&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Common stock warrants&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;13,633,070&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;166,403&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Total&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;15,211,975&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,394,360&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</hsgx:ScheduleOfSharesOfCommonStockReservedForFutureIssuanceTableTextBlock>
  <hsgx:PrepaidExpensesAndOtherCurrentAssetsTextBlock contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" id="id_11655837_3633C0C5-A177-4594-9957-511956E80FDF_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;4. PREPAID EXPENSES AND OTHER CURRENT ASSETS&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 Prepaid expenses and other current assets consisted of the
 following:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="82%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;As of&lt;br /&gt;
 December&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;(in
 thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Deposits&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;67&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Undelivered laboratory and office equipment&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;17&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Insurance&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;95&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;42&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Other current assets&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;68&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;195&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Prepaid expenses and other current assets&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;173&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;321&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</hsgx:PrepaidExpensesAndOtherCurrentAssetsTextBlock>
  <hsgx:DeferredRentAndLeaseIncentive contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_F517A3E7-CD09-482E-A458-78C5E43ED953_1_4">533000</hsgx:DeferredRentAndLeaseIncentive>
  <hsgx:FairMarketValueOfPrivatePlacementWarrantsAtIssuance contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_F517A3E7-CD09-482E-A458-78C5E43ED953_1_30">30704000</hsgx:FairMarketValueOfPrivatePlacementWarrantsAtIssuance>
  <hsgx:WarrantDisclosureTextBlock contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" id="id_11655837_0F828905-5FE6-4C9B-A3CA-1E52860D1D13_1_0">&lt;div&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr style="break-inside: avoid"&gt;
 &lt;td valign="top" width="4%" align="left"&gt;&lt;b&gt;9.&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;&lt;b&gt;WARRANTS&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &lt;b&gt;Investor Warrants&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 In September 2016, in connection with the Private Placement, the
 Company issued common stock warrants to the investors to purchase
 up to 13,333,334 shares of our common stock at an exercise price of
 $2.25 per share. The warrants include a cashless-exercise feature
 that may be exercised solely in the event there is no effective
 registration statement registering, or no current prospectus
 available for, the resale of the shares of common stock underlying
 the warrants as of the six-month anniversary of the closing of the
 Private Placement. The warrants became exercisable following
 approval of the Private Placement by our stockholders in the fourth
 quarter of 2016 and expire five years after the date of such
 stockholder approval. The warrants were valued at $2.28 per share
 using a Monte Carlo simulation and are marked-to-market on a
 quarterly basis with the change in value recorded as warrant
 expense or income on the consolidated statements of operations.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &lt;b&gt;Placement Agent Warrants&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 In September 2016, in connection with the Private Placement, the
 Company issued HCW and certain of its affiliates warrants for the
 purchase of 133,333 shares of common stock at an exercise price of
 $2.25 per share. The HCW warrants became exercisable following
 approval of the Private Placement by our stockholders in the fourth
 quarter of 2016 and expire five years after the date of such
 stockholder approval. The warrants were valued at $2.28 per share
 using a Monte Carlo simulation and are marked-to-market on a
 quarterly basis with the change in value recorded as warrant
 expense or income on the consolidated statements of operations.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &lt;b&gt;Affiliates of an Advisor Warrant&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 On July&amp;#xA0;20, 2012, the Company issued a warrant to purchase its
 common stock to affiliates of an advisor. The warrant provides the
 holders with the right to purchase an aggregate of 161,977 shares
 of the Company&amp;#x2019;s common stock at a per share exercise price
 of $0.01. The warrants are exercisable, in whole or in part,
 immediately upon issuance and may be exercised on a cashless basis.
 The warrants expire on the tenth anniversary of issuance. The fair
 value of the warrants as of July&amp;#xA0;20, 2012 was estimated using
 the OM with the following inputs: (a)&amp;#xA0;risk-free interest rate
 of 0.22%; (b)&amp;#xA0;implied volatility of the Company&amp;#x2019;s common
 stock of 99%; and (c)&amp;#xA0;the expected term to a liquidity event
 of 1.7 years. On December&amp;#xA0;3, 2014, the Company completed its
 IPO and warrants for 5,839 shares of common stock were surrendered
 and common stock was issued by the Company to Purpose, Co. for the
 warrant shares surrendered. As of December&amp;#xA0;31, 2016 and 2015,
 warrants to purchase an aggregate of 156,138 shares of the
 Company&amp;#x2019;s common stock at an exercise price of $0.01 are
 outstanding.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &lt;b&gt;Consulting Agreement Warrant&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 In March 2015, in connection with a consulting agreement entered
 into for an interim chief financial officer, the Company issued a
 common stock warrant as compensation to the consulting firm. The
 warrant provides the holder with the right to purchase an aggregate
 of 7,398 shares of the Company&amp;#x2019;s common stock at a per share
 exercise price of $9.75, the closing price of the Company&amp;#x2019;s
 common stock on the date of issuance. The warrant vested and became
 exercisable in monthly installments over 24 months beginning
 September&amp;#xA0;30, 2015 and expires on the tenth anniversary of
 issuance. The warrant is equity classified and accounted for using
 the fair value approach. The fair value of the warrant is estimated
 using the Black-Scholes option pricing model and is subject to
 re-measurement at each reporting period until the measurement date
 is reached. On December&amp;#xA0;21, 2015, the Company terminated the
 consulting agreement resulting in the forfeiture of 50%
 (3,699)&amp;#xA0;of the shares eligible for exercise under the warrant.
 The remaining 3,699 shares were vested and exercisable on
 December&amp;#xA0;31, 2016 and December&amp;#xA0;31, 2015.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 18pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"&gt;
 &amp;#xA0;&lt;/p&gt;


 &lt;/div&gt;</hsgx:WarrantDisclosureTextBlock>
  <hsgx:PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" id="id_11655837_AEB71B1C-1300-4719-A4F6-BD81B6873C93_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 The Company provides for depreciation and amortization using the
 straight-line method over the estimated useful lives of the assets,
 which are as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="32%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td width="63%"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" nowrap="nowrap"&gt;
 &lt;p style="MARGIN-BOTTOM: 1pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 Asset Category&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 1pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 Estimated Useful Lives&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Office equipment&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;3 to 5 years&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Laboratory equipment&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;3 to 5 years&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Leasehold improvements&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;Shorter of the remaining lease term or useful
 life&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</hsgx:PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock>
  <hsgx:EffectiveIncomeTaxRateReconciliationPermanentDifferences contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" unitRef="pure" decimals="3" id="id_11655837_9FA36880-6F95-410B-BEC1-B0E0D4FEC8F9_1_2">0.290</hsgx:EffectiveIncomeTaxRateReconciliationPermanentDifferences>
  <hsgx:InitialPublicOfferingCostsPolicyTextBlock contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" id="id_11655837_54235993-BCFD-4019-BD30-D6A3A7D72121_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;Initial Public Offering Costs&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 The Company deferred direct incremental costs attributable with the
 IPO of its common stock prior to the closing of the IPO. These
 costs represent legal, accounting and other direct costs related to
 the Company&amp;#x2019;s efforts to raise capital through a public sale
 of its common stock. Upon completion of the IPO, $3.9 million of
 IPO costs were reclassified to additional paid-in capital as a
 reduction of the IPO proceeds. As of December&amp;#xA0;31, 2014, the
 Company had paid $2.9 million with the remaining $1.0 million
 included in accounts payable in the consolidated balance sheet.
 This amount was subsequently paid in 2015.&lt;/p&gt;
 &lt;/div&gt;</hsgx:InitialPublicOfferingCostsPolicyTextBlock>
  <hsgx:LicenseAgreementsPolicyTextBlock contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" id="id_11655837_F9F3DB0E-8556-450D-A5AA-5791CFE57533_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;License Agreements&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 Costs associated with licenses of technology are expensed as
 incurred and are included in research and development expenses.&lt;/p&gt;
 &lt;/div&gt;</hsgx:LicenseAgreementsPolicyTextBlock>
  <hsgx:PatentCostsPolicyTextBlock contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" id="id_11655837_B10EE7F9-F3D5-4095-86B1-B34C9A0D1708_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"&gt;
 &lt;b&gt;Patent Costs&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 Costs related to filing and pursuing patent applications are
 recorded as general and administrative expense as incurred since
 the recoverability of such expenditures is uncertain.&lt;/p&gt;
 &lt;/div&gt;</hsgx:PatentCostsPolicyTextBlock>
  <hsgx:WarrantAccountingPolicyTextBlock contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" id="id_11655837_0DAE8913-2FFA-4A71-9EB5-39D823D639F7_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;b&gt;Warrant Accounting&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 As noted in Note 9, the Company classifies warrants to purchase
 shares of its common stock as a liability on its consolidated
 balance sheet if the warrant is a free-standing financial
 instrument that may require the Company to transfer consideration
 upon exercise. Each warrant of this type is initially recorded at
 fair value on date of grant using the Monte Carlo simulation model
 and net of issuance costs, and is subsequently re-measured to fair
 value at each subsequent balance sheet date. Changes in fair value
 of the warrants are recognized as a component of other income
 (expense), net in the consolidated statement of operations. The
 Company will continue to adjust the liability for changes in fair
 value until the earlier of the exercise or expiration of the
 warrants.&lt;/p&gt;
 &lt;/div&gt;</hsgx:WarrantAccountingPolicyTextBlock>
  <hsgx:NetIncomeLossAvailableToSeriesAPreferredStock contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_9676DC27-A3EF-4B08-B121-A6B6911EBC2F_1_2">-2345000</hsgx:NetIncomeLossAvailableToSeriesAPreferredStock>
  <hsgx:StockIssuedDuringPeriodPreferredStockValue contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_11655837_5A0DEAA9-8FA8-403D-B739-D326D818EDBC_7007_22">0</hsgx:StockIssuedDuringPeriodPreferredStockValue>
  <hsgx:EffectiveIncomeTaxRateReconciliationNetOperatingLossLimitation contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" unitRef="pure" decimals="3" id="id_11655837_9FA36880-6F95-410B-BEC1-B0E0D4FEC8F9_1_3">-1.111</hsgx:EffectiveIncomeTaxRateReconciliationNetOperatingLossLimitation>
  <hsgx:EffectiveIncomeTaxRateReconciliationRAndDCreditLimitation contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0" unitRef="pure" decimals="3" id="id_11655837_9FA36880-6F95-410B-BEC1-B0E0D4FEC8F9_1_4">-0.015</hsgx:EffectiveIncomeTaxRateReconciliationRAndDCreditLimitation>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0_2021628x2039180" unitRef="shares" decimals="INF" id="id_11655837_4AE35B66-6263-4455-8972-B15FC36D4207_1001_2">166403</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0_2021628x2039754" unitRef="shares" decimals="INF" id="id_11655837_4AE35B66-6263-4455-8972-B15FC36D4207_2001_0">1578905</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0_2022410x2022419" unitRef="iso4217_USD" decimals="-3" id="id_11655837_C8CDBCD2-A7E8-4C56-A079-BCD9A063E3D8_1001_1">30704000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
  <us-gaap:FairValueAdjustmentOfWarrants contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0_2022410x2022419" unitRef="iso4217_USD" decimals="-3" id="id_11655837_C8CDBCD2-A7E8-4C56-A079-BCD9A063E3D8_1001_2">17507000</us-gaap:FairValueAdjustmentOfWarrants>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0_2025317x2022619" id="id_11655837_9D59D34B-448C-4FAF-A6E9-512FD74E0A44_1001_3">P2Y4D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0_2025317x2041099" id="id_11655837_221B4776-CDDF-4F75-8802-3671377CDC93_1001_1">P3M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
  <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0_2025317x2041099" unitRef="iso4217_USD" decimals="-3" id="id_11655837_5A0DEAA9-8FA8-403D-B739-D326D818EDBC_7003_18">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0_2025317x2041099" unitRef="iso4217_USD" decimals="-3" id="id_11655837_5A0DEAA9-8FA8-403D-B739-D326D818EDBC_7003_24">0</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0_2025317x2041099" unitRef="shares" decimals="INF" id="id_11655837_942CD0BF-A20C-4D47-824E-ACE757FC85CE_5001_2">3301</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0_2025317x2041099" unitRef="iso4217_USD_per_shares" decimals="0" id="id_11655837_A53E2444-FE4F-4F74-815C-FA924807C41A_5001_2">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0_2025317x2041099" unitRef="shares" decimals="INF" id="id_11655837_5A0DEAA9-8FA8-403D-B739-D326D818EDBC_7003_600019">-3301</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
  <hsgx:StockIssuedDuringPeriodPreferredStockValue contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0_2025317x2041099" unitRef="iso4217_USD" decimals="-3" id="id_11655837_5A0DEAA9-8FA8-403D-B739-D326D818EDBC_7003_22">0</hsgx:StockIssuedDuringPeriodPreferredStockValue>
  <us-gaap:BusinessAcquisitionEffectiveDateOfAcquisition1 contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0_2027704x2293940" id="id_11655837_82DB38DE-AF84-4E21-A1E4-9F569EFD65C7_1001_0">2011-05-13</us-gaap:BusinessAcquisitionEffectiveDateOfAcquisition1>
  <hsgx:ClassOfWarrantOrRightExercisableExpirationPeriod contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0_2027723x2283059" id="id_11655837_6C944E68-201D-497B-9EE4-BBB539A7CF8A_1002_3">P5Y</hsgx:ClassOfWarrantOrRightExercisableExpirationPeriod>
  <hsgx:ClassOfWarrantOrRightExercisablePeriod contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0_2027723x2283059" id="id_11655837_6C944E68-201D-497B-9EE4-BBB539A7CF8A_1002_2">P6M</hsgx:ClassOfWarrantOrRightExercisablePeriod>
  <us-gaap:AdjustmentOfWarrantsGrantedForServices contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0_2027723x2394050" unitRef="iso4217_USD" decimals="2" id="id_11655837_B5EF8294-DA1A-4946-9F7E-C56AF2DB0E10_1002_3">2.28</us-gaap:AdjustmentOfWarrantsGrantedForServices>
  <hsgx:ClassOfWarrantOrRightExercisableExpirationPeriod contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0_2027723x2394050" id="id_11655837_B5EF8294-DA1A-4946-9F7E-C56AF2DB0E10_1002_2">P5Y</hsgx:ClassOfWarrantOrRightExercisableExpirationPeriod>
  <hsgx:DefinedContributionPlanEmployeeEligibilityAge contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0_2028497x2030148" id="id_11655837_C8097552-D5D9-4EC2-9311-100E7927E976_1001_0">P21Y</hsgx:DefinedContributionPlanEmployeeEligibilityAge>
  <us-gaap:RoyaltyExpense contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0_2028497x2030148_2029856x2151732" unitRef="iso4217_USD" decimals="INF" id="id_11655837_1FD2A9F2-231B-438A-AC76-8E0016BE46AF_1001_1">10000</us-gaap:RoyaltyExpense>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0_2028497x2030148_2030037x2023509" id="id_11655837_E96A65D5-D382-49A4-BBDC-0068E2F498AB_2002_1">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0_2028497x2030148_2030037x2031893" id="id_11655837_E96A65D5-D382-49A4-BBDC-0068E2F498AB_2001_1">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:RoyaltyExpense contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0_2028497x2030148_2036820x2068097" unitRef="iso4217_USD" decimals="INF" id="id_11655837_3F9291BA-8F81-419C-8DA0-1147BAF206AB_1001_0">20000</us-gaap:RoyaltyExpense>
  <hsgx:RoyaltyPaymentPercentage contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0_2028497x2030148_2038064x2336713" unitRef="pure" decimals="INF" id="id_11655837_6EF2B0AA-F664-42F1-9105-7D8F60D3AE21_1001_1">0.03</hsgx:RoyaltyPaymentPercentage>
  <hsgx:RoyaltyPaymentPercentageAsPercentageOfGrantReceived contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0_2028497x2030148_2038064x2336713" unitRef="pure" decimals="INF" id="id_11655837_6EF2B0AA-F664-42F1-9105-7D8F60D3AE21_1001_3">1.00</hsgx:RoyaltyPaymentPercentageAsPercentageOfGrantReceived>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0_2028497x2033371_2030037x2023509" id="id_11655837_E96A65D5-D382-49A4-BBDC-0068E2F498AB_3002_2">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0_2028497x2033371_2030037x2031893" id="id_11655837_E96A65D5-D382-49A4-BBDC-0068E2F498AB_3001_2">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <hsgx:RoyaltyPaymentPercentage contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0_2028497x2033371_2038064x2336713" unitRef="pure" decimals="INF" id="id_11655837_6EF2B0AA-F664-42F1-9105-7D8F60D3AE21_2001_2">0.05</hsgx:RoyaltyPaymentPercentage>
  <hsgx:RoyaltyPaymentPercentageAsPercentageOfGrantReceived contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0_2028497x2033371_2038064x2336713" unitRef="pure" decimals="INF" id="id_11655837_6EF2B0AA-F664-42F1-9105-7D8F60D3AE21_2001_4">3.00</hsgx:RoyaltyPaymentPercentageAsPercentageOfGrantReceived>
  <us-gaap:PaymentsForProceedsFromTenantAllowance contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0_2028497x2033371_2038438x2142064" unitRef="iso4217_USD" decimals="INF" id="id_11655837_3B2BAEF4-32E3-42F1-BC0D-B070F8156E23_1001_0">3200000000</us-gaap:PaymentsForProceedsFromTenantAllowance>
  <us-gaap:PaymentsForProceedsFromTenantAllowance contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0_2028497x2033371_2038438x2240869" unitRef="iso4217_USD" decimals="INF" id="id_11655837_3B2BAEF4-32E3-42F1-BC0D-B070F8156E23_2001_1">1000000</us-gaap:PaymentsForProceedsFromTenantAllowance>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0_2029841x2029413" unitRef="iso4217_USD" decimals="-3" id="id_11655837_5BDC6FE6-2849-4B6E-8481-0D6FD0744ED5_1001_1">1057000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:RestrictedStockExpense contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0_2029841x2029413" unitRef="iso4217_USD" decimals="-3" id="id_11655837_8FA11797-04AB-46E0-8AAE-AEA61A40519E_1001_1">2000</us-gaap:RestrictedStockExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0_2029841x2035076" unitRef="iso4217_USD" decimals="-3" id="id_11655837_5BDC6FE6-2849-4B6E-8481-0D6FD0744ED5_2001_0">491000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0_2029841x2035076_2038452x2183197" unitRef="iso4217_USD" decimals="-5" id="id_11655837_7442F8D7-2D4D-4BC2-86FB-09636C3F6B44_1001_2">3000000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
  <hsgx:PercentageOfReimbursementExpenses contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0_2029841x2035076_2038452x2183197" unitRef="pure" decimals="2" id="id_11655837_7442F8D7-2D4D-4BC2-86FB-09636C3F6B44_1001_0">0.50</hsgx:PercentageOfReimbursementExpenses>
  <hsgx:PercentageOfReimbursementExpensesSubjectToAcceptance contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0_2029841x2035076_2038452x2183197" unitRef="pure" decimals="2" id="id_11655837_7442F8D7-2D4D-4BC2-86FB-09636C3F6B44_1001_1">0.50</hsgx:PercentageOfReimbursementExpensesSubjectToAcceptance>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0_2029856x2112516" unitRef="iso4217_USD" decimals="-5" id="id_11655837_A17C9037-EA62-4CAD-A97B-6BF6BB28B1C7_1001_0">3200000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0_2029856x2151732" unitRef="iso4217_USD" decimals="-5" id="id_11655837_FDB2003B-6EFF-4A7F-A9F2-080F1FE9B6A6_1001_0">700000</us-gaap:ResearchAndDevelopmentExpense>
  <hsgx:PercentageOfRoyaltyOffsetting contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0_2029856x2151732" unitRef="pure" decimals="2" id="id_11655837_1FD2A9F2-231B-438A-AC76-8E0016BE46AF_2001_2">0.50</hsgx:PercentageOfRoyaltyOffsetting>
  <us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0_2030037x2028633" id="id_11655837_E96A65D5-D382-49A4-BBDC-0068E2F498AB_3_3">Shorter of the remaining  lease term or useful life</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
  <us-gaap:OperatingLossCarryforwardsExpirationDate contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0_2031777x2024782" id="id_11655837_F58303BF-A32D-4120-87E5-203E27551ADE_1001_1">2036-12-31</us-gaap:OperatingLossCarryforwardsExpirationDate>
  <us-gaap:OperatingLossCarryforwardsExpirationDate contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0_2031777x2037951" id="id_11655837_F58303BF-A32D-4120-87E5-203E27551ADE_2001_3">2036-12-31</us-gaap:OperatingLossCarryforwardsExpirationDate>
  <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0_2035448x2031417" unitRef="iso4217_USD" decimals="-5" id="id_11655837_6C55B9EC-B951-4E97-BF6B-4F0E28F0FC4F_2_0">200000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0_2036820x2068097" unitRef="iso4217_USD" decimals="-5" id="id_11655837_B247ABC3-1C74-4961-83E9-DBBE77BA41D9_1001_0">1000000</us-gaap:ResearchAndDevelopmentExpense>
  <hsgx:AdditionalRoyaltyExpense contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0_2036820x2068097" unitRef="iso4217_USD" decimals="-3" id="id_11655837_3F9291BA-8F81-419C-8DA0-1147BAF206AB_2001_2">30000</hsgx:AdditionalRoyaltyExpense>
  <hsgx:AdditionalNonRefundableRoyaltyFeePaymentDescription contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0_2036820x2068097" id="id_11655837_3F9291BA-8F81-419C-8DA0-1147BAF206AB_2001_3">2016 through           2019</hsgx:AdditionalNonRefundableRoyaltyFeePaymentDescription>
  <us-gaap:LesseeLeasingArrangementsOperatingLeasesRenewalTerm contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0_2038438x2142064" id="id_11655837_A377027C-6814-47BD-A8D6-4A4B37EB60D0_1_1">P5Y</us-gaap:LesseeLeasingArrangementsOperatingLeasesRenewalTerm>
  <hsgx:NumberOfAdditionalRenewalOptions contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0_2038438x2142064" unitRef="Options" decimals="INF" id="id_11655837_A377027C-6814-47BD-A8D6-4A4B37EB60D0_1_0">2</hsgx:NumberOfAdditionalRenewalOptions>
  <us-gaap:LesseeLeasingArrangementsOperatingLeasesRenewalTerm contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0_2038438x2240869" id="id_11655837_A377027C-6814-47BD-A8D6-4A4B37EB60D0_2_1">P5Y</us-gaap:LesseeLeasingArrangementsOperatingLeasesRenewalTerm>
  <hsgx:NumberOfAdditionalRenewalOptions contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0_2038438x2240869" unitRef="Options" decimals="INF" id="id_11655837_A377027C-6814-47BD-A8D6-4A4B37EB60D0_2_0">1</hsgx:NumberOfAdditionalRenewalOptions>
  <us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0_2038452x2128515" unitRef="iso4217_USD" decimals="-5" id="id_11655837_4C09E3B2-695D-40E0-83E5-C27E63516AAE_1001_0">100000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
  <hsgx:CollaborationAgreementTerminationNoticePeriodOnUnremediedMaterialBreach contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0_2038452x2183197" id="id_11655837_C628C0D1-9E31-45A9-925D-5AE7F50EB195_1001_1">P60D</hsgx:CollaborationAgreementTerminationNoticePeriodOnUnremediedMaterialBreach>
  <hsgx:CollaborationAgreementTerminationNoticePeriod contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0_2038452x2183197" id="id_11655837_C628C0D1-9E31-45A9-925D-5AE7F50EB195_1001_0">P90D</hsgx:CollaborationAgreementTerminationNoticePeriod>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0_2039549x2037928" unitRef="shares" decimals="INF" id="id_11655837_4AE35B66-6263-4455-8972-B15FC36D4207_3001_1">5962817</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0_2039549x2159266" unitRef="iso4217_USD" decimals="-3" id="id_11655837_7EE727ED-2B5B-4314-A01B-2ACB6184A985_5001_7">0</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0_2039549x2159266" unitRef="shares" decimals="INF" id="id_11655837_7EE727ED-2B5B-4314-A01B-2ACB6184A985_5001_400008">-10743</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <hsgx:StockIssuedDuringPeriodSharesPreferredStock contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0_2039549x2159266" unitRef="shares" decimals="0" id="id_11655837_7EE727ED-2B5B-4314-A01B-2ACB6184A985_5001_400006">24159</hsgx:StockIssuedDuringPeriodSharesPreferredStock>
  <hsgx:StockIssuedDuringPeriodPreferredStockValue contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0_2039549x2159266" unitRef="iso4217_USD" decimals="-3" id="id_11655837_7EE727ED-2B5B-4314-A01B-2ACB6184A985_5001_5">0</hsgx:StockIssuedDuringPeriodPreferredStockValue>
  <us-gaap:AdjustmentOfWarrantsGrantedForServices contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0_2040137x2032595" unitRef="iso4217_USD" decimals="-5" id="id_11655837_102311C5-EE81-4B25-95D6-D4CD4F86911D_1001_5">3100000</us-gaap:AdjustmentOfWarrantsGrantedForServices>
  <us-gaap:ConversionOfStockSharesConverted1 contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0_2040137x2032595" unitRef="shares" decimals="INF" id="id_11655837_DD744067-5A4C-4DA1-BFCD-AE0955DF4828_1001_1">444.44</us-gaap:ConversionOfStockSharesConverted1>
  <hsgx:FairValueOfWarrantLiabilitiesInExcessOfProceedsReceived contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0_2040137x2032595" unitRef="iso4217_USD" decimals="-5" id="id_11655837_102311C5-EE81-4B25-95D6-D4CD4F86911D_1001_4">400000</hsgx:FairValueOfWarrantLiabilitiesInExcessOfProceedsReceived>
  <hsgx:BeneficialOwnershipMinimumPercentageOfOutstandingCommonStock contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0_2040137x2032595" unitRef="pure" decimals="INF" id="id_11655837_102311C5-EE81-4B25-95D6-D4CD4F86911D_1001_0">0.50</hsgx:BeneficialOwnershipMinimumPercentageOfOutstandingCommonStock>
  <hsgx:ClassOfWarrantOrRightExercisableExpirationPeriod contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0_2040137x2032595" id="id_11655837_102311C5-EE81-4B25-95D6-D4CD4F86911D_1001_1">P5Y</hsgx:ClassOfWarrantOrRightExercisableExpirationPeriod>
  <hsgx:ClassOfWarrantOrRightExercisablePeriod contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0_2040137x2032595" id="id_11655837_102311C5-EE81-4B25-95D6-D4CD4F86911D_1001_2">P6M</hsgx:ClassOfWarrantOrRightExercisablePeriod>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0_2040323x2025075" unitRef="iso4217_USD" decimals="-3" id="id_11655837_5A0DEAA9-8FA8-403D-B739-D326D818EDBC_7005_800015">1548000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0_2040323x2025075" unitRef="iso4217_USD" decimals="-3" id="id_11655837_5A0DEAA9-8FA8-403D-B739-D326D818EDBC_7005_18">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0_2040323x2025075" unitRef="iso4217_USD" decimals="-3" id="id_11655837_5A0DEAA9-8FA8-403D-B739-D326D818EDBC_7005_24">0</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0_2040323x2025075" unitRef="iso4217_USD" decimals="-3" id="id_11655837_5A0DEAA9-8FA8-403D-B739-D326D818EDBC_7005_800016">2000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <hsgx:StockIssuedDuringPeriodPreferredStockValue contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0_2040323x2025075" unitRef="iso4217_USD" decimals="-3" id="id_11655837_5A0DEAA9-8FA8-403D-B739-D326D818EDBC_7005_22">0</hsgx:StockIssuedDuringPeriodPreferredStockValue>
  <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0_2040323x2027302" unitRef="iso4217_USD" decimals="-3" id="id_11655837_5A0DEAA9-8FA8-403D-B739-D326D818EDBC_7001_18">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0_2040323x2027302" unitRef="shares" decimals="INF" id="id_11655837_5A0DEAA9-8FA8-403D-B739-D326D818EDBC_7001_400017">3685</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0_2040323x2027302" unitRef="iso4217_USD" decimals="-3" id="id_11655837_5A0DEAA9-8FA8-403D-B739-D326D818EDBC_7001_24">0</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0_2040323x2027302" unitRef="shares" decimals="INF" id="id_11655837_5A0DEAA9-8FA8-403D-B739-D326D818EDBC_7001_400025">4774398</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0_2040323x2027302" unitRef="iso4217_USD" decimals="-3" id="id_11655837_5A0DEAA9-8FA8-403D-B739-D326D818EDBC_7001_500020">26000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0_2040323x2027302" unitRef="iso4217_USD" decimals="-3" id="id_11655837_5A0DEAA9-8FA8-403D-B739-D326D818EDBC_7001_500016">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0_2040323x2027302" unitRef="shares" decimals="INF" id="id_11655837_5A0DEAA9-8FA8-403D-B739-D326D818EDBC_7001_400021">2596059</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0_2040323x2027302" unitRef="shares" decimals="INF" id="id_11655837_5A0DEAA9-8FA8-403D-B739-D326D818EDBC_7001_400019">3301</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
  <hsgx:StockIssuedDuringPeriodPreferredStockValue contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0_2040323x2027302" unitRef="iso4217_USD" decimals="-3" id="id_11655837_5A0DEAA9-8FA8-403D-B739-D326D818EDBC_7001_22">0</hsgx:StockIssuedDuringPeriodPreferredStockValue>
  <us-gaap:NetIncomeLoss contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0_2040323x2037658" unitRef="iso4217_USD" decimals="-3" id="id_11655837_5A0DEAA9-8FA8-403D-B739-D326D818EDBC_7006_900026">-16208000</us-gaap:NetIncomeLoss>
  <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0_2040323x2037658" unitRef="iso4217_USD" decimals="-3" id="id_11655837_5A0DEAA9-8FA8-403D-B739-D326D818EDBC_7006_18">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0_2040323x2037658" unitRef="iso4217_USD" decimals="-3" id="id_11655837_5A0DEAA9-8FA8-403D-B739-D326D818EDBC_7006_24">0</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <hsgx:StockIssuedDuringPeriodPreferredStockValue contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0_2040323x2037658" unitRef="iso4217_USD" decimals="-3" id="id_11655837_5A0DEAA9-8FA8-403D-B739-D326D818EDBC_7006_22">0</hsgx:StockIssuedDuringPeriodPreferredStockValue>
  <us-gaap:PaymentsToSuppliers contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0_2040972x2099546" unitRef="iso4217_USD" decimals="-5" id="id_11655837_34EC763B-4AFE-4EDC-AF5F-C96D6CB3EFA5_1001_0">600000</us-gaap:PaymentsToSuppliers>
  <us-gaap:LongTermPurchaseCommitmentDescription contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0_2040972x2163139" id="id_11655837_4F52247A-4CAB-4623-86A5-29FE3949BF1B_1003_3">The initial term of the agreement is  three years and will automatically renew from year to year thereafter unless  otherwise terminated with at least 180 days&apos; notice by either party.</us-gaap:LongTermPurchaseCommitmentDescription>
  <hsgx:OriginalAgreementDate contextRef="eol_PE717962--1610-K0012_STD_366_20161231_0_2040972x2163139" id="id_11655837_A15627CC-77BD-445D-8610-F809C9386E0C_2001_0">2015-09-15</hsgx:OriginalAgreementDate>
  <us-gaap:PaymentsToSuppliers contextRef="eol_PE717962--1610-K0012_STD_92_20161231_0_2040972x2099546" unitRef="iso4217_USD" decimals="-5" id="id_11655837_34EC763B-4AFE-4EDC-AF5F-C96D6CB3EFA5_1002_0">200000</us-gaap:PaymentsToSuppliers>
  <context id="eol_PE717962--1610-K0012_STD_92_20161231_0_2040972x2099546">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">hsgx:EngineeringAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-10-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_366_20161231_0_2040972x2163139">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">hsgx:CollagenSupplyAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_366_20161231_0_2040972x2099546">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">hsgx:EngineeringAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_366_20161231_0_2040323x2037658">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_366_20161231_0_2040323x2027302">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_366_20161231_0_2040323x2025075">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_366_20161231_0_2040137x2032595">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_366_20161231_0_2039549x2159266">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hsgx:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_366_20161231_0_2039549x2037928">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_366_20161231_0_2038452x2183197">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">hsgx:IntrexonMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_366_20161231_0_2038452x2128515">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">hsgx:PurposeCoMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_366_20161231_0_2038438x2240869">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">hsgx:LexingtonMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_366_20161231_0_2038438x2142064">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">hsgx:WalthamMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_366_20161231_0_2036820x2068097">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">hsgx:TissueProcessorSubLicenseAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_366_20161231_0_2035448x2031417">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_366_20161231_0_2031777x2037951">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_366_20161231_0_2031777x2024782">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_366_20161231_0_2030037x2028633">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_366_20161231_0_2029856x2151732">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">hsgx:TissueRegenerationLicenseAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_366_20161231_0_2029856x2112516">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">hsgx:HydrogelLicenseAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_366_20161231_0_2029841x2035076_2038452x2183197">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">hsgx:IntrexonMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_366_20161231_0_2029841x2035076">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_366_20161231_0_2029841x2029413">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_366_20161231_0_2028497x2033371_2038438x2240869">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">hsgx:LexingtonMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_366_20161231_0_2028497x2033371_2038438x2142064">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">hsgx:WalthamMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_366_20161231_0_2028497x2033371_2038064x2336713">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">hsgx:OcsAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_366_20161231_0_2028497x2033371_2030037x2031893">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_366_20161231_0_2028497x2033371_2030037x2023509">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_366_20161231_0_2028497x2030148_2038064x2336713">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">hsgx:OcsAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_366_20161231_0_2028497x2030148_2036820x2068097">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">hsgx:TissueProcessorSubLicenseAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_366_20161231_0_2028497x2030148_2030037x2031893">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_366_20161231_0_2028497x2030148_2030037x2023509">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_366_20161231_0_2028497x2030148_2029856x2151732">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">hsgx:TissueRegenerationLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_366_20161231_0_2028497x2030148">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_366_20161231_0_2027723x2394050">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">hsgx:PlacementAgentWarrantMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_366_20161231_0_2027723x2283059">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">hsgx:InvestorWarrantsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_366_20161231_0_2027704x2293940">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">hsgx:ProChonBiotechLtdMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_366_20161231_0_2025317x2041099">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_366_20161231_0_2025317x2022619">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_366_20161231_0_2022410x2022419">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_366_20161231_0_2021628x2039754">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_366_20161231_0_2021628x2039180">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_366_20161231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_365_20171231_0_2029102x2377267_2039338x2038269">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">hsgx:TwoThousandAndThirteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioForecastMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_365_20171231_0_2027922x2423931_2029102x2253325_2039338x2038269">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">hsgx:EipAmendmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">hsgx:TwoThousandAndThirteenEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioForecastMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_365_20151231_0_2040972x2163139">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">hsgx:CollagenSupplyAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_365_20151231_0_2040323x2037658">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_365_20151231_0_2040323x2027302">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_365_20151231_0_2040323x2025075">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_365_20151231_0_2038452x2128515">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">hsgx:PurposeCoMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_365_20151231_0_2035448x2031417">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_365_20151231_0_2029841x2035076_2038452x2183197">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">hsgx:IntrexonMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_365_20151231_0_2029841x2035076">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_365_20151231_0_2029841x2029413">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_365_20151231_0_2025317x2041099">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_365_20151231_0_2025317x2022619">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_365_20151231_0_2021628x2039754">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_365_20151231_0_2021628x2039180">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_365_20151231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_31_20150131_0_2040137x2030849">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-01-31</endDate>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_31_20141031_0_2029102x2253325_2037398x2038872">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">hsgx:TwoThousandAndThirteenEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-10-01</startDate>
      <endDate>2014-10-31</endDate>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_31_20141031_0_2029102x2253325">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">hsgx:TwoThousandAndThirteenEquityIncentivePlanMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-10-01</startDate>
      <endDate>2014-10-31</endDate>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_31_20141031_0_2027922x2423931_2029102x2253325">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">hsgx:EipAmendmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">hsgx:TwoThousandAndThirteenEquityIncentivePlanMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-10-01</startDate>
      <endDate>2014-10-31</endDate>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_31_20140731_0_2033330x2361826_2039383x2035998">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">hsgx:SiliconValleyBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-07-01</startDate>
      <endDate>2014-07-31</endDate>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_31_20140731_0_2033330x2361826">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">hsgx:SiliconValleyBankMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-07-01</startDate>
      <endDate>2014-07-31</endDate>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_31_20120731_0_2029102x2176993_2037398x2038872">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">hsgx:TwoThousandAndTwelveEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-07-01</startDate>
      <endDate>2012-07-31</endDate>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_31_20120731_0_2029102x2176993">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">hsgx:TwoThousandAndTwelveEquityIncentivePlanMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-07-01</startDate>
      <endDate>2012-07-31</endDate>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_30_20150930_0_2040972x2163139">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">hsgx:CollagenSupplyAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-09-01</startDate>
      <endDate>2015-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_30_20120630_0_2036820x2068097">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">hsgx:TissueProcessorSubLicenseAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-06-01</startDate>
      <endDate>2012-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_273_20150930_0_2027723x2068134">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">hsgx:ConsultingAgreementWarrantMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_1_20161231_0_2027723x2068134">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">hsgx:ConsultingAgreementWarrantMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-12-31</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_1_20151231_0_2027723x2068134">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">hsgx:ConsultingAgreementWarrantMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-12-31</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_1_20141231_0_2040137x2029877">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-12-31</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_1_20160929_0_2040137x2032595">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-09-29</startDate>
      <endDate>2016-09-29</endDate>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_1_20160929_0_2039549x2037928_2040137x2032595">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-09-29</startDate>
      <endDate>2016-09-29</endDate>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_1_20160929_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
    </entity>
    <period>
      <startDate>2016-09-29</startDate>
      <endDate>2016-09-29</endDate>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_1_20160616_0_2027922x2423931_2029102x2253325">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">hsgx:EipAmendmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">hsgx:TwoThousandAndThirteenEquityIncentivePlanMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-06-16</startDate>
      <endDate>2016-06-16</endDate>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_1_20120720_0_2027723x2424282">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">hsgx:AffiliatesOfAdvisorWarrantMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-07-20</startDate>
      <endDate>2012-07-20</endDate>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_1_20170222_0_2039338x2038269_2040972x2163139">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">hsgx:CollagenSupplyAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioForecastMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-02-22</startDate>
      <endDate>2017-02-22</endDate>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_1_20151221_0_2027723x2068134">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">hsgx:ConsultingAgreementWarrantMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-12-21</startDate>
      <endDate>2015-12-21</endDate>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_1_20141203_0_2040137x2029877">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-12-03</startDate>
      <endDate>2014-12-03</endDate>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_1_20141203_0_2029102x2377267">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">hsgx:TwoThousandAndThirteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-12-03</startDate>
      <endDate>2014-12-03</endDate>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_1_20141203_0_2027723x2424282">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">hsgx:AffiliatesOfAdvisorWarrantMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-12-03</startDate>
      <endDate>2014-12-03</endDate>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_1_20141203_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
    </entity>
    <period>
      <startDate>2014-12-03</startDate>
      <endDate>2014-12-03</endDate>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_1_20110513_0_2027704x2293940">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">hsgx:ProChonBiotechLtdMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-05-13</startDate>
      <endDate>2011-05-13</endDate>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_0_20161231_0_2040972x2099546">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">hsgx:EngineeringAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_0_20161231_0_2040323x2039180">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_0_20161231_0_2040323x2037658">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_0_20161231_0_2040323x2027302">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_0_20161231_0_2040323x2025075">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_0_20161231_0_2040137x2032595">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_0_20161231_0_2039550x2037985">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:US</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_0_20161231_0_2039549x2159266">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hsgx:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_0_20161231_0_2038452x2183197">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">hsgx:IntrexonMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_0_20161231_0_2038064x2336713">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">hsgx:OcsAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_0_20161231_0_2037554x2255485_2040137x2032595">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">hsgx:MembersOfBoardOfDirectorsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_0_20161231_0_2036820x2339473_2038452x2183197">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">hsgx:IntrexonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">hsgx:CommercialMilestonesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_0_20161231_0_2036820x2313845_2038452x2183197">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">hsgx:IntrexonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">hsgx:SalesMilestoneMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_0_20161231_0_2036820x2068097">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">hsgx:TissueProcessorSubLicenseAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_0_20161231_0_2035448x2031417">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_0_20161231_0_2033330x2361826">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">hsgx:SiliconValleyBankMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_0_20161231_0_2031777x2037951">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_0_20161231_0_2031777x2024782">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_0_20161231_0_2031777x2024390">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_0_20161231_0_2030037x2037949">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_0_20161231_0_2030037x2031893">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_0_20161231_0_2030037x2028633">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_0_20161231_0_2030037x2024062">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_0_20161231_0_2030037x2023509">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_0_20161231_0_2029856x2151732">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">hsgx:TissueRegenerationLicenseAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_0_20161231_0_2029856x2112516">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">hsgx:HydrogelLicenseAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_0_20161231_0_2027829x2103098">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">hsgx:WarrantLiabilityMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_0_20161231_0_2027723x2424282">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">hsgx:AffiliatesOfAdvisorWarrantMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_0_20161231_0_2027723x2283059">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">hsgx:InvestorWarrantsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_0_20161231_0_2026315x2029281">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_0_20161231_0_2025317x2041099">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_0_20161231_0_2025317x2022619">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_0_20161231_0_2022410x2026970_2026315x2029281">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_0_20161231_0_2022410x2026970_2025340x2029281">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_0_20161231_0_2022410x2026970">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_0_20161231_0_2022410x2022419_2027829x2103098">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">hsgx:WarrantLiabilityMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_0_20161231_0_2022410x2022419">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_0_20161231_0_2022410x2021995">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_0_20161231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_0_20151231_0_2040323x2039180">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_0_20151231_0_2040323x2037658">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_0_20151231_0_2040323x2027302">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_0_20151231_0_2040323x2025075">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_0_20151231_0_2039550x2037985">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:US</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_0_20151231_0_2039550x2032405">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:IL</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_0_20151231_0_2039549x2159266">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hsgx:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_0_20151231_0_2038452x2183197">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">hsgx:IntrexonMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_0_20151231_0_2035448x2031417">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_0_20151231_0_2033330x2361826">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">hsgx:SiliconValleyBankMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_0_20151231_0_2031777x2037951">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_0_20151231_0_2031777x2024782">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_0_20151231_0_2031777x2024390">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_0_20151231_0_2030037x2037949">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_0_20151231_0_2030037x2031893">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_0_20151231_0_2030037x2028633">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_0_20151231_0_2030037x2024062">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_0_20151231_0_2030037x2023509">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_0_20151231_0_2027723x2424282">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">hsgx:AffiliatesOfAdvisorWarrantMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_0_20151231_0_2026315x2029281">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_0_20151231_0_2025317x2041099">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_0_20151231_0_2025317x2022619">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_0_20151231_0_2022410x2026970_2026315x2029281">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_0_20151231_0_2022410x2026970_2025340x2029281">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_0_20151231_0_2022410x2026970">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_0_20151231_0_2022410x2022419">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_0_20151231_0_2022410x2021995">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_0_20151231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_0_20141231_0_2040323x2037658">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_0_20141231_0_2040323x2027302">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_0_20141231_0_2040323x2025075">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_0_20141231_0_2040137x2029877">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_0_20141231_0_2029102x2176993">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">hsgx:TwoThousandAndTwelveEquityIncentivePlanMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_0_20141231_0_2025317x2041099">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_0_20141231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_0_20160930_0_2027723x2394050">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">hsgx:PlacementAgentWarrantMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-09-30</instant>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_0_20160930_0_2027723x2283059">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">hsgx:InvestorWarrantsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-09-30</instant>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_0_20160929_0_2040137x2032595">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-09-29</instant>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_0_20160929_0_2039549x2037928_2040137x2032595">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-09-29</instant>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_0_20160929_0_2039549x2037928">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-09-29</instant>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_0_20160630_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
    </entity>
    <period>
      <instant>2016-06-30</instant>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_0_20120720_0_2027723x2424282">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">hsgx:AffiliatesOfAdvisorWarrantMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-07-20</instant>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_0_20120630_0_2038452x2128515">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">hsgx:PurposeCoMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-06-30</instant>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_0_20170314_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
    </entity>
    <period>
      <instant>2017-03-14</instant>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_0_20150331_0_2027723x2068134">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">hsgx:ConsultingAgreementWarrantMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-03-31</instant>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_0_20150131_0_2040137x2030849">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-01-31</instant>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_0_20141203_0_2040137x2029877">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-12-03</instant>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_0_20141203_0_2029102x2377267">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">hsgx:TwoThousandAndThirteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-12-03</instant>
    </period>
  </context>
  <context id="eol_PE717962--1610-K0012_STD_0_20140731_0_2033330x2361826">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001372299</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">hsgx:SiliconValleyBankMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-07-31</instant>
    </period>
  </context>
  <unit id="pure">
    <measure>pure</measure>
  </unit>
  <unit id="iso4217_USD_per_shares">
    <divide>
      <unitNumerator>
        <measure>iso4217:USD</measure>
      </unitNumerator>
      <unitDenominator>
        <measure>shares</measure>
      </unitDenominator>
    </divide>
  </unit>
  <unit id="shares">
    <measure>shares</measure>
  </unit>
  <unit id="iso4217_USD">
    <measure>iso4217:USD</measure>
  </unit>
  <unit id="Segment">
    <measure>hsgx:Segment</measure>
  </unit>
  <unit id="Options">
    <measure>hsgx:Options</measure>
  </unit>
</xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>hsgx-20161231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- RR Donnelley Xcelerate Taxonomy Schema, based on XBRL 2.1  http://www.rrdonnelley.com/ -->
<!-- Version: 6.23.6 -->
<!-- Round: 5 -->
<!-- Creation date: 2017-03-15T19:04:29Z -->
<!-- Copyright (c) 2005-2013 R.R. Donnelley & Sons Company All Rights Reserved. -->
<schema xmlns="http://www.w3.org/2001/XMLSchema"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:us-gaap="http://fasb.org/us-gaap/2016-01-31"
  xmlns:us-types="http://fasb.org/us-types/2016-01-31"
  xmlns:hsgx="http://www.histogenics.com/20161231"
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  xmlns:country="http://xbrl.sec.gov/country/2016-01-31"
  xmlns:currency="http://xbrl.sec.gov/currency/2016-01-31"
  xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31"
  xmlns:exch="http://xbrl.sec.gov/exch/2016-01-31"
  xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31"
  xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31"
  xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31"
  targetNamespace="http://www.histogenics.com/20161231"
  elementFormDefault="qualified" attributeFormDefault="unqualified">
  <annotation>
    <appinfo>
      <link:roleType roleURI="http://www.histogenics.com/taxonomy/role/DocumentandEntityInformation" id="DocumentandEntityInformation">
        <link:definition>101 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.histogenics.com/taxonomy/role/StatementOfFinancialPositionClassified" id="Role_StatementOfFinancialPositionClassified">
        <link:definition>103 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.histogenics.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical" id="Role_StatementOfFinancialPositionClassifiedParen">
        <link:definition>104 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.histogenics.com/taxonomy/role/StatementOfIncomeAlternative" id="Role_StatementOfIncomeAlternative">
        <link:definition>105 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.histogenics.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome" id="Role_StatementOfShareholdersEquityAndOtherComprehensiveIncome">
        <link:definition>106 - Statement - Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.histogenics.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncomeParenthetical" id="Role_StatementOfShareholdersEquityAndOtherComprehensiveIncomeParen">
        <link:definition>107 - Statement - Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Parenthetical)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.histogenics.com/taxonomy/role/StatementOfCashFlowsIndirect" id="Role_StatementOfCashFlowsIndirect">
        <link:definition>108 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.histogenics.com/taxonomy/role/StatementOfCashFlowsIndirectParenthetical" id="Role_StatementOfCashFlowsIndirectParen">
        <link:definition>109 - Statement - Consolidated Statements of Cash Flows (Parenthetical)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsNatureOfOperations" id="Role_NotesToFinancialStatementsNatureOfOperations">
        <link:definition>110 - Disclosure - Nature of Business</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock" id="Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock">
        <link:definition>111 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock" id="Role_NotesToFinancialStatementsEarningsPerShareTextBlock">
        <link:definition>112 - Disclosure - Loss Per Common Share</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsPrepaidExpensesAndOtherCurrentAssetsTextBlock" id="Role_NotesToFinancialStatementsPrepaidExpensesAndOtherCurrentAssetsTextBlock">
        <link:definition>113 - Disclosure - Prepaid Expenses and Other Current Assets</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock" id="Role_NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock">
        <link:definition>114 - Disclosure - Property and Equipment</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="Role_NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
        <link:definition>115 - Disclosure - Accrued Expenses</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock" id="Role_NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock">
        <link:definition>116 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock" id="Role_NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock">
        <link:definition>117 - Disclosure - Capital Stock</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsWarrantDisclosureTextBlock" id="Role_NotesToFinancialStatementsWarrantDisclosureTextBlock">
        <link:definition>118 - Disclosure - Warrants</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlock" id="Role_NotesToFinancialStatementsDebtDisclosureTextBlock">
        <link:definition>119 - Disclosure - Equipment Loan Payable</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="Role_NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
        <link:definition>120 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock" id="Role_NotesToFinancialStatementsIncomeTaxDisclosureTextBlock">
        <link:definition>121 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsPensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="Role_NotesToFinancialStatementsPensionAndOtherPostretirementBenefitsDisclosureTextBlock">
        <link:definition>122 - Disclosure - Employee Benefits</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock" id="Role_NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock">
        <link:definition>123 - Disclosure - Related Parties</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock" id="Role_NotesToFinancialStatementsSubsequentEventsTextBlock">
        <link:definition>124 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies" id="Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies">
        <link:definition>125 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockTables" id="Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockTables">
        <link:definition>126 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlockTables" id="Role_NotesToFinancialStatementsEarningsPerShareTextBlockTables">
        <link:definition>127 - Disclosure - Loss Per Common Share (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsPrepaidExpensesAndOtherCurrentAssetsTextBlockTables" id="Role_NotesToFinancialStatementsPrepaidExpensesAndOtherCurrentAssetsTextBlockTables">
        <link:definition>128 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlockTables" id="Role_NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlockTables">
        <link:definition>129 - Disclosure - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlockTables" id="Role_NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlockTables">
        <link:definition>130 - Disclosure - Accrued Expenses (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlockTables" id="Role_NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlockTables">
        <link:definition>131 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlockTables" id="Role_NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlockTables">
        <link:definition>132 - Disclosure - Capital Stock (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlockTables" id="Role_NotesToFinancialStatementsDebtDisclosureTextBlockTables">
        <link:definition>133 - Disclosure - Equipment Loan Payable (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables" id="Role_NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables">
        <link:definition>134 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlockTables" id="Role_NotesToFinancialStatementsIncomeTaxDisclosureTextBlockTables">
        <link:definition>135 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.histogenics.com/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformation" id="DisclosureNatureOfBusinessAdditionalInformation">
        <link:definition>136 - Disclosure - Nature of Business - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.histogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation" id="DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation">
        <link:definition>137 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.histogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfOperationsInDifferentGeographicRegions" id="DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfOperationsInDifferentGeographicRegions">
        <link:definition>138 - Disclosure - Summary of Significant Accounting Policies - Summary of Operations in Different Geographic Regions (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.histogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasis" id="DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasis">
        <link:definition>139 - Disclosure - Summary of Significant Accounting Policies - Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.histogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfLiabilitiesMeasuredAtFairValue" id="DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfLiabilitiesMeasuredAtFairValue">
        <link:definition>140 - Disclosure - Summary of Significant Accounting Policies - Schedule of Reconciliation of Liabilities Measured at Fair Value (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.histogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfDepreciationAndAmortizationUsingStraightlineMethodOverEstimatedUsefulLivesOfAssets" id="DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfDepreciationAndAmortizationUsingStraightlineMethodOverEstimatedUsefulLivesOfAssets">
        <link:definition>141 - Disclosure - Summary of Significant Accounting Policies - Schedule of Depreciation and Amortization using Straight-line Method over Estimated Useful Lives of Assets (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.histogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfIntangibleAssetsNetOfAccumulatedImpairmentCharges" id="DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfIntangibleAssetsNetOfAccumulatedImpairmentCharges">
        <link:definition>142 - Disclosure - Summary of Significant Accounting Policies - Summary of Intangible Assets, Net of Accumulated Impairment Charges (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.histogenics.com/taxonomy/role/DisclosureLossPerCommonShareScheduleOfBasicAndDilutedLossPerCommonShare" id="DisclosureLossPerCommonShareScheduleOfBasicAndDilutedLossPerCommonShare">
        <link:definition>143 - Disclosure - Loss Per Common Share - Schedule of Basic and Diluted Loss Per Common Share (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.histogenics.com/taxonomy/role/DisclosureLossPerCommonShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShare" id="DisclosureLossPerCommonShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShare">
        <link:definition>144 - Disclosure - Loss Per Common Share - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.histogenics.com/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssets" id="DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssets">
        <link:definition>145 - Disclosure - Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.histogenics.com/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipment" id="DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipment">
        <link:definition>146 - Disclosure - Property and Equipment - Schedule of Property and Equipment (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.histogenics.com/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformation" id="DisclosurePropertyAndEquipmentAdditionalInformation">
        <link:definition>147 - Disclosure - Property and Equipment - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.histogenics.com/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpenses" id="DisclosureAccruedExpensesScheduleOfAccruedExpenses">
        <link:definition>148 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.histogenics.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation" id="DisclosureCommitmentsAndContingenciesAdditionalInformation">
        <link:definition>149 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.histogenics.com/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMinimumAnnualLeaseCommitmentsUnderNonCancellableOperatingLeases" id="DisclosureCommitmentsAndContingenciesScheduleOfMinimumAnnualLeaseCommitmentsUnderNonCancellableOperatingLeases">
        <link:definition>150 - Disclosure - Commitments and Contingencies - Schedule of Minimum Annual Lease Commitments Under Non-Cancellable Operating Leases (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.histogenics.com/taxonomy/role/DisclosureCapitalStockAdditionalInformation" id="DisclosureCapitalStockAdditionalInformation">
        <link:definition>151 - Disclosure - Capital Stock - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.histogenics.com/taxonomy/role/DisclosureCapitalStockScheduleOfCommonStockReservedForFutureIssuance" id="DisclosureCapitalStockScheduleOfCommonStockReservedForFutureIssuance">
        <link:definition>152 - Disclosure - Capital Stock - Schedule of Common Stock Reserved for Future Issuance (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.histogenics.com/taxonomy/role/DisclosureWarrantsAdditionalInformation" id="DisclosureWarrantsAdditionalInformation">
        <link:definition>153 - Disclosure - Warrants - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.histogenics.com/taxonomy/role/DisclosureEquipmentLoanPayableScheduleOfOutstandingBorrowingObligations" id="DisclosureEquipmentLoanPayableScheduleOfOutstandingBorrowingObligations">
        <link:definition>154 - Disclosure - Equipment Loan Payable - Schedule of Outstanding Borrowing Obligations (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.histogenics.com/taxonomy/role/DisclosureEquipmentLoanPayableAdditionalInformation" id="DisclosureEquipmentLoanPayableAdditionalInformation">
        <link:definition>155 - Disclosure - Equipment Loan Payable - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.histogenics.com/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformation" id="DisclosureStockBasedCompensationAdditionalInformation">
        <link:definition>156 - Disclosure - Stock-Based Compensation - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.histogenics.com/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityUnderThe2012And2013Plans" id="DisclosureStockBasedCompensationSummaryOfStockOptionActivityUnderThe2012And2013Plans">
        <link:definition>157 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity Under the 2012 and 2013 Plans (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.histogenics.com/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationAboutStockOptionActivity" id="DisclosureStockBasedCompensationAdditionalInformationAboutStockOptionActivity">
        <link:definition>158 - Disclosure - Stock-Based Compensation - Additional Information about Stock Option Activity (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.histogenics.com/taxonomy/role/DisclosureStockBasedCompensationScheduleOfRestrictedStockAwardsUnderThe2012And2013Plans" id="DisclosureStockBasedCompensationScheduleOfRestrictedStockAwardsUnderThe2012And2013Plans">
        <link:definition>159 - Disclosure - Stock-Based Compensation - Schedule of Restricted Stock Awards Under the 2012 and 2013 Plans (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.histogenics.com/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockBasedCompensation" id="DisclosureStockBasedCompensationSummaryOfStockBasedCompensation">
        <link:definition>160 - Disclosure - Stock-Based Compensation - Summary of Stock-Based Compensation (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.histogenics.com/taxonomy/role/DisclosureStockBasedCompensationSummaryOfWeightedAverageAssumptionsUsedInTheBlackScholesOptionPricingModelToDetermineTheFairValueOfTheEmployeeStockOptionGrants" id="DisclosureStockBasedCompensationSummaryOfWeightedAverageAssumptionsUsedInTheBlackScholesOptionPricingModelToDetermineTheFairValueOfTheEmployeeStockOptionGrants">
        <link:definition>161 - Disclosure - Stock-Based Compensation - Summary of Weighted-Average Assumptions Used in the Black-Scholes Option Pricing Model to Determine the Fair Value of the Employee Stock Option Grants (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.histogenics.com/taxonomy/role/DisclosureStockBasedCompensationSummaryOfWeightedAverageAssumptionsUsedInTheBlackScholesOptionPricingModelToDetermineTheFairValueOfTheNonEmployeeStockOptionGrants" id="DisclosureStockBasedCompensationSummaryOfWeightedAverageAssumptionsUsedInTheBlackScholesOptionPricingModelToDetermineTheFairValueOfTheNonEmployeeStockOptionGrants">
        <link:definition>162 - Disclosure - Stock-Based Compensation - Summary of Weighted-Average Assumptions Used in the Black-Scholes Option Pricing Model to Determine the Fair Value of the Non-Employee Stock Option Grants (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.histogenics.com/taxonomy/role/DisclosureIncomeTaxesComponentsOfLossBeforeIncomeTaxes" id="DisclosureIncomeTaxesComponentsOfLossBeforeIncomeTaxes">
        <link:definition>163 - Disclosure - Income Taxes - Components of Loss Before Income Taxes (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.histogenics.com/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseBenefitComputedAtStatutoryFederalIncomeTaxRate" id="DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseBenefitComputedAtStatutoryFederalIncomeTaxRate">
        <link:definition>164 - Disclosure - Income Taxes - Schedule of Reconciliation of Income Tax Expense (Benefit) Computed at Statutory Federal Income Tax Rate (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.histogenics.com/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilities" id="DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilities">
        <link:definition>165 - Disclosure - Income Taxes - Components of Deferred Tax Assets and Liabilities (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.histogenics.com/taxonomy/role/DisclosureIncomeTaxesAdditionalInformation" id="DisclosureIncomeTaxesAdditionalInformation">
        <link:definition>166 - Disclosure - Income Taxes - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.histogenics.com/taxonomy/role/DisclosureIncomeTaxesSummaryOfChangesInUnrecognizedTaxBenefits" id="DisclosureIncomeTaxesSummaryOfChangesInUnrecognizedTaxBenefits">
        <link:definition>167 - Disclosure - Income Taxes - Summary of Changes In Unrecognized Tax Benefits (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.histogenics.com/taxonomy/role/DisclosureEmployeeBenefitsAdditionalInformation" id="DisclosureEmployeeBenefitsAdditionalInformation">
        <link:definition>168 - Disclosure - Employee Benefits - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.histogenics.com/taxonomy/role/DisclosureRelatedPartiesAdditionalInformation" id="DisclosureRelatedPartiesAdditionalInformation">
        <link:definition>169 - Disclosure - Related Parties - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.histogenics.com/taxonomy/role/DisclosureSubsequentEventsAdditionalInformation" id="DisclosureSubsequentEventsAdditionalInformation">
        <link:definition>170 - Disclosure - Subsequent Events - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:href="hsgx-20161231_cal.xml" xlink:title="Calculation Links, all"/>
      <link:linkbaseRef xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:href="hsgx-20161231_def.xml" xlink:title="Definition Links, all"/>
      <link:linkbaseRef xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:href="hsgx-20161231_lab.xml" xlink:title="Label Links, all"/>
      <link:linkbaseRef xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:href="hsgx-20161231_pre.xml" xlink:title="Presentation Links, all"/>
    </appinfo>
  </annotation>
  <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <import namespace="http://fasb.org/us-types/2016-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2016/elts/us-types-2016-01-31.xsd"/>
  <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <import namespace="http://fasb.org/us-gaap/2016-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/country/2016-01-31" schemaLocation="http://xbrl.sec.gov/country/2016/country-2016-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/currency/2016-01-31" schemaLocation="http://xbrl.sec.gov/currency/2016/currency-2016-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/dei/2014-01-31" schemaLocation="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/exch/2016-01-31" schemaLocation="http://xbrl.sec.gov/exch/2016/exch-2016-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/naics/2011-01-31" schemaLocation="http://xbrl.sec.gov/naics/2011/naics-2011-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/stpr/2011-01-31" schemaLocation="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd"/>
  <element name="AccruedClinicalExpensesCurrent" id="hsgx_AccruedClinicalExpensesCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AdditionalNonRefundableRoyaltyFeePaymentDescription" id="hsgx_AdditionalNonRefundableRoyaltyFeePaymentDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AdditionalRoyaltyExpense" id="hsgx_AdditionalRoyaltyExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AdjustmentOfWarrantsGrantedForServicesPerShareValue" id="hsgx_AdjustmentOfWarrantsGrantedForServicesPerShareValue" type="num:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AffiliatesOfAdvisorWarrantMember" id="hsgx_AffiliatesOfAdvisorWarrantMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="BeneficialOwnershipMinimumPercentageOfOutstandingCommonStock" id="hsgx_BeneficialOwnershipMinimumPercentageOfOutstandingCommonStock" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ClassOfWarrantOrRightExercisableExpirationPeriod" id="hsgx_ClassOfWarrantOrRightExercisableExpirationPeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ClassOfWarrantOrRightExercisablePeriod" id="hsgx_ClassOfWarrantOrRightExercisablePeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsIssuedForService" id="hsgx_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsIssuedForService" type="num:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ClassOfWarrantOrRightForfeitureInPeriod" id="hsgx_ClassOfWarrantOrRightForfeitureInPeriod" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ClassOfWarrantOrRightForfeitureInPeriodPercentage" id="hsgx_ClassOfWarrantOrRightForfeitureInPeriodPercentage" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsIssuedForService" id="hsgx_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsIssuedForService" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ClassOfWarrantOrRightNumberOfSecuritiesSurrendered" id="hsgx_ClassOfWarrantOrRightNumberOfSecuritiesSurrendered" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ClassOfWarrantOrRightVestedAndExercisable" id="hsgx_ClassOfWarrantOrRightVestedAndExercisable" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="CollaborationAgreementTerminationNoticePeriod" id="hsgx_CollaborationAgreementTerminationNoticePeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="CollaborationAgreementTerminationNoticePeriodOnUnremediedMaterialBreach" id="hsgx_CollaborationAgreementTerminationNoticePeriodOnUnremediedMaterialBreach" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="CollagenSupplyAgreementMember" id="hsgx_CollagenSupplyAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="CommercializationMilestonesObligation" id="hsgx_CommercializationMilestonesObligation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="CommercialMilestonesMember" id="hsgx_CommercialMilestonesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ConsultingAgreementWarrantMember" id="hsgx_ConsultingAgreementWarrantMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DeferredRentAndLeaseIncentive" id="hsgx_DeferredRentAndLeaseIncentive" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DeferredTaxAssetsCapitalizedStartUpCosts" id="hsgx_DeferredTaxAssetsCapitalizedStartUpCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DeferredTaxLiabilitiesChangeInAccountingMethod" id="hsgx_DeferredTaxLiabilitiesChangeInAccountingMethod" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DefinedContributionPlanEmployeeEligibilityAge" id="hsgx_DefinedContributionPlanEmployeeEligibilityAge" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DevelopmentCostReimbursementCommitment" id="hsgx_DevelopmentCostReimbursementCommitment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DocumentAndEntityInformationAbstract" id="hsgx_DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="EffectiveIncomeTaxRateReconciliationNetOperatingLossLimitation" id="hsgx_EffectiveIncomeTaxRateReconciliationNetOperatingLossLimitation" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="EffectiveIncomeTaxRateReconciliationPermanentDifferences" id="hsgx_EffectiveIncomeTaxRateReconciliationPermanentDifferences" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="EffectiveIncomeTaxRateReconciliationRAndDCreditLimitation" id="hsgx_EffectiveIncomeTaxRateReconciliationRAndDCreditLimitation" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="EipAmendmentMember" id="hsgx_EipAmendmentMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="EngineeringAgreementMember" id="hsgx_EngineeringAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="FairMarketValueOfPrivatePlacementWarrantsAtIssuance" id="hsgx_FairMarketValueOfPrivatePlacementWarrantsAtIssuance" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="FairValueInputAmountTransferBetweenLevels" id="hsgx_FairValueInputAmountTransferBetweenLevels" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="FairValueOfWarrantLiabilitiesInExcessOfProceedsReceived" id="hsgx_FairValueOfWarrantLiabilitiesInExcessOfProceedsReceived" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="GrossProceedsFromIssuanceOfCommonStockPreferredStockAndWarrants" id="hsgx_GrossProceedsFromIssuanceOfCommonStockPreferredStockAndWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="HydrogelLicenseAgreementMember" id="hsgx_HydrogelLicenseAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="IncomeTaxesDisclosureLineItems" id="hsgx_IncomeTaxesDisclosureLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="IncomeTaxesDisclosureTable" id="hsgx_IncomeTaxesDisclosureTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem"/>
  <element name="InitialPublicOfferingCostsPolicyTextBlock" id="hsgx_InitialPublicOfferingCostsPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="IntrexonMember" id="hsgx_IntrexonMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="InvestorWarrantsMember" id="hsgx_InvestorWarrantsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="LexingtonMember" id="hsgx_LexingtonMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="LicenseAgreementsPolicyTextBlock" id="hsgx_LicenseAgreementsPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="MaximumPercentageOfRecognitionOfTaxBenefitsFromUncertainTaxPositions" id="hsgx_MaximumPercentageOfRecognitionOfTaxBenefitsFromUncertainTaxPositions" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="MaximumThresholdPercentageOfBeneficialCommonStockInterestOnHoldersDiscretion" id="hsgx_MaximumThresholdPercentageOfBeneficialCommonStockInterestOnHoldersDiscretion" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="MembersOfBoardOfDirectorsMember" id="hsgx_MembersOfBoardOfDirectorsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="MinimumThresholdPercentageOfBeneficialCommonStockInterest" id="hsgx_MinimumThresholdPercentageOfBeneficialCommonStockInterest" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="NatureOfBusinessAbstract" id="hsgx_NatureOfBusinessAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="NatureOfBusinessAndBasisOfPresentationLineItems" id="hsgx_NatureOfBusinessAndBasisOfPresentationLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="NatureOfBusinessAndBasisOfPresentationTable" id="hsgx_NatureOfBusinessAndBasisOfPresentationTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem"/>
  <element name="NetIncomeLossAvailableToSeriesAPreferredStock" id="hsgx_NetIncomeLossAvailableToSeriesAPreferredStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="NumberOfAdditionalRenewalOptions" id="hsgx_NumberOfAdditionalRenewalOptions" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="OcsAgreementMember" id="hsgx_OcsAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="OperatingLossCarryforwardsNetOfLimitations" id="hsgx_OperatingLossCarryforwardsNetOfLimitations" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="OriginalAgreementDate" id="hsgx_OriginalAgreementDate" type="xbrli:dateItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PatentCostsPolicyTextBlock" id="hsgx_PatentCostsPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PaymentForLicenseAgreementReimbursementOfCosts" id="hsgx_PaymentForLicenseAgreementReimbursementOfCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PercentageOfReimbursementExpenses" id="hsgx_PercentageOfReimbursementExpenses" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PercentageOfReimbursementExpensesSubjectToAcceptance" id="hsgx_PercentageOfReimbursementExpensesSubjectToAcceptance" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PercentageOfRoyaltyOffsetting" id="hsgx_PercentageOfRoyaltyOffsetting" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PlacementAgentWarrantMember" id="hsgx_PlacementAgentWarrantMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PrepaidExpensesAndOtherCurrentAssetsTextBlock" id="hsgx_PrepaidExpensesAndOtherCurrentAssetsTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ProceedsFromIssuanceInitialPublicOfferingNet" id="hsgx_ProceedsFromIssuanceInitialPublicOfferingNet" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ProChonBiotechLtdMember" id="hsgx_ProChonBiotechLtdMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" id="hsgx_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PurchaseCommitmentNonrefundablePayment" id="hsgx_PurchaseCommitmentNonrefundablePayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PurposeCoMember" id="hsgx_PurposeCoMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="RemainingOfferingCostsIncludedInAccountsPayable" id="hsgx_RemainingOfferingCostsIncludedInAccountsPayable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="RepaymentPeriod" id="hsgx_RepaymentPeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="RoyaltyPaymentPercentage" id="hsgx_RoyaltyPaymentPercentage" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="RoyaltyPaymentPercentageAsPercentageOfGrantReceived" id="hsgx_RoyaltyPaymentPercentageAsPercentageOfGrantReceived" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SalesMilestoneMember" id="hsgx_SalesMilestoneMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SalesMilestonesPaymentsObligation" id="hsgx_SalesMilestonesPaymentsObligation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ScheduleOfSharesOfCommonStockReservedForFutureIssuanceTableTextBlock" id="hsgx_ScheduleOfSharesOfCommonStockReservedForFutureIssuanceTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SeriesAConvertiblePreferredStockMember" id="hsgx_SeriesAConvertiblePreferredStockMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue" id="hsgx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue" type="num:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SiliconValleyBankMember" id="hsgx_SiliconValleyBankMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="StockIssuedDuringPeriodPreferredStockValue" id="hsgx_StockIssuedDuringPeriodPreferredStockValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="StockIssuedDuringPeriodSharesOverallotmentNetOfFeesAndIssuanceCosts" id="hsgx_StockIssuedDuringPeriodSharesOverallotmentNetOfFeesAndIssuanceCosts" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="StockIssuedDuringPeriodSharesPreferredStock" id="hsgx_StockIssuedDuringPeriodSharesPreferredStock" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="StockIssuedDuringPeriodValueOverallotmentNetOfFeesAndIssuanceCosts" id="hsgx_StockIssuedDuringPeriodValueOverallotmentNetOfFeesAndIssuanceCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SummaryOfSignificantAccountingPoliciesLineItems" id="hsgx_SummaryOfSignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SummaryOfSignificantAccountingPoliciesTable" id="hsgx_SummaryOfSignificantAccountingPoliciesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem"/>
  <element name="TissueProcessorSubLicenseAgreementMember" id="hsgx_TissueProcessorSubLicenseAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="TissueRegenerationLicenseAgreementMember" id="hsgx_TissueRegenerationLicenseAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="TwoThousandAndThirteenEmployeeStockPurchasePlanMember" id="hsgx_TwoThousandAndThirteenEmployeeStockPurchasePlanMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="TwoThousandAndThirteenEquityIncentivePlanMember" id="hsgx_TwoThousandAndThirteenEquityIncentivePlanMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="TwoThousandAndTwelveEquityIncentivePlanMember" id="hsgx_TwoThousandAndTwelveEquityIncentivePlanMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="WalthamMember" id="hsgx_WalthamMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="WarrantAccountingPolicyTextBlock" id="hsgx_WarrantAccountingPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="WarrantDisclosureTextBlock" id="hsgx_WarrantDisclosureTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="WarrantLiabilityMember" id="hsgx_WarrantLiabilityMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>hsgx-20161231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- RR Donnelley Xcelerate Taxonomy Calculation Linkbase, based on XBRL 2.1  http://www.rrdonnelley.com/ -->
<!-- Version: 6.23.6 -->
<!-- Round: 5 -->
<!-- Creation date: 2017-03-15T19:04:29Z -->
<!-- Copyright (c) 2005-2013 R.R. Donnelley & Sons Company All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#DocumentandEntityInformation" roleURI="http://www.histogenics.com/taxonomy/role/DocumentandEntityInformation"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#Role_StatementOfFinancialPositionClassified" roleURI="http://www.histogenics.com/taxonomy/role/StatementOfFinancialPositionClassified"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#Role_StatementOfFinancialPositionClassifiedParen" roleURI="http://www.histogenics.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#Role_StatementOfIncomeAlternative" roleURI="http://www.histogenics.com/taxonomy/role/StatementOfIncomeAlternative"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#Role_StatementOfShareholdersEquityAndOtherComprehensiveIncome" roleURI="http://www.histogenics.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#Role_StatementOfShareholdersEquityAndOtherComprehensiveIncomeParen" roleURI="http://www.histogenics.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncomeParenthetical"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#Role_StatementOfCashFlowsIndirect" roleURI="http://www.histogenics.com/taxonomy/role/StatementOfCashFlowsIndirect"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#Role_StatementOfCashFlowsIndirectParen" roleURI="http://www.histogenics.com/taxonomy/role/StatementOfCashFlowsIndirectParenthetical"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#DisclosureNatureOfBusinessAdditionalInformation" roleURI="http://www.histogenics.com/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation" roleURI="http://www.histogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfOperationsInDifferentGeographicRegions" roleURI="http://www.histogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfOperationsInDifferentGeographicRegions"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasis" roleURI="http://www.histogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasis"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfLiabilitiesMeasuredAtFairValue" roleURI="http://www.histogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfLiabilitiesMeasuredAtFairValue"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfDepreciationAndAmortizationUsingStraightlineMethodOverEstimatedUsefulLivesOfAssets" roleURI="http://www.histogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfDepreciationAndAmortizationUsingStraightlineMethodOverEstimatedUsefulLivesOfAssets"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfIntangibleAssetsNetOfAccumulatedImpairmentCharges" roleURI="http://www.histogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfIntangibleAssetsNetOfAccumulatedImpairmentCharges"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#DisclosureLossPerCommonShareScheduleOfBasicAndDilutedLossPerCommonShare" roleURI="http://www.histogenics.com/taxonomy/role/DisclosureLossPerCommonShareScheduleOfBasicAndDilutedLossPerCommonShare"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#DisclosureLossPerCommonShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShare" roleURI="http://www.histogenics.com/taxonomy/role/DisclosureLossPerCommonShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShare"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssets" roleURI="http://www.histogenics.com/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssets"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipment" roleURI="http://www.histogenics.com/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipment"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#DisclosurePropertyAndEquipmentAdditionalInformation" roleURI="http://www.histogenics.com/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#DisclosureAccruedExpensesScheduleOfAccruedExpenses" roleURI="http://www.histogenics.com/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpenses"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#DisclosureCommitmentsAndContingenciesAdditionalInformation" roleURI="http://www.histogenics.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#DisclosureCommitmentsAndContingenciesScheduleOfMinimumAnnualLeaseCommitmentsUnderNonCancellableOperatingLeases" roleURI="http://www.histogenics.com/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMinimumAnnualLeaseCommitmentsUnderNonCancellableOperatingLeases"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#DisclosureCapitalStockAdditionalInformation" roleURI="http://www.histogenics.com/taxonomy/role/DisclosureCapitalStockAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#DisclosureCapitalStockScheduleOfCommonStockReservedForFutureIssuance" roleURI="http://www.histogenics.com/taxonomy/role/DisclosureCapitalStockScheduleOfCommonStockReservedForFutureIssuance"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#DisclosureWarrantsAdditionalInformation" roleURI="http://www.histogenics.com/taxonomy/role/DisclosureWarrantsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#DisclosureEquipmentLoanPayableScheduleOfOutstandingBorrowingObligations" roleURI="http://www.histogenics.com/taxonomy/role/DisclosureEquipmentLoanPayableScheduleOfOutstandingBorrowingObligations"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#DisclosureEquipmentLoanPayableAdditionalInformation" roleURI="http://www.histogenics.com/taxonomy/role/DisclosureEquipmentLoanPayableAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#DisclosureStockBasedCompensationAdditionalInformation" roleURI="http://www.histogenics.com/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#DisclosureStockBasedCompensationSummaryOfStockOptionActivityUnderThe2012And2013Plans" roleURI="http://www.histogenics.com/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityUnderThe2012And2013Plans"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#DisclosureStockBasedCompensationAdditionalInformationAboutStockOptionActivity" roleURI="http://www.histogenics.com/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationAboutStockOptionActivity"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#DisclosureStockBasedCompensationScheduleOfRestrictedStockAwardsUnderThe2012And2013Plans" roleURI="http://www.histogenics.com/taxonomy/role/DisclosureStockBasedCompensationScheduleOfRestrictedStockAwardsUnderThe2012And2013Plans"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#DisclosureStockBasedCompensationSummaryOfStockBasedCompensation" roleURI="http://www.histogenics.com/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockBasedCompensation"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#DisclosureStockBasedCompensationSummaryOfWeightedAverageAssumptionsUsedInTheBlackScholesOptionPricingModelToDetermineTheFairValueOfTheEmployeeStockOptionGrants" roleURI="http://www.histogenics.com/taxonomy/role/DisclosureStockBasedCompensationSummaryOfWeightedAverageAssumptionsUsedInTheBlackScholesOptionPricingModelToDetermineTheFairValueOfTheEmployeeStockOptionGrants"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#DisclosureStockBasedCompensationSummaryOfWeightedAverageAssumptionsUsedInTheBlackScholesOptionPricingModelToDetermineTheFairValueOfTheNonEmployeeStockOptionGrants" roleURI="http://www.histogenics.com/taxonomy/role/DisclosureStockBasedCompensationSummaryOfWeightedAverageAssumptionsUsedInTheBlackScholesOptionPricingModelToDetermineTheFairValueOfTheNonEmployeeStockOptionGrants"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#DisclosureIncomeTaxesComponentsOfLossBeforeIncomeTaxes" roleURI="http://www.histogenics.com/taxonomy/role/DisclosureIncomeTaxesComponentsOfLossBeforeIncomeTaxes"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseBenefitComputedAtStatutoryFederalIncomeTaxRate" roleURI="http://www.histogenics.com/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseBenefitComputedAtStatutoryFederalIncomeTaxRate"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilities" roleURI="http://www.histogenics.com/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilities"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#DisclosureIncomeTaxesAdditionalInformation" roleURI="http://www.histogenics.com/taxonomy/role/DisclosureIncomeTaxesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#DisclosureIncomeTaxesSummaryOfChangesInUnrecognizedTaxBenefits" roleURI="http://www.histogenics.com/taxonomy/role/DisclosureIncomeTaxesSummaryOfChangesInUnrecognizedTaxBenefits"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#DisclosureEmployeeBenefitsAdditionalInformation" roleURI="http://www.histogenics.com/taxonomy/role/DisclosureEmployeeBenefitsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#DisclosureRelatedPartiesAdditionalInformation" roleURI="http://www.histogenics.com/taxonomy/role/DisclosureRelatedPartiesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#DisclosureSubsequentEventsAdditionalInformation" roleURI="http://www.histogenics.com/taxonomy/role/DisclosureSubsequentEventsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#Role_NotesToFinancialStatementsNatureOfOperations" roleURI="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsNatureOfOperations"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock" roleURI="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies" roleURI="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockTables" roleURI="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#Role_NotesToFinancialStatementsEarningsPerShareTextBlock" roleURI="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#Role_NotesToFinancialStatementsEarningsPerShareTextBlockTables" roleURI="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#Role_NotesToFinancialStatementsPrepaidExpensesAndOtherCurrentAssetsTextBlock" roleURI="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsPrepaidExpensesAndOtherCurrentAssetsTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#Role_NotesToFinancialStatementsPrepaidExpensesAndOtherCurrentAssetsTextBlockTables" roleURI="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsPrepaidExpensesAndOtherCurrentAssetsTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#Role_NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock" roleURI="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#Role_NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlockTables" roleURI="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#Role_NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" roleURI="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#Role_NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlockTables" roleURI="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#Role_NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock" roleURI="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#Role_NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlockTables" roleURI="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#Role_NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock" roleURI="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#Role_NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlockTables" roleURI="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#Role_NotesToFinancialStatementsWarrantDisclosureTextBlock" roleURI="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsWarrantDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#Role_NotesToFinancialStatementsDebtDisclosureTextBlock" roleURI="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#Role_NotesToFinancialStatementsDebtDisclosureTextBlockTables" roleURI="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#Role_NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" roleURI="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#Role_NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables" roleURI="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#Role_NotesToFinancialStatementsIncomeTaxDisclosureTextBlock" roleURI="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#Role_NotesToFinancialStatementsIncomeTaxDisclosureTextBlockTables" roleURI="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#Role_NotesToFinancialStatementsPensionAndOtherPostretirementBenefitsDisclosureTextBlock" roleURI="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsPensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#Role_NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock" roleURI="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#Role_NotesToFinancialStatementsSubsequentEventsTextBlock" roleURI="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock"/>
  <calculationLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/DocumentandEntityInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/StatementOfFinancialPositionClassified">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:label="us-gaap_AccountsPayableRelatedPartiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRentCreditCurrent" xlink:label="us-gaap_DeferredRentCreditCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="us-gaap_DeferredRentCreditNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueLeasesCurrent" xlink:label="us-gaap_DeferredRevenueLeasesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="us-gaap_DueToRelatedPartiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DueToRelatedPartiesNoncurrent" xlink:label="us-gaap_DueToRelatedPartiesNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncentiveFromLessor" xlink:label="us-gaap_IncentiveFromLessor"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LoansPayableCurrent" xlink:label="us-gaap_LoansPayableCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermLoansPayable" xlink:label="us-gaap_LongTermLoansPayable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductWarrantyAccrualNoncurrent" xlink:label="us-gaap_ProductWarrantyAccrualNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="1.0300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1.0400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="1.0500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" order="1.0600" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="1.1400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_DueToRelatedPartiesNoncurrent" order="1.1500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_DeferredRentCreditNoncurrent" order="1.1600" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_IncentiveFromLessor" order="1.1700" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LongTermLoansPayable" order="1.1800" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_ProductWarrantyAccrualNoncurrent" order="1.1900" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="1.2000" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="1.2500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="1.0700" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableRelatedPartiesCurrent" order="1.0800" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1.0900" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_DueToRelatedPartiesCurrent" order="1.1000" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_DeferredRentCreditCurrent" order="1.1100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_DeferredRevenueLeasesCurrent" order="1.1200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LoansPayableCurrent" order="1.1300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="1.2100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="1.2200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="1.2300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="1.2400" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/StatementOfIncomeAlternative">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentOfWarrantsGrantedForServices" xlink:label="us-gaap_AdjustmentOfWarrantsGrantedForServices"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="1.0500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NonoperatingIncomeExpense" order="1.1000" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InterestExpense" order="1.0600" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="1.0700" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_AdjustmentOfWarrantsGrantedForServices" order="1.0800" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="1.0900" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" order="1.0300" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncomeParenthetical">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/StatementOfCashFlowsIndirect">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentOfWarrantsGrantedForServices" xlink:label="us-gaap_AdjustmentOfWarrantsGrantedForServices"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_DeferredRentAndLeaseIncentive" xlink:label="hsgx_DeferredRentAndLeaseIncentive"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepaymentsOfDebt" xlink:label="us-gaap_RepaymentsOfDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" order="1.1300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" order="1.1500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" order="1.2000" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" order="1.1600" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="1.1700" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_RepaymentsOfDebt" order="1.1800" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="1.1900" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_NetIncomeLoss" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_Depreciation" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="hsgx_DeferredRentAndLeaseIncentive" order="1.0300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" order="1.0400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_ShareBasedCompensation" order="1.0500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="1.0600" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_AdjustmentOfWarrantsGrantedForServices" order="1.0700" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="1.0800" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent" order="1.0900" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="1.1000" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" order="1.1100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="1.1200" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/StatementOfCashFlowsIndirectParenthetical">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfOperationsInDifferentGeographicRegions">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasis">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfLiabilitiesMeasuredAtFairValue">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfDepreciationAndAmortizationUsingStraightlineMethodOverEstimatedUsefulLivesOfAssets">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfIntangibleAssetsNetOfAccumulatedImpairmentCharges">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" order="1.0200" weight="-1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/DisclosureLossPerCommonShareScheduleOfBasicAndDilutedLossPerCommonShare">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:label="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_NetIncomeLossAvailableToSeriesAPreferredStock" xlink:label="hsgx_NetIncomeLossAvailableToSeriesAPreferredStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLoss" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="hsgx_NetIncomeLossAvailableToSeriesAPreferredStock" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="1.0300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="1.0400" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="1.0500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" order="1.0600" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/DisclosureLossPerCommonShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShare">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssets">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepositAssets" xlink:label="us-gaap_DepositAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Supplies" xlink:label="us-gaap_Supplies"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_DepositAssets" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_Supplies" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidInsurance" order="1.0300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent" order="1.0400" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipment">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1.0300" weight="-1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpenses">
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_AccruedClinicalExpensesCurrent" xlink:label="hsgx_AccruedClinicalExpensesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="hsgx_AccruedClinicalExpensesCurrent" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="1.0300" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMinimumAnnualLeaseCommitmentsUnderNonCancellableOperatingLeases">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" order="1.0300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" order="1.0400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" order="1.0500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" order="1.0600" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/DisclosureCapitalStockAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/DisclosureCapitalStockScheduleOfCommonStockReservedForFutureIssuance">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/DisclosureWarrantsAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/DisclosureEquipmentLoanPayableScheduleOfOutstandingBorrowingObligations">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LoansPayable" xlink:label="us-gaap_LoansPayable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LoansPayableCurrent" xlink:label="us-gaap_LoansPayableCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermLoansPayable" xlink:label="us-gaap_LongTermLoansPayable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LoansPayable" xlink:to="us-gaap_LoansPayableCurrent" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LoansPayable" xlink:to="us-gaap_LongTermLoansPayable" order="1.0200" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/DisclosureEquipmentLoanPayableAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityUnderThe2012And2013Plans">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationAboutStockOptionActivity">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/DisclosureStockBasedCompensationScheduleOfRestrictedStockAwardsUnderThe2012And2013Plans">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockBasedCompensation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/DisclosureStockBasedCompensationSummaryOfWeightedAverageAssumptionsUsedInTheBlackScholesOptionPricingModelToDetermineTheFairValueOfTheEmployeeStockOptionGrants">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/DisclosureStockBasedCompensationSummaryOfWeightedAverageAssumptionsUsedInTheBlackScholesOptionPricingModelToDetermineTheFairValueOfTheNonEmployeeStockOptionGrants">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/DisclosureIncomeTaxesComponentsOfLossBeforeIncomeTaxes">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" order="1.0200" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseBenefitComputedAtStatutoryFederalIncomeTaxRate">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_EffectiveIncomeTaxRateReconciliationNetOperatingLossLimitation" xlink:label="hsgx_EffectiveIncomeTaxRateReconciliationNetOperatingLossLimitation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_EffectiveIncomeTaxRateReconciliationPermanentDifferences" xlink:label="hsgx_EffectiveIncomeTaxRateReconciliationPermanentDifferences"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_EffectiveIncomeTaxRateReconciliationRAndDCreditLimitation" xlink:label="hsgx_EffectiveIncomeTaxRateReconciliationRAndDCreditLimitation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="hsgx_EffectiveIncomeTaxRateReconciliationPermanentDifferences" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="hsgx_EffectiveIncomeTaxRateReconciliationNetOperatingLossLimitation" order="1.0300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="hsgx_EffectiveIncomeTaxRateReconciliationRAndDCreditLimitation" order="1.0400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="1.0500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" order="1.0600" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilities">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_DeferredTaxAssetsCapitalizedStartUpCosts" xlink:label="hsgx_DeferredTaxAssetsCapitalizedStartUpCosts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_DeferredTaxLiabilitiesChangeInAccountingMethod" xlink:label="hsgx_DeferredTaxLiabilitiesChangeInAccountingMethod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:label="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" order="1.0900" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="hsgx_DeferredTaxLiabilitiesChangeInAccountingMethod" order="1.1000" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" order="1.0300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="hsgx_DeferredTaxAssetsCapitalizedStartUpCosts" order="1.0400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOther" order="1.0500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsNet" order="1.0800" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="1.1100" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsGross" order="1.0600" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="1.0700" weight="-1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/DisclosureIncomeTaxesAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/DisclosureIncomeTaxesSummaryOfChangesInUnrecognizedTaxBenefits">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/DisclosureEmployeeBenefitsAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/DisclosureRelatedPartiesAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/DisclosureSubsequentEventsAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsNatureOfOperations">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlockTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsPrepaidExpensesAndOtherCurrentAssetsTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsPrepaidExpensesAndOtherCurrentAssetsTextBlockTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlockTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlockTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlockTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlockTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsWarrantDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlockTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlockTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsPensionAndOtherPostretirementBenefitsDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock">
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>hsgx-20161231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- RR Donnelley Xcelerate Taxonomy Definition Linkbase, based on XBRL 2.1  http://www.rrdonnelley.com/ -->
<!-- Version: 6.23.6 -->
<!-- Round: 5 -->
<!-- Creation date: 2017-03-15T19:04:29Z -->
<!-- Copyright (c) 2005-2013 R.R. Donnelley & Sons Company All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#DocumentandEntityInformation" roleURI="http://www.histogenics.com/taxonomy/role/DocumentandEntityInformation"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#Role_StatementOfFinancialPositionClassified" roleURI="http://www.histogenics.com/taxonomy/role/StatementOfFinancialPositionClassified"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#Role_StatementOfFinancialPositionClassifiedParen" roleURI="http://www.histogenics.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#Role_StatementOfIncomeAlternative" roleURI="http://www.histogenics.com/taxonomy/role/StatementOfIncomeAlternative"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#Role_StatementOfShareholdersEquityAndOtherComprehensiveIncome" roleURI="http://www.histogenics.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#Role_StatementOfShareholdersEquityAndOtherComprehensiveIncomeParen" roleURI="http://www.histogenics.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncomeParenthetical"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#Role_StatementOfCashFlowsIndirect" roleURI="http://www.histogenics.com/taxonomy/role/StatementOfCashFlowsIndirect"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#Role_StatementOfCashFlowsIndirectParen" roleURI="http://www.histogenics.com/taxonomy/role/StatementOfCashFlowsIndirectParenthetical"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#DisclosureNatureOfBusinessAdditionalInformation" roleURI="http://www.histogenics.com/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation" roleURI="http://www.histogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfOperationsInDifferentGeographicRegions" roleURI="http://www.histogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfOperationsInDifferentGeographicRegions"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasis" roleURI="http://www.histogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasis"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfLiabilitiesMeasuredAtFairValue" roleURI="http://www.histogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfLiabilitiesMeasuredAtFairValue"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfDepreciationAndAmortizationUsingStraightlineMethodOverEstimatedUsefulLivesOfAssets" roleURI="http://www.histogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfDepreciationAndAmortizationUsingStraightlineMethodOverEstimatedUsefulLivesOfAssets"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfIntangibleAssetsNetOfAccumulatedImpairmentCharges" roleURI="http://www.histogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfIntangibleAssetsNetOfAccumulatedImpairmentCharges"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#DisclosureLossPerCommonShareScheduleOfBasicAndDilutedLossPerCommonShare" roleURI="http://www.histogenics.com/taxonomy/role/DisclosureLossPerCommonShareScheduleOfBasicAndDilutedLossPerCommonShare"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#DisclosureLossPerCommonShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShare" roleURI="http://www.histogenics.com/taxonomy/role/DisclosureLossPerCommonShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShare"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssets" roleURI="http://www.histogenics.com/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssets"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipment" roleURI="http://www.histogenics.com/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipment"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#DisclosurePropertyAndEquipmentAdditionalInformation" roleURI="http://www.histogenics.com/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#DisclosureAccruedExpensesScheduleOfAccruedExpenses" roleURI="http://www.histogenics.com/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpenses"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#DisclosureCommitmentsAndContingenciesAdditionalInformation" roleURI="http://www.histogenics.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#DisclosureCommitmentsAndContingenciesScheduleOfMinimumAnnualLeaseCommitmentsUnderNonCancellableOperatingLeases" roleURI="http://www.histogenics.com/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMinimumAnnualLeaseCommitmentsUnderNonCancellableOperatingLeases"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#DisclosureCapitalStockAdditionalInformation" roleURI="http://www.histogenics.com/taxonomy/role/DisclosureCapitalStockAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#DisclosureCapitalStockScheduleOfCommonStockReservedForFutureIssuance" roleURI="http://www.histogenics.com/taxonomy/role/DisclosureCapitalStockScheduleOfCommonStockReservedForFutureIssuance"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#DisclosureWarrantsAdditionalInformation" roleURI="http://www.histogenics.com/taxonomy/role/DisclosureWarrantsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#DisclosureEquipmentLoanPayableScheduleOfOutstandingBorrowingObligations" roleURI="http://www.histogenics.com/taxonomy/role/DisclosureEquipmentLoanPayableScheduleOfOutstandingBorrowingObligations"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#DisclosureEquipmentLoanPayableAdditionalInformation" roleURI="http://www.histogenics.com/taxonomy/role/DisclosureEquipmentLoanPayableAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#DisclosureStockBasedCompensationAdditionalInformation" roleURI="http://www.histogenics.com/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#DisclosureStockBasedCompensationSummaryOfStockOptionActivityUnderThe2012And2013Plans" roleURI="http://www.histogenics.com/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityUnderThe2012And2013Plans"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#DisclosureStockBasedCompensationAdditionalInformationAboutStockOptionActivity" roleURI="http://www.histogenics.com/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationAboutStockOptionActivity"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#DisclosureStockBasedCompensationScheduleOfRestrictedStockAwardsUnderThe2012And2013Plans" roleURI="http://www.histogenics.com/taxonomy/role/DisclosureStockBasedCompensationScheduleOfRestrictedStockAwardsUnderThe2012And2013Plans"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#DisclosureStockBasedCompensationSummaryOfStockBasedCompensation" roleURI="http://www.histogenics.com/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockBasedCompensation"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#DisclosureStockBasedCompensationSummaryOfWeightedAverageAssumptionsUsedInTheBlackScholesOptionPricingModelToDetermineTheFairValueOfTheEmployeeStockOptionGrants" roleURI="http://www.histogenics.com/taxonomy/role/DisclosureStockBasedCompensationSummaryOfWeightedAverageAssumptionsUsedInTheBlackScholesOptionPricingModelToDetermineTheFairValueOfTheEmployeeStockOptionGrants"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#DisclosureStockBasedCompensationSummaryOfWeightedAverageAssumptionsUsedInTheBlackScholesOptionPricingModelToDetermineTheFairValueOfTheNonEmployeeStockOptionGrants" roleURI="http://www.histogenics.com/taxonomy/role/DisclosureStockBasedCompensationSummaryOfWeightedAverageAssumptionsUsedInTheBlackScholesOptionPricingModelToDetermineTheFairValueOfTheNonEmployeeStockOptionGrants"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#DisclosureIncomeTaxesComponentsOfLossBeforeIncomeTaxes" roleURI="http://www.histogenics.com/taxonomy/role/DisclosureIncomeTaxesComponentsOfLossBeforeIncomeTaxes"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseBenefitComputedAtStatutoryFederalIncomeTaxRate" roleURI="http://www.histogenics.com/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseBenefitComputedAtStatutoryFederalIncomeTaxRate"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilities" roleURI="http://www.histogenics.com/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilities"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#DisclosureIncomeTaxesAdditionalInformation" roleURI="http://www.histogenics.com/taxonomy/role/DisclosureIncomeTaxesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#DisclosureIncomeTaxesSummaryOfChangesInUnrecognizedTaxBenefits" roleURI="http://www.histogenics.com/taxonomy/role/DisclosureIncomeTaxesSummaryOfChangesInUnrecognizedTaxBenefits"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#DisclosureEmployeeBenefitsAdditionalInformation" roleURI="http://www.histogenics.com/taxonomy/role/DisclosureEmployeeBenefitsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#DisclosureRelatedPartiesAdditionalInformation" roleURI="http://www.histogenics.com/taxonomy/role/DisclosureRelatedPartiesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#DisclosureSubsequentEventsAdditionalInformation" roleURI="http://www.histogenics.com/taxonomy/role/DisclosureSubsequentEventsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#Role_NotesToFinancialStatementsNatureOfOperations" roleURI="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsNatureOfOperations"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock" roleURI="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies" roleURI="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockTables" roleURI="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#Role_NotesToFinancialStatementsEarningsPerShareTextBlock" roleURI="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#Role_NotesToFinancialStatementsEarningsPerShareTextBlockTables" roleURI="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#Role_NotesToFinancialStatementsPrepaidExpensesAndOtherCurrentAssetsTextBlock" roleURI="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsPrepaidExpensesAndOtherCurrentAssetsTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#Role_NotesToFinancialStatementsPrepaidExpensesAndOtherCurrentAssetsTextBlockTables" roleURI="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsPrepaidExpensesAndOtherCurrentAssetsTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#Role_NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock" roleURI="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#Role_NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlockTables" roleURI="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#Role_NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" roleURI="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#Role_NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlockTables" roleURI="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#Role_NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock" roleURI="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#Role_NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlockTables" roleURI="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#Role_NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock" roleURI="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#Role_NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlockTables" roleURI="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#Role_NotesToFinancialStatementsWarrantDisclosureTextBlock" roleURI="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsWarrantDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#Role_NotesToFinancialStatementsDebtDisclosureTextBlock" roleURI="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#Role_NotesToFinancialStatementsDebtDisclosureTextBlockTables" roleURI="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#Role_NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" roleURI="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#Role_NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables" roleURI="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#Role_NotesToFinancialStatementsIncomeTaxDisclosureTextBlock" roleURI="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#Role_NotesToFinancialStatementsIncomeTaxDisclosureTextBlockTables" roleURI="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#Role_NotesToFinancialStatementsPensionAndOtherPostretirementBenefitsDisclosureTextBlock" roleURI="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsPensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#Role_NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock" roleURI="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#Role_NotesToFinancialStatementsSubsequentEventsTextBlock" roleURI="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension"/>
  <definitionLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/DocumentandEntityInformation">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/StatementOfFinancialPositionClassified">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_SeriesAConvertiblePreferredStockMember" xlink:label="hsgx_SeriesAConvertiblePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="hsgx_SeriesAConvertiblePreferredStockMember" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/StatementOfIncomeAlternative">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_SeriesAConvertiblePreferredStockMember" xlink:label="hsgx_SeriesAConvertiblePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_StockIssuedDuringPeriodPreferredStockValue" xlink:label="hsgx_StockIssuedDuringPeriodPreferredStockValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_StockIssuedDuringPeriodSharesOverallotmentNetOfFeesAndIssuanceCosts" xlink:label="hsgx_StockIssuedDuringPeriodSharesOverallotmentNetOfFeesAndIssuanceCosts"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_StockIssuedDuringPeriodSharesPreferredStock" xlink:label="hsgx_StockIssuedDuringPeriodSharesPreferredStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_StockIssuedDuringPeriodValueOverallotmentNetOfFeesAndIssuanceCosts" xlink:label="hsgx_StockIssuedDuringPeriodValueOverallotmentNetOfFeesAndIssuanceCosts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="hsgx_SeriesAConvertiblePreferredStockMember" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="1.2600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1.2700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="1.2800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="1.2500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="hsgx_StockIssuedDuringPeriodPreferredStockValue" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="hsgx_StockIssuedDuringPeriodSharesPreferredStock" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="hsgx_StockIssuedDuringPeriodValueOverallotmentNetOfFeesAndIssuanceCosts" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="hsgx_StockIssuedDuringPeriodSharesOverallotmentNetOfFeesAndIssuanceCosts" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" order="1.1600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" order="1.1700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" order="1.1800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="1.1900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="1.2000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="1.2100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="1.2200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="3.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncomeParenthetical">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_SeriesAConvertiblePreferredStockMember" xlink:label="hsgx_SeriesAConvertiblePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="hsgx_SeriesAConvertiblePreferredStockMember" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="3.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/StatementOfCashFlowsIndirect">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/StatementOfCashFlowsIndirectParenthetical">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1" xlink:label="us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_NatureOfBusinessAndBasisOfPresentationLineItems" xlink:label="hsgx_NatureOfBusinessAndBasisOfPresentationLineItems"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_NatureOfBusinessAndBasisOfPresentationTable" xlink:label="hsgx_NatureOfBusinessAndBasisOfPresentationTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_ProceedsFromIssuanceInitialPublicOfferingNet" xlink:label="hsgx_ProceedsFromIssuanceInitialPublicOfferingNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_ProChonBiotechLtdMember" xlink:label="hsgx_ProChonBiotechLtdMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="hsgx_ProChonBiotechLtdMember" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="hsgx_NatureOfBusinessAndBasisOfPresentationLineItems" xlink:to="hsgx_NatureOfBusinessAndBasisOfPresentationTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="hsgx_NatureOfBusinessAndBasisOfPresentationLineItems" xlink:to="us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="hsgx_NatureOfBusinessAndBasisOfPresentationLineItems" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="hsgx_NatureOfBusinessAndBasisOfPresentationLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="hsgx_NatureOfBusinessAndBasisOfPresentationLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="hsgx_NatureOfBusinessAndBasisOfPresentationLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="hsgx_NatureOfBusinessAndBasisOfPresentationLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="hsgx_NatureOfBusinessAndBasisOfPresentationLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="hsgx_NatureOfBusinessAndBasisOfPresentationLineItems" xlink:to="hsgx_ProceedsFromIssuanceInitialPublicOfferingNet" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="hsgx_NatureOfBusinessAndBasisOfPresentationTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="hsgx_NatureOfBusinessAndBasisOfPresentationTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsFairValueDisclosureRecurring" xlink:label="us-gaap_AssetsFairValueDisclosureRecurring"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_FairValueInputAmountTransferBetweenLevels" xlink:label="hsgx_FairValueInputAmountTransferBetweenLevels"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsDiscountRate" xlink:label="us-gaap_FairValueInputsDiscountRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="us-gaap_InProcessResearchAndDevelopmentMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureRecurring" xlink:label="us-gaap_LiabilitiesFairValueDisclosureRecurring"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_MaximumPercentageOfRecognitionOfTaxBenefitsFromUncertainTaxPositions" xlink:label="hsgx_MaximumPercentageOfRecognitionOfTaxBenefitsFromUncertainTaxPositions"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_RemainingOfferingCostsIncludedInAccountsPayable" xlink:label="hsgx_RemainingOfferingCostsIncludedInAccountsPayable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="hsgx_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_SummaryOfSignificantAccountingPoliciesTable" xlink:label="hsgx_SummaryOfSignificantAccountingPoliciesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1.1900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="1.2000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_InProcessResearchAndDevelopmentMember" order="1.1700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="1.1600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="1.1800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="hsgx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="hsgx_SummaryOfSignificantAccountingPoliciesTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="hsgx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="hsgx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfReportableSegments" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="hsgx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AssetsFairValueDisclosureRecurring" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="hsgx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosureRecurring" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="hsgx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="hsgx_FairValueInputAmountTransferBetweenLevels" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="hsgx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="hsgx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="hsgx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="hsgx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_FairValueInputsDiscountRate" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="hsgx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="hsgx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="hsgx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="hsgx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="hsgx_RemainingOfferingCostsIncludedInAccountsPayable" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="hsgx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="hsgx_MaximumPercentageOfRecognitionOfTaxBenefitsFromUncertainTaxPositions" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="hsgx_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="hsgx_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="hsgx_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="3.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="hsgx_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="4.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfOperationsInDifferentGeographicRegions">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/country/2016/country-2016-01-31.xsd#country_IL" xlink:label="country_IL"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NoncurrentAssets" xlink:label="us-gaap_NoncurrentAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="us-gaap_SegmentGeographicalDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="us-gaap_SegmentGeographicalDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="us-gaap_StatementGeographicalAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/country/2016/country-2016-01-31.xsd#country_US" xlink:label="country_US"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_StatementGeographicalAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentGeographicalDomain" xlink:to="country_US" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentGeographicalDomain" xlink:to="country_IL" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_NoncurrentAssets" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementGeographicalAxis" xlink:to="us-gaap_SegmentGeographicalDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementGeographicalAxis" xlink:to="us-gaap_SegmentGeographicalDomain_2" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasis">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_WarrantLiabilityMember" xlink:label="hsgx_WarrantLiabilityMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosure" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" order="3.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_MoneyMarketFundsMember" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="hsgx_WarrantLiabilityMember" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_LiabilitiesFairValueDisclosure" order="1.0800" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfLiabilitiesMeasuredAtFairValue">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="1.0100" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfDepreciationAndAmortizationUsingStraightlineMethodOverEstimatedUsefulLivesOfAssets">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_OfficeEquipmentMember" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_RangeAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="2.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfIntangibleAssetsNetOfAccumulatedImpairmentCharges">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="us-gaap_InProcessResearchAndDevelopmentMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_InProcessResearchAndDevelopmentMember" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/DisclosureLossPerCommonShareScheduleOfBasicAndDilutedLossPerCommonShare">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/DisclosureLossPerCommonShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShare">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockCompensationPlanMember" xlink:label="us-gaap_StockCompensationPlanMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_StockCompensationPlanMember" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssets">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipment">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SoftwareDevelopmentMember" xlink:label="us-gaap_SoftwareDevelopmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_OfficeEquipmentMember" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_SoftwareDevelopmentMember" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformation">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpenses">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation">
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_AdditionalNonRefundableRoyaltyFeePaymentDescription" xlink:label="hsgx_AdditionalNonRefundableRoyaltyFeePaymentDescription"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_AdditionalRoyaltyExpense" xlink:label="hsgx_AdditionalRoyaltyExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_2"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_CollagenSupplyAgreementMember" xlink:label="hsgx_CollagenSupplyAgreementMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ContractualObligation" xlink:label="us-gaap_ContractualObligation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ContractualObligationFutureMinimumPaymentsDueRemainderOfFiscalYear" xlink:label="us-gaap_ContractualObligationFutureMinimumPaymentsDueRemainderOfFiscalYear"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_EngineeringAgreementMember" xlink:label="hsgx_EngineeringAgreementMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GrantsReceivable" xlink:label="us-gaap_GrantsReceivable"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_HydrogelLicenseAgreementMember" xlink:label="hsgx_HydrogelLicenseAgreementMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm" xlink:label="us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_LexingtonMember" xlink:label="hsgx_LexingtonMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermPurchaseCommitmentAmount" xlink:label="us-gaap_LongTermPurchaseCommitmentAmount"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:label="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:label="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:label="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermPurchaseCommitmentDescription" xlink:label="us-gaap_LongTermPurchaseCommitmentDescription"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermPurchaseCommitmentPeriod" xlink:label="us-gaap_LongtermPurchaseCommitmentPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_NumberOfAdditionalRenewalOptions" xlink:label="hsgx_NumberOfAdditionalRenewalOptions"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_OcsAgreementMember" xlink:label="hsgx_OcsAgreementMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="us-gaap_OperatingLeasesRentExpenseNet"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_PaymentForLicenseAgreementReimbursementOfCosts" xlink:label="hsgx_PaymentForLicenseAgreementReimbursementOfCosts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsForProceedsFromTenantAllowance" xlink:label="us-gaap_PaymentsForProceedsFromTenantAllowance"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToSuppliers" xlink:label="us-gaap_PaymentsToSuppliers"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_PercentageOfRoyaltyOffsetting" xlink:label="hsgx_PercentageOfRoyaltyOffsetting"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_PurchaseCommitmentNonrefundablePayment" xlink:label="hsgx_PurchaseCommitmentNonrefundablePayment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:label="us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:label="us-gaap_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:label="us-gaap_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:label="us-gaap_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_RoyaltyPaymentPercentage" xlink:label="hsgx_RoyaltyPaymentPercentage"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_RoyaltyPaymentPercentageAsPercentageOfGrantReceived" xlink:label="hsgx_RoyaltyPaymentPercentageAsPercentageOfGrantReceived"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_TissueProcessorSubLicenseAgreementMember" xlink:label="hsgx_TissueProcessorSubLicenseAgreementMember"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_TissueRegenerationLicenseAgreementMember" xlink:label="hsgx_TissueRegenerationLicenseAgreementMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_WalthamMember" xlink:label="hsgx_WalthamMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="hsgx_TissueProcessorSubLicenseAgreementMember" order="1.2500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="hsgx_HydrogelLicenseAgreementMember" order="1.2400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="hsgx_TissueRegenerationLicenseAgreementMember" order="1.2900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:to="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:to="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:to="hsgx_EngineeringAgreementMember" order="1.2700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:to="hsgx_CollagenSupplyAgreementMember" order="1.3100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="hsgx_NumberOfAdditionalRenewalOptions" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_OperatingLeasesRentExpenseNet" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_PaymentsForProceedsFromTenantAllowance" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_ContractualObligation" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_RoyaltyExpense" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="hsgx_PercentageOfRoyaltyOffsetting" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="hsgx_PaymentForLicenseAgreementReimbursementOfCosts" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_ContractualObligationFutureMinimumPaymentsDueRemainderOfFiscalYear" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="hsgx_AdditionalRoyaltyExpense" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="hsgx_AdditionalNonRefundableRoyaltyFeePaymentDescription" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_GrantsReceivable" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="hsgx_RoyaltyPaymentPercentage" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="hsgx_RoyaltyPaymentPercentageAsPercentageOfGrantReceived" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_PaymentsToSuppliers" order="1.1600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" order="1.1700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LongTermPurchaseCommitmentAmount" order="1.1800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="hsgx_PurchaseCommitmentNonrefundablePayment" order="1.1900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LongtermPurchaseCommitmentPeriod" order="1.2000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LongTermPurchaseCommitmentDescription" order="1.2100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="3.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_RangeAxis" order="4.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" order="5.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" order="6.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="1.2300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="1.3000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:to="us-gaap_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:to="us-gaap_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:to="hsgx_WalthamMember" order="1.2200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:to="hsgx_LexingtonMember" order="1.2800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="hsgx_OcsAgreementMember" order="1.2600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_2" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMinimumAnnualLeaseCommitmentsUnderNonCancellableOperatingLeases">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/DisclosureCapitalStockAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentOfWarrantsGrantedForServices" xlink:label="us-gaap_AdjustmentOfWarrantsGrantedForServices"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_BeneficialOwnershipMinimumPercentageOfOutstandingCommonStock" xlink:label="hsgx_BeneficialOwnershipMinimumPercentageOfOutstandingCommonStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_ClassOfWarrantOrRightExercisableExpirationPeriod" xlink:label="hsgx_ClassOfWarrantOrRightExercisableExpirationPeriod"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_ClassOfWarrantOrRightExercisablePeriod" xlink:label="hsgx_ClassOfWarrantOrRightExercisablePeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsIssuedForService" xlink:label="hsgx_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsIssuedForService"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsIssuedForService" xlink:label="hsgx_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsIssuedForService"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertiblePreferredStockTermsOfConversion" xlink:label="us-gaap_ConvertiblePreferredStockTermsOfConversion"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_FairValueOfWarrantLiabilitiesInExcessOfProceedsReceived" xlink:label="hsgx_FairValueOfWarrantLiabilitiesInExcessOfProceedsReceived"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_GrossProceedsFromIssuanceOfCommonStockPreferredStockAndWarrants" xlink:label="hsgx_GrossProceedsFromIssuanceOfCommonStockPreferredStockAndWarrants"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_MaximumThresholdPercentageOfBeneficialCommonStockInterestOnHoldersDiscretion" xlink:label="hsgx_MaximumThresholdPercentageOfBeneficialCommonStockInterestOnHoldersDiscretion"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_MembersOfBoardOfDirectorsMember" xlink:label="hsgx_MembersOfBoardOfDirectorsMember"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_MinimumThresholdPercentageOfBeneficialCommonStockInterest" xlink:label="hsgx_MinimumThresholdPercentageOfBeneficialCommonStockInterest"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:label="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="1.2400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="hsgx_GrossProceedsFromIssuanceOfCommonStockPreferredStockAndWarrants" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="hsgx_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsIssuedForService" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="hsgx_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsIssuedForService" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="hsgx_BeneficialOwnershipMinimumPercentageOfOutstandingCommonStock" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="hsgx_ClassOfWarrantOrRightExercisableExpirationPeriod" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="hsgx_ClassOfWarrantOrRightExercisablePeriod" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="hsgx_FairValueOfWarrantLiabilitiesInExcessOfProceedsReceived" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_AdjustmentOfWarrantsGrantedForServices" order="1.1600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="1.1700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="1.1800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1.1900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="hsgx_MinimumThresholdPercentageOfBeneficialCommonStockInterest" order="1.2000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="hsgx_MaximumThresholdPercentageOfBeneficialCommonStockInterestOnHoldersDiscretion" order="1.2100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ConvertiblePreferredStockTermsOfConversion" order="1.2200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" order="1.2300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_TitleOfIndividualAxis" order="3.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="hsgx_MembersOfBoardOfDirectorsMember" order="1.2500" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/DisclosureCapitalStockScheduleOfCommonStockReservedForFutureIssuance">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AwardTypeAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/DisclosureWarrantsAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentOfWarrantsGrantedForServices" xlink:label="us-gaap_AdjustmentOfWarrantsGrantedForServices"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_AdjustmentOfWarrantsGrantedForServicesPerShareValue" xlink:label="hsgx_AdjustmentOfWarrantsGrantedForServicesPerShareValue"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_AffiliatesOfAdvisorWarrantMember" xlink:label="hsgx_AffiliatesOfAdvisorWarrantMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_2"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_ClassOfWarrantOrRightExercisableExpirationPeriod" xlink:label="hsgx_ClassOfWarrantOrRightExercisableExpirationPeriod"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_ClassOfWarrantOrRightExercisablePeriod" xlink:label="hsgx_ClassOfWarrantOrRightExercisablePeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_ClassOfWarrantOrRightForfeitureInPeriod" xlink:label="hsgx_ClassOfWarrantOrRightForfeitureInPeriod"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_ClassOfWarrantOrRightForfeitureInPeriodPercentage" xlink:label="hsgx_ClassOfWarrantOrRightForfeitureInPeriodPercentage"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_ClassOfWarrantOrRightNumberOfSecuritiesSurrendered" xlink:label="hsgx_ClassOfWarrantOrRightNumberOfSecuritiesSurrendered"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_ClassOfWarrantOrRightVestedAndExercisable" xlink:label="hsgx_ClassOfWarrantOrRightVestedAndExercisable"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_ConsultingAgreementWarrantMember" xlink:label="hsgx_ConsultingAgreementWarrantMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="us-gaap_FairValueAssumptionsExpectedTerm"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_FairValueAssumptionsExpectedVolatilityRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_FairValueAssumptionsRiskFreeInterestRate"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_InvestorWarrantsMember" xlink:label="hsgx_InvestorWarrantsMember"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_PlacementAgentWarrantMember" xlink:label="hsgx_PlacementAgentWarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="hsgx_InvestorWarrantsMember" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="hsgx_PlacementAgentWarrantMember" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="hsgx_ConsultingAgreementWarrantMember" order="1.1600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="hsgx_AffiliatesOfAdvisorWarrantMember" order="1.1700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="hsgx_ClassOfWarrantOrRightExercisablePeriod" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="hsgx_ClassOfWarrantOrRightExercisableExpirationPeriod" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="hsgx_AdjustmentOfWarrantsGrantedForServicesPerShareValue" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_AdjustmentOfWarrantsGrantedForServices" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_FairValueAssumptionsRiskFreeInterestRate" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_FairValueAssumptionsExpectedVolatilityRate" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_FairValueAssumptionsExpectedTerm" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="hsgx_ClassOfWarrantOrRightNumberOfSecuritiesSurrendered" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="hsgx_ClassOfWarrantOrRightForfeitureInPeriod" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="hsgx_ClassOfWarrantOrRightVestedAndExercisable" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="hsgx_ClassOfWarrantOrRightForfeitureInPeriodPercentage" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/DisclosureEquipmentLoanPayableScheduleOfOutstandingBorrowingObligations">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LoansPayable" xlink:label="us-gaap_LoansPayable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LoansPayableCurrent" xlink:label="us-gaap_LoansPayableCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermLoansPayable" xlink:label="us-gaap_LongTermLoansPayable"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_SiliconValleyBankMember" xlink:label="hsgx_SiliconValleyBankMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LoansPayable" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LoansPayableCurrent" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermLoansPayable" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="hsgx_SiliconValleyBankMember" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/DisclosureEquipmentLoanPayableAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCredit" xlink:label="us-gaap_LineOfCredit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrimeRateMember" xlink:label="us-gaap_PrimeRateMember"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_SiliconValleyBankMember" xlink:label="hsgx_SiliconValleyBankMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain_2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_DebtInstrumentTerm" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_LineOfCredit" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="dei_LegalEntityAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_VariableRateAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="hsgx_SiliconValleyBankMember" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VariableRateDomain" xlink:to="us-gaap_PrimeRateMember" order="1.0900" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardDateAxis" xlink:label="us-gaap_AwardDateAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardDateDomain" xlink:label="us-gaap_AwardDateDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardDateDomain" xlink:label="us-gaap_AwardDateDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_EipAmendmentMember" xlink:label="hsgx_EipAmendmentMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedStockExpense" xlink:label="us-gaap_RestrictedStockExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioForecastMember" xlink:label="us-gaap_ScenarioForecastMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue" xlink:label="hsgx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_TwoThousandAndThirteenEmployeeStockPurchasePlanMember" xlink:label="hsgx_TwoThousandAndThirteenEmployeeStockPurchasePlanMember"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_TwoThousandAndThirteenEquityIncentivePlanMember" xlink:label="hsgx_TwoThousandAndThirteenEquityIncentivePlanMember"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_TwoThousandAndTwelveEquityIncentivePlanMember" xlink:label="hsgx_TwoThousandAndTwelveEquityIncentivePlanMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="hsgx_EipAmendmentMember" order="1.1700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1.2000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="hsgx_TwoThousandAndTwelveEquityIncentivePlanMember" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="hsgx_TwoThousandAndThirteenEquityIncentivePlanMember" order="1.2100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="hsgx_TwoThousandAndThirteenEmployeeStockPurchasePlanMember" order="1.2300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_ScenarioForecastMember" order="1.1800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementScenarioAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="3.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="4.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardDateAxis" order="5.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_VestingAxis" order="6.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="hsgx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_RestrictedStockExpense" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="1.1900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="1.2200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" order="1.1600" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityUnderThe2012And2013Plans">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationAboutStockOptionActivity">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/DisclosureStockBasedCompensationScheduleOfRestrictedStockAwardsUnderThe2012And2013Plans">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="1.0700" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockBasedCompensation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/DisclosureStockBasedCompensationSummaryOfWeightedAverageAssumptionsUsedInTheBlackScholesOptionPricingModelToDetermineTheFairValueOfTheEmployeeStockOptionGrants">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/DisclosureStockBasedCompensationSummaryOfWeightedAverageAssumptionsUsedInTheBlackScholesOptionPricingModelToDetermineTheFairValueOfTheNonEmployeeStockOptionGrants">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/DisclosureIncomeTaxesComponentsOfLossBeforeIncomeTaxes">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseBenefitComputedAtStatutoryFederalIncomeTaxRate">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilities">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/DisclosureIncomeTaxesAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_2"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_IncomeTaxesDisclosureLineItems" xlink:label="hsgx_IncomeTaxesDisclosureLineItems"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_IncomeTaxesDisclosureTable" xlink:label="hsgx_IncomeTaxesDisclosureTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExaminationDescription" xlink:label="us-gaap_IncomeTaxExaminationDescription"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLossCarryforwardsExpirationDate" xlink:label="us-gaap_OperatingLossCarryforwardsExpirationDate"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_OperatingLossCarryforwardsNetOfLimitations" xlink:label="hsgx_OperatingLossCarryforwardsNetOfLimitations"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit" xlink:label="us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_ForeignCountryMember" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="hsgx_IncomeTaxesDisclosureLineItems" xlink:to="hsgx_IncomeTaxesDisclosureTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="hsgx_IncomeTaxesDisclosureLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="hsgx_IncomeTaxesDisclosureLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="hsgx_IncomeTaxesDisclosureLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsExpirationDate" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="hsgx_IncomeTaxesDisclosureLineItems" xlink:to="hsgx_OperatingLossCarryforwardsNetOfLimitations" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="hsgx_IncomeTaxesDisclosureLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="hsgx_IncomeTaxesDisclosureLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="hsgx_IncomeTaxesDisclosureLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="hsgx_IncomeTaxesDisclosureLineItems" xlink:to="us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="hsgx_IncomeTaxesDisclosureLineItems" xlink:to="us-gaap_IncomeTaxExaminationDescription" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="hsgx_IncomeTaxesDisclosureTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/DisclosureIncomeTaxesSummaryOfChangesInUnrecognizedTaxBenefits">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/DisclosureEmployeeBenefitsAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_DefinedContributionPlanEmployeeEligibilityAge" xlink:label="hsgx_DefinedContributionPlanEmployeeEligibilityAge"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DefinedContributionPlanTable" xlink:label="us-gaap_DefinedContributionPlanTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="hsgx_DefinedContributionPlanEmployeeEligibilityAge" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DefinedContributionPlanTable" xlink:to="us-gaap_RangeAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="1.0300" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/DisclosureRelatedPartiesAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_CollaborationAgreementTerminationNoticePeriod" xlink:label="hsgx_CollaborationAgreementTerminationNoticePeriod"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_CollaborationAgreementTerminationNoticePeriodOnUnremediedMaterialBreach" xlink:label="hsgx_CollaborationAgreementTerminationNoticePeriodOnUnremediedMaterialBreach"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_CommercializationMilestonesObligation" xlink:label="hsgx_CommercializationMilestonesObligation"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_CommercialMilestonesMember" xlink:label="hsgx_CommercialMilestonesMember"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_DevelopmentCostReimbursementCommitment" xlink:label="hsgx_DevelopmentCostReimbursementCommitment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="us-gaap_DueToRelatedPartiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_2"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_IntrexonMember" xlink:label="hsgx_IntrexonMember"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_PercentageOfReimbursementExpenses" xlink:label="hsgx_PercentageOfReimbursementExpenses"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_PercentageOfReimbursementExpensesSubjectToAcceptance" xlink:label="hsgx_PercentageOfReimbursementExpensesSubjectToAcceptance"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_PurposeCoMember" xlink:label="hsgx_PurposeCoMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_SalesMilestoneMember" xlink:label="hsgx_SalesMilestoneMember"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_SalesMilestonesPaymentsObligation" xlink:label="hsgx_SalesMilestonesPaymentsObligation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="hsgx_CommercialMilestonesMember" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="hsgx_SalesMilestoneMember" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="hsgx_CollaborationAgreementTerminationNoticePeriod" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="hsgx_CollaborationAgreementTerminationNoticePeriodOnUnremediedMaterialBreach" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="hsgx_CommercializationMilestonesObligation" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="hsgx_SalesMilestonesPaymentsObligation" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="hsgx_PercentageOfReimbursementExpenses" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="hsgx_PercentageOfReimbursementExpensesSubjectToAcceptance" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DueToRelatedPartiesCurrent" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="hsgx_DevelopmentCostReimbursementCommitment" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="hsgx_IntrexonMember" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="hsgx_PurposeCoMember" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="3.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/DisclosureSubsequentEventsAdditionalInformation">
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_CollagenSupplyAgreementMember" xlink:label="hsgx_CollagenSupplyAgreementMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:label="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:label="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_OriginalAgreementDate" xlink:label="hsgx_OriginalAgreementDate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_RepaymentPeriod" xlink:label="hsgx_RepaymentPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioForecastMember" xlink:label="us-gaap_ScenarioForecastMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:to="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:to="hsgx_CollagenSupplyAgreementMember" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_ScenarioForecastMember" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="hsgx_OriginalAgreementDate" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="hsgx_RepaymentPeriod" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_StatementScenarioAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" order="2.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsNatureOfOperations">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockTables">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlockTables">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsPrepaidExpensesAndOtherCurrentAssetsTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsPrepaidExpensesAndOtherCurrentAssetsTextBlockTables">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlockTables">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlockTables">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlockTables">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlockTables">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsWarrantDisclosureTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlockTables">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlockTables">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsPensionAndOtherPostretirementBenefitsDisclosureTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock">
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>hsgx-20161231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- RR Donnelley Xcelerate Taxonomy Labels Linkbase, based on XBRL 2.1  http://www.rrdonnelley.com/ -->
<!-- Version: 6.23.6 -->
<!-- Round: 5 -->
<!-- Creation date: 2017-03-15T19:04:29Z -->
<!-- Copyright (c) 2005-2013 R.R. Donnelley & Sons Company All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US" id="id_11655837_2025283_1_1">Accounting Policies [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US" id="id_11655837_2025283_2_1">Accounting Policies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US" id="id_11655837_2027886_1_1">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US" id="id_11655837_2027886_2_1">Accrued Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" id="id_11655837_2026150_1_1">Accounts Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" id="id_11655837_2026150_2_1">Accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:label="us-gaap_AccountsPayableRelatedPartiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableRelatedPartiesCurrent_lbl" xml:lang="en-US" id="id_11655837_2026584_1_1">Accounts Payable, Related Parties, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableRelatedPartiesCurrent_lbl" xml:lang="en-US" id="id_11655837_2026584_2_1">Accounts payable due to Intrexon Corporation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:to="us-gaap_AccountsPayableRelatedPartiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_AccruedClinicalExpensesCurrent" xlink:label="hsgx_AccruedClinicalExpensesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hsgx_AccruedClinicalExpensesCurrent_lbl" xml:lang="en-US" id="id_11655837_2323005_3_1">Accrued clinical expenses current.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hsgx_AccruedClinicalExpensesCurrent_lbl" xml:lang="en-US" id="id_11655837_2323005_1_1">Accrued Clinical Expenses Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hsgx_AccruedClinicalExpensesCurrent_lbl" xml:lang="en-US" id="id_11655837_2323005_2_1">Accrued clinical expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hsgx_AccruedClinicalExpensesCurrent" xlink:to="hsgx_AccruedClinicalExpensesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" id="id_11655837_2027889_1_1">Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" id="id_11655837_2027889_2_1">Accrued expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" id="id_11655837_2027889_6_1">Total accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US" id="id_11655837_2022470_1_1">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US" id="id_11655837_2022470_14_1">Less: accumulated depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_AdditionalNonRefundableRoyaltyFeePaymentDescription" xlink:label="hsgx_AdditionalNonRefundableRoyaltyFeePaymentDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hsgx_AdditionalNonRefundableRoyaltyFeePaymentDescription_lbl" xml:lang="en-US" id="id_11655837_2399257_3_1">Additional non refundable royalty fee payment description.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hsgx_AdditionalNonRefundableRoyaltyFeePaymentDescription_lbl" xml:lang="en-US" id="id_11655837_2399257_1_1">Additional non refundable royalty fee payment description</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hsgx_AdditionalNonRefundableRoyaltyFeePaymentDescription_lbl" xml:lang="en-US" id="id_11655837_2399257_2_1">Additional non-refundable royalty fee payment description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hsgx_AdditionalNonRefundableRoyaltyFeePaymentDescription" xlink:to="hsgx_AdditionalNonRefundableRoyaltyFeePaymentDescription_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US" id="id_11655837_2024642_1_1">Additional Paid in Capital, Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US" id="id_11655837_2024642_2_1">Additional paid-in capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US" id="id_11655837_2025075_1_1">Additional Paid-in Capital [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US" id="id_11655837_2025075_2_1">Additional Paid-in Capital [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_AdditionalRoyaltyExpense" xlink:label="hsgx_AdditionalRoyaltyExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hsgx_AdditionalRoyaltyExpense_lbl" xml:lang="en-US" id="id_11655837_2399255_3_1">Additional royalty expense.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hsgx_AdditionalRoyaltyExpense_lbl" xml:lang="en-US" id="id_11655837_2399255_1_1">Additional Royalty Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hsgx_AdditionalRoyaltyExpense_lbl" xml:lang="en-US" id="id_11655837_2399255_2_1">Additional non-refundable royalty fee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hsgx_AdditionalRoyaltyExpense" xlink:to="hsgx_AdditionalRoyaltyExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentOfWarrantsGrantedForServices" xlink:label="us-gaap_AdjustmentOfWarrantsGrantedForServices"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentOfWarrantsGrantedForServices_lbl" xml:lang="en-US" id="id_11655837_2021615_1_1">Adjustment of Warrants Granted for Services</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentOfWarrantsGrantedForServices_lbl" xml:lang="en-US" id="id_11655837_2021615_2_1">Warrant expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AdjustmentOfWarrantsGrantedForServices_lbl" xml:lang="en-US" id="id_11655837_2021615_12_1">Warrant expense in connection with private placement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AdjustmentOfWarrantsGrantedForServices_lbl" xml:lang="en-US" id="id_11655837_2021615_14_1">Warrant expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentOfWarrantsGrantedForServices" xlink:to="us-gaap_AdjustmentOfWarrantsGrantedForServices_lbl"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_AdjustmentOfWarrantsGrantedForServicesPerShareValue" xlink:label="hsgx_AdjustmentOfWarrantsGrantedForServicesPerShareValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hsgx_AdjustmentOfWarrantsGrantedForServicesPerShareValue_lbl" xml:lang="en-US" id="id_11655837_2424317_3_1">Adjustment of warrants granted for services per share value.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hsgx_AdjustmentOfWarrantsGrantedForServicesPerShareValue_lbl" xml:lang="en-US" id="id_11655837_2424317_1_1">Adjustment Of Warrants Granted For Services Per Share Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hsgx_AdjustmentOfWarrantsGrantedForServicesPerShareValue_lbl" xml:lang="en-US" id="id_11655837_2424317_2_1">Warrant expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hsgx_AdjustmentOfWarrantsGrantedForServicesPerShareValue" xlink:to="hsgx_AdjustmentOfWarrantsGrantedForServicesPerShareValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US" id="id_11655837_2022912_1_1">Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US" id="id_11655837_2022912_2_1">Stock-based compensation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xml:lang="en-US" id="id_11655837_2035272_1_1">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xml:lang="en-US" id="id_11655837_2035272_2_1">IPO costs reclassified to additional paid-in capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xml:lang="en-US" id="id_11655837_2035272_12_1">Issuance of common stock, net issuance costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xml:lang="en-US" id="id_11655837_2023564_1_1">Adjustments to Additional Paid in Capital, Warrant Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xml:lang="en-US" id="id_11655837_2023564_2_1">Issuance of warrant as part of the consideration for the consulting related to financial support services in March 2015</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" id="id_11655837_2023126_1_1">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" id="id_11655837_2023126_2_1">Adjustments to reconcile net loss to net cash used in operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_AffiliatesOfAdvisorWarrantMember" xlink:label="hsgx_AffiliatesOfAdvisorWarrantMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hsgx_AffiliatesOfAdvisorWarrantMember_lbl" xml:lang="en-US" id="id_11655837_2424282_3_1">Affiliates of advisor [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hsgx_AffiliatesOfAdvisorWarrantMember_lbl" xml:lang="en-US" id="id_11655837_2424282_1_1">Affiliates Of Advisor Warrant [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hsgx_AffiliatesOfAdvisorWarrantMember_lbl" xml:lang="en-US" id="id_11655837_2424282_2_1">Affiliates Of Advisor Warrant [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hsgx_AffiliatesOfAdvisorWarrantMember" xlink:to="hsgx_AffiliatesOfAdvisorWarrantMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" id="id_11655837_2023781_1_1">Allocated Share-based Compensation Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" id="id_11655837_2023781_2_1">Stock-based compensation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" id="id_11655837_2024215_1_1">Amendment Flag</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" id="id_11655837_2024215_2_1">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" id="id_11655837_2022267_1_1">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" id="id_11655837_2022267_2_1">Anti-dilutive securities excluded from computation of earnings per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US" id="id_11655837_2021628_1_1">Antidilutive Securities [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US" id="id_11655837_2021628_2_1">Antidilutive Securities [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" id="id_11655837_2024873_1_1">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" id="id_11655837_2024873_2_1">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US" id="id_11655837_2021396_1_1">Antidilutive Securities, Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US" id="id_11655837_2021396_2_1">Antidilutive Securities, Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US" id="id_11655837_2035280_1_1">Arrangements and Non-arrangement Transactions [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US" id="id_11655837_2035280_2_1">Arrangements and Non-arrangement Transactions [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" id="id_11655837_2023136_1_1">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" id="id_11655837_2023136_6_1">Total assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" id="id_11655837_2023790_1_1">Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" id="id_11655837_2023790_6_1">Total current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" id="id_11655837_2027691_1_1">Assets, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" id="id_11655837_2027691_2_1">Current assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xml:lang="en-US" id="id_11655837_2022272_1_1">Assets, Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xml:lang="en-US" id="id_11655837_2022272_2_1">Assets, fair value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xml:lang="en-US" id="id_11655837_2027256_1_1">Assets, Fair Value Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xml:lang="en-US" id="id_11655837_2027256_2_1">Assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsFairValueDisclosureRecurring" xlink:label="us-gaap_AssetsFairValueDisclosureRecurring"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsFairValueDisclosureRecurring_lbl" xml:lang="en-US" id="id_11655837_2022702_1_1">Assets, Fair Value Disclosure, Recurring</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsFairValueDisclosureRecurring_lbl" xml:lang="en-US" id="id_11655837_2022702_2_1">Assets, fair value disclosure, recurring</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosureRecurring" xlink:to="us-gaap_AssetsFairValueDisclosureRecurring_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardDateAxis" xlink:label="us-gaap_AwardDateAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardDateAxis_lbl" xml:lang="en-US" id="id_11655837_2027922_1_1">Award Date [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AwardDateAxis_lbl" xml:lang="en-US" id="id_11655837_2027922_2_1">Award Date [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardDateDomain" xlink:label="us-gaap_AwardDateDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardDateDomain_lbl" xml:lang="en-US" id="id_11655837_2023580_1_1">Award Date [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AwardDateDomain_lbl" xml:lang="en-US" id="id_11655837_2023580_2_1">Award Date [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardDateDomain" xlink:to="us-gaap_AwardDateDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US" id="id_11655837_2025317_1_1">Award Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US" id="id_11655837_2025317_2_1">Award Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US" id="id_11655837_2026403_1_1">Basis of Accounting, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US" id="id_11655837_2026403_2_1">Basis of Accounting</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_BeneficialOwnershipMinimumPercentageOfOutstandingCommonStock" xlink:label="hsgx_BeneficialOwnershipMinimumPercentageOfOutstandingCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hsgx_BeneficialOwnershipMinimumPercentageOfOutstandingCommonStock_lbl" xml:lang="en-US" id="id_11655837_2221812_3_1">Beneficial ownership minimum percentage of outstanding common stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hsgx_BeneficialOwnershipMinimumPercentageOfOutstandingCommonStock_lbl" xml:lang="en-US" id="id_11655837_2221812_1_1">Beneficial Ownership Minimum Percentage Of Outstanding Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hsgx_BeneficialOwnershipMinimumPercentageOfOutstandingCommonStock_lbl" xml:lang="en-US" id="id_11655837_2221812_2_1">Minimum percentage of outstanding common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hsgx_BeneficialOwnershipMinimumPercentageOfOutstandingCommonStock" xlink:to="hsgx_BeneficialOwnershipMinimumPercentageOfOutstandingCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xml:lang="en-US" id="id_11655837_2022941_1_1">Business Acquisition, Acquiree [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xml:lang="en-US" id="id_11655837_2022941_2_1">Business Acquisition, Acquiree [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xml:lang="en-US" id="id_11655837_2027704_1_1">Business Acquisition [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xml:lang="en-US" id="id_11655837_2027704_2_1">Business Acquisition [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1" xlink:label="us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1_lbl" xml:lang="en-US" id="id_11655837_2026829_1_1">Business Acquisition, Effective Date of Acquisition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1_lbl" xml:lang="en-US" id="id_11655837_2026829_2_1">Business acquisition date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1" xlink:to="us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xml:lang="en-US" id="id_11655837_2026621_1_1">Business Combination, Consideration Transferred</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xml:lang="en-US" id="id_11655837_2026621_2_1">Consideration paid to acquisition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" id="id_11655837_2025118_1_1">Cash and Cash Equivalents, at Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" id="id_11655837_2025118_4_1">Cash and cash equivalents-End of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" id="id_11655837_2025118_5_1">Cash and cash equivalents-Beginning of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" id="id_11655837_2025118_2_1">Cash and cash equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" id="id_11655837_2025118_12_1">Cash and cash equivalents, carrying amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xml:lang="en-US" id="id_11655837_2025340_1_1">Cash and Cash Equivalents [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xml:lang="en-US" id="id_11655837_2025340_2_1">Cash and Cash Equivalents [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_CashAndCashEquivalentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xml:lang="en-US" id="id_11655837_2021652_1_1">Cash and Cash Equivalents, Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xml:lang="en-US" id="id_11655837_2021652_2_1">Cash and cash equivalents, fair value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xml:lang="en-US" id="id_11655837_2023171_1_1">Cash and Cash Equivalents, Period Increase (Decrease)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xml:lang="en-US" id="id_11655837_2023171_6_1">Net increase (decrease) in cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US" id="id_11655837_2025342_1_1">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US" id="id_11655837_2025342_2_1">Cash and Cash Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xml:lang="en-US" id="id_11655837_2022303_1_1">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xml:lang="en-US" id="id_11655837_2022303_2_1">Restricted Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US" id="id_11655837_2027969_1_1">Class of Stock [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US" id="id_11655837_2027969_2_1">Class of Stock [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US" id="id_11655837_2035316_1_1">Class of Stock [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US" id="id_11655837_2035316_2_1">Class of Stock [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US" id="id_11655837_2027723_1_1">Class of Warrant or Right [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US" id="id_11655837_2027723_2_1">Class of Warrant or Right [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xml:lang="en-US" id="id_11655837_2026851_1_1">Class of Warrant or Right [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xml:lang="en-US" id="id_11655837_2026851_2_1">Class of Warrant or Right [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_ClassOfWarrantOrRightExercisableExpirationPeriod" xlink:label="hsgx_ClassOfWarrantOrRightExercisableExpirationPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hsgx_ClassOfWarrantOrRightExercisableExpirationPeriod_lbl" xml:lang="en-US" id="id_11655837_2277789_3_1">Class of warrant or right exercisable expiration period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hsgx_ClassOfWarrantOrRightExercisableExpirationPeriod_lbl" xml:lang="en-US" id="id_11655837_2277789_1_1">Class Of Warrant Or Right Exercisable Expiration Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hsgx_ClassOfWarrantOrRightExercisableExpirationPeriod_lbl" xml:lang="en-US" id="id_11655837_2277789_2_1">Warrants expiry period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hsgx_ClassOfWarrantOrRightExercisableExpirationPeriod" xlink:to="hsgx_ClassOfWarrantOrRightExercisableExpirationPeriod_lbl"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_ClassOfWarrantOrRightExercisablePeriod" xlink:label="hsgx_ClassOfWarrantOrRightExercisablePeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hsgx_ClassOfWarrantOrRightExercisablePeriod_lbl" xml:lang="en-US" id="id_11655837_2310954_3_1">Class of warrant or right exercisable period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hsgx_ClassOfWarrantOrRightExercisablePeriod_lbl" xml:lang="en-US" id="id_11655837_2310954_1_1">Class Of Warrant Or Right Exercisable Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hsgx_ClassOfWarrantOrRightExercisablePeriod_lbl" xml:lang="en-US" id="id_11655837_2310954_2_1">Warrants exercisable period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hsgx_ClassOfWarrantOrRightExercisablePeriod" xlink:to="hsgx_ClassOfWarrantOrRightExercisablePeriod_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US" id="id_11655837_2024048_1_1">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US" id="id_11655837_2024048_2_1">Class of Warrants or right to purchase common stock, exercise price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US" id="id_11655837_2024048_12_1">Net exercise of warrants, exercise price per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsIssuedForService" xlink:label="hsgx_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsIssuedForService"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hsgx_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsIssuedForService_lbl" xml:lang="en-US" id="id_11655837_2214268_3_1">Class of warrant or right exercise price of warrants or rights issued for service.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hsgx_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsIssuedForService_lbl" xml:lang="en-US" id="id_11655837_2214268_1_1">Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Issued For Service</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hsgx_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsIssuedForService_lbl" xml:lang="en-US" id="id_11655837_2214268_2_1">Warrants granted to placement agent, exercise price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hsgx_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsIssuedForService" xlink:to="hsgx_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsIssuedForService_lbl"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_ClassOfWarrantOrRightForfeitureInPeriod" xlink:label="hsgx_ClassOfWarrantOrRightForfeitureInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hsgx_ClassOfWarrantOrRightForfeitureInPeriod_lbl" xml:lang="en-US" id="id_11655837_2340444_3_1">Class of warrant or right forfeiture in period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hsgx_ClassOfWarrantOrRightForfeitureInPeriod_lbl" xml:lang="en-US" id="id_11655837_2340444_1_1">Class Of Warrant Or Right Forfeiture In Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="hsgx_ClassOfWarrantOrRightForfeitureInPeriod_lbl" xml:lang="en-US" id="id_11655837_2340444_14_1">Warrants, forfeiture</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hsgx_ClassOfWarrantOrRightForfeitureInPeriod" xlink:to="hsgx_ClassOfWarrantOrRightForfeitureInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_ClassOfWarrantOrRightForfeitureInPeriodPercentage" xlink:label="hsgx_ClassOfWarrantOrRightForfeitureInPeriodPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hsgx_ClassOfWarrantOrRightForfeitureInPeriodPercentage_lbl" xml:lang="en-US" id="id_11655837_2293941_3_1">Class of warrant or right forfeiture in period percentage.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hsgx_ClassOfWarrantOrRightForfeitureInPeriodPercentage_lbl" xml:lang="en-US" id="id_11655837_2293941_1_1">Class Of Warrant Or Right Forfeiture In Period Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hsgx_ClassOfWarrantOrRightForfeitureInPeriodPercentage_lbl" xml:lang="en-US" id="id_11655837_2293941_2_1">Warrants, percentage of forfeiture</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hsgx_ClassOfWarrantOrRightForfeitureInPeriodPercentage" xlink:to="hsgx_ClassOfWarrantOrRightForfeitureInPeriodPercentage_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xml:lang="en-US" id="id_11655837_2027294_1_1">Class of Warrant or Right [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xml:lang="en-US" id="id_11655837_2027294_2_1">Class of Warrant or Right [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US" id="id_11655837_2026641_1_1">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US" id="id_11655837_2026641_2_1">Class of Warrants or right to purchase common stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US" id="id_11655837_2026641_12_1">Net exercise of warrants, shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsIssuedForService" xlink:label="hsgx_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsIssuedForService"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hsgx_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsIssuedForService_lbl" xml:lang="en-US" id="id_11655837_2357011_3_1">Class of warrant or right number of securities called by warrants or rights issued for service.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hsgx_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsIssuedForService_lbl" xml:lang="en-US" id="id_11655837_2357011_1_1">Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights Issued For Service</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hsgx_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsIssuedForService_lbl" xml:lang="en-US" id="id_11655837_2357011_2_1">Warrants granted to placement agent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hsgx_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsIssuedForService" xlink:to="hsgx_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsIssuedForService_lbl"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_ClassOfWarrantOrRightNumberOfSecuritiesSurrendered" xlink:label="hsgx_ClassOfWarrantOrRightNumberOfSecuritiesSurrendered"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hsgx_ClassOfWarrantOrRightNumberOfSecuritiesSurrendered_lbl" xml:lang="en-US" id="id_11655837_2366093_3_1">Class of warrant or right number of securities surrendered.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hsgx_ClassOfWarrantOrRightNumberOfSecuritiesSurrendered_lbl" xml:lang="en-US" id="id_11655837_2366093_1_1">Class Of Warrant Or Right Number Of Securities Surrendered</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hsgx_ClassOfWarrantOrRightNumberOfSecuritiesSurrendered_lbl" xml:lang="en-US" id="id_11655837_2366093_2_1">Surrender of warrant to satisfy related liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hsgx_ClassOfWarrantOrRightNumberOfSecuritiesSurrendered" xlink:to="hsgx_ClassOfWarrantOrRightNumberOfSecuritiesSurrendered_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xml:lang="en-US" id="id_11655837_2026204_1_1">Class of Warrant or Right [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xml:lang="en-US" id="id_11655837_2026204_2_1">Class of Warrant or Right [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightTable_lbl"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_ClassOfWarrantOrRightVestedAndExercisable" xlink:label="hsgx_ClassOfWarrantOrRightVestedAndExercisable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hsgx_ClassOfWarrantOrRightVestedAndExercisable_lbl" xml:lang="en-US" id="id_11655837_2276872_3_1">Class of warrant or right vested and exercisable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hsgx_ClassOfWarrantOrRightVestedAndExercisable_lbl" xml:lang="en-US" id="id_11655837_2276872_1_1">Class Of Warrant Or Right Vested And Exercisable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hsgx_ClassOfWarrantOrRightVestedAndExercisable_lbl" xml:lang="en-US" id="id_11655837_2276872_2_1">Warrants vested and exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hsgx_ClassOfWarrantOrRightVestedAndExercisable" xlink:to="hsgx_ClassOfWarrantOrRightVestedAndExercisable_lbl"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_CollaborationAgreementTerminationNoticePeriod" xlink:label="hsgx_CollaborationAgreementTerminationNoticePeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hsgx_CollaborationAgreementTerminationNoticePeriod_lbl" xml:lang="en-US" id="id_11655837_2340926_3_1">Collaboration Agreement Termination Notice Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hsgx_CollaborationAgreementTerminationNoticePeriod_lbl" xml:lang="en-US" id="id_11655837_2340926_1_1">Collaboration Agreement Termination Notice Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hsgx_CollaborationAgreementTerminationNoticePeriod_lbl" xml:lang="en-US" id="id_11655837_2340926_2_1">Collaboration Agreement cancellation notification</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hsgx_CollaborationAgreementTerminationNoticePeriod" xlink:to="hsgx_CollaborationAgreementTerminationNoticePeriod_lbl"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_CollaborationAgreementTerminationNoticePeriodOnUnremediedMaterialBreach" xlink:label="hsgx_CollaborationAgreementTerminationNoticePeriodOnUnremediedMaterialBreach"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hsgx_CollaborationAgreementTerminationNoticePeriodOnUnremediedMaterialBreach_lbl" xml:lang="en-US" id="id_11655837_2201866_3_1">Collaboration Agreement Termination Notice Period On Unremedied Material Breach</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hsgx_CollaborationAgreementTerminationNoticePeriodOnUnremediedMaterialBreach_lbl" xml:lang="en-US" id="id_11655837_2201866_1_1">Collaboration Agreement Termination Notice Period On Unremedied Material Breach</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hsgx_CollaborationAgreementTerminationNoticePeriodOnUnremediedMaterialBreach_lbl" xml:lang="en-US" id="id_11655837_2201866_2_1">Collaboration Agreement cancellation with material breach that cannot be remedied</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hsgx_CollaborationAgreementTerminationNoticePeriodOnUnremediedMaterialBreach" xlink:to="hsgx_CollaborationAgreementTerminationNoticePeriodOnUnremediedMaterialBreach_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US" id="id_11655837_2023406_1_1">Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US" id="id_11655837_2023406_2_1">Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_CollagenSupplyAgreementMember" xlink:label="hsgx_CollagenSupplyAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hsgx_CollagenSupplyAgreementMember_lbl" xml:lang="en-US" id="id_11655837_2163139_3_1">Collagen Supply Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hsgx_CollagenSupplyAgreementMember_lbl" xml:lang="en-US" id="id_11655837_2163139_1_1">Collagen Supply Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hsgx_CollagenSupplyAgreementMember_lbl" xml:lang="en-US" id="id_11655837_2163139_2_1">Collagen Supply Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hsgx_CollagenSupplyAgreementMember" xlink:to="hsgx_CollagenSupplyAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_CommercializationMilestonesObligation" xlink:label="hsgx_CommercializationMilestonesObligation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hsgx_CommercializationMilestonesObligation_lbl" xml:lang="en-US" id="id_11655837_2394052_3_1">Commercialization milestones obligation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hsgx_CommercializationMilestonesObligation_lbl" xml:lang="en-US" id="id_11655837_2394052_1_1">Commercialization Milestones Obligation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hsgx_CommercializationMilestonesObligation_lbl" xml:lang="en-US" id="id_11655837_2394052_2_1">Commercialization milestones obligation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hsgx_CommercializationMilestonesObligation" xlink:to="hsgx_CommercializationMilestonesObligation_lbl"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_CommercialMilestonesMember" xlink:label="hsgx_CommercialMilestonesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hsgx_CommercialMilestonesMember_lbl" xml:lang="en-US" id="id_11655837_2339473_3_1">Commercialization milestones.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hsgx_CommercialMilestonesMember_lbl" xml:lang="en-US" id="id_11655837_2339473_1_1">Commercial Milestones [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hsgx_CommercialMilestonesMember_lbl" xml:lang="en-US" id="id_11655837_2339473_2_1">Commercialization Milestones [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hsgx_CommercialMilestonesMember" xlink:to="hsgx_CommercialMilestonesMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" id="id_11655837_2022745_1_1">Commitments and Contingencies</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" id="id_11655837_2022745_2_1">Commitments and contingencies (Note 7)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US" id="id_11655837_2026024_1_1">Commitments and Contingencies Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US" id="id_11655837_2026024_2_1">Commitments and Contingencies Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" id="id_11655837_2027090_1_1">Commitments and Contingencies Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" id="id_11655837_2027090_2_1">Commitments and Contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US" id="id_11655837_2026025_1_1">Common Stock, Capital Shares Reserved for Future Issuance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US" id="id_11655837_2026025_2_1">Common stock reserved for future issuance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US" id="id_11655837_2027302_1_1">Common Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US" id="id_11655837_2027302_2_1">Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" id="id_11655837_2021893_1_1">Common Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" id="id_11655837_2021893_2_1">Common stock price per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" id="id_11655837_2021893_12_1">Common stock, par value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" id="id_11655837_2024271_1_1">Common Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" id="id_11655837_2024271_2_1">Common stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" id="id_11655837_2022978_1_1">Common Stock, Shares, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" id="id_11655837_2022978_2_1">Common stock, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" id="id_11655837_2022748_1_1">Common Stock, Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" id="id_11655837_2022748_2_1">Common stock, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" id="id_11655837_2025780_1_1">Common Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" id="id_11655837_2025780_2_1">Common stock, $0.01 par value; 100,000,000 shares authorized, 20,647,612 and 13,273,470 shares issued and outstanding at December 31, 2016 and 2015, respectively</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xml:lang="en-US" id="id_11655837_2024059_1_1">Compensation and Retirement Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xml:lang="en-US" id="id_11655837_2024059_2_1">Compensation and Retirement Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CompensationRelatedCostsAbstract" xlink:label="us-gaap_CompensationRelatedCostsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationRelatedCostsAbstract_lbl" xml:lang="en-US" id="id_11655837_2021435_1_1">Compensation Related Costs [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CompensationRelatedCostsAbstract_lbl" xml:lang="en-US" id="id_11655837_2021435_2_1">Compensation Related Costs [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsAbstract" xlink:to="us-gaap_CompensationRelatedCostsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xml:lang="en-US" id="id_11655837_2021436_1_1">Compensation Related Costs, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xml:lang="en-US" id="id_11655837_2021436_2_1">Stock-Based Compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US" id="id_11655837_2024939_1_1">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US" id="id_11655837_2024939_2_1">Concentration of Credit Risk</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xml:lang="en-US" id="id_11655837_2024062_1_1">Construction in Progress [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xml:lang="en-US" id="id_11655837_2024062_2_1">Construction in Progress [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionInProgressMember" xlink:to="us-gaap_ConstructionInProgressMember_lbl"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_ConsultingAgreementWarrantMember" xlink:label="hsgx_ConsultingAgreementWarrantMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hsgx_ConsultingAgreementWarrantMember_lbl" xml:lang="en-US" id="id_11655837_2068134_3_1">Consulting Agreement Warrant Member</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hsgx_ConsultingAgreementWarrantMember_lbl" xml:lang="en-US" id="id_11655837_2068134_1_1">Consulting Agreement Warrant Member</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hsgx_ConsultingAgreementWarrantMember_lbl" xml:lang="en-US" id="id_11655837_2068134_2_1">Consulting Agreement Warrant [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hsgx_ConsultingAgreementWarrantMember" xlink:to="hsgx_ConsultingAgreementWarrantMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ContractualObligation" xlink:label="us-gaap_ContractualObligation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractualObligation_lbl" xml:lang="en-US" id="id_11655837_2024281_1_1">Contractual Obligation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractualObligation_lbl" xml:lang="en-US" id="id_11655837_2024281_2_1">One-time payment amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligation" xlink:to="us-gaap_ContractualObligation_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ContractualObligationFutureMinimumPaymentsDueRemainderOfFiscalYear" xlink:label="us-gaap_ContractualObligationFutureMinimumPaymentsDueRemainderOfFiscalYear"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractualObligationFutureMinimumPaymentsDueRemainderOfFiscalYear_lbl" xml:lang="en-US" id="id_11655837_2021676_1_1">Contractual Obligation, Future Minimum Payments Due, Remainder of Fiscal Year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractualObligationFutureMinimumPaymentsDueRemainderOfFiscalYear_lbl" xml:lang="en-US" id="id_11655837_2021676_2_1">Potential milestone payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligationFutureMinimumPaymentsDueRemainderOfFiscalYear" xlink:to="us-gaap_ContractualObligationFutureMinimumPaymentsDueRemainderOfFiscalYear_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xml:lang="en-US" id="id_11655837_2026036_1_1">Conversion of Stock, Shares Converted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xml:lang="en-US" id="id_11655837_2026036_2_1">Conversion of preferred stock in to common stock, preferred stock converted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertiblePreferredStockTermsOfConversion" xlink:label="us-gaap_ConvertiblePreferredStockTermsOfConversion"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertiblePreferredStockTermsOfConversion_lbl" xml:lang="en-US" id="id_11655837_2023420_1_1">Convertible Preferred Stock, Terms of Conversion</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertiblePreferredStockTermsOfConversion_lbl" xml:lang="en-US" id="id_11655837_2023420_2_1">Convertible preferred stock, terms of conversion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockTermsOfConversion" xlink:to="us-gaap_ConvertiblePreferredStockTermsOfConversion_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US" id="id_11655837_2024507_1_1">Current Fiscal Year End Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US" id="id_11655837_2024507_2_1">Current Fiscal Year End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US" id="id_11655837_2026667_1_1">Debt Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US" id="id_11655837_2026667_2_1">Debt Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US" id="id_11655837_2022560_1_1">Debt Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US" id="id_11655837_2022560_2_1">Equipment Loan Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xml:lang="en-US" id="id_11655837_2025392_1_1">Debt Instrument, Basis Spread on Variable Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xml:lang="en-US" id="id_11655837_2025392_2_1">Amount of loan bears interest basis spread on variable rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US" id="id_11655837_2022149_1_1">Debt Instrument, Interest Rate, Stated Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US" id="id_11655837_2022149_2_1">Line of credit facility, interest rate, stated percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xml:lang="en-US" id="id_11655837_2021687_1_1">Debt Instrument [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xml:lang="en-US" id="id_11655837_2021687_2_1">Debt Instrument [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTable_lbl" xml:lang="en-US" id="id_11655837_2023206_1_1">Schedule of Long-term Debt Instruments [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentTable_lbl" xml:lang="en-US" id="id_11655837_2023206_2_1">Schedule of Long-term Debt Instruments [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTerm_lbl" xml:lang="en-US" id="id_11655837_2026457_1_1">Debt Instrument, Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentTerm_lbl" xml:lang="en-US" id="id_11655837_2026457_2_1">Bank loan and security agreement, repayment period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTerm" xlink:to="us-gaap_DebtInstrumentTerm_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredChargesPolicyTextBlock" xlink:label="us-gaap_DeferredChargesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredChargesPolicyTextBlock_lbl" xml:lang="en-US" id="id_11655837_2026232_1_1">Deferred Charges, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredChargesPolicyTextBlock_lbl" xml:lang="en-US" id="id_11655837_2026232_2_1">Deferred Rent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredChargesPolicyTextBlock" xlink:to="us-gaap_DeferredChargesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xml:lang="en-US" id="id_11655837_2025828_1_1">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xml:lang="en-US" id="id_11655837_2025828_2_1">Schedule of Prepaid Expenses and Other Current Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xml:lang="en-US" id="id_11655837_2023213_1_1">Deferred Tax Liabilities, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xml:lang="en-US" id="id_11655837_2023213_19_1">Total deferred tax liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_DeferredRentAndLeaseIncentive" xlink:label="hsgx_DeferredRentAndLeaseIncentive"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hsgx_DeferredRentAndLeaseIncentive_lbl" xml:lang="en-US" id="id_11655837_2284594_3_1">Deferred rent and lease incentive.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hsgx_DeferredRentAndLeaseIncentive_lbl" xml:lang="en-US" id="id_11655837_2284594_1_1">Deferred Rent And Lease Incentive</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="hsgx_DeferredRentAndLeaseIncentive_lbl" xml:lang="en-US" id="id_11655837_2284594_14_1">Deferred rent and lease incentive</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hsgx_DeferredRentAndLeaseIncentive" xlink:to="hsgx_DeferredRentAndLeaseIncentive_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRentCreditCurrent" xlink:label="us-gaap_DeferredRentCreditCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRentCreditCurrent_lbl" xml:lang="en-US" id="id_11655837_2023646_1_1">Deferred Rent Credit, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredRentCreditCurrent_lbl" xml:lang="en-US" id="id_11655837_2023646_2_1">Current portion of deferred rent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRentCreditCurrent" xlink:to="us-gaap_DeferredRentCreditCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="us-gaap_DeferredRentCreditNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRentCreditNoncurrent_lbl" xml:lang="en-US" id="id_11655837_2023446_1_1">Deferred Rent Credit, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredRentCreditNoncurrent_lbl" xml:lang="en-US" id="id_11655837_2023446_2_1">Deferred rent, long-term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRentCreditNoncurrent" xlink:to="us-gaap_DeferredRentCreditNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueLeasesCurrent" xlink:label="us-gaap_DeferredRevenueLeasesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueLeasesCurrent_lbl" xml:lang="en-US" id="id_11655837_2024310_1_1">Deferred Revenue, Leases, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredRevenueLeasesCurrent_lbl" xml:lang="en-US" id="id_11655837_2024310_2_1">Current portion of deferred lease incentive</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueLeasesCurrent" xlink:to="us-gaap_DeferredRevenueLeasesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_DeferredTaxAssetsCapitalizedStartUpCosts" xlink:label="hsgx_DeferredTaxAssetsCapitalizedStartUpCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hsgx_DeferredTaxAssetsCapitalizedStartUpCosts_lbl" xml:lang="en-US" id="id_11655837_2214903_3_1">Deferred Tax Assets Capitalized Start Up Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hsgx_DeferredTaxAssetsCapitalizedStartUpCosts_lbl" xml:lang="en-US" id="id_11655837_2214903_1_1">Deferred Tax Assets Capitalized Start Up Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hsgx_DeferredTaxAssetsCapitalizedStartUpCosts_lbl" xml:lang="en-US" id="id_11655837_2214903_2_1">Capitalized start-up costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hsgx_DeferredTaxAssetsCapitalizedStartUpCosts" xlink:to="hsgx_DeferredTaxAssetsCapitalizedStartUpCosts_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US" id="id_11655837_2027341_1_1">Deferred Tax Assets, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US" id="id_11655837_2027341_6_1">Deferred tax assets before valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsGrossAbstract" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract_lbl" xml:lang="en-US" id="id_11655837_2022571_1_1">Deferred Tax Assets, Gross [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract_lbl" xml:lang="en-US" id="id_11655837_2022571_2_1">Deferred tax assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsGrossAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US" id="id_11655837_2023450_1_1">Deferred Tax Assets, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US" id="id_11655837_2023450_6_1">Net deferred tax assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US" id="id_11655837_2026242_1_1">Deferred Tax Assets, Net of Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US" id="id_11655837_2026242_6_1">Deferred tax assets, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US" id="id_11655837_2027555_1_1">Deferred Tax Assets, Operating Loss Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US" id="id_11655837_2027555_2_1">Net operating loss carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xml:lang="en-US" id="id_11655837_2023648_1_1">Deferred Tax Assets, Other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xml:lang="en-US" id="id_11655837_2023648_2_1">Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl" xml:lang="en-US" id="id_11655837_2035352_1_1">Deferred Tax Assets, Property, Plant and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl" xml:lang="en-US" id="id_11655837_2035352_2_1">Depreciation and amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl" xml:lang="en-US" id="id_11655837_2025608_1_1">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl" xml:lang="en-US" id="id_11655837_2025608_2_1">Accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" id="id_11655837_2024095_1_1">Deferred Tax Assets, Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" id="id_11655837_2024095_14_1">Valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xml:lang="en-US" id="id_11655837_2025175_1_1">Deferred Tax Liabilities, Gross [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xml:lang="en-US" id="id_11655837_2025175_2_1">Deferred tax liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_DeferredTaxLiabilitiesChangeInAccountingMethod" xlink:label="hsgx_DeferredTaxLiabilitiesChangeInAccountingMethod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hsgx_DeferredTaxLiabilitiesChangeInAccountingMethod_lbl" xml:lang="en-US" id="id_11655837_2200015_3_1">Deferred Tax Liabilities Change in Accounting Method</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hsgx_DeferredTaxLiabilitiesChangeInAccountingMethod_lbl" xml:lang="en-US" id="id_11655837_2200015_1_1">Deferred Tax Liabilities Change in Accounting Method</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="hsgx_DeferredTaxLiabilitiesChangeInAccountingMethod_lbl" xml:lang="en-US" id="id_11655837_2200015_14_1">Change in accounting method</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hsgx_DeferredTaxLiabilitiesChangeInAccountingMethod" xlink:to="hsgx_DeferredTaxLiabilitiesChangeInAccountingMethod_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:label="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_lbl" xml:lang="en-US" id="id_11655837_2022575_1_1">Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_lbl" xml:lang="en-US" id="id_11655837_2022575_14_1">IPR&amp;D</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:to="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems_lbl" xml:lang="en-US" id="id_11655837_2025845_1_1">Defined Contribution Plan Disclosure [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems_lbl" xml:lang="en-US" id="id_11655837_2025845_2_1">Defined Contribution Plan Disclosure [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanDisclosureLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_DefinedContributionPlanEmployeeEligibilityAge" xlink:label="hsgx_DefinedContributionPlanEmployeeEligibilityAge"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hsgx_DefinedContributionPlanEmployeeEligibilityAge_lbl" xml:lang="en-US" id="id_11655837_2310625_3_1">Defined Contribution Plan Employee Eligibility Age</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hsgx_DefinedContributionPlanEmployeeEligibilityAge_lbl" xml:lang="en-US" id="id_11655837_2310625_1_1">Defined Contribution Plan Employee Eligibility Age</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hsgx_DefinedContributionPlanEmployeeEligibilityAge_lbl" xml:lang="en-US" id="id_11655837_2310625_2_1">Defined contribution plan eligibility years of age for employees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hsgx_DefinedContributionPlanEmployeeEligibilityAge" xlink:to="hsgx_DefinedContributionPlanEmployeeEligibilityAge_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xml:lang="en-US" id="id_11655837_2027568_1_1">Defined Contribution Plan, Employer Discretionary Contribution Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xml:lang="en-US" id="id_11655837_2027568_2_1">Defined benefit plan contribution by employer</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DefinedContributionPlanTable" xlink:label="us-gaap_DefinedContributionPlanTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanTable_lbl" xml:lang="en-US" id="id_11655837_2024983_1_1">Defined Contribution Plan [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedContributionPlanTable_lbl" xml:lang="en-US" id="id_11655837_2024983_2_1">Defined Contribution Plan [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanTable" xlink:to="us-gaap_DefinedContributionPlanTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepositAssets" xlink:label="us-gaap_DepositAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepositAssets_lbl" xml:lang="en-US" id="id_11655837_2026696_1_1">Deposit Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepositAssets_lbl" xml:lang="en-US" id="id_11655837_2026696_2_1">Deposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositAssets" xlink:to="us-gaap_DepositAssets_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US" id="id_11655837_2025421_1_1">Depreciation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US" id="id_11655837_2025421_2_1">Depreciation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US" id="id_11655837_2025421_12_1">Depreciation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_DevelopmentCostReimbursementCommitment" xlink:label="hsgx_DevelopmentCostReimbursementCommitment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hsgx_DevelopmentCostReimbursementCommitment_lbl" xml:lang="en-US" id="id_11655837_2348299_3_1">Amount committed for reimbursement of development costs of new technology.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hsgx_DevelopmentCostReimbursementCommitment_lbl" xml:lang="en-US" id="id_11655837_2348299_1_1">Development Cost Reimbursement Commitment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hsgx_DevelopmentCostReimbursementCommitment_lbl" xml:lang="en-US" id="id_11655837_2348299_2_1">Reimbursement for development cost, amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hsgx_DevelopmentCostReimbursementCommitment" xlink:to="hsgx_DevelopmentCostReimbursementCommitment_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DilutiveSecuritiesAbstract" xlink:label="us-gaap_DilutiveSecuritiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DilutiveSecuritiesAbstract_lbl" xml:lang="en-US" id="id_11655837_2024332_1_1">Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DilutiveSecuritiesAbstract_lbl" xml:lang="en-US" id="id_11655837_2024332_2_1">Effect of dilutive securities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DilutiveSecuritiesAbstract" xlink:to="us-gaap_DilutiveSecuritiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US" id="id_11655837_2026720_1_1">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US" id="id_11655837_2026720_2_1">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" id="id_11655837_2025443_1_1">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" id="id_11655837_2025443_2_1">Stock-Based Compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_DocumentAndEntityInformationAbstract" xlink:label="hsgx_DocumentAndEntityInformationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hsgx_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US" id="id_11655837_2260742_3_1">Document and entity information.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hsgx_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US" id="id_11655837_2260742_1_1">Document And Entity Information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hsgx_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US" id="id_11655837_2260742_2_1">Document And Entity Information [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hsgx_DocumentAndEntityInformationAbstract" xlink:to="hsgx_DocumentAndEntityInformationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" id="id_11655837_2025647_1_1">Document Fiscal Period Focus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" id="id_11655837_2025647_2_1">Document Fiscal Period Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" id="id_11655837_2024142_1_1">Document Fiscal Year Focus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" id="id_11655837_2024142_2_1">Document Fiscal Year Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" id="id_11655837_2023078_1_1">Document Period End Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" id="id_11655837_2023078_2_1">Document Period End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" id="id_11655837_2022383_1_1">Document Type</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" id="id_11655837_2022383_2_1">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DomesticCountryMember_lbl" xml:lang="en-US" id="id_11655837_2024782_1_1">Domestic Tax Authority [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DomesticCountryMember_lbl" xml:lang="en-US" id="id_11655837_2024782_2_1">U.S. Federal [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="us-gaap_DueToRelatedPartiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DueToRelatedPartiesCurrent_lbl" xml:lang="en-US" id="id_11655837_2027399_1_1">Due to Related Parties, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DueToRelatedPartiesCurrent_lbl" xml:lang="en-US" id="id_11655837_2027399_2_1">Accrued expenses due to Intrexon Corporation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DueToRelatedPartiesCurrent_lbl" xml:lang="en-US" id="id_11655837_2027399_12_1">Accrued expenses due to related party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueToRelatedPartiesCurrent" xlink:to="us-gaap_DueToRelatedPartiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DueToRelatedPartiesNoncurrent" xlink:label="us-gaap_DueToRelatedPartiesNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DueToRelatedPartiesNoncurrent_lbl" xml:lang="en-US" id="id_11655837_2025460_1_1">Due to Related Parties, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DueToRelatedPartiesNoncurrent_lbl" xml:lang="en-US" id="id_11655837_2025460_2_1">Accrued expenses due to Intrexon Corporation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueToRelatedPartiesNoncurrent" xlink:to="us-gaap_DueToRelatedPartiesNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US" id="id_11655837_2022611_1_1">Earnings Per Share [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US" id="id_11655837_2022611_2_1">Earnings Per Share [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" id="id_11655837_2024783_1_1">Earnings Per Share, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" id="id_11655837_2024783_2_1">Earnings (loss) per share-basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" id="id_11655837_2024783_12_1">Loss per common share-basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" id="id_11655837_2025654_1_1">Earnings Per Share, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" id="id_11655837_2025654_2_1">Earnings (loss) per share-diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" id="id_11655837_2025654_12_1">Loss per common share-diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US" id="id_11655837_2025461_1_1">Earnings Per Share, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US" id="id_11655837_2025461_2_1">Earnings (Loss) per Common Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US" id="id_11655837_2027799_1_1">Earnings Per Share [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US" id="id_11655837_2027799_2_1">Loss Per Common Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US" id="id_11655837_2027801_1_1">Effective Income Tax Rate Reconciliation, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US" id="id_11655837_2027801_6_1">Income tax expense (benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl" xml:lang="en-US" id="id_11655837_2024559_1_1">Effective Income Tax Rate Reconciliation, Percent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl" xml:lang="en-US" id="id_11655837_2024559_2_1">(Increase) decrease income tax benefit resulting from:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" id="id_11655837_2028055_1_1">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" id="id_11655837_2028055_2_1">Federal income tax (benefit) at statutory rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" id="id_11655837_2023920_1_1">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" id="id_11655837_2023920_2_1">Change in valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_EffectiveIncomeTaxRateReconciliationNetOperatingLossLimitation" xlink:label="hsgx_EffectiveIncomeTaxRateReconciliationNetOperatingLossLimitation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hsgx_EffectiveIncomeTaxRateReconciliationNetOperatingLossLimitation_lbl" xml:lang="en-US" id="id_11655837_2423934_3_1">Effective income tax rate reconciliation net operating loss limitation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hsgx_EffectiveIncomeTaxRateReconciliationNetOperatingLossLimitation_lbl" xml:lang="en-US" id="id_11655837_2423934_1_1">Effective Income Tax Rate Reconciliation Net Operating Loss Limitation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hsgx_EffectiveIncomeTaxRateReconciliationNetOperatingLossLimitation_lbl" xml:lang="en-US" id="id_11655837_2423934_2_1">Net Operating Loss Limitation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hsgx_EffectiveIncomeTaxRateReconciliationNetOperatingLossLimitation" xlink:to="hsgx_EffectiveIncomeTaxRateReconciliationNetOperatingLossLimitation_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xml:lang="en-US" id="id_11655837_2025872_1_1">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xml:lang="en-US" id="id_11655837_2025872_2_1">Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_EffectiveIncomeTaxRateReconciliationPermanentDifferences" xlink:label="hsgx_EffectiveIncomeTaxRateReconciliationPermanentDifferences"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hsgx_EffectiveIncomeTaxRateReconciliationPermanentDifferences_lbl" xml:lang="en-US" id="id_11655837_2338109_3_1">Effective Income Tax Rate Reconciliation Permanent Differences</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hsgx_EffectiveIncomeTaxRateReconciliationPermanentDifferences_lbl" xml:lang="en-US" id="id_11655837_2338109_1_1">Effective Income Tax Rate Reconciliation Permanent Differences</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hsgx_EffectiveIncomeTaxRateReconciliationPermanentDifferences_lbl" xml:lang="en-US" id="id_11655837_2338109_2_1">Permanent differences</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hsgx_EffectiveIncomeTaxRateReconciliationPermanentDifferences" xlink:to="hsgx_EffectiveIncomeTaxRateReconciliationPermanentDifferences_lbl"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_EffectiveIncomeTaxRateReconciliationRAndDCreditLimitation" xlink:label="hsgx_EffectiveIncomeTaxRateReconciliationRAndDCreditLimitation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hsgx_EffectiveIncomeTaxRateReconciliationRAndDCreditLimitation_lbl" xml:lang="en-US" id="id_11655837_2423935_3_1">Effective income tax rate reconciliation R and D credit limitation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hsgx_EffectiveIncomeTaxRateReconciliationRAndDCreditLimitation_lbl" xml:lang="en-US" id="id_11655837_2423935_1_1">Effective Income Tax Rate Reconciliation R and D Credit Limitation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hsgx_EffectiveIncomeTaxRateReconciliationRAndDCreditLimitation_lbl" xml:lang="en-US" id="id_11655837_2423935_2_1">R&amp;D Credit Limitation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hsgx_EffectiveIncomeTaxRateReconciliationRAndDCreditLimitation" xlink:to="hsgx_EffectiveIncomeTaxRateReconciliationRAndDCreditLimitation_lbl"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_EipAmendmentMember" xlink:label="hsgx_EipAmendmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hsgx_EipAmendmentMember_lbl" xml:lang="en-US" id="id_11655837_2423931_3_1">EIP Amendment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hsgx_EipAmendmentMember_lbl" xml:lang="en-US" id="id_11655837_2423931_1_1">EIP Amendment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hsgx_EipAmendmentMember_lbl" xml:lang="en-US" id="id_11655837_2423931_2_1">EIP Amendment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hsgx_EipAmendmentMember" xlink:to="hsgx_EipAmendmentMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US" id="id_11655837_2021517_1_1">Employee-related Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US" id="id_11655837_2021517_2_1">Accrued compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US" id="id_11655837_2023675_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US" id="id_11655837_2023675_2_1">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" id="id_11655837_2027807_1_1">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" id="id_11655837_2027807_2_1">Unrecognized compensation cost, recognition period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xml:lang="en-US" id="id_11655837_2024351_1_1">Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xml:lang="en-US" id="id_11655837_2024351_2_1">Unrecognized compensation cost related to restricted stock awards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US" id="id_11655837_2035400_1_1">Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US" id="id_11655837_2035400_2_1">Unrecognized compensation cost related to outstanding options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US" id="id_11655837_2022619_1_1">Employee Stock Option [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US" id="id_11655837_2022619_2_1">Stock Options [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_EngineeringAgreementMember" xlink:label="hsgx_EngineeringAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hsgx_EngineeringAgreementMember_lbl" xml:lang="en-US" id="id_11655837_2099546_3_1">Engineering agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hsgx_EngineeringAgreementMember_lbl" xml:lang="en-US" id="id_11655837_2099546_1_1">Engineering Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hsgx_EngineeringAgreementMember_lbl" xml:lang="en-US" id="id_11655837_2099546_2_1">Engineering Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hsgx_EngineeringAgreementMember" xlink:to="hsgx_EngineeringAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" id="id_11655837_2022397_1_1">Entity Central Index Key</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" id="id_11655837_2022397_2_1">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US" id="id_11655837_2025882_1_1">Entity Common Stock, Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US" id="id_11655837_2025882_2_1">Entity Common Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US" id="id_11655837_2024569_1_1">Entity Current Reporting Status</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US" id="id_11655837_2024569_2_1">Entity Current Reporting Status</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityDomain_lbl" xml:lang="en-US" id="id_11655837_2026748_1_1">Entity [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityDomain_lbl" xml:lang="en-US" id="id_11655837_2026748_2_1">Entity [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US" id="id_11655837_2025883_1_1">Entity Filer Category</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US" id="id_11655837_2025883_2_1">Entity Filer Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US" id="id_11655837_2023269_1_1">Entity Public Float</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US" id="id_11655837_2023269_2_1">Entity Public Float</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" id="id_11655837_2021744_1_1">Entity Registrant Name</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" id="id_11655837_2021744_2_1">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US" id="id_11655837_2026118_1_1">Entity Voluntary Filers</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US" id="id_11655837_2026118_2_1">Entity Voluntary Filers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US" id="id_11655837_2023680_1_1">Entity Well-known Seasoned Issuer</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US" id="id_11655837_2023680_2_1">Entity Well-known Seasoned Issuer</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquipmentMember_lbl" xml:lang="en-US" id="id_11655837_2023509_1_1">Equipment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquipmentMember_lbl" xml:lang="en-US" id="id_11655837_2023509_2_1">Laboratory Equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US" id="id_11655837_2025026_1_1">Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US" id="id_11655837_2025026_2_1">Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US" id="id_11655837_2027813_1_1">Equity Component [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US" id="id_11655837_2027813_2_1">Equity Component [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_FairMarketValueOfPrivatePlacementWarrantsAtIssuance" xlink:label="hsgx_FairMarketValueOfPrivatePlacementWarrantsAtIssuance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hsgx_FairMarketValueOfPrivatePlacementWarrantsAtIssuance_lbl" xml:lang="en-US" id="id_11655837_2305711_3_1">Fair market value of private placement warrants at issuance.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hsgx_FairMarketValueOfPrivatePlacementWarrantsAtIssuance_lbl" xml:lang="en-US" id="id_11655837_2305711_1_1">Fair Market Value Of Private Placement Warrants At Issuance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hsgx_FairMarketValueOfPrivatePlacementWarrantsAtIssuance_lbl" xml:lang="en-US" id="id_11655837_2305711_2_1">Fair market value of private placement warrants at issuance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hsgx_FairMarketValueOfPrivatePlacementWarrantsAtIssuance" xlink:to="hsgx_FairMarketValueOfPrivatePlacementWarrantsAtIssuance_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US" id="id_11655837_2027610_1_1">Fair Value Adjustment of Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US" id="id_11655837_2027610_2_1">Change in fair value of warrant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US" id="id_11655837_2027610_12_1">Deduct change in fair value of warrant liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US" id="id_11655837_2027610_14_1">Change in fair value of warrant liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US" id="id_11655837_2024160_1_1">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US" id="id_11655837_2024160_2_1">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xml:lang="en-US" id="id_11655837_2028078_1_1">Fair Value Measurements, Recurring and Nonrecurring [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xml:lang="en-US" id="id_11655837_2028078_2_1">Fair Value Measurements, Recurring and Nonrecurring [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xml:lang="en-US" id="id_11655837_2026313_1_1">Asset Class [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xml:lang="en-US" id="id_11655837_2026313_2_1">Asset Class [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="us-gaap_FairValueAssumptionsExpectedTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssumptionsExpectedTerm_lbl" xml:lang="en-US" id="id_11655837_2027828_1_1">Fair Value Assumptions, Expected Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssumptionsExpectedTerm_lbl" xml:lang="en-US" id="id_11655837_2027828_2_1">Fair value of the warrants, expected term to liquidity even</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssumptionsExpectedTerm" xlink:to="us-gaap_FairValueAssumptionsExpectedTerm_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_FairValueAssumptionsExpectedVolatilityRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US" id="id_11655837_2035422_1_1">Fair Value Assumptions, Expected Volatility Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US" id="id_11655837_2035422_2_1">Fair value of the warrants, implied volatility</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_FairValueAssumptionsExpectedVolatilityRate_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_FairValueAssumptionsRiskFreeInterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US" id="id_11655837_2035423_1_1">Fair Value Assumptions, Risk Free Interest Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US" id="id_11655837_2035423_2_1">Fair value of the warrants, risk-free interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_FairValueAssumptionsRiskFreeInterestRate_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xml:lang="en-US" id="id_11655837_2026315_1_1">Asset Class [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xml:lang="en-US" id="id_11655837_2026315_2_1">Asset Class [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueByAssetClassAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US" id="id_11655837_2022410_1_1">Fair Value, Hierarchy [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US" id="id_11655837_2022410_2_1">Fair Value, Hierarchy [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByLiabilityClassAxis_lbl" xml:lang="en-US" id="id_11655837_2027829_1_1">Liability Class [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueByLiabilityClassAxis_lbl" xml:lang="en-US" id="id_11655837_2027829_2_1">Liability Class [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueByLiabilityClassAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US" id="id_11655837_2025479_1_1">Fair Value Disclosures [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US" id="id_11655837_2025479_2_1">Fair Value Disclosures [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_FairValueInputAmountTransferBetweenLevels" xlink:label="hsgx_FairValueInputAmountTransferBetweenLevels"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hsgx_FairValueInputAmountTransferBetweenLevels_lbl" xml:lang="en-US" id="id_11655837_2311958_3_1">The fair value input amount of assets and liabilities between levels.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hsgx_FairValueInputAmountTransferBetweenLevels_lbl" xml:lang="en-US" id="id_11655837_2311958_1_1">Fair Value Input Amount Transfer Between Levels</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hsgx_FairValueInputAmountTransferBetweenLevels_lbl" xml:lang="en-US" id="id_11655837_2311958_2_1">Transfers between Levels 1, 2 and 3</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hsgx_FairValueInputAmountTransferBetweenLevels" xlink:to="hsgx_FairValueInputAmountTransferBetweenLevels_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsDiscountRate" xlink:label="us-gaap_FairValueInputsDiscountRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsDiscountRate_lbl" xml:lang="en-US" id="id_11655837_2023951_1_1">Fair Value Inputs, Discount Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsDiscountRate_lbl" xml:lang="en-US" id="id_11655837_2023951_2_1">Discount rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsDiscountRate" xlink:to="us-gaap_FairValueInputsDiscountRate_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US" id="id_11655837_2026970_1_1">Fair Value, Inputs, Level 1 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US" id="id_11655837_2026970_2_1">Quoted Prices in Active Markets (Level 1) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US" id="id_11655837_2021995_1_1">Fair Value, Inputs, Level 2 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US" id="id_11655837_2021995_2_1">Significant Other Observable Inputs (Level 2) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US" id="id_11655837_2022419_1_1">Fair Value, Inputs, Level 3 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US" id="id_11655837_2022419_2_1">Significant Unobservable Inputs (Level 3) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_lbl" xml:lang="en-US" id="id_11655837_2023114_1_1">Fair Value by Liability Class [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_lbl" xml:lang="en-US" id="id_11655837_2023114_2_1">Fair Value by Liability Class [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" xml:lang="en-US" id="id_11655837_2022233_1_1">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" xml:lang="en-US" id="id_11655837_2022233_2_1">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl" xml:lang="en-US" id="id_11655837_2025259_1_1">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl" xml:lang="en-US" id="id_11655837_2025259_2_1">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xml:lang="en-US" id="id_11655837_2024167_1_1">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xml:lang="en-US" id="id_11655837_2024167_2_1">Schedule of Reconciliation of Liabilities Measured at Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US" id="id_11655837_2025260_1_1">Fair Value Measurement, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US" id="id_11655837_2025260_2_1">Fair Value Measurements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US" id="id_11655837_2023956_1_1">Fair Value Hierarchy [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US" id="id_11655837_2023956_2_1">Fair Value Hierarchy [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_lbl" xml:lang="en-US" id="id_11655837_2024371_1_1">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_lbl" xml:lang="en-US" id="id_11655837_2024371_2_1">Issuance of warrants,</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xml:lang="en-US" id="id_11655837_2028090_1_1">Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xml:lang="en-US" id="id_11655837_2028090_4_1">Ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xml:lang="en-US" id="id_11655837_2028090_5_1">Beginning balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US" id="id_11655837_2028091_1_1">Fair Value of Financial Instruments, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US" id="id_11655837_2028091_2_1">Financial Instruments Indexed to and Potentially Settled in the Company's Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_FairValueOfWarrantLiabilitiesInExcessOfProceedsReceived" xlink:label="hsgx_FairValueOfWarrantLiabilitiesInExcessOfProceedsReceived"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hsgx_FairValueOfWarrantLiabilitiesInExcessOfProceedsReceived_lbl" xml:lang="en-US" id="id_11655837_2099797_3_1">Fair value of warrant liabilities in excess of proceeds received.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hsgx_FairValueOfWarrantLiabilitiesInExcessOfProceedsReceived_lbl" xml:lang="en-US" id="id_11655837_2099797_1_1">Fair Value Of Warrant Liabilities In Excess Of Proceeds Received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hsgx_FairValueOfWarrantLiabilitiesInExcessOfProceedsReceived_lbl" xml:lang="en-US" id="id_11655837_2099797_2_1">Excess fair value of warrant liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hsgx_FairValueOfWarrantLiabilitiesInExcessOfProceedsReceived" xlink:to="hsgx_FairValueOfWarrantLiabilitiesInExcessOfProceedsReceived_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xml:lang="en-US" id="id_11655837_2029393_1_1">Finite-Lived Intangible Assets, Accumulated Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xml:lang="en-US" id="id_11655837_2029393_14_1">Accumulated Impairment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US" id="id_11655837_2035448_1_1">Finite-Lived Intangible Assets by Major Class [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US" id="id_11655837_2035448_2_1">Finite-Lived Intangible Assets by Major Class [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xml:lang="en-US" id="id_11655837_2021793_1_1">Finite-Lived Intangible Assets, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xml:lang="en-US" id="id_11655837_2021793_2_1">Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xml:lang="en-US" id="id_11655837_2024610_1_1">Finite-Lived Intangible Assets [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xml:lang="en-US" id="id_11655837_2024610_2_1">Finite-Lived Intangible Assets [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xml:lang="en-US" id="id_11655837_2027645_1_1">Finite-Lived Intangible Assets, Major Class Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xml:lang="en-US" id="id_11655837_2027645_2_1">Finite-Lived Intangible Assets, Major Class Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US" id="id_11655837_2031338_1_1">Finite-Lived Intangible Assets, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US" id="id_11655837_2031338_2_1">Intangible asset, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US" id="id_11655837_2031338_6_1">Net Book Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US" id="id_11655837_2031338_12_1">Net Book Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCountryMember_lbl" xml:lang="en-US" id="id_11655837_2024390_1_1">Foreign Tax Authority [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ForeignCountryMember_lbl" xml:lang="en-US" id="id_11655837_2024390_2_1">Foreign [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCountryMember" xlink:to="us-gaap_ForeignCountryMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xml:lang="en-US" id="id_11655837_2027002_1_1">Foreign Currency Transactions and Translations Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xml:lang="en-US" id="id_11655837_2027002_2_1">Foreign Currency Translation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" id="id_11655837_2024630_1_1">General and Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" id="id_11655837_2024630_2_1">General and administrative</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US" id="id_11655837_2029413_1_1">General and Administrative Expense [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US" id="id_11655837_2029413_2_1">General and Administrative [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xml:lang="en-US" id="id_11655837_2024406_1_1">Goodwill and Intangible Assets Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xml:lang="en-US" id="id_11655837_2024406_2_1">Goodwill and Intangible Assets Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl" xml:lang="en-US" id="id_11655837_2021808_1_1">Goodwill and Intangible Assets, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl" xml:lang="en-US" id="id_11655837_2021808_2_1">Intangible Asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GrantsReceivable" xlink:label="us-gaap_GrantsReceivable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrantsReceivable_lbl" xml:lang="en-US" id="id_11655837_2033059_1_1">Grants Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GrantsReceivable_lbl" xml:lang="en-US" id="id_11655837_2033059_2_1">Accrued and received grants, aggregate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrantsReceivable" xlink:to="us-gaap_GrantsReceivable_lbl"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_GrossProceedsFromIssuanceOfCommonStockPreferredStockAndWarrants" xlink:label="hsgx_GrossProceedsFromIssuanceOfCommonStockPreferredStockAndWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hsgx_GrossProceedsFromIssuanceOfCommonStockPreferredStockAndWarrants_lbl" xml:lang="en-US" id="id_11655837_2399263_3_1">Gross proceeds from issuance of common stock, preferred stock and warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hsgx_GrossProceedsFromIssuanceOfCommonStockPreferredStockAndWarrants_lbl" xml:lang="en-US" id="id_11655837_2399263_1_1">Gross proceeds from issuance of common stock, preferred stock and warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hsgx_GrossProceedsFromIssuanceOfCommonStockPreferredStockAndWarrants_lbl" xml:lang="en-US" id="id_11655837_2399263_2_1">Gross proceeds from issuance of common stock, preferred stock and warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hsgx_GrossProceedsFromIssuanceOfCommonStockPreferredStockAndWarrants" xlink:to="hsgx_GrossProceedsFromIssuanceOfCommonStockPreferredStockAndWarrants_lbl"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_HydrogelLicenseAgreementMember" xlink:label="hsgx_HydrogelLicenseAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hsgx_HydrogelLicenseAgreementMember_lbl" xml:lang="en-US" id="id_11655837_2112516_3_1">Hydrogel License Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hsgx_HydrogelLicenseAgreementMember_lbl" xml:lang="en-US" id="id_11655837_2112516_1_1">Hydrogel License Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hsgx_HydrogelLicenseAgreementMember_lbl" xml:lang="en-US" id="id_11655837_2112516_2_1">Hydrogel License Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hsgx_HydrogelLicenseAgreementMember" xlink:to="hsgx_HydrogelLicenseAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/country/2016/country-2016-01-31.xsd#country_IL" xlink:label="country_IL"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_IL_lbl" xml:lang="en-US" id="id_11655837_2032405_1_1">ISRAEL</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="country_IL_lbl" xml:lang="en-US" id="id_11655837_2032405_2_1">Israel [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_IL" xlink:to="country_IL_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_lbl" xml:lang="en-US" id="id_11655837_2031389_1_1">Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_lbl" xml:lang="en-US" id="id_11655837_2031389_2_1">Impairment of intangible asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_lbl" xml:lang="en-US" id="id_11655837_2031389_12_1">Impairment of intangible assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US" id="id_11655837_2031391_1_1">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US" id="id_11655837_2031391_2_1">Impairment of Long-Lived Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncentiveFromLessor" xlink:label="us-gaap_IncentiveFromLessor"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncentiveFromLessor_lbl" xml:lang="en-US" id="id_11655837_2032010_1_1">Incentive from Lessor</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncentiveFromLessor_lbl" xml:lang="en-US" id="id_11655837_2032010_2_1">Deferred lease incentive, long-term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncentiveFromLessor" xlink:to="us-gaap_IncentiveFromLessor_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xml:lang="en-US" id="id_11655837_2031567_1_1">Income (Loss) from Continuing Operations before Income Taxes, Domestic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xml:lang="en-US" id="id_11655837_2031567_2_1">U.S.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xml:lang="en-US" id="id_11655837_2031568_1_1">Income (Loss) from Continuing Operations before Income Taxes, Foreign</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xml:lang="en-US" id="id_11655837_2031568_2_1">Foreign</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_lbl" xml:lang="en-US" id="id_11655837_2034280_1_1">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_lbl" xml:lang="en-US" id="id_11655837_2034280_6_1">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US" id="id_11655837_2034283_1_1">Income Statement [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US" id="id_11655837_2034283_2_1">Income Statement [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US" id="id_11655837_2029841_1_1">Income Statement Location [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US" id="id_11655837_2029841_2_1">Income Statement Location [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US" id="id_11655837_2031134_1_1">Income Statement Location [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US" id="id_11655837_2031134_2_1">Income Statement Location [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US" id="id_11655837_2031777_1_1">Income Tax Authority [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US" id="id_11655837_2031777_2_1">Income Tax Authority [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xml:lang="en-US" id="id_11655837_2029842_1_1">Income Tax Authority [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xml:lang="en-US" id="id_11655837_2029842_2_1">Income Tax Authority [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US" id="id_11655837_2029645_1_1">Income Tax Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US" id="id_11655837_2029645_2_1">Income Tax Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" id="id_11655837_2029440_1_1">Income Tax Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" id="id_11655837_2029440_2_1">Income Taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_IncomeTaxesDisclosureLineItems" xlink:label="hsgx_IncomeTaxesDisclosureLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hsgx_IncomeTaxesDisclosureLineItems_lbl" xml:lang="en-US" id="id_11655837_2293595_3_1">Income Taxes Disclosure [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hsgx_IncomeTaxesDisclosureLineItems_lbl" xml:lang="en-US" id="id_11655837_2293595_1_1">Income Taxes Disclosure [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hsgx_IncomeTaxesDisclosureLineItems_lbl" xml:lang="en-US" id="id_11655837_2293595_2_1">Income Taxes Disclosure [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hsgx_IncomeTaxesDisclosureLineItems" xlink:to="hsgx_IncomeTaxesDisclosureLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_IncomeTaxesDisclosureTable" xlink:label="hsgx_IncomeTaxesDisclosureTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hsgx_IncomeTaxesDisclosureTable_lbl" xml:lang="en-US" id="id_11655837_2288958_3_1">Income Taxes Disclosure [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hsgx_IncomeTaxesDisclosureTable_lbl" xml:lang="en-US" id="id_11655837_2288958_1_1">Income Taxes Disclosure [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hsgx_IncomeTaxesDisclosureTable_lbl" xml:lang="en-US" id="id_11655837_2288958_2_1">Income Taxes Disclosure [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hsgx_IncomeTaxesDisclosureTable" xlink:to="hsgx_IncomeTaxesDisclosureTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xml:lang="en-US" id="id_11655837_2033273_1_1">Income Taxes Paid, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xml:lang="en-US" id="id_11655837_2033273_2_1">Cash paid for taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExaminationDescription" xlink:label="us-gaap_IncomeTaxExaminationDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExaminationDescription_lbl" xml:lang="en-US" id="id_11655837_2028780_1_1">Income Tax Examination, Description</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxExaminationDescription_lbl" xml:lang="en-US" id="id_11655837_2028780_2_1">Income tax examination description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExaminationDescription" xlink:to="us-gaap_IncomeTaxExaminationDescription_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US" id="id_11655837_2034647_1_1">Income Tax, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US" id="id_11655837_2034647_2_1">Income Taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US" id="id_11655837_2031782_1_1">Increase (Decrease) in Accounts Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US" id="id_11655837_2031782_2_1">Accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_lbl" xml:lang="en-US" id="id_11655837_2029194_1_1">Increase (Decrease) in Accounts Payable, Related Parties</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_lbl" xml:lang="en-US" id="id_11655837_2029194_2_1">Accounts payable due to Intrexon Corporation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US" id="id_11655837_2029195_1_1">Increase (Decrease) in Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US" id="id_11655837_2029195_2_1">Accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent_lbl" xml:lang="en-US" id="id_11655837_2033279_1_1">Increase (Decrease) in Due to Related Parties, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent_lbl" xml:lang="en-US" id="id_11655837_2033279_2_1">Accrued expenses due to Intrexon Corporation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent" xlink:to="us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" id="id_11655837_2032424_1_1">Increase (Decrease) in Operating Capital [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" id="id_11655837_2032424_2_1">Changes in operating assets and liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" id="id_11655837_2031795_1_1">Increase (Decrease) in Prepaid Expense and Other Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" id="id_11655837_2031795_14_1">Prepaid expenses and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:label="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_lbl" xml:lang="en-US" id="id_11655837_2033893_1_1">Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_lbl" xml:lang="en-US" id="id_11655837_2033893_2_1">Nonparticipating warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:to="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US" id="id_11655837_2029856_1_1">Indefinite-lived Intangible Assets [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US" id="id_11655837_2029856_2_1">Indefinite-lived Intangible Assets [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xml:lang="en-US" id="id_11655837_2028106_1_1">Indefinite-lived Intangible Assets, Major Class Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xml:lang="en-US" id="id_11655837_2028106_2_1">Indefinite-lived Intangible Assets, Major Class Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_InitialPublicOfferingCostsPolicyTextBlock" xlink:label="hsgx_InitialPublicOfferingCostsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hsgx_InitialPublicOfferingCostsPolicyTextBlock_lbl" xml:lang="en-US" id="id_11655837_2343054_3_1">Initial Public Offering Costs [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hsgx_InitialPublicOfferingCostsPolicyTextBlock_lbl" xml:lang="en-US" id="id_11655837_2343054_1_1">Initial Public Offering Costs [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hsgx_InitialPublicOfferingCostsPolicyTextBlock_lbl" xml:lang="en-US" id="id_11655837_2343054_2_1">Initial Public Offering Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hsgx_InitialPublicOfferingCostsPolicyTextBlock" xlink:to="hsgx_InitialPublicOfferingCostsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="us-gaap_InProcessResearchAndDevelopmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InProcessResearchAndDevelopmentMember_lbl" xml:lang="en-US" id="id_11655837_2031417_1_1">In Process Research and Development [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InProcessResearchAndDevelopmentMember_lbl" xml:lang="en-US" id="id_11655837_2031417_2_1">IPR&amp;D [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InProcessResearchAndDevelopmentMember" xlink:to="us-gaap_InProcessResearchAndDevelopmentMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US" id="id_11655837_2030293_1_1">Interest Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US" id="id_11655837_2030293_14_1">Interest expense, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US" id="id_11655837_2040921_1_1">Interest Paid, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US" id="id_11655837_2040921_2_1">Cash paid for interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_IntrexonMember" xlink:label="hsgx_IntrexonMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hsgx_IntrexonMember_lbl" xml:lang="en-US" id="id_11655837_2183197_3_1">Intrexon [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hsgx_IntrexonMember_lbl" xml:lang="en-US" id="id_11655837_2183197_1_1">Intrexon [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hsgx_IntrexonMember_lbl" xml:lang="en-US" id="id_11655837_2183197_2_1">Intrexon [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hsgx_IntrexonMember" xlink:to="hsgx_IntrexonMember_lbl"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_InvestorWarrantsMember" xlink:label="hsgx_InvestorWarrantsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hsgx_InvestorWarrantsMember_lbl" xml:lang="en-US" id="id_11655837_2283059_3_1">Investor warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hsgx_InvestorWarrantsMember_lbl" xml:lang="en-US" id="id_11655837_2283059_1_1">Investor Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hsgx_InvestorWarrantsMember_lbl" xml:lang="en-US" id="id_11655837_2283059_2_1">Investor Warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hsgx_InvestorWarrantsMember" xlink:to="hsgx_InvestorWarrantsMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IPOMember_lbl" xml:lang="en-US" id="id_11655837_2029877_1_1">IPO [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IPOMember_lbl" xml:lang="en-US" id="id_11655837_2029877_2_1">IPO [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US" id="id_11655837_2028633_1_1">Leasehold Improvements [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US" id="id_11655837_2028633_2_1">Leasehold Improvements [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US" id="id_11655837_2033330_1_1">Legal Entity [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US" id="id_11655837_2033330_2_1">Legal Entity [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm" xlink:label="us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm_lbl" xml:lang="en-US" id="id_11655837_2030772_1_1">Lessee Leasing Arrangements, Operating Leases, Renewal Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm_lbl" xml:lang="en-US" id="id_11655837_2030772_2_1">Additional operating lease term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm" xlink:to="us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm_lbl"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_LexingtonMember" xlink:label="hsgx_LexingtonMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hsgx_LexingtonMember_lbl" xml:lang="en-US" id="id_11655837_2240869_3_1">Lexington [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hsgx_LexingtonMember_lbl" xml:lang="en-US" id="id_11655837_2240869_1_1">Lexington [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hsgx_LexingtonMember_lbl" xml:lang="en-US" id="id_11655837_2240869_2_1">Lexington [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hsgx_LexingtonMember" xlink:to="hsgx_LexingtonMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" id="id_11655837_2031177_1_1">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" id="id_11655837_2031177_6_1">Total liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" id="id_11655837_2031178_1_1">Liabilities and Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" id="id_11655837_2031178_6_1">Total liabilities and stockholders' equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" id="id_11655837_2031608_1_1">Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" id="id_11655837_2031608_6_1">Total current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" id="id_11655837_2028362_1_1">Liabilities, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" id="id_11655837_2028362_2_1">Current liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xml:lang="en-US" id="id_11655837_2029681_1_1">Financial and Nonfinancial Liabilities, Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xml:lang="en-US" id="id_11655837_2029681_2_1">Liabilities, fair value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosure" xlink:to="us-gaap_LiabilitiesFairValueDisclosure_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl" xml:lang="en-US" id="id_11655837_2034691_1_1">Liabilities, Fair Value Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl" xml:lang="en-US" id="id_11655837_2034691_2_1">Liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureRecurring" xlink:label="us-gaap_LiabilitiesFairValueDisclosureRecurring"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesFairValueDisclosureRecurring_lbl" xml:lang="en-US" id="id_11655837_2030774_1_1">Liabilities, Fair Value Disclosure, Recurring</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesFairValueDisclosureRecurring_lbl" xml:lang="en-US" id="id_11655837_2030774_2_1">Liabilities, fair value disclosure, recurring</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosureRecurring" xlink:to="us-gaap_LiabilitiesFairValueDisclosureRecurring_lbl"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_LicenseAgreementsPolicyTextBlock" xlink:label="hsgx_LicenseAgreementsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hsgx_LicenseAgreementsPolicyTextBlock_lbl" xml:lang="en-US" id="id_11655837_2351880_3_1">License Agreements Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hsgx_LicenseAgreementsPolicyTextBlock_lbl" xml:lang="en-US" id="id_11655837_2351880_1_1">License Agreements Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hsgx_LicenseAgreementsPolicyTextBlock_lbl" xml:lang="en-US" id="id_11655837_2351880_2_1">License Agreements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hsgx_LicenseAgreementsPolicyTextBlock" xlink:to="hsgx_LicenseAgreementsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCredit" xlink:label="us-gaap_LineOfCredit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCredit_lbl" xml:lang="en-US" id="id_11655837_2034338_1_1">Long-term Line of Credit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LineOfCredit_lbl" xml:lang="en-US" id="id_11655837_2034338_2_1">Borrowings outstanding under line of credit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCredit" xlink:to="us-gaap_LineOfCredit_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xml:lang="en-US" id="id_11655837_2032317_1_1">Line of Credit Facility, Maximum Borrowing Capacity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xml:lang="en-US" id="id_11655837_2032317_2_1">Amount of loan to purchase equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LoansPayable" xlink:label="us-gaap_LoansPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LoansPayable_lbl" xml:lang="en-US" id="id_11655837_2031469_1_1">Loans Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LoansPayable_lbl" xml:lang="en-US" id="id_11655837_2031469_6_1">Total debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansPayable" xlink:to="us-gaap_LoansPayable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LoansPayableCurrent" xlink:label="us-gaap_LoansPayableCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LoansPayableCurrent_lbl" xml:lang="en-US" id="id_11655837_2028380_1_1">Loans Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LoansPayableCurrent_lbl" xml:lang="en-US" id="id_11655837_2028380_2_1">Current portion of equipment loan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LoansPayableCurrent_lbl" xml:lang="en-US" id="id_11655837_2028380_14_1">Less: current portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansPayableCurrent" xlink:to="us-gaap_LoansPayableCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:label="us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_lbl" xml:lang="en-US" id="id_11655837_2033357_1_1">Long-lived Assets by Geographic Areas [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_lbl" xml:lang="en-US" id="id_11655837_2033357_2_1">Summary of Operations in Different Geographic Regions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:to="us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermLoansPayable" xlink:label="us-gaap_LongTermLoansPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermLoansPayable_lbl" xml:lang="en-US" id="id_11655837_2034940_1_1">Loans Payable, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermLoansPayable_lbl" xml:lang="en-US" id="id_11655837_2034940_2_1">Equipment loan, long-term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LongTermLoansPayable_lbl" xml:lang="en-US" id="id_11655837_2034940_12_1">Long-term debt, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermLoansPayable" xlink:to="us-gaap_LongTermLoansPayable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermPurchaseCommitmentAmount" xlink:label="us-gaap_LongTermPurchaseCommitmentAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermPurchaseCommitmentAmount_lbl" xml:lang="en-US" id="id_11655837_2032926_1_1">Long-term Purchase Commitment, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermPurchaseCommitmentAmount_lbl" xml:lang="en-US" id="id_11655837_2032926_2_1">Minimum amount of material and/or services</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermPurchaseCommitmentAmount" xlink:to="us-gaap_LongTermPurchaseCommitmentAmount_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:label="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_lbl" xml:lang="en-US" id="id_11655837_2040972_1_1">Category of Item Purchased [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_lbl" xml:lang="en-US" id="id_11655837_2040972_2_1">Category of Item Purchased [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:to="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:label="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_lbl" xml:lang="en-US" id="id_11655837_2034941_1_1">Long-term Purchase Commitment, Category of Item Purchased [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_lbl" xml:lang="en-US" id="id_11655837_2034941_2_1">Long-term Purchase Commitment, Category of Item Purchased [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:to="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermPurchaseCommitmentDescription" xlink:label="us-gaap_LongTermPurchaseCommitmentDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermPurchaseCommitmentDescription_lbl" xml:lang="en-US" id="id_11655837_2028167_1_1">Long-term Purchase Commitment, Description</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermPurchaseCommitmentDescription_lbl" xml:lang="en-US" id="id_11655837_2028167_2_1">Supplier agreement description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermPurchaseCommitmentDescription" xlink:to="us-gaap_LongTermPurchaseCommitmentDescription_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermPurchaseCommitmentPeriod" xlink:label="us-gaap_LongtermPurchaseCommitmentPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongtermPurchaseCommitmentPeriod_lbl" xml:lang="en-US" id="id_11655837_2032079_1_1">Long-term Purchase Commitment, Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongtermPurchaseCommitmentPeriod_lbl" xml:lang="en-US" id="id_11655837_2032079_2_1">Initial term of the agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermPurchaseCommitmentPeriod" xlink:to="us-gaap_LongtermPurchaseCommitmentPeriod_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingenciesLineItems_lbl" xml:lang="en-US" id="id_11655837_2033181_1_1">Loss Contingencies [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LossContingenciesLineItems_lbl" xml:lang="en-US" id="id_11655837_2033181_2_1">Loss Contingencies [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingenciesTable_lbl" xml:lang="en-US" id="id_11655837_2030134_1_1">Loss Contingencies [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LossContingenciesTable_lbl" xml:lang="en-US" id="id_11655837_2030134_2_1">Loss Contingencies [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MaximumMember_lbl" xml:lang="en-US" id="id_11655837_2033371_1_1">Maximum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MaximumMember_lbl" xml:lang="en-US" id="id_11655837_2033371_2_1">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MaximumMember" xlink:to="us-gaap_MaximumMember_lbl"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_MaximumPercentageOfRecognitionOfTaxBenefitsFromUncertainTaxPositions" xlink:label="hsgx_MaximumPercentageOfRecognitionOfTaxBenefitsFromUncertainTaxPositions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hsgx_MaximumPercentageOfRecognitionOfTaxBenefitsFromUncertainTaxPositions_lbl" xml:lang="en-US" id="id_11655837_2105640_3_1">Maximum Percentage Of Recognition Of Tax Benefits From Uncertain Tax Positions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hsgx_MaximumPercentageOfRecognitionOfTaxBenefitsFromUncertainTaxPositions_lbl" xml:lang="en-US" id="id_11655837_2105640_1_1">Maximum Percentage Of Recognition Of Tax Benefits From Uncertain Tax Positions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hsgx_MaximumPercentageOfRecognitionOfTaxBenefitsFromUncertainTaxPositions_lbl" xml:lang="en-US" id="id_11655837_2105640_2_1">Maximum percentage of recognition of tax benefits from uncertain tax positions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hsgx_MaximumPercentageOfRecognitionOfTaxBenefitsFromUncertainTaxPositions" xlink:to="hsgx_MaximumPercentageOfRecognitionOfTaxBenefitsFromUncertainTaxPositions_lbl"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_MaximumThresholdPercentageOfBeneficialCommonStockInterestOnHoldersDiscretion" xlink:label="hsgx_MaximumThresholdPercentageOfBeneficialCommonStockInterestOnHoldersDiscretion"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hsgx_MaximumThresholdPercentageOfBeneficialCommonStockInterestOnHoldersDiscretion_lbl" xml:lang="en-US" id="id_11655837_2423929_3_1">Maximum threshold percentage of beneficial common stock interest on holders discretion.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hsgx_MaximumThresholdPercentageOfBeneficialCommonStockInterestOnHoldersDiscretion_lbl" xml:lang="en-US" id="id_11655837_2423929_1_1">Maximum Threshold Percentage Of Beneficial Common Stock Interest On Holders Discretion</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hsgx_MaximumThresholdPercentageOfBeneficialCommonStockInterestOnHoldersDiscretion_lbl" xml:lang="en-US" id="id_11655837_2423929_2_1">Maximum threshold percentage of beneficial common stock interest on holder's discretion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hsgx_MaximumThresholdPercentageOfBeneficialCommonStockInterestOnHoldersDiscretion" xlink:to="hsgx_MaximumThresholdPercentageOfBeneficialCommonStockInterestOnHoldersDiscretion_lbl"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_MembersOfBoardOfDirectorsMember" xlink:label="hsgx_MembersOfBoardOfDirectorsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hsgx_MembersOfBoardOfDirectorsMember_lbl" xml:lang="en-US" id="id_11655837_2255485_3_1">Members of board of directors.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hsgx_MembersOfBoardOfDirectorsMember_lbl" xml:lang="en-US" id="id_11655837_2255485_1_1">Members Of Board Of Directors [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hsgx_MembersOfBoardOfDirectorsMember_lbl" xml:lang="en-US" id="id_11655837_2255485_2_1">Members of Board of Directors [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hsgx_MembersOfBoardOfDirectorsMember" xlink:to="hsgx_MembersOfBoardOfDirectorsMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinimumMember_lbl" xml:lang="en-US" id="id_11655837_2030148_1_1">Minimum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MinimumMember_lbl" xml:lang="en-US" id="id_11655837_2030148_2_1">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinimumMember" xlink:to="us-gaap_MinimumMember_lbl"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_MinimumThresholdPercentageOfBeneficialCommonStockInterest" xlink:label="hsgx_MinimumThresholdPercentageOfBeneficialCommonStockInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hsgx_MinimumThresholdPercentageOfBeneficialCommonStockInterest_lbl" xml:lang="en-US" id="id_11655837_2423926_3_1">Minimum threshold percentage of beneficial common stock interest.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hsgx_MinimumThresholdPercentageOfBeneficialCommonStockInterest_lbl" xml:lang="en-US" id="id_11655837_2423926_1_1">Minimum Threshold Percentage Of Beneficial Common Stock Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hsgx_MinimumThresholdPercentageOfBeneficialCommonStockInterest_lbl" xml:lang="en-US" id="id_11655837_2423926_2_1">Minimum threshold percentage of beneficial common stock interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hsgx_MinimumThresholdPercentageOfBeneficialCommonStockInterest" xlink:to="hsgx_MinimumThresholdPercentageOfBeneficialCommonStockInterest_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xml:lang="en-US" id="id_11655837_2029281_1_1">Money Market Funds [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xml:lang="en-US" id="id_11655837_2029281_2_1">Money Market Funds [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_NatureOfBusinessAbstract" xlink:label="hsgx_NatureOfBusinessAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hsgx_NatureOfBusinessAbstract_lbl" xml:lang="en-US" id="id_11655837_2242752_3_1">Nature Of Business [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hsgx_NatureOfBusinessAbstract_lbl" xml:lang="en-US" id="id_11655837_2242752_1_1">Nature Of Business [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hsgx_NatureOfBusinessAbstract_lbl" xml:lang="en-US" id="id_11655837_2242752_2_1">Nature Of Business [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hsgx_NatureOfBusinessAbstract" xlink:to="hsgx_NatureOfBusinessAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_NatureOfBusinessAndBasisOfPresentationLineItems" xlink:label="hsgx_NatureOfBusinessAndBasisOfPresentationLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hsgx_NatureOfBusinessAndBasisOfPresentationLineItems_lbl" xml:lang="en-US" id="id_11655837_2294753_3_1">Nature Of Business And Basis Of Presentation [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hsgx_NatureOfBusinessAndBasisOfPresentationLineItems_lbl" xml:lang="en-US" id="id_11655837_2294753_1_1">Nature of Business and Basis of Presentation [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hsgx_NatureOfBusinessAndBasisOfPresentationLineItems_lbl" xml:lang="en-US" id="id_11655837_2294753_2_1">Nature Of Business And Basis Of Presentation [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hsgx_NatureOfBusinessAndBasisOfPresentationLineItems" xlink:to="hsgx_NatureOfBusinessAndBasisOfPresentationLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_NatureOfBusinessAndBasisOfPresentationTable" xlink:label="hsgx_NatureOfBusinessAndBasisOfPresentationTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hsgx_NatureOfBusinessAndBasisOfPresentationTable_lbl" xml:lang="en-US" id="id_11655837_2285127_3_1">Nature Of Business And Basis Of Presentation [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hsgx_NatureOfBusinessAndBasisOfPresentationTable_lbl" xml:lang="en-US" id="id_11655837_2285127_1_1">Nature Of Business And Basis Of Presentation [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hsgx_NatureOfBusinessAndBasisOfPresentationTable_lbl" xml:lang="en-US" id="id_11655837_2285127_2_1">Nature Of Business And Basis Of Presentation [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hsgx_NatureOfBusinessAndBasisOfPresentationTable" xlink:to="hsgx_NatureOfBusinessAndBasisOfPresentationTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US" id="id_11655837_2034374_1_1">Nature of Operations [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US" id="id_11655837_2034374_2_1">Nature of Business</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_lbl" xml:lang="en-US" id="id_11655837_2032942_1_1">Net Cash Provided by (Used in) Financing Activities, Continuing Operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_lbl" xml:lang="en-US" id="id_11655837_2032942_6_1">Net cash provided by financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US" id="id_11655837_2033388_1_1">Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US" id="id_11655837_2033388_2_1">CASH FLOWS FROM FINANCING ACTIVITIES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_lbl" xml:lang="en-US" id="id_11655837_2030371_1_1">Net Cash Provided by (Used in) Investing Activities, Continuing Operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_lbl" xml:lang="en-US" id="id_11655837_2030371_2_1">Net cash used in investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US" id="id_11655837_2030817_1_1">Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US" id="id_11655837_2030817_2_1">CASH FLOWS FROM INVESTING ACTIVITIES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl" xml:lang="en-US" id="id_11655837_2034376_1_1">Net Cash Provided by (Used in) Operating Activities, Continuing Operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl" xml:lang="en-US" id="id_11655837_2034376_6_1">Net cash used in operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US" id="id_11655837_2029047_1_1">Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US" id="id_11655837_2029047_2_1">CASH FLOWS FROM OPERATING ACTIVITIES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" id="id_11655837_2030161_1_1">Net Income (Loss) Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" id="id_11655837_2030161_2_1">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" id="id_11655837_2030161_6_1">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US" id="id_11655837_2032110_1_1">Net Income (Loss) Available to Common Stockholders, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US" id="id_11655837_2032110_2_1">Loss attributable to common stockholders-basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US" id="id_11655837_2032110_6_1">Numerator for basic EPS-Earnings (loss) attributable to common stockholders</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl" xml:lang="en-US" id="id_11655837_2031650_1_1">Net Income (Loss) Available to Common Stockholders, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl" xml:lang="en-US" id="id_11655837_2031650_2_1">Loss attributable to common stockholders-diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl" xml:lang="en-US" id="id_11655837_2031650_6_1">Numerator for diluted EPS-Earnings (loss) attributable to common stockholders after assumed conversions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_lbl" xml:lang="en-US" id="id_11655837_2028415_1_1">Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_lbl" xml:lang="en-US" id="id_11655837_2028415_2_1">Numerator:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_NetIncomeLossAvailableToSeriesAPreferredStock" xlink:label="hsgx_NetIncomeLossAvailableToSeriesAPreferredStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hsgx_NetIncomeLossAvailableToSeriesAPreferredStock_lbl" xml:lang="en-US" id="id_11655837_2399250_3_1">Net income loss available to Series A preferred stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hsgx_NetIncomeLossAvailableToSeriesAPreferredStock_lbl" xml:lang="en-US" id="id_11655837_2399250_1_1">Net Income Loss Available To Series A Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hsgx_NetIncomeLossAvailableToSeriesAPreferredStock_lbl" xml:lang="en-US" id="id_11655837_2399250_2_1">Net Loss attributable to Series A Preferred Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hsgx_NetIncomeLossAvailableToSeriesAPreferredStock" xlink:to="hsgx_NetIncomeLossAvailableToSeriesAPreferredStock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" id="id_11655837_2032113_1_1">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" id="id_11655837_2032113_2_1">Recently Adopted Accounting Pronouncements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US" id="id_11655837_2029294_1_1">Noncash Investing and Financing Items [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US" id="id_11655837_2029294_2_1">Supplemental Disclosure of Non-Cash Items:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NoncurrentAssets" xlink:label="us-gaap_NoncurrentAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncurrentAssets_lbl" xml:lang="en-US" id="id_11655837_2029297_1_1">Long-Lived Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NoncurrentAssets_lbl" xml:lang="en-US" id="id_11655837_2029297_2_1">Long-lived assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncurrentAssets" xlink:to="us-gaap_NoncurrentAssets_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US" id="id_11655837_2029055_1_1">Nonoperating Income (Expense)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US" id="id_11655837_2029055_6_1">Total other income (expense), net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:label="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_lbl" xml:lang="en-US" id="id_11655837_2032769_1_1">Nonvested Restricted Stock Shares Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_lbl" xml:lang="en-US" id="id_11655837_2032769_2_1">Schedule of Restricted Stock Awards Under the 2012 and 2013 Plans</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:to="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_NumberOfAdditionalRenewalOptions" xlink:label="hsgx_NumberOfAdditionalRenewalOptions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hsgx_NumberOfAdditionalRenewalOptions_lbl" xml:lang="en-US" id="id_11655837_2370723_3_1">Number Of Additional Renewal Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hsgx_NumberOfAdditionalRenewalOptions_lbl" xml:lang="en-US" id="id_11655837_2370723_1_1">Number Of Additional Renewal Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hsgx_NumberOfAdditionalRenewalOptions_lbl" xml:lang="en-US" id="id_11655837_2370723_2_1">Number of additional renewal terms</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hsgx_NumberOfAdditionalRenewalOptions" xlink:to="hsgx_NumberOfAdditionalRenewalOptions_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US" id="id_11655837_2041010_1_1">Number of Operating Segments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US" id="id_11655837_2041010_2_1">Number of operating segments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xml:lang="en-US" id="id_11655837_2034760_1_1">Number of Reportable Segments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xml:lang="en-US" id="id_11655837_2034760_2_1">Number of reporting segment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfReportableSegments" xlink:to="us-gaap_NumberOfReportableSegments_lbl"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_OcsAgreementMember" xlink:label="hsgx_OcsAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hsgx_OcsAgreementMember_lbl" xml:lang="en-US" id="id_11655837_2336713_3_1">OCS Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hsgx_OcsAgreementMember_lbl" xml:lang="en-US" id="id_11655837_2336713_1_1">OCS Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hsgx_OcsAgreementMember_lbl" xml:lang="en-US" id="id_11655837_2336713_2_1">OCS Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hsgx_OcsAgreementMember" xlink:to="hsgx_OcsAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OfficeEquipmentMember_lbl" xml:lang="en-US" id="id_11655837_2031893_1_1">Office Equipment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OfficeEquipmentMember_lbl" xml:lang="en-US" id="id_11655837_2031893_2_1">Office Equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficeEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US" id="id_11655837_2029967_1_1">Operating Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US" id="id_11655837_2029967_6_1">Total operating expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US" id="id_11655837_2032532_1_1">Operating Expenses [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US" id="id_11655837_2032532_2_1">Operating expenses:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" id="id_11655837_2032376_1_1">Operating Income (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" id="id_11655837_2032376_2_1">Loss from operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xml:lang="en-US" id="id_11655837_2028198_1_1">Operating Leases, Future Minimum Payments Due</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xml:lang="en-US" id="id_11655837_2028198_6_1">Total minimum lease payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_lbl" xml:lang="en-US" id="id_11655837_2032533_1_1">Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_lbl" xml:lang="en-US" id="id_11655837_2032533_2_1">Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" xml:lang="en-US" id="id_11655837_2030177_1_1">Operating Leases, Future Minimum Payments Due, Next Twelve Months</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" xml:lang="en-US" id="id_11655837_2030177_2_1">2017</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_lbl" xml:lang="en-US" id="id_11655837_2028693_1_1">Operating Leases, Future Minimum Payments, Due in Five Years</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_lbl" xml:lang="en-US" id="id_11655837_2028693_2_1">2021</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl" xml:lang="en-US" id="id_11655837_2028879_1_1">Operating Leases, Future Minimum Payments, Due in Four Years</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl" xml:lang="en-US" id="id_11655837_2028879_2_1">2020</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xml:lang="en-US" id="id_11655837_2032535_1_1">Operating Leases, Future Minimum Payments, Due in Three Years</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xml:lang="en-US" id="id_11655837_2032535_2_1">2019</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xml:lang="en-US" id="id_11655837_2034763_1_1">Operating Leases, Future Minimum Payments, Due in Two Years</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xml:lang="en-US" id="id_11655837_2034763_2_1">2018</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_lbl" xml:lang="en-US" id="id_11655837_2031666_1_1">Operating Leases, Future Minimum Payments, Due Thereafter</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_lbl" xml:lang="en-US" id="id_11655837_2031666_2_1">Thereafter</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="us-gaap_OperatingLeasesRentExpenseNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesRentExpenseNet_lbl" xml:lang="en-US" id="id_11655837_2028881_1_1">Operating Leases, Rent Expense, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesRentExpenseNet_lbl" xml:lang="en-US" id="id_11655837_2028881_2_1">Rent expense under operating lease agreements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesRentExpenseNet" xlink:to="us-gaap_OperatingLeasesRentExpenseNet_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US" id="id_11655837_2028431_1_1">Operating Loss Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US" id="id_11655837_2028431_2_1">NOL carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLossCarryforwardsExpirationDate" xlink:label="us-gaap_OperatingLossCarryforwardsExpirationDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsExpirationDate_lbl" xml:lang="en-US" id="id_11655837_2033223_1_1">Operating Loss Carryforwards, Expiration Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLossCarryforwardsExpirationDate_lbl" xml:lang="en-US" id="id_11655837_2033223_2_1">NOL carryforwards, expiration date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsExpirationDate" xlink:to="us-gaap_OperatingLossCarryforwardsExpirationDate_lbl"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_OperatingLossCarryforwardsNetOfLimitations" xlink:label="hsgx_OperatingLossCarryforwardsNetOfLimitations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hsgx_OperatingLossCarryforwardsNetOfLimitations_lbl" xml:lang="en-US" id="id_11655837_2283441_3_1">Operating loss carryforwards net of limitations.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hsgx_OperatingLossCarryforwardsNetOfLimitations_lbl" xml:lang="en-US" id="id_11655837_2283441_1_1">Operating Loss Carryforwards Net Of Limitations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hsgx_OperatingLossCarryforwardsNetOfLimitations_lbl" xml:lang="en-US" id="id_11655837_2283441_2_1">NOL carry forwards, net of limitations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hsgx_OperatingLossCarryforwardsNetOfLimitations" xlink:to="hsgx_OperatingLossCarryforwardsNetOfLimitations_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US" id="id_11655837_2032787_1_1">Organization, Consolidation and Presentation of Financial Statements [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US" id="id_11655837_2032787_2_1">Organization, Consolidation and Presentation of Financial Statements [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_OriginalAgreementDate" xlink:label="hsgx_OriginalAgreementDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hsgx_OriginalAgreementDate_lbl" xml:lang="en-US" id="id_11655837_2329357_3_1">Original agreement date.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hsgx_OriginalAgreementDate_lbl" xml:lang="en-US" id="id_11655837_2329357_1_1">Original agreement date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hsgx_OriginalAgreementDate_lbl" xml:lang="en-US" id="id_11655837_2329357_2_1">Original agreement date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hsgx_OriginalAgreementDate" xlink:to="hsgx_OriginalAgreementDate_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" id="id_11655837_2032125_1_1">Other Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US" id="id_11655837_2032125_2_1">Accrued other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xml:lang="en-US" id="id_11655837_2029757_1_1">Other Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xml:lang="en-US" id="id_11655837_2029757_2_1">Other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract_lbl" xml:lang="en-US" id="id_11655837_2029562_1_1">Other Income and Expenses [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract_lbl" xml:lang="en-US" id="id_11655837_2029562_2_1">Other income (expense):</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_OtherIncomeAndExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US" id="id_11655837_2029084_1_1">Other Nonoperating Income (Expense)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US" id="id_11655837_2029084_2_1">Other expense, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xml:lang="en-US" id="id_11655837_2030849_1_1">Over-Allotment Option [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xml:lang="en-US" id="id_11655837_2030849_2_1">Overallotment Option [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OverAllotmentOptionMember" xlink:to="us-gaap_OverAllotmentOptionMember_lbl"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_PatentCostsPolicyTextBlock" xlink:label="hsgx_PatentCostsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hsgx_PatentCostsPolicyTextBlock_lbl" xml:lang="en-US" id="id_11655837_2374290_3_1">Patent Costs Policy.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hsgx_PatentCostsPolicyTextBlock_lbl" xml:lang="en-US" id="id_11655837_2374290_1_1">Patent Costs [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hsgx_PatentCostsPolicyTextBlock_lbl" xml:lang="en-US" id="id_11655837_2374290_2_1">Patent Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hsgx_PatentCostsPolicyTextBlock" xlink:to="hsgx_PatentCostsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US" id="id_11655837_2034226_1_1">Payables and Accruals [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US" id="id_11655837_2034226_2_1">Payables and Accruals [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_PaymentForLicenseAgreementReimbursementOfCosts" xlink:label="hsgx_PaymentForLicenseAgreementReimbursementOfCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hsgx_PaymentForLicenseAgreementReimbursementOfCosts_lbl" xml:lang="en-US" id="id_11655837_2251915_3_1">Payment For License Agreement Reimbursement Of Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hsgx_PaymentForLicenseAgreementReimbursementOfCosts_lbl" xml:lang="en-US" id="id_11655837_2251915_1_1">Payment For License Agreement Reimbursement Of Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hsgx_PaymentForLicenseAgreementReimbursementOfCosts_lbl" xml:lang="en-US" id="id_11655837_2251915_2_1">Reimbursement for development cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hsgx_PaymentForLicenseAgreementReimbursementOfCosts" xlink:to="hsgx_PaymentForLicenseAgreementReimbursementOfCosts_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsForProceedsFromTenantAllowance" xlink:label="us-gaap_PaymentsForProceedsFromTenantAllowance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForProceedsFromTenantAllowance_lbl" xml:lang="en-US" id="id_11655837_2030207_1_1">Payments for (Proceeds from) Tenant Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsForProceedsFromTenantAllowance_lbl" xml:lang="en-US" id="id_11655837_2030207_2_1">Construction allowance to total cost of tenant improvements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForProceedsFromTenantAllowance" xlink:to="us-gaap_PaymentsForProceedsFromTenantAllowance_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US" id="id_11655837_2039222_1_1">Payments of Stock Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US" id="id_11655837_2039222_2_1">Issuance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US" id="id_11655837_2039222_12_1">Payments related to IPO</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" id="id_11655837_2034791_1_1">Payments to Acquire Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" id="id_11655837_2034791_14_1">Purchases of property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToSuppliers" xlink:label="us-gaap_PaymentsToSuppliers"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToSuppliers_lbl" xml:lang="en-US" id="id_11655837_2032830_1_1">Payments to Suppliers</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsToSuppliers_lbl" xml:lang="en-US" id="id_11655837_2032830_2_1">Amount paid to suppliers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToSuppliers" xlink:to="us-gaap_PaymentsToSuppliers_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xml:lang="en-US" id="id_11655837_2041049_1_1">Pension and Other Postretirement Benefits Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xml:lang="en-US" id="id_11655837_2041049_2_1">Employee Benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_PercentageOfReimbursementExpenses" xlink:label="hsgx_PercentageOfReimbursementExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hsgx_PercentageOfReimbursementExpenses_lbl" xml:lang="en-US" id="id_11655837_2267522_3_1">Percentage of reimbursement expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hsgx_PercentageOfReimbursementExpenses_lbl" xml:lang="en-US" id="id_11655837_2267522_1_1">Percentage Of Reimbursement Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hsgx_PercentageOfReimbursementExpenses_lbl" xml:lang="en-US" id="id_11655837_2267522_2_1">Percentage of reimbursement expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hsgx_PercentageOfReimbursementExpenses" xlink:to="hsgx_PercentageOfReimbursementExpenses_lbl"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_PercentageOfReimbursementExpensesSubjectToAcceptance" xlink:label="hsgx_PercentageOfReimbursementExpensesSubjectToAcceptance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hsgx_PercentageOfReimbursementExpensesSubjectToAcceptance_lbl" xml:lang="en-US" id="id_11655837_2394055_3_1">Percentage of reimbursement expenses subject to acceptance.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hsgx_PercentageOfReimbursementExpensesSubjectToAcceptance_lbl" xml:lang="en-US" id="id_11655837_2394055_1_1">Percentage Of Reimbursement Expenses Subject To Acceptance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hsgx_PercentageOfReimbursementExpensesSubjectToAcceptance_lbl" xml:lang="en-US" id="id_11655837_2394055_2_1">Percentage of reimbursement expenses subject to acceptance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hsgx_PercentageOfReimbursementExpensesSubjectToAcceptance" xlink:to="hsgx_PercentageOfReimbursementExpensesSubjectToAcceptance_lbl"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_PercentageOfRoyaltyOffsetting" xlink:label="hsgx_PercentageOfRoyaltyOffsetting"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hsgx_PercentageOfRoyaltyOffsetting_lbl" xml:lang="en-US" id="id_11655837_2360854_3_1">Percentage of royalty offsetting.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hsgx_PercentageOfRoyaltyOffsetting_lbl" xml:lang="en-US" id="id_11655837_2360854_1_1">Percentage Of Royalty Offsetting</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hsgx_PercentageOfRoyaltyOffsetting_lbl" xml:lang="en-US" id="id_11655837_2360854_2_1">Percentage of royalty offsetting</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hsgx_PercentageOfRoyaltyOffsetting" xlink:to="hsgx_PercentageOfRoyaltyOffsetting_lbl"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_PlacementAgentWarrantMember" xlink:label="hsgx_PlacementAgentWarrantMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hsgx_PlacementAgentWarrantMember_lbl" xml:lang="en-US" id="id_11655837_2394050_3_1">Placement Agent Warrant Member</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hsgx_PlacementAgentWarrantMember_lbl" xml:lang="en-US" id="id_11655837_2394050_1_1">Placement Agent Warrant [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hsgx_PlacementAgentWarrantMember_lbl" xml:lang="en-US" id="id_11655837_2394050_2_1">Placement Agent Warrant [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hsgx_PlacementAgentWarrantMember" xlink:to="hsgx_PlacementAgentWarrantMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US" id="id_11655837_2029102_1_1">Plan Name [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US" id="id_11655837_2029102_2_1">Plan Name [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US" id="id_11655837_2039004_1_1">Plan Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US" id="id_11655837_2039004_2_1">Plan Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US" id="id_11655837_2028253_1_1">Preferred Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US" id="id_11655837_2028253_2_1">Convertible preferred stock, par value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US" id="id_11655837_2028253_12_1">Preferred stock par value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" id="id_11655837_2028472_1_1">Preferred Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" id="id_11655837_2028472_2_1">Convertible preferred stock, shares authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" id="id_11655837_2028472_12_1">Preferred stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US" id="id_11655837_2039242_1_1">Preferred Stock, Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US" id="id_11655837_2039242_2_1">Convertible preferred stock, shares issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US" id="id_11655837_2039242_12_1">Preferred stock, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US" id="id_11655837_2030412_1_1">Preferred Stock, Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US" id="id_11655837_2030412_2_1">Convertible preferred stock, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US" id="id_11655837_2034043_1_1">Preferred Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US" id="id_11655837_2034043_2_1">Convertible preferred stock, $0.01 par value; 30,000,000 shares authorized, 13,416.4734 and 0 shares issued and outstanding at December 31, 2016 and 2015, respectively</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US" id="id_11655837_2037836_1_1">Prepaid Expense and Other Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US" id="id_11655837_2037836_2_1">Prepaid expenses and other current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US" id="id_11655837_2037836_6_1">Prepaid expenses and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_lbl" xml:lang="en-US" id="id_11655837_2033006_1_1">Prepaid Expense and Other Assets, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_lbl" xml:lang="en-US" id="id_11655837_2033006_2_1">Prepaid Expense and Other Assets, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_PrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:label="hsgx_PrepaidExpensesAndOtherCurrentAssetsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hsgx_PrepaidExpensesAndOtherCurrentAssetsTextBlock_lbl" xml:lang="en-US" id="id_11655837_2106167_3_1">Prepaid Expenses And Other Current Assets [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hsgx_PrepaidExpensesAndOtherCurrentAssetsTextBlock_lbl" xml:lang="en-US" id="id_11655837_2106167_1_1">Prepaid Expenses And Other Current Assets [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hsgx_PrepaidExpensesAndOtherCurrentAssetsTextBlock_lbl" xml:lang="en-US" id="id_11655837_2106167_2_1">Prepaid Expenses and Other Current Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hsgx_PrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:to="hsgx_PrepaidExpensesAndOtherCurrentAssetsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidInsurance_lbl" xml:lang="en-US" id="id_11655837_2029114_1_1">Prepaid Insurance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidInsurance_lbl" xml:lang="en-US" id="id_11655837_2029114_2_1">Insurance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidInsurance" xlink:to="us-gaap_PrepaidInsurance_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrimeRateMember" xlink:label="us-gaap_PrimeRateMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrimeRateMember_lbl" xml:lang="en-US" id="id_11655837_2035998_1_1">Prime Rate [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrimeRateMember_lbl" xml:lang="en-US" id="id_11655837_2035998_2_1">Prime Rate [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrimeRateMember" xlink:to="us-gaap_PrimeRateMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl" xml:lang="en-US" id="id_11655837_2031945_1_1">Reclassification, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl" xml:lang="en-US" id="id_11655837_2031945_2_1">Reclassifications</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrivatePlacementMember_lbl" xml:lang="en-US" id="id_11655837_2032595_1_1">Private Placement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrivatePlacementMember_lbl" xml:lang="en-US" id="id_11655837_2032595_2_1">Private Placement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US" id="id_11655837_2037843_1_1">Proceeds from Issuance Initial Public Offering</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US" id="id_11655837_2037843_2_1">Gross proceeds from initial public offering</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_ProceedsFromIssuanceInitialPublicOfferingNet" xlink:label="hsgx_ProceedsFromIssuanceInitialPublicOfferingNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hsgx_ProceedsFromIssuanceInitialPublicOfferingNet_lbl" xml:lang="en-US" id="id_11655837_2162980_3_1">Proceeds from issuance initial public offering net.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hsgx_ProceedsFromIssuanceInitialPublicOfferingNet_lbl" xml:lang="en-US" id="id_11655837_2162980_1_1">Proceeds From Issuance Initial Public Offering Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hsgx_ProceedsFromIssuanceInitialPublicOfferingNet_lbl" xml:lang="en-US" id="id_11655837_2162980_2_1">Net proceeds from initial public offering</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hsgx_ProceedsFromIssuanceInitialPublicOfferingNet" xlink:to="hsgx_ProceedsFromIssuanceInitialPublicOfferingNet_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" id="id_11655837_2035013_1_1">Proceeds from Issuance of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" id="id_11655837_2035013_2_1">Proceeds from overallotment, net of issuance costs of $377</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants_lbl" xml:lang="en-US" id="id_11655837_2032598_1_1">Proceeds from Issuance of Preferred Stock, Preference Stock, and Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants_lbl" xml:lang="en-US" id="id_11655837_2032598_2_1">Proceeds from issuance of common stock, preferred stock, and warrants in connection with private placement, net of issuance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants_lbl" xml:lang="en-US" id="id_11655837_2032598_12_1">Proceeds from issuance of issuance of common stock, preferred stock and warrants, net of issuance costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US" id="id_11655837_2039031_1_1">Proceeds from Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US" id="id_11655837_2039031_2_1">Cash received upon exercise of options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US" id="id_11655837_2039031_12_1">Proceeds from exercise of stock options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_ProChonBiotechLtdMember" xlink:label="hsgx_ProChonBiotechLtdMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hsgx_ProChonBiotechLtdMember_lbl" xml:lang="en-US" id="id_11655837_2293940_3_1">ProChon Biotech Ltd. [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hsgx_ProChonBiotechLtdMember_lbl" xml:lang="en-US" id="id_11655837_2293940_1_1">ProChon Biotech Ltd. [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hsgx_ProChonBiotechLtdMember_lbl" xml:lang="en-US" id="id_11655837_2293940_2_1">ProChon [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hsgx_ProChonBiotechLtdMember" xlink:to="hsgx_ProChonBiotechLtdMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductWarrantyAccrualNoncurrent" xlink:label="us-gaap_ProductWarrantyAccrualNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProductWarrantyAccrualNoncurrent_lbl" xml:lang="en-US" id="id_11655837_2033028_1_1">Product Warranty Accrual, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProductWarrantyAccrualNoncurrent_lbl" xml:lang="en-US" id="id_11655837_2033028_2_1">Warrant liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductWarrantyAccrualNoncurrent" xlink:to="us-gaap_ProductWarrantyAccrualNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US" id="id_11655837_2040239_1_1">Property, Plant and Equipment [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US" id="id_11655837_2040239_2_1">Property, Plant and Equipment [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US" id="id_11655837_2030037_1_1">Property, Plant and Equipment, Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US" id="id_11655837_2030037_2_1">Property, Plant and Equipment, Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US" id="id_11655837_2029375_1_1">Property, Plant and Equipment Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US" id="id_11655837_2029375_2_1">Property and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl" xml:lang="en-US" id="id_11655837_2036012_1_1">Property, Plant and Equipment, Estimated Useful Lives</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl" xml:lang="en-US" id="id_11655837_2036012_2_1">Estimated Useful Lives</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" xlink:label="hsgx_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hsgx_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock_lbl" xml:lang="en-US" id="id_11655837_2330841_3_1">Property Plant And Equipment Estimated Useful Lives Table [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hsgx_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock_lbl" xml:lang="en-US" id="id_11655837_2330841_1_1">Property Plant And Equipment Estimated Useful Lives [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hsgx_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock_lbl" xml:lang="en-US" id="id_11655837_2330841_2_1">Schedule of Depreciation and Amortization using Straight-line Method over Estimated Useful Lives of Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hsgx_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" xlink:to="hsgx_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US" id="id_11655837_2035051_1_1">Property, Plant and Equipment, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US" id="id_11655837_2035051_2_1">Total property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US" id="id_11655837_2035053_1_1">Property, Plant and Equipment [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US" id="id_11655837_2035053_2_1">Property, Plant and Equipment [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" id="id_11655837_2035024_1_1">Property, Plant and Equipment, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" id="id_11655837_2035024_2_1">Property and equipment, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" id="id_11655837_2035024_6_1">Property and equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US" id="id_11655837_2036191_1_1">Property, Plant and Equipment, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US" id="id_11655837_2036191_2_1">Property and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US" id="id_11655837_2030893_1_1">Property, Plant and Equipment [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US" id="id_11655837_2030893_2_1">Schedule of Property and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US" id="id_11655837_2029377_1_1">Property, Plant and Equipment, Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US" id="id_11655837_2029377_2_1">Property, Plant and Equipment, Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US" id="id_11655837_2028944_1_1">Property, Plant and Equipment, Useful Life</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US" id="id_11655837_2028944_2_1">Estimated Useful Lives</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_PurchaseCommitmentNonrefundablePayment" xlink:label="hsgx_PurchaseCommitmentNonrefundablePayment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hsgx_PurchaseCommitmentNonrefundablePayment_lbl" xml:lang="en-US" id="id_11655837_2259115_3_1">Purchase commitment non-refundable payment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hsgx_PurchaseCommitmentNonrefundablePayment_lbl" xml:lang="en-US" id="id_11655837_2259115_1_1">Purchase Commitment Nonrefundable Payment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hsgx_PurchaseCommitmentNonrefundablePayment_lbl" xml:lang="en-US" id="id_11655837_2259115_2_1">Non-refundable payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hsgx_PurchaseCommitmentNonrefundablePayment" xlink:to="hsgx_PurchaseCommitmentNonrefundablePayment_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:label="us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_lbl" xml:lang="en-US" id="id_11655837_2030673_1_1">Purchase Commitment, Remaining Minimum Amount Committed</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_lbl" xml:lang="en-US" id="id_11655837_2030673_2_1">Additional payments due</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:to="us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_lbl"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_PurposeCoMember" xlink:label="hsgx_PurposeCoMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hsgx_PurposeCoMember_lbl" xml:lang="en-US" id="id_11655837_2128515_3_1">Purpose Co [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hsgx_PurposeCoMember_lbl" xml:lang="en-US" id="id_11655837_2128515_1_1">Purpose Co [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hsgx_PurposeCoMember_lbl" xml:lang="en-US" id="id_11655837_2128515_2_1">Purpose, Co. [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hsgx_PurposeCoMember" xlink:to="hsgx_PurposeCoMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RangeAxis_lbl" xml:lang="en-US" id="id_11655837_2028497_1_1">Range [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RangeAxis_lbl" xml:lang="en-US" id="id_11655837_2028497_2_1">Range [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RangeMember_lbl" xml:lang="en-US" id="id_11655837_2030442_1_1">Range [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RangeMember_lbl" xml:lang="en-US" id="id_11655837_2030442_2_1">Range [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_RangeMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:label="us-gaap_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_lbl" xml:lang="en-US" id="id_11655837_2038438_1_1">Name of Property [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_lbl" xml:lang="en-US" id="id_11655837_2038438_2_1">Name of Property [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:to="us-gaap_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:label="us-gaap_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_lbl" xml:lang="en-US" id="id_11655837_2038636_1_1">Name of Property [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_lbl" xml:lang="en-US" id="id_11655837_2038636_2_1">Name of Property [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:to="us-gaap_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US" id="id_11655837_2030464_1_1">Related Party [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US" id="id_11655837_2030464_2_1">Related Party [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl" xml:lang="en-US" id="id_11655837_2036569_1_1">Related Party Transaction, Amounts of Transaction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl" xml:lang="en-US" id="id_11655837_2036569_2_1">Payment in exchange of eliminating minimum annual order of material and/or services and any other amounts due supplier</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl" xml:lang="en-US" id="id_11655837_2036569_12_1">Reimbursement for development cost, paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl" xml:lang="en-US" id="id_11655837_2035044_1_1">Related Party Transaction, Expenses from Transactions with Related Party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl" xml:lang="en-US" id="id_11655837_2035044_2_1">Research and development expense from transaction with Intrexon</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US" id="id_11655837_2039282_1_1">Related Party Transactions [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US" id="id_11655837_2039282_2_1">Related Party Transactions [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US" id="id_11655837_2038452_1_1">Related Party [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US" id="id_11655837_2038452_2_1">Related Party [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US" id="id_11655837_2040692_1_1">Related Party Transactions Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US" id="id_11655837_2040692_2_1">Related Parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_RemainingOfferingCostsIncludedInAccountsPayable" xlink:label="hsgx_RemainingOfferingCostsIncludedInAccountsPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hsgx_RemainingOfferingCostsIncludedInAccountsPayable_lbl" xml:lang="en-US" id="id_11655837_2297485_3_1">Remaining offering costs included in accounts payable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hsgx_RemainingOfferingCostsIncludedInAccountsPayable_lbl" xml:lang="en-US" id="id_11655837_2297485_1_1">Remaining Offering Costs Included In Accounts Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hsgx_RemainingOfferingCostsIncludedInAccountsPayable_lbl" xml:lang="en-US" id="id_11655837_2297485_2_1">Remaining amount of IPO costs included in accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hsgx_RemainingOfferingCostsIncludedInAccountsPayable" xlink:to="hsgx_RemainingOfferingCostsIncludedInAccountsPayable_lbl"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_RepaymentPeriod" xlink:label="hsgx_RepaymentPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hsgx_RepaymentPeriod_lbl" xml:lang="en-US" id="id_11655837_2222478_3_1">Repayment period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hsgx_RepaymentPeriod_lbl" xml:lang="en-US" id="id_11655837_2222478_1_1">Repayment Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hsgx_RepaymentPeriod_lbl" xml:lang="en-US" id="id_11655837_2222478_2_1">Repayment period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hsgx_RepaymentPeriod" xlink:to="hsgx_RepaymentPeriod_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepaymentsOfDebt" xlink:label="us-gaap_RepaymentsOfDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfDebt_lbl" xml:lang="en-US" id="id_11655837_2035073_1_1">Repayments of Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfDebt_lbl" xml:lang="en-US" id="id_11655837_2035073_14_1">Repayments on equipment term loan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfDebt" xlink:to="us-gaap_RepaymentsOfDebt_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" xml:lang="en-US" id="id_11655837_2038064_1_1">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" xml:lang="en-US" id="id_11655837_2038064_2_1">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" xml:lang="en-US" id="id_11655837_2040697_1_1">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" xml:lang="en-US" id="id_11655837_2040697_2_1">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" id="id_11655837_2038837_1_1">Research and Development Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" id="id_11655837_2038837_2_1">Research and development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" id="id_11655837_2038837_12_1">Research and development expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" id="id_11655837_2035076_1_1">Research and Development Expense [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" id="id_11655837_2035076_2_1">Research and Development [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US" id="id_11655837_2038838_1_1">Research and Development Expense, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US" id="id_11655837_2038838_2_1">Research and Development Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xml:lang="en-US" id="id_11655837_2031755_1_1">Cash and Cash Equivalents [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xml:lang="en-US" id="id_11655837_2031755_2_1">Cash and Cash Equivalents [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_lbl" xml:lang="en-US" id="id_11655837_2040445_1_1">Restricted Cash and Cash Equivalents, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_lbl" xml:lang="en-US" id="id_11655837_2040445_2_1">Restricted cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedStockExpense" xlink:label="us-gaap_RestrictedStockExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockExpense_lbl" xml:lang="en-US" id="id_11655837_2040272_1_1">Restricted Stock or Unit Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedStockExpense_lbl" xml:lang="en-US" id="id_11655837_2040272_2_1">Restricted stock-based compensation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockExpense" xlink:to="us-gaap_RestrictedStockExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockMember_lbl" xml:lang="en-US" id="id_11655837_2041099_1_1">Restricted Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedStockMember_lbl" xml:lang="en-US" id="id_11655837_2041099_2_1">Restricted Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" id="id_11655837_2037317_1_1">Retained Earnings (Accumulated Deficit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" id="id_11655837_2037317_2_1">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US" id="id_11655837_2037658_1_1">Retained Earnings [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US" id="id_11655837_2037658_2_1">Accumulated Deficit [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US" id="id_11655837_2039697_1_1">Revenue Recognition, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US" id="id_11655837_2039697_2_1">Revenue Recognition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RoyaltyExpense_lbl" xml:lang="en-US" id="id_11655837_2035683_1_1">Royalty Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RoyaltyExpense_lbl" xml:lang="en-US" id="id_11655837_2035683_2_1">Non-refundable royalty fee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyExpense" xlink:to="us-gaap_RoyaltyExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_RoyaltyPaymentPercentage" xlink:label="hsgx_RoyaltyPaymentPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hsgx_RoyaltyPaymentPercentage_lbl" xml:lang="en-US" id="id_11655837_2057928_3_1">Royalty payment percentage.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hsgx_RoyaltyPaymentPercentage_lbl" xml:lang="en-US" id="id_11655837_2057928_1_1">Royalty Payment Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hsgx_RoyaltyPaymentPercentage_lbl" xml:lang="en-US" id="id_11655837_2057928_2_1">Royalties payment, rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hsgx_RoyaltyPaymentPercentage" xlink:to="hsgx_RoyaltyPaymentPercentage_lbl"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_RoyaltyPaymentPercentageAsPercentageOfGrantReceived" xlink:label="hsgx_RoyaltyPaymentPercentageAsPercentageOfGrantReceived"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hsgx_RoyaltyPaymentPercentageAsPercentageOfGrantReceived_lbl" xml:lang="en-US" id="id_11655837_2156044_3_1">Royalty payment percentage as percentage of grant received.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hsgx_RoyaltyPaymentPercentageAsPercentageOfGrantReceived_lbl" xml:lang="en-US" id="id_11655837_2156044_1_1">Royalty Payment Percentage As Percentage Of Grant Received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hsgx_RoyaltyPaymentPercentageAsPercentageOfGrantReceived_lbl" xml:lang="en-US" id="id_11655837_2156044_2_1">Royalty payment percentage as percentage of grant received</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hsgx_RoyaltyPaymentPercentageAsPercentageOfGrantReceived" xlink:to="hsgx_RoyaltyPaymentPercentageAsPercentageOfGrantReceived_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US" id="id_11655837_2036416_1_1">Sale of Stock [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US" id="id_11655837_2036416_2_1">Sale of Stock [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xml:lang="en-US" id="id_11655837_2040712_1_1">Sale of Stock, Price Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xml:lang="en-US" id="id_11655837_2040712_2_1">Initial public offering price per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_SalesMilestoneMember" xlink:label="hsgx_SalesMilestoneMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hsgx_SalesMilestoneMember_lbl" xml:lang="en-US" id="id_11655837_2313845_3_1">Sales milestones.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hsgx_SalesMilestoneMember_lbl" xml:lang="en-US" id="id_11655837_2313845_1_1">Sales Milestone [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hsgx_SalesMilestoneMember_lbl" xml:lang="en-US" id="id_11655837_2313845_2_1">Sales Milestones [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hsgx_SalesMilestoneMember" xlink:to="hsgx_SalesMilestoneMember_lbl"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_SalesMilestonesPaymentsObligation" xlink:label="hsgx_SalesMilestonesPaymentsObligation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hsgx_SalesMilestonesPaymentsObligation_lbl" xml:lang="en-US" id="id_11655837_2393706_3_1">Sales milestones payments obligation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hsgx_SalesMilestonesPaymentsObligation_lbl" xml:lang="en-US" id="id_11655837_2393706_1_1">Sales Milestones Payments Obligation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hsgx_SalesMilestonesPaymentsObligation_lbl" xml:lang="en-US" id="id_11655837_2393706_2_1">Sales milestones</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hsgx_SalesMilestonesPaymentsObligation" xlink:to="hsgx_SalesMilestonesPaymentsObligation_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="us-gaap_SalesRevenueNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalesRevenueNet_lbl" xml:lang="en-US" id="id_11655837_2028303_1_1">Revenue, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SalesRevenueNet_lbl" xml:lang="en-US" id="id_11655837_2028303_2_1">Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNet" xlink:to="us-gaap_SalesRevenueNet_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioForecastMember" xlink:label="us-gaap_ScenarioForecastMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScenarioForecastMember_lbl" xml:lang="en-US" id="id_11655837_2038269_1_1">Scenario, Forecast [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScenarioForecastMember_lbl" xml:lang="en-US" id="id_11655837_2038269_2_1">Scenario, Forecast [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScenarioForecastMember" xlink:to="us-gaap_ScenarioForecastMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScenarioUnspecifiedDomain_lbl" xml:lang="en-US" id="id_11655837_2036952_1_1">Scenario, Unspecified [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScenarioUnspecifiedDomain_lbl" xml:lang="en-US" id="id_11655837_2036952_2_1">Scenario, Unspecified [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_ScenarioUnspecifiedDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US" id="id_11655837_2039094_1_1">Schedule of Accrued Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US" id="id_11655837_2039094_2_1">Schedule of Accrued Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US" id="id_11655837_2035513_1_1">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US" id="id_11655837_2035513_2_1">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" id="id_11655837_2036741_1_1">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" id="id_11655837_2036741_2_1">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xml:lang="en-US" id="id_11655837_2039891_1_1">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xml:lang="en-US" id="id_11655837_2039891_2_1">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl" xml:lang="en-US" id="id_11655837_2039303_1_1">Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl" xml:lang="en-US" id="id_11655837_2039303_2_1">Summary of Stock-Based Compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock_lbl" xml:lang="en-US" id="id_11655837_2040288_1_1">Schedule of Debt [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock_lbl" xml:lang="en-US" id="id_11655837_2040288_2_1">Schedule of Outstanding Borrowing Obligations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDebtTableTextBlock" xlink:to="us-gaap_ScheduleOfDebtTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US" id="id_11655837_2038079_1_1">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US" id="id_11655837_2038079_2_1">Components of Deferred Tax Assets and Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US" id="id_11655837_2036959_1_1">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US" id="id_11655837_2036959_2_1">Schedule of Basic and Diluted Loss Per Common Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US" id="id_11655837_2039307_1_1">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US" id="id_11655837_2039307_2_1">Schedule of Reconciliation of Income Tax Expense (Benefit) Computed at Statutory Federal Income Tax Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xml:lang="en-US" id="id_11655837_2037678_1_1">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xml:lang="en-US" id="id_11655837_2037678_2_1">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xml:lang="en-US" id="id_11655837_2029172_1_1">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xml:lang="en-US" id="id_11655837_2029172_2_1">Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xml:lang="en-US" id="id_11655837_2041123_1_1">Schedule of Finite-Lived Intangible Assets [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xml:lang="en-US" id="id_11655837_2041123_2_1">Schedule of Finite-Lived Intangible Assets [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xml:lang="en-US" id="id_11655837_2037332_1_1">Schedule of Finite-Lived Intangible Assets [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xml:lang="en-US" id="id_11655837_2037332_2_1">Summary of Intangible Assets, Net of Accumulated Impairment Charges</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xml:lang="en-US" id="id_11655837_2038476_1_1">Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xml:lang="en-US" id="id_11655837_2038476_2_1">Schedule of Minimum Annual Lease Commitments Under Non-Cancellable Operating Leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xml:lang="en-US" id="id_11655837_2038082_1_1">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xml:lang="en-US" id="id_11655837_2038082_2_1">Components of Loss Before Income Taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US" id="id_11655837_2040473_1_1">Property, Plant and Equipment [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US" id="id_11655837_2040473_2_1">Property, Plant and Equipment [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl" xml:lang="en-US" id="id_11655837_2036599_1_1">Schedule of Segment Reporting Information, by Segment [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl" xml:lang="en-US" id="id_11655837_2036599_2_1">Schedule of Segment Reporting Information, by Segment [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock_lbl" xml:lang="en-US" id="id_11655837_2039528_1_1">Schedule of Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Grant Date Intrinsic Value [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock_lbl" xml:lang="en-US" id="id_11655837_2039528_2_1">Additional Information about Stock Option Activity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US" id="id_11655837_2038480_1_1">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US" id="id_11655837_2038480_2_1">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" id="id_11655837_2039316_1_1">Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" id="id_11655837_2039316_2_1">Summary of Stock Option Activity Under the 2012 and 2013 Plans</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionBySupplierTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionBySupplierTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionBySupplierTextBlock_lbl" xml:lang="en-US" id="id_11655837_2039899_1_1">Schedule of Share-based Goods and Nonemployee Services Transaction by Supplier [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionBySupplierTextBlock_lbl" xml:lang="en-US" id="id_11655837_2039899_2_1">Summary of Weighted-Average Assumptions Used in the Black-Scholes Option Pricing Model to Determine the Fair Value of the Non-Employee Stock Option Grants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionBySupplierTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionBySupplierTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" id="id_11655837_2036601_1_1">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" id="id_11655837_2036601_2_1">Summary of Weighted-Average Assumptions Used in the Black-Scholes Option Pricing Model to Determine the Fair Value of the Employee Stock Option Grants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_ScheduleOfSharesOfCommonStockReservedForFutureIssuanceTableTextBlock" xlink:label="hsgx_ScheduleOfSharesOfCommonStockReservedForFutureIssuanceTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hsgx_ScheduleOfSharesOfCommonStockReservedForFutureIssuanceTableTextBlock_lbl" xml:lang="en-US" id="id_11655837_2105796_3_1">Schedule of shares of common stock reserved for future issuance.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hsgx_ScheduleOfSharesOfCommonStockReservedForFutureIssuanceTableTextBlock_lbl" xml:lang="en-US" id="id_11655837_2105796_1_1">Schedule Of Shares Of Common Stock Reserved For Future Issuance [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hsgx_ScheduleOfSharesOfCommonStockReservedForFutureIssuanceTableTextBlock_lbl" xml:lang="en-US" id="id_11655837_2105796_2_1">Schedule of Common Stock Reserved for Future Issuance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hsgx_ScheduleOfSharesOfCommonStockReservedForFutureIssuanceTableTextBlock" xlink:to="hsgx_ScheduleOfSharesOfCommonStockReservedForFutureIssuanceTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xml:lang="en-US" id="id_11655837_2040478_1_1">Schedule of Stock by Class [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xml:lang="en-US" id="id_11655837_2040478_2_1">Schedule of Stock by Class [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xml:lang="en-US" id="id_11655837_2033707_1_1">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xml:lang="en-US" id="id_11655837_2033707_2_1">Summary of Changes In Unrecognized Tax Benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="us-gaap_SegmentGeographicalDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentGeographicalDomain_lbl" xml:lang="en-US" id="id_11655837_2034488_1_1">Geographical [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentGeographicalDomain_lbl" xml:lang="en-US" id="id_11655837_2034488_2_1">Geographical [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentGeographicalDomain" xlink:to="us-gaap_SegmentGeographicalDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingAbstract_lbl" xml:lang="en-US" id="id_11655837_2039912_1_1">Segment Reporting [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingAbstract_lbl" xml:lang="en-US" id="id_11655837_2039912_2_1">Segment Reporting [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingInformationLineItems_lbl" xml:lang="en-US" id="id_11655837_2039533_1_1">Segment Reporting Information [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingInformationLineItems_lbl" xml:lang="en-US" id="id_11655837_2039533_2_1">Segment Reporting Information [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_SegmentReportingInformationLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US" id="id_11655837_2035536_1_1">Segment Reporting, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US" id="id_11655837_2035536_2_1">Segment and Geographic Information</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_SeriesAConvertiblePreferredStockMember" xlink:label="hsgx_SeriesAConvertiblePreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hsgx_SeriesAConvertiblePreferredStockMember_lbl" xml:lang="en-US" id="id_11655837_2159266_3_1">Series A convertible preferred stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hsgx_SeriesAConvertiblePreferredStockMember_lbl" xml:lang="en-US" id="id_11655837_2159266_1_1">Series A- Convertible Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hsgx_SeriesAConvertiblePreferredStockMember_lbl" xml:lang="en-US" id="id_11655837_2159266_2_1">Series A Convertible Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hsgx_SeriesAConvertiblePreferredStockMember" xlink:to="hsgx_SeriesAConvertiblePreferredStockMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xml:lang="en-US" id="id_11655837_2037928_1_1">Series A Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xml:lang="en-US" id="id_11655837_2037928_2_1">Series A Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" id="id_11655837_2039916_1_1">Share-based Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" id="id_11655837_2039916_2_1">Stock-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US" id="id_11655837_2036265_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US" id="id_11655837_2036265_2_1">Stock options vesting period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xml:lang="en-US" id="id_11655837_2038869_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xml:lang="en-US" id="id_11655837_2038869_2_1">Stock options vesting percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" id="id_11655837_2036267_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" id="id_11655837_2036267_4_1">Number of shares, Unvested ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" id="id_11655837_2036267_5_1">Number of shares, Unvested beginning balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" id="id_11655837_2036766_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" id="id_11655837_2036766_4_1">Weighted-average grant date fair value, Unvested ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" id="id_11655837_2036766_5_1">Weighted-average grant date fair value, Unvested beginning balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US" id="id_11655837_2037346_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US" id="id_11655837_2037346_14_1">Vesting of restricted stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" id="id_11655837_2037932_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" id="id_11655837_2037932_2_1">Vesting of restricted stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US" id="id_11655837_2036442_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US" id="id_11655837_2036442_2_1">Term of stock options granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xml:lang="en-US" id="id_11655837_2039120_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xml:lang="en-US" id="id_11655837_2039120_2_1">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US" id="id_11655837_2036986_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US" id="id_11655837_2036986_2_1">Expected dividend yield</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" id="id_11655837_2039919_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" id="id_11655837_2039919_2_1">Expected term (in years)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US" id="id_11655837_2039121_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US" id="id_11655837_2039121_2_1">Expected volatility</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US" id="id_11655837_2039734_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US" id="id_11655837_2039734_2_1">Risk-free interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" id="id_11655837_2035719_1_1">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" id="id_11655837_2035719_2_1">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xml:lang="en-US" id="id_11655837_2037349_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xml:lang="en-US" id="id_11655837_2037349_2_1">Increase in authorized shares of common stock amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US" id="id_11655837_2039920_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US" id="id_11655837_2039920_2_1">Number of shares authorized for issuance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US" id="id_11655837_2039921_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US" id="id_11655837_2039921_2_1">Aggregate Intrinsic Value, Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US" id="id_11655837_2035721_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US" id="id_11655837_2035721_2_1">Number of Options, Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_11655837_2035124_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_11655837_2035124_2_1">Weighted Average Exercise Price, Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" id="id_11655837_2037513_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" id="id_11655837_2037513_2_1">Weighted Average Remaining Contractual Term, Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US" id="id_11655837_2039324_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US" id="id_11655837_2039324_2_1">Intrinsic value of options exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US" id="id_11655837_2039736_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US" id="id_11655837_2039736_14_1">Number of Options, Cancelled</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" id="id_11655837_2039326_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" id="id_11655837_2039326_2_1">Number of Options, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" id="id_11655837_2039536_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" id="id_11655837_2039536_2_1">Weighted-average grant date fair value per share of employee option grants within the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" id="id_11655837_2034501_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" id="id_11655837_2034501_2_1">Aggregate Intrinsic Value, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" id="id_11655837_2041150_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" id="id_11655837_2041150_4_1">Number of Options, Outstanding Ending Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" id="id_11655837_2041150_5_1">Number of Options, Outstanding Beginning Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_11655837_2035540_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_11655837_2035540_4_1">Weighted Average Exercise Price, Outstanding Ending Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_11655837_2035540_5_1">Weighted Average Exercise Price, Outstanding Beginning Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue" xlink:label="hsgx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hsgx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" id="id_11655837_2204957_3_1">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hsgx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" id="id_11655837_2204957_1_1">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hsgx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" id="id_11655837_2204957_2_1">Weighted average grant date fair value of options outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hsgx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue" xlink:to="hsgx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" id="id_11655837_2036768_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" id="id_11655837_2036768_2_1">Weighted Average Remaining Contractual Term, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xml:lang="en-US" id="id_11655837_2039738_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xml:lang="en-US" id="id_11655837_2039738_2_1">Aggregate Intrinsic Value, Vested and expected to vest outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US" id="id_11655837_2040313_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US" id="id_11655837_2040313_2_1">Number of Options, Vested and expected to vest outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_11655837_2040497_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_11655837_2040497_2_1">Weighted Average Exercise Price, Vested and expected to vest outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" id="id_11655837_2040749_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" id="id_11655837_2040749_2_1">Weighted Average Remaining Contractual Term, Vested and expected to vest outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" id="id_11655837_2036988_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" id="id_11655837_2036988_2_1">Weighted average grant date fair value of vested options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xml:lang="en-US" id="id_11655837_2036770_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xml:lang="en-US" id="id_11655837_2036770_2_1">Increase in authorized shares, percentage of common stock outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US" id="id_11655837_2036771_1_1">Equity Award [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US" id="id_11655837_2036771_2_1">Equity Award [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_11655837_2038291_1_1">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_11655837_2038291_2_1">Weighted Average Exercise Price, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_11655837_2037515_1_1">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_11655837_2037515_2_1">Weighted Average Exercise Price, Cancelled</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_11655837_2036990_1_1">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_11655837_2036990_2_1">Weighted Average Exercise Price, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xml:lang="en-US" id="id_11655837_2038872_1_1">Share-based Compensation Award, Tranche One [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xml:lang="en-US" id="id_11655837_2038872_2_1">First Anniversary of Original Vesting Date [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionAbstract" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionAbstract_lbl" xml:lang="en-US" id="id_11655837_2034503_1_1">Share-based Goods and Nonemployee Services Transaction [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionAbstract_lbl" xml:lang="en-US" id="id_11655837_2034503_2_1">Share-based Goods and Nonemployee Services Transaction [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionAbstract" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate_lbl" xml:lang="en-US" id="id_11655837_2040124_1_1">Share-based Goods and Nonemployee Services Transaction, Valuation Method, Expected Dividend Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate_lbl" xml:lang="en-US" id="id_11655837_2040124_2_1">Expected dividend yield</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1_lbl" xml:lang="en-US" id="id_11655837_2036272_1_1">Share-based Goods and Nonemployee Services Transaction, Valuation Method, Expected Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1_lbl" xml:lang="en-US" id="id_11655837_2036272_2_1">Expected term (in years)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate_lbl" xml:lang="en-US" id="id_11655837_2037519_1_1">Share-based Goods and Nonemployee Services Transaction, Valuation Method, Expected Volatility Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate_lbl" xml:lang="en-US" id="id_11655837_2037519_2_1">Expected volatility</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate_lbl" xml:lang="en-US" id="id_11655837_2038716_1_1">Share-based Goods and Nonemployee Services Transaction, Valuation Method, Risk Free Interest Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate_lbl" xml:lang="en-US" id="id_11655837_2038716_2_1">Risk-free interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US" id="id_11655837_2039125_1_1">Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US" id="id_11655837_2039125_4_1">Ending Balance, Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US" id="id_11655837_2039125_5_1">Beginning Balance, Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" id="id_11655837_2038494_1_1">Significant Accounting Policies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" id="id_11655837_2038494_2_1">Summary of Significant Accounting Policies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit" xlink:label="us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit_lbl" xml:lang="en-US" id="id_11655837_2036087_1_1">Significant Change in Unrecognized Tax Benefits is Reasonably Possible, Amount of Unrecorded Benefit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit_lbl" xml:lang="en-US" id="id_11655837_2036087_2_1">Unrecognized tax benefits may be recognized by the end of 2016</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit" xlink:to="us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit_lbl"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_SiliconValleyBankMember" xlink:label="hsgx_SiliconValleyBankMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hsgx_SiliconValleyBankMember_lbl" xml:lang="en-US" id="id_11655837_2361826_3_1">Silicon Valley Bank [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hsgx_SiliconValleyBankMember_lbl" xml:lang="en-US" id="id_11655837_2361826_1_1">Silicon Valley Bank [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hsgx_SiliconValleyBankMember_lbl" xml:lang="en-US" id="id_11655837_2361826_2_1">Silicon Valley Bank [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hsgx_SiliconValleyBankMember" xlink:to="hsgx_SiliconValleyBankMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SoftwareDevelopmentMember" xlink:label="us-gaap_SoftwareDevelopmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SoftwareDevelopmentMember_lbl" xml:lang="en-US" id="id_11655837_2037949_1_1">Software Development [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SoftwareDevelopmentMember_lbl" xml:lang="en-US" id="id_11655837_2037949_2_1">Software [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SoftwareDevelopmentMember" xlink:to="us-gaap_SoftwareDevelopmentMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xml:lang="en-US" id="id_11655837_2037951_1_1">State and Local Jurisdiction [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xml:lang="en-US" id="id_11655837_2037951_2_1">U.S. State [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US" id="id_11655837_2039549_1_1">Class of Stock [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US" id="id_11655837_2039549_2_1">Class of Stock [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US" id="id_11655837_2040323_1_1">Equity Components [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US" id="id_11655837_2040323_2_1">Equity Components [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="us-gaap_StatementGeographicalAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementGeographicalAxis_lbl" xml:lang="en-US" id="id_11655837_2039550_1_1">Geographical [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementGeographicalAxis_lbl" xml:lang="en-US" id="id_11655837_2039550_2_1">Geographical [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementGeographicalAxis" xlink:to="us-gaap_StatementGeographicalAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" id="id_11655837_2039551_1_1">Statement [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" id="id_11655837_2039551_2_1">Statement [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US" id="id_11655837_2038498_1_1">Statement of Cash Flows [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US" id="id_11655837_2038498_2_1">Statement of Cash Flows [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US" id="id_11655837_2039336_1_1">Statement of Financial Position [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US" id="id_11655837_2039336_2_1">Statement of Financial Position [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US" id="id_11655837_2040324_1_1">Statement of Stockholders' Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US" id="id_11655837_2040324_2_1">Statement of Stockholders' Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementScenarioAxis_lbl" xml:lang="en-US" id="id_11655837_2039338_1_1">Scenario [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementScenarioAxis_lbl" xml:lang="en-US" id="id_11655837_2039338_2_1">Scenario [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_StatementScenarioAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US" id="id_11655837_2038726_1_1">Statement [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US" id="id_11655837_2038726_2_1">Statement [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockCompensationPlanMember" xlink:label="us-gaap_StockCompensationPlanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockCompensationPlanMember_lbl" xml:lang="en-US" id="id_11655837_2039754_1_1">Stock Compensation Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockCompensationPlanMember_lbl" xml:lang="en-US" id="id_11655837_2039754_2_1">Unvested Restricted Stock and Options to Purchase Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockCompensationPlanMember" xlink:to="us-gaap_StockCompensationPlanMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" id="id_11655837_2035141_1_1">Stockholders' Equity Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" id="id_11655837_2035141_4_1">Ending Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" id="id_11655837_2035141_5_1">Beginning Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" id="id_11655837_2035141_6_1">Total stockholders' equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" id="id_11655837_2035553_1_1">Stockholders' Equity Attributable to Parent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" id="id_11655837_2035553_2_1">Convertible preferred stock and stockholders' equity:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xml:lang="en-US" id="id_11655837_2039341_1_1">Stockholders' Equity Note [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xml:lang="en-US" id="id_11655837_2039341_2_1">Stockholders' Equity Note [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US" id="id_11655837_2035142_1_1">Stockholders' Equity Note Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US" id="id_11655837_2035142_2_1">Capital Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_StockIssuedDuringPeriodPreferredStockValue" xlink:label="hsgx_StockIssuedDuringPeriodPreferredStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hsgx_StockIssuedDuringPeriodPreferredStockValue_lbl" xml:lang="en-US" id="id_11655837_2423925_3_1">Stock issued during period preferred stock value.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hsgx_StockIssuedDuringPeriodPreferredStockValue_lbl" xml:lang="en-US" id="id_11655837_2423925_1_1">Stock Issued During Period Preferred Stock Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hsgx_StockIssuedDuringPeriodPreferredStockValue_lbl" xml:lang="en-US" id="id_11655837_2423925_2_1">Issuance of Series A convertible preferred stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hsgx_StockIssuedDuringPeriodPreferredStockValue" xlink:to="hsgx_StockIssuedDuringPeriodPreferredStockValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US" id="id_11655837_2038112_1_1">Stock Issued During Period, Shares, Conversion of Convertible Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US" id="id_11655837_2038112_2_1">Conversion of Series A convertible preferred stock, Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" id="id_11655837_2038730_1_1">Stock Issued During Period, Shares, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" id="id_11655837_2038730_2_1">Issuance of common stock related to private placement, Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" id="id_11655837_2038730_12_1">Sale of common stock shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_StockIssuedDuringPeriodSharesOverallotmentNetOfFeesAndIssuanceCosts" xlink:label="hsgx_StockIssuedDuringPeriodSharesOverallotmentNetOfFeesAndIssuanceCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hsgx_StockIssuedDuringPeriodSharesOverallotmentNetOfFeesAndIssuanceCosts_lbl" xml:lang="en-US" id="id_11655837_2319331_3_1">Stock Issued During Period Shares Overallotment Net Of Fees And Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hsgx_StockIssuedDuringPeriodSharesOverallotmentNetOfFeesAndIssuanceCosts_lbl" xml:lang="en-US" id="id_11655837_2319331_1_1">Stock Issued During Period Shares Overallotment Net Of Fees And Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hsgx_StockIssuedDuringPeriodSharesOverallotmentNetOfFeesAndIssuanceCosts_lbl" xml:lang="en-US" id="id_11655837_2319331_2_1">Issuance of common stock from overallotment, net of underwriting fees and issuance costs of $377, Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hsgx_StockIssuedDuringPeriodSharesOverallotmentNetOfFeesAndIssuanceCosts" xlink:to="hsgx_StockIssuedDuringPeriodSharesOverallotmentNetOfFeesAndIssuanceCosts_lbl"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_StockIssuedDuringPeriodSharesPreferredStock" xlink:label="hsgx_StockIssuedDuringPeriodSharesPreferredStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hsgx_StockIssuedDuringPeriodSharesPreferredStock_lbl" xml:lang="en-US" id="id_11655837_2084009_3_1">Stock Issued During Period Shares Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hsgx_StockIssuedDuringPeriodSharesPreferredStock_lbl" xml:lang="en-US" id="id_11655837_2084009_1_1">Stock Issued During Period Shares Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hsgx_StockIssuedDuringPeriodSharesPreferredStock_lbl" xml:lang="en-US" id="id_11655837_2084009_2_1">Issuance of Series A convertible preferred stock, Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hsgx_StockIssuedDuringPeriodSharesPreferredStock" xlink:to="hsgx_StockIssuedDuringPeriodSharesPreferredStock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl" xml:lang="en-US" id="id_11655837_2040326_1_1">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl" xml:lang="en-US" id="id_11655837_2040326_2_1">Vesting of restricted stock, Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" id="id_11655837_2035145_1_1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" id="id_11655837_2035145_2_1">Exercise of common stock options, Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" id="id_11655837_2035145_14_1">Number of Options, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US" id="id_11655837_2037191_1_1">Stock Issued During Period, Value, Conversion of Convertible Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US" id="id_11655837_2037191_2_1">Conversion of Series A convertible preferred stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" id="id_11655837_2038306_1_1">Stock Issued During Period, Value, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" id="id_11655837_2038306_2_1">Issuance of common stock related to private placement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_StockIssuedDuringPeriodValueOverallotmentNetOfFeesAndIssuanceCosts" xlink:label="hsgx_StockIssuedDuringPeriodValueOverallotmentNetOfFeesAndIssuanceCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hsgx_StockIssuedDuringPeriodValueOverallotmentNetOfFeesAndIssuanceCosts_lbl" xml:lang="en-US" id="id_11655837_2289112_3_1">Stock Issued During Period Value Overallotment Net Of Fees And Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hsgx_StockIssuedDuringPeriodValueOverallotmentNetOfFeesAndIssuanceCosts_lbl" xml:lang="en-US" id="id_11655837_2289112_1_1">Stock Issued During Period Value Overallotment Net Of Fees And Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hsgx_StockIssuedDuringPeriodValueOverallotmentNetOfFeesAndIssuanceCosts_lbl" xml:lang="en-US" id="id_11655837_2289112_2_1">Issuance of common stock from overallotment, net of underwriting fees and issuance costs of $377</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hsgx_StockIssuedDuringPeriodValueOverallotmentNetOfFeesAndIssuanceCosts" xlink:to="hsgx_StockIssuedDuringPeriodValueOverallotmentNetOfFeesAndIssuanceCosts_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_lbl" xml:lang="en-US" id="id_11655837_2033735_1_1">Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_lbl" xml:lang="en-US" id="id_11655837_2033735_2_1">Vesting of restricted stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US" id="id_11655837_2038502_1_1">Stock Issued During Period, Value, Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US" id="id_11655837_2038502_2_1">Exercise of common stock options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US" id="id_11655837_2035892_1_1">Subsequent Event [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US" id="id_11655837_2035892_2_1">Subsequent Event [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US" id="id_11655837_2039760_1_1">Subsequent Events [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US" id="id_11655837_2039760_2_1">Subsequent Events [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US" id="id_11655837_2040768_1_1">Subsequent Events [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US" id="id_11655837_2040768_2_1">Subsequent Events</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US" id="id_11655837_2039938_1_1">Subsequent Event [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US" id="id_11655837_2039938_2_1">Subsequent Event [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US" id="id_11655837_2040137_1_1">Sale of Stock [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US" id="id_11655837_2040137_2_1">Sale of Stock [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="hsgx_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hsgx_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xml:lang="en-US" id="id_11655837_2153280_3_1">Summary Of Significant Accounting Policies [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hsgx_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xml:lang="en-US" id="id_11655837_2153280_1_1">Summary Of Significant Accounting Policies [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hsgx_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xml:lang="en-US" id="id_11655837_2153280_2_1">Summary Of Significant Accounting Policies [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hsgx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="hsgx_SummaryOfSignificantAccountingPoliciesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_SummaryOfSignificantAccountingPoliciesTable" xlink:label="hsgx_SummaryOfSignificantAccountingPoliciesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hsgx_SummaryOfSignificantAccountingPoliciesTable_lbl" xml:lang="en-US" id="id_11655837_2317292_3_1">Summary Of Significant Accounting Policies [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hsgx_SummaryOfSignificantAccountingPoliciesTable_lbl" xml:lang="en-US" id="id_11655837_2317292_1_1">Summary Of Significant Accounting Policies [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hsgx_SummaryOfSignificantAccountingPoliciesTable_lbl" xml:lang="en-US" id="id_11655837_2317292_2_1">Summary Of Significant Accounting Policies [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hsgx_SummaryOfSignificantAccountingPoliciesTable" xlink:to="hsgx_SummaryOfSignificantAccountingPoliciesTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US" id="id_11655837_2036634_1_1">Supplemental Cash Flow Information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US" id="id_11655837_2036634_2_1">Supplemental Disclosure of Cash Flow information:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Supplies" xlink:label="us-gaap_Supplies"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Supplies_lbl" xml:lang="en-US" id="id_11655837_2035561_1_1">Prepaid Supplies</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Supplies_lbl" xml:lang="en-US" id="id_11655837_2035561_2_1">Undelivered laboratory and office equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Supplies" xlink:to="us-gaap_Supplies_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xml:lang="en-US" id="id_11655837_2037014_1_1">Temporary Equity, Carrying Amount, Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xml:lang="en-US" id="id_11655837_2037014_4_1">Ending Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xml:lang="en-US" id="id_11655837_2037014_5_1">Beginning Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xml:lang="en-US" id="id_11655837_2038127_1_1">Temporary Equity, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xml:lang="en-US" id="id_11655837_2038127_2_1">Temporary equity, par value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xml:lang="en-US" id="id_11655837_2039949_1_1">Temporary Equity, Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xml:lang="en-US" id="id_11655837_2039949_4_1">Ending Balance, Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xml:lang="en-US" id="id_11655837_2039949_5_1">Beginning Balance, Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesOutstanding" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TextBlockAbstract" xlink:label="us-gaap_TextBlockAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TextBlockAbstract_lbl" xml:lang="en-US" id="id_11655837_2033750_1_1">Text Block [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TextBlockAbstract_lbl" xml:lang="en-US" id="id_11655837_2033750_2_1">Text Block [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TextBlockAbstract" xlink:to="us-gaap_TextBlockAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_TissueProcessorSubLicenseAgreementMember" xlink:label="hsgx_TissueProcessorSubLicenseAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hsgx_TissueProcessorSubLicenseAgreementMember_lbl" xml:lang="en-US" id="id_11655837_2068097_3_1">Tissue Processor Sub License Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hsgx_TissueProcessorSubLicenseAgreementMember_lbl" xml:lang="en-US" id="id_11655837_2068097_1_1">Tissue Processor Sub License Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hsgx_TissueProcessorSubLicenseAgreementMember_lbl" xml:lang="en-US" id="id_11655837_2068097_2_1">Tissue Processor Sub License Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hsgx_TissueProcessorSubLicenseAgreementMember" xlink:to="hsgx_TissueProcessorSubLicenseAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_TissueRegenerationLicenseAgreementMember" xlink:label="hsgx_TissueRegenerationLicenseAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hsgx_TissueRegenerationLicenseAgreementMember_lbl" xml:lang="en-US" id="id_11655837_2151732_3_1">Tissue Regeneration License Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hsgx_TissueRegenerationLicenseAgreementMember_lbl" xml:lang="en-US" id="id_11655837_2151732_1_1">Tissue Regeneration License Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hsgx_TissueRegenerationLicenseAgreementMember_lbl" xml:lang="en-US" id="id_11655837_2151732_2_1">Tissue Regeneration License Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hsgx_TissueRegenerationLicenseAgreementMember" xlink:to="hsgx_TissueRegenerationLicenseAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TitleOfIndividualAxis_lbl" xml:lang="en-US" id="id_11655837_2037554_1_1">Title of Individual [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TitleOfIndividualAxis_lbl" xml:lang="en-US" id="id_11655837_2037554_2_1">Title of Individual [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xml:lang="en-US" id="id_11655837_2037555_1_1">Relationship to Entity [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xml:lang="en-US" id="id_11655837_2037555_2_1">Relationship to Entity [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" id="id_11655837_2038518_1_1">Trading Symbol</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" id="id_11655837_2038518_2_1">Trading Symbol</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_TwoThousandAndThirteenEmployeeStockPurchasePlanMember" xlink:label="hsgx_TwoThousandAndThirteenEmployeeStockPurchasePlanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hsgx_TwoThousandAndThirteenEmployeeStockPurchasePlanMember_lbl" xml:lang="en-US" id="id_11655837_2377267_3_1">Two Thousand And Thirteen Employee Stock Purchase Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hsgx_TwoThousandAndThirteenEmployeeStockPurchasePlanMember_lbl" xml:lang="en-US" id="id_11655837_2377267_1_1">Two Thousand And Thirteen Employee Stock Purchase Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hsgx_TwoThousandAndThirteenEmployeeStockPurchasePlanMember_lbl" xml:lang="en-US" id="id_11655837_2377267_2_1">2013 Employee Stock Purchase Plan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hsgx_TwoThousandAndThirteenEmployeeStockPurchasePlanMember" xlink:to="hsgx_TwoThousandAndThirteenEmployeeStockPurchasePlanMember_lbl"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_TwoThousandAndThirteenEquityIncentivePlanMember" xlink:label="hsgx_TwoThousandAndThirteenEquityIncentivePlanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hsgx_TwoThousandAndThirteenEquityIncentivePlanMember_lbl" xml:lang="en-US" id="id_11655837_2253325_3_1">Two Thousand And Thirteen Equity Incentive Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hsgx_TwoThousandAndThirteenEquityIncentivePlanMember_lbl" xml:lang="en-US" id="id_11655837_2253325_1_1">Two Thousand And Thirteen Equity Incentive Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hsgx_TwoThousandAndThirteenEquityIncentivePlanMember_lbl" xml:lang="en-US" id="id_11655837_2253325_2_1">2013 Equity Incentive Plan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hsgx_TwoThousandAndThirteenEquityIncentivePlanMember" xlink:to="hsgx_TwoThousandAndThirteenEquityIncentivePlanMember_lbl"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_TwoThousandAndTwelveEquityIncentivePlanMember" xlink:label="hsgx_TwoThousandAndTwelveEquityIncentivePlanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hsgx_TwoThousandAndTwelveEquityIncentivePlanMember_lbl" xml:lang="en-US" id="id_11655837_2176993_3_1">Two Thousand And Twelve Equity Incentive Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hsgx_TwoThousandAndTwelveEquityIncentivePlanMember_lbl" xml:lang="en-US" id="id_11655837_2176993_1_1">Two Thousand And Twelve Equity Incentive Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hsgx_TwoThousandAndTwelveEquityIncentivePlanMember_lbl" xml:lang="en-US" id="id_11655837_2176993_2_1">2012 Equity Incentive Plan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hsgx_TwoThousandAndTwelveEquityIncentivePlanMember" xlink:to="hsgx_TwoThousandAndTwelveEquityIncentivePlanMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US" id="id_11655837_2036820_1_1">Type of Arrangement and Non-arrangement Transactions [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US" id="id_11655837_2036820_2_1">Type of Arrangement and Non-arrangement Transactions [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US" id="id_11655837_2037031_1_1">Unrecognized Tax Benefits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US" id="id_11655837_2037031_4_1">Unrecognized tax benefit, end of year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US" id="id_11655837_2037031_5_1">Unrecognized tax benefit, beginning of year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US" id="id_11655837_2037031_2_1">Unrecognized tax benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions_lbl" xml:lang="en-US" id="id_11655837_2035177_1_1">Unrecognized Tax Benefits, Decrease Resulting from Current Period Tax Positions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions_lbl" xml:lang="en-US" id="id_11655837_2035177_14_1">Increase (decrease) related to current year positions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xml:lang="en-US" id="id_11655837_2038338_1_1">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xml:lang="en-US" id="id_11655837_2038338_2_1">Accrued interest and penalties related to unrecognized tax benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl" xml:lang="en-US" id="id_11655837_2037751_1_1">Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl" xml:lang="en-US" id="id_11655837_2037751_2_1">Interest and penalties related to uncertain tax benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities_lbl" xml:lang="en-US" id="id_11655837_2040538_1_1">Unrecognized Tax Benefits, Increase Resulting from Settlements with Taxing Authorities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities_lbl" xml:lang="en-US" id="id_11655837_2040538_2_1">Settlements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/country/2016/country-2016-01-31.xsd#country_US" xlink:label="country_US"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_US_lbl" xml:lang="en-US" id="id_11655837_2037985_1_1">UNITED STATES</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="country_US_lbl" xml:lang="en-US" id="id_11655837_2037985_2_1">United States [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_US" xlink:to="country_US_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" id="id_11655837_2035182_1_1">Use of Estimates, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" id="id_11655837_2035182_2_1">Use of Estimates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US" id="id_11655837_2033770_1_1">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US" id="id_11655837_2033770_2_1">Increase (Decrease) in valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VariableRateAxis_lbl" xml:lang="en-US" id="id_11655837_2039383_1_1">Variable Rate [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_VariableRateAxis_lbl" xml:lang="en-US" id="id_11655837_2039383_2_1">Variable Rate [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VariableRateDomain_lbl" xml:lang="en-US" id="id_11655837_2037226_1_1">Variable Rate [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_VariableRateDomain_lbl" xml:lang="en-US" id="id_11655837_2037226_2_1">Variable Rate [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableRateDomain" xlink:to="us-gaap_VariableRateDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VestingAxis_lbl" xml:lang="en-US" id="id_11655837_2037398_1_1">Vesting [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_VestingAxis_lbl" xml:lang="en-US" id="id_11655837_2037398_2_1">Vesting [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VestingDomain_lbl" xml:lang="en-US" id="id_11655837_2039178_1_1">Vesting [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_VestingDomain_lbl" xml:lang="en-US" id="id_11655837_2039178_2_1">Vesting [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_VestingDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_WalthamMember" xlink:label="hsgx_WalthamMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hsgx_WalthamMember_lbl" xml:lang="en-US" id="id_11655837_2142064_3_1">Waltham [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hsgx_WalthamMember_lbl" xml:lang="en-US" id="id_11655837_2142064_1_1">Waltham [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hsgx_WalthamMember_lbl" xml:lang="en-US" id="id_11655837_2142064_2_1">Waltham [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hsgx_WalthamMember" xlink:to="hsgx_WalthamMember_lbl"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_WarrantAccountingPolicyTextBlock" xlink:label="hsgx_WarrantAccountingPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hsgx_WarrantAccountingPolicyTextBlock_lbl" xml:lang="en-US" id="id_11655837_2378531_3_1">Warrant accounting.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hsgx_WarrantAccountingPolicyTextBlock_lbl" xml:lang="en-US" id="id_11655837_2378531_1_1">Warrant Accounting [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hsgx_WarrantAccountingPolicyTextBlock_lbl" xml:lang="en-US" id="id_11655837_2378531_2_1">Warrant Accounting</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hsgx_WarrantAccountingPolicyTextBlock" xlink:to="hsgx_WarrantAccountingPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_WarrantDisclosureTextBlock" xlink:label="hsgx_WarrantDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hsgx_WarrantDisclosureTextBlock_lbl" xml:lang="en-US" id="id_11655837_2324349_3_1">Warrant [Disclosure Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hsgx_WarrantDisclosureTextBlock_lbl" xml:lang="en-US" id="id_11655837_2324349_1_1">Warrant [Disclosure Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hsgx_WarrantDisclosureTextBlock_lbl" xml:lang="en-US" id="id_11655837_2324349_2_1">Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hsgx_WarrantDisclosureTextBlock" xlink:to="hsgx_WarrantDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_WarrantLiabilityMember" xlink:label="hsgx_WarrantLiabilityMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="hsgx_WarrantLiabilityMember_lbl" xml:lang="en-US" id="id_11655837_2103098_3_1">Warrant liability.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="hsgx_WarrantLiabilityMember_lbl" xml:lang="en-US" id="id_11655837_2103098_1_1">Warrant Liability [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="hsgx_WarrantLiabilityMember_lbl" xml:lang="en-US" id="id_11655837_2103098_2_1">Warrant Liability [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hsgx_WarrantLiabilityMember" xlink:to="hsgx_WarrantLiabilityMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US" id="id_11655837_2039180_1_1">Warrant [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US" id="id_11655837_2039180_2_1">Warrants Exercisable into Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract_lbl" xml:lang="en-US" id="id_11655837_2035776_1_1">Warrants and Rights Note Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract_lbl" xml:lang="en-US" id="id_11655837_2035776_2_1">Warrants and Rights Note Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="us-gaap_WarrantsAndRightsNoteDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:label="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_lbl" xml:lang="en-US" id="id_11655837_2038917_1_1">Warrants Not Settleable in Cash, Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_lbl" xml:lang="en-US" id="id_11655837_2038917_2_1">Fair value of warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:to="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_lbl" xml:lang="en-US" id="id_11655837_2036663_1_1">Incremental Weighted Average Shares Attributable to Dilutive Effect [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_lbl" xml:lang="en-US" id="id_11655837_2036663_2_1">Effect of dilutive securities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:to="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" id="id_11655837_2035931_1_1">Weighted Average Number of Shares Outstanding, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" id="id_11655837_2035931_2_1">Weighted-average shares used to compute loss per common share-diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" id="id_11655837_2035931_6_1">Denominator for diluted EPS-adjusted weighted average shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" id="id_11655837_2038354_1_1">Weighted Average Number of Shares Outstanding, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" id="id_11655837_2038354_2_1">Weighted-average number of common shares used in earnings (loss) per share-basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" id="id_11655837_2038354_12_1">Weighted-average shares used to compute loss per common share-basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_lbl" xml:lang="en-US" id="id_11655837_2037575_1_1">Weighted Average Number of Shares Outstanding Reconciliation [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_lbl" xml:lang="en-US" id="id_11655837_2037575_2_1">Denominator:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_lbl"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>hsgx-20161231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- RR Donnelley Xcelerate Taxonomy Presentation Linkbase, based on XBRL 2.1  http://www.rrdonnelley.com/ -->
<!-- Version: 6.23.6 -->
<!-- Round: 5 -->
<!-- Creation date: 2017-03-15T19:04:29Z -->
<!-- Copyright (c) 2005-2013 R.R. Donnelley & Sons Company All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#DocumentandEntityInformation" roleURI="http://www.histogenics.com/taxonomy/role/DocumentandEntityInformation"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#Role_StatementOfFinancialPositionClassified" roleURI="http://www.histogenics.com/taxonomy/role/StatementOfFinancialPositionClassified"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#Role_StatementOfFinancialPositionClassifiedParen" roleURI="http://www.histogenics.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#Role_StatementOfIncomeAlternative" roleURI="http://www.histogenics.com/taxonomy/role/StatementOfIncomeAlternative"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#Role_StatementOfShareholdersEquityAndOtherComprehensiveIncome" roleURI="http://www.histogenics.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#Role_StatementOfShareholdersEquityAndOtherComprehensiveIncomeParen" roleURI="http://www.histogenics.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncomeParenthetical"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#Role_StatementOfCashFlowsIndirect" roleURI="http://www.histogenics.com/taxonomy/role/StatementOfCashFlowsIndirect"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#Role_StatementOfCashFlowsIndirectParen" roleURI="http://www.histogenics.com/taxonomy/role/StatementOfCashFlowsIndirectParenthetical"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#DisclosureNatureOfBusinessAdditionalInformation" roleURI="http://www.histogenics.com/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation" roleURI="http://www.histogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfOperationsInDifferentGeographicRegions" roleURI="http://www.histogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfOperationsInDifferentGeographicRegions"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasis" roleURI="http://www.histogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasis"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfLiabilitiesMeasuredAtFairValue" roleURI="http://www.histogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfLiabilitiesMeasuredAtFairValue"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfDepreciationAndAmortizationUsingStraightlineMethodOverEstimatedUsefulLivesOfAssets" roleURI="http://www.histogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfDepreciationAndAmortizationUsingStraightlineMethodOverEstimatedUsefulLivesOfAssets"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfIntangibleAssetsNetOfAccumulatedImpairmentCharges" roleURI="http://www.histogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfIntangibleAssetsNetOfAccumulatedImpairmentCharges"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#DisclosureLossPerCommonShareScheduleOfBasicAndDilutedLossPerCommonShare" roleURI="http://www.histogenics.com/taxonomy/role/DisclosureLossPerCommonShareScheduleOfBasicAndDilutedLossPerCommonShare"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#DisclosureLossPerCommonShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShare" roleURI="http://www.histogenics.com/taxonomy/role/DisclosureLossPerCommonShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShare"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssets" roleURI="http://www.histogenics.com/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssets"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipment" roleURI="http://www.histogenics.com/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipment"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#DisclosurePropertyAndEquipmentAdditionalInformation" roleURI="http://www.histogenics.com/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#DisclosureAccruedExpensesScheduleOfAccruedExpenses" roleURI="http://www.histogenics.com/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpenses"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#DisclosureCommitmentsAndContingenciesAdditionalInformation" roleURI="http://www.histogenics.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#DisclosureCommitmentsAndContingenciesScheduleOfMinimumAnnualLeaseCommitmentsUnderNonCancellableOperatingLeases" roleURI="http://www.histogenics.com/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMinimumAnnualLeaseCommitmentsUnderNonCancellableOperatingLeases"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#DisclosureCapitalStockAdditionalInformation" roleURI="http://www.histogenics.com/taxonomy/role/DisclosureCapitalStockAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#DisclosureCapitalStockScheduleOfCommonStockReservedForFutureIssuance" roleURI="http://www.histogenics.com/taxonomy/role/DisclosureCapitalStockScheduleOfCommonStockReservedForFutureIssuance"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#DisclosureWarrantsAdditionalInformation" roleURI="http://www.histogenics.com/taxonomy/role/DisclosureWarrantsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#DisclosureEquipmentLoanPayableScheduleOfOutstandingBorrowingObligations" roleURI="http://www.histogenics.com/taxonomy/role/DisclosureEquipmentLoanPayableScheduleOfOutstandingBorrowingObligations"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#DisclosureEquipmentLoanPayableAdditionalInformation" roleURI="http://www.histogenics.com/taxonomy/role/DisclosureEquipmentLoanPayableAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#DisclosureStockBasedCompensationAdditionalInformation" roleURI="http://www.histogenics.com/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#DisclosureStockBasedCompensationSummaryOfStockOptionActivityUnderThe2012And2013Plans" roleURI="http://www.histogenics.com/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityUnderThe2012And2013Plans"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#DisclosureStockBasedCompensationAdditionalInformationAboutStockOptionActivity" roleURI="http://www.histogenics.com/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationAboutStockOptionActivity"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#DisclosureStockBasedCompensationScheduleOfRestrictedStockAwardsUnderThe2012And2013Plans" roleURI="http://www.histogenics.com/taxonomy/role/DisclosureStockBasedCompensationScheduleOfRestrictedStockAwardsUnderThe2012And2013Plans"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#DisclosureStockBasedCompensationSummaryOfStockBasedCompensation" roleURI="http://www.histogenics.com/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockBasedCompensation"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#DisclosureStockBasedCompensationSummaryOfWeightedAverageAssumptionsUsedInTheBlackScholesOptionPricingModelToDetermineTheFairValueOfTheEmployeeStockOptionGrants" roleURI="http://www.histogenics.com/taxonomy/role/DisclosureStockBasedCompensationSummaryOfWeightedAverageAssumptionsUsedInTheBlackScholesOptionPricingModelToDetermineTheFairValueOfTheEmployeeStockOptionGrants"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#DisclosureStockBasedCompensationSummaryOfWeightedAverageAssumptionsUsedInTheBlackScholesOptionPricingModelToDetermineTheFairValueOfTheNonEmployeeStockOptionGrants" roleURI="http://www.histogenics.com/taxonomy/role/DisclosureStockBasedCompensationSummaryOfWeightedAverageAssumptionsUsedInTheBlackScholesOptionPricingModelToDetermineTheFairValueOfTheNonEmployeeStockOptionGrants"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#DisclosureIncomeTaxesComponentsOfLossBeforeIncomeTaxes" roleURI="http://www.histogenics.com/taxonomy/role/DisclosureIncomeTaxesComponentsOfLossBeforeIncomeTaxes"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseBenefitComputedAtStatutoryFederalIncomeTaxRate" roleURI="http://www.histogenics.com/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseBenefitComputedAtStatutoryFederalIncomeTaxRate"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilities" roleURI="http://www.histogenics.com/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilities"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#DisclosureIncomeTaxesAdditionalInformation" roleURI="http://www.histogenics.com/taxonomy/role/DisclosureIncomeTaxesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#DisclosureIncomeTaxesSummaryOfChangesInUnrecognizedTaxBenefits" roleURI="http://www.histogenics.com/taxonomy/role/DisclosureIncomeTaxesSummaryOfChangesInUnrecognizedTaxBenefits"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#DisclosureEmployeeBenefitsAdditionalInformation" roleURI="http://www.histogenics.com/taxonomy/role/DisclosureEmployeeBenefitsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#DisclosureRelatedPartiesAdditionalInformation" roleURI="http://www.histogenics.com/taxonomy/role/DisclosureRelatedPartiesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#DisclosureSubsequentEventsAdditionalInformation" roleURI="http://www.histogenics.com/taxonomy/role/DisclosureSubsequentEventsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#Role_NotesToFinancialStatementsNatureOfOperations" roleURI="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsNatureOfOperations"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock" roleURI="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies" roleURI="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockTables" roleURI="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#Role_NotesToFinancialStatementsEarningsPerShareTextBlock" roleURI="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#Role_NotesToFinancialStatementsEarningsPerShareTextBlockTables" roleURI="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#Role_NotesToFinancialStatementsPrepaidExpensesAndOtherCurrentAssetsTextBlock" roleURI="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsPrepaidExpensesAndOtherCurrentAssetsTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#Role_NotesToFinancialStatementsPrepaidExpensesAndOtherCurrentAssetsTextBlockTables" roleURI="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsPrepaidExpensesAndOtherCurrentAssetsTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#Role_NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock" roleURI="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#Role_NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlockTables" roleURI="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#Role_NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" roleURI="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#Role_NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlockTables" roleURI="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#Role_NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock" roleURI="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#Role_NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlockTables" roleURI="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#Role_NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock" roleURI="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#Role_NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlockTables" roleURI="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#Role_NotesToFinancialStatementsWarrantDisclosureTextBlock" roleURI="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsWarrantDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#Role_NotesToFinancialStatementsDebtDisclosureTextBlock" roleURI="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#Role_NotesToFinancialStatementsDebtDisclosureTextBlockTables" roleURI="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#Role_NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" roleURI="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#Role_NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables" roleURI="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#Role_NotesToFinancialStatementsIncomeTaxDisclosureTextBlock" roleURI="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#Role_NotesToFinancialStatementsIncomeTaxDisclosureTextBlockTables" roleURI="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#Role_NotesToFinancialStatementsPensionAndOtherPostretirementBenefitsDisclosureTextBlock" roleURI="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsPensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#Role_NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock" roleURI="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="hsgx-20161231.xsd#Role_NotesToFinancialStatementsSubsequentEventsTextBlock" roleURI="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock"/>
  <presentationLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/DocumentandEntityInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_DocumentAndEntityInformationAbstract" xlink:label="hsgx_DocumentAndEntityInformationAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hsgx_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentType" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hsgx_DocumentAndEntityInformationAbstract" xlink:to="dei_AmendmentFlag" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hsgx_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentPeriodEndDate" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hsgx_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hsgx_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hsgx_DocumentAndEntityInformationAbstract" xlink:to="dei_TradingSymbol" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hsgx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityRegistrantName" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hsgx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCentralIndexKey" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hsgx_DocumentAndEntityInformationAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hsgx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hsgx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hsgx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityVoluntaryFilers" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hsgx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityFilerCategory" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hsgx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hsgx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityPublicFloat" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/StatementOfFinancialPositionClassified" xlink:title="104000 - Statement - Statement of Financial Position, Classified">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:label="us-gaap_AccountsPayableRelatedPartiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRentCreditCurrent" xlink:label="us-gaap_DeferredRentCreditCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="us-gaap_DeferredRentCreditNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredRevenueLeasesCurrent" xlink:label="us-gaap_DeferredRevenueLeasesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="us-gaap_DueToRelatedPartiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DueToRelatedPartiesNoncurrent" xlink:label="us-gaap_DueToRelatedPartiesNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncentiveFromLessor" xlink:label="us-gaap_IncentiveFromLessor"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LoansPayableCurrent" xlink:label="us-gaap_LoansPayableCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermLoansPayable" xlink:label="us-gaap_LongTermLoansPayable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProductWarrantyAccrualNoncurrent" xlink:label="us-gaap_ProductWarrantyAccrualNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableRelatedPartiesCurrent" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DueToRelatedPartiesCurrent" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DeferredRentCreditCurrent" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DeferredRevenueLeasesCurrent" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LoansPayableCurrent" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_Assets" order="1.2100" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="1.2200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_DueToRelatedPartiesNoncurrent" order="1.2300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_DeferredRentCreditNoncurrent" order="1.2400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_IncentiveFromLessor" order="1.2500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LongTermLoansPayable" order="1.2600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_ProductWarrantyAccrualNoncurrent" order="1.2700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_Liabilities" order="1.2800" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="1.2900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="1.3000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="1.3100" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_SeriesAConvertiblePreferredStockMember" xlink:label="hsgx_SeriesAConvertiblePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="hsgx_SeriesAConvertiblePreferredStockMember" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/StatementOfIncomeAlternative" xlink:title="124100 - Statement - Statement of Income">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentOfWarrantsGrantedForServices" xlink:label="us-gaap_AdjustmentOfWarrantsGrantedForServices"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="us-gaap_SalesRevenueNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_SalesRevenueNet" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherIncomeAndExpensesAbstract" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_InterestExpense" order="1.1500" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_AdjustmentOfWarrantsGrantedForServices" order="1.1700" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="1.1800" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome" xlink:title="148600 - Statement - Statement of Shareholders' Equity">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_SeriesAConvertiblePreferredStockMember" xlink:label="hsgx_SeriesAConvertiblePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_2"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_StockIssuedDuringPeriodPreferredStockValue" xlink:label="hsgx_StockIssuedDuringPeriodPreferredStockValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_StockIssuedDuringPeriodSharesOverallotmentNetOfFeesAndIssuanceCosts" xlink:label="hsgx_StockIssuedDuringPeriodSharesOverallotmentNetOfFeesAndIssuanceCosts"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_StockIssuedDuringPeriodSharesPreferredStock" xlink:label="hsgx_StockIssuedDuringPeriodSharesPreferredStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_StockIssuedDuringPeriodValueOverallotmentNetOfFeesAndIssuanceCosts" xlink:label="hsgx_StockIssuedDuringPeriodValueOverallotmentNetOfFeesAndIssuanceCosts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="hsgx_SeriesAConvertiblePreferredStockMember" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="1.2600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1.2700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="1.2800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="1.2500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="hsgx_StockIssuedDuringPeriodPreferredStockValue" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="hsgx_StockIssuedDuringPeriodSharesPreferredStock" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_2" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_2" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="hsgx_StockIssuedDuringPeriodValueOverallotmentNetOfFeesAndIssuanceCosts" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="hsgx_StockIssuedDuringPeriodSharesOverallotmentNetOfFeesAndIssuanceCosts" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="1.2100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="1.2200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_2" order="1.2300" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_2" order="1.2400" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="12.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncomeParenthetical">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_SeriesAConvertiblePreferredStockMember" xlink:label="hsgx_SeriesAConvertiblePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="hsgx_SeriesAConvertiblePreferredStockMember" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="2.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="3.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/StatementOfCashFlowsIndirect" xlink:title="152200 - Statement - Statement of Cash Flows">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentOfWarrantsGrantedForServices" xlink:label="us-gaap_AdjustmentOfWarrantsGrantedForServices"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_DeferredRentAndLeaseIncentive" xlink:label="hsgx_DeferredRentAndLeaseIncentive"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_FairMarketValueOfPrivatePlacementWarrantsAtIssuance" xlink:label="hsgx_FairMarketValueOfPrivatePlacementWarrantsAtIssuance"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RepaymentsOfDebt" xlink:label="us-gaap_RepaymentsOfDebt"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="hsgx_DeferredRentAndLeaseIncentive" order="1.0200" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentOfWarrantsGrantedForServices" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="1.0700" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_RepaymentsOfDebt" order="1.1400" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="1.1700" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetIncomeLoss" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="1.2100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" order="1.2200" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="hsgx_FairMarketValueOfPrivatePlacementWarrantsAtIssuance" order="1.2300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" order="1.2400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" order="1.2500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" order="1.2600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" order="1.2700" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1.2800" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_2" order="1.2900" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" order="1.3000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="1.3100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_IncomeTaxesPaidNet" order="1.3200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" order="1.3300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/StatementOfCashFlowsIndirectParenthetical">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1" xlink:label="us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_NatureOfBusinessAbstract" xlink:label="hsgx_NatureOfBusinessAbstract"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_NatureOfBusinessAndBasisOfPresentationLineItems" xlink:label="hsgx_NatureOfBusinessAndBasisOfPresentationLineItems"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_NatureOfBusinessAndBasisOfPresentationTable" xlink:label="hsgx_NatureOfBusinessAndBasisOfPresentationTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_ProceedsFromIssuanceInitialPublicOfferingNet" xlink:label="hsgx_ProceedsFromIssuanceInitialPublicOfferingNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_ProChonBiotechLtdMember" xlink:label="hsgx_ProChonBiotechLtdMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="hsgx_ProChonBiotechLtdMember" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hsgx_NatureOfBusinessAbstract" xlink:to="hsgx_NatureOfBusinessAndBasisOfPresentationTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hsgx_NatureOfBusinessAndBasisOfPresentationLineItems" xlink:to="us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hsgx_NatureOfBusinessAndBasisOfPresentationLineItems" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hsgx_NatureOfBusinessAndBasisOfPresentationLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hsgx_NatureOfBusinessAndBasisOfPresentationLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hsgx_NatureOfBusinessAndBasisOfPresentationLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hsgx_NatureOfBusinessAndBasisOfPresentationLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hsgx_NatureOfBusinessAndBasisOfPresentationLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hsgx_NatureOfBusinessAndBasisOfPresentationLineItems" xlink:to="hsgx_ProceedsFromIssuanceInitialPublicOfferingNet" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hsgx_NatureOfBusinessAndBasisOfPresentationTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hsgx_NatureOfBusinessAndBasisOfPresentationTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hsgx_NatureOfBusinessAndBasisOfPresentationTable" xlink:to="hsgx_NatureOfBusinessAndBasisOfPresentationLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsFairValueDisclosureRecurring" xlink:label="us-gaap_AssetsFairValueDisclosureRecurring"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_FairValueInputAmountTransferBetweenLevels" xlink:label="hsgx_FairValueInputAmountTransferBetweenLevels"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsDiscountRate" xlink:label="us-gaap_FairValueInputsDiscountRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="us-gaap_InProcessResearchAndDevelopmentMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureRecurring" xlink:label="us-gaap_LiabilitiesFairValueDisclosureRecurring"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_MaximumPercentageOfRecognitionOfTaxBenefitsFromUncertainTaxPositions" xlink:label="hsgx_MaximumPercentageOfRecognitionOfTaxBenefitsFromUncertainTaxPositions"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_RemainingOfferingCostsIncludedInAccountsPayable" xlink:label="hsgx_RemainingOfferingCostsIncludedInAccountsPayable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="hsgx_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_SummaryOfSignificantAccountingPoliciesTable" xlink:label="hsgx_SummaryOfSignificantAccountingPoliciesTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="hsgx_SummaryOfSignificantAccountingPoliciesTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_InProcessResearchAndDevelopmentMember" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hsgx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hsgx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfReportableSegments" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hsgx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AssetsFairValueDisclosureRecurring" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hsgx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosureRecurring" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hsgx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="hsgx_FairValueInputAmountTransferBetweenLevels" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hsgx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hsgx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hsgx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hsgx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_FairValueInputsDiscountRate" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hsgx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hsgx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hsgx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hsgx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="hsgx_RemainingOfferingCostsIncludedInAccountsPayable" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hsgx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="hsgx_MaximumPercentageOfRecognitionOfTaxBenefitsFromUncertainTaxPositions" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hsgx_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hsgx_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hsgx_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="12.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hsgx_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="13.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hsgx_SummaryOfSignificantAccountingPoliciesTable" xlink:to="hsgx_SummaryOfSignificantAccountingPoliciesLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfOperationsInDifferentGeographicRegions">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/country/2016/country-2016-01-31.xsd#country_IL" xlink:label="country_IL"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NoncurrentAssets" xlink:label="us-gaap_NoncurrentAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="us-gaap_SegmentGeographicalDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="us-gaap_StatementGeographicalAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/country/2016/country-2016-01-31.xsd#country_US" xlink:label="country_US"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_StatementGeographicalAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_SegmentReportingInformationLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentGeographicalDomain" xlink:to="country_US" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentGeographicalDomain" xlink:to="country_IL" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_NoncurrentAssets" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementGeographicalAxis" xlink:to="us-gaap_SegmentGeographicalDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasis">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_WarrantLiabilityMember" xlink:label="hsgx_WarrantLiabilityMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosure" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" order="12.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_MoneyMarketFundsMember" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="hsgx_WarrantLiabilityMember" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_LiabilitiesFairValueDisclosure" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfLiabilitiesMeasuredAtFairValue">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="1.0400" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfDepreciationAndAmortizationUsingStraightlineMethodOverEstimatedUsefulLivesOfAssets">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_OfficeEquipmentMember" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_RangeAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfIntangibleAssetsNetOfAccumulatedImpairmentCharges">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="us-gaap_InProcessResearchAndDevelopmentMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" order="1.0300" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_InProcessResearchAndDevelopmentMember" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/DisclosureLossPerCommonShareScheduleOfBasicAndDilutedLossPerCommonShare">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DilutiveSecuritiesAbstract" xlink:label="us-gaap_DilutiveSecuritiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:label="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_NetIncomeLossAvailableToSeriesAPreferredStock" xlink:label="hsgx_NetIncomeLossAvailableToSeriesAPreferredStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DilutiveSecuritiesAbstract" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DilutiveSecuritiesAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_DilutiveSecuritiesAbstract" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:to="us-gaap_NetIncomeLoss" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:to="hsgx_NetIncomeLossAvailableToSeriesAPreferredStock" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:to="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/DisclosureLossPerCommonShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShare">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockCompensationPlanMember" xlink:label="us-gaap_StockCompensationPlanMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_StockCompensationPlanMember" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssets">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DepositAssets" xlink:label="us-gaap_DepositAssets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Supplies" xlink:label="us-gaap_Supplies"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_DepositAssets" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_Supplies" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidInsurance" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsCurrent" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipment">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SoftwareDevelopmentMember" xlink:label="us-gaap_SoftwareDevelopmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1.0700" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_OfficeEquipmentMember" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_SoftwareDevelopmentMember" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_Depreciation" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpenses">
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_AccruedClinicalExpensesCurrent" xlink:label="hsgx_AccruedClinicalExpensesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="hsgx_AccruedClinicalExpensesCurrent" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation">
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_AdditionalNonRefundableRoyaltyFeePaymentDescription" xlink:label="hsgx_AdditionalNonRefundableRoyaltyFeePaymentDescription"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_AdditionalRoyaltyExpense" xlink:label="hsgx_AdditionalRoyaltyExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_CollagenSupplyAgreementMember" xlink:label="hsgx_CollagenSupplyAgreementMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ContractualObligation" xlink:label="us-gaap_ContractualObligation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ContractualObligationFutureMinimumPaymentsDueRemainderOfFiscalYear" xlink:label="us-gaap_ContractualObligationFutureMinimumPaymentsDueRemainderOfFiscalYear"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_EngineeringAgreementMember" xlink:label="hsgx_EngineeringAgreementMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GrantsReceivable" xlink:label="us-gaap_GrantsReceivable"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_HydrogelLicenseAgreementMember" xlink:label="hsgx_HydrogelLicenseAgreementMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm" xlink:label="us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_LexingtonMember" xlink:label="hsgx_LexingtonMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermPurchaseCommitmentAmount" xlink:label="us-gaap_LongTermPurchaseCommitmentAmount"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:label="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:label="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermPurchaseCommitmentDescription" xlink:label="us-gaap_LongTermPurchaseCommitmentDescription"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongtermPurchaseCommitmentPeriod" xlink:label="us-gaap_LongtermPurchaseCommitmentPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="us-gaap_LossContingenciesLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="us-gaap_LossContingenciesTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_NumberOfAdditionalRenewalOptions" xlink:label="hsgx_NumberOfAdditionalRenewalOptions"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_OcsAgreementMember" xlink:label="hsgx_OcsAgreementMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="us-gaap_OperatingLeasesRentExpenseNet"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_PaymentForLicenseAgreementReimbursementOfCosts" xlink:label="hsgx_PaymentForLicenseAgreementReimbursementOfCosts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsForProceedsFromTenantAllowance" xlink:label="us-gaap_PaymentsForProceedsFromTenantAllowance"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PaymentsToSuppliers" xlink:label="us-gaap_PaymentsToSuppliers"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_PercentageOfRoyaltyOffsetting" xlink:label="hsgx_PercentageOfRoyaltyOffsetting"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_PurchaseCommitmentNonrefundablePayment" xlink:label="hsgx_PurchaseCommitmentNonrefundablePayment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:label="us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:label="us-gaap_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:label="us-gaap_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_RoyaltyPaymentPercentage" xlink:label="hsgx_RoyaltyPaymentPercentage"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_RoyaltyPaymentPercentageAsPercentageOfGrantReceived" xlink:label="hsgx_RoyaltyPaymentPercentageAsPercentageOfGrantReceived"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_TissueProcessorSubLicenseAgreementMember" xlink:label="hsgx_TissueProcessorSubLicenseAgreementMember"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_TissueRegenerationLicenseAgreementMember" xlink:label="hsgx_TissueRegenerationLicenseAgreementMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_WalthamMember" xlink:label="hsgx_WalthamMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="hsgx_TissueProcessorSubLicenseAgreementMember" order="1.2500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LossContingenciesTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="hsgx_HydrogelLicenseAgreementMember" order="1.2400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="hsgx_TissueRegenerationLicenseAgreementMember" order="1.2900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:to="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:to="hsgx_EngineeringAgreementMember" order="1.2700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:to="hsgx_CollagenSupplyAgreementMember" order="1.3100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="hsgx_NumberOfAdditionalRenewalOptions" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_OperatingLeasesRentExpenseNet" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_PaymentsForProceedsFromTenantAllowance" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_ContractualObligation" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_RoyaltyExpense" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="hsgx_PercentageOfRoyaltyOffsetting" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="hsgx_PaymentForLicenseAgreementReimbursementOfCosts" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_ContractualObligationFutureMinimumPaymentsDueRemainderOfFiscalYear" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="hsgx_AdditionalRoyaltyExpense" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="hsgx_AdditionalNonRefundableRoyaltyFeePaymentDescription" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_GrantsReceivable" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="hsgx_RoyaltyPaymentPercentage" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="hsgx_RoyaltyPaymentPercentageAsPercentageOfGrantReceived" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_PaymentsToSuppliers" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LongTermPurchaseCommitmentAmount" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="hsgx_PurchaseCommitmentNonrefundablePayment" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LongtermPurchaseCommitmentPeriod" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LongTermPurchaseCommitmentDescription" order="1.2100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="12.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_RangeAxis" order="13.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" order="14.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" order="15.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="1.2300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="1.3000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:to="us-gaap_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:to="hsgx_WalthamMember" order="1.2200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:to="hsgx_LexingtonMember" order="1.2800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="hsgx_OcsAgreementMember" order="1.2600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMinimumAnnualLeaseCommitmentsUnderNonCancellableOperatingLeases">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/DisclosureCapitalStockAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentOfWarrantsGrantedForServices" xlink:label="us-gaap_AdjustmentOfWarrantsGrantedForServices"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_BeneficialOwnershipMinimumPercentageOfOutstandingCommonStock" xlink:label="hsgx_BeneficialOwnershipMinimumPercentageOfOutstandingCommonStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_ClassOfWarrantOrRightExercisableExpirationPeriod" xlink:label="hsgx_ClassOfWarrantOrRightExercisableExpirationPeriod"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_ClassOfWarrantOrRightExercisablePeriod" xlink:label="hsgx_ClassOfWarrantOrRightExercisablePeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsIssuedForService" xlink:label="hsgx_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsIssuedForService"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsIssuedForService" xlink:label="hsgx_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsIssuedForService"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConvertiblePreferredStockTermsOfConversion" xlink:label="us-gaap_ConvertiblePreferredStockTermsOfConversion"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_FairValueOfWarrantLiabilitiesInExcessOfProceedsReceived" xlink:label="hsgx_FairValueOfWarrantLiabilitiesInExcessOfProceedsReceived"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_GrossProceedsFromIssuanceOfCommonStockPreferredStockAndWarrants" xlink:label="hsgx_GrossProceedsFromIssuanceOfCommonStockPreferredStockAndWarrants"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_MaximumThresholdPercentageOfBeneficialCommonStockInterestOnHoldersDiscretion" xlink:label="hsgx_MaximumThresholdPercentageOfBeneficialCommonStockInterestOnHoldersDiscretion"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_MembersOfBoardOfDirectorsMember" xlink:label="hsgx_MembersOfBoardOfDirectorsMember"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_MinimumThresholdPercentageOfBeneficialCommonStockInterest" xlink:label="hsgx_MinimumThresholdPercentageOfBeneficialCommonStockInterest"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:label="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="1.2400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="hsgx_GrossProceedsFromIssuanceOfCommonStockPreferredStockAndWarrants" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="hsgx_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsIssuedForService" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="hsgx_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsIssuedForService" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="hsgx_BeneficialOwnershipMinimumPercentageOfOutstandingCommonStock" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="hsgx_ClassOfWarrantOrRightExercisableExpirationPeriod" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="hsgx_ClassOfWarrantOrRightExercisablePeriod" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="hsgx_FairValueOfWarrantLiabilitiesInExcessOfProceedsReceived" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_AdjustmentOfWarrantsGrantedForServices" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="hsgx_MinimumThresholdPercentageOfBeneficialCommonStockInterest" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="hsgx_MaximumThresholdPercentageOfBeneficialCommonStockInterestOnHoldersDiscretion" order="1.2100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ConvertiblePreferredStockTermsOfConversion" order="1.2200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" order="1.2300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_TitleOfIndividualAxis" order="12.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="hsgx_MembersOfBoardOfDirectorsMember" order="1.2500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/DisclosureCapitalStockScheduleOfCommonStockReservedForFutureIssuance">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AwardTypeAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/DisclosureWarrantsAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AdjustmentOfWarrantsGrantedForServices" xlink:label="us-gaap_AdjustmentOfWarrantsGrantedForServices"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_AdjustmentOfWarrantsGrantedForServicesPerShareValue" xlink:label="hsgx_AdjustmentOfWarrantsGrantedForServicesPerShareValue"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_AffiliatesOfAdvisorWarrantMember" xlink:label="hsgx_AffiliatesOfAdvisorWarrantMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_ClassOfWarrantOrRightExercisableExpirationPeriod" xlink:label="hsgx_ClassOfWarrantOrRightExercisableExpirationPeriod"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_ClassOfWarrantOrRightExercisablePeriod" xlink:label="hsgx_ClassOfWarrantOrRightExercisablePeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_ClassOfWarrantOrRightForfeitureInPeriod" xlink:label="hsgx_ClassOfWarrantOrRightForfeitureInPeriod"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_ClassOfWarrantOrRightForfeitureInPeriodPercentage" xlink:label="hsgx_ClassOfWarrantOrRightForfeitureInPeriodPercentage"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_ClassOfWarrantOrRightNumberOfSecuritiesSurrendered" xlink:label="hsgx_ClassOfWarrantOrRightNumberOfSecuritiesSurrendered"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_ClassOfWarrantOrRightVestedAndExercisable" xlink:label="hsgx_ClassOfWarrantOrRightVestedAndExercisable"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_ConsultingAgreementWarrantMember" xlink:label="hsgx_ConsultingAgreementWarrantMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="us-gaap_FairValueAssumptionsExpectedTerm"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_FairValueAssumptionsExpectedVolatilityRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_FairValueAssumptionsRiskFreeInterestRate"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_InvestorWarrantsMember" xlink:label="hsgx_InvestorWarrantsMember"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_PlacementAgentWarrantMember" xlink:label="hsgx_PlacementAgentWarrantMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="hsgx_InvestorWarrantsMember" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="hsgx_PlacementAgentWarrantMember" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="hsgx_ConsultingAgreementWarrantMember" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="hsgx_AffiliatesOfAdvisorWarrantMember" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="hsgx_ClassOfWarrantOrRightExercisablePeriod" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="hsgx_ClassOfWarrantOrRightExercisableExpirationPeriod" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="hsgx_AdjustmentOfWarrantsGrantedForServicesPerShareValue" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_AdjustmentOfWarrantsGrantedForServices" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_FairValueAssumptionsRiskFreeInterestRate" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_FairValueAssumptionsExpectedVolatilityRate" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_FairValueAssumptionsExpectedTerm" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="hsgx_ClassOfWarrantOrRightNumberOfSecuritiesSurrendered" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="hsgx_ClassOfWarrantOrRightForfeitureInPeriod" order="1.1100" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="hsgx_ClassOfWarrantOrRightVestedAndExercisable" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="hsgx_ClassOfWarrantOrRightForfeitureInPeriodPercentage" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/DisclosureEquipmentLoanPayableScheduleOfOutstandingBorrowingObligations">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LoansPayable" xlink:label="us-gaap_LoansPayable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LoansPayableCurrent" xlink:label="us-gaap_LoansPayableCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermLoansPayable" xlink:label="us-gaap_LongTermLoansPayable"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_SiliconValleyBankMember" xlink:label="hsgx_SiliconValleyBankMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LoansPayable" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LoansPayableCurrent" order="1.0200" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermLoansPayable" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="dei_LegalEntityAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="hsgx_SiliconValleyBankMember" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/DisclosureEquipmentLoanPayableAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCredit" xlink:label="us-gaap_LineOfCredit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PrimeRateMember" xlink:label="us-gaap_PrimeRateMember"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_SiliconValleyBankMember" xlink:label="hsgx_SiliconValleyBankMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_DebtInstrumentTerm" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_LineOfCredit" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="dei_LegalEntityAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_VariableRateAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="hsgx_SiliconValleyBankMember" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateDomain" xlink:to="us-gaap_PrimeRateMember" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardDateAxis" xlink:label="us-gaap_AwardDateAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardDateDomain" xlink:label="us-gaap_AwardDateDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_EipAmendmentMember" xlink:label="hsgx_EipAmendmentMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedStockExpense" xlink:label="us-gaap_RestrictedStockExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioForecastMember" xlink:label="us-gaap_ScenarioForecastMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue" xlink:label="hsgx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_TwoThousandAndThirteenEmployeeStockPurchasePlanMember" xlink:label="hsgx_TwoThousandAndThirteenEmployeeStockPurchasePlanMember"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_TwoThousandAndThirteenEquityIncentivePlanMember" xlink:label="hsgx_TwoThousandAndThirteenEquityIncentivePlanMember"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_TwoThousandAndTwelveEquityIncentivePlanMember" xlink:label="hsgx_TwoThousandAndTwelveEquityIncentivePlanMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateDomain" xlink:to="hsgx_EipAmendmentMember" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="hsgx_TwoThousandAndTwelveEquityIncentivePlanMember" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="hsgx_TwoThousandAndThirteenEquityIncentivePlanMember" order="1.2100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="hsgx_TwoThousandAndThirteenEmployeeStockPurchasePlanMember" order="1.2300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_ScenarioForecastMember" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementScenarioAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="12.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="13.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardDateAxis" order="14.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_VestingAxis" order="15.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="hsgx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_RestrictedStockExpense" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="1.2200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityUnderThe2012And2013Plans">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="1.0300" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="1.0400" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationAboutStockOptionActivity">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/DisclosureStockBasedCompensationScheduleOfRestrictedStockAwardsUnderThe2012And2013Plans">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="1.0200" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockBasedCompensation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CompensationRelatedCostsAbstract" xlink:label="us-gaap_CompensationRelatedCostsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationRelatedCostsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/DisclosureStockBasedCompensationSummaryOfWeightedAverageAssumptionsUsedInTheBlackScholesOptionPricingModelToDetermineTheFairValueOfTheEmployeeStockOptionGrants">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/DisclosureStockBasedCompensationSummaryOfWeightedAverageAssumptionsUsedInTheBlackScholesOptionPricingModelToDetermineTheFairValueOfTheNonEmployeeStockOptionGrants">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionAbstract" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionAbstract" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionAbstract" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionAbstract" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionAbstract" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/DisclosureIncomeTaxesComponentsOfLossBeforeIncomeTaxes">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseBenefitComputedAtStatutoryFederalIncomeTaxRate">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_EffectiveIncomeTaxRateReconciliationNetOperatingLossLimitation" xlink:label="hsgx_EffectiveIncomeTaxRateReconciliationNetOperatingLossLimitation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_EffectiveIncomeTaxRateReconciliationPermanentDifferences" xlink:label="hsgx_EffectiveIncomeTaxRateReconciliationPermanentDifferences"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_EffectiveIncomeTaxRateReconciliationRAndDCreditLimitation" xlink:label="hsgx_EffectiveIncomeTaxRateReconciliationRAndDCreditLimitation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="hsgx_EffectiveIncomeTaxRateReconciliationPermanentDifferences" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="hsgx_EffectiveIncomeTaxRateReconciliationNetOperatingLossLimitation" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="hsgx_EffectiveIncomeTaxRateReconciliationRAndDCreditLimitation" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilities">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_DeferredTaxAssetsCapitalizedStartUpCosts" xlink:label="hsgx_DeferredTaxAssetsCapitalizedStartUpCosts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsGrossAbstract" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_DeferredTaxLiabilitiesChangeInAccountingMethod" xlink:label="hsgx_DeferredTaxLiabilitiesChangeInAccountingMethod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:label="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="hsgx_DeferredTaxAssetsCapitalizedStartUpCosts" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsOther" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" order="1.0700" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="hsgx_DeferredTaxLiabilitiesChangeInAccountingMethod" order="1.0800" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="1.0900" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsGrossAbstract" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="1.1100" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/DisclosureIncomeTaxesAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_IncomeTaxesDisclosureLineItems" xlink:label="hsgx_IncomeTaxesDisclosureLineItems"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_IncomeTaxesDisclosureTable" xlink:label="hsgx_IncomeTaxesDisclosureTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxExaminationDescription" xlink:label="us-gaap_IncomeTaxExaminationDescription"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OperatingLossCarryforwardsExpirationDate" xlink:label="us-gaap_OperatingLossCarryforwardsExpirationDate"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_OperatingLossCarryforwardsNetOfLimitations" xlink:label="hsgx_OperatingLossCarryforwardsNetOfLimitations"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit" xlink:label="us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_ForeignCountryMember" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="hsgx_IncomeTaxesDisclosureTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hsgx_IncomeTaxesDisclosureLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hsgx_IncomeTaxesDisclosureLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hsgx_IncomeTaxesDisclosureLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsExpirationDate" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hsgx_IncomeTaxesDisclosureLineItems" xlink:to="hsgx_OperatingLossCarryforwardsNetOfLimitations" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hsgx_IncomeTaxesDisclosureLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hsgx_IncomeTaxesDisclosureLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hsgx_IncomeTaxesDisclosureLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hsgx_IncomeTaxesDisclosureLineItems" xlink:to="us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hsgx_IncomeTaxesDisclosureLineItems" xlink:to="us-gaap_IncomeTaxExaminationDescription" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hsgx_IncomeTaxesDisclosureTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hsgx_IncomeTaxesDisclosureTable" xlink:to="hsgx_IncomeTaxesDisclosureLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/DisclosureIncomeTaxesSummaryOfChangesInUnrecognizedTaxBenefits">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" order="1.0200" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefits_2" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/DisclosureEmployeeBenefitsAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_DefinedContributionPlanEmployeeEligibilityAge" xlink:label="hsgx_DefinedContributionPlanEmployeeEligibilityAge"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DefinedContributionPlanTable" xlink:label="us-gaap_DefinedContributionPlanTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="hsgx_DefinedContributionPlanEmployeeEligibilityAge" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanTable" xlink:to="us-gaap_RangeAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanTable" xlink:to="us-gaap_DefinedContributionPlanDisclosureLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/DisclosureRelatedPartiesAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_CollaborationAgreementTerminationNoticePeriod" xlink:label="hsgx_CollaborationAgreementTerminationNoticePeriod"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_CollaborationAgreementTerminationNoticePeriodOnUnremediedMaterialBreach" xlink:label="hsgx_CollaborationAgreementTerminationNoticePeriodOnUnremediedMaterialBreach"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_CommercializationMilestonesObligation" xlink:label="hsgx_CommercializationMilestonesObligation"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_CommercialMilestonesMember" xlink:label="hsgx_CommercialMilestonesMember"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_DevelopmentCostReimbursementCommitment" xlink:label="hsgx_DevelopmentCostReimbursementCommitment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="us-gaap_DueToRelatedPartiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_IntrexonMember" xlink:label="hsgx_IntrexonMember"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_PercentageOfReimbursementExpenses" xlink:label="hsgx_PercentageOfReimbursementExpenses"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_PercentageOfReimbursementExpensesSubjectToAcceptance" xlink:label="hsgx_PercentageOfReimbursementExpensesSubjectToAcceptance"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_PurposeCoMember" xlink:label="hsgx_PurposeCoMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_SalesMilestoneMember" xlink:label="hsgx_SalesMilestoneMember"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_SalesMilestonesPaymentsObligation" xlink:label="hsgx_SalesMilestonesPaymentsObligation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="hsgx_CommercialMilestonesMember" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="hsgx_SalesMilestoneMember" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="hsgx_CollaborationAgreementTerminationNoticePeriod" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="hsgx_CollaborationAgreementTerminationNoticePeriodOnUnremediedMaterialBreach" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="hsgx_CommercializationMilestonesObligation" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="hsgx_SalesMilestonesPaymentsObligation" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="hsgx_PercentageOfReimbursementExpenses" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="hsgx_PercentageOfReimbursementExpensesSubjectToAcceptance" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DueToRelatedPartiesCurrent" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="hsgx_DevelopmentCostReimbursementCommitment" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="hsgx_IntrexonMember" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="hsgx_PurposeCoMember" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="12.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/DisclosureSubsequentEventsAdditionalInformation">
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_CollagenSupplyAgreementMember" xlink:label="hsgx_CollagenSupplyAgreementMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:label="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:label="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_OriginalAgreementDate" xlink:label="hsgx_OriginalAgreementDate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_RepaymentPeriod" xlink:label="hsgx_RepaymentPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioForecastMember" xlink:label="us-gaap_ScenarioForecastMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:to="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:to="hsgx_CollagenSupplyAgreementMember" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_ScenarioForecastMember" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="hsgx_OriginalAgreementDate" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="hsgx_RepaymentPeriod" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_StatementScenarioAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsNatureOfOperations">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_NatureOfOperations" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredChargesPolicyTextBlock" xlink:label="us-gaap_DeferredChargesPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_InitialPublicOfferingCostsPolicyTextBlock" xlink:label="hsgx_InitialPublicOfferingCostsPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_LicenseAgreementsPolicyTextBlock" xlink:label="hsgx_LicenseAgreementsPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_PatentCostsPolicyTextBlock" xlink:label="hsgx_PatentCostsPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_WarrantAccountingPolicyTextBlock" xlink:label="hsgx_WarrantAccountingPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="hsgx_InitialPublicOfferingCostsPolicyTextBlock" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DeferredChargesPolicyTextBlock" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="hsgx_LicenseAgreementsPolicyTextBlock" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="hsgx_PatentCostsPolicyTextBlock" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="1.2100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="1.2200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="hsgx_WarrantAccountingPolicyTextBlock" order="1.2300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="1.2400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:label="us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" xlink:label="hsgx_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="hsgx_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsPrepaidExpensesAndOtherCurrentAssetsTextBlock">
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_PrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:label="hsgx_PrepaidExpensesAndOtherCurrentAssetsTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TextBlockAbstract" xlink:label="us-gaap_TextBlockAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TextBlockAbstract" xlink:to="hsgx_PrepaidExpensesAndOtherCurrentAssetsTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsPrepaidExpensesAndOtherCurrentAssetsTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TextBlockAbstract" xlink:label="us-gaap_TextBlockAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TextBlockAbstract" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_ScheduleOfSharesOfCommonStockReservedForFutureIssuanceTableTextBlock" xlink:label="hsgx_ScheduleOfSharesOfCommonStockReservedForFutureIssuanceTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="hsgx_ScheduleOfSharesOfCommonStockReservedForFutureIssuanceTableTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsWarrantDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_TextBlockAbstract" xlink:label="us-gaap_TextBlockAbstract"/>
    <loc xlink:type="locator" xlink:href="hsgx-20161231.xsd#hsgx_WarrantDisclosureTextBlock" xlink:label="hsgx_WarrantDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TextBlockAbstract" xlink:to="hsgx_WarrantDisclosureTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDebtTableTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:label="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionBySupplierTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionBySupplierTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionBySupplierTextBlock" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsPensionAndOtherPostretirementBenefitsDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2016/elts/us-gaap-2016-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g293850g01z41.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g293850g01z41.jpg
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M #P \ / #P \ / #P \ / #P \ / #P \ / #P \ / #P \ / #P \ / #P
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M!)]? EYZA3@@J4Z(N8W(4Q)4 ^=^2>W5%FG77U4;B(B[EI],=LZS:55U(/\
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M5]G4&;@[79TJP)2G.;>ZGMQE0,[5NGNX 9^4RFS"[1?HKPKK\6"W4QNID1E
M<E:<HJ6V]3-5O8&V"A\E(Z/L+>W7;]I;V+8:B3*BS'-OP$4<>TK(4C/[G#E1
MK@(3GKIVZ&=;QVNU;7^TEMSJ_P -G8.BZT*_N5#!T0W9C NL_P J#PN0=MZ
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MOPI)8OB1\\^Y)\.62/WN.?<DSQ]F7(AR> '@!X > '@!X > '@!X > '@!X
M> '@!X > '@!X > '@!X > '@!X > '@!X > '@!X > '@!X > '@!X > '@
M!X > '@!X > '@"[8MM:U43E%<9W0"",$BBT"IU25S&K'(?<RL(1.7Y+DG'%
M&NP-Q6?"DK@K-F$LPRXS^D4[F%:SE$ Q/ #P \ / #P \ / #P \ / #P \
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MP \ / #P \ / #P \ / #P \ / #P \ / #P \ / #P \ / #P \ / #P \
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MB]/0E8+7V'VM=D_R6=J?\2]"_P!G_B'B]/0E8+7V'VM=D_R6=J?\2]"_V?\
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M&VL:]ODA[E&AD;+ A+XQAR7*K78R)MK^L*@U=%AK]X<,S/.EXU F+I(Q:Q"
M3I\<>-PVQ(RY4G#[,RJ?9)R7>KI+:Q^ACLUR7.P+AID@*(7!B+<XYC[=EM !
MQY<J!7BBQ;9$H+:$5V,FMB(5=L8012P(E##R<4E$6%,3=,\IRY%0&=]S?-F
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MIYJ0_-\6UU^UJ5,LK&0S1YJR++,<K!;!4067JH13KI7'#B>@G@@> '@!X >
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MA/O-^W/P(>75>P_J*=9_^MV:_0GWF_;GX$/+JO8?U%.L_P#UNS7Z$^\W[<_
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M.5E[K=+7.6O,X(.[6N:I2)#:DK+_  \.YIV6J/,PXUC%"O(4ZSVLH*1:OAA
M2JQ\XP7H<<8K6$N&/&/ 0\5_V7LZ,'<+HU6XPXK:QV_7XB/0M,7$'\.7N-%Q
M&SUX8J]=CPXCZQX^X>@KP000E\?80BAABBPL8X1X8\!#Q6'_ )+V7O\ J*=9
M_P#K=FOT)]YOVY^!#RZKV']13K/_ -;LU^A/O-^W/P(>75>P_J*=9_\ K=FO
MT)]YOVY^!#RZKV']13K/_P!;LU^A/O-^W/P(>75>P_J*=9_^MV:_0GWF_;GX
M$/+JO9 L7>OJ"WC\1+:I[\:!6%NK?P&,7\/SNJ;'X7Z,GQJ5W&F2ZUV:V-NI
M+_[:MGB/B:O)_P"<6>&7_/@0\NJ]A0[U]0!98F?&*>_!QTU[/635#^'YW5IE
MBWN^YSCZF2K]:X[E_P!G,<?/'S4TOL^'A[/_ ../L"'EU7LJ-CM5T$M\6>+6
MG-G6>+O%WBYQ8_AK]O)N+?!(I <(\6>).KV7Q^+YJM6,7>)??^:*5X"$_P 2
MW%'-B$/%?]E[+@,[W=0PM\N5#*N_A)-@E@G/$1G\/[NO0OFYZWQOEIB]RKUL
MBL$I:_S-CX$ER2;.+X\WP^<?BY^\$/+JO9.?U%.L_P#UNS7Z$^\W[<_ AY=5
M[#^HIUG_ .MV:_0GWF_;GX$/+JO8?U%.L_\ UNS7Z$^\W[<_ AY=5[#^HIUG
M_P"MV:_0GWF_;GX$/+JO8?U%.L__ %NS7Z$^\W[<_ AY=5[*?EW2Z4YT#8K/
M7VZLQ;*0]68QN7\.[N9E08"OS.%WU,W3YZS<URI#YR..W\[?CGL_,X83_$^+
MCQGP$/%?]E[.\:[R=.V2N+J,2=O@]5!W:Y(+6-?P^.Z92N'(TXI(*E\7#>ZU
M3QC[M6"66&O:J8PSP1221Q28X9Y<<A#RZKV5J#MCT*K4;@RMJ+:=<:0J"J%\
M?!_#;[?Q4;U %)E*#I7*D?6#&O9J!I<\Y!5::/.$=)GEG4PARRYYY"'EU7L8
MN'\1'K+'AC''3[,8888XX888=$N\F.&&&/'&...../7/CC'''CCCC''CCCCC
MCCCCCCV>!#RZKV?7]13K/_UNS7Z$^\W[<_ AY=5[-@)S8'>U8 Y+^)G$&S"J
MAD5BPK+*F'.*-Z+&:OP55'$2!:E^][F7'S I@##"M//VQ6Z4$N.6' A9/ ,M
MW.WFJZ1%A%S4'K*VL;Y6NM1;B)5FSCCV\WA%QD7@$,G%KCB>C?!N"J1Y8,/_
M ,%5C.5H;=^"U6)0418>D\CFE[8:\CLZ_J8+NR9Y=K;!=-9:XYB39L8')H0E
M5P=SF8.U/<AK6EZPI:_<CZ\U\RX+;2/!Y2+I0ED3"8$PAURMRL7=DN,[1ZA9
M*J;(E%#+T3>ANP#(176%TK,VP"=2LE5,VK;/KA2N*)K-G7+G=K);4!/P#V:J
MZRXIE0+=:N> _@0^D:V;PJ-Y&<@.QDE.V$JSVK*P]JR\Y+EF\.OB+M@"T":A
ML//<$E*]0F+M2C[U>2P.(U*U^E+EG6N5X;$4D>(A';-V&NZDUZY;.;^2&"FA
M+Q)J9[ NC*3NT5\+7SNF248^OS\Q;C&#HK!"S#6QELY5:TWRT$\_$<,@%CLF
M8:QL4#RI%Y9BU$O?B(5A-ZP$IX!Y!<<M8J8AARH"[UWU6/,13NS0SE8Z93.E
MC+P-M?# EN>>...>>>>.....>>>>>?9QQQQ_SSSSSS_QQQQQ_P#?/@%6".01
MDF&^A97B@PRJBG(.RTQUV54*!#6>7IN5!CQA]*LWK%?B._P.CL\W<1MFK?RA
MXK6(Y.0+5X!1A;^%-OK5KX3Q-=)HXE?(-EV+X?IP>\U<6[(%>DEXSYSD.3B*
M,IZ]2XPQS&![Z[=L_P#K81_.0%UDEBAQ]^:2.+#V\<>])GCAC[>?_KCWLN>.
M/;S_ /UQ[? *VTNBPE@969E+1#PL5\,)XMQPVB$E@LQFQZV %4:0R"Y?(E#1
M\L,#"AU"K9NWR5^K3K023388<@*&EVKT(3SH0C=@5;5B_:CH20^A-D/*\2GV
M>;TI5'/O.8#WM<7;6WEEFUM7JOF"]:G<5EF!002D%XQ!3%A[C3'D,[73^#V8
MK0-(#YB*#@LS+18=<XBQ( &U(92Z6ZK!+Y>6Q4R)+#< - ;TU&U<&VK ^2T+
MO7QT]6Y.(7CP \ 7.RMM:^U"(@.;!/\ (2C:X+Y5,*P@XP$[<:^OE6H[/4!K
M0PP:M5@JX$*FBMJN/DKCQ]*6Q;EBQYP]\+2M[)[!:QU0( G&VTYVAS('*,0K
M-#U1MC:]KZ="51EPNPDQNK$ER) @(^ T)YM&CM0:,BD(5:_-KYB7&+P(G]2[
MC.+,@8"M$V\Q:D&KX8'=9"MRU2OQ34 PZA(4O6K(WFKZI')5I0RRS4N:7S^&
M6&4'-7YCCX7@')(>%1 <F;*QGF%Q%>M_-PU+EB3,;S5XNXSQ4J]>6_-GG6YX
MDPK0U<[<G//$6$&4O/&'@";E[0:(A7T1JRV!4R7=DZ\I[;5"T(5FLU,]77OI
MKF'83!E7"RY)2;'BWK^=UB=,5\6.CNRR$+-7 <3RIBP\,N>!;G7<NM==F!H%
MQ9X@Y,G5JW\(O331"N-&7F$4J4C#(0%CKPY3"W&(U0$U331;#BK%KFYQ#<SC
M&$\Z8D#.\ / *2][%3=9C1)AW,\ QAQM4D89;SH%+\<[4]L ]54Q<G NE>SJ
M>LL)4<*ANW,:XZ"S<A^<MUX\O?X C*&V$XGLDWJ>EPWS-Z[1KD#$O.MMCQ)=
M2*U0'$X*V.SIE./6EHKG1*T+'(2FW6#,?$_N24,)(I\(PW;XM(,=OO7);9MC
M4=#)\E;JUHI1RN9Z@V]6U_/>"#8BABE0V[:1H=3$[8R";&M>K#G:U/5,83@)
ML,3M6R.B#=OBT8EUJ #F0 H72&,#$T#SY0$-YKV\\K]!7R$8';&-B.#.G!Q0
MR/">,L+5B"6?YS'Y7"?B*?X0$0][&3]:4@))T)V1-!E=$O7HBY"$/&*\C=L-
MG%IB8,O2 QA+$/"<:38@' 7,<T M:\1J1WB-7&;'+D"O#=Y:L+O=K6P]JPL-
ME1@+*65?TD["'LMP!;'N!Q1&M4XN-5+-8A7)P'"*V,-6S54?5,S2TL?IU@X%
M@4%_[7:E1_71L)6TPM@LSPJC%N@(8(8VMTX8TM4F2E5DD"R+; U4V!_6!1 (
M&(D2 XA;N5;]>M*#/\"@C>O8>RDU 'I46'=4(QEU=Q7@K4MEH8YX8B@!A&UB
MX<C%%9BALQ1W1URM9PCL0Q3X8R\8RQ1R<98\ 6'P!&LG9'2ZD9-@#SCG5)K]
M5OG(1UUEN*59;2$GQO[< $$A0"Z,87$(F29,=A'7[A-QE&5[TU0'8Y'WL:X1
MO0[ +L'JTZ@/VS\R;0II6KL#<S^3V?K39NH;JQ57%B@Y&2%]=VHGIS+D+IK)
M*F6Y*U1%@;8ADDBJVI[->S!"+#HL;+"[)&PE'8U L042<U^("P$U0]5NB3(
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M*\Q*]Z/66?9VHB0&<37/)D5VR[&)&\'')ICIQ0R#B&NPJK<35?Y*^=KN-^_
MT'/IS*KZ1F$^-%!VD?K2Q7=K[ ;]T)^@6!39*;6* C  0V0)4 95RLL(<)P.
M.#J*X$J$(#KL4VM:&5;I/;;BY7K[/=Y7A@)<&A=?GA]FW>..............
M...../9QQQQ_QQQQQQ_QQQQQ_P#7'@A^^ >4A=RN:DW9NC5^TM@;.'Z\U\TC
M^[@_8);:+_0H5^O-Q1(@KNI<VNXU5A]JT'[&KU^K#KF]9C!D-5L8$?/0RNXP
MW[8U:ETIC/I\9%1%V2W*OT-I=?WK8BLO[]CV]J;:FMA>WMH0(X-ZU!OV VZR
MZUGVYI>P_&]<+0;:*-N;6.OVD8,920-''Z5#,PR[6=<<KP?YL=JOA351<^*?
M7 THH=A7#572IGVTQK]K!P1=H.( @#VEMZ-X"92FNPMH%@%![QJ#YK#<D+8M
MFB5T1J)@HV' :OCA3:"B8QIFCP)%=J[/'IR%[E_$=80_%VN>0]?%KV93<BV-
MC2-C<$LQ]S2/<S6?41I=&Z \- 5 "1)'M.CMZW)9,QPK"4F-?)IBYK9X&1HO
M^<\ZV?\ B_EXBPNLO?,T,?\ 7J4QIJ6#D/LR$LLL/.PUPN0J5=G;CWGJ%-<*
MML"8**U4:6QT^-<:2X'8GT[C&TF$]KE1RJ9 5<!(X].#\VQWI>>K'< IOEM@
M4V 7KL?.9UD5V2N3([K.Q6)Z*QMUQU&=P)C[@ZIE7@N7%T6=%V*-J_%4X*WP
M-V6:81 6+@U?NR5OV9K^\I]T%J\.2: Z&==I](]R.SF[JKFY75=CIM?6W;2$
MNNFO &.(XOB0POU'R=&UI/<XJC@0?7P.O7D-ALZU:J$3U2RK/HW=O!]W"N7%
MKG4HN,V+)C;-LA:AU&6VC#S)\6#FEG$0$[HU?".CFKR9281953'S>/LGCM5\
M,/AR"&>>[^Z2VL=:IUN;L7K?03PXZWV'44J;V6$Z[YDVUZ(I6U[:MJTP.>=?
M'7VB<Y3Y_8FM;X[8\+S6/ U&"F79I%VH;%2FYNJZ8<^!FK9V[-XVCV[57%EL
ML? T-W-*7C:>9$7QJE4UR&3V3JQ:2DNMS,VK&UDAK***N7IFQ@^1UV QD<AV
M&PQV(#--%I3_ .:.S.76E)YY'LRM3&["Z L,U6M19)PHJ9@HTI/BTZ9N6C!F
M5JU)??D^+6KW\K$,$GQ,_?BPPR]_+V^]R,DUX > '@!X N9MBT,F&14Q7=BQ
M7,[O(O$Y$@,F:[#-)_Z\;V#%*+E!\THN<N).+TLLE'CC'WI.<H^,N.0//5AW
M=M['K6P%AFZB&&TE=L_B"PB[_*:B\F&]9ZU[=W,A*)8L6^G:.MEBLACPJ"28
M_FEJK&\25^!&.-:8M?L\C45L_GJTN;OLJ,#LIO\ )4=?+#CKK:IX3&IZMV3O
MI^I(&:*O,K(K:F4$%K95$A#M/2V\@BF0MA-@"[\2F<_ERT9D":[6P?PM3DA)
M9!*L-95Z7-7\C4&[&G:=#1[<V:06!IU_^B#!E<#-A8LK6JD^2U?(4IJ].@@;
M'M$F>C>XHX4E&XN85BM[G(?<(T^..>)1D_0YK8US1)$WLZZI:<>/H(Q<),P8
M].\KZ1+@O33QNA&=I2]9122A,_>.%P5X!2%T\J<M#,C8J<9V> U1Y@#=YY..
MK-F%U#M#BQ423*?*:QG5]F,>*< Q$=;IA_R&QMRT[>R"B.49'T>6W@K:7M;"
M)F V%M,3V6YC*1/B!XU6;,*-*_*%P<+$9G8[?3K:UQJQDU_L4G!>PTYMJFV(
M\Y$AK;:\782;2&O]B:KR9*2P(.#:C4GUCE^TR:&N6))V@N^+? 18=I5N$'8!
M+Q7*QTI3L;JT I;,7U/DQN!EM']A-7Q##!!B4*SA04A$XQ,5)># Y[TX$#"J
M#6.DB^T!5PY.45 :;,DBI&YGE5&1SEKTXT9>OU1)$[8J5Y)X0XG(;@3(R8<>
MW&I1R,$1(O&Q+S_XQ\WB=&M[?_\ 98CX_P"? , =MM]%U-%'7+[C7ZRDC$S,
MLIPW;[MJ_7\VQWXLEL$B3: [#&[5*BU0+K%BI47G8>3&%9!YM0JVPM13:RMR
MB!OBI3=.]WBOU_V2?XGM+8'/9XJZ#SWDZJ^TK5[.DJH*_P!6E3I$0W2*WU*)
M*9UL$U?*[,H(;#;>#%J*$94W#93#).2A16J((6-YS9QC)64I:P4_<VX"O<6Z
MLVL(B.FBFQ=@(P$Z$;Z=DQ3D5-1A6'A7>]*$JE6VFJT#&+9CROO8&<.$G6R:
M65XHLB4YO3CDXE(SCS=C2Z[B/G83;V9&]@=9+B'KY ,Z=*K[O9:CIC8K,%O\
MVZ$B%Q2F*4Z&AVZD#(C<2#%]*B('F.!VQXNY$[(3D9'Q$)O?X5'NML=HUPE"
M+*GN%/U<=8:3RNJ=!C+JJS?9]CVE6Q/KTA6:W3FVMA%-$-5LVO8_J@,U!>4Z
MUFO#0+7^*2LS"I3^-]CG2MOWZN]7JDY;?#D-:C>J.DMRR97XE)835F\8-[8I
M.KL/)3C1[*-63012#';D3JS&Z@"O%G-4F&5I;.&8<O?#EP,[;&/;*V]O%ET$
ML=A-9F!^19@J/J+B<#A[%@+5<-5.Z]JT2-$4F9]!N8;50;:E#8.RXX<%>G(Z
MJ%7(659;E:EKX+I:X;WX?I4ABV4&C)@1T8(FQQ#J:Z+;&J"EP-A964>'IU#K
M!".QSDQH1&2D-HC'2XDSXJX6>(.,\N(_;R(==L<_I3.CA]*.C+\]C8R]Y3!<
MF<*?R_,/'NWLN+5?Y?*;XWMK\>S/XG$4W/\ Q[G_ "!YTO\ OI_QW"Z+2UV=
MU+KV0<K[7,$1FP>%>N.U94RT$.;=9+SBE6",C3(\)+(/;MQ;#9># U5I:LK5
MP1V"0@PJT(<6*3#PXN?5./,MR#V(DO:![).%S=Z^7FJ$ML7M*24"P%DV&H)2
M[JY!OC^6*HH+C3,;8:#"S1[)RH5DUN/IB5L-!4W@*0;1A05.&%.M]1[]:7=P
M84;9*V>(,3IL+3VRFW6)5H>3ZC:'O)\8"76L==&-NM]0ZN795^O3;12J:MB=
M0BKJVU@FT!=&L!4!9*%P>UOJ=KKDU=BV;C8O\]T=+5*XW8KL-4+*X\,#'>M!
M*)^>N)J<#B^EM6P2KM<9C%R%;<;Y2\Q1<_'MT:O/_MR!QV[5U,XKVU:1;MRV
M(5/M:M7XE<5NRF_*@IF'?48>T2@4#B8+XUY=8W$"J5M  13'BR[CO*Z.$8B[
M2J)Y 2TLO#E=A"*)Q;9O.[\.=#[ @+/1'5+.\]DUU0>;FADQ^<-B,A(:5-7:
M*J2U\.V9<*5!C&EV8KAHFSC$0L2$'5DDNL#T*F%W19G@;CP+'_)PKWYW]'6Z
MI);;LI@5.Q6'8"D^K(\B_ Z ]::++\)KJ,SOO4B,U5GL* A:#;&A7!FQM4#F
MM\BO,&<CMU['C110K2ND2V(.E(W2[K$XGI7X,F6MP;HF$Z]:B45T]I&$%R'(
MD]F[*4?@J H#19PWU'0BF]1YSS/M0'U%82^8(+5KEJ-!9*@XG:QB&V@,J+#Q
MLEO5.O98EVD:*1_<&_W75B$OZQDTLQ"+X<,W[FW%87MDNF2(["&)U0>LFLKB
M6?O:^O#PL.RE8Q5G8G&R3P8L1<:7*V95BQQ)CLIV%VVL;3PYT^Q!716]$Z[P
M)J\E,^M+^<SPR]JBFI]P5=FB2U^1O(+AU7Q$I:%;0J1+A;< 6T96K-?("01:
MB%(P<NM;(4:V\5F:J[-L^^U5'$7] *"NUL$SUK<>:X/M1H#;HKY/9J2*-^G#
MQ.I]I8%*5U<OL$#*3M0A9$X%C:9Q\A&W0P@@$47[U0W);!:9%GM.ET;KPMDO
MV)V,BM,D)@4I38U<\[]T2U-2J!KW*HO'C.>$N;4!D/N1_'MBH<,<H^ /'DCO
M[?I7K[TV;DAPK.1BYT_2'_:GJ+]<1W9S?9J&K,C)74]@55O+&Y=Z!KH]UH7]
M!NPP6HF"[6#K'S@20C5$&AJ$IR=%;3/*JA]!\]D]V[*DVNI6-(LH%H0@-!0N
M-0NEL"^FLI,D,W^14G:AHNF-A**O87852J@MJ#L+3SOP!J)\UU+NA&"0VVVU
MXD(E.]7>E96SNM>=:=/,NC]<1I3.\67JYC<'VXKDW%SF"AG74%8";RIR7[%B
MUERX-@-BV>7BR^#6H,CZ;&#HN1M&G-,#<W1^C@:#A, .CNB4YC>+.=N*OD'5
M[2C4(Q0R1S9Y7Y)71J4!/-2'*+"&7"(I)>YDLP\PTY8<;$L AYW[MW9:AW]J
M1.EW54T<YM;/U^RH:==&E6HMHU9K[D-TGF>NLINSVT-N"QV4$W0^G  +-7M\
MZ?I!6;;]EI#W1XH=8&DJ.^WM.%(UL5Y;>O\ V-.L&Z^R #<!F=(X&L6G!*2F
M-5U.HU4NXY*!*Y51J<H<V2R*LY"6G*2,6;-N]ZB8X)XB;$ &H)%T0:4*+:S:
M^>7JTZO1C:$>S3NU9A79!9WXO@4W20KC)</\L/QW&O!L:D];CNU.6IYQU;%N
M@H/K8!-%QMA#%#7]?#&6Q0!$=AWQ4 /A&U2ZS&\=2>V]FKO9;8*LVZ^0!>C1
MVO\ 71%<81>Q68L0X*DF;>E4A?'TKFAUNB79BP\!KZ)S3IM@YC]>CN0Q8048
M9V2Q#:&;NO@2.]=IP ^U6L->4.RBJI,AABTJ1YUC:8.!9T>HSLKD&9@M1(C:
M[/\ . MO:X16UH;'EKZ#C2BZK.&TB[Q7SP2PUD:5EF/:=+<799)<]$;M%P+&
MYHFK;$KP6%=B-PI*1G/?7SK87P$B"C8OIZT$ 5QE4P4C7UQFM+P(>/AG(TP=
MWX?$^=>U/X)PP79>3*/7=5[';]-*EO9&R1H[+3_\E=EBF?76Q#VQE)K86,87
M#-++&0*\5"R3LTJCC]A).QM 2WF75B(/VBF."XP-WM+"V '$TK=51O2MJQ]C
M_!#.VV]B,HY)VE5Y!..H!XY->\8>P9WG4QI&UWA27RV57:%]=BV\/;2P%>DB
MB8>0\@D45O5ZV-.U&*DEEEK"Q^5GM!Y1F^P^SF!>8K^N]PUV_2+%/VI8!S&F
M[TM4"VLV5'T?UZFT_I>CO:(/N/%@V"Z6&;<6^!:E/(]#EIHNC-<W[+>LZP(*
MYT:BR5#I=2)<MJD19AUDTSW [$ *&N5FT'[/K.AW$TC;)5* 9Q:!RT?4-N1"
M-<&8]@-$XML#PL![KS0N$;!O0D:FZUMO,3L#5) XRE'D1B&5P;Y7;O/0C:9/
M88E"82.K5]=976L-M2BA;0S%%(=GEC5FSRGP)"478ER4A7YQPDHBN5F: E9X
MQJ3VZ4>?,W @O-9,.YC77$6Q;4C2]8[8LZRA(W"V9>^SKH$U(G5K>+4X53"9
MJC(7-0,9V2+0I1#*@\3%4GH0'<X_;+6#@8<#]A-A%-0/K^ [%@CHP=V,ZGC$
MPDMV=;,MZ?7K\\:<U[L4:U2S+I>D"7]G'".RVA+79Y*VTE)-(+9.V<5_4*"@
MMBQ%UV#W3IW'[W(W+>3U++#7F_-<(#3SP\(U 04:$H,4GW!?0AK/KC,HR-<Y
M  IKR' 4&;$V,/8 )20H@$A\],68L$0:VV K53\G:&+UK0-CK%O8CJY[  NP
M?;)"B[@^%ZL1K#\K=\RX68&."H2J5I@D!+65W4REPNQS%8ZUM NGY"]FTRV*
M],'%V]N32)TE<$";A$> +M-RMC'E"!!3 :Y8AS)/%%EA3F9C:Z#PRACDSLR<
MWS5'#F"&7&'*6SS#7E$,>=BMM,0%4U@R6[#EH:;'LAH%>N#FE@U57B=U5DVB
MJB'*A<F76AX]X'66+I:P3PA+ ;4,,4ERWQ.-KR\\"Z]:=A$).YMGKG9T[1<W
MX23UVNN':6QM]FN-I:HGI^NQA="GT*.L)IT2*'(#"HU38](MF*<L-+9=G-K;
MA5UWCD)WTT(I/",\=W6,N.AMB;=.[Z B& L;NV")?OI6W$JW;]NP+3 NN>S"
MRJ]5+V(.>7.FE6#6GK&-A6].I@^=K+9<N_$862R,C+CQ7$=(Z5KQC@/IE;>S
M57LYK]5 :^0+>AB*)L@@Q,EG8K-6*\W1C/HFH+*$1L.ARHX.V"QS!L*).18=
MD8"]@#^#)8L= SK5>*J,[WO[5W=_;+7K"BO8J6]M?ZD-GU%\P51K==6Q<D[J
M,*H-JALI@MLLLU<CJ35JOFXV=BJHX=F?;++"J@%>SBVD%Z/D5+*=NF,X<W8B
MSH[!; =C=S#F?L2X,"T@+RV285ASPU>"URK'M\OC#8UJJ@KHY) M54HDJRL-
M U_7G=B^K.-AA[,E>(OA!#P'+O-+\,>@K*>V]U;E[-[QTJLLQ;7BXI:[T Z"
M@9)'9$YDJKQ=\[3J+N3J/!Q**U(#3W>1]7%@^?-,@.X2:! 6OUJ+/PUGQP11
M/-W\-_J/2"/#G"./#*3.7+##'#F63W/B2<XX\<<R2?#PCC]_/GCWLO<CPP][
MGGW<,<?9CP(??@&4PG:("SDF #5U+LOEG6^P_'6L\L7N-81FJ3!BGT-G8.$L
M>6QY*DJ!)K,H.V55FCN2-5E5N0VZJC*1YR'8BQVG?;B1M7N%I KK\_L/#X]6
M@#W3)U]LTV?  JS9N5\H/HJ<]@HR%1X <I;"46%3V*E%R9:KRQ(3HJRCZ$[
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MY+4<HFO;YMUI(,[W%>.?FS!E'SE\:/G("KJVS]-.+NU(Z<W(C&[APBNYM@@
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M(FHJ1>E:DQ2#0_ LB>U:+6F!K6Y?@EY6X?D+%N0TG1OG5H8M$J]G"<28M<&
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M&7-B#9_&W* &5W>P >ZT,6O!83CXO![*Y87\Z12Z$9KAM1J:Y0W$7L1&3-@
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MF;J1-C645RV'IT;K>*E;7I&-4 .PJ5@'4=W0"*+(J$;&QZ:(R74"H1K'14F
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MSV-!=B9P>5@=UVEG)KN\ISA4BO4J<1WU&[0A*$YK]:Q=NC4^-*&T'/5 #8?
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MI&7=?R:=0,P!1T#%(VYE>)]YN-<$KVQM<<P8$A;KNM;<)\6=1@]<'MK%=;U
M'&&V8S[7DH[<S7A>Q@VQN3!'-8?"& WAR<]B0T<JLTH=A6K(N5V:Q91P'\6N
M0=\A(.*6: .WIE=4[?35C?RG79NL[!QV@#;0VZ>V5> WN,%[[9;7>>P6U#2
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M0%- ?B$#+-!I!1#K7/>^<IA]R,GV=&616O=C0Z^,V7M!+6LI$(\Y2%@ROLU
M/GN,+@0H-Y#QC@5,I8M4;/,W#75EE P\1?&EDX$69W-_4W!MZF-4:ZUL91KL
M+:\3]<1T%@]7;XQ#&$+FP$&OAY'AIKAWP30(*3"-%WYS]%<.%9Q?%PA!6KS
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M[2628^WUZ)B)MB83T>PJ%F7B1<]A3CYE&7@A$R\O =)^*+*J\$65267ASI7
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M&/-_@6;<_P!)1@Z\Z]+'U"9^V*\,I+(IJ4GB%:FE=A@V$T]?&TILW6IVX)I
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M.V9Z.)*ZP$^S&T=MQ5BPE%,:0T?KBA7,#B :X>:5=HW&]%;_ *05KU+U:FO
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MY;;.-@AN6(Q00H3MRZ\Z7XS3$] T(HS&T9,-.J]@I.1=372C:J1W(",:RS$
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M+(Q1,D[9!8SF&.U&X0"W =-K"7FF*K#1)AIX&KA8K%\T0EF4I4P[QBNEB$W
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M^P.'L"GJ':^E=UNY>2I.$(2+!BT44')-7%/@FU5YOE5\U?;Z]<Q>@"B+P]5
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MIFH#O61[Q!W-9J*,,EUP@Z^8DOGG7@U1N*^HVQ?/B]5LJ7A;##IPFOSBP$:
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M9EJZVQ,=2I7LU<K#(J&=0J)(/0LS1C3%*0V%N6AF9"J9&BIQWYJS?X+C9_4
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MUPFIWFPG@M@1YPZ>P8VIH+,3![@J"I#P-G'K2<C"T]'5EX"L*XRG@(:<\ /
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MU(JTA2_,4(RX<<\S7B$\<,&=NW-GSE+8EQJUJM*#F7/+BL/ITA];B*E3K01
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MF0"QTQ7@)=8)D=A-[)@'+:E:#U8A6"5<F9LT?2/CM<D?F1U*M($$CZ)D; 5
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ML9O@!X > '@!X!AK[>>X7Y!V_P#3=U\_UOP:GX_SJP^WGN%^0=O_ $W=?/\
M6_ GX_SJP^WGN%^0=O\ TW=?/];\"?C_ #JP^WGN%^0=O_3=U\_UOP)^/\ZL
M/MY[A?D';_TW=?/];\"?C_.K#[>>X7Y!V_\ 3=U\_P!;\"?C_.K#[>>X7Y!V
M_P#3=U\_UOP)^/\ .K#[>>X7Y!V_]-W7S_6_ GX_SJP^WGN%^0=O_3=U\_UO
MP)^/\ZL/MY[A?D';_P!-W7S_ %OP)^/\ZL/MY[A?D';_ --W7S_6_ GX_P Z
ML/MY[A?D';_TW=?/];\"?C_.K#[>>X7Y!V_]-W7S_6_ GX_SJP^WGN%^0=O_
M $W=?/\ 6_ GX_SJP^WGN%^0=O\ TW=?/];\"?C_ #JP^WGN%^0=O_3=U\_U
MOP)^/\ZL/MY[A?D';_TW=?/];\"?C_.K#[>>X7Y!V_\ 3=U\_P!;\"?C_.K#
M[>>X7Y!V_P#3=U\_UOP)^/\ .K#[>>X7Y!V_]-W7S_6_ GX_SJP^WGN%^0=O
M_3=U\_UOP)^/\ZL/MY[A?D';_P!-W7S_ %OP)^/\ZL/MY[A?D';_ --W7S_6
M_ GX_P ZL/MY[A?D';_TW=?/];\"?C_.K#[>>X7Y!V_]-W7S_6_ GX_SJP^W
MGN%^0=O_ $W=?/\ 6_ GX_SJP^WGN%^0=O\ TW=?/];\"?C_ #JP^WGN%^0=
MO_3=U\_UOP)^/\ZL/MY[A?D';_TW=?/];\"?C_.K#[>>X7Y!V_\ 3=U\_P!;
M\"?C_.K#[>>X7Y!V_P#3=U\_UOP)^/\ .K#[>>X7Y!V_]-W7S_6_ GX_SJP^
MWGN%^0=O_3=U\_UOP)^/\ZL/MY[A?D';_P!-W7S_ %OP)^/\ZL/MY[A?D';_
M --W7S_6_ GX_P ZL/MY[A?D';_TW=?/];\"?C_.K#[>>X7Y!V_]-W7S_6_
MGX_SJP^WGN%^0=O_ $W=?/\ 6_ GX_SJP^WGN%^0=O\ TW=?/];\"?C_ #JP
M^WGN%^0=O_3=U\_UOP)^/\ZL/MY[A?D';_TW=?/];\"?C_.K#[>>X7Y!V_\
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M>X7Y!V_]-W7S_6_ GX_SJP^WGN%^0=O_ $W=?/\ 6_ GX_SJP^WGN%^0=O\
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ME(F?H"YF.7Z(LX3JT,*?M+HF',ACP\_-1#C62WG=&K+>5%WV.,SPOS+X$L-
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M9#*_M@%LO'ENP(=C+F"&$AS/006_66&0:\1$QU9R3,FNS>.(T+T1.*2T1C,
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M'BL7G4QL$.D[%Y6[&&JD#@.2E':(3[>FF02+'@F+";8#OV ^:"/Z3*Q&%]6
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M@!X > '@!X > '@!X > '@!X > '@!X > '@!X > '@!X > '@!X > '@!X
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MH)#7BDKV"<U;%/DQLLM0JDU\L%K&>O1M43G%CZF@G'2U+(R:@\ / #P \ /
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MOG$?0XYH7\K%3GBE4X^%[*T/N"'6%ZMUB#,0,(77*('/U;A0C6."U!?'F*Y
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MJ=<>+%"Q]>.H/&C1]2.&I1H4:D,56G3JQ15ZU>*.&&/"/#''@#O^ '@!X >
M'@!X > '@!X > '@!X > '@!X > '@!X > '@!X > '@!X > '@!X > '@!X
M > '@!X > '@!X > '@!X > '@!X > '@"KV]KS)]0G\6O5$BIL,YKUQ5DUK
M=4X8Y"01LZL'P@:V<"WH^,CRW3M';.1I<RL15C(BX7%2\XP%+/O@LZHP4-_A
MY5%D@LDT01KM2 INS-=;$6=)E33YL?3"X?547=Z$RMJ,&<,)>-:3,M+;JX2D
MUZE"AZMQ)J%>JXEZQ%G),H86;<[7>['7&JO(/CH#L._+LJ5I*:D9Z[PR==W?
M(&1IE+ 0BU]>>W[3V5SD)Q7U<A=BH;26G(AKR[9-6WMBU]7%5\/6]E RD0A=
M%E=]5'..4Y%B9^D6U&,P_6JC8@*%-OVX?V;3X5:E7,?1NF=3:#UQG/>27/73
MHIV:EXUJ-D=C0P7&$?([3I'22]VI)*H?9FH253=:QAEZ(5F_A_/%Q2LI".>U
M=K>/+9G=ER&[ 4@Y0,Z"J':^CON,3)\$2,H96KJ?-N57HVA=9B$8RT]0B+PU
MBK6F$=40'V6>-BZJ%G=9V+.Y]+M@'6=&9$^MJ'6]%3<-7O\ 545\JWW* 0ZG
M=BE[=+\)#F"RU:X@%[0!+W"I';3E[6&*E$9/#S /9"Y<J"APB<3?,]FO,\2$
M9NGC78"E:>R%\<]))9?[UJ)A?UD5R)OW'/>3MLB;X LRU X!E,!5(:.X7Z]B
MT3G.1WK%H=RV+]/$D*HKA,6?_P!7_P!4:((]=FXKU;SU3F561NU6\LIOFSVI
M=H5U(,<V/9V M[!V86$P>C.-6M#?MT"@I4K-@'8 >,7 !"NH5U78"@HF)-;X
M5F.5Z[F/'WION=2KA+("%/<:TU#K0GFY:-*A5XEKZ.5^QU:PTO:6&U0036&I
M?QVFE)%6D#U(STL9E$ Q#477-&(67U$$^=8ICK8V6;7711B7[^N'8+KG4^NR
M2_4ZI6(URTV$F1G5Z^J5%Q"[>!VWBKKW#ZB.;!K..:NQL^.,4NP!U&<DW2R_
M,PBX!6ZN^9^LZ1CD=4?T ?JB84 RC='SGI]"ZCU '8.;AKYD(0U7NUWV=7)T
M;.6N.;E<;=$-8P?3KU98)A1)9H^YQ8JYUYQX+Y5FL2W'$O)#I [7 <@J2YK0
M@6O[..L+DYF)VDD;V<F%;O8HV"KM@0F,*).#(FF-W"ZLW)%:;:C>"7BM:E?U
M];L(5G6HDXV1';RN6=CAUKHUL46PZ];S,NJR[FF@>ER];=)BC%:9;F'76@X!
M]L&:I&XE9W8;VXEMGB4+]?.[[Y-;J8T&@H0HP4QT0-X9])LMVQKJW41C6>G=
M#K$.*((*PLED"8586 EH2K.J]KIY2FVXM[!H05XI9!^YAJD33]E0U:1**BIN
M1()'@V8#.;9L)K-MO5JWDZHS^;_A\; ))3NFUZNC:]5MU1W_ -9P819GJPP=
M#W/WXG[T3N>!?*/<QS%Z/M BH8</CGBA-7+V!\-"F?&F$0"RL[?CHJ_6I=F7
MHNUGVS8C'1CUHI@GS<TNPB:"LV^*@DZL$^JR7URS#%BUC5=K&@=3"RF2>4\O
M17;F7%=W9PM/-4,21-V039;1>9WN?N]T+.3,&P':H03ZSF4WTJ;( DN;UZ_]
M6ZT&ZTU6D-FKWV1E3F:E3K-3KK&OO7*U,$V##!M&Y7)7829"N38#@3UBW/E%
MU/R#HY="6T<UC&%7*)84F#FZZ#UU^];8;.R%P#JE#=45VG&&KZL0M9'&((U4
M $$LQ?W6$& HPL]J*M%3%4A)UGA6+KK#]H=!VV"IK>#DVH!( ".>17P2IFFB
MB/9F8BNZ!7Q?803<+ S!-:V2,AT;SEB!4I5$U']5V+E'<]-CA86)R";;I^Z/
M&VWD-#M=U,8]]GMA%P%'6L%UPZI;$Z^AFADLD:C2KL;NPCC EN'VAR@9LP5T
MN2AD7#_(EZ9+DY8^)4D$9Q>HR G'5/I-&L'-<BMD.C5BFU%"23BB+"R2:KK]
M5!1\DLIU^(QI%ZUPT:'#6/0Y*^&FV[8;H1VX:M25<<>#C XPQ:^SNE!9@,%-
M\;?K4J&C>AS?I][U"VUH]54^=>.>N6 W> WCT1D\+"=/&;K<_P!##.5/J^VR
MXO!):VJ3EMWL^&>XIB<627(S0&F*(K<S-]F54_=WU>]J=+VUTVGLG9BJTI"V
M=;VZ5X!--L.PR,XV2#JD=Z[4]>&9@90&0NH11C*#=@'\Q#,$(9U0V82E4P-7
M!+>KB3OG.>:YBMXZ$;:R7F=7K/BDO"C.PB;X!P%YB"\2OR5TUI?6.0>XN,6G
M+NO&,?&;UHRN9NX(1D)R/D7:S:5G?6![)A/,P3OK]7W6.A<ZG2C9(L84KX.8
M)D.6-X:MV'*S'C9,=*V*VN>X8CM74C91 1+P@Q<J=058UW4+%+[K/8Y-WF*@
M85PT/*'=?6E1/9TY1Z[7% )_P_'R\.EQAI:6JF!0+?M=#OQD3_'T2>VOV\X[
M)(1 #G'KZ/,3EIX++<65@D,CKWZY"U;E!Q+H\E>BS%_UX[0^H^M<=2FE/8F,
M\S$4?8UPALXFWU+CO6G-U204[V7J;^%7"B[47P5>#8FDZ>,@+3S@9,/=H4Q#
M0[(N9:W"9$4R<2>5(TA];^-Y<6?J[#M'LD^;0W!176W5A+0:YHY-0O7FCF*0
M==;VAKW'CL!;CK#EAK6MIQV]=@B"H6F-AN!VLH/4ZA6-FGJ! FE+9E^/)>]D
M=<%QV?EK;X$Z32]L)03!?5&+B@'<UR@(AGO7,1?*(YTBX()#>LWY8SS!KG+7
MNQ38J*F$L/L0L<-KTQ)I!VM]:L:]NBPR\.OKHT.LNFG]L"IKN97@G>>],;H1
M-K"%^_S7@GI55)FHJ%E>)%L*Y L$LE(3-(23R'X4IQ5]=4T9A^RATCRLR5'1
M8H$F7:D>W+C53H6(FW5A\AVJ<.QK=1UN:X&>H&:C.JM46E[?-J^E#+8P>0:6
M9>::;)=1:83V2TC?T>@J[RR<B*WU;B$Q/?%O?-\+N5_,1Q!\_:]-^6R)X1W>
M9>1?R7-[XN/&'%_FUQ![:_$7/(A-^ '@!X > '@!X > '@!X > '@!X > '@
M!X > '@!X > '@!X > '@!X > '@!X > '@!X > '@!X > '@!X > '@!X >
M '@!X > '@'FY_$?438#K1W%WX(VH[J9Q+Z9[<PUD/6&A@2[R=M1=U]MNVKN
M2:RK# $+TVIE--R^'E%P\3XGR2ND8?#M7A@J*N-?&/\ 7Q3_ *4\)1W=J]W%
M77]K%"U(657:TE:I87EG;S;%?;%.(L!4#!M%TW(U#C5LA:VYM+!?*D!T5^^6
M-T5X1</9@&>T3'4YA(QIIM1X*5:[^.^%IZK<:NX'SA661< #;5W7<I#.<8X,
M:X>@FO%-Y*RIB>&5@&?-U4VLR]>F&4I">JH-':, <9,S"Q9UPZ4FF*E7CDV#
MO]]&CNCSF.)+ZLM;K8Z^>RA1)-/E2):,OU[>]B@TE7QO'%8F#/&68+7# Z!4
M/>/7#L@6OD,RDID@!H2+<O<;J<&E^T;CMO7>Q6 @.5U>XO\ 7S6FXJ[33@(6
ME1(;MEJK^8.:=<82A.M+=>-&V$X3>?\ F:^J6;HAV6L[RREV)<XY0C>U>S%*
M!V4<@77>FF$#9,[9:M>BJAQNL/C[QLB[9<>F17>ASL,G--UX*D%G72YL 1)J
MB_!1NUX:NRQ3N7ILXHWQ23KP1?=]Q#W4MVM.T+$F,Y6G5>AYVFX+/7J4HX;,
M=6!L1=<6\NI;=L<C<L4\V:/D1;V*QIM /Q%3( Q]LP4('IL3#%Q6#, L*%C6
ME[J7SCNSV/L/R:E3:/B5IMAPH<PS@VEN1+- XWMJP,T:4YV+=K,@FOA5J[.6
M=^ZJVA8%5\;ZW;UH!,SAQ5=X$09!"BWQ,3,9Q'4<'9?MF]Z,&&2^:+34ZM?4
MW9]@5\-E8"+<KQLG2@128]<!E?- V(<ANCMO"KKC,OJ%W,7M"S"M6;7"[2E'
MW1THD9X<IQX>3K)O;UH9.R)/3D5- 8@4.^<=2UXU6P2S<AJ02Z7J7;$5NLUA
MD6)T,D>!@8Z6DY;5:A$++L;,JEJQ\7>FX4B011<)U:/K9?9_;>N&GL($)KR1
M5H:65B.T1ADP!>:RVQ:P95471U5.1:PUT_$&9KFWJ>READJ1@;\/TMK:\R30
M*U,V/N1!"A/<SZB^\S,P]QGHS<$;26;0Z;8.O=0_Q)*?&J1K"7N*>QV/KVS:
M]O:UD(:[67HW3MG&]3%RF5RT.,-!&@);"!%7.&5^[[+PL5BZE<)SICD-9I[]
M,E=I?UW7P! ?A89_>E]"?*S*&#(;=5 =>=$[D252RSGG82!@8]C']LMJT$:1
M!8S3S$ZE<2XI(.WJ%\2/!):3JU-EVV:'T3V0/;;VYMS7Y-5C!"T$@Q40I"#,
M,2Q(Y*^P&-&)?,E%UU:\J-KWQ%22<,\+NKV:$GR8K@ #@M"N7&<2-^.7HQX#
M[R;-6]?:?<6"77<D[YUUU'V>V4#;[A2FS+MW:NUU12;-6+V$1RH/!TT8>Z2!
ME\B1%6)AQ! SILHUA*M14\!%A56<?>CG#0TW2W^S)&GNT[05S'&,=!;;<45#
M9&NT6P$M(7(6D'U[UHL)'%K]BNG''ZUJTH;FPYSM64*T1;F =:D/L=01*8UU
M\<14(G=;9^QV35*HJA]2VS[5?[6Q-@.^5LU"_IG5[L,G:[QG580C6U596+;&
MJ&"X])*YS;-B>;7%$Q YF4K"P5D<L?KK:6+;:1RE.W@X3')U[[";:[!:>:',
M.G)(!QGUZJ,Z'4(G*9(#6=6M.G+VM<OM)::#IP+=2&>"((Q6B4JPRV*1"&Y:
M0UJ[4D'61(AU_5BN)G5V_B!; 4-6K.UI%13J46Y$V+LP(G-P5D2WK(+IL;J,
M9L-8*##++@'%FX=B.CFN2W(SI)@$#  $^M:UVF MM1Y1"+;XI2^V-WXJA9'#
MM0\$;^P[4U[4,NLM6=R.OFC.+H5T=5YR8/KG;/7/*H:^:5W&E0B#KX+9[5DT
M#B9&^!:9=4'1#(I7TIO8!BN"79OOEPW8HF3N8Z;@HD!(4NLIMU-VCTAV&LM:
MJRM=$382]G]KW+6>P [H-J, 9@9%M/0D2J<V"(<Q>MY>:;W /<TE'KT0[1?%
M25+YE1?93&UNG[':&]R743LT^[D!UC*VS:UZ]+5U:E;+F>MENK;[0=DM5$.P
M8E7:6\$&7T_8"F&06H3?D,@N20ERUA29FZU5YI&) BG-VTN5.-M#1.W-E;#O
M*_1[9&9@5J8R=W=/7V!+::2A74]007ZU]B(\^6^13:PP!V2+#;3532EB48<P
MMACX3KE W#?^1*> O_:]1SB5TH)>C_$2V[=4[S/:Z^Q+Q(,IH!L^DL3#3&G!
M MWZTJ&[;NUXZUPI3>BVLDQ[:;NIV6&IJR+*IPENK':;Z)I=*(=,(5DUTM:^
M^:I>,0OW::EG9B B%+&DV(>P,FO!15@2& W<I7U[;.Z]TZI36T=;8+(*F,AK
MCM>J98L-6Y=M5XG$JV(A4ZLBJ6O]@;'$CSHIWET*M6[_ +;@()XV B(6; Z*
MKW"RV%M# Q(5L*7L.8THZ+=C'86S$U5KWPHZL,/1J;2^)=X>2OCQ!1EYR8P&
M4X-?MU5*LYC.T/W!?=P;% )US7 X!3F^BJQ[U C0!&913/UI6MV6=IJH4TS8
MMQM'BV*=N:.ITJ:/>$2EP)UCQV98E#W5;$&DO')^H?BHE>QG;[9&8+822(E
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MG)2<V[^-OFYGG+S+EGR#M?%FD/! \ / #P \ / #P \ / #P \ / #P \ /
M#P \ / #P \ IRR@J:>8>CZZ,EH%ME,M=Q=[>90O?]=9:BT!3:Q:2N1OVZM*
M>!55EI?CP&PTJ^(H")I_!^%0K8Q@7'P \ / #P"'"  RY7M4P8^$93NE2QR>
MI5]_"KZJ=OSEC5R&OSGS#5D*%K=PK?QK80Q62=V\0EPRN7;4TH ! !E@9$'
MCX!HZ*Q?N? A]_+*:^6(6BY<E<GESDLWBA@O>O%C!.[-.0*E;MPD0LV;MJ>>
M0"8\ / #P \ / #P \ / #P \ / #P"G7T%3)O2WLJZ,EE=5%>9U1>-8E"\'
M ]=<[BZ0:17IM>_$(MUC5]15KMSYZA9DRM+P:Q')A*.JY1 7'P \ / #P \
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/!X > '@!X > '@!X!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g293850g36l77.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g293850g36l77.jpg
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M 0$! 0$! 0$! 0'_P  1" !Y .$# 1$  A$! Q$!_\0 'P !  $$ P$! 0
M          @&!PD*! 4+ P$"_\0 11    4$  $%# 8)! ,!     @,$!08
M 0<($0D86)?6$A,4%1E15W:1E;?4(3<X>)C3"A8U-CE!=+2U%R(Q0E9A9Y;_
MQ  8 0$! 0$!                 @$#!/_$ "X1 0 ! @((!@(" P
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M1Z&_EI?]CO4_[M."?A=%J.$ZYWSU=$FF>256X+I"$TP>!XK18R:'M;%3\-K
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M,@R@UK=R<CN*'27$KO>[HJ2OTT(.2.*K*1LVPQIB\:]=^.&/;_:?9EEHDH%
MH% H(X[8?4B[^O&%_C5CVK\/:C=5^LIKV9^.L)'5"E KLI8_:Y6KA#E*&YNE
M"!O:W98U+O"$@T[2\IY&H;74U4H(+0A:U 8E(2;N/A/@2=:W";U)Y*]2C3*
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M$0A"OPL$(;6O>][WM:UK<;T (@C#80!!&&_'@(-["#?A?A?A>W&U^%[7M?\
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MN,<BZ#QF\GRK&3D4CNK1(N[11[)\.D3P=X0X*$J4/@C.U+U?>Q'V-4=X\'3
M.5&DDF51,15$SJM/.)AE47B8W=5ZJEI0*!0*!0*!0*!0*!0*!0*!0*!0*#S=
MZ/0M-COZOX+ZG1G_  B&@K&@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@
(4"@P_P!!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g293850g45n27.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g293850g45n27.jpg
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M 0$! 0$! 0$! 0'_P  1" %H EX# 1$  A$! Q$!_\0 'P !  (" @,! 0
M          <(!0D$!@(#"@$+_\0 9A   0,$ 0 #" L)"P@%" L !0,$!@ !
M @<("1'6$A,4%1@A6)<6&3$X5E=XE9:WU"(R051Q=X&3M!<C-U%287:AL;73
M)#15<G21E+(*8F>2P28H,T)%HJ;")2<U.413969HA/'_Q  8 0$! 0$!
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M38Q5(* 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
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M_K&V5Z>',N=0@H!0"@% * 4 H"/=A?>0O\X45_:%Z$>*W^S)"H44 H!0"@%
M* 4 H!0"@% :)M3_ /WC',_^9+6%OR?^2C:]=U@MR]#SFQFJ!0"@% * 4 H!
M0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0&&T9
M[Z?>_P G#BE]:W-6N-?>?AZ([T]RG?5[%#>21;7\?Z)WA?(I9*=R0^= @7"8
MCQV+: UJ&W)MA7D7:(1IMK43%=5R;'&*S[,Q=R8'$HU)'8P<_$N'V+8H/,XB
MW&&3HN^[)WJLW"B\RY46DY/0F:C):OUSLM*7A>9J4Y&QKCYJ!.2<N^/,*XUX
MO-2Z(U^4@VG(=J^"PN<; 1?BX.$N7]E4E-R%Z>-')"B](N'"RV6=@_(Y=HB[
M_5MW;;=VE?D;PJ&!0"@% =.GTR@>OXH5E^S)9%H/"A-FMC$IF9T7&HV+\8/F
MPQCXP-&73,:SN\)/&;!IX0Y3NX>NFS5'NUUDL,@B;1)UL\0U9KYS&7$PE45B
MF<SDXR%PW&3R$6%QE$Q-IN50T5CEB;IM8S(RR3)VH,"CO"2+W%LO=JV5LEGW
M-EYOB316I;>'H9C8.TM8ZC#C3^U-B0768 O( \1$&I_+ ,.$$Y3(%LVX"-#R
M,A?CF;P\:7341$B&ZRC\@JGG@T;JY896M"Q.!YS_ &AK75(T09VAL*$:X$2"
M3!86"*3N5 HB.-3"2+YMH[%!+T^^'MB,D.N$U$ X1HHL2)*IJ8,VRV6&5K D
MW@IW',B\_A$V?S,7$)9'Y,2UU*LX-/&(,JS).H?,D@0.3J1>1(M55<Q)Q./2
M:/F<QKRR3K >9'N<D[)N4[W [=0"@(?U5OO4^[GD[9ZLE5Y?;6TI(PN5DF8&
M3,H\E)@Q8R -#04G+!F$<F/B4_'CH$R]AQ0\/$G!+\.1=MB+91MB*TUC]UDP
M4(>M99%NBJX<*IH(()YK+KK9XI(HHI8WS4554SOC@FFGACEGGGGE;'#&U\LK
MVM:]Z _$%T7**+ELLDX;N$DUT%T%,%45T5<+*)+(JIWRP525PRQS34PRRPSP
MRMEC>]KVO0'MH!0"@% <9T]9L$L5GSMLS1R61;XJNETFZ62[E3%%NABHMGAC
M=9=;/!)%.U^[54RQPPQRRRM:X!)XT77<M47399TRNC9XV27247:7<)]]0LY1
MPRNHA==+]\1LKCAWQ/[O#NL?/0'1MA?>0O\ .%%?VA>A'BM_LR0J%% * 4 H
M!0"@% * 4 H!0&B34GGZ1CFI?\'_ -5UNO\ G]A[7S?U7_W7KNL%N7H<'@MW
MNS8W5(* 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
M * 4 H!0"@% * PVC/?3[W^3AQ2^M;FK7&OO/P]$=Z>Y3OJ]C5/R(ECF?<$N
M-?' CITY,P3'BWPBW-&9- ><?'[B=L5[L($DR=-@H%UM NTD497UY:+QO8;6
M98-T6)AZ^:#(V_1.Q]YECDZK%M9M=V8]KX1>TSB6OZ(UO.D(MNSV;C^13%;*
M00OQ?;D)TAVNND#?*I6''_"+Q@[KT\<;ZS:X972\9B2>39:2+9,WC;%7 2K=
M-X1]V&:M7_71]$I-P5#(H!0"@->?2ID.+PG@?R (\QV:)/0+>*IX2H3B+6+F
M2I9V19LX</B+9K=-VWFKJ6N R42*MW0ZX4YDS+."PEFS<D6RVNZ^X;<BJ96B
MXJF5E.W9F?'/P-PVH(Y;\$6W2E-]Z/-'MFS>(='%;<!-K+X=IR:E)4X>0",[
M>%"PK17':KP)C'6D-/REM@M'DV<>:K#F N*#\-;:B+M8X7]8^-QTJ:JIJ7XZ
MDFO_ -(LVK2Z9=J9QC/P?U@]++J2)[TU?Q0TC/4,R$-VIS1U;KR38IWQLYN(
ME>L]RA'KMDKE:]VQ)HF\N\&O,.Y69/T&SM#/!9'#/')BEQ+6I>Z-4&X]@;,Y
M>:.26W0Q)8G>C1DG'C1VUWA!BZ:CYKSQ+<Q-4:IFT^#9.<,DGC0#H2+WF4?(
M,UU6JT?Y?7;V7<N1RO@S[AK-*S_Y77_&^>;]"YNTN0VPFFR=HP6=;WD^F="G
MNEPST)LK<8R1C8:]U?J)#HZ-6[=A6OQFP'K;O>M1.R]_^(8RXF.#E@30<3%V
M %FAI*3,%T1E+9+T9\=*,-=M1,T#R([9YD:@UYKKFANK8''6!\54-SC2L2V1
M%"J.YIK&^3DLB#'V;;"CL<2]F<3#C6#^$%VPI5ME/!@D4K+CLB>,WI P&IV4
MRM6$ISZ*,O$JMQVY!3S8+K@S)F/+78DYY1\D]O[%@_,CBUA/@;T=IZ$(:]W,
M^V6R9:@'CTRF@7/&6=QR!1J-SK!$(4-D,A@N7D9@4GK)5P*TOVM^JP>VR3EX
MZ6,>*P.K\9(//QF@>CHU!">1_(2! >1_-;FC'=G& ,\37DZL-U\"YK3.\6BQ
M8L*?^Q-O)S>MQ!$V6%(8G&YQ\3DH0@*D&3(@R";MPNZK7C_';\>!W[:G*@]'
M.9VN8UJ_<>S$'41YS:-XG3^*[4Y+Q>[V81\_&8B-FK:-<21D'67,0QV+E@^3
MMMW2H\ FR\O[^;%NWT6<B&;T$I3MJ;PWZ]5UN>!SXM-!?(O0/*=;8_,G9[?E
ME*AO/&$2;B3&=LQL*I"QFL)1LT)#X,'T<@'<RJ,M(Q!(U"7^<X98,#T];R7Q
MD?DYX+-QXQ9]^[A@U:WZWWI3FND:KF>XY\C]<Z*:=%OX5RP9K<:9OPWY#>SR
M9;#W)'C$#5W+&XOQ DL.A!28OWJ(@8<A,64V[>(P]R^;D1(1"3MDVJMVKBR;
MT_U\D:;TK756W!S?TY&%XIS_ ';RKE/ (!)>2F[H[%9=Q+Y8;[GWL)/-XR<V
MA(M:<K=,0G7K65E7P5P98B106:N<7K ;B(($F;7".%U\P3\X*(@[393^J_\
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M@% :)-0>?I$^:V5O/:RFKL;W_BO[$4O-_P"[E_NO7=8+<O0X/!;O=FQNJ04
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M2UR:,FS?)L*;WMDW&-\D4L+HCT,K6R19IWQ;)7M:^">-[4!QFD;CH\N2D#
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MA\3'1ZSQ3#-1-HD],.V;91RI@FIG@A@K=7+!//+'"]L<KV Z#LK"VQ-9H%(
M3"25#QM$9B!=L"K9X!D6,3E(B3HM$#+"[UIX.3S#W8HE$+.TF#E5)_WEQ=KW
MG(".)"1>["0B\?"P*21=1K*X?)#IB27 -\!N$/D8J5X"QR8@Z96-E"K\.T'^
M$,K9 F@]P_(*&<GC9D+)/GG]L"U2?==[P[K[[N<>ZZOX^JW70'G0"@% * 4
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M\L\NKW+7O>_N6]RUK=75;S4!DZ 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
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MK"U6^XX6VXZC9I5(* 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
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M#G@>MONW3+N-1J:--N:Q<PZ9MS#J'RQO/8JM&I8UCPHJ=/N8T=3+9"SK<&$
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MZ1ZPF)B+!-7P5_$-,ZTU]*M'D"NH2VMH+&AAYH#SBQ-^2R?/BKZ3+XOB*+=
M7\FE*;B]U$I7QQOQ-^U#F* 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4!'N
MPOO(7^<**_M"]"/%;_9DA4** 4 H!0"@% * 4 H!0"@-$_'GW\7./^ET/_N=
M_7=8+<O0X/%[WZFQBJ04 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0'S)
M;*XK;#Y"2[IGB^L-K;@"RZ*;QBKQAHZ.3,B$T]OUN"XSZDD1;5NT8]'L!4J,
M#]FB4GD"=K 9G&W&+4HTP7569)NVKSE#>G#:<\;O%:STZ2I7X92ATXM2Z?V=
MU-K8X;C,;?V_$Y]NGHY.2H;8NB>-W$R5<*)>PTO+=_Z?RVGH34^ZB9K7]BNN
M'K-#:&G(KK2?-M=BG,.C4G.R1)CX'#YA$0@YPY(9K,3NZ=2C>D\(OZ[@J6E^
M2F'56J[JEPVKW5FVIO%L=>K.8:CXTQ[B_%SN72(<<!K;'GU.N3&B-NN-5A8Y
MPT%[57A#YA(]+IP60[1DL+>:[74,3F2C7@K:X=XQE9]T^A1# H$5:.T*.]K;
MPA8:YL32JTG/XZNXJ:DG^\)XS$ZE-M5[$=;7WSJ?;NKNBZVKR3U-K&'Z;&<Y
M>0#"9M-?1(T5T%.Q,1@F\FS;?$1CB@3 N[TU.9*U0VD1?R,8]9I@539V6/2P
M-(F4=1NU,JTY;5J]2I.E_E5-3;[.F'/[)MTJ)S2<<CK^ZD1>W(]TP^P>#@W*
M4<<Y1K7AQ'),1T6QO:'[6E4*FCPERD3U4O%TT1,D)MN.;[*,SA[%;K>.73QN
M/57?/K8YIU_Y1A;#VYR%;LE7WIKC2_QE11*>'[72>\MPE->).[^;/1TONCW=
M:ID;_5O[K9;<L@T*'$M(_ .-A;3ID".A&UUHTP9M@BIW83B&-X9 I5BD=%R
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MB#=)F@U;HM$,4\4&J2"2;='%'+'-'%)##&R2>*66..2=L,;6PRQQOCU7M:]
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MAQXX>-$JU7EZ\7NN_;UDVET,B@% >.>6.&.6>5^K'&U\LKW_  6M;KO?]%J
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MU7+NZK1L2S1N\0;*765NH@DM@EG=52^6%^[RZTZM1EXK?[,E:A10"@% * 4
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M^GWO\G#BE]:W-6N-?>?AZ([T]RG?5[%79\2>"NBLXONV,DYIQ1>VF.+Z=BW
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M=>7\W>^Y(Z?CU^'N;/*XG04 H"/=A?>0O\X45_:%Z$>*W^S)"H44 H!0"@%
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MOBSP;6MWGN\%6^:M[V4[G.W7CW+ZC+Q6_P!F2M0HH!0"@(&Y/[\#\7- [3Y
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MT#A94AC(7WBA\';_ +]S&[[]R+,6\WFH!0"@% * 4 H!0"@% * 4 H!0"@%
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M=E,6=GRC!J@J\Q98*JILL%\\\&:6>23;%).]\:>$?=@)7H!U=7N4 H!0"@%
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MR_L[0#R_.('QV@?F67]G: >7YQ ^.T#\RR_L[0#R_.('QV@?F67]G: >7YQ
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MXPGQYQ?+67"K)L4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
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M-=/W>Y4QME_NZ[>;]%!!X,QS(?A=-FW30QOY[]QC:U[_ );^[>@2@YM * 4
MH!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H"L<4]^9OOY,?$CZ
MU.;%"ZEO?HCW<+_>=\3_ )-.B?JNBU \7O?J66H04 H!0"@% * 4 H!0"@%
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MF^_DQ\2/K4YL4+J6]^B/=PO]YWQ/^33HGZKHM0/%[WZEEJ$% * 4 H!0"@%
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MYCU6_);\'\5=*NY3X>ASI[]7CZFVRN9T% * 4 H!0"@% * 4 H!0"@% * 4
MH!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% 5CBGOS-]_)CXD?6IS8H7
M4M[]$>[A?[SOB?\ )IT3]5T6H'B][]2RU""@% * 4 H!0"@% * 4 H!0"@%
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M>=-__P"3FP;=?Y'R?F_1_572KN4^'H<Z>_5X^IMLKF=!0"@% * 4 H!0"@%
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M:_;,GK!5+(1J(VJ5&1<^A!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
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DQ08[(QT@29MB";-ZS=9LEEL'.#9VV7R2LDNEEF#4)3F_8__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g293850g91i69.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g293850g91i69.jpg
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M5<011:;#SRS)O QUR5D+ZV2J5UGEY%@C!XWL9XS(<PJ[0)&U=T8X!IM+O@\
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MD:O+FL5V7'^-'E>JW^<087]; T T!ZMFU/\ 0N[;?W \/?<\KNO."?- - -
M- - - - - - - - - >(/H?0-NZ&LKO'N"\6Y-O>R_:'E_,%I[.JPXGRC(FW
M9[M(;,I]MV(-G>-<LR=9R9$U"/A\<U*]Y$VMSU9GHIG4IA:>;4]XE39JW1CE
MP:)7'GIM1M6OSVE2S&UM;,K29TT993\SK3->L?;;XKL-1I[/'E3G6^YF9K%
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MZ^L[//W%+QH=?YOPXH]0G0\@T T!\'/YG7_:C_YHZ UENU;_ $3,+^X_1_\
M7K)KK8NX^R.-K_'_ *HL8QGA_)N9).1AL84V7NDI$L"R<BRAR(G6:,#.$VI7
M2H+K(%!(7"R20"!A'K.'AQXZTVE>1)NXF?\ $,;N/H#WC_L\?]_ZFW9SZ/X+
ML6LNJ^1^(8W<?0'O'_9X_P"_]-NSGT?P-BUEU7R/Q#&[CZ ]X_[/'_?^FW9S
MZ/X&Q:RZKY'XAC=Q] >\?]GC_O\ TV[.?1_ V+675?)D"P_BK(>(-O6$:QDR
MIRE.GW>^CU;;1<N1$CE6*=80EV3=\4$%EB=RJZCGJ!1$X&ZVZG)0#@1B:=JG
M^ON5IJS7_;V,\C'\QM?\'1_T9=<CJ<K0&'3='OBV^;9%9T+U<&\C;4G3X[/'
MU7%&:N#Y;RA0$TU8]!4$8=)00 ?*IIRQ0Z!!0IE#="9^UE*%SW/A]LX.=<L>
M%^FZG$U5]\.\6T[OLB5RX2E7&F5&KQKR'JM9]45)-1NU6=^4O)20<B@V0/*2
M1O) <D;H$233:-D4Q."0JFU=$SA3/'&MWNRYQ75*[C@JOE57HMDL;$D[3BH-
M5/ 3E66[OCC@I#"'5Z!Z>1'CW0<B/IXU?K]+S"=")PY^/?ZWDX[;8=I2,=NG
M*IRI.[?8%WB8F]SULHD@L6X\<>("Y-("7J]R4.KZ0A,/-?&6TY=VF9D5Q#>"
M1JK91P=(P(B0_1_=%*(<B!AYXY#GS#R \:N_[W^/.Z\R9,Z!N+ATHI\DD/Y$
MSCUG!U0 13(=!(R@&,(^(=)BAX ;S>?PXTCVSQ\XX P.[M=\NY#)E@E'>%'B
M[O%Z,?-QBLD4[)NY/8HIPY0D(]C&N7(2$B")3(=RLDS5[TW> D<!Z4S27,V5
M=KBN$?&^_22Q>5(=WWA]ER>V7=/<-IVSBYY?W42DQ%K2#V-;4Z.<*E3G["F#
M=4[1@PA@,F /'SI0#@=0&YO)2&77X1(8XL)M4Q?'N(VK46:S=XRT>D=L _S%
M>S-V4)*- ,H)RM'K@IWC=@*O +D(D8Z*A$"G#O")G'I* B;@! VHK2?/R[#[
M-6OX[5E2_//U)L0;7,M$L%;BI9S+%=I/"<@H40 O!BD-T@7D1Z@ZN!$>0\0
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M#0'P<_F=?]J/_FCH#66[5O\ 1,PO[C]'_P!>LFNMB[C[(XVO\?\ JBC]CO\
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MA$=6=::TP?G!G.'E[]O*HNUQ?_:HC_AKWZ7_ ,P-<;5[\]D=+%W'X)$U#8T
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MQIMJ,M(PNZ5PSJDDKWMO$C5K2#J(L;EG!2<:*/DJ:IE2(R;8"\*F PATB?P
M3@4Q3>Z 2 'CP\P\\DS:4/\ 7975GQ%T%@JU.$"I5R"9R*ARD%:158@5(QA]
MT!"'<F455(!BAPH<I!,(#T@(<"-?D^=*F3H8^GO7"W#Q)%D'5TE39D*!"AX
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M;"V$LQ5VB1L)?&\*28C'#ILCY'-ED4S10*%68AW_ ').#(E549E2X$"(MTQ
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M$SC^U8G^ZG7M:L?DN/9F;?XOAW1JQ:['$V>]OWY_M=_Q6,!?["?:P_Q>]_\
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M6%GK&WMG=G-O9-Z_9X*WS-8LT.I$*!LTF<)NW]FHGVJ0!D7MC<FR.#IRT4;
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M\P_BBM'4G%M):4;1[U59HA(O4D2.5=VOQK?3N@;_ $?\H;^]-_$.N(.AT T
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MY3(R*0%"+C'SLQG;YN4Q6YDTS'6.FF<[+56NP,@&L@: : ^:JJ:"9U53="9
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M'/A^]:*Y4ORW^;JB7F^;-7*9Z?5>5Z"E(3U2?=)"% A"%\J5Z2D(4 *0I0X
MI2@ %      U#LKEN1UNA1H#8?Q9@;LU[O4L39#:2.V'UZ0N&*"@\Q=DC=;-
MT&*S)D][@VNP%L4RG7) U:F,2S,!GLLF9JWJMR<PMFB5G5M>&:5PJ!3<V[5;
MXSC#3A^P49V1,+CVM]M>E7<22I9W%,!<MU$+C*;(]]4B3&/HNK9'8TR5)(B(
MB_+(5Q"-=E>\CY6"P+\_DFK:_"M\+V!OA'_*&_O3?Q#KD#"CV_\ \Z1W<?\
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M[M2^N.^_<AR#K-O\7P[H'HSZX@: : ZZ6_L:[_:O_,70$<: : : : : : :
M: : : : KBM_F!3_  I3_1(Z J#0#0&G5\U!_GH;1_K"RG_*&H:Z?QX\/<&L
MS0W\S'S1EH1V+)THS<(*N 3*KTME"<G#I. EX%4J/(F 0XYYUT,VHBJE2B>J
MK Y-=RZ#YC).+"<SE)X:-423 HG(F=%/NC($*9!-NF=4Z1#=3=$3'6,7W1S"
M\Z^:\3#V;L4K\WYCV1EZVKXDL-UEFU:@<F0]<R0,<YD6E$M:/DJ,XL@FFHTC
M82W-5%HM9^O^2&6141$J! *<IUA$Q4K-/;CC]=')@NS1RCFC$T^6HY*I,O4)
M]J80(UF!(LQE$"")1=1DFV2/'RS8W B55FX/TE$ .!#\E!Y7VPN=9NOD&1G;
M-NGEK588&@/F8]W*F<-T5$U 5*U61:*NR=(*IJ'*B8&Y^I,J@%*(\\%#GG-J
MRGAN_:B>Q4XSY\#(TG(NT! 1336*'(<<BD;S?I3!U%$P>'G(4/IAX\9V:1@\
MG-*=H7#?2MSYE/>>>Z7VC"98/5O)Q$6[P0Z@:."@14X!YSHF 137(4?RPI'.
M)?TY2>&L--*9E/)TXD<IUG+A^L)/A;U"H5V46'G\C9KGY] <(F'T_P#CYQX$
M//I8_+S(U:A4R5[W^7:K=KQ7>23<SMC7ZU2'6GY Q1(H8HB4%E0#C@WFX'GS
M>'HUZ,%6E:5OK6.D_:,%.5K#5_S$NY0J44Z?M61@(^E'[Y./B&:A@ZBHJ/7B
MI"*+B00.#9L"[@$Q!3NNCW6B>>ZZL;\+WON= 5ZR[/O))5#N'-NI< (^Z.=&
M0E'JQ"B(=1A[B,33Y*/_ ./TC_=>(:R#3ZFTA1FI=$3 <4I1^D)P\QA3=JDZ
M@Y\>#<<^/OZ'=7+<CJ]"E54>C7#)=NKU!H%<EK?=+9)MX:MUF!9JOYB:E'0B
M5NQ8,T0%1==00$0*4. *4QC"!2B(+JL&R7E-?.4KL%A%:Q);\,4XRB-E--B+
M%C.O;.:+&;;Y\\9BAHG9[&\R2:Z%L[6G7LW>SMFN[QC)RCH\A*6=NV:-7C.O
MQG&?[7?Y:Y^8 L=[ [YYWA'ZV,Q_<GM^NEO\7P[H'H-G_*&_O3?Q#KB#"EV_
MH<]DGNW#WX?&OW9,>Z+Y[%5ZWH\O8A# ( 7@2]0<CX\AP( /'' >/AQX<>/O
MZ'6EJN3\WR=LV2ZC%#@1$WF#CD>1X#CPX'Q'^81#G0T>BAM!K<=5MMV&X..(
M=NA%X\I[04A4*U$%BP;4%?ZV*AP5.N' E ..HP@(B("(^C+<ER4'SW>RZLZY
M"MT^E( [U%9'J.F!U#IK$!,2J#TIF*0.KO3+&Y #)EYZ2]9R 4).+K.VZI5(
MQ,XMTBNFQ4@ZVZZ@E-W:@\&24,4Q3$42+X'5#O"*(D5,4YP(M==\0R360=H.
M54RH(((M7G=E.19JX<E%PJJB01*5=)95NV.LY54(5,$G*;<2-":TC&+JK+!<
ML:T0.H,^537[Q$S06"*:X';(I*F7(DS)W@K&<+#WBA5  [9,I>\.9$4F0%22
M#DTKURBNG'+0%,3=F<J,GQF[DS))RB9$"1JR;5TL1NJ59 R!5#H*CT)(F$3M
M5#JKJK"4CG\A4*6PXIOX):Y3OYI@M1RL<PQLNQ=@XD&CU@J)TY S51HU2!LF
M#L13$W0DW.U$#(& SCCE8C5)!95TLI+IB?J>Z?"5>#2URK725?(][KR:8(IQ
M%ML#%%(!*8"-491T#0I>"E_*M>[*(B0H^'/''&O.U$Z./@]UAS9LO1$L[*0X
MWC[50\1_^(7#OC[W_/\ @//QY_W_ /PT5ZWKN9_D_%TP=<MYZ_33^OE^H;_-
M'4.9V^@/.&[93YYINR^O6M_<YIFNUC\5Q[L$&;-;?MXK%JR#';EV1'V/;I7,
M45I9,(:7DWI6#/=EMON>1_4I[7TQG:[(+81J64VA)F&=1TLJW<.8.->E?33=
MNX-.D83SB@+O:/(=G!D,A%%L>8IQM/UW&BEF?(VFP[GT<?2=N+B2,<3D?-II
MY-F+I,,83*S95O 06/WY+',1DA)BBA9&Y&0-,_V3QB8FETTXZL'+L]][,ZV1
MEE:JMW982G8NR!2<)PLS!Y<87"%6/FS=A?\ &RY;!5Y%6OSTB6!M.$8FUI7U
MFZ*:,?.C,+4+V$EXM=%M78N7=C'WAS!%.<,@;$)/$N8H#!F-Z)4[C-.J>^IC
MU_&9QE)AFVJ&>MP\0HC3;!:[-9#PM@MN!Y; ECMK.R.4:1+.6]N(FSCKA%UN
M(CZE:34SK59+WGR\5[E-3LVZ!"J1<93ZI=+RCB:/*U3I5@SI)1!;);5MHRJC
M^=FG=\3KS[*]3@WV[B:C4Z[(IXE9JDQ["6J%E;$S=UUM%MO3?QPPPFE;P=?<
MI/LQU%ILM9AJ^DL22I8N%8QON<]07>._9$S.M:&N+T;'8C3C//R>-7.!6CU_
MD]13#1IV,OYH5)URT<V"_P!_(OI?A%\8@Y\I-=F*M/SZS"DT5A%LKSCQS!,F
MM]W;2D7:*L@^;H7&,5>R.-(F<H$.O!JJRDO,*,<D6<ED9+5ZLUYW"S+2UUJ?
MWU__ %^0<6=N?9SR4 :J)Q'KGD&U2R;1JA;I-GF>KJU(#2V]>T8RGX"*+>5X
M9FNXLLSM1;/&UX<W6,CZ_(V-&9%5\VLTVU)6E//!S=/2;HKP!VNX&'V682W3
M/X:E#CA7!LE@+*<,S>8ER1?,H^K%IFI[(\!4UK>]-/SR]=GUX9K6VYHV%FWD
M#(5XD)>7 L5;:XB8Q_9JZ7.,*[SK +(MU<QMPGKE5I';35V].K!JW:6MI@F*
MV0'$>G.QV;,N1],D&RN29ZR3YG4W@MKA^:GP0E3Q9+1(3A&S*)7*[B66U./M
MDLM9!=3V*WSSW:E]<=]^Y#D'4M_B^'= ]&?7$#0#0'72W]C7?[5_YBZ CC0&
M,S<IC#=!(Y^O.1,6U::O0GVT1U>VO3 9<]9N.,";DX1SF>1G;=EG'"EPKOK]
MK>1/7!AJ..]CZ]D-P:.I$K69:!A8-^XD9,:40ISKFTX5-U;\R+JU3.U,E)FM
M.Y/)]UK5,9W.O"$-:$=I+[(LAC^9S!4H>XERJ_IN/Y2GGME6Q"\R':JD;%#F
M-BUG#"C-)H;'8DIV(D@_KEG=.5+XI-^-\8$,TC"W:R5G'-82B,@V^)R)%;>:
M)&VN>M\YMMNMKR!G#&.+K4R1B;18Y6N69&5HUKR=ZD-T[&9Q&WR3H4BV?6RS
M1UV5LLH0)LY=Z+/?TTB^1\@,^U^E37*/J,LM4(R+O!8B+LL'$[8KE:K#4#7[
M>5)M;=CZLVZ?IU;.V;U&>V504U#Y-L=.FEHFEY$5BV"UD</WUP%_I3/&_*S1
M\=J[3"[DM:[V@E E]\F>;R-KLUOAMM6=83;PW@V.,K)7Y"V5_(.6+A@EGBO%
M5!CY2Z/ 5Q^\QBSL4?E4MHM4ODMO;HIBX?54\&K(B4FSE2:UPF6X6>B*;Q0Y
M[3/(F-'V0B7[.S9NG XWC6%*M6/=K6-<H3KTV[S-09^<5B-N%!:PH62M;88C
M#]?P?;;L]J- R"G*R=XF*]'V*9 M8![*RO><7*,<YG%9L[6,K/;-^NK%\3)W
M^C^LF34Q&EE6T)M,+>NBN1=OA*!&Y:7A6B=0]2I"UXB=8ONE@9>3PKFM7:S;
MF'B,.@M5,90,/!A_2N&7LKZ7QBZ82V?O;!@#M!L?9;Q%>L@Y%R/,1C3'N",3
MYW:9"MF$;C[),?1Y??@_N5I>/X:#<68BL)*WS;S)4"6KTQ5[3/5V;59Y,862
M7@9II!@W9:HH<MTPG9I_ZW8$IXWQSV@E:SC'OWEN+%X)9YJOTU)4-F3"[B&M
M-%R-N;WZVB4F9MZ:LN<C-YB!Q%,[,WE?;5^UP1ADU[ A.L)V60N":839BZL+
M.CBS]S[&5/0R5Q6_S I_A2G^B1T!4&@&@-.KYJ#_ #T-H_UA93_E#4-=/X\>
M'N#6:HD!;;#*.V],82TA*LHY6263AV*\@NBP06;I.'#AN@DL/D1%'"!'"BA.
MY)WA.\$ $-=".,?,"_\ K-=MD7)0=!A(5:2M+M%#UPR,6D=-BXE2'%&09N"C
M[IG&1CGEJBHB8B;QPF9\JW-WR"+=TW?'BR..;[P^F._#?!E'KE,N-"/6X_*,
M+ZT9$R#%S NY809.G:I.@R+B($ "156(8J8B9%(BB(F3[T$Q.75GV^.:N7.\
MAE,QKEV&S7AJYPN5*^SL1ZI(0=?AYB3:DEA<'F$7'=2*(*$34))Q[5JJZ/PX
M14-PCWQA%7H4.4TYUB-?'AA=B.IA:HA"D3"D3,:Q6C@*9F@#-2,56*($2)TF
M.BJV(<Q1 A^MZ)QZA*?J'JX;U]O7WNX F/'MVR VN,77; JX8EDQ%$PO/+#(
ME*5,52N45FHKF4*H*0D[Q-%P"8GZC%[LB@#'$9M8>^D#H7)62QR48FU!!J,P
M@N8IT'0*MUD!%/J,=2.EHQ8Q0=)<%Z"+"T42Y,98 ,4Q#2^MW/W73C?4NGGF
MO"X^DAE9A-TN3B9 %6LZ9DZ12Y#O"O"E(L5(YU$R)B1R<B9Q4 4$DQ*GWQNY
M*L1$N59BU*NR\O*W*K?^O/;$QI0VWB2L;1S:;0_2K$*H\>."IK)&5FGI.].'
M6V9&[I-!)0P@0KATL3DO4JF@NF =72<9GR=91DKQI?Z]C6 2KL&<K>/8%7,
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MQ"LR3RO2UUDLR6)G*5:M%M6658!=61@VSN:2KJ%4E'U3B4SVOZI3-7A^L7Y
M*T8Y%[-!HO7X>=IC&TUN%LR+A] IFW$,Z2B[MCG8M"94LE)41M4)D$*ZC'US
M=[.XR86^66L*#)*F)6^*>2:D+"&L6O(F5,:1=/[!9[N1M>VFSQ>/5<1U-I!S
MS#$.,:_)GIQ)VO1A;=6VCR(ODEDF%MD5(^N.X619JUF6%BHMC80:\>]:KSC1
M>QFE6S:V5:Q?OU^5R!<3V*WSSW:E]<=]^Y#D'2W^+X=T#T9]<0?P1  $1'@
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M^<-1](>D/2'HUT_CQX>X,??8:Q2LSO+L4>@0%5G&WO+:221B@8%3N$(1J"8
M("'4/?\ )!X'W8%\WG#H_CN9MW>9,VKZ_M\Q1;[(YO;2IPK->6<(/CS,6Q28
M.)-@Q5738KJJH$14\JE% .[,Y*)52LRHB4P*KB8&[RAQ+E[)B'&E_AV,!=*;
M7['&QRI56#>18I*&CSEZ1*JQ=%X=LUC='NU6ZR9S><QC#Y^;M/"DK@]U/'&"
MDTDGPEW5PU7F^"-+M@*I0>- JN,*PP@D8F3"<;Q<:0Q/5!QW"B#H%%#G.NY>
M'04 4CN%5#'%$$ $O63HTK;5IRU3OUNQR:WAJ$GG/EROO++"@+=0Z:A#I+)*
MBFH5=,R:J:A!Z3IG(8"F Q3!T](@!@$.!X'6C)>;M^Q_,V!)*=GD%D8)@JY4
MAU'292.7#LR!VO$<<Y5# R3 YUG*ABE26<I-T$RJ$(Z$<VK4;WYO-6;,Z+ON
M*^R1ABPN7CN8I<T*1%V+4KN'-T-5'3QFDL870+=14';Q02-6S51X( R!9RY'
MRD4F2+>*VL;\_/@KL/#EY\EM$Y<72:$A'VBOM9&0CV:\*2<AE"(J-I)D<ZII
M"92$Q1*(-HV6?K$>"D9K%$;*JIBZ<(-QWYP,&/[-&>;?6XL6SE^9XW65<"LW
M3;.05CU .@11-PL4BI5$TE722?NS]XW76,V5,HN!BDTH3\K7"[KE=@#'OD6U
MYBF8A&S1AFRD \5,6.F(N9C9)(7Z1.L6@+,'+M)E))$6(1:.D!:N>%>[4;F(
M8W3)[>?-,ZS4%M#3-<3'N@C+Y9K3$SK<Q@#A)E&E2,W-WC<IVSI%PH9$J@"9
M)4#D "FZ4.$AZ-%Y=[^*\&'Z1."D@_4 1,!WCHX"/'(@9<Y@$>/#D>>?#PU#
MNKEN78X>A3GQ48\FI2-AH\B2DA+/V<8Q37=-6*!WC]PFU;$6>OEFS)FD994@
M*.GCA!JW((JN%DD2'.4#8RM>VFW;5<#Y/9I;9-G^*)N1V0K1M]W(26ZV3O=C
MM2]XQ) 2]NIT!AIQFN99+Y'N<VJI!56>K5'>4-.VFC[!2WJU9/$O5.4RU+_R
MNB../G,%J/8'?/.\(_6QF/[D]OUNW^+X=T#T&S_E#?WIOXAUQ!CJ[3'!4;N=
MV?W?;U,3SVKQ>9+W@C'[^Q1K5!\_AFUCSMCABK(-&;E1)NY7;%4[Q-%90B9Q
M#@Q@#QU5[/LQ,5R:[F!1?YDEP,R15<NMX62T&[<AE5EUL?59-)),A>3G44/-
M 4A"AXF,80  Y]\-3A//RIIV[7_'BG\HA9O\S*;?GBICQFZ#+;YARHLA(DHM
M6%%6**<S<DL9-O).54&SAZF,>V;J@#P[H2B=LFUZG1.FQPT^)=3/K/"RNMW"
M?<RD8-[/5_MQQO7,:5_/=FD8BJ,5(EBYL>&O+I@K5J*KIPF[4C;FP34;PJ)R
M).G2;4&Z3;N ;J.SCK:;22I&_6CBM7O.-IRVXB=,?V2P7:W;I$JC)/,JC51;
ME%4CO"8,DTP[E-0BJHN\C)'-RHY8J " +'4;/F[TP"!N@$N+DXR<N_"F_CAB
M2%KQ6F_Q5T+ *K:G5DIE*GY S=%[/UR EG"+9,_<(OY*&:R"XHBN<H(@FZ54
M\F3.=8Q.HH]:BACG'=+_ (IPF7QXT(=]'RY$BGC')"D2.FLJV<"=4P)B*2/=
M]V7NQ'OCJ 8QCJG 4Q65.B*9")'TII1OCQGE0%OVXW+]BQG#5)_!."QB$C*/
MXZ;?JQ#2:,Q:-*TY=L!19NY",;-DG<X$6V=+N'3)$A5A237147;E5GE;EPC=
MG\"$8?,F8;A'-75<M-5%[<7$NE16DPA1ZY#-F%8C8=^^1F9*W6B*82$B=_-E
MK+1>N'!JA*LAD#A(IO$$B)NFFEU]]V_7D7R>VZ3ILLY%S3'+3])=S4.-WK\O
M6(:^UZ*AVDN%/0L4C*Q!FRZ]7>.SSDD@LE%E>L8QFV2AWKEJ4KN8.]319S]O
M]]_TQ')W/]P8M/:_,:6K+@05ROLY5WTS;),^1I^1FHF:C:Q)*R<HZG@</HMH
MHW,=L"14A604>1:,DJLR6?D3:J+CEV++<RZ[O.'7$Z>K:224)))79%_^/NR^
MVCXAF=LF=Z7DW,#NXV+*V,\AXUJUA<55W#R%):VVGE0>3\I'UR/0).MK&%AA
MW<1"OY)LZ;1B<DSD>Y$Q%)L)/&D>7%]6TZ/.&H\QP@WZ6G]?+]0W^:.N1H[?
M0&I*ZVY[?=S':.=L-2=QR(,*5&5''T_'WQFV!6Q8QGT$*>R87BO+E17627B_
M+3A)M.Z6:2\,H_BY!NX9N5$QU7^J5]>_T&XJS75WB;/LK[+,N/,7Y,;M9*.?
MM0L&.,CP0&7I65*,[,!HFWU.1*99%5%PB=(LG&"X5=PK\QFC@RR)FCUYT5J=
M'B@6IZT#-UE+<9L(R+1\YU]Z+US-71_+62@+>M:[1\+&V^+LN[V6JLA)H1:<
M;(,HL83(>-6K*,AW3*/2MTC7YFV1%CKM6N%>D>:5I-9<+J3YH"W*\R79[N-R
ML*?'U<@HC R6-<BH1YK!/[AK%6GN0UD[V?$4CF&.;P-9RK"G8@M2&F18G$,M
M;(%1VR*^@9F4:N)MHK?[1K.EVF *@&S=F["4Z#D2T2N6^XL:9Y4C F4W+1[2
M3O"..T4[''Y-6&ZQ#<T0^R\*KO$WL:S4?Y)C%,S7*$D:UJ$XD6YOOONIYC1
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M_P#7#?\ :+G2'2+KGUK?7G?R,JE)Q+\!(9N\;%%%ZR6X!=JN42B8AP 1 2B
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MS#1ZAD6@R!Y>I7J'93M:D5F;N-4>QK\G6V5592*+9ZT4, "!T'2"2R9@$IR
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M>(WM/3!9+IQ=."-*RK"UQ^^=W,P[PT,TAFB;9LF4O24 ,8 #DP\>(B/I$?\
MT#Z>[-F//."XNL)"8,=(@N-B*!RD5+$I*(]7')CE>H"(%Y\>>GD1XYX#D>.
MY#9BU6%7%N-.A<U4LIW*O5QC7XN1(@R24<]")6R1S"JY<*N%.3<=1CG54$0$
M/$/, CQJ2\L\?BOF-QSA>93KAQOI2\RGO=N>WK)3IG<K?1W*UKF8B +,/E+%
M;8=5T9E7HM@GW["-E8U-HX0617 4NZ I4A(F<H+ L8VL9<^]U+[ICE4*TU<_
M+RIV&R';$]333:UATQ<B=-0@EN]W5%P'(]384EK. B50#<%,B=)0JI4QZA3
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MIMVL^B^ /:'NRY^#M)_;HSE_2-IMVL^B^ /:'NRY^#M)_;HSE_2-IMVL^B^
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M_6[?XOAW0/0=UQ T T T T T T T T T T T T T T!YPO;)E*7M,]V8%
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MQO=I)-R\TG,M3K*IP! G8'?/.\(_6QF/[D]OUJW^+X=T#T'=<0- - - - -
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MNQ+'BXD$4[\4JW?.%4US+F9&3*'>.E"H#^2$OOP\NUY@JV:R!7*M#K$C\IY
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M2?KT : S)]@=\\[PC];&8_N3V_6;?XOAW0/0=UQ T T T T T T T T T T
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M$=JW"B.OT"U3\; 9B^%;C3[7EI_#>KZFG7Z _&P&8OA6XT^UY:?PWIZFG7Z
M_&P&8OA6XT^UY:?PWIZFG7Z _&P&8OA6XT^UY:?PWIZFG7Z _&P&8OA6XT^U
MY:?PWIZFG7Z _&P&8OA6XT^UY:?PWIZFG7Z _&P&8OA6XT^UY:?PWIZFG7Z
M_&P&8OA6XT^UY:?PWIZFG7Z _&P&8OA6XT^UY:?PWIZFG7Z _&P&8OA6XT^U
MY:?PWIZFG7Z!=KL5[!#)FT3=?A_<7.[AJ+<XK&<G87[RLQ-,GXN0E2S=+LE6
M33;/WDJX;-S(+3J;LYE43@=)N=,H <Y3!';E1'7Z!LW:P!H!H#C/$!=-5FX&
M @JDZ0,(<@'B \\!Y_-H"F/6PK^NT_X(W^]H!ZV%?UVG_!&_WM /6PK^NT_X
M(W^]H!ZV%?UVG_!&_P![0#UL*_KM/^"-_O: >MA7]=I_P1O][0#UL*_KM/\
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M(LD=8B8IE5()@,!V(3<W:?85N6E%^OT9J-<SH- - - - - :?_:O?HZ,N_\
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M7,9[[D9TJN$R4*KL=BJ1!/IS,=]GZNO1\=VK)64JK6JDQGK1#Q:&81PW0(R
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ML=YZB,6629E,B9"C\-Y L]^K5@H,.GC=B\GML-KR975ZK/*V64D9E]4WSF#
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M8>E):9QM;Y&KOIZ/&*F_)DF+UE+L/*4GI&\E%RC1]%O0;O$4G;11PS469.2
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+S>7UP.XT T!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6771356128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Mar. 14, 2017</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hsgx_DocumentAndEntityInformationAbstract', window );"><strong>Document And Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">HSGX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Histogenics Corporation<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001372299<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Smaller Reporting Company<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,168,090<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>State aggregate market value of voting and non-voting common equity held by non-affiliates computed by reference to price at which the common equity was last sold, or average bid and asked price of such common equity, as of the last business day of registrant's most recently completed second fiscal quarter. The public float should be reported on the cover page of the registrants form 10K.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hsgx_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Document and entity information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hsgx_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hsgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6771722112">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 31,908<span></span>
</td>
<td class="nump">$ 30,915<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">173<span></span>
</td>
<td class="nump">321<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">32,081<span></span>
</td>
<td class="nump">31,236<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">3,860<span></span>
</td>
<td class="nump">5,213<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible asset, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Restricted cash</a></td>
<td class="nump">137<span></span>
</td>
<td class="nump">137<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">36,078<span></span>
</td>
<td class="nump">36,786<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,588<span></span>
</td>
<td class="nump">2,024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableRelatedPartiesCurrent', window );">Accounts payable due to Intrexon Corporation</a></td>
<td class="nump">360<span></span>
</td>
<td class="nump">229<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">2,097<span></span>
</td>
<td class="nump">1,444<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Accrued expenses due to Intrexon Corporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,546<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditCurrent', window );">Current portion of deferred rent</a></td>
<td class="nump">136<span></span>
</td>
<td class="nump">126<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueLeasesCurrent', window );">Current portion of deferred lease incentive</a></td>
<td class="nump">407<span></span>
</td>
<td class="nump">407<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LoansPayableCurrent', window );">Current portion of equipment loan</a></td>
<td class="nump">583<span></span>
</td>
<td class="nump">583<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">5,171<span></span>
</td>
<td class="nump">6,359<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesNoncurrent', window );">Accrued expenses due to Intrexon Corporation</a></td>
<td class="nump">3,040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditNoncurrent', window );">Deferred rent, long-term</a></td>
<td class="nump">315<span></span>
</td>
<td class="nump">451<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncentiveFromLessor', window );">Deferred lease incentive, long-term</a></td>
<td class="nump">610<span></span>
</td>
<td class="nump">1,017<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermLoansPayable', window );">Equipment loan, long-term</a></td>
<td class="nump">178<span></span>
</td>
<td class="nump">761<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductWarrantyAccrualNoncurrent', window );">Warrant liability</a></td>
<td class="nump">13,197<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">22,511<span></span>
</td>
<td class="nump">8,588<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 7)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Convertible preferred stock and stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Convertible preferred stock, $0.01 par value; 30,000,000 shares authorized, 13,416.4734 and 0 shares issued and outstanding at December 31, 2016 and 2015, respectively</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.01 par value; 100,000,000 shares authorized, 20,647,612 and 13,273,470 shares issued and outstanding at December 31, 2016 and 2015, respectively</a></td>
<td class="nump">159<span></span>
</td>
<td class="nump">132<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">195,181<span></span>
</td>
<td class="nump">193,631<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(181,773)<span></span>
</td>
<td class="num">(165,565)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">13,567<span></span>
</td>
<td class="nump">28,198<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 36,078<span></span>
</td>
<td class="nump">$ 36,786<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount for accounts payable to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39622-107864<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6801-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3044-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14326-108349<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For a classified balance sheet, the cumulative difference as of the balance sheet date between the payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, within one year of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=7501430&amp;loc=d3e39927-112707<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentCreditCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For a classified balance sheet, the cumulative difference between the rental income or payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, more than one year after the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.26(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=7501430&amp;loc=d3e39927-112707<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentCreditNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueLeasesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents revenue received, but not recognized for financial reporting purposes, which is anticipated to be recognized for financial reporting purposes within one year of the reporting date or one operating cycle, if longer. Such deferred revenue may consist of and include amounts paid in advance by lessees and purchase price adjustments for leases acquired in a business combination or other transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueLeasesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Portion of the carrying amount as of the balance sheet date of obligations due all related parties that is payable after one year or beyond the normal operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.23)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncentiveFromLessor">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the deferred credit for an incentive or inducement received by a lessee from a lessor, in order to motivate the lessee to enter the lease agreement, which incentive or inducement is to be recognized as a reduction of rental expense over the lease term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Lease Incentive<br> -URI http://asc.fasb.org/extlink&amp;oid=6516590<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 55<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6584307&amp;loc=d3e41620-112719<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=7501430&amp;loc=d3e40010-112707<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7501430&amp;loc=d3e39896-112707<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncentiveFromLessor</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of portion of long-term loans payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermLoansPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermLoansPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductWarrantyAccrualNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and due after one year (or beyond the operating cycle if longer) for estimated claims under standard and extended warranty protection rights granted to customers.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14394-108349<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductWarrantyAccrualNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash and equivalents whose use in whole or in part is restricted for the long-term, generally by contractual agreements or regulatory requirements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6771449840">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Convertible preferred stock, shares authorized</a></td>
<td class="nump">30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">20,647,612<span></span>
</td>
<td class="nump">13,273,470<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">20,647,612<span></span>
</td>
<td class="nump">13,273,470<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=hsgx_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Convertible preferred stock, par value</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Convertible preferred stock, shares authorized</a></td>
<td class="nump">30,000,000<span></span>
</td>
<td class="nump">30,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Convertible preferred stock, shares issued</a></td>
<td class="nump">13,416.4734<span></span>
</td>
<td class="nump">0.0000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Convertible preferred stock, shares outstanding</a></td>
<td class="nump">13,416.4734<span></span>
</td>
<td class="nump">0.0000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=hsgx_SeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=hsgx_SeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6772582432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueNet', window );">Revenue</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">21,577<span></span>
</td>
<td class="nump">23,243<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">8,530<span></span>
</td>
<td class="nump">8,266<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Impairment of intangible asset</a></td>
<td class="nump">200<span></span>
</td>
<td class="nump">310<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">30,307<span></span>
</td>
<td class="nump">31,819<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(30,307)<span></span>
</td>
<td class="num">(31,819)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense, net</a></td>
<td class="num">(60)<span></span>
</td>
<td class="num">(133)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense, net</a></td>
<td class="num">(248)<span></span>
</td>
<td class="num">(72)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentOfWarrantsGrantedForServices', window );">Warrant expense</a></td>
<td class="num">(3,100)<span></span>
</td>
<td class="num">(11)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liability</a></td>
<td class="nump">17,507<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense), net</a></td>
<td class="nump">14,099<span></span>
</td>
<td class="num">(205)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(16,208)<span></span>
</td>
<td class="num">(32,024)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Loss attributable to common stockholders-basic</a></td>
<td class="num">(13,863)<span></span>
</td>
<td class="num">(32,024)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Loss attributable to common stockholders-diluted</a></td>
<td class="num">$ (31,370)<span></span>
</td>
<td class="num">$ (32,024)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Loss per common share-basic</a></td>
<td class="num">$ (0.97)<span></span>
</td>
<td class="num">$ (2.42)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Loss per common share-diluted</a></td>
<td class="num">$ (2.18)<span></span>
</td>
<td class="num">$ (2.42)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares used to compute loss per common share-basic</a></td>
<td class="nump">14,256,954<span></span>
</td>
<td class="nump">13,231,126<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares used to compute loss per common share-diluted</a></td>
<td class="nump">14,389,192<span></span>
</td>
<td class="nump">13,231,126<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentOfWarrantsGrantedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustment for noncash service expenses paid for by granting of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentOfWarrantsGrantedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=65016374&amp;loc=d3e4984-109258<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1252-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=6939902&amp;loc=d3e20148-110875<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net income after adjustments for dividends on preferred stock (declared in the period) and/or cumulative preferred stock (accumulated for the period).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1377-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net Income or Loss Available to Common Stockholders plus adjustments resulting from the assumption that dilutive convertible securities were converted, options or warrants were exercised, or that other shares were issued upon the satisfaction of certain conditions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1505-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1377-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1505-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Weighted-Average Number of Common Shares Outstanding<br> -URI http://asc.fasb.org/extlink&amp;oid=6528421<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6772540016">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Series A Convertible Preferred Stock [Member]</div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Accumulated Deficit [Member]</div></th>
<th class="th"><div>Restricted Stock [Member]</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Ending Balance at Dec. 31, 2015</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Dec. 31, 2014</a></td>
<td class="nump">$ 54,206<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 127<span></span>
</td>
<td class="nump">$ 187,620<span></span>
</td>
<td class="num">$ (133,541)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance, Shares at Dec. 31, 2014</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,746,519<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,493<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hsgx_StockIssuedDuringPeriodValueOverallotmentNetOfFeesAndIssuanceCosts', window );">Issuance of common stock from overallotment, net of underwriting fees and issuance costs of $377</a></td>
<td class="nump">4,738<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">4,733<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hsgx_StockIssuedDuringPeriodSharesOverallotmentNetOfFeesAndIssuanceCosts', window );">Issuance of common stock from overallotment, net of underwriting fees and issuance costs of $377, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">465,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Issuance of warrant as part of the consideration for the consulting related to financial support services in March 2015</a></td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Vesting of restricted stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Vesting of restricted stock, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,303<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,303)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">1,228<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,228<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of common stock options</a></td>
<td class="nump">39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of common stock options, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,458<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(32,024)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(32,024)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2015</a></td>
<td class="nump">28,198<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 132<span></span>
</td>
<td class="nump">193,631<span></span>
</td>
<td class="num">(165,565)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance, Shares at Dec. 31, 2015</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,268,280<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,190<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock related to private placement</a></td>
<td class="nump">26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock related to private placement, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,596,059<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hsgx_StockIssuedDuringPeriodPreferredStockValue', window );">Issuance of Series A convertible preferred stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hsgx_StockIssuedDuringPeriodSharesPreferredStock', window );">Issuance of Series A convertible preferred stock, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,159<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of Series A convertible preferred stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of Series A convertible preferred stock, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,743)<span></span>
</td>
<td class="nump">4,774,398<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Ending Balance at Dec. 31, 2016</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Ending Balance, Shares at Dec. 31, 2016</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,416<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Vesting of restricted stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Vesting of restricted stock, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,301<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,301)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">1,548<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,548<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of common stock options</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of common stock options, Shares</a></td>
<td class="nump">3,685<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,685<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (16,208)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16,208)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2016</a></td>
<td class="nump">$ 13,567<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 159<span></span>
</td>
<td class="nump">$ 195,181<span></span>
</td>
<td class="num">$ (181,773)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance, Shares at Dec. 31, 2016</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,645,723<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,889<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hsgx_StockIssuedDuringPeriodPreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period preferred stock value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hsgx_StockIssuedDuringPeriodPreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hsgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hsgx_StockIssuedDuringPeriodSharesOverallotmentNetOfFeesAndIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period Shares Overallotment Net Of Fees And Issuance Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hsgx_StockIssuedDuringPeriodSharesOverallotmentNetOfFeesAndIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hsgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hsgx_StockIssuedDuringPeriodSharesPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period Shares Preferred Stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hsgx_StockIssuedDuringPeriodSharesPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hsgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hsgx_StockIssuedDuringPeriodValueOverallotmentNetOfFeesAndIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period Value Overallotment Net Of Fees And Issuance Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hsgx_StockIssuedDuringPeriodValueOverallotmentNetOfFeesAndIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hsgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of recognized equity-based compensation during the period, that is, the amount recognized as expense in the income statement (or as asset if compensation is capitalized). Alternate captions include the words "stock-based compensation".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=66904339&amp;loc=d3e4534-113899<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=65896087&amp;loc=d3e11149-113907<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=65896087&amp;loc=d3e11178-113907<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=28183637&amp;loc=d3e4724-112606<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Warrant<br> -URI http://asc.fasb.org/extlink&amp;oid=6528364<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=hsgx_SeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=hsgx_SeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6770550832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Issuance of common stock, net issuance costs</a></td>
<td class="nump">$ 377<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">0.01<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=hsgx_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Temporary equity, par value</a></td>
<td class="nump">0.01<span></span>
</td>
<td class="nump">0.01<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65877616&amp;loc=d3e177068-122764<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=hsgx_SeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=hsgx_SeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6771510496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (16,208)<span></span>
</td>
<td class="num">$ (32,024)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">1,673<span></span>
</td>
<td class="nump">1,614<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hsgx_DeferredRentAndLeaseIncentive', window );">Deferred rent and lease incentive</a></td>
<td class="num">(533)<span></span>
</td>
<td class="num">(322)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Impairment of intangible asset</a></td>
<td class="nump">200<span></span>
</td>
<td class="nump">310<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">1,548<span></span>
</td>
<td class="nump">1,228<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant</a></td>
<td class="num">(17,507)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentOfWarrantsGrantedForServices', window );">Warrant expense in connection with private placement</a></td>
<td class="nump">3,100<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">148<span></span>
</td>
<td class="nump">475<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent', window );">Accrued expenses due to Intrexon Corporation</a></td>
<td class="nump">1,494<span></span>
</td>
<td class="nump">1,539<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(435)<span></span>
</td>
<td class="num">(2,844)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties', window );">Accounts payable due to Intrexon Corporation</a></td>
<td class="nump">131<span></span>
</td>
<td class="nump">211<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">653<span></span>
</td>
<td class="num">(232)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations', window );">Net cash used in operating activities</a></td>
<td class="num">(25,736)<span></span>
</td>
<td class="num">(30,034)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(320)<span></span>
</td>
<td class="num">(1,949)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations', window );">Net cash used in investing activities</a></td>
<td class="num">(320)<span></span>
</td>
<td class="num">(1,949)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants', window );">Proceeds from issuance of common stock, preferred stock, and warrants in connection with private placement, net of issuance costs</a></td>
<td class="nump">27,630<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from overallotment, net of issuance costs of $377</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,738<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayments on equipment term loan</a></td>
<td class="num">(583)<span></span>
</td>
<td class="num">(406)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">39<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations', window );">Net cash provided by financing activities</a></td>
<td class="nump">27,049<span></span>
</td>
<td class="nump">4,371<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="nump">993<span></span>
</td>
<td class="num">(27,612)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents-Beginning of period</a></td>
<td class="nump">30,915<span></span>
</td>
<td class="nump">58,527<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents-End of period</a></td>
<td class="nump">31,908<span></span>
</td>
<td class="nump">30,915<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental Disclosure of Non-Cash Items:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hsgx_FairMarketValueOfPrivatePlacementWarrantsAtIssuance', window );">Fair market value of private placement warrants at issuance</a></td>
<td class="nump">30,704<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental Disclosure of Cash Flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Cash paid for taxes</a></td>
<td class="nump">257<span></span>
</td>
<td class="nump">79<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">$ 66<span></span>
</td>
<td class="nump">$ 94<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hsgx_DeferredRentAndLeaseIncentive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred rent and lease incentive.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hsgx_DeferredRentAndLeaseIncentive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hsgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hsgx_FairMarketValueOfPrivatePlacementWarrantsAtIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair market value of private placement warrants at issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hsgx_FairMarketValueOfPrivatePlacementWarrantsAtIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hsgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentOfWarrantsGrantedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustment for noncash service expenses paid for by granting of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentOfWarrantsGrantedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3044-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49171198&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=6939902&amp;loc=d3e20148-110875<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the obligations due for goods and services provided by the following types of related parties: a parent company and its subsidiaries, subsidiaries of a common parent, an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management, an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations to be paid to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management; an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for interest during the period net of cash paid for interest that is capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3574-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3574-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholder, which takes precedence over common stockholders in the event of liquidation and from issuance of rights to purchase common shares at a predetermined price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (j)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3255-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6762062928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows (Parenthetical)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfCashFlowsAbstract', window );"><strong>Statement of Cash Flows [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Issuance costs</a></td>
<td class="nump">$ 377<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfCashFlowsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfCashFlowsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6929165840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Nature of Business</a></td>
<td class="text"><div>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="break-inside: avoid">
 <td valign="top" width="4%" align="left"><b>1.</b></td>
 <td valign="top" align="left"><b>NATURE OF BUSINESS</b></td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="break-inside: avoid">
 <td valign="top" width="4%" align="left"><b>Organization</b></td>
 <td valign="top" align="left"></td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 Histogenics Corporation (the &#x201C;Company&#x201D;) was
 incorporated under the laws of the Commonwealth of Massachusetts on
 June&#xA0;28, 2000 and has its principal operations in Waltham,
 Massachusetts. In 2006, the Company&#x2019;s board of directors
 approved a corporate reorganization pursuant to which the Company
 incorporated as a Delaware corporation. The Company is a
 regenerative medicine company engaged in developing and
 commercializing products in the musculoskeletal segment of the
 marketplace. The Company combines cell therapy and tissue
 engineering technologies to develop products for tissue repair and
 regeneration and is initially focused on patients suffering from
 cartilage-derived pain and immobility. The Company&#x2019;s most
 advanced product, NeoCart, is currently in a Phase 3 clinical trial
 in the United States (the &#x201C;U.S.&#x201D;) under a special
 protocol assessment with the U.S. Food and Drug Administration
 (&#x201C;FDA&#x201D;) for the treatment of knee cartilage damage.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 On May&#xA0;13, 2011, the Company completed the acquisition of
 ProChon Biotech Ltd. (&#x201C;ProChon&#x201D;), a privately-held
 biotechnology company focused on modulating the fibroblast growth
 factor system for consideration of $2.2 million to enable it to
 create more effective solutions for tissue regeneration.
 ProChon&#x2019;s products combine cell regeneration technologies
 with proprietary growth factors and biocompatible scaffolds to
 restore injured or chronically damaged tissues. The acquisition of
 ProChon provided the Company with access to a significant portfolio
 of intellectual property, including proprietary cell growth
 factors, in addition to furthering opportunities for the use of
 biomaterials to create more effective solutions for regenerating
 human tissue. The acquisition led to the initial recognition of
 goodwill, which was subsequently written off in 2011, and
 intangible assets including IPR&amp;D and a licensing agreement
 which have been impaired as discussed in Note 2.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 On December&#xA0;18, 2014, the Company formed a wholly owned
 subsidiary, Histogenics Securities Corporation, under the laws of
 the Commonwealth of Massachusetts.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 On September&#xA0;29, 2016, the Company closed a private placement
 of common stock, preferred stock and warrants, contemplated by a
 securities purchase agreement dated September&#xA0;15, 2016, with
 certain institutional and accredited investors. The net proceeds
 after deducting placement agent fees and other transaction-related
 expenses was $27.6 million. See Note 8, Capital Stock, for further
 discussion of the private placement.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 Since its inception, the Company has devoted substantially all of
 its efforts to product development, recruiting management and
 technical staff, raising capital, starting up production and
 building infrastructure and has not yet generated revenues from its
 planned principal operations. Expenses have primarily been for
 research and development and related administrative costs.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 The Company is subject to a number of risks. The developmental
 nature of its activities is such that significant inherent risks
 exist in the Company&#x2019;s operations. Principal among these
 risks are the successful development of therapeutics, successfully
 enrolling patients in its clinical trials in a timely manner,
 obtaining regulatory approval for any of its product candidates in
 any jurisdiction, compliance with government regulations, ability
 to obtain adequate financing, protection of proprietary
 therapeutics, fluctuations in operating results, dependence on key
 personnel and collaborative partners, adoption of the
 Company&#x2019;s products by the physician community, rapid
 technological changes inherent in the markets targeted, and
 substitute products and competition from larger companies.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">

 The consolidated financial statements have been prepared on a
 going-concern basis, which contemplates the realization of assets
 and the satisfaction of liabilities in the normal course of
 business. As shown in the accompanying consolidated financial
 statements, the Company has incurred losses and cash flow deficits
 from operations for the years ended December&#xA0;31, 2016 and
 2015. The Company has financed operations to date primarily through
 private placements of equity securities, including the sale of
 common stock and preferred stock, and the related issuance of
 warrants in September 2016, the issuance of common stock in the
 initial public offering completed in December 2014, and borrowings
 under debt agreements. The Company has incurred losses and negative
 cash flows from operations since inception resulting in an
 accumulated deficit at December&#xA0;31, 2016 of $181.8 million.
 The Company anticipates that it will continue to incur net losses
 for the next several years. The Company believes that its existing
 cash and cash equivalents will be sufficient to fund its projected
 cash needs into the middle of 2018, and it has the ability to
 reduce or defer operating expenses as may be needed to fund its
 operations into the middle of the third quarter of 2018. The
 Company will require additional capital to complete the filing of a
 biologics license application with the FDA and commercialize
 NeoCart, if approved, and for the future development of its
 existing product candidates. However, the terms of such financing
 may not be on favorable terms or available to the
 Company.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 <b>Initial public offering</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 On December&#xA0;3, 2014, the Company completed its initial public
 offering (&#x201C;IPO&#x201D;) whereby the Company sold 5,909,091
 shares of common stock at a price of $11.00 per share. The shares
 began trading on the Nasdaq Global Market on December&#xA0;3, 2014.
 Gross proceeds from the offering were $65 million. In January 2015,
 the underwriters exercised a portion of their overallotment option
 and purchased an additional 465,000 shares of the Company&#x2019;s
 common stock at $11.00 per share, resulting in an additional $5.1
 million in gross proceeds. After giving effect to underwriting
 discounts and commissions and offering expenses payable by the
 Company, net proceeds were $61.3 million.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 18pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 &#xA0;</p>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6003-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=SL51803626-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6762117296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><div>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="break-inside: avoid">
 <td valign="top" width="4%" align="left"><b>2.</b></td>
 <td valign="top" align="left"><b>SUMMARY OF SIGNIFICANT ACCOUNTING
 POLICIES</b></td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 <b>Basis of Accounting</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 The consolidated financial statements are prepared in conformity
 with accounting principles generally accepted in the United States
 of America (&#x201C;U.S. GAAP&#x201D;). The consolidated financial
 statements include the accounts of Histogenics Corporation and its
 wholly-owned subsidiaries, ProChon and Histogenics Securities
 Corporation. All significant intercompany accounts and transactions
 are eliminated in consolidation.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 <b>Reclassifications</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 The Company has reclassified certain prior period amounts to
 conform to the current period presentation. The amounts
 reclassified impact Accounts Payable and Accounts Payable due to
 Intrexon Corporation (&#x201C;Intrexon&#x201D;) for the year ended
 December&#xA0;31, 2015.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 <b>Use of Estimates</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 The preparation of the Company&#x2019;s consolidated financial
 statements requires it to make estimates and assumptions that
 impact the reported amounts of assets, liabilities, revenues and
 expenses and the disclosure of contingent assets and liabilities in
 the Company&#x2019;s consolidated financial statements and
 accompanying notes. The most significant estimates in the
 Company&#x2019;s consolidated financial statements relate to the
 valuation of equity awards, warrant liability, recoverability of
 deferred tax assets, estimated useful lives of fixed assets and
 intangible assets. The Company bases estimates and assumptions on
 historical experience when available and on various factors that it
 believes to be reasonable under the circumstances. The Company
 evaluates its estimates and assumptions on an ongoing basis. The
 Company&#x2019;s actual results may differ from these estimates
 under different assumptions or conditions.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 18pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 <b>Foreign Currency Translation</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 The Company&#x2019;s consolidated financial statements are prepared
 in U.S. dollars. The Company&#x2019;s foreign subsidiary uses the
 U.S. dollar as its functional and reporting currency, as management
 determined that the U.S. dollar is the primary currency of the
 economic environment in which the subsidiary operates. When
 transactions are required to be paid in the local currency of the
 foreign subsidiary, any resulting foreign currency transaction gain
 or loss is recorded as a component of &#x201C;Other income
 (expense), net&#x201D; in the consolidated statements of
 operations.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 <b>Segment and Geographic Information</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 Operating segments are defined as components of an enterprise about
 which separate discrete financial information is available for
 evaluation by the chief operating decision-maker
 (&#x201C;CODM&#x201D;) or decision-making group in making decisions
 regarding resource allocation and assessing performance. The
 Company operates in two geographic regions: the United States
 (Massachusetts) and Israel (Tel Aviv) and views its operations as
 two operating segments: Histogenics Corporation (United States) and
 ProChon (Israel) as the CODM reviews separate discrete financial
 information in making decisions regarding resource allocations and
 assessing performance. Operating segments that have similar
 economic characteristics can be aggregated. As the nature of the
 products, customers, and methods to distribute products are the
 same and the nature of the regulatory environment, the production
 processes and historical and estimated future margins are similar,
 the two operating segments have been aggregated into one reporting
 segment as they have similar economic characteristics.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 Information about the Company&#x2019;s operations in different
 geographic regions is presented in the tables below:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="66%"></td>
 <td valign="bottom" width="11%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="11%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>December&#xA0;31,<br />
 2016</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>December&#xA0;31,<br />
 2015</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="6" align="center"><b>(in
 thousands)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Long-lived assets:</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 United States</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">3,860</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">5,204</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Israel</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">9</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Total long-lived assets</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">3,860</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">5,213</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 <b>Fair Value Measurements</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 The carrying amounts reported in the Company&#x2019;s consolidated
 financial statements for cash and cash equivalents, accounts
 payable, equipment loan, and accrued liabilities approximate their
 respective fair values because of the short-term nature of these
 accounts.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 Fair value is defined as the price that would be received if
 selling an asset or paid to transfer a liability in the principal
 or most advantageous market for the asset or liability in an
 orderly transaction between market participants on the measurement
 date.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 Fair value should be based on the assumptions that market
 participants would use when pricing an asset or liability and is
 based on a fair value hierarchy that prioritizes the information
 used to develop those assumptions. The fair value hierarchy gives
 the highest priority to quoted prices in active markets (observable
 inputs) and the lowest priority to the Company&#x2019;s assumptions
 (unobservable inputs). Fair value measurements should be disclosed
 separately by level within the fair value hierarchy. For assets and
 liabilities recorded at fair value, it is the Company&#x2019;s
 policy to maximize the use of observable inputs and minimize the
 use of unobservable inputs when developing fair value measurements,
 in accordance with established fair value hierarchy.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 Fair value measurements for assets and liabilities where there
 exists limited or no observable market data are based primarily
 upon estimates, and often are calculated based on the economic and
 competitive environment, the characteristics of the asset or
 liability and other factors. Therefore, the results cannot be
 determined with precision and may not be realized in an actual sale
 or immediate settlement of the asset or liability. Additionally,
 there may be inherent weaknesses in any valuation technique, and
 changes in the underlying assumptions used, including discount
 rates and estimates of future cash flows, could significantly
 affect the results of current or future values.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 Additionally, from time to time, the Company may be required to
 record at fair value other assets on a nonrecurring basis, such as
 assets held for sale and certain other assets. These nonrecurring
 fair value adjustments typically involve application of
 lower-of-cost-or-market accounting or write-downs of individual
 assets.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 The fair value hierarchy gives the highest priority to unadjusted
 quoted prices in active markets for identical assets (Level 1), and
 the lowest priority to unobservable inputs (Level 3). The
 Company&#x2019;s financial assets are classified within the fair
 value hierarchy based on the lowest level of inputs that is
 significant to the fair value measurement. The three levels of the
 fair value hierarchy, and its applicability to the Company&#x2019;s
 financial assets, are described below.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 62px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 <i>Level 1</i>: Unadjusted quoted prices in active markets that are
 accessible at the measurement date of identical, unrestricted
 assets.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 62px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 <i>Level 2</i>: Quoted prices for similar assets, or inputs that
 are observable, either directly or indirectly, for substantially
 the full term through corroboration with observable market data.
 Level 2 includes investments valued at quoted prices adjusted for
 legal or contractual restrictions specific to the security.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 62px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 <i>Level 3</i>: Pricing inputs are unobservable for the assets,
 that is, inputs that reflect the reporting entity&#x2019;s own
 assumptions about the assumptions market participants would use in
 pricing the assets. Level 3 includes private investments that are
 supported by little or no market activity.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 Level 3 valuations are for instruments that are not traded in
 active markets or are subject to transfer restrictions and may be
 adjusted to reflect illiquidity and/or non-transferability, with
 such adjustment generally based on available market evidence. In
 the absence of such evidence, management&#x2019;s best estimate is
 used.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 An adjustment to the pricing method used within either Level 1 or
 Level 2 inputs could generate a fair value measurement that
 effectively falls in a lower level in the hierarchy. The Company
 had no assets or liabilities classified as Level 1 or Level 2 as of
 December&#xA0;31, 2016 and 2015 other than the money market fund
 described in the &#x201C;Cash and Cash Equivalents&#x201D; section
 below and there were no material re-measurements of fair value with
 respect to financial assets and liabilities, during the periods
 presented, other than those assets and liabilities that are
 measured at fair value on a recurring basis. Other than the
 warrants issued in connection with the private placement
 transaction which closed on September&#xA0;29, 2016, the Company
 had no assets or liabilities classified as Level 3 as of
 December&#xA0;31, 2016 and 2015.&#xA0;Transfers are calculated on
 values as of the transfer date. There were no transfers between
 Levels 1, 2 and 3 during the twelve months ended December&#xA0;31,
 2016 and 2015.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 The fair value of the warrants was determined using a Monte Carlo
 simulation model.&#xA0;This model incorporated several assumptions
 at each valuation date including: the price of the Company&#x2019;s
 common stock on the date of valuation, the historical volatility of
 the price of the Company&#x2019;s common stock, the remaining
 contractual term of the warrant and estimates of the probability of
 a fundamental transaction occurring. See Note 8, Capital Stock, for
 further discussion of the private placement.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="92%" align="center" border="0">
 <tr>
 <td width="46%"></td>
 <td valign="bottom" width="9%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="9%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="9%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="9%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom" nowrap="nowrap">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; WIDTH: 39.5pt; BORDER-BOTTOM: rgb(0,0,0) 1pt solid; MARGIN-TOP: 0pt">
 <b>Description</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Total</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Quoted</b><br />
 <b>prices in</b><br />
 <b>active&#xA0;markets</b><br />
 <b>(Level 1)</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Significant</b><br />
 <b>other</b><br />
 <b>observable&#xA0;inputs</b><br />
 <b>(Level 2)</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Significant</b><br />
 <b>unobservable</b><br />
 <b>inputs</b><br />
 <b>(Level 3)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="14" align="center"><b>(in
 thousands)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 <b>December&#xA0;31, 2016</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 <b>Assets:</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Money market funds</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">30,318</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">30,318</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 <b>Liabilities:</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Warrant liability</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">13,197</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">13,197</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 <b>December&#xA0;31, 2015</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Money market funds</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">25,764</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">25,764</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 The following table provides a reconciliation of all liabilities
 measured at fair value using Level 3 significant unobservable
 inputs:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="68%" align="center" border="0">
 <tr>
 <td width="67%"></td>
 <td valign="bottom" width="25%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">
 <b>As&#xA0;of&#xA0;December&#xA0;31,&#xA0;2016</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center"><b>(in
 thousands)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Beginning balance, January&#xA0;1, 2016</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Issuance of warrants,</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">30,704</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Change in fair value of warrant liability</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(17,507</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Ending balance</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">13,197</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 <b>Cash and Cash Equivalents</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 Cash and cash equivalents include cash in readily available
 checking and savings accounts and money market funds. The Company
 considers all highly liquid investments with an original maturity
 of three months or less from the date of purchase to be cash
 equivalents.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 The Company&#x2019;s cash equivalents, which consist of money market
 funds, are measured at fair value on a recurring basis. As of
 December&#xA0;31, 2016 and 2015, the carrying amount of cash and
 cash equivalents was $31.9 million and $30.9 million, respectively,
 which approximates fair value and was determined based upon Level 1
 inputs. Money market funds are valued using quoted market prices
 with no valuation adjustments applied. Accordingly, these
 securities are categorized as Level 1 and had a balance of $30.3
 million and $25.8 million as of December&#xA0;31, 2016 and 2015,
 respectively, shown in the table above.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 <b>Concentration of Credit Risk</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 Financial instruments, which potentially subject the Company to
 significant concentration of credit risk, consist primarily of cash
 and cash equivalents. The Company maintains deposits in federally
 insured financial institutions in excess of federally insured
 limits. The Company has not experienced any losses in such accounts
 and management believes that the Company is not exposed to
 significant credit risk due to the financial position of the
 depository institutions in which those deposits are held. The
 Company has no financial instruments with off-balance sheet risk of
 loss.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 18pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 <b>Property and Equipment</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 Property and equipment are recorded at historical cost. Costs for
 capital assets not yet placed into service are capitalized as
 construction in progress, and will be depreciated in accordance
 with the below guidelines once placed into service. Maintenance and
 repair costs are expensed as incurred. Costs which materially
 improve or extend the lives of existing assets are capitalized. The
 Company provides for depreciation and amortization using the
 straight-line method over the estimated useful lives of the assets,
 which are as follows:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="32%"></td>
 <td valign="bottom" width="5%"></td>
 <td width="63%"></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" nowrap="nowrap">
 <p style="MARGIN-BOTTOM: 1pt; FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-TOP: 0pt">
 Asset Category</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom">
 <p style="MARGIN-BOTTOM: 1pt; FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-TOP: 0pt">
 Estimated Useful Lives</p>
 </td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Office equipment</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">3 to 5 years</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Laboratory equipment</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">3 to 5 years</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Leasehold improvements</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">Shorter of the remaining lease term or useful
 life</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 Upon retirement or sale, the cost of assets disposed and the
 related accumulated depreciation are removed from the accounts and
 any resulting gain or loss is recorded in the consolidated
 statements of operations.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 <b>Impairment of Long-Lived Assets</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 Long-lived assets consist primarily of property and equipment and
 identifiable intangible assets. When impairment indicators exist,
 the Company&#x2019;s management evaluates long-lived assets for
 potential impairment. An impairment loss is recorded if and when
 events and circumstances indicate that assets might be impaired and
 the undiscounted cash flows estimated to be generated by those
 assets are less than the carrying amount of those assets. While the
 Company&#x2019;s current and historical operating losses and
 negative cash flows are indicators of impairment, management
 believes that future cash flows to be received support the carrying
 value of its long-lived assets.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 Impairments, if any, are recognized in earnings. An impairment loss
 would be recognized in an amount equal to the excess of the
 carrying amount over the undiscounted expected future cash
 flows.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 <b>Intangible Asset</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 The Company&#x2019;s intangible asset consists of acquired
 in-process research and development (&#x201C;IPR&amp;D&#x201D;)
 obtained through the acquisition of ProChon. IPR&amp;D represents
 the fair value assigned to research and development assets that
 have not been completed at the date of acquisition. The value
 assigned to acquired IPR&amp;D is determined by estimating the
 costs to develop the acquired technology into commercially viable
 products, estimating the resulting revenue from the projects, and
 discounting the net cash flows to present value. The revenue and
 costs projections used to value acquired IPR&amp;D were adjusted
 based on the probability of success of developing a new product.
 Additionally, the projections considered the relevant market sizes
 and growth factors, expected trends in technology and the nature
 and expected timing of new product introductions by the Company and
 its competitors. The rates utilized to discount the net cash flows
 to their present value were commensurate with the stage of
 development of the projects and uncertainties in the economic
 estimates used in the projections described above.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 IPR&amp;D is considered an indefinite-lived intangible asset and is
 assessed for impairment annually or more frequently if impairment
 indicators exist. When performing the impairment assessment, the
 Company first assesses qualitative factors to determine whether it
 is necessary to recalculate the fair value of its acquired
 IPR&amp;D. If the Company believes, as a result of the qualitative
 assessment, that it is more likely than not that the fair value of
 acquired IPR&amp;D is less than its carrying amount, it calculates
 the fair value using the same methodology as described above. If
 the carrying value of the Company&#x2019;s acquired IPR&amp;D
 exceeds its fair value, then an impairment charge is taken and the
 intangible asset is written-down to its fair value. During the
 fourth quarter the Company deemed the value of the IPR&amp;D to be
 zero for the year ended December&#xA0;31, 2016 as it has no plans
 to advance the technology or use it in any future clinical
 development activities. The result was a write-off of $0.2 million.
 For the year ended December&#xA0;31, 2015, the Company determined
 that there was impairment of its IPR&amp;D of $0.3 million. The
 Company performed its annual impairment test of its IPR&amp;D as of
 December&#xA0;31, 2015 using an income approach, including a
 discount rate of 13%, applied to probability-adjusted after-tax
 cash flows. The Company believes that the assumptions are
 representative of those a market participant would use in
 estimating the fair value of the IPR&amp;D.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 Intangible asset, net of accumulated impairment charges, are
 summarized as follows:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 &#xA0;</p>
 <table style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" align="center" border="0">
 <tr>
 <td width="50%"></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="10" align="center"><b>As of
 December&#xA0;31,&#xA0;2016</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="10" align="center"><b>As of December&#xA0;31,
 2015</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Cost</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Accumulated</b><br />
 <b>Impairment</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Net&#xA0;Book</b><br />
 <b>Value</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Cost</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Accumulated</b><br />
 <b>Impairment</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Net&#xA0;Book</b><br />
 <b>Value</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="10" align="center"><b>(in
 thousands)</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="10" align="center"><b>(in
 thousands)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 IPR&amp;D</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">630</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(630</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">630</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(430</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">200</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">630</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(630</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">630</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(430</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">200</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 <b>Initial Public Offering Costs</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 The Company deferred direct incremental costs attributable with the
 IPO of its common stock prior to the closing of the IPO. These
 costs represent legal, accounting and other direct costs related to
 the Company&#x2019;s efforts to raise capital through a public sale
 of its common stock. Upon completion of the IPO, $3.9 million of
 IPO costs were reclassified to additional paid-in capital as a
 reduction of the IPO proceeds. As of December&#xA0;31, 2014, the
 Company had paid $2.9 million with the remaining $1.0 million
 included in accounts payable in the consolidated balance sheet.
 This amount was subsequently paid in 2015.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 <b>Restricted Cash</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 Restricted cash represents cash held in a depository account at a
 financial institution to collateralize a conditional stand-by
 letter of credit related to the Company&#x2019;s Lexington,
 Massachusetts facility lease agreement. Restricted cash is reported
 as non-current unless the restrictions are expected to be released
 in the next twelve months.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 <b>Deferred Rent</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 Deferred rent consists of the difference between cash payments and
 the recognition of rent expense on a straight-line basis for the
 facilities the Company occupies. The Company&#x2019;s leases for its
 Waltham, Massachusetts facility and its Lexington, Massachusetts
 facility provide for fixed increases in minimum annual rental
 payments. The total amount of rental payments due over each lease
 term is being charged to rent expense ratably over the life of each
 lease, respectively.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 <b>Financial Instruments Indexed to and Potentially Settled in the
 Company&#x2019;s Common Stock</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 The Company evaluates all financial instruments issued in
 connection with its equity offerings when determining the proper
 accounting treatment for such instruments in the Company&#x2019;s
 financial statements. The Company considers a number of generally
 accepted accounting principles under U.S. GAAP to determine such
 treatment and evaluates the features of the instrument to determine
 the appropriate accounting treatment. The Company utilizes the
 Probability Weighted Expected Return Method (&#x201C;PWERM&#x201D;),
 Option Pricing Model (&#x201C;OM&#x201D;) or other appropriate
 methods to determine the fair value of its derivative financial
 instruments. For financial instruments indexed to and potentially
 settled in the Company&#x2019;s common stock that are determined to
 be classified as liabilities on the consolidated balance sheet,
 changes in fair value are recorded as a gain or loss in the
 Company&#x2019;s consolidated statement of operations with the
 corresponding amount recorded as an adjustment to the liability on
 its consolidated balance sheet.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 <b>Revenue Recognition</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 In the future, if we generate revenue, it may be through license
 agreements, collaborations and product sales. The Company
 recognizes revenue when all four of the following criteria are met:
 (1)&#xA0;persuasive evidence that an agreement exists;
 (2)&#xA0;delivery of the products and/or services has occurred;
 (3)&#xA0;the selling price is fixed or determinable; and
 (4)&#xA0;collectability is reasonably assured. The Company did not
 recognize any revenue for the years ended December&#xA0;31, 2016
 and 2015.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 <b>Research and Development Costs</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 Research and development costs are charged to expense as incurred.
 These costs include, but are not limited to: license fees related
 to the acquisition of in-licensed products; employee-related
 expenses, including salaries, benefits and travel; expenses
 incurred under agreements with contract research organizations and
 investigative sites that conduct clinical trials and preclinical
 studies; the cost of acquiring, developing and manufacturing
 clinical trial materials; facilities, depreciation and other
 expenses, which include direct and allocated expenses for rent and
 maintenance of facilities; insurance and other supplies; and costs
 associated with preclinical activities and regulatory
 operations.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 Costs for certain development activities, such as clinical trials,
 are recognized based on an evaluation of the progress to completion
 of specific tasks using data such as patient enrollment, clinical
 site activations, or information provided to the Company by its
 vendors with respect to their actual costs incurred. Payments for
 these activities are based on the terms of the individual
 arrangements, which may differ from the pattern of costs incurred,
 and are reflected in the consolidated financial statements as
 prepaid or accrued research and development expense.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 <i>Collaboration Arrangements</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 Costs reimbursed to a collaborator for work that it performs are
 recorded as research and development expenses. These reimbursements
 can include payments for work performed, or a milestone for which a
 payment is due, the reimbursements or development milestone
 achievement are recorded as research and development expense.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 In September 2014, the Company entered into a collaboration
 agreement with Intrexon Corporation (&#x201C;Intrexon&#x201D;) for
 the development and commercialization of allogeneic cell
 therapeutics for the treatment or repair of damaged articular
 hyaline cartilage in humans, utilizing Intrexon&#x2019;s proprietary
 technology (the &#x201C;Collaboration Agreement&#x201D;). Under the
 terms of the Collaboration Agreement, the Company is responsible
 for the costs of development and commercialization, with some
 exceptions. Refer to Note 14,&#xA0;<i>Related
 Parties</i>&#xA0;for
 further details on all terms, conditions and exceptions of this
 collaboration.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 <b>License Agreements</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 Costs associated with licenses of technology are expensed as
 incurred and are included in research and development expenses.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 18pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 <b>Patent Costs</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 Costs related to filing and pursuing patent applications are
 recorded as general and administrative expense as incurred since
 the recoverability of such expenditures is uncertain.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 <b>Stock-Based Compensation</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 The Company accounts for grants of stock options and restricted
 stock based on their grant date fair value and recognizes
 compensation expense over their vesting period. The Company
 estimates the fair value of stock options as of the date of grant
 using the Black-Scholes option pricing model and restricted stock
 based on the fair value of the underlying common stock as
 determined by management or the value of the services provided,
 whichever is more readily determinable.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 Stock-based compensation expense represents the cost of the grant
 date fair value of employee stock option grants recognized over the
 requisite service period of the awards (usually the vesting period)
 on a straight-line basis, net of estimated forfeitures. The expense
 is adjusted for actual forfeitures at year end. Stock-based
 compensation expense recognized in the consolidated financial
 statements is based on awards that are ultimately expected to
 vest.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 For stock option grants with performance-based milestones, the
 expense is recorded over the remaining service period after the
 point when the achievement of the milestone is probable or the
 performance condition has been achieved. For stock option grants
 with both performance-based milestones and market conditions,
 expense is recorded over the derived service period after the point
 when the achievement of the performance-based milestone is probable
 or the performance condition has been achieved. The Company issued
 performance-based awards in 2015, but not in 2016.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 The Company accounts for stock options and restricted stock awards
 to non-employees using the fair value approach. Stock options and
 restricted stock awards to non-employees are subject to periodic
 revaluation over their vesting terms.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 <b>Income Taxes</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 The Company accounts for income taxes under the liability method,
 which requires the recognition of deferred tax assets and
 liabilities for the expected future tax consequences of events that
 have been included in the financial statements. Under this method,
 deferred tax assets and liabilities are determined on the basis of
 the differences between the financial statements and tax basis of
 assets and liabilities using enacted tax rates in effect for the
 year in which the differences are expected to reverse. The effect
 of a change in tax rates on deferred tax assets and liabilities is
 recognized in income in the period that includes the enactment
 date.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 The Company recognizes net deferred tax assets to the extent that
 the Company believes these assets are more likely than not to be
 realized. In making such a determination, management considers all
 available positive and negative evidence, including future
 reversals of existing taxable temporary differences, projected
 future taxable income, tax-planning strategies, and results of
 recent operations. If management determines that the Company would
 be able to realize its deferred tax assets in the future, in excess
 of its net recorded amount, management would make an adjustment to
 the deferred tax asset valuation allowance, which would reduce the
 provision for income taxes.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 The Company records uncertain tax positions on the basis of a
 two-step process whereby (1)&#xA0;management determines whether it
 is more likely than not that the tax positions will be sustained on
 the basis of the technical merits of the position and (2)&#xA0;for
 those tax positions that meet the more likely than not recognition
 threshold, management recognizes the largest amount of tax benefit
 that is more than 50 percent likely to be realized upon ultimate
 settlement with the related tax authority. The Company recognizes
 interest and penalties related to unrecognized tax benefits within
 income tax expense. Any accrued interest and penalties are included
 within the related tax liability.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 <b>Earnings (Loss) per Common Share</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 Earnings (loss) per common share is calculated using the two-class
 method, which is an earnings allocation formula that determines
 earnings (loss) per share for the holders of the Company&#x2019;s
 common shares and participating securities. All series of preferred
 stock contain participation rights in any dividend paid by the
 Company and are deemed to be participating securities. Earnings
 available to common stockholders and participating convertible
 redeemable preferred shares are allocated to each share on an
 as-converted basis as if all of the earnings for the period had
 been distributed. The participating securities include a
 contractual obligation to share in losses of the Company and are
 included in the calculation of net loss per share in the periods
 that have a net loss.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 Diluted earnings per share is computed using the more dilutive of
 (a)&#xA0;the two-class method, or (b)&#xA0;the if-converted method.
 The Company allocates earnings first to preferred stockholders
 based on dividend rights and then to common and preferred
 stockholders based on ownership interests. The weighted-average
 number of common shares included in the computation of diluted
 earnings (loss) gives effect to all potentially dilutive common
 equivalent shares, including outstanding stock options, warrants,
 convertible redeemable preferred stock and the potential issuance
 of stock upon the conversion of the Company&#x2019;s convertible
 notes. Common stock equivalent shares are excluded from the
 computation of diluted earnings (loss) per share if their effect is
 antidilutive.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 <b>Warrant Accounting</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 As noted in Note 9, the Company classifies warrants to purchase
 shares of its common stock as a liability on its consolidated
 balance sheet if the warrant is a free-standing financial
 instrument that may require the Company to transfer consideration
 upon exercise. Each warrant of this type is initially recorded at
 fair value on date of grant using the Monte Carlo simulation model
 and net of issuance costs, and is subsequently re-measured to fair
 value at each subsequent balance sheet date. Changes in fair value
 of the warrants are recognized as a component of other income
 (expense), net in the consolidated statement of operations. The
 Company will continue to adjust the liability for changes in fair
 value until the earlier of the exercise or expiration of the
 warrants.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 <b>Recently Adopted Accounting Pronouncements</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 In November 2015, Financial Accounting Standards Board (&#x201C;the
 FASB&#x201D;) issued Accounting Standard Update (&#x201C;ASU&#x201D;)
 No.&#xA0;2015-17, Income Taxes (Topic 740): Balance Sheet
 Classification of Deferred Taxes. The new standard requires that
 deferred tax assets and liabilities be classified as noncurrent in
 a classified statement of financial position. The Company
 prospectively adopted this guidance in the fourth quarter of 2015,
 which resulted in the removal of gross deferred tax assets and
 liabilities from the Company&#x2019;s consolidated balance sheet.
 The net impact was zero and the prior period was not
 retrospectively adjusted.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 In November 2014, the FASB issued ASU No.&#xA0;2014-16, Derivatives
 and Hedging (Topic 815): Determining Whether the Host Contract in a
 Hybrid Financial Instrument Issued in the Form of a Share Is More
 Akin to Debt or to Equity. This standard provides guidance to
 eliminate the existing diversity in practice in accounting for
 hybrid financial instruments issued in the form of a share. A
 hybrid financial instrument consists of a &#x201C;host
 contract&#x201D; into which one or more derivative terms have been
 embedded. This guidance requires an entity to consider the terms
 and features of the entire financial instrument, including the
 embedded derivative features, in order to determine whether the
 nature of the host contract is more akin to debt or to equity. This
 guidance is effective for fiscal years and interim periods
 beginning after December&#xA0;15, 2015, with early adoption
 permitted. A reporting entity should apply this guidance using a
 modified retrospective approach by recording a cumulative-effect
 adjustment to equity as of the beginning of the annual period of
 adoption. Retrospective application is permitted to all relevant
 prior periods. The Company has concluded that this guidance has no
 impact on the presentation of its results of operations, financial
 position and disclosures.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 In August 2014, the FASB issued ASU No.&#xA0;2014-15, Presentation
 of Financial Statements&#x2014;Going Concern (Subtopic 2015-40):
 Disclosure of Uncertainties about an Entity&#x2019;s Ability to
 Continue as a Going Concern. This guidance addresses
 management&#x2019;s responsibility in evaluating whether there is
 substantial doubt about a company&#x2019;s ability to continue as a
 going concern and to provide related footnote disclosures. The
 guidance is effective for fiscal years ending after
 December&#xA0;15, 2016 and for interim periods within those fiscal
 years. The adoption of this standard did not have a material impact
 on our consolidated financial statements and related
 disclosures.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 In June 2014, the FASB issued ASU No.&#xA0;2014-12,
 Compensation-Stock Compensation (Topic 718): Accounting for
 Share-Based Payments When the Terms of an Award Provide That a
 Performance Target Could be Achieved after the Requisite Service
 Period. This standard provides guidance requiring when there is a
 performance target that affects vesting of equity awards granted
 and could be achieved after the requisite service period to be
 treated as a performance condition. A reporting entity should apply
 existing guidance on stock-based compensation, as it relates to
 such awards. This guidance is effective for annual periods and
 interim periods within those annual periods beginning after
 December&#xA0;15, 2015 with early adoption permitted using either
 of two methods: (i)&#xA0;prospective to all awards granted or
 modified after the effective date; or (ii)&#xA0;retrospective to
 all awards with performance targets that are outstanding as of the
 beginning of the earliest annual period presented in the financial
 statements and to all new or modified awards thereafter, with the
 cumulative effect of applying this guidance as an adjustment to the
 opening retained earnings balance as of the beginning of the
 earliest annual period presented in the financial statements. The
 Company issued performance-based awards during the year ended
 December&#xA0;31, 2015. The Company adopted this guidance on a
 prospective basis and there have not been any performance-based
 awards since the effective date of the guidance.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 <b>Recently Issued Accounting Pronouncements</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 In November 2016, the FASB issued guidance that requires restricted
 cash and restricted cash equivalents be included with cash and cash
 equivalents when reconciling the total beginning and ending amounts
 for the periods shown on the statement of cash flows. The new
 standard is effective for us on January&#xA0;1, 2018 using a
 retrospective transition method to each period presented. Early
 adoption is permitted. We are currently evaluating the timing of
 our adoption and the expected impact that this standard could have
 on our consolidated financial statements and related
 disclosures.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 In March 2016, the FASB issued ASU No.&#xA0;2016-09,
 Compensation-Stock Compensation (Topic 718): Improvements to
 Employee Shared-Based Payment Accounting. This standard provides
 guidance on accounting for employee share-based payments. This
 guidance addresses several aspects of the accounting for
 share-based payment award transactions, including: (a)&#xA0;income
 tax consequences; (b)&#xA0;classification of awards as either
 equity or liabilities; and (c)&#xA0;classification on the statement
 of cash flows.&#xA0;This standard will be effective for fiscal
 years beginning after December&#xA0;15, 2016, including interim
 periods within those fiscal years.&#xA0;The Company is evaluating
 the impact of this guidance on the presentation of its results of
 operations, financial position and disclosures.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 In February 2016, the FASB, issued ASU No.&#xA0;2016-02, Leases
 (Topic 842). The ASU requires companies to recognize on the balance
 sheet the assets and liabilities for the rights and obligations
 created by leased assets. ASU 2016-02 will be effective for the
 Company in the first quarter of 2019, with early adoption
 permitted. The Company is currently evaluating the impact that the
 adoption of ASU 2016-02 will have on the Company&#x2019;s
 consolidated financial statements or related disclosures.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 In May 2014, the FASB issued ASU No.&#xA0;2014-09, Revenue from
 Contracts with Customers (Topic 606), which requires an entity to
 recognize the amount of revenue to which it expects to be entitled
 for the transfer of promised goods or services to customers. ASU
 2014-09 will replace most existing revenue recognition guidance in
 U.S. GAAP when it becomes effective. In July 2015, the FASB issued
 a one-year deferral of the effective date of the new revenue
 recognition standard. The new guidance will be effective for the
 Company&#x2019;s first quarter of fiscal year 2018 and early
 application for fiscal year 2017 would be permitted. The Company is
 evaluating the impact of this guidance on the presentation of its
 results of operations, financial position and disclosures.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 18pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 &#xA0;</p>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18861-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18726-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18743-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18854-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6929209920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Common Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Loss Per Common Share</a></td>
<td class="text"><div>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="break-inside: avoid">
 <td valign="top" width="4%" align="left"><b>3.</b></td>
 <td valign="top" align="left"><b>LOSS PER COMMON SHARE</b></td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 Basic and diluted loss per common share are calculated as
 follows:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" align="center" border="0">
 <tr>
 <td width="76%"></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"><b>For the Year Ended</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2016</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2015</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="6" align="center"><b>(In thousands,
 except share and<br />
 per share data</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Numerator:</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Net loss</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(16,208</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(32,024</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Net Loss attributable to Series A Preferred Stock (a)</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(2,345</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Numerator for basic EPS&#x2014;Earnings (loss) attributable to
 common stockholders</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(13,863</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(32,024</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Effect of dilutive securities:</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Deduct change in fair value of warrant liability</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(17,507</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Numerator for diluted EPS&#x2014;Earnings (loss) attributable to
 common stockholders after assumed conversions</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(31,370</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(32,024</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Denominator:</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Weighted-average number of common shares used in earnings (loss)
 per<br />
 share&#x2014;basic</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">14,256,954</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">13,231,126</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Effect of dilutive securities:</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Nonparticipating warrants</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">132,238</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Denominator for diluted EPS&#x2014;adjusted weighted average
 shares</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">14,389,192</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">13,231,126</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Earnings (loss) per share&#x2014;basic</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(0.97</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(2.42</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Earnings (loss) per share&#x2014;diluted</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(2.18</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(2.42</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="break-inside: avoid">
 <td valign="top" width="4%" align="left">(a)</td>
 <td valign="top" align="left">The Series A Preferred Stock
 participates in income and losses</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 The following potentially dilutive securities have been excluded
 from the computation of diluted weighted-average shares
 outstanding, as they would be anti-dilutive (in common stock
 equivalent shares):</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="70%"></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"><b>As of December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2016</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2015</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Unvested restricted stock and options to purchase common stock</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,578,905</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,227,957</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Series A preferred stock unconverted</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5,962,817</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Warrants exercisable into common stock</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">166,403</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">166,403</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 </table>
 <br class="Apple-interchange-newline" /></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1278-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1252-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=65016374&amp;loc=d3e4984-109258<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6762117296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TextBlockAbstract', window );"><strong>Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hsgx_PrepaidExpensesAndOtherCurrentAssetsTextBlock', window );">Prepaid Expenses and Other Current Assets</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>4. PREPAID EXPENSES AND OTHER CURRENT ASSETS</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 Prepaid expenses and other current assets consisted of the
 following:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="82%"></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>As of<br />
 December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2016</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2015</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="6" align="center"><b>(in
 thousands)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Deposits</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">10</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">67</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Undelivered laboratory and office equipment</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">17</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Insurance</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">95</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">42</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Other current assets</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">68</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">195</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Prepaid expenses and other current assets</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">173</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">321</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hsgx_PrepaidExpensesAndOtherCurrentAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepaid Expenses And Other Current Assets [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hsgx_PrepaidExpensesAndOtherCurrentAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hsgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6929260832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div>
 <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 <b>5. PROPERTY AND EQUIPMENT</b></p>
 <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 Property and equipment consisted of the following:</p>
 <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">
 &#xA0;</p>
 <table cellspacing="0" cellpadding="0" width="76%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center">
 <tr>
 <td width="65%"></td>
 <td valign="bottom" width="12%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="11%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>December&#xA0;31,<br />
 2016</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>December&#xA0;31,<br />
 2015</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="6" align="center"><b>(in
 thousands)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Office equipment</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">266</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">539</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Laboratory equipment</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4,443</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4,337</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Leasehold improvements</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">7,683</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">7,683</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Construction in progress</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">759</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">547</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Software</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">96</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">96</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Total property and equipment</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">13,247</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">13,202</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Less: accumulated depreciation</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(9,387</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(7,989</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Property and equipment, net</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">3,860</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">5,213</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 Depreciation expense related to property and equipment amounted to
 $1.7 million and $1.6 million for the years ended December&#xA0;31,
 2016 and 2015, respectively.</p>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13-14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=64827811&amp;loc=d3e1361-107760<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64862545&amp;loc=d3e2921-110230<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6762117296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Expenses</a></td>
<td class="text"><div>
 <table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" border="0" cellpadding="0" cellspacing="0" width="100%">
 <tr style="page-break-inside:avoid">
 <td width="4%" valign="top" align="left"><b>6.</b></td>
 <td align="left" valign="top"><b>ACCRUED EXPENSES</b></td>
 </tr>
 </table>
 <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 Accrued expenses consisted of the following:</p>
 <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">
 &#xA0;</p>
 <table cellspacing="0" cellpadding="0" width="76%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center">
 <tr>
 <td width="76%"></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="6" align="center" style="border-bottom:1.00pt solid #000000"><b>As of
 December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>2016</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>2015</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="6" align="center" style="border-bottom:1.00pt solid #000000"><b>(in thousands)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Accrued compensation</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,402</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">758</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Accrued clinical expenses</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">187</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">138</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Accrued other</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">508</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">548</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Total accrued expenses</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2,097</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,444</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6929260832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><div>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="PAGE-BREAK-INSIDE: avoid">
 <td valign="top" width="4%" align="left"><b>7.</b></td>
 <td valign="top" align="left"><b>COMMITMENTS AND
 CONTINGENCIES</b></td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 <b>Operating Leases</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 The Company leases office and research facilities in Waltham,
 Massachusetts under a non-cancellable operating lease, which
 expires in December 2017, with two additional five-year renewal
 options. Terms of the agreement provide for an initial rent-free
 period and future rent escalation, and provide that in addition to
 minimum lease rental payments, the Company is responsible for a
 pro-rata share of common area operating expenses. In June 2014, the
 Company entered into a lease agreement to rent a facility in
 Lexington, Massachusetts. The commencement date of the lease was
 July&#xA0;9, 2014 with a term that extends through June&#xA0;1,
 2023, with one additional five-year renewal option. Terms of the
 lease agreement provide for an initial rent-free period and future
 rent escalation, and provide that in addition to minimum lease
 rental payments, the Company is responsible for a pro-rata share of
 operating expenses. The Company&#x2019;s wholly-owned subsidiary,
 ProChon, leased a facility in Woburn, Massachusetts which expired
 in 2016 and was not renewed.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 Aggregate minimum annual lease commitments of the Company under its
 non-cancellable operating leases as of December&#xA0;31, 2016, are
 as follows:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0">
 <tr>
 <td width="79%"></td>
 <td valign="bottom" width="15%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom" colspan="4" nowrap="nowrap" align="center">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; WIDTH: 116.9pt; BORDER-BOTTOM: #000000 1pt solid; MARGIN-TOP: 0pt" align="center"><b>For the Year Ended December&#xA0;31,</b></p>
 </td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center">
 <b>(in&#xA0;thousands)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 2017</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2,266</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 2018</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">754</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 2019</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">586</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 2020</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">596</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 2021</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">605</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Thereafter</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">926</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Total minimum lease payments</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">5,733</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 Rent expense under operating lease agreements amounted to $1.0
 million and $1.1 million for the years ended December&#xA0;31, 2016
 and 2015, respectively.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 As an inducement to enter into its Waltham facility lease, the
 lessor agreed to provide the Company with a construction allowance
 of up to $3.2 million towards the total cost of tenant
 improvements. As an inducement to enter into its Lexington facility
 lease, the lessor agreed to provide the Company with a construction
 allowance of up to $1.0 million towards the total cost of tenant
 improvements. The Company has recorded these costs in the
 consolidated balance sheet as leasehold improvements, with the
 corresponding liability as deferred lease incentive. These
 liabilities are amortized on a straight-line basis over the term of
 the lease as a reduction of rent expense.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 18pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt">
 <b>License Agreements</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 From time to time, the Company enters into various licensing
 agreements whereby the Company may use certain technologies in
 conjunction with its product research and development.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 Licensing agreements and the Company&#x2019;s commitments under the
 agreements are as follows:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <i>Hydrogel License</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 In May 2005, the Company entered into an exclusive license
 agreement with Angiotech Pharmaceuticals (US), Inc. for the use of
 certain patents, patent applications, and knowledge related to the
 manufacture and use of a hydrogel material in conjunction with
 NeoCart and certain other products (&#x201C;Hydrogel License
 Agreement&#x201D;). As of December&#xA0;31, 2016, the Company has
 paid an aggregate $3.2 million in commercialization milestones
 under the terms of the Hydrogel License Agreement, which has been
 expensed to research and development.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 Under the terms of the Hydrogel License Agreement, the
 Company&#x2019;s future commitments include:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="PAGE-BREAK-INSIDE: avoid">
 <td width="5%">&#xA0;</td>
 <td valign="top" width="2%" align="left">&#x2022;</td>
 <td valign="top" width="1%">&#xA0;</td>
 <td valign="top" align="left">A one-time $3.0 million payment upon
 approval of an eligible product by the FDA; and</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="PAGE-BREAK-INSIDE: avoid">
 <td width="5%">&#xA0;</td>
 <td valign="top" width="2%" align="left">&#x2022;</td>
 <td valign="top" width="1%">&#xA0;</td>
 <td valign="top" align="left">Single digit royalties on the net
 sales of NeoCart and certain other future products.</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <i>Tissue Regeneration License</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 In April 2001, the Company entered into an exclusive license
 agreement with The Board of Trustees of the Leland Stanford Junior
 University (&#x201C;Stanford University&#x201D;) for the use of
 certain technology to develop, manufacture and sell licensed
 products in the field of growth and regeneration of cartilage
 (&#x201C;Tissue Regeneration License Agreement&#x201D;). The term of
 the Tissue Regeneration License Agreement extends to the expiration
 date of Stanford University&#x2019;s last to expire domestic or
 foreign patents. As of December&#xA0;31, 2016, the Company has paid
 an aggregate $0.7 million in patent reimbursement costs, royalty
 fees, and commercialization milestone payments under the terms of
 the Tissue Regeneration License Agreement, which have been recorded
 to research and development expense.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 Under the terms of the Tissue Regeneration License Agreement, the
 Company&#x2019;s future commitments include:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="PAGE-BREAK-INSIDE: avoid">
 <td width="5%">&#xA0;</td>
 <td valign="top" width="2%" align="left">&#x2022;</td>
 <td valign="top" width="1%">&#xA0;</td>
 <td valign="top" align="left">A one-time $0.3 million payment upon
 approval of an eligible product by the FDA;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="PAGE-BREAK-INSIDE: avoid">
 <td width="5%">&#xA0;</td>
 <td valign="top" width="2%" align="left">&#x2022;</td>
 <td valign="top" width="1%">&#xA0;</td>
 <td valign="top" align="left">An annual minimum non-refundable
 royalty fee of $10 thousand for the life of the license that may be
 used to offset up to 50% of each earned royalty described below;
 and</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="PAGE-BREAK-INSIDE: avoid">
 <td width="5%">&#xA0;</td>
 <td valign="top" width="2%" align="left">&#x2022;</td>
 <td valign="top" width="1%">&#xA0;</td>
 <td valign="top" align="left">Low single digit royalties on net
 sales.</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <i>Honeycomb License</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 In March 2013, the Company entered into a license agreement with
 Koken Co., Ltd. (&#x201C;Koken&#x201D;) and paid a fee for a
 non-exclusive, non-transferable and non-sublicensable right to use
 its know-how related to the process for manufacturing atelocollagen
 honeycomb sponge materials, which is used in scaffolds (the
 &#x201C;Honeycomb License Agreement&#x201D;). Under the terms of the
 Honeycomb License Agreement, future commitments will be based on
 the amount of materials supplied to the Company and may vary from
 period to period over the term of the agreement.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 18pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt">
 <i>Tissue Processor Sub-License</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 In December 2005, the Company entered into an exclusive agreement
 to sub-license certain technology from Purpose, Co.
 (&#x201C;Purpose&#x201D;), which is owned by a stockholder of the
 Company (&#x201C;Sub-License Agreement&#x201D;). Purpose entered into
 the original license agreement (&#x201C;Original Agreement&#x201D;)
 with Brigham and Women&#x2019;s Hospital, Inc. (&#x201C;Brigham and
 Women&#x2019;s&#x201D;) in August 2001. The Original Agreement shall
 remain in effect for the licensed patents owned by Brigham and
 Women&#x2019;s unless extended or terminated as provided for in the
 agreement. The technology is to be used to develop, manufacture,
 use and sell licensed products that cultivate cell or tissue
 development. The Sub-License Agreement extends to the expiration
 date of the last to expire domestic or foreign patents covered by
 the agreement. As of December&#xA0;31, 2016, the Company has paid
 an aggregate $1.0 million in royalty and sub-license payments under
 the terms of the Sub-License Agreement.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 The Sub-License Agreement was amended and restated in June 2012.
 Under the amended and restated agreement, the Company made Purpose
 the sole supplier of equipment the Company uses in its
 manufacturing processes, and granted Purpose distribution rights of
 the Company&#x2019;s products for certain territories. In exchange,
 Purpose allowed for the use of its technology (owned or licensed)
 and manufactured and serviced exogenous tissue processors used by
 the Company. Under the terms of the agreement, as amended, Purpose
 granted the Company:&#xA0;(a)&#xA0;exclusive rights to all of
 Purpose&#x2019;s technology (owned or licensed) related to the
 exogenous tissue processors, (b)&#xA0;continued supply of exogenous
 tissue processors during the Company&#x2019;s clinical trials, and
 (c)&#xA0;rights to manufacture the exogenous tissue processors at
 any location the Company chooses. In exchange for such
 consideration, the Company granted Purpose an exclusive license in
 Japan for the use of all of the Company&#x2019;s technology and made
 a payment of $0.3 million to reimburse Purpose for development
 costs on a next generation tissue processor.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 In May 2016, the Original Agreement was amended whereby the Company
 acquired the development and commercialization rights to NeoCart
 for the Japanese market from Purpose. Under the terms of the
 amended agreement, the Company assumes sole responsibility for and
 rights to the development and commercialization of NeoCart in
 Japan. In exchange for the transfer of development and
 commercialization rights, the Company will pay a success-based
 milestone to Purpose upon conditional approval of NeoCart in Japan,
 as well as commercial milestones and a low single digit royalty on
 Japanese sales of NeoCart, upon full approval, if any, in Japan</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 In addition to the above, the Company&#x2019;s future commitments
 under the terms of the Original Agreement and Sub-License Agreement
 include:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="PAGE-BREAK-INSIDE: avoid">
 <td width="5%">&#xA0;</td>
 <td valign="top" width="2%" align="left">&#x2022;</td>
 <td valign="top" width="1%">&#xA0;</td>
 <td valign="top" align="left">A minimum non-refundable annual
 royalty fee of $20 thousand, for the life of the license;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="PAGE-BREAK-INSIDE: avoid">
 <td width="5%">&#xA0;</td>
 <td valign="top" width="2%" align="left">&#x2022;</td>
 <td valign="top" width="1%">&#xA0;</td>
 <td valign="top" align="left">An additional, non-refundable annual
 royalty fee of $30 thousand from 2016 through 2019;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="PAGE-BREAK-INSIDE: avoid">
 <td width="5%">&#xA0;</td>
 <td valign="top" width="2%" align="left">&#x2022;</td>
 <td valign="top" width="1%">&#xA0;</td>
 <td valign="top" align="left">$10.2 million in potential milestone
 payments; and</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="PAGE-BREAK-INSIDE: avoid">
 <td width="5%">&#xA0;</td>
 <td valign="top" width="2%" align="left">&#x2022;</td>
 <td valign="top" width="1%">&#xA0;</td>
 <td valign="top" align="left">Low single digit royalties on net
 sales of a licensed product.</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>The OCS Agreement</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 In connection with its research and development, the Company
 received grants from the Office of Chief Scientist of the Ministry
 of Industry and Trade in Israel (&#x201C;OCS&#x201D;) in the
 aggregate of $1.1 million for funding the fibroblast growth factor
 (&#x201C;FGF&#x201D;) program. In consideration for this grant, the
 Company is committed to pay royalties at a rate of 3% to 5% of the
 sales of sponsored products developed using the grant money, up to
 the amount of the participation payments received. The Company
 committed to pay up to 100% of grants received plus interest
 according to the LIBOR interest rate if the sponsored product is
 produced in Israel. If the manufacturing of the sponsored product
 takes place outside of Israel, the royalties can increase up to,
 but no more than, 300% of grants received plus interest based on
 the LIBOR interest rate, depending on the percentage of the
 manufacturing of sponsored product that takes place outside of
 Israel.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>Engineering Agreement</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 The Company entered into an agreement with a development
 corporation to purchase a multi-unit bioreactor system. Pursuant to
 the agreement, as of December&#xA0;31, 2016, the Company made total
 payments in an aggregate amount of $0.6 million of which $0.2
 million was made in 2016 after acceptance of the final product.
 There are no additional payments due under this agreement.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>Collagen Supply Agreement</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 In September 2015, the Company entered into an agreement with
 Collagen Solutions (UK) Limited (the &#x201C;Supplier&#x201D;) to
 purchase soluble collagen that meets specifications provided by the
 Company. The initial term of the agreement is three years and will
 automatically renew from year to year thereafter unless otherwise
 terminated with at least 180 days&#x2019; notice by either party.
 Pursuant to the agreement, starting 12 months after entering into
 the agreement, the Company will be required to order a minimum
 amount of material and/or services totaling $0.2 million from the
 Supplier in each calendar year until the expiration of the initial
 term of the agreement. The Company also committed to pay a
 non-refundable payment totaling $0.1 million by the end of 2015.
 This expense was recorded to research and development expense as of
 December&#xA0;31, 2015.</p>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6449706&amp;loc=d3e16207-108621<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=68068213&amp;loc=d3e12565-110249<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14435-108349<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=73718637&amp;loc=d3e25287-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6598140032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capital Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Capital Stock</a></td>
<td class="text"><div>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="break-inside: avoid">
 <td valign="top" width="4%" align="left"><b>8.</b></td>
 <td valign="top" align="left"><b>CAPITAL STOCK</b></td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 On September&#xA0;29, 2016, the Company closed the private
 placement contemplated by the securities purchase agreement (the
 &#x201C;Purchase Agreement&#x201D;), dated September&#xA0;15, 2016,
 between the Company and certain institutional and accredited
 investors in which the Company received gross proceeds of $30.0
 million (the &#x201C;Private Placement&#x201D;). The net proceeds
 after deducting placement agent fees and other transaction-related
 expenses was $27.6 million. At the closing, the Company issued
 2,596,059 shares of the Company&#x2019;s common stock at a per share
 price of $2.25 and 24,158.8693 shares of the Company&#x2019;s
 newly-created Series A Convertible Preferred Stock (&#x201C;Series A
 Preferred Stock&#x201D;), which are convertible into approximately
 10,737,275 shares of common stock. As part of the Private
 Placement, the investors received warrants to purchase up to
 13,333,334 shares of the Company&#x2019;s common stock at an
 exercise price of $2.25 per share.&#xA0;The placement agent for the
 Private Placement, H.C. Wainwright&#xA0;&amp; Co. LLC
 (&#x201C;HCW&#x201D;), and certain of its affiliates were also
 granted warrants to purchase 133,333 shares of the Company&#x2019;s
 common stock at an exercise price of $2.25 per share in exchange
 for the services provided by HCW. The placement agent warrants were
 considered a financing cost of the Company and included in warrant
 expense within the consolidated statements of operations.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 The warrants include a cashless-exercise feature that may be
 exercised solely in the event there is no effective registration
 statement, or no current prospectus available for, the resale of
 the shares of common stock underlying the warrants as of the
 six-month anniversary of the closing of the Private Placement. Upon
 a fundamental transaction, the holders of the warrant may require
 the Company to purchase any unexercised warrants in an amount equal
 to the Black-Scholes value of the option. A fundamental transaction
 is defined as a merger, sale of assets, sale of the Company,
 recapitalization of stock and a sale of stock whereby any owner
 after the transaction would own greater than 50% of the outstanding
 common stock in the Company. The warrants became exercisable
 following approval of the Private Placement by our stockholders in
 the fourth quarter of 2016 and expire five years after the date of
 such stockholder approval.&#xA0;The Company determined the warrants
 are classified as a liability on the consolidated balance sheet
 because they contain a provision whereby in a fundamental
 transaction (as described above), the holder can elect to receive
 either the amount they are entitled to on an as-if-exercised basis
 or an amount based on the Black-Scholes value of the warrants at
 the time of the fundamental transaction.&#xA0;At the issuance date,
 the warrants were recorded at the fair value of $30.7 million and
 approximately $0.4 million excess of the fair value of the
 liability recorded for these warrants over the proceeds received
 was recorded as a charge to earnings in the third quarter of 2016
 and is included in warrant expense within the consolidated
 statement of operations. In connection with the Private Placement,
 the Company incurred expenses of $3.1 million in warrant expense
 within the consolidated statements of operations.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 Concurrent with the closing of the Private Placement, the
 Company&#x2019;s&#xA0;Certificate of Incorporation was amended by
 the filing of a Certificate of Designation to create the Series A
 Preferred Stock.&#xA0;The Series A Preferred Stock has a par value
 of $0.01 and each share is convertible into 444.44 shares of common
 stock, at a conversion price of $2.25 per share, at the option of
 the holder.&#xA0;The Series A Preferred Stock has no voting rights
 and is only entitled to dividends as declared on an as-converted
 basis.&#xA0;The Series A Preferred Stock contains no liquidation
 preferences or redemption rights and shares in distributions of the
 Company on an as-converted basis with the common stock.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 As part of the Private Placement, affiliates of certain members of
 the Company&#x2019;s Board of Directors purchased an aggregate of
 283,046 shares of common stock, an aggregate of 2,563.1439 shares
 of Series A Preferred Stock and received warrants to purchase up to
 1,422,221 shares of common stock at an exercise price of $2.25 per
 share in the Private Placement.&#xA0;These amounts are included in
 the amounts noted above.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 <b>Common Stock-100,000,000 shares authorized</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 The holders of shares of common stock are entitled to one vote per
 share. The holders of shares of common stock are not entitled to
 receive dividends, unless declared by the Company&#x2019;s board of
 directors out of legally available funds, if ever.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 <i>Reserved for future issuance</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 The Company has reserved for future issuance the following number
 of shares of common stock:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="68%" align="center" border="0">
 <tr>
 <td width="64%"></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"><b>As of December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2016</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2015</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Vesting of restricted stock</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,889</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5,190</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Options to purchase common stock</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,577,016</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,222,767</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Common stock warrants</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">13,633,070</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">166,403</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Total</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">15,211,975</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,394,360</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 <b>Preferred Stock-30,000,000 shares authorized</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 S<b>eries A Convertible Preferred Stock</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 On September&#xA0;29, 2016, the Company issued 24,158.8693 shares
 of newly-created Series A Convertible Preferred Stock, which were
 convertible into approximately 10,737,275 shares of common stock at
 an initial conversion price of $2.25. The Series A Preferred Stock
 has a par value of $0.01 and each share is convertible into 444.44
 shares of common stock at the option of the holder. The holders of
 Series A Preferred Stock have no voting rights, share in both
 income and losses and are only entitled to dividends as declared on
 an as-converted basis. The Series A Preferred Stock contains no
 liquidation preferences or redemption rights and shares in the
 distribution of the Company on an as-converted basis with the
 common stock. The Series A Preferred Stock shall not be converted
 if, after giving effect to the conversion, the holder and its
 affiliated persons would own beneficially more than 4.99% of our
 common stock (subject to adjustment up to 9.99% solely at the
 holder&#x2019;s discretion upon 61 days&#x2019; prior notice to us
 or, solely as to a holder, if such limitation is waived by such
 holder upon execution of the private placement agreement).</p>


 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74567-122707<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21484-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21488-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23285-112656<br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Preferred Stock<br> -URI http://asc.fasb.org/extlink&amp;oid=6521494<br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21564-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6648674704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TextBlockAbstract', window );"><strong>Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hsgx_WarrantDisclosureTextBlock', window );">Warrants</a></td>
<td class="text"><div>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="break-inside: avoid">
 <td valign="top" width="4%" align="left"><b>9.</b></td>
 <td valign="top" align="left"><b>WARRANTS</b></td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 <b>Investor Warrants</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 In September 2016, in connection with the Private Placement, the
 Company issued common stock warrants to the investors to purchase
 up to 13,333,334 shares of our common stock at an exercise price of
 $2.25 per share. The warrants include a cashless-exercise feature
 that may be exercised solely in the event there is no effective
 registration statement registering, or no current prospectus
 available for, the resale of the shares of common stock underlying
 the warrants as of the six-month anniversary of the closing of the
 Private Placement. The warrants became exercisable following
 approval of the Private Placement by our stockholders in the fourth
 quarter of 2016 and expire five years after the date of such
 stockholder approval. The warrants were valued at $2.28 per share
 using a Monte Carlo simulation and are marked-to-market on a
 quarterly basis with the change in value recorded as warrant
 expense or income on the consolidated statements of operations.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 <b>Placement Agent Warrants</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 In September 2016, in connection with the Private Placement, the
 Company issued HCW and certain of its affiliates warrants for the
 purchase of 133,333 shares of common stock at an exercise price of
 $2.25 per share. The HCW warrants became exercisable following
 approval of the Private Placement by our stockholders in the fourth
 quarter of 2016 and expire five years after the date of such
 stockholder approval. The warrants were valued at $2.28 per share
 using a Monte Carlo simulation and are marked-to-market on a
 quarterly basis with the change in value recorded as warrant
 expense or income on the consolidated statements of operations.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 <b>Affiliates of an Advisor Warrant</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 On July&#xA0;20, 2012, the Company issued a warrant to purchase its
 common stock to affiliates of an advisor. The warrant provides the
 holders with the right to purchase an aggregate of 161,977 shares
 of the Company&#x2019;s common stock at a per share exercise price
 of $0.01. The warrants are exercisable, in whole or in part,
 immediately upon issuance and may be exercised on a cashless basis.
 The warrants expire on the tenth anniversary of issuance. The fair
 value of the warrants as of July&#xA0;20, 2012 was estimated using
 the OM with the following inputs: (a)&#xA0;risk-free interest rate
 of 0.22%; (b)&#xA0;implied volatility of the Company&#x2019;s common
 stock of 99%; and (c)&#xA0;the expected term to a liquidity event
 of 1.7 years. On December&#xA0;3, 2014, the Company completed its
 IPO and warrants for 5,839 shares of common stock were surrendered
 and common stock was issued by the Company to Purpose, Co. for the
 warrant shares surrendered. As of December&#xA0;31, 2016 and 2015,
 warrants to purchase an aggregate of 156,138 shares of the
 Company&#x2019;s common stock at an exercise price of $0.01 are
 outstanding.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 <b>Consulting Agreement Warrant</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 In March 2015, in connection with a consulting agreement entered
 into for an interim chief financial officer, the Company issued a
 common stock warrant as compensation to the consulting firm. The
 warrant provides the holder with the right to purchase an aggregate
 of 7,398 shares of the Company&#x2019;s common stock at a per share
 exercise price of $9.75, the closing price of the Company&#x2019;s
 common stock on the date of issuance. The warrant vested and became
 exercisable in monthly installments over 24 months beginning
 September&#xA0;30, 2015 and expires on the tenth anniversary of
 issuance. The warrant is equity classified and accounted for using
 the fair value approach. The fair value of the warrant is estimated
 using the Black-Scholes option pricing model and is subject to
 re-measurement at each reporting period until the measurement date
 is reached. On December&#xA0;21, 2015, the Company terminated the
 consulting agreement resulting in the forfeiture of 50%
 (3,699)&#xA0;of the shares eligible for exercise under the warrant.
 The remaining 3,699 shares were vested and exercisable on
 December&#xA0;31, 2016 and December&#xA0;31, 2015.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 18pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 &#xA0;</p>


 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hsgx_WarrantDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrant [Disclosure Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hsgx_WarrantDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hsgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6929259824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equipment Loan Payable<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Equipment Loan Payable</a></td>
<td class="text"><div>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="break-inside: avoid">
 <td valign="top" width="4%" align="left"><b>10.</b></td>
 <td valign="top" align="left"><b>EQUIPMENT LOAN PAYABLE</b></td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 As of December&#xA0;31, 2016 and 2015, the Company had the
 following outstanding borrowing obligations:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="66%"></td>
 <td valign="bottom" width="13%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="12%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>December&#xA0;31,<br />
 2016</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>December&#xA0;31,<br />
 2015</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="6" align="center">
 <b>(in&#xA0;thousands)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Silicon Valley Bank Equipment Loan Payable</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">761</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,344</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Less: current portion</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(583</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(583</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Long-term debt, net</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">178</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">761</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 In July 2014, the Company entered into a loan and security
 agreement with Silicon Valley Bank, which provides for a line of
 credit to finance certain equipment purchases up to an aggregate of
 $1.8 million through March&#xA0;31, 2015. The line has been fully
 drawn and is payable in 36 monthly installments of principal and
 interest, with an annual interest rate of 2.75% plus the greater of
 3.25% and the prime rate in effect at the time of each draw, as
 published in the Wall Street Journal. The outstanding balance on
 the line of credit is secured by a first priority lien over all
 equipment purchased using the line of credit.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 In accordance with the terms of the equipment line of credit, the
 Company issued a warrant to Silicon Valley Bank in July 2014 to
 purchase 6,566 shares of our common stock at an exercise price per
 share of $7.99.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 The equipment line of credit includes customary operating but
 non-financial covenants, including limitations on the
 Company&#x2019;s ability to incur additional indebtedness, issue
 dividends, sell assets, engage in any business other than its
 current business, merge or consolidate with other entities, create
 liens on our assets, make investments, repurchase stock in certain
 instances, enter into transactions with affiliates, make payments
 on subordinated indebtedness and transfer or encumber any
 collateral securing the debt.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 As of December&#xA0;31, 2016 and 2015, $0.8 and $1.3 million
 respectively, of borrowings were outstanding under the line of
 credit and the Company was in compliance with all required
 covenants.</p>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20,22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6762020384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><div>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="break-inside: avoid">
 <td valign="top" width="4%" align="left"><b>11.</b></td>
 <td valign="top" align="left"><b>STOCK-BASED COMPENSATION</b></td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 <b>Restricted Stock Awards and Stock Options</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 The Company adopted the 2012 Equity Incentive Plan, as amended
 (&#x201C;2012 Plan&#x201D;) in July 2012 pursuant to which 609,389
 shares of common stock were authorized for issuance to employees,
 officers, directors, consultants and advisors of the Company as of
 December&#xA0;31, 2014. Upon the closing of the IPO on
 December&#xA0;3, 2014, no further grants will be made under the
 2012 Plan as the 2013 Equity Incentive Plan (&#x201C;2013
 Plan&#x201D;) replaced the 2012 Plan on this date. The 2012 Plan
 provided for the grant of incentive stock options, non-statutory
 stock options, rights to purchase restricted stock, stock
 appreciation rights, phantom stock awards and stock units. In
 connection with the issuance of restricted common stock, the
 Company maintains a repurchase right and shares of restricted
 common stock are released from such repurchase right over a period
 of time of continued service by the recipient. Recipients of
 incentive stock options shall be eligible to purchase shares of the
 Company&#x2019;s common stock at an exercise price equal to no less
 than the estimated fair value of such stock on the date of grant.
 Stock options generally vest 25% on the first anniversary of the
 original vesting date, with the balance vesting monthly over the
 remaining three years, unless they contain specific performance
 and/or market-based vesting provisions. The maximum term of stock
 options granted under the 2012 Plan is ten years.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 In determining the exercise prices for options granted, the board
 of directors considered the fair value of the common stock as of
 the measurement date. The fair value of the common stock was
 determined by the board of directors based on a variety of
 different factors, including valuations prepared by third party
 valuation specialists, Company&#x2019;s financial position, the
 status of development efforts within the Company, the composition
 and ability of the current scientific and management teams, the
 current climate in the marketplace, the illiquid nature of the
 Company&#x2019;s common stock, arm&#x2019;s length sale of the
 Company&#x2019;s preferred stock, the effect of the rights and
 preferences of the preferred stockholders, and the prospects of a
 liquidity event, among others.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 <b>2013 Equity Incentive Plan</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 The Company&#x2019;s board of directors adopted the 2013 Plan in
 November 2013 which the stockholders approved in October 2014. The
 2013 Plan provides for the grant of incentive stock options,
 non-statutory stock options, rights to purchase restricted stock,
 stock appreciation rights and stock units. In connection with the
 issuance of restricted common stock, the Company maintains a
 repurchase right and shares of restricted common stock are released
 from such repurchase right over a period of time of continued
 service by the recipient. Recipients of stock options shall be
 eligible to purchase shares of the Company&#x2019;s common stock at
 an exercise price equal to no less than the estimated fair value of
 such stock on the date of grant. Stock options generally vest 25%
 on the first anniversary of the original vesting date, with the
 balance vesting monthly over the remaining three years, unless they
 contain specific performance and/or market-based vesting
 provisions. The maximum term of stock options granted under the
 2013 Plan is ten years. In June 2016, the Company&#x2019;s
 stockholders approved an amendment to the EIP to increase the
 number of shares of common stock available for issuance under the
 2013 Plan by 300,000 shares and increase the number of shares of
 common stock automatically added to the 2013 Plan on January&#xA0;1
 of each year during the term of the 2013 Plan, starting with
 January&#xA0;1, 2017 (the &#x201C;EIP Amendment&#x201D;). Following
 adoption of the EIP Amendment, the number of shares of common stock
 available for issuance under the 2013 Plan is subject to an
 automatic annual increase on the first day of the Company&#x2019;s
 calendar year beginning in 2017 equal to the lesser of
 (a)&#xA0;4.0% of the total number of shares of common stock
 outstanding on December&#xA0;31 of the prior year or, (b)&#xA0;the
 number determined by the Company&#x2019;s Board of Directors
 Accordingly, the number of shares of common stock available for
 issuance under the EIP was increased by 825,904 shares effective
 January&#xA0;1, 2017. To the extent any awards under the 2013 Plan
 are forfeited, terminate, expire, lapse without the issuance of
 shares, or if the Company repurchases shares subject to awards
 under the 2013 Plan, those shares will again become available for
 issuance under the 2013 Plan.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 <b>2013 Employee Stock Purchase Plan</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 The Company&#x2019;s board of directors adopted the 2013 Employee
 Stock Purchase Plan (&#x201C;2013 ESPP&#x201D;) in November 2013
 which the stockholders approved in October 2014. The 2013 ESPP
 became effective upon the closing of the IPO on December&#xA0;3,
 2014. The Company&#x2019;s 2013 ESPP qualifies under
 Section&#xA0;423 of the Internal Revenue Code of 1986, as amended
 (the &#x201C;Code&#x201D;). Under the 2013 ESPP, 103,665 shares of
 the Company&#x2019;s common stock are authorized for issuance to
 eligible employees. The number of shares reserved for issuance
 under the 2013 ESPP is automatically increased on the first
 business day of each of the Company&#x2019;s fiscal years,
 commencing in 2015, by a number equal to the lowest of
 (a)&#xA0;51,832 shares of common stock,(b) 1% of the shares of
 common stock outstanding on the last business day of the prior
 fiscal year; or (c)&#xA0;the number of shares determined by the
 Company&#x2019;s Board of Directors. Accordingly, the number of
 authorized shares of the Company&#x2019;s common stock authorized
 for issuance to eligible employees under the 2013 ESPP was
 increased by 206,476 shares effective January&#xA0;1, 2017. The
 number of shares reserved under the 2013 ESPP will automatically be
 adjusted in the event of a stock split, stock dividend or a reverse
 stock split (including an adjustment to the per-purchase period
 share limit). The Company&#x2019;s 2013 ESPP permits each eligible
 employee to purchase common stock through payroll deductions. There
 was no activity under the Plan in 2016 and 2015.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 Stock option activity under the 2012 and 2013 plans is summarized
 as follows:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" align="center" border="0">
 <tr>
 <td width="61%"></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Number</b><br />
 <b>of Options</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Weighted-</b><br />
 <b>Average</b><br />
 <b>Exercise</b><br />
 <b>Price</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Weighted-</b><br />
 <b>Average</b><br />
 <b>Remaining</b><br />
 <b>Contractual</b><br />
 <b>Term</b><br />
 <b>(in years)</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Aggregate</b><br />
 <b>Intrinsic</b><br />
 <b>Value</b><br />
 <b>(in&#xA0;thousands)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Outstanding at December&#xA0;31, 2015</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,229,339</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">7.32</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">9.0</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(4,679</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Granted</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">464,240</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2.02</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Exercised</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(3,685</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">0.76</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Cancelled</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(112,878</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4.97</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Outstanding at December&#xA0;31, 2016</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,577,016</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">5.95</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">8.4</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">71</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Vested and expected to vest at December&#xA0;31, 2016</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,492,341</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">5.97</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">8.4</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">69</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Exercisable at December&#xA0;31, 2016</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">561,693</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">6.79</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">7.8</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">52</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 As of December&#xA0;31, 2016 and 2015, the unrecognized
 compensation cost related to outstanding options was $2.6 million
 and $3.9 million, respectively, and is expected to be recognized as
 expense over approximately 2.01 years and 2.68 years, respectively.
 The intrinsic value of options exercised during the years ended
 December&#xA0;31, 2016 and 2015 was $10 thousand and $0.3 million,
 respectively.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 As of December&#xA0;31, 2016, the weighted average grant date fair
 value of vested options was $4.71 and the weighted average grant
 date fair value of options outstanding was $3.67.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 Additional information about the Company&#x2019;s stock option
 activity is as follows:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 &#xA0;</p>
 <table style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" align="center" border="0">
 <tr>
 <td width="82%"></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center">
 <b>Year&#xA0;Ended&#xA0;December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2016</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2015</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Weighted-average grant date fair value per share of employee option
 grants within the year</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1.26</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">4.08</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Cash received upon exercise of options</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">39</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 Restricted stock awards under the 2012 and 2013 plans are
 summarized as follows:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="64%"></td>
 <td valign="bottom" width="13%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="12%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Number&#xA0;of</b><br />
 <b>Shares</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Weighted&#xA0;Average</b><br />
 <b>Grant Date&#xA0;Fair</b><br />
 <b>Value</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Unvested at December&#xA0;31, 2015</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5,190</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1.07</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Vesting of restricted stock</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(3,301</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Unvested at December&#xA0;31, 2016</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,889</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">0.83</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 As of December&#xA0;31, 2016 and 2015, the unrecognized
 compensation cost related to restricted stock awards was $1
 thousand and $4 thousand respectively, and is expected to be
 recognized as expense over approximately 0.3 years and 1.2 years,
 respectively.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 <b>Stock-Based Compensation Expense</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 The Company granted stock options to employees for the years ended
 December&#xA0;31, 2016 and 2015. The Company estimates the fair
 value of stock options as of the date of grant using the
 Black-Scholes option pricing model and restricted stock based on
 the fair value of the award. Stock options and restricted stock
 issued to non-board member, non-employees are accounted for using
 the fair value approach and are subject to periodic revaluation
 over their vesting terms.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 For all periods from inception to date, stock-based compensation
 for all options granted and restricted stock awards are classified
 as research and development expense and general and administrative
 expense. Stock compensation expense amounted to approximately $1.5
 million and $1.2 million for the years ended December&#xA0;31, 2016
 and 2015, respectively. Included in the table below is restricted
 stock-based compensation expense of $2 thousand and $4 thousand,
 respectively, recorded in general and administrative expense during
 the years ended December&#xA0;31, 2016 and 2015.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 Stock-based compensation is as follows:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 &#xA0;</p>
 <table style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="76%"></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"><b>Year Ended</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2016</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2015</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="6" align="center">
 <b>(in&#xA0;thousands)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Research and development</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">491</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">451</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 General and administrative</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,057</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">777</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Total stock-based compensation expense</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,548</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,228</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 The weighted-average assumptions used in the Black-Scholes option
 pricing model to determine the fair value of the employee stock
 option grants were as follows:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="83%"></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"><b>Year Ended</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2016</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2015</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Risk-free interest rate</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1.73</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1.68</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Expected volatility</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">72.5</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">62.6</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Expected term (in years)</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6.08</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6.04</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Expected dividend yield</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">0.0</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">0.0</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 The weighted-average assumptions used in the Black-Scholes option
 pricing model to determine the fair value of the non-employee stock
 option grants were as follows:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="83%"></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"><b>Year Ended</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2016</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2015</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Risk-free interest rate</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1.57</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1.79</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Expected volatility</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">63.5</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">63.2</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Expected term (in years)</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">7.00</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6.16</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Expected dividend yield</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">0.0</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">0.0</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 <b><i>Risk-free Interest Rate</i></b>. The risk-free interest rate
 assumption is based on observed interest rates appropriate for the
 expected term of the stock option grants.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 <b><i>Expected Volatility</i></b>. Due to the Company&#x2019;s
 limited operating history and lack of company-specific historical
 or implied volatility, the expected volatility assumption is based
 on historical volatilities of a peer group of similar companies
 whose share prices are publicly available. The peer group was
 developed based on companies in the biotechnology and medical
 device industries.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 <b><i>Expected Term</i></b>. The expected term represents the
 period of time that options are expected to be outstanding. Because
 the Company does not have historical exercise behavior, through
 December&#xA0;31, 2016 it determined the expected life assumption
 using the simplified method, which is an average of the contractual
 term of the option and its vesting period.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 <b><i>Expected Dividend Yield</i></b>. The expected dividend yield
 assumption is based on the fact that the Company has never paid
 cash dividends and has no present intention to pay cash
 dividends.</p>


 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 40<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65895303&amp;loc=d3e17540-113929<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68057994&amp;loc=d3e25284-112666<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5444-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6929200272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><div>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="break-inside: avoid">
 <td valign="top" width="4%" align="left"><b>12.</b></td>
 <td valign="top" align="left"><b>INCOME TAXES</b></td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 For the years ended December&#xA0;31, 2016 and 2015, the Company
 did not record a current or deferred income tax expense or benefit
 due to current and historical losses incurred by the Company.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 The components of loss before income taxes were as follows:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 &#xA0;</p>
 <table style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="71%"></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"><b>As of December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2016</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2015</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="6" align="center"><b>(in
 thousands)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 U.S.</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(15,838</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(31,382</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Foreign</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(369</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(691</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Total</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(16,208</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(32,073</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 A reconciliation of income tax expense (benefit) computed at the
 statutory federal income tax rate to income taxes as reflected in
 the financial statements is as follows:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="79%"></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center">
 <b>As&#xA0;of&#xA0;December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2016</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2015</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Federal income tax (benefit) at statutory rate</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">34.0</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">34.0</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 (Increase) decrease income tax benefit resulting from:</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Permanent differences</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">29.0</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(1.2</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Net Operating Loss Limitation</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(111.1</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 R&amp;D Credit Limitation</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(1.5</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Change in valuation allowance</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">48.7</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(31.7</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Other</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">0.9</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(1.2</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Income tax expense (benefit)</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">0.0</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">0.0</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 Deferred taxes are recognized for temporary differences between the
 basis of assets and liabilities for financial statement and income
 tax purposes. The significant components of the Company&#x2019;s
 deferred tax assets and liabilities are comprised of the
 following:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="71%"></td>
 <td valign="bottom" width="8%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"><b>As of December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2016</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2015</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Deferred tax assets:</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Net operating loss carryforwards</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">16,146</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">28,200</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Depreciation and amortization</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6,229</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6,688</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Accrued expenses</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,082</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,183</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Capitalized start-up costs</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">10,037</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">8,531</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Other</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">75</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">259</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Deferred tax assets before valuation allowance</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">34,569</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">44,861</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Valuation allowance</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(34,569</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(43,751</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,110</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Deferred tax liabilities</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 IPR&amp;D</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(36</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Change in accounting method</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(1,074</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(1,110</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Net deferred tax assets</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 The Company has evaluated the positive and negative evidence
 bearing upon the realizability of its deferred tax assets. As of
 December&#xA0;31, 2016 and 2015, based on the Company&#x2019;s
 history of operating losses, the Company has concluded that it is
 not more likely than not that the benefit of its deferred tax
 assets will be realized. Accordingly, the Company has provided a
 full valuation allowance for deferred tax assets as of
 December&#xA0;31, 2016 and 2015. The valuation allowance decreased
 $9.2 million during the year ended December&#xA0;31, 2016, due
 primarily to a reduction of net operating losses generated. The
 valuation allowance increased by $11.8 million during the year
 ended December&#xA0;31, 2015, due primarily to net operating losses
 generated and capitalized expenses. In addition, the reduction in
 net operating losses were related to Section 382 limits as a result
 in a change in ownership.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 During November 2015, the FASB issued ASU 2015-17, &#x201C;Balance
 Sheet Classification of Deferred Taxes&#x201D;, which simplifies the
 presentation of deferred income taxes. This ASU requires that
 deferred tax assets and liabilities be classified as non-current in
 a statement of financial position. We early adopted ASU 2015-17
 effective December&#xA0;31, 2015 on a prospective basis. Adoption
 of this ASU resulted in the removal of gross deferred tax assets
 and liabilities from the Company&#x2019;s Consolidated Balance Sheet
 at December&#xA0;31, 2015. The impact was zero. No prior periods
 were retrospectively adjusted. As of December&#xA0;31, 2016 and
 2015, the Company had U.S. federal NOL carryforwards of $24.5
 million, and $55.5 million, respectively, which may be available to
 offset future income tax liabilities and expire at various dates
 through 2036. As of December&#xA0;31, 2016 and 2015, the Company
 also had U.S. state NOL carryforwards of $24.3 million and $55.4
 million, respectively, which may be available to offset future
 income tax liabilities and expire at various dates through 2036. At
 December&#xA0;31, 2016 and 2015, the Company also had $26.1 million
 and $25.6 million, respectively, of foreign NOL carryforwards which
 may be available to offset future income tax liabilities, which
 carryforwards do not expire.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 Utilization of the NOL and research and development credit
 carryforwards may be subject to a substantial annual limitation due
 to ownership change limitations that have occurred or that could
 occur in the future, as required by Section&#xA0;382 and
 Section&#xA0;383 of the Code, as well as similar state and foreign
 provisions. These ownership changes may limit the amount of NOL and
 research and development credit carryforwards that can be utilized
 annually to offset future taxable income and tax, respectively. In
 general, an &#x201C;ownership change&#x201D; as defined by
 Section&#xA0;382 of the Code results from a transaction or series
 of transactions over a three-year period resulting in an ownership
 change of more than 50 percentage points of the outstanding stock
 of a company by certain stockholders. The Company has completed a
 study to assess whether an ownership change has occurred or whether
 there have been multiple ownership changes since its formation. The
 results of this study indicated we experienced ownership changes,
 as defined by Section&#xA0;382 of the Code, in each of 2006, 2011,
 2012, 2013, and 2016. The Company has not recorded NOLs that, as a
 result of these restrictions, will expire unused. The limitations
 were approximately $47.1 million in 2015 and $100.1 million in
 2016.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 The changes in the Company&#x2019;s unrecognized tax benefits are
 summarized as follows:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="79%"></td>
 <td valign="bottom" width="8%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center">
 <b>As&#xA0;of&#xA0;December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2016</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2015</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="6" align="center"><b>(in
 thousands)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Unrecognized tax benefit, beginning of year</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">687</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">811</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Increase (decrease) related to current year positions</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(125</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(124</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Settlements</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Unrecognized tax benefit, end of year</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">562</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">687</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 As of December&#xA0;31, 2016 and 2015, the total amount of
 unrecognized tax benefits was $0.6 million and $0.7 million,
 respectively which, if recognized, would favorably affect the
 effective income tax rate in future periods. Note that liabilities
 for unrecognized tax benefits have been recorded to the extent that
 they do not exceed the Company&#x2019;s available losses that are
 not limited as a result of ownership changes that have occurred
 under Section&#xA0;382 of the Code. Reductions to unrecognized tax
 benefits for limitations on the utilization of net operating losses
 due to ownership changes occurring during the year has been
 reflected in the table as reductions based on tax positions related
 to the current year. Histogenics accrues interest and penalties
 related to unrecognized tax benefits as a component of its
 provision for income taxes. No accrued interest and penalties
 related to the Company&#x2019;s unrecognized tax benefits has been
 accrued as of December&#xA0;31, 2016 and 2015. The Company believes
 that it is reasonably possible that none of its unrecognized tax
 benefits, may be recognized at the end of 2016. The Company or one
 of its subsidiaries files income tax returns in the United States
 and various states and Israel. The Company is subject to U.S.
 federal, state and local income tax examinations by tax authorities
 for years 2001 through present. Carryforward attributes that were
 generated in earlier periods remain subject to examination to the
 extent the year in which they were used or will be used remains
 open for examination. The tax years which remain subject to
 examination by tax authorities in Israel, as of December&#xA0;31,
 2016, include years 2013 through the present.</p>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32718-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32639-109319<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6648296688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefits<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Compensation and Retirement Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Employee Benefits</a></td>
<td class="text"><div>
 <table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" border="0" cellpadding="0" cellspacing="0" width="100%">
 <tr style="page-break-inside:avoid">
 <td width="4%" valign="top" align="left"><b>13.</b></td>
 <td align="left" valign="top"><b>EMPLOYEE BENEFITS</b></td>
 </tr>
 </table>
 <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 The Company has a defined contribution 401(k) plan for employees
 who are at least 21 years of age. Employees are eligible to
 participate in the plan beginning on the first day of the calendar
 quarter following their date of hire. Under the terms of the plan,
 employees may make voluntary contributions as a percent of
 compensation. No matching contributions have been made by the
 Company since the adoption of the 401(k) plan.</p>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for pension and other postretirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 80<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=65877416&amp;loc=SL14450702-114947<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=65897934&amp;loc=d3e2410-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39675-114964<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66047640&amp;loc=d3e39622-114963<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6929200272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Parties<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Parties</a></td>
<td class="text"><div>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="break-inside: avoid">
 <td valign="top" width="4%" align="left"><b>14.</b></td>
 <td valign="top" align="left"><b>RELATED PARTIES</b></td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 <b>Intrexon Corporation</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 In September 2014, the Company entered into an Exclusive Channel
 Collaboration agreement with Intrexon (the &#x201C;Collaboration
 Agreement&#x201D;) to use Intrexon&#x2019;s proprietary technology
 for the development and commercialization of allogeneic cell
 therapeutics (the &#x201C;Collaboration Products&#x201D;) to treat or
 repair damaged articular hyaline cartilage in humans. The term of
 the Collaboration Agreement commenced upon the effective date,
 September&#xA0;30, 2014, and continues until either written notice
 of termination is given by the Company within ninety days, or if
 either party creates a material breach that cannot be remedied
 within sixty days.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 Under the terms of the Collaboration Agreement, the Company is
 solely responsible for the costs to develop and commercialize any
 Collaboration Products with the following exceptions: (i)&#xA0;the
 establishment of certain manufacturing capabilities and facilities;
 (ii)&#xA0;the cost of basic research related to Intrexon&#x2019;s
 proprietary technology outside of costs related to the
 Collaboration Products; (iii)&#xA0;payments related to certain
 in-licensed third party IP; (iv)&#xA0;the costs of filing,
 prosecution and maintenance of Intrexon patents; and (v)&#xA0;any
 other costs mutually agreed upon as being the responsibility of
 Intrexon. As partial consideration, the Company will pay
 commercialization milestones totaling $12 million, if and when
 achieved, and sales milestones totaling $22.5 million, if and when
 achieved. The milestone payments are payable in cash or shares of
 the Company&#x2019;s common stock at the option of the Company. In
 the event the Company is sold prior to making any of these
 milestone payments and the Collaboration Agreement is transferred
 in the sale, the milestone payments would be payable in cash. The
 Company is also required to make low double digit royalty payments
 to Intrexon on any gross profit arising from the sale of
 Collaboration Products and to pay an intermediate double digit
 percentage of any sublicensing revenue it receives.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 Under the terms of the Collaboration Agreement, the Company
 reimburses Intrexon for 50% of the product research and development
 costs with the remaining 50% due after acceptance by the FDA or
 equivalent regulatory authority of an Investigational New Drug
 Application or equivalent regulatory filing of a collaboration
 product or upon 90 day written notice of cancellation by the
 Company. Total incurred expenses were $3.0 million and $3.1 million
 for the year ended December&#xA0;31, 2016 and 2015, respectively.
 The total accrued expenses due Intrexon at December&#xA0;31, 2016
 and December&#xA0;31, 2015 was $3.0 million and $1.5 million,
 respectively. Amounts are reflected as current liabilities in the
 consolidated balance sheet as of December&#xA0;31, 2015. Amounts
 have been reclassified to long term liabilities in the consolidated
 balance sheet as of December&#xA0;31, 2016, as a result of a change
 in circumstances, including the plans for products that we are
 developing as a part of the Exclusive Channel Collaboration with
 Intrexon. These expenses were included in research and development
 in the consolidated statement of operations.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 <b>Purpose, Co.</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 In June 2012, the Company entered into an agreement with Purpose,
 Co. to amend its previous agreements. In the previous agreements,
 Purpose, Co. granted the Company a perpetual license to its patents
 related to its exogenous tissue processor which is used in the
 development of the Company&#x2019;s products. In exchange, the
 Company granted Purpose, Co. a perpetual license to all of the
 Company&#x2019;s biotechnology and biomaterial for use in Japan. The
 agreement provides for Purpose, Co. to manufacture and sell
 machinery to the Company for cost until the Company&#x2019;s
 products become commercially viable. The Company has also agreed to
 pay royalties on any third-party revenue generated using Purpose,
 Co.&#x2019;s licensed technology.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 Under the June 2012 amendment, the Company received exclusive
 rights to all of Purpose, Co.&#x2019;s technology related to the
 exogenous tissue processor, continued supply of exogenous tissue
 processors during the Company&#x2019;s clinical trials, and rights
 to manufacture the exogenous tissue processors at any location the
 Company chooses. In exchange for such consideration, the Company
 named Purpose, Co. the sole manufacturer of equipment and also
 clarified the geographic territories of the exclusive license that
 Purpose Co. was granted for use of the Company&#x2019;s technology.
 Also, the Company agreed to reimburse Purpose, Co. for $0.3 million
 of development costs on a next generation tissue processer. Refer
 to the discussion under Note 7,&#xA0;<i>Tissue Processor
 Sub-License</i>.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 In May 2016, the Company acquired the development and
 commercialization rights to NeoCart for the Japanese market from
 Purpose, Co. Under the terms of the amended agreement, the Company
 assumes sole responsibility for and rights to the development and
 commercialization of NeoCart in Japan. In exchange for the transfer
 of development and commercialization rights, the Company will pay a
 success-based milestone to Purpose upon conditional approval of
 NeoCart in Japan, as well as commercial milestones and a low single
 digit royalty on Japanese sales of NeoCart, upon full approval, if
 any, in Japan.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 The amounts that have been paid to Purpose, Co. under this
 agreement were $0.1 and $0.2 million for the years ended
 December&#xA0;31, 2016 and 2015, respectively.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 <b>Board of Director Affiliates</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 Affiliates of certain members of the Company&#x2019;s Board of
 Directors participated in the Private Placement as described in
 Note 8.</p>


 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39622-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39678-107864<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6648543616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><div>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="PAGE-BREAK-INSIDE: avoid">
 <td valign="top" width="4%" align="left"><b>15.</b></td>
 <td valign="top" align="left"><b>SUBSEQUENT EVENTS</b></td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 On February&#xA0;22, 2017, the Company entered into an amendment
 with Collagen Solutions (UK) LTD (the &#x201C;Supplier&#x201D;). The
 original agreement was entered into on September&#xA0;15, 2015.
 Pursuant to the amendment, the Company agrees to pay the Supplier
 approximately $0.1 million in exchange for eliminating the minimum
 annual order of material and/or services and any other amounts due
 Supplier. The payment of $0.1 million will be made over the 18
 months following the date of the amendment.</p>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6772139328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Accounting</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 <b>Basis of Accounting</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 The consolidated financial statements are prepared in conformity
 with accounting principles generally accepted in the United States
 of America (&#x201C;U.S. GAAP&#x201D;). The consolidated financial
 statements include the accounts of Histogenics Corporation and its
 wholly-owned subsidiaries, ProChon and Histogenics Securities
 Corporation. All significant intercompany accounts and transactions
 are eliminated in consolidation.</p>
 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassifications</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>Reclassifications</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 The Company has reclassified certain prior period amounts to
 conform to the current period presentation. The amounts
 reclassified impact Accounts Payable and Accounts Payable due to
 Intrexon Corporation (&#x201C;Intrexon&#x201D;) for the year ended
 December&#xA0;31, 2015.</p>
 </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 <b>Use of Estimates</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 The preparation of the Company&#x2019;s consolidated financial
 statements requires it to make estimates and assumptions that
 impact the reported amounts of assets, liabilities, revenues and
 expenses and the disclosure of contingent assets and liabilities in
 the Company&#x2019;s consolidated financial statements and
 accompanying notes. The most significant estimates in the
 Company&#x2019;s consolidated financial statements relate to the
 valuation of equity awards, warrant liability, recoverability of
 deferred tax assets, estimated useful lives of fixed assets and
 intangible assets. The Company bases estimates and assumptions on
 historical experience when available and on various factors that it
 believes to be reasonable under the circumstances. The Company
 evaluates its estimates and assumptions on an ongoing basis. The
 Company&#x2019;s actual results may differ from these estimates
 under different assumptions or conditions.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="break-inside: avoid">
 <td valign="top" width="4%" align="left"></td>
 <td valign="top" align="left"></td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Translation</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt">
 <b>Foreign Currency Translation</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 The Company&#x2019;s consolidated financial statements are prepared
 in U.S. dollars. The Company&#x2019;s foreign subsidiary uses the
 U.S. dollar as its functional and reporting currency, as management
 determined that the U.S. dollar is the primary currency of the
 economic environment in which the subsidiary operates. When
 transactions are required to be paid in the local currency of the
 foreign subsidiary, any resulting foreign currency transaction gain
 or loss is recorded as a component of &#x201C;Other income
 (expense), net&#x201D; in the consolidated statements of
 operations.</p>
 </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment and Geographic Information</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>Segment and Geographic Information</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 Operating segments are defined as components of an enterprise about
 which separate discrete financial information is available for
 evaluation by the chief operating decision-maker
 (&#x201C;CODM&#x201D;) or decision-making group in making decisions
 regarding resource allocation and assessing performance. The
 Company operates in two geographic regions: the United States
 (Massachusetts) and Israel (Tel Aviv) and views its operations as
 two operating segments: Histogenics Corporation (United States) and
 ProChon (Israel) as the CODM reviews separate discrete financial
 information in making decisions regarding resource allocations and
 assessing performance. Operating segments that have similar
 economic characteristics can be aggregated. As the nature of the
 products, customers, and methods to distribute products are the
 same and the nature of the regulatory environment, the production
 processes and historical and estimated future margins are similar,
 the two operating segments have been aggregated into one reporting
 segment as they have similar economic characteristics.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 Information about the Company&#x2019;s operations in different
 geographic regions is presented in the tables below:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="66%"></td>
 <td valign="bottom" width="11%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="11%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>December&#xA0;31,<br />
 2016</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>December&#xA0;31,<br />
 2015</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="6" align="center"><b>(in
 thousands)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Long-lived assets:</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 United States</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">3,860</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">5,204</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Israel</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">9</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Total long-lived assets</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">3,860</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">5,213</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 <b>Fair Value Measurements</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 The carrying amounts reported in the Company&#x2019;s consolidated
 financial statements for cash and cash equivalents, accounts
 payable, equipment loan, and accrued liabilities approximate their
 respective fair values because of the short-term nature of these
 accounts.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 Fair value is defined as the price that would be received if
 selling an asset or paid to transfer a liability in the principal
 or most advantageous market for the asset or liability in an
 orderly transaction between market participants on the measurement
 date.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 Fair value should be based on the assumptions that market
 participants would use when pricing an asset or liability and is
 based on a fair value hierarchy that prioritizes the information
 used to develop those assumptions. The fair value hierarchy gives
 the highest priority to quoted prices in active markets (observable
 inputs) and the lowest priority to the Company&#x2019;s assumptions
 (unobservable inputs). Fair value measurements should be disclosed
 separately by level within the fair value hierarchy. For assets and
 liabilities recorded at fair value, it is the Company&#x2019;s
 policy to maximize the use of observable inputs and minimize the
 use of unobservable inputs when developing fair value measurements,
 in accordance with established fair value hierarchy.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 Fair value measurements for assets and liabilities where there
 exists limited or no observable market data are based primarily
 upon estimates, and often are calculated based on the economic and
 competitive environment, the characteristics of the asset or
 liability and other factors. Therefore, the results cannot be
 determined with precision and may not be realized in an actual sale
 or immediate settlement of the asset or liability. Additionally,
 there may be inherent weaknesses in any valuation technique, and
 changes in the underlying assumptions used, including discount
 rates and estimates of future cash flows, could significantly
 affect the results of current or future values.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 Additionally, from time to time, the Company may be required to
 record at fair value other assets on a nonrecurring basis, such as
 assets held for sale and certain other assets. These nonrecurring
 fair value adjustments typically involve application of
 lower-of-cost-or-market accounting or write-downs of individual
 assets.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 The fair value hierarchy gives the highest priority to unadjusted
 quoted prices in active markets for identical assets (Level 1), and
 the lowest priority to unobservable inputs (Level 3). The
 Company&#x2019;s financial assets are classified within the fair
 value hierarchy based on the lowest level of inputs that is
 significant to the fair value measurement. The three levels of the
 fair value hierarchy, and its applicability to the Company&#x2019;s
 financial assets, are described below.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 62px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 <i>Level 1</i>: Unadjusted quoted prices in active markets that are
 accessible at the measurement date of identical, unrestricted
 assets.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 62px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 <i>Level 2</i>: Quoted prices for similar assets, or inputs that
 are observable, either directly or indirectly, for substantially
 the full term through corroboration with observable market data.
 Level 2 includes investments valued at quoted prices adjusted for
 legal or contractual restrictions specific to the security.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 62px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 <i>Level 3</i>: Pricing inputs are unobservable for the assets,
 that is, inputs that reflect the reporting entity&#x2019;s own
 assumptions about the assumptions market participants would use in
 pricing the assets. Level 3 includes private investments that are
 supported by little or no market activity.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 Level 3 valuations are for instruments that are not traded in
 active markets or are subject to transfer restrictions and may be
 adjusted to reflect illiquidity and/or non-transferability, with
 such adjustment generally based on available market evidence. In
 the absence of such evidence, management&#x2019;s best estimate is
 used.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 An adjustment to the pricing method used within either Level 1 or
 Level 2 inputs could generate a fair value measurement that
 effectively falls in a lower level in the hierarchy. The Company
 had no assets or liabilities classified as Level 1 or Level 2 as of
 December&#xA0;31, 2016 and 2015 other than the money market fund
 described in the &#x201C;Cash and Cash Equivalents&#x201D; section
 below and there were no material re-measurements of fair value with
 respect to financial assets and liabilities, during the periods
 presented, other than those assets and liabilities that are
 measured at fair value on a recurring basis. Other than the
 warrants issued in connection with the private placement
 transaction which closed on September&#xA0;29, 2016, the Company
 had no assets or liabilities classified as Level 3 as of
 December&#xA0;31, 2016 and 2015.&#xA0;Transfers are calculated on
 values as of the transfer date. There were no transfers between
 Levels 1, 2 and 3 during the twelve months ended December&#xA0;31,
 2016 and 2015.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 The fair value of the warrants was determined using a Monte Carlo
 simulation model.&#xA0;This model incorporated several assumptions
 at each valuation date including: the price of the Company&#x2019;s
 common stock on the date of valuation, the historical volatility of
 the price of the Company&#x2019;s common stock, the remaining
 contractual term of the warrant and estimates of the probability of
 a fundamental transaction occurring. See Note 8, Capital Stock, for
 further discussion of the private placement.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="92%" align="center" border="0">
 <tr>
 <td width="46%"></td>
 <td valign="bottom" width="9%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="9%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="9%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="9%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom" nowrap="nowrap">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; WIDTH: 39.5pt; BORDER-BOTTOM: rgb(0,0,0) 1pt solid; MARGIN-TOP: 0pt">
 <b>Description</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Total</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Quoted</b><br />
 <b>prices in</b><br />
 <b>active&#xA0;markets</b><br />
 <b>(Level 1)</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Significant</b><br />
 <b>other</b><br />
 <b>observable&#xA0;inputs</b><br />
 <b>(Level 2)</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Significant</b><br />
 <b>unobservable</b><br />
 <b>inputs</b><br />
 <b>(Level 3)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="14" align="center"><b>(in
 thousands)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 <b>December&#xA0;31, 2016</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 <b>Assets:</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Money market funds</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">30,318</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">30,318</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 <b>Liabilities:</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Warrant liability</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">13,197</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">13,197</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 <b>December&#xA0;31, 2015</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Money market funds</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">25,764</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">25,764</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 The following table provides a reconciliation of all liabilities
 measured at fair value using Level 3 significant unobservable
 inputs:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="68%" align="center" border="0">
 <tr>
 <td width="67%"></td>
 <td valign="bottom" width="25%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center">
 <b>As&#xA0;of&#xA0;December&#xA0;31,&#xA0;2016</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center"><b>(in
 thousands)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Beginning balance, January&#xA0;1, 2016</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Issuance of warrants,</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">30,704</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Change in fair value of warrant liability</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(17,507</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Ending balance</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">13,197</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 &#xA0;</p>
 </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>Cash and Cash Equivalents</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 Cash and cash equivalents include cash in readily available
 checking and savings accounts and money market funds. The Company
 considers all highly liquid investments with an original maturity
 of three months or less from the date of purchase to be cash
 equivalents.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 The Company&#x2019;s cash equivalents, which consist of money market
 funds, are measured at fair value on a recurring basis. As of
 December&#xA0;31, 2016 and 2015, the carrying amount of cash and
 cash equivalents was $31.9 million and $30.9 million, respectively,
 which approximates fair value and was determined based upon Level 1
 inputs. Money market funds are valued using quoted market prices
 with no valuation adjustments applied. Accordingly, these
 securities are categorized as Level 1 and had a balance of $30.3
 million and $25.8 million as of December&#xA0;31, 2016 and 2015,
 respectively, shown in the table above.</p>
 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>Concentration of Credit Risk</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 Financial instruments, which potentially subject the Company to
 significant concentration of credit risk, consist primarily of cash
 and cash equivalents. The Company maintains deposits in federally
 insured financial institutions in excess of federally insured
 limits. The Company has not experienced any losses in such accounts
 and management believes that the Company is not exposed to
 significant credit risk due to the financial position of the
 depository institutions in which those deposits are held. The
 Company has no financial instruments with off-balance sheet risk of
 loss.</p>
 </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt">
 <b>Property and Equipment</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 Property and equipment are recorded at historical cost. Costs for
 capital assets not yet placed into service are capitalized as
 construction in progress, and will be depreciated in accordance
 with the below guidelines once placed into service. Maintenance and
 repair costs are expensed as incurred. Costs which materially
 improve or extend the lives of existing assets are capitalized. The
 Company provides for depreciation and amortization using the
 straight-line method over the estimated useful lives of the assets,
 which are as follows:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="32%"></td>
 <td valign="bottom" width="5%"></td>
 <td width="63%"></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" nowrap="nowrap">
 <p style="MARGIN-BOTTOM: 1pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt">
 Asset Category</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom">
 <p style="MARGIN-BOTTOM: 1pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt">
 Estimated Useful Lives</p>
 </td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Office equipment</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">3 to 5 years</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Laboratory equipment</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">3 to 5 years</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Leasehold improvements</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">Shorter of the remaining lease term or useful
 life</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 Upon retirement or sale, the cost of assets disposed and the
 related accumulated depreciation are removed from the accounts and
 any resulting gain or loss is recorded in the consolidated
 statements of operations.</p>
 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>Impairment of Long-Lived Assets</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 Long-lived assets consist primarily of property and equipment and
 identifiable intangible assets. When impairment indicators exist,
 the Company&#x2019;s management evaluates long-lived assets for
 potential impairment. An impairment loss is recorded if and when
 events and circumstances indicate that assets might be impaired and
 the undiscounted cash flows estimated to be generated by those
 assets are less than the carrying amount of those assets. While the
 Company&#x2019;s current and historical operating losses and
 negative cash flows are indicators of impairment, management
 believes that future cash flows to be received support the carrying
 value of its long-lived assets.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 Impairments, if any, are recognized in earnings. An impairment loss
 would be recognized in an amount equal to the excess of the
 carrying amount over the undiscounted expected future cash
 flows.</p>
 </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Intangible Asset</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>Intangible Asset</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 The Company&#x2019;s intangible asset consists of acquired
 in-process research and development (&#x201C;IPR&amp;D&#x201D;)
 obtained through the acquisition of ProChon. IPR&amp;D represents
 the fair value assigned to research and development assets that
 have not been completed at the date of acquisition. The value
 assigned to acquired IPR&amp;D is determined by estimating the
 costs to develop the acquired technology into commercially viable
 products, estimating the resulting revenue from the projects, and
 discounting the net cash flows to present value. The revenue and
 costs projections used to value acquired IPR&amp;D were adjusted
 based on the probability of success of developing a new product.
 Additionally, the projections considered the relevant market sizes
 and growth factors, expected trends in technology and the nature
 and expected timing of new product introductions by the Company and
 its competitors. The rates utilized to discount the net cash flows
 to their present value were commensurate with the stage of
 development of the projects and uncertainties in the economic
 estimates used in the projections described above.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 IPR&amp;D is considered an indefinite-lived intangible asset and is
 assessed for impairment annually or more frequently if impairment
 indicators exist. When performing the impairment assessment, the
 Company first assesses qualitative factors to determine whether it
 is necessary to recalculate the fair value of its acquired
 IPR&amp;D. If the Company believes, as a result of the qualitative
 assessment, that it is more likely than not that the fair value of
 acquired IPR&amp;D is less than its carrying amount, it calculates
 the fair value using the same methodology as described above. If
 the carrying value of the Company&#x2019;s acquired IPR&amp;D
 exceeds its fair value, then an impairment charge is taken and the
 intangible asset is written-down to its fair value. During the
 fourth quarter the Company deemed the value of the IPR&amp;D to be
 zero for the year ended December&#xA0;31, 2016 as it has no plans
 to advance the technology or use it in any future clinical
 development activities. The result was a write-off of $0.2 million.
 For the year ended December&#xA0;31, 2015, the Company determined
 that there was impairment of its IPR&amp;D of $0.3 million. The
 Company performed its annual impairment test of its IPR&amp;D as of
 December&#xA0;31, 2015 using an income approach, including a
 discount rate of 13%, applied to probability-adjusted after-tax
 cash flows. The Company believes that the assumptions are
 representative of those a market participant would use in
 estimating the fair value of the IPR&amp;D.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 Intangible asset, net of accumulated impairment charges, are
 summarized as follows:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0">
 <tr>
 <td width="50%"></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"><b>As of
 December&#xA0;31,&#xA0;2016</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"><b>As of December&#xA0;31,
 2015</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Cost</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Accumulated</b><br />
 <b>Impairment</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Net&#xA0;Book</b><br />
 <b>Value</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Cost</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Accumulated</b><br />
 <b>Impairment</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Net&#xA0;Book</b><br />
 <b>Value</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"><b>(in thousands)</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"><b>(in thousands)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 IPR&amp;D</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">630</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(630</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">630</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(430</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">200</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">630</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(630</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">630</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(430</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">200</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hsgx_InitialPublicOfferingCostsPolicyTextBlock', window );">Initial Public Offering Costs</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>Initial Public Offering Costs</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 The Company deferred direct incremental costs attributable with the
 IPO of its common stock prior to the closing of the IPO. These
 costs represent legal, accounting and other direct costs related to
 the Company&#x2019;s efforts to raise capital through a public sale
 of its common stock. Upon completion of the IPO, $3.9 million of
 IPO costs were reclassified to additional paid-in capital as a
 reduction of the IPO proceeds. As of December&#xA0;31, 2014, the
 Company had paid $2.9 million with the remaining $1.0 million
 included in accounts payable in the consolidated balance sheet.
 This amount was subsequently paid in 2015.</p>
 </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted Cash</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>Restricted Cash</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 Restricted cash represents cash held in a depository account at a
 financial institution to collateralize a conditional stand-by
 letter of credit related to the Company&#x2019;s Lexington,
 Massachusetts facility lease agreement. Restricted cash is reported
 as non-current unless the restrictions are expected to be released
 in the next twelve months.</p>
 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredChargesPolicyTextBlock', window );">Deferred Rent</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>Deferred Rent</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 Deferred rent consists of the difference between cash payments and
 the recognition of rent expense on a straight-line basis for the
 facilities the Company occupies. The Company&#x2019;s leases for its
 Waltham, Massachusetts facility and its Lexington, Massachusetts
 facility provide for fixed increases in minimum annual rental
 payments. The total amount of rental payments due over each lease
 term is being charged to rent expense ratably over the life of each
 lease, respectively.</p>
 </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Financial Instruments Indexed to and Potentially Settled in the Company's Common Stock</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>Financial Instruments Indexed to and Potentially Settled in the
 Company&#x2019;s Common Stock</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 The Company evaluates all financial instruments issued in
 connection with its equity offerings when determining the proper
 accounting treatment for such instruments in the Company&#x2019;s
 financial statements. The Company considers a number of generally
 accepted accounting principles under U.S. GAAP to determine such
 treatment and evaluates the features of the instrument to determine
 the appropriate accounting treatment. The Company utilizes the
 Probability Weighted Expected Return Method (&#x201C;PWERM&#x201D;),
 Option Pricing Model (&#x201C;OM&#x201D;) or other appropriate
 methods to determine the fair value of its derivative financial
 instruments. For financial instruments indexed to and potentially
 settled in the Company&#x2019;s common stock that are determined to
 be classified as liabilities on the consolidated balance sheet,
 changes in fair value are recorded as a gain or loss in the
 Company&#x2019;s consolidated statement of operations with the
 corresponding amount recorded as an adjustment to the liability on
 its consolidated balance sheet.</p>
 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>Revenue Recognition</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 In the future, if we generate revenue, it may be through license
 agreements, collaborations and product sales. The Company
 recognizes revenue when all four of the following criteria are met:
 (1)&#xA0;persuasive evidence that an agreement exists;
 (2)&#xA0;delivery of the products and/or services has occurred;
 (3)&#xA0;the selling price is fixed or determinable; and
 (4)&#xA0;collectability is reasonably assured. The Company did not
 recognize any revenue for the years ended December&#xA0;31, 2016
 and 2015.</p>
 </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 <b>Research and Development Costs</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 Research and development costs are charged to expense as incurred.
 These costs include, but are not limited to: license fees related
 to the acquisition of in-licensed products; employee-related
 expenses, including salaries, benefits and travel; expenses
 incurred under agreements with contract research organizations and
 investigative sites that conduct clinical trials and preclinical
 studies; the cost of acquiring, developing and manufacturing
 clinical trial materials; facilities, depreciation and other
 expenses, which include direct and allocated expenses for rent and
 maintenance of facilities; insurance and other supplies; and costs
 associated with preclinical activities and regulatory
 operations.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 Costs for certain development activities, such as clinical trials,
 are recognized based on an evaluation of the progress to completion
 of specific tasks using data such as patient enrollment, clinical
 site activations, or information provided to the Company by its
 vendors with respect to their actual costs incurred. Payments for
 these activities are based on the terms of the individual
 arrangements, which may differ from the pattern of costs incurred,
 and are reflected in the consolidated financial statements as
 prepaid or accrued research and development expense.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 <i>Collaboration Arrangements</i></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 Costs reimbursed to a collaborator for work that it performs are
 recorded as research and development expenses. These reimbursements
 can include payments for work performed, or a milestone for which a
 payment is due, the reimbursements or development milestone
 achievement are recorded as research and development expense.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 In September 2014, the Company entered into a collaboration
 agreement with Intrexon Corporation (&#x201C;Intrexon&#x201D;) for
 the development and commercialization of allogeneic cell
 therapeutics for the treatment or repair of damaged articular
 hyaline cartilage in humans, utilizing Intrexon&#x2019;s proprietary
 technology (the &#x201C;Collaboration Agreement&#x201D;). Under the
 terms of the Collaboration Agreement, the Company is responsible
 for the costs of development and commercialization, with some
 exceptions. Refer to Note 14,&#xA0;<i>Related
 Parties</i>&#xA0;for
 further details on all terms, conditions and exceptions of this
 collaboration.</p>
 <p>&#xA0;</p>


 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hsgx_LicenseAgreementsPolicyTextBlock', window );">License Agreements</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>License Agreements</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 Costs associated with licenses of technology are expensed as
 incurred and are included in research and development expenses.</p>
 </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hsgx_PatentCostsPolicyTextBlock', window );">Patent Costs</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt">
 <b>Patent Costs</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 Costs related to filing and pursuing patent applications are
 recorded as general and administrative expense as incurred since
 the recoverability of such expenditures is uncertain.</p>
 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>Stock-Based Compensation</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 The Company accounts for grants of stock options and restricted
 stock based on their grant date fair value and recognizes
 compensation expense over their vesting period. The Company
 estimates the fair value of stock options as of the date of grant
 using the Black-Scholes option pricing model and restricted stock
 based on the fair value of the underlying common stock as
 determined by management or the value of the services provided,
 whichever is more readily determinable.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 Stock-based compensation expense represents the cost of the grant
 date fair value of employee stock option grants recognized over the
 requisite service period of the awards (usually the vesting period)
 on a straight-line basis, net of estimated forfeitures. The expense
 is adjusted for actual forfeitures at year end. Stock-based
 compensation expense recognized in the consolidated financial
 statements is based on awards that are ultimately expected to
 vest.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 For stock option grants with performance-based milestones, the
 expense is recorded over the remaining service period after the
 point when the achievement of the milestone is probable or the
 performance condition has been achieved. For stock option grants
 with both performance-based milestones and market conditions,
 expense is recorded over the derived service period after the point
 when the achievement of the performance-based milestone is probable
 or the performance condition has been achieved. The Company issued
 performance-based awards in 2015, but not in 2016.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 The Company accounts for stock options and restricted stock awards
 to non-employees using the fair value approach. Stock options and
 restricted stock awards to non-employees are subject to periodic
 revaluation over their vesting terms.</p>
 </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>Income Taxes</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 The Company accounts for income taxes under the liability method,
 which requires the recognition of deferred tax assets and
 liabilities for the expected future tax consequences of events that
 have been included in the financial statements. Under this method,
 deferred tax assets and liabilities are determined on the basis of
 the differences between the financial statements and tax basis of
 assets and liabilities using enacted tax rates in effect for the
 year in which the differences are expected to reverse. The effect
 of a change in tax rates on deferred tax assets and liabilities is
 recognized in income in the period that includes the enactment
 date.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 The Company recognizes net deferred tax assets to the extent that
 the Company believes these assets are more likely than not to be
 realized. In making such a determination, management considers all
 available positive and negative evidence, including future
 reversals of existing taxable temporary differences, projected
 future taxable income, tax-planning strategies, and results of
 recent operations. If management determines that the Company would
 be able to realize its deferred tax assets in the future, in excess
 of its net recorded amount, management would make an adjustment to
 the deferred tax asset valuation allowance, which would reduce the
 provision for income taxes.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 The Company records uncertain tax positions on the basis of a
 two-step process whereby (1)&#xA0;management determines whether it
 is more likely than not that the tax positions will be sustained on
 the basis of the technical merits of the position and (2)&#xA0;for
 those tax positions that meet the more likely than not recognition
 threshold, management recognizes the largest amount of tax benefit
 that is more than 50 percent likely to be realized upon ultimate
 settlement with the related tax authority. The Company recognizes
 interest and penalties related to unrecognized tax benefits within
 income tax expense. Any accrued interest and penalties are included
 within the related tax liability.</p>
 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings (Loss) per Common Share</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>Earnings (Loss) per Common Share</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 Earnings (loss) per common share is calculated using the two-class
 method, which is an earnings allocation formula that determines
 earnings (loss) per share for the holders of the Company&#x2019;s
 common shares and participating securities. All series of preferred
 stock contain participation rights in any dividend paid by the
 Company and are deemed to be participating securities. Earnings
 available to common stockholders and participating convertible
 redeemable preferred shares are allocated to each share on an
 as-converted basis as if all of the earnings for the period had
 been distributed. The participating securities include a
 contractual obligation to share in losses of the Company and
 are&#xA0;included in the calculation of net loss per share in the
 periods that have a net loss.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 Diluted earnings per share is computed using the more dilutive of
 (a)&#xA0;the two-class method, or (b)&#xA0;the if-converted method.
 The Company allocates earnings first to preferred stockholders
 based on dividend rights and then to common and preferred
 stockholders based on ownership interests. The weighted-average
 number of common shares included in the computation of diluted
 earnings (loss) gives effect to all potentially dilutive common
 equivalent shares, including outstanding stock options, warrants,
 convertible redeemable preferred stock and the potential issuance
 of stock upon the conversion of the Company&#x2019;s convertible
 notes. Common stock equivalent shares are excluded from the
 computation of diluted earnings (loss) per share if their effect is
 antidilutive.</p>
 </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hsgx_WarrantAccountingPolicyTextBlock', window );">Warrant Accounting</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 <b>Warrant Accounting</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 As noted in Note 9, the Company classifies warrants to purchase
 shares of its common stock as a liability on its consolidated
 balance sheet if the warrant is a free-standing financial
 instrument that may require the Company to transfer consideration
 upon exercise. Each warrant of this type is initially recorded at
 fair value on date of grant using the Monte Carlo simulation model
 and net of issuance costs, and is subsequently re-measured to fair
 value at each subsequent balance sheet date. Changes in fair value
 of the warrants are recognized as a component of other income
 (expense), net in the consolidated statement of operations. The
 Company will continue to adjust the liability for changes in fair
 value until the earlier of the exercise or expiration of the
 warrants.</p>
 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Pronouncements</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 <b>Recently Adopted Accounting Pronouncements</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 In November 2015, Financial Accounting Standards Board (&#x201C;the
 FASB&#x201D;) issued Accounting Standard Update (&#x201C;ASU&#x201D;)
 No.&#xA0;2015-17, Income Taxes (Topic 740): Balance Sheet
 Classification of Deferred Taxes. The new standard requires that
 deferred tax assets and liabilities be classified as noncurrent in
 a classified statement of financial position. The Company
 prospectively adopted this guidance in the fourth quarter of 2015,
 which resulted in the removal of gross deferred tax assets and
 liabilities from the Company&#x2019;s consolidated balance sheet.
 The net impact was zero and the prior period was not
 retrospectively adjusted.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 In November 2014, the FASB issued ASU No.&#xA0;2014-16, Derivatives
 and Hedging (Topic 815): Determining Whether the Host Contract in a
 Hybrid Financial Instrument Issued in the Form of a Share Is More
 Akin to Debt or to Equity. This standard provides guidance to
 eliminate the existing diversity in practice in accounting for
 hybrid financial instruments issued in the form of a share. A
 hybrid financial instrument consists of a &#x201C;host
 contract&#x201D; into which one or more derivative terms have been
 embedded. This guidance requires an entity to consider the terms
 and features of the entire financial instrument, including the
 embedded derivative features, in order to determine whether the
 nature of the host contract is more akin to debt or to equity. This
 guidance is effective for fiscal years and interim periods
 beginning after December&#xA0;15, 2015, with early adoption
 permitted. A reporting entity should apply this guidance using a
 modified retrospective approach by recording a cumulative-effect
 adjustment to equity as of the beginning of the annual period of
 adoption. Retrospective application is permitted to all relevant
 prior periods. The Company has concluded that this guidance has no
 impact on the presentation of its results of operations, financial
 position and disclosures.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 In August 2014, the FASB issued ASU No.&#xA0;2014-15, Presentation
 of Financial Statements&#x2014;Going Concern (Subtopic 2015-40):
 Disclosure of Uncertainties about an Entity&#x2019;s Ability to
 Continue as a Going Concern. This guidance addresses
 management&#x2019;s responsibility in evaluating whether there is
 substantial doubt about a company&#x2019;s ability to continue as a
 going concern and to provide related footnote disclosures. The
 guidance is effective for fiscal years ending after
 December&#xA0;15, 2016 and for interim periods within those fiscal
 years. The adoption of this standard did not have a material impact
 on our consolidated financial statements and related
 disclosures.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 In June 2014, the FASB issued ASU No.&#xA0;2014-12,
 Compensation-Stock Compensation (Topic 718): Accounting for
 Share-Based Payments When the Terms of an Award Provide That a
 Performance Target Could be Achieved after the Requisite Service
 Period. This standard provides guidance requiring when there is a
 performance target that affects vesting of equity awards granted
 and could be achieved after the requisite service period to be
 treated as a performance condition. A reporting entity should apply
 existing guidance on stock-based compensation, as it relates to
 such awards. This guidance is effective for annual periods and
 interim periods within those annual periods beginning after
 December&#xA0;15, 2015 with early adoption permitted using either
 of two methods: (i)&#xA0;prospective to all awards granted or
 modified after the effective date; or (ii)&#xA0;retrospective to
 all awards with performance targets that are outstanding as of the
 beginning of the earliest annual period presented in the financial
 statements and to all new or modified awards thereafter, with the
 cumulative effect of applying this guidance as an adjustment to the
 opening retained earnings balance as of the beginning of the
 earliest annual period presented in the financial statements. The
 Company issued performance-based awards during the year ended
 December&#xA0;31, 2015. The Company adopted this guidance on a
 prospective basis and there have not been any performance-based
 awards since the effective date of the guidance.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 <b>Recently Issued Accounting Pronouncements</b></p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 In November 2016, the FASB issued guidance that requires restricted
 cash and restricted cash equivalents be included with cash and cash
 equivalents when reconciling the total beginning and ending amounts
 for the periods shown on the statement of cash flows. The new
 standard is effective for us on January&#xA0;1, 2018 using a
 retrospective transition method to each period presented. Early
 adoption is permitted. We are currently evaluating the timing of
 our adoption and the expected impact that this standard could have
 on our consolidated financial statements and related
 disclosures.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 In March 2016, the FASB issued ASU No.&#xA0;2016-09,
 Compensation-Stock Compensation (Topic 718): Improvements to
 Employee Shared-Based Payment Accounting. This standard provides
 guidance on accounting for employee share-based payments. This
 guidance addresses several aspects of the accounting for
 share-based payment award transactions, including: (a)&#xA0;income
 tax consequences; (b)&#xA0;classification of awards as either
 equity or liabilities; and (c)&#xA0;classification on the statement
 of cash flows.&#xA0;This standard will be effective for fiscal
 years beginning after December&#xA0;15, 2016, including interim
 periods within those fiscal years.&#xA0;The Company is evaluating
 the impact of this guidance on the presentation of its results of
 operations, financial position and disclosures.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 In February 2016, the FASB, issued ASU
 No.&#xA0;2016-02,&#xA0;<i>Leases
 (Topic 842)</i>. The ASU requires companies to recognize on the
 balance sheet the assets and liabilities for the rights and
 obligations created by leased assets. ASU 2016-02 will be effective
 for the Company in the first quarter of 2019, with early adoption
 permitted. The Company is currently evaluating the impact that the
 adoption of ASU 2016-02 will have on the Company&#x2019;s
 consolidated financial statements or related disclosures.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 In May 2014, the FASB issued ASU No.&#xA0;2014-09, Revenue from
 Contracts with Customers (Topic 606), which requires an entity to
 recognize the amount of revenue to which it expects to be entitled
 for the transfer of promised goods or services to customers. ASU
 2014- 09 will replace most existing revenue recognition guidance in
 U.S. GAAP when it becomes effective. In July 2015, the FASB issued
 a one-year deferral of the effective date of the new revenue
 recognition standard. The new guidance will be effective for the
 Company&#x2019;s first quarter of fiscal year 2018 and early
 application for fiscal year 2017 would be permitted. The Company is
 evaluating the impact of this guidance on the presentation of its
 results of operations, financial position and disclosures.</p>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hsgx_InitialPublicOfferingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Initial Public Offering Costs [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hsgx_InitialPublicOfferingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hsgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hsgx_LicenseAgreementsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreements Policy [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hsgx_LicenseAgreementsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hsgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hsgx_PatentCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Patent Costs Policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hsgx_PatentCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hsgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hsgx_WarrantAccountingPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrant accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hsgx_WarrantAccountingPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hsgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 305<br> -SubTopic 10<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6375392&amp;loc=d3e26790-107797<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4273-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 305<br> -SubTopic 10<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6375392&amp;loc=d3e26790-107797<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18726-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 55<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6875567&amp;loc=d3e14489-108613<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68064133&amp;loc=d3e61082-112788<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=28088331&amp;loc=SL29635902-196195<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13537-108611<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13531-108611<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68064133&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredChargesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for deferral and amortization of significant deferred charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredChargesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=73719730&amp;loc=d3e13279-108611<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=64802544&amp;loc=d3e202-110218<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32840-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65884525&amp;loc=d3e40913-109327<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32809-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=75116654&amp;loc=d3e32247-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=75116654&amp;loc=d3e32280-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassifications that affects the comparability of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6359566&amp;loc=d3e326-107755<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Research and Development<br> -URI http://asc.fasb.org/extlink&amp;oid=6523717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.B.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18726-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6061-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6143-108592<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=64851502&amp;loc=d3e6132-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6648138464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock', window );">Summary of Operations in Different Geographic Regions</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 Information about the Company&#x2019;s operations in different
 geographic regions is presented in the tables below:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="66%"></td>
 <td valign="bottom" width="11%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="11%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>December&#xA0;31,<br />
 2016</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>December&#xA0;31,<br />
 2015</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="6" align="center"><b>(in
 thousands)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Long-lived assets:</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 United States</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">3,860</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">5,204</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Israel</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">9</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Total long-lived assets</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">3,860</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">5,213</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 The fair value of the warrants was determined using a Monte Carlo
 simulation model.&#xA0;This model incorporated several assumptions
 at each valuation date including: the price of the Company&#x2019;s
 common stock on the date of valuation, the historical volatility of
 the price of the Company&#x2019;s common stock, the remaining
 contractual term of the warrant and estimates of the probability of
 a fundamental transaction occurring. See Note 8, Capital Stock, for
 further discussion of the private placement.</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="92%" align="center" border="0">
 <tr>
 <td width="46%"></td>
 <td valign="bottom" width="9%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="9%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="9%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="9%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom" nowrap="nowrap">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; WIDTH: 39.5pt; BORDER-BOTTOM: rgb(0,0,0) 1pt solid; MARGIN-TOP: 0pt">
 <b>Description</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Total</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Quoted</b><br />
 <b>prices in</b><br />
 <b>active&#xA0;markets</b><br />
 <b>(Level 1)</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Significant</b><br />
 <b>other</b><br />
 <b>observable&#xA0;inputs</b><br />
 <b>(Level 2)</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>Significant</b><br />
 <b>unobservable</b><br />
 <b>inputs</b><br />
 <b>(Level 3)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="14" align="center"><b>(in
 thousands)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 <b>December&#xA0;31, 2016</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 <b>Assets:</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Money market funds</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">30,318</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">30,318</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 <b>Liabilities:</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Warrant liability</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">13,197</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">13,197</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 <b>December&#xA0;31, 2015</b></p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Money market funds</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">25,764</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">25,764</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 &#xA0;</p>
 </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of Reconciliation of Liabilities Measured at Fair Value</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 The following table provides a reconciliation of all liabilities
 measured at fair value using Level 3 significant unobservable
 inputs:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0">
 <tr>
 <td width="67%"></td>
 <td valign="bottom" width="25%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center">
 <b>As&#xA0;of&#xA0;December&#xA0;31,&#xA0;2016</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>(in thousands)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Beginning balance, January&#xA0;1, 2016</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Issuance of warrants,</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">30,704</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Change in fair value of warrant liability</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(17,507</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Ending balance</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">13,197</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hsgx_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock', window );">Schedule of Depreciation and Amortization using Straight-line Method over Estimated Useful Lives of Assets</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 The Company provides for depreciation and amortization using the
 straight-line method over the estimated useful lives of the assets,
 which are as follows:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="32%"></td>
 <td valign="bottom" width="5%"></td>
 <td width="63%"></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" nowrap="nowrap">
 <p style="MARGIN-BOTTOM: 1pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt">
 Asset Category</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom">
 <p style="MARGIN-BOTTOM: 1pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt">
 Estimated Useful Lives</p>
 </td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Office equipment</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">3 to 5 years</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Laboratory equipment</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">3 to 5 years</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Leasehold improvements</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">Shorter of the remaining lease term or useful
 life</td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Summary of Intangible Assets, Net of Accumulated Impairment Charges</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 Intangible asset, net of accumulated impairment charges, are
 summarized as follows:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0">
 <tr>
 <td width="50%"></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"><b>As of
 December&#xA0;31,&#xA0;2016</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"><b>As of December&#xA0;31,
 2015</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Cost</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Accumulated</b><br />
 <b>Impairment</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Net&#xA0;Book</b><br />
 <b>Value</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Cost</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Accumulated</b><br />
 <b>Impairment</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Net&#xA0;Book</b><br />
 <b>Value</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"><b>(in thousands)</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="10" align="center"><b>(in thousands)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 IPR&amp;D</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">630</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(630</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">630</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(430</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">200</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">630</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(630</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">630</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(430</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">200</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hsgx_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Property Plant And Equipment Estimated Useful Lives Table [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hsgx_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hsgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19279-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-lived assets, excluding financial instruments, long-term customer relationships of a financial institution, mortgage rights, deferred policy acquisition costs, and deferred tax assets, by geographic areas located in the entity's country of domicile and foreign countries in which the entity holds assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=68060357&amp;loc=d3e9038-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19190-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6929132896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Common Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Basic and Diluted Loss Per Common Share</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 Basic and diluted loss per common share are calculated as
 follows:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" align="center" border="0">
 <tr>
 <td width="76%"></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"><b>For the Year Ended</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2016</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2015</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="6" align="center"><b>(In thousands,
 except share and<br />
 per share data</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Numerator:</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Net loss</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(16,208</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(32,024</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Net Loss attributable to Series A Preferred Stock (a)</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(2,345</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Numerator for basic EPS&#x2014;Earnings (loss) attributable to
 common stockholders</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(13,863</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(32,024</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Effect of dilutive securities:</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Deduct change in fair value of warrant liability</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(17,507</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Numerator for diluted EPS&#x2014;Earnings (loss) attributable to
 common stockholders after assumed conversions</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(31,370</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(32,024</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Denominator:</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Weighted-average number of common shares used in earnings (loss)
 per<br />
 share&#x2014;basic</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">14,256,954</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">13,231,126</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Effect of dilutive securities:</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Nonparticipating warrants</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">132,238</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Denominator for diluted EPS&#x2014;adjusted weighted average
 shares</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">14,389,192</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">13,231,126</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Earnings (loss) per share&#x2014;basic</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(0.97</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(2.42</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Earnings (loss) per share&#x2014;diluted</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(2.18</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(2.42</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" border="0">
 <tr style="break-inside: avoid">
 <td valign="top" width="4%" align="left">(a)</td>
 <td valign="top" align="left">The Series A Preferred Stock
 participates in income and losses</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 &#xA0;</p>
 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 The following potentially dilutive securities have been excluded
 from the computation of diluted weighted-average shares
 outstanding, as they would be anti-dilutive (in common stock
 equivalent shares):</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="70%"></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"><b>As of December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2016</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2015</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Unvested restricted stock and options to purchase common stock</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,578,905</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,227,957</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Series A preferred stock unconverted</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5,962,817</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Warrants exercisable into common stock</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">166,403</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">166,403</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 &#xA0;</p>


 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6929195760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TextBlockAbstract', window );"><strong>Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">Schedule of Prepaid Expenses and Other Current Assets</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt">
 Prepaid expenses and other current assets consisted of the
 following:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="82%"></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>As of<br />
 December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2016</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2015</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="6" align="center"><b>(in
 thousands)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Deposits</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">10</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">67</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Undelivered laboratory and office equipment</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">17</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Insurance</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">95</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">42</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Other current assets</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">68</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">195</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Prepaid expenses and other current assets</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">173</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">321</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6759532512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment</a></td>
<td class="text"><div>
 <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 Property and equipment consisted of the following:</p>
 <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">
 &#xA0;</p>
 <table cellspacing="0" cellpadding="0" width="76%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center">
 <tr>
 <td width="65%"></td>
 <td valign="bottom" width="12%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="11%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>December&#xA0;31,<br />
 2016</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>December&#xA0;31,<br />
 2015</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="6" align="center"><b>(in
 thousands)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Office equipment</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">266</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">539</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Laboratory equipment</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4,443</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4,337</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Leasehold improvements</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">7,683</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">7,683</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Construction in progress</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">759</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">547</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Software</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">96</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">96</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Total property and equipment</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">13,247</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">13,202</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Less: accumulated depreciation</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(9,387</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(7,989</td>
 <td nowrap="nowrap" valign="bottom">)&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Property and equipment, net</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">3,860</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">5,213</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6648144496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses</a></td>
<td class="text"><div>
 <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 Accrued expenses consisted of the following:</p>
 <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">
 &#xA0;</p>
 <table cellspacing="0" cellpadding="0" width="76%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center">
 <tr>
 <td width="76%"></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="6" align="center" style="border-bottom:1.00pt solid #000000"><b>As of
 December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>2016</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>2015</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="6" align="center" style="border-bottom:1.00pt solid #000000"><b>(in thousands)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style="margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Accrued compensation</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,402</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">758</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Accrued clinical expenses</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">187</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">138</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Accrued other</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">508</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">548</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Total accrued expenses</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2,097</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,444</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6762151120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock', window );">Schedule of Minimum Annual Lease Commitments Under Non-Cancellable Operating Leases</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 Aggregate minimum annual lease commitments of the Company under its
 non-cancellable operating leases as of December&#xA0;31, 2016, are
 as follows:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="68%" align="center" border="0">
 <tr>
 <td width="79%"></td>
 <td valign="bottom" width="15%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom" colspan="4" nowrap="nowrap" align="center">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; WIDTH: 116.9pt; BORDER-BOTTOM: #000000 1pt solid; MARGIN-TOP: 0pt" align="center"><b>For the Year Ended December&#xA0;31,</b></p>
 </td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center">
 <b>(in&#xA0;thousands)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 2017</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2,266</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 2018</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">754</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 2019</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">586</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 2020</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">596</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 2021</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">605</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Thereafter</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">926</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Total minimum lease payments</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">5,733</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6648144496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capital Stock (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hsgx_ScheduleOfSharesOfCommonStockReservedForFutureIssuanceTableTextBlock', window );">Schedule of Common Stock Reserved for Future Issuance</a></td>
<td class="text"><div>
 <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
 The Company has reserved for future issuance the following number
 of shares of common stock:</p>
 <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">
 &#xA0;</p>
 <table cellspacing="0" cellpadding="0" width="68%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center">
 <tr>
 <td width="64%"></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="6" align="center" style="border-bottom:1.00pt solid #000000"><b>As of
 December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>2016</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"><b>2015</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Vesting of restricted stock</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,889</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5,190</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Options to purchase common stock</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,577,016</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,222,767</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Common stock warrants</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">13,633,070</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">166,403</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
 <td valign="top">
 <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">
 Total</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">15,211,975</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,394,360</td>
 <td nowrap="nowrap" valign="bottom">&#xA0;</td>
 </tr>
 <tr style="font-size:1px;">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hsgx_ScheduleOfSharesOfCommonStockReservedForFutureIssuanceTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of shares of common stock reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hsgx_ScheduleOfSharesOfCommonStockReservedForFutureIssuanceTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hsgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6762133776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equipment Loan Payable (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">Schedule of Outstanding Borrowing Obligations</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 As of December&#xA0;31, 2016 and 2015, the Company had the
 following outstanding borrowing obligations:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="66%"></td>
 <td valign="bottom" width="13%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="12%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>December&#xA0;31,<br />
 2016</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>December&#xA0;31,<br />
 2015</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="6" align="center">
 <b>(in&#xA0;thousands)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Silicon Valley Bank Equipment Loan Payable</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">761</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,344</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Less: current portion</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(583</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(583</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Long-term debt, net</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">178</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">761</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>


 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6757210432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity Under the 2012 and 2013 Plans</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 Stock option activity under the 2012 and 2013 plans is summarized
 as follows:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" align="center" border="0">
 <tr>
 <td width="61%"></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Number</b><br />
 <b>of Options</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Weighted-</b><br />
 <b>Average</b><br />
 <b>Exercise</b><br />
 <b>Price</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Weighted-</b><br />
 <b>Average</b><br />
 <b>Remaining</b><br />
 <b>Contractual</b><br />
 <b>Term</b><br />
 <b>(in years)</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Aggregate</b><br />
 <b>Intrinsic</b><br />
 <b>Value</b><br />
 <b>(in&#xA0;thousands)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Outstanding at December&#xA0;31, 2015</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,229,339</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">7.32</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">9.0</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(4,679</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Granted</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">464,240</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2.02</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Exercised</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(3,685</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">0.76</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Cancelled</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(112,878</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4.97</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Outstanding at December&#xA0;31, 2016</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,577,016</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">5.95</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">8.4</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">71</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Vested and expected to vest at December&#xA0;31, 2016</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,492,341</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">5.97</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">8.4</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">69</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Exercisable at December&#xA0;31, 2016</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">561,693</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">6.79</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">7.8</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">52</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock', window );">Additional Information about Stock Option Activity</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 Additional information about the Company&#x2019;s stock option
 activity is as follows:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 &#xA0;</p>
 <table style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" align="center" border="0">
 <tr>
 <td width="82%"></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center">
 <b>Year&#xA0;Ended&#xA0;December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2016</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2015</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Weighted-average grant date fair value per share of employee option
 grants within the year</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1.26</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">4.08</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Cash received upon exercise of options</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">39</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 </table>
 <br class="Apple-interchange-newline" /></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock', window );">Schedule of Restricted Stock Awards Under the 2012 and 2013 Plans</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 Restricted stock awards under the 2012 and 2013 plans are
 summarized as follows:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="64%"></td>
 <td valign="bottom" width="13%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="12%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Number&#xA0;of</b><br />
 <b>Shares</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Weighted&#xA0;Average</b><br />
 <b>Grant Date&#xA0;Fair</b><br />
 <b>Value</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Unvested at December&#xA0;31, 2015</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5,190</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1.07</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Vesting of restricted stock</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(3,301</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Unvested at December&#xA0;31, 2016</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,889</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">0.83</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Summary of Stock-Based Compensation</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 Stock-based compensation is as follows:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="76%"></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>Year Ended</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2016</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2015</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="6" align="center">
 <b>(in&#xA0;thousands)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Research and development</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">491</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">451</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 General and administrative</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,057</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">777</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Total stock-based compensation expense</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,548</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,228</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Summary of Weighted-Average Assumptions Used in the Black-Scholes Option Pricing Model to Determine the Fair Value of the Employee Stock Option Grants</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 The weighted-average assumptions used in the Black-Scholes option
 pricing model to determine the fair value of the employee stock
 option grants were as follows:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="83%"></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>Year Ended</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2016</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2015</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Risk-free interest rate</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1.73</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1.68</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Expected volatility</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">72.5</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">62.6</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Expected term (in years)</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6.08</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6.04</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Expected dividend yield</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">0.0</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">0.0</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionBySupplierTextBlock', window );">Summary of Weighted-Average Assumptions Used in the Black-Scholes Option Pricing Model to Determine the Fair Value of the Non-Employee Stock Option Grants</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt">
 The weighted-average assumptions used in the Black-Scholes option
 pricing model to determine the fair value of the non-employee stock
 option grants were as follows:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="83%"></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>Year Ended</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2016</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2015</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Risk-free interest rate</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1.57</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1.79</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Expected volatility</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">63.5</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">63.2</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Expected term (in years)</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">7.00</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6.16</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Expected dividend yield</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">0.0</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">0.0</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of total share-based compensation cost, including the amounts attributable to each share-based compensation plan and any related tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the total intrinsic value of options exercised (or share units converted), share-based liabilities paid, and the total fair value of shares vested during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for share options (or share units) that were outstanding at the beginning and end of the year, vested and expected to vest, exercisable or convertible at the end of the year, and the number of share options or share units that were granted, exercised or converted, forfeited, and expired during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionBySupplierTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of each transaction in which an entity acquires goods or services other than employee services in exchange for equity securities of the company, including the purpose of the transaction, identification and quantity of the securities issued, the accounting made, disclosure of amounts by which report lines were affected, and noncash effects on the statement of cash flows.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5444-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68057994&amp;loc=d3e25284-112666<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedGoodsAndNonemployeeServicesTransactionBySupplierTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6771581712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Components of Loss Before Income Taxes</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 he components of loss before income taxes were as follows:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 &#xA0;</p>
 <table style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="71%"></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"><b>As of December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2016</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2015</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="6" align="center"><b>(in
 thousands)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 U.S.</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(15,838</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(31,382</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Foreign</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(369</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(691</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Total</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(16,208</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(32,073</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Reconciliation of Income Tax Expense (Benefit) Computed at Statutory Federal Income Tax Rate</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 A reconciliation of income tax expense (benefit) computed at the
 statutory federal income tax rate to income taxes as reflected in
 the financial statements is as follows:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="79%"></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center">
 <b>As&#xA0;of&#xA0;December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2016</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2015</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Federal income tax (benefit) at statutory rate</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">34.0</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">34.0</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 (Increase) decrease income tax benefit resulting from:</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Permanent differences</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">29.0</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(1.2</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Net Operating Loss Limitation</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(111.1</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 R&amp;D Credit Limitation</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(1.5</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Change in valuation allowance</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">48.7</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(31.7</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Other</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">0.9</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(1.2</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Income tax expense (benefit)</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">0.0</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">0.0</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 &#xA0;</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 &#xA0;</p>


 </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Components of Deferred Tax Assets and Liabilities</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 Deferred taxes are recognized for temporary differences between the
 basis of assets and liabilities for financial statement and income
 tax purposes. The significant components of the Company&#x2019;s
 deferred tax assets and liabilities are comprised of the
 following:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &quot;Times New Roman&quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="71%"></td>
 <td valign="bottom" width="8%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"><b>As of December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2016</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"><b>2015</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Deferred tax assets:</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Net operating loss carryforwards</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">16,146</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">28,200</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Depreciation and amortization</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6,229</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6,688</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Accrued expenses</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,082</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,183</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Capitalized start-up costs</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">10,037</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">8,531</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Other</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">75</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">259</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Deferred tax assets before valuation allowance</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">34,569</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">44,861</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Valuation allowance</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(34,569</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(43,751</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,110</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Deferred tax liabilities</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 IPR&amp;D</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(36</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Change in accounting method</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(1,074</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid" bgcolor="#CCEEFF">
 <td valign="top"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(1,110</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; break-inside: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &quot;Times New Roman&quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Net deferred tax assets</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">$</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Summary of Changes In Unrecognized Tax Benefits</a></td>
<td class="text"><div>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt">
 The changes in the Company&#x2019;s unrecognized tax benefits are
 summarized as follows:</p>
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt">
 &#xA0;</p>
 <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0">
 <tr>
 <td width="79%"></td>
 <td valign="bottom" width="8%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">
 <b>As&#xA0;of&#xA0;December&#xA0;31,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2016</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2015</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" colspan="6" align="center"><b>(in
 thousands)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Unrecognized tax benefit, beginning of year</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">687</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">811</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Increase (decrease) related to current year positions</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(125</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(124</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Settlements</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom" nowrap="nowrap" align="right">
 &#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid">
 <td valign="top">
 <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em">
 Unrecognized tax benefit, end of year</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">562</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">687</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt">
 &#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 217<br> -URI http://asc.fasb.org/extlink&amp;oid=75116239&amp;loc=d3e36027-109320<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6771194880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business - Additional Information (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 29, 2016</div></th>
<th class="th"><div>Dec. 03, 2014</div></th>
<th class="th"><div>May 13, 2011</div></th>
<th class="th"><div>Jan. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hsgx_NatureOfBusinessAndBasisOfPresentationLineItems', window );"><strong>Nature Of Business And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants', window );">Proceeds from issuance of issuance of common stock, preferred stock and warrants, net of issuance costs</a></td>
<td class="nump">$ 27,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,630<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (181,773)<span></span>
</td>
<td class="num">$ (165,565)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hsgx_ProceedsFromIssuanceInitialPublicOfferingNet', window );">Net proceeds from initial public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 61,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=hsgx_ProChonBiotechLtdMember', window );">ProChon [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hsgx_NatureOfBusinessAndBasisOfPresentationLineItems', window );"><strong>Nature Of Business And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1', window );">Business acquisition date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">May 13,  2011<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Consideration paid to acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hsgx_NatureOfBusinessAndBasisOfPresentationLineItems', window );"><strong>Nature Of Business And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Sale of common stock shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,909,091<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Initial public offering price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Gross proceeds from initial public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 65,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Overallotment Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hsgx_NatureOfBusinessAndBasisOfPresentationLineItems', window );"><strong>Nature Of Business And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Sale of common stock shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">465,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Initial public offering price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Gross proceeds from initial public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hsgx_NatureOfBusinessAndBasisOfPresentationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nature Of Business And Basis Of Presentation [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hsgx_NatureOfBusinessAndBasisOfPresentationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hsgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hsgx_ProceedsFromIssuanceInitialPublicOfferingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance initial public offering net.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hsgx_ProceedsFromIssuanceInitialPublicOfferingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hsgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when the acquirer obtains control of the acquiree, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=73531572&amp;loc=d3e845-128460<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Acquisition Date<br> -URI http://asc.fasb.org/extlink&amp;oid=6919109<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 25<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=73531572&amp;loc=d3e848-128460<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65885119&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEffectiveDateOfAcquisition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=6911251&amp;loc=d3e6578-128477<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=6911251&amp;loc=d3e6613-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholder, which takes precedence over common stockholders in the event of liquidation and from issuance of rights to purchase common shares at a predetermined price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=hsgx_ProChonBiotechLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=hsgx_ProChonBiotechLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6772751632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 03, 2014 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($) </div>
<div>Segment</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hsgx_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reporting segment | Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hsgx_FairValueInputAmountTransferBetweenLevels', window );">Transfers between Levels 1, 2 and 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, carrying amount</a></td>
<td class="nump">$ 58,527,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,908,000<span></span>
</td>
<td class="nump">30,915,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Impairment of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">$ 310,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueInputsDiscountRate', window );">Discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Book Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">IPO costs reclassified to additional paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">377,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments related to IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 377,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hsgx_MaximumPercentageOfRecognitionOfTaxBenefitsFromUncertainTaxPositions', window );">Maximum percentage of recognition of tax benefits from uncertain tax positions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hsgx_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments related to IPO</a></td>
<td class="nump">2,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hsgx_RemainingOfferingCostsIncludedInAccountsPayable', window );">Remaining amount of IPO costs included in accounts payable</a></td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">IPR&amp;D [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hsgx_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Impairment of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Book Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets (Level 1) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hsgx_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureRecurring', window );">Assets, fair value disclosure, recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureRecurring', window );">Liabilities, fair value disclosure, recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets (Level 1) [Member] | Money Market Funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hsgx_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,300,000<span></span>
</td>
<td class="nump">25,800,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hsgx_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureRecurring', window );">Assets, fair value disclosure, recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureRecurring', window );">Liabilities, fair value disclosure, recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hsgx_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureRecurring', window );">Assets, fair value disclosure, recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureRecurring', window );">Liabilities, fair value disclosure, recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hsgx_FairValueInputAmountTransferBetweenLevels">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value input amount of assets and liabilities between levels.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hsgx_FairValueInputAmountTransferBetweenLevels</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hsgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hsgx_MaximumPercentageOfRecognitionOfTaxBenefitsFromUncertainTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum Percentage Of Recognition Of Tax Benefits From Uncertain Tax Positions</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hsgx_MaximumPercentageOfRecognitionOfTaxBenefitsFromUncertainTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hsgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hsgx_RemainingOfferingCostsIncludedInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining offering costs included in accounts payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hsgx_RemainingOfferingCostsIncludedInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hsgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hsgx_SummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary Of Significant Accounting Policies [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hsgx_SummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hsgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureRecurring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the aggregate of the assets reported on the balance sheet at period end measured at fair value on a recurring basis by the entity. This element is intended to be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureRecurring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3044-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueInputsDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest rate used to find the present value of an amount to be paid or received in the future as an input to measure fair value.  For example, but not limited to, weighted average cost of capital (WACC), cost of capital, cost of equity and cost of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueInputsDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureRecurring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregation of the liabilities reported on the balance sheet measured at fair value on a recurring basis by the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureRecurring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6760045744">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Summary of Operations in Different Geographic Regions (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-lived assets</a></td>
<td class="nump">$ 3,860<span></span>
</td>
<td class="nump">$ 5,213<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementGeographicalAxis=country_US', window );">United States [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-lived assets</a></td>
<td class="nump">$ 3,860<span></span>
</td>
<td class="nump">5,204<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementGeographicalAxis=country_IL', window );">Israel [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-lived assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=68060357&amp;loc=d3e9038-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementGeographicalAxis=country_IL">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementGeographicalAxis=country_IL</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6772926160">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=hsgx_WarrantLiabilityMember', window );">Warrant Liability [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="nump">$ 13,197<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">30,318<span></span>
</td>
<td class="nump">$ 25,764<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets (Level 1) [Member] | Money Market Funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">30,318<span></span>
</td>
<td class="nump">$ 25,764<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3) [Member] | Warrant Liability [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="nump">$ 13,197<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=hsgx_WarrantLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=hsgx_WarrantLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6771603360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Reconciliation of Liabilities Measured at Fair Value (Detail)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liability</a></td>
<td class="nump">$ 17,507<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues', window );">Issuance of warrants,</a></td>
<td class="nump">30,704<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liability</a></td>
<td class="num">(17,507)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending balance</a></td>
<td class="nump">$ 13,197<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=6939902&amp;loc=d3e20148-110875<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6773090144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Depreciation and Amortization using Straight-line Method over Estimated Useful Lives of Assets (Detail)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2016</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives', window );">Estimated Useful Lives</a></td>
<td class="text">Shorter of the remaining  lease term or useful life<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum [Member] | Office Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Lives</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum [Member] | Laboratory Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Lives</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum [Member] | Office Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Lives</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum [Member] | Laboratory Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Lives</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=68058157&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 35<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=68071081&amp;loc=d3e1205-110223<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6771254240">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Summary of Intangible Assets, Net of Accumulated Impairment Charges (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Cost</a></td>
<td class="nump">$ 630<span></span>
</td>
<td class="nump">$ 630<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Impairment</a></td>
<td class="num">(630)<span></span>
</td>
<td class="num">(430)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Book Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">IPR&amp;D [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Cost</a></td>
<td class="nump">630<span></span>
</td>
<td class="nump">630<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Impairment</a></td>
<td class="num">(630)<span></span>
</td>
<td class="num">(430)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Book Value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6771656144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Common Share - Schedule of Basic and Diluted Loss Per Common Share (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (16,208)<span></span>
</td>
<td class="num">$ (32,024)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hsgx_NetIncomeLossAvailableToSeriesAPreferredStock', window );">Net Loss attributable to Series A Preferred Stock</a></td>
<td class="num">(2,345)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Numerator for basic EPS-Earnings (loss) attributable to common stockholders</a></td>
<td class="num">(13,863)<span></span>
</td>
<td class="num">(32,024)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Deduct change in fair value of warrant liability</a></td>
<td class="num">(17,507)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Numerator for diluted EPS-Earnings (loss) attributable to common stockholders after assumed conversions</a></td>
<td class="num">$ (31,370)<span></span>
</td>
<td class="num">$ (32,024)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average number of common shares used in earnings (loss) per share-basic</a></td>
<td class="nump">14,256,954<span></span>
</td>
<td class="nump">13,231,126<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants', window );">Nonparticipating warrants</a></td>
<td class="nump">132,238<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Denominator for diluted EPS-adjusted weighted average shares</a></td>
<td class="nump">14,389,192<span></span>
</td>
<td class="nump">13,231,126<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Earnings (loss) per share-basic</a></td>
<td class="num">$ (0.97)<span></span>
</td>
<td class="num">$ (2.42)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Earnings (loss) per share-diluted</a></td>
<td class="num">$ (2.18)<span></span>
</td>
<td class="num">$ (2.42)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hsgx_NetIncomeLossAvailableToSeriesAPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net income loss available to Series A preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hsgx_NetIncomeLossAvailableToSeriesAPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hsgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DilutiveSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DilutiveSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=65016374&amp;loc=d3e4984-109258<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1252-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=6939902&amp;loc=d3e20148-110875<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of call options and warrants using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1757-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Treasury Stock Method<br> -URI http://asc.fasb.org/extlink&amp;oid=6527216<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Call Option<br> -URI http://asc.fasb.org/extlink&amp;oid=6506649<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Warrant<br> -URI http://asc.fasb.org/extlink&amp;oid=6528364<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net income after adjustments for dividends on preferred stock (declared in the period) and/or cumulative preferred stock (accumulated for the period).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1377-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net Income or Loss Available to Common Stockholders plus adjustments resulting from the assumption that dilutive convertible securities were converted, options or warrants were exercised, or that other shares were issued upon the satisfaction of certain conditions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1505-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1377-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1505-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=64863997&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Weighted-Average Number of Common Shares Outstanding<br> -URI http://asc.fasb.org/extlink&amp;oid=6528421<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6760074848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Common Share - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Detail) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from computation of earnings per share</a></td>
<td class="nump">5,962,817<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember', window );">Unvested Restricted Stock and Options to Purchase Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from computation of earnings per share</a></td>
<td class="nump">1,578,905<span></span>
</td>
<td class="nump">1,227,957<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants Exercisable into Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from computation of earnings per share</a></td>
<td class="nump">166,403<span></span>
</td>
<td class="nump">166,403<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Antidilution<br> -URI http://asc.fasb.org/extlink&amp;oid=6505113<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Diluted Earnings Per Share<br> -URI http://asc.fasb.org/extlink&amp;oid=6510752<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Contingent Stock Agreement<br> -URI http://asc.fasb.org/extlink&amp;oid=6508534<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6929200272">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>Prepaid Expense and Other Assets, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepositAssets', window );">Deposits</a></td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">$ 67<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Supplies', window );">Undelivered laboratory and office equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Insurance</a></td>
<td class="nump">95<span></span>
</td>
<td class="nump">42<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">68<span></span>
</td>
<td class="nump">195<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">$ 173<span></span>
</td>
<td class="nump">$ 321<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of the asset transferred to a third party to serve as a deposit, which typically serves as security against failure by the transferor to perform under terms of an agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8,17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6787-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5865-108316<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Assets<br> -URI http://asc.fasb.org/extlink&amp;oid=6509628<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Supplies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration paid in advance for supplies that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(7)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6787-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Supplies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6771296368">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment - Schedule of Property and Equipment (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 13,247<span></span>
</td>
<td class="nump">$ 13,202<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="num">(9,387)<span></span>
</td>
<td class="num">(7,989)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">3,860<span></span>
</td>
<td class="nump">5,213<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">266<span></span>
</td>
<td class="nump">539<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Laboratory Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">4,443<span></span>
</td>
<td class="nump">4,337<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">7,683<span></span>
</td>
<td class="nump">7,683<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in Progress [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">759<span></span>
</td>
<td class="nump">547<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember', window );">Software [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 96<span></span>
</td>
<td class="nump">$ 96<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6762113168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 1,673<span></span>
</td>
<td class="nump">$ 1,614<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6769932560">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses - Schedule of Accrued Expenses (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation</a></td>
<td class="nump">$ 1,402<span></span>
</td>
<td class="nump">$ 758<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hsgx_AccruedClinicalExpensesCurrent', window );">Accrued clinical expenses</a></td>
<td class="nump">187<span></span>
</td>
<td class="nump">138<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Accrued other</a></td>
<td class="nump">508<span></span>
</td>
<td class="nump">548<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses</a></td>
<td class="nump">$ 2,097<span></span>
</td>
<td class="nump">$ 1,444<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hsgx_AccruedClinicalExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued clinical expenses current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hsgx_AccruedClinicalExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hsgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e7018-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Liabilities<br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6774532864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2012 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($) </div>
<div>Options</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesRentExpenseNet', window );">Rent expense under operating lease agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,577,000<span></span>
</td>
<td class="nump">23,243,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=hsgx_WalthamMember', window );">Waltham [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hsgx_NumberOfAdditionalRenewalOptions', window );">Number of additional renewal terms | Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm', window );">Additional operating lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=hsgx_LexingtonMember', window );">Lexington [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hsgx_NumberOfAdditionalRenewalOptions', window );">Number of additional renewal terms | Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm', window );">Additional operating lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=hsgx_HydrogelLicenseAgreementMember', window );">Hydrogel License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">One-time payment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=hsgx_TissueRegenerationLicenseAgreementMember', window );">Tissue Regeneration License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">One-time payment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hsgx_PercentageOfRoyaltyOffsetting', window );">Percentage of royalty offsetting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum [Member] | Waltham [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromTenantAllowance', window );">Construction allowance to total cost of tenant improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum [Member] | Lexington [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromTenantAllowance', window );">Construction allowance to total cost of tenant improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum [Member] | Tissue Regeneration License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Non-refundable royalty fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=hsgx_TissueProcessorSubLicenseAgreementMember', window );">Tissue Processor Sub License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hsgx_PaymentForLicenseAgreementReimbursementOfCosts', window );">Reimbursement for development cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationFutureMinimumPaymentsDueRemainderOfFiscalYear', window );">Potential milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,200,000<span></span>
</td>
<td class="nump">10,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hsgx_AdditionalRoyaltyExpense', window );">Additional non-refundable royalty fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hsgx_AdditionalNonRefundableRoyaltyFeePaymentDescription', window );">Additional non-refundable royalty fee payment description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2016 through           2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=hsgx_TissueProcessorSubLicenseAgreementMember', window );">Tissue Processor Sub License Agreement [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Non-refundable royalty fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=hsgx_EngineeringAgreementMember', window );">Engineering Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToSuppliers', window );">Amount paid to suppliers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted', window );">Additional payments due</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=hsgx_CollagenSupplyAgreementMember', window );">Collagen Supply Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentAmount', window );">Minimum amount of material and/or services</a></td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hsgx_PurchaseCommitmentNonrefundablePayment', window );">Non-refundable payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermPurchaseCommitmentPeriod', window );">Initial term of the agreement</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentDescription', window );">Supplier agreement description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The initial term of the agreement is  three years and will automatically renew from year to year thereafter unless  otherwise terminated with at least 180 days' notice by either party.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=hsgx_OcsAgreementMember', window );">OCS Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrantsReceivable', window );">Accrued and received grants, aggregate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=hsgx_OcsAgreementMember', window );">OCS Agreement [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hsgx_RoyaltyPaymentPercentage', window );">Royalties payment, rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hsgx_RoyaltyPaymentPercentageAsPercentageOfGrantReceived', window );">Royalty payment percentage as percentage of grant received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=hsgx_OcsAgreementMember', window );">OCS Agreement [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hsgx_RoyaltyPaymentPercentage', window );">Royalties payment, rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hsgx_RoyaltyPaymentPercentageAsPercentageOfGrantReceived', window );">Royalty payment percentage as percentage of grant received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hsgx_AdditionalNonRefundableRoyaltyFeePaymentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional non refundable royalty fee payment description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hsgx_AdditionalNonRefundableRoyaltyFeePaymentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hsgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hsgx_AdditionalRoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional royalty expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hsgx_AdditionalRoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hsgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hsgx_NumberOfAdditionalRenewalOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Additional Renewal Options</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hsgx_NumberOfAdditionalRenewalOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hsgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hsgx_PaymentForLicenseAgreementReimbursementOfCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment For License Agreement Reimbursement Of Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hsgx_PaymentForLicenseAgreementReimbursementOfCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hsgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hsgx_PercentageOfRoyaltyOffsetting">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of royalty offsetting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hsgx_PercentageOfRoyaltyOffsetting</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hsgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hsgx_PurchaseCommitmentNonrefundablePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase commitment non-refundable payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hsgx_PurchaseCommitmentNonrefundablePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hsgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hsgx_RoyaltyPaymentPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty payment percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hsgx_RoyaltyPaymentPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hsgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hsgx_RoyaltyPaymentPercentageAsPercentageOfGrantReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty payment percentage as percentage of grant received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hsgx_RoyaltyPaymentPercentageAsPercentageOfGrantReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hsgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationFutureMinimumPaymentsDueRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation maturing in the remainder of the fiscal year following the latest fiscal year ended.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationFutureMinimumPaymentsDueRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrantsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrantsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of the lessee's leasing arrangement renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermPurchaseCommitmentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum amount the entity agreed to spend under the long-term purchase commitment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermPurchaseCommitmentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermPurchaseCommitmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Describes the terms of a significant arrangement with a supplier (excluding an unconditional purchase obligation) to acquire goods or services over a period of time beyond one year or the normal operating cycle, if longer, which may include identification of the goods or services to be purchased, pricing, effects on pricing of failing to reach minimum quantities required to be purchased, cancellation rights, and termination provisions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermPurchaseCommitmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermPurchaseCommitmentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period covered by the long-term purchase commitment, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermPurchaseCommitmentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesRentExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41499-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesRentExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromTenantAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net cash outflow or inflow from monetary allowance granted by the landlord to a tenant to entice tenant to move into landlords building which will enable the tenant to prepare the leased premises for tenants occupancy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromTenantAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToSuppliers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments of cash to suppliers for goods and services during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToSuppliers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum amount to be expended to satisfy the terms of arrangements in which the entity has agreed to expend funds to procure goods or services, excluding long-term purchase commitments or unconditional purchase obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=hsgx_WalthamMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=hsgx_WalthamMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=hsgx_LexingtonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=hsgx_LexingtonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=hsgx_HydrogelLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=hsgx_HydrogelLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=hsgx_TissueRegenerationLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=hsgx_TissueRegenerationLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=hsgx_TissueProcessorSubLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=hsgx_TissueProcessorSubLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=hsgx_EngineeringAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=hsgx_EngineeringAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=hsgx_CollagenSupplyAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=hsgx_CollagenSupplyAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=hsgx_OcsAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=hsgx_OcsAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6759769136">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Schedule of Minimum Annual Lease Commitments Under Non-Cancellable Operating Leases (Detail)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract', window );"><strong>Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent', window );">2017</a></td>
<td class="nump">$ 2,266<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">2018</a></td>
<td class="nump">754<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears', window );">2019</a></td>
<td class="nump">586<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears', window );">2020</a></td>
<td class="nump">596<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears', window );">2021</a></td>
<td class="nump">605<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter', window );">Thereafter</a></td>
<td class="nump">926<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Total minimum lease payments</a></td>
<td class="nump">$ 5,733<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6772500416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capital Stock - Additional Information (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 29, 2016</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,647,612<span></span>
</td>
<td class="nump">13,273,470<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Conversion of preferred stock in to common stock, preferred stock converted</a></td>
<td class="nump">10,737,275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants', window );">Proceeds from issuance of issuance of common stock, preferred stock and warrants, net of issuance costs</a></td>
<td class="nump">$ 27,600<span></span>
</td>
<td class="nump">$ 27,630<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentOfWarrantsGrantedForServices', window );">Warrant expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,100<span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hsgx_MinimumThresholdPercentageOfBeneficialCommonStockInterest', window );">Minimum threshold percentage of beneficial common stock interest</a></td>
<td class="nump">4.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hsgx_MaximumThresholdPercentageOfBeneficialCommonStockInterestOnHoldersDiscretion', window );">Maximum threshold percentage of beneficial common stock interest on holder's discretion</a></td>
<td class="nump">9.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockTermsOfConversion', window );">Convertible preferred stock, terms of conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The  Series A Preferred Stock shall not be converted if, after giving effect to the  conversion, the holder and its affiliated persons would own beneficially more  than 4.99% of our common stock (subject to adjustment up to 9.99% solely at the  holder's discretion upon 61 days' prior notice to us or, solely as to a holder,  if such limitation is waived by such holder upon execution of the private  placement agreement).<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">24,158.8693<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock par value</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hsgx_GrossProceedsFromIssuanceOfCommonStockPreferredStockAndWarrants', window );">Gross proceeds from issuance of common stock, preferred stock and warrants</a></td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">2,596,059<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock price per share</a></td>
<td class="nump">$ 2.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Conversion of preferred stock in to common stock, preferred stock converted</a></td>
<td class="nump">10,737,275<span></span>
</td>
<td class="nump">444.44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrants or right to purchase common stock</a></td>
<td class="nump">13,333,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrants or right to purchase common stock, exercise price</a></td>
<td class="nump">$ 2.25<span></span>
</td>
<td class="nump">$ 2.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hsgx_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsIssuedForService', window );">Warrants granted to placement agent</a></td>
<td class="nump">133,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants', window );">Proceeds from issuance of issuance of common stock, preferred stock and warrants, net of issuance costs</a></td>
<td class="nump">$ 27,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hsgx_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsIssuedForService', window );">Warrants granted to placement agent, exercise price</a></td>
<td class="nump">$ 2.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hsgx_BeneficialOwnershipMinimumPercentageOfOutstandingCommonStock', window );">Minimum percentage of outstanding common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hsgx_ClassOfWarrantOrRightExercisableExpirationPeriod', window );">Warrants expiry period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hsgx_ClassOfWarrantOrRightExercisablePeriod', window );">Warrants exercisable period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure', window );">Fair value of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hsgx_FairValueOfWarrantLiabilitiesInExcessOfProceedsReceived', window );">Excess fair value of warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentOfWarrantsGrantedForServices', window );">Warrant expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member] | Members of Board of Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">283,046<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,563.1439<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrants or right to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,422,221<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrants or right to purchase common stock, exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member] | Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">24,158.8693<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Conversion of preferred stock in to common stock, preferred stock converted</a></td>
<td class="nump">444.44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hsgx_BeneficialOwnershipMinimumPercentageOfOutstandingCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Beneficial ownership minimum percentage of outstanding common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hsgx_BeneficialOwnershipMinimumPercentageOfOutstandingCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hsgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hsgx_ClassOfWarrantOrRightExercisableExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or right exercisable expiration period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hsgx_ClassOfWarrantOrRightExercisableExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hsgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hsgx_ClassOfWarrantOrRightExercisablePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or right exercisable period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hsgx_ClassOfWarrantOrRightExercisablePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hsgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hsgx_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsIssuedForService">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or right exercise price of warrants or rights issued for service.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hsgx_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsIssuedForService</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hsgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hsgx_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsIssuedForService">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or right number of securities called by warrants or rights issued for service.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hsgx_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsIssuedForService</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hsgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hsgx_FairValueOfWarrantLiabilitiesInExcessOfProceedsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of warrant liabilities in excess of proceeds received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hsgx_FairValueOfWarrantLiabilitiesInExcessOfProceedsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hsgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hsgx_GrossProceedsFromIssuanceOfCommonStockPreferredStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross proceeds from issuance of common stock, preferred stock and warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hsgx_GrossProceedsFromIssuanceOfCommonStockPreferredStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hsgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hsgx_MaximumThresholdPercentageOfBeneficialCommonStockInterestOnHoldersDiscretion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum threshold percentage of beneficial common stock interest on holders discretion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hsgx_MaximumThresholdPercentageOfBeneficialCommonStockInterestOnHoldersDiscretion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hsgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hsgx_MinimumThresholdPercentageOfBeneficialCommonStockInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum threshold percentage of beneficial common stock interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hsgx_MinimumThresholdPercentageOfBeneficialCommonStockInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hsgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentOfWarrantsGrantedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustment for noncash service expenses paid for by granting of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentOfWarrantsGrantedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockTermsOfConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Specific terms relevant to convertibility. Includes class of preferred stock and number of shares convertible into, exercise (or conversion) price or rates, dates relevant to conversion timing and events relevant to conversion. Describe also any beneficial conversion features. where convertible preferred stock with a nondetachable conversion feature is in-the-money at commitment date. For contingently convertible preferred stock, discuss the circumstances of the contingency, including the events or changes in circumstance that would cause the contingency to be met and any of the significant features necessary to understand the conversion rights and the timing of those rights. Include also an events or changes in circumstance, if any, that could adjust or change the contingency, conversion price, or number of shares, including significant terms of those changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21521-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Contingently Convertible Instruments<br> -URI http://asc.fasb.org/extlink&amp;oid=6508575<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21538-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockTermsOfConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholder, which takes precedence over common stockholders in the event of liquidation and from issuance of rights to purchase common shares at a predetermined price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of warrants not settleable in cash classified as equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsNotSettleableInCashFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=hsgx_MembersOfBoardOfDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=hsgx_MembersOfBoardOfDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6760484672">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Capital Stock - Schedule of Common Stock Reserved for Future Issuance (Detail) - shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance</a></td>
<td class="nump">15,211,975<span></span>
</td>
<td class="nump">1,394,360<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrants Exercisable into Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance</a></td>
<td class="nump">13,633,070<span></span>
</td>
<td class="nump">166,403<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance</a></td>
<td class="nump">1,889<span></span>
</td>
<td class="nump">5,190<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance</a></td>
<td class="nump">1,577,016<span></span>
</td>
<td class="nump">1,222,767<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6773618992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 21, 2015</div></th>
<th class="th"><div>Dec. 03, 2014</div></th>
<th class="th"><div>Jul. 20, 2012</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Mar. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentOfWarrantsGrantedForServices', window );">Warrant expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,100,000<span></span>
</td>
<td class="nump">$ 11,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=hsgx_InvestorWarrantsMember', window );">Investor Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrants or right to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,333,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrants or right to purchase common stock, exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hsgx_ClassOfWarrantOrRightExercisablePeriod', window );">Warrants exercisable period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hsgx_ClassOfWarrantOrRightExercisableExpirationPeriod', window );">Warrants expiry period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hsgx_AdjustmentOfWarrantsGrantedForServicesPerShareValue', window );">Warrant expense</a></td>
<td class="nump">$ 2.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=hsgx_PlacementAgentWarrantMember', window );">Placement Agent Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrants or right to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">133,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrants or right to purchase common stock, exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hsgx_ClassOfWarrantOrRightExercisableExpirationPeriod', window );">Warrants expiry period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentOfWarrantsGrantedForServices', window );">Warrant expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=hsgx_ConsultingAgreementWarrantMember', window );">Consulting Agreement Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrants or right to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,398<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrants or right to purchase common stock, exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.75<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hsgx_ClassOfWarrantOrRightExercisablePeriod', window );">Warrants exercisable period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hsgx_ClassOfWarrantOrRightExercisableExpirationPeriod', window );">Warrants expiry period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hsgx_ClassOfWarrantOrRightForfeitureInPeriod', window );">Warrants, forfeiture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,699)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hsgx_ClassOfWarrantOrRightVestedAndExercisable', window );">Warrants vested and exercisable</a></td>
<td class="nump">3,699<span></span>
</td>
<td class="nump">3,699<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hsgx_ClassOfWarrantOrRightForfeitureInPeriodPercentage', window );">Warrants, percentage of forfeiture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=hsgx_AffiliatesOfAdvisorWarrantMember', window );">Affiliates Of Advisor Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrants or right to purchase common stock</a></td>
<td class="nump">156,138<span></span>
</td>
<td class="nump">156,138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">161,977<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">156,138<span></span>
</td>
<td class="nump">156,138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrants or right to purchase common stock, exercise price</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hsgx_ClassOfWarrantOrRightExercisableExpirationPeriod', window );">Warrants expiry period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate', window );">Fair value of the warrants, risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.22%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate', window );">Fair value of the warrants, implied volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedTerm', window );">Fair value of the warrants, expected term to liquidity even</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hsgx_ClassOfWarrantOrRightNumberOfSecuritiesSurrendered', window );">Surrender of warrant to satisfy related liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,839<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hsgx_AdjustmentOfWarrantsGrantedForServicesPerShareValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustment of warrants granted for services per share value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hsgx_AdjustmentOfWarrantsGrantedForServicesPerShareValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hsgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hsgx_ClassOfWarrantOrRightExercisableExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or right exercisable expiration period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hsgx_ClassOfWarrantOrRightExercisableExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hsgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hsgx_ClassOfWarrantOrRightExercisablePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or right exercisable period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hsgx_ClassOfWarrantOrRightExercisablePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hsgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hsgx_ClassOfWarrantOrRightForfeitureInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or right forfeiture in period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hsgx_ClassOfWarrantOrRightForfeitureInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hsgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hsgx_ClassOfWarrantOrRightForfeitureInPeriodPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or right forfeiture in period percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hsgx_ClassOfWarrantOrRightForfeitureInPeriodPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hsgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hsgx_ClassOfWarrantOrRightNumberOfSecuritiesSurrendered">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or right number of securities surrendered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hsgx_ClassOfWarrantOrRightNumberOfSecuritiesSurrendered</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hsgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hsgx_ClassOfWarrantOrRightVestedAndExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or right vested and exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hsgx_ClassOfWarrantOrRightVestedAndExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hsgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentOfWarrantsGrantedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustment for noncash service expenses paid for by granting of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentOfWarrantsGrantedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period the instrument, asset or liability is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExpectedTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Measure of dispersion, in percentage terms (for instance, the standard deviation or variance), for a given stock price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Risk-free interest rate assumption used in valuing an instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=hsgx_InvestorWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=hsgx_InvestorWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=hsgx_PlacementAgentWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=hsgx_PlacementAgentWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=hsgx_ConsultingAgreementWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=hsgx_ConsultingAgreementWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=hsgx_AffiliatesOfAdvisorWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=hsgx_AffiliatesOfAdvisorWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6703773408">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Equipment Loan Payable - Schedule of Outstanding Borrowing Obligations (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LoansPayableCurrent', window );">Less: current portion</a></td>
<td class="num">$ (583)<span></span>
</td>
<td class="num">$ (583)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermLoansPayable', window );">Long-term debt, net</a></td>
<td class="nump">178<span></span>
</td>
<td class="nump">761<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=hsgx_SiliconValleyBankMember', window );">Silicon Valley Bank [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LoansPayable', window );">Total debt</a></td>
<td class="nump">$ 761<span></span>
</td>
<td class="nump">$ 1,344<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16)(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of portion of long-term loans payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermLoansPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermLoansPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=hsgx_SiliconValleyBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=hsgx_SiliconValleyBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6773093872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equipment Loan Payable - Additional Information (Detail) - Silicon Valley Bank [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Amount of loan to purchase equipment</a></td>
<td class="nump">$ 1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Line of credit facility, interest rate, stated percentage</a></td>
<td class="nump">3.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Bank loan and security agreement, repayment period</a></td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Net exercise of warrants, shares</a></td>
<td class="nump">6,566<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Net exercise of warrants, exercise price per share</a></td>
<td class="nump">$ 7.99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Borrowings outstanding under line of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=hsgx_SiliconValleyBankMember', window );">Prime Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Amount of loan bears interest basis spread on variable rate</a></td>
<td class="nump">2.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=hsgx_SiliconValleyBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=hsgx_SiliconValleyBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_PrimeRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_PrimeRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6771942016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Additional Information (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 16, 2016</div></th>
<th class="th"><div>Dec. 03, 2014</div></th>
<th class="th"><div>Oct. 31, 2014</div></th>
<th class="th"><div>Jul. 31, 2012</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation cost related to outstanding options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,600<span></span>
</td>
<td class="nump">$ 3,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value of options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value of vested options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.71<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hsgx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value of options outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,548<span></span>
</td>
<td class="nump">1,228<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=hsgx_TwoThousandAndTwelveEquityIncentivePlanMember', window );">2012 Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">609,389<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Stock options vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Term of stock options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=hsgx_TwoThousandAndTwelveEquityIncentivePlanMember', window );">2012 Equity Incentive Plan [Member] | First Anniversary of Original Vesting Date [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Stock options vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=hsgx_TwoThousandAndThirteenEquityIncentivePlanMember', window );">2013 Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Stock options vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Term of stock options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=hsgx_TwoThousandAndThirteenEquityIncentivePlanMember', window );">2013 Equity Incentive Plan [Member] | First Anniversary of Original Vesting Date [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Stock options vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=hsgx_TwoThousandAndThirteenEquityIncentivePlanMember', window );">2013 Equity Incentive Plan [Member] | EIP Amendment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Increase in authorized shares of common stock amount</a></td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Increase in authorized shares, percentage of common stock outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=hsgx_TwoThousandAndThirteenEmployeeStockPurchasePlanMember', window );">2013 Employee Stock Purchase Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">103,665<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Increase in authorized shares of common stock amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,832<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Increase in authorized shares, percentage of common stock outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,057<span></span>
</td>
<td class="nump">777<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedStockExpense', window );">Restricted stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementScenarioAxis=us-gaap_ScenarioForecastMember', window );">Scenario, Forecast [Member] | 2013 Equity Incentive Plan [Member] | EIP Amendment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Increase in authorized shares of common stock amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">825,904<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementScenarioAxis=us-gaap_ScenarioForecastMember', window );">Scenario, Forecast [Member] | 2013 Employee Stock Purchase Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Increase in authorized shares of common stock amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">206,476<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation cost, recognition period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 4 days<span></span>
</td>
<td class="text">2 years 8 months 5 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation cost, recognition period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 months 18 days<span></span>
</td>
<td class="text">1 year 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation cost related to restricted stock awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hsgx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Grant Date Fair Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hsgx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hsgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized cost of unvested share-based awards, other than options, awarded to employees as compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized cost of unvested options awarded to employees as compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedStockExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The noncash expense that represents the cost of restricted stock or unit distributed to employees as compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedStockExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under an established share-based compensation plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of share-based compensation awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=hsgx_TwoThousandAndTwelveEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=hsgx_TwoThousandAndTwelveEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=hsgx_TwoThousandAndThirteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=hsgx_TwoThousandAndThirteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=hsgx_EipAmendmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=hsgx_EipAmendmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=hsgx_TwoThousandAndThirteenEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=hsgx_TwoThousandAndThirteenEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementScenarioAxis=us-gaap_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementScenarioAxis=us-gaap_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6772039504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Stock Option Activity Under the 2012 and 2013 Plans (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, Outstanding Beginning Balance</a></td>
<td class="nump">1,229,339<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Options, Granted</a></td>
<td class="nump">464,240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of Options, Exercised</a></td>
<td class="num">(3,685)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of Options, Cancelled</a></td>
<td class="num">(112,878)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, Outstanding Ending Balance</a></td>
<td class="nump">1,577,016<span></span>
</td>
<td class="nump">1,229,339<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of Options, Vested and expected to vest outstanding</a></td>
<td class="nump">1,492,341<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Options, Exercisable</a></td>
<td class="nump">561,693<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding Beginning Balance</a></td>
<td class="nump">$ 7.32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted</a></td>
<td class="nump">2.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercised</a></td>
<td class="nump">0.76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Cancelled</a></td>
<td class="nump">4.97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding Ending Balance</a></td>
<td class="nump">5.95<span></span>
</td>
<td class="nump">$ 7.32<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Vested and expected to vest outstanding</a></td>
<td class="nump">5.97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercisable</a></td>
<td class="nump">$ 6.79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term, Outstanding</a></td>
<td class="text">8 years 4 months 24 days<span></span>
</td>
<td class="text">9 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term, Vested and expected to vest outstanding</a></td>
<td class="text">8 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term, Exercisable</a></td>
<td class="text">7 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding</a></td>
<td class="nump">$ 71<span></span>
</td>
<td class="nump">$ 4,679<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, Vested and expected to vest outstanding</a></td>
<td class="nump">69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable</a></td>
<td class="nump">$ 52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of fully vested and expected to vest options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>As of the balance sheet date, the number of shares into which fully vested and expected to vest stock options outstanding can be converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>As of the balance sheet date, the weighted-average exercise price for outstanding stock options that are fully vested or expected to vest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6772169152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Additional Information about Stock Option Activity (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value per share of employee option grants within the year</a></td>
<td class="nump">$ 1.26<span></span>
</td>
<td class="nump">$ 4.08<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Cash received upon exercise of options</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 39<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (j)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66902209&amp;loc=d3e3255-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6927306832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of Restricted Stock Awards Under the 2012 and 2013 Plans (Detail) - Restricted Stock [Member]<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2016 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of shares, Unvested beginning balance | shares</a></td>
<td class="nump">5,190<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vesting of restricted stock | shares</a></td>
<td class="num">(3,301)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of shares, Unvested ending balance | shares</a></td>
<td class="nump">1,889<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value, Unvested beginning balance | $ / shares</a></td>
<td class="nump">$ 1.07<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vesting of restricted stock | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value, Unvested ending balance | $ / shares</a></td>
<td class="nump">$ 0.83<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value of nonvested awards on equity-based plans excluding option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6648779088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Stock-Based Compensation (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 1,548<span></span>
</td>
<td class="nump">$ 1,228<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">491<span></span>
</td>
<td class="nump">451<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 1,057<span></span>
</td>
<td class="nump">$ 777<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6771782864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Weighted-Average Assumptions Used in the Black-Scholes Option Pricing Model to Determine the Fair Value of the Employee Stock Option Grants (Detail)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.73%<span></span>
</td>
<td class="nump">1.68%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">72.50%<span></span>
</td>
<td class="nump">62.60%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years 29 days<span></span>
</td>
<td class="text">6 years 15 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6772926224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Weighted-Average Assumptions Used in the Black-Scholes Option Pricing Model to Determine the Fair Value of the Non-Employee Stock Option Grants (Detail)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionAbstract', window );"><strong>Share-based Goods and Nonemployee Services Transaction [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.57%<span></span>
</td>
<td class="nump">1.79%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">63.50%<span></span>
</td>
<td class="nump">63.20%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">6 years 1 month 28 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the expected term of a nonvested share or option award issued to other than an employee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68057994&amp;loc=d3e25284-112666<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period an equity-based award is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68057994&amp;loc=d3e25284-112666<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage amount by which a share price is expected to fluctuate during the expected term of a nonvested share or option award issued to other than an employee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68057994&amp;loc=d3e25284-112666<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing a nonvested share or option award issued to other than an employee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68057994&amp;loc=d3e25284-112666<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6757482464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Components of Loss Before Income Taxes (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">U.S.</a></td>
<td class="num">$ (15,838)<span></span>
</td>
<td class="num">$ (31,382)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="num">(369)<span></span>
</td>
<td class="num">(691)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Total</a></td>
<td class="num">$ (16,208)<span></span>
</td>
<td class="num">$ (32,073)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6703741968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Reconciliation of Income Tax Expense (Benefit) Computed at Statutory Federal Income Tax Rate (Detail)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal income tax (benefit) at statutory rate</a></td>
<td class="nump">34.00%<span></span>
</td>
<td class="nump">34.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>(Increase) decrease income tax benefit resulting from:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hsgx_EffectiveIncomeTaxRateReconciliationPermanentDifferences', window );">Permanent differences</a></td>
<td class="nump">29.00%<span></span>
</td>
<td class="num">(1.20%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hsgx_EffectiveIncomeTaxRateReconciliationNetOperatingLossLimitation', window );">Net Operating Loss Limitation</a></td>
<td class="num">(111.10%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hsgx_EffectiveIncomeTaxRateReconciliationRAndDCreditLimitation', window );">R&amp;D Credit Limitation</a></td>
<td class="num">(1.50%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">48.70%<span></span>
</td>
<td class="num">(31.70%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="nump">0.90%<span></span>
</td>
<td class="num">(1.20%)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Income tax expense (benefit)</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hsgx_EffectiveIncomeTaxRateReconciliationNetOperatingLossLimitation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation net operating loss limitation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hsgx_EffectiveIncomeTaxRateReconciliationNetOperatingLossLimitation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hsgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hsgx_EffectiveIncomeTaxRateReconciliationPermanentDifferences">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation Permanent Differences</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hsgx_EffectiveIncomeTaxRateReconciliationPermanentDifferences</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hsgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hsgx_EffectiveIncomeTaxRateReconciliationRAndDCreditLimitation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation R and D credit limitation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hsgx_EffectiveIncomeTaxRateReconciliationRAndDCreditLimitation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hsgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32698-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32698-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32687-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6774617328">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Components of Deferred Tax Assets and Liabilities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGrossAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 16,146<span></span>
</td>
<td class="nump">$ 28,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment', window );">Depreciation and amortization</a></td>
<td class="nump">6,229<span></span>
</td>
<td class="nump">6,688<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">2,082<span></span>
</td>
<td class="nump">1,183<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hsgx_DeferredTaxAssetsCapitalizedStartUpCosts', window );">Capitalized start-up costs</a></td>
<td class="nump">10,037<span></span>
</td>
<td class="nump">8,531<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">75<span></span>
</td>
<td class="nump">259<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Deferred tax assets before valuation allowance</a></td>
<td class="nump">34,569<span></span>
</td>
<td class="nump">44,861<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(34,569)<span></span>
</td>
<td class="num">(43,751)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Deferred tax assets, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,110<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts', window );">IPR&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(36)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hsgx_DeferredTaxLiabilitiesChangeInAccountingMethod', window );">Change in accounting method</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,074)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,110)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hsgx_DeferredTaxAssetsCapitalizedStartUpCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets Capitalized Start Up Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hsgx_DeferredTaxAssetsCapitalizedStartUpCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hsgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hsgx_DeferredTaxLiabilitiesChangeInAccountingMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liabilities Change in Accounting Method</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hsgx_DeferredTaxLiabilitiesChangeInAccountingMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hsgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Deferred Tax Liability<br> -URI http://asc.fasb.org/extlink&amp;oid=6510232<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32537-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Deferred Tax Asset<br> -URI http://asc.fasb.org/extlink&amp;oid=6510090<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGrossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGrossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=68052875&amp;loc=d3e28680-109314<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32621-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32621-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32632-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=68052875&amp;loc=d3e28680-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=68052875&amp;loc=d3e28680-109314<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32632-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from research and development costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32621-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32632-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=68052875&amp;loc=d3e28680-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6760793744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hsgx_IncomeTaxesDisclosureLineItems', window );"><strong>Income Taxes Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Increase (Decrease) in valuation allowance</a></td>
<td class="num">$ (9,200,000)<span></span>
</td>
<td class="nump">$ 11,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hsgx_OperatingLossCarryforwardsNetOfLimitations', window );">NOL carry forwards, net of limitations</a></td>
<td class="nump">100,100,000<span></span>
</td>
<td class="nump">47,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">562,000<span></span>
</td>
<td class="nump">687,000<span></span>
</td>
<td class="nump">$ 811,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Accrued interest and penalties related to unrecognized tax benefits</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense', window );">Interest and penalties related to uncertain tax benefits</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit', window );">Unrecognized tax benefits may be recognized by the end of 2016</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationDescription', window );">Income tax examination description</a></td>
<td class="text">The  Company is subject to U.S. federal, state and local income tax examinations by  tax authorities for years 2001 through present. Carryforward attributes that  were generated in earlier periods remain subject to examination to the extent  the year in which they were used or will be used remains open for examination.  The tax years which remain subject to examination by tax authorities in Israel,  as of December 31, 2016, include years 2013 through the present.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">U.S. Federal [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hsgx_IncomeTaxesDisclosureLineItems', window );"><strong>Income Taxes Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">NOL carryforwards</a></td>
<td class="nump">$ 24,500,000<span></span>
</td>
<td class="nump">55,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsExpirationDate', window );">NOL carryforwards, expiration date</a></td>
<td class="text">Dec. 31,  2036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">U.S. State [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hsgx_IncomeTaxesDisclosureLineItems', window );"><strong>Income Taxes Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">NOL carryforwards</a></td>
<td class="nump">$ 24,300,000<span></span>
</td>
<td class="nump">55,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsExpirationDate', window );">NOL carryforwards, expiration date</a></td>
<td class="text">Dec. 31,  2036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hsgx_IncomeTaxesDisclosureLineItems', window );"><strong>Income Taxes Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">NOL carryforwards</a></td>
<td class="nump">$ 26,100,000<span></span>
</td>
<td class="nump">$ 25,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hsgx_IncomeTaxesDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income Taxes Disclosure [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hsgx_IncomeTaxesDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hsgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hsgx_OperatingLossCarryforwardsNetOfLimitations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating loss carryforwards net of limitations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hsgx_OperatingLossCarryforwardsNetOfLimitations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hsgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A brief description of status of the tax examination, significant findings to date, and the entity's position with respect to the findings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expiration date of each operating loss carryforward included in operating loss carryforward, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the unrecognized tax benefit of a position taken for which it is reasonably possible that the total amount thereof will significantly increase or decrease within twelve months of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=SL6600010-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Unrecognized Tax Benefit<br> -URI http://asc.fasb.org/extlink&amp;oid=6527854<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=75116654&amp;loc=d3e32123-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6759438480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Summary of Changes In Unrecognized Tax Benefits (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefit, beginning of year</a></td>
<td class="nump">$ 687<span></span>
</td>
<td class="nump">$ 811<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions', window );">Increase (decrease) related to current year positions</a></td>
<td class="num">(125)<span></span>
</td>
<td class="num">(124)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities', window );">Settlements</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefit, end of year</a></td>
<td class="nump">$ 562<span></span>
</td>
<td class="nump">$ 687<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=SL6600010-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Unrecognized Tax Benefit<br> -URI http://asc.fasb.org/extlink&amp;oid=6527854<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from settlements with taxing authorities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65882285&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6929268464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefits - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanDisclosureLineItems', window );"><strong>Defined Contribution Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Defined benefit plan contribution by employer</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanDisclosureLineItems', window );"><strong>Defined Contribution Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hsgx_DefinedContributionPlanEmployeeEligibilityAge', window );">Defined contribution plan eligibility years of age for employees</a></td>
<td class="text">21 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hsgx_DefinedContributionPlanEmployeeEligibilityAge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Defined Contribution Plan Employee Eligibility Age</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hsgx_DefinedContributionPlanEmployeeEligibilityAge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hsgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6773697296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Parties - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Jun. 30, 2012</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Accrued expenses due to related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,546<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=hsgx_IntrexonMember', window );">Intrexon [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hsgx_CollaborationAgreementTerminationNoticePeriod', window );">Collaboration Agreement cancellation notification</a></td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hsgx_CollaborationAgreementTerminationNoticePeriodOnUnremediedMaterialBreach', window );">Collaboration Agreement cancellation with material breach that cannot be remedied</a></td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Accrued expenses due to related party</a></td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=hsgx_IntrexonMember', window );">Intrexon [Member] | Commercialization Milestones [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hsgx_CommercializationMilestonesObligation', window );">Commercialization milestones obligation</a></td>
<td class="nump">12,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=hsgx_IntrexonMember', window );">Intrexon [Member] | Sales Milestones [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hsgx_SalesMilestonesPaymentsObligation', window );">Sales milestones</a></td>
<td class="nump">$ 22,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=hsgx_IntrexonMember', window );">Intrexon [Member] | Research and Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hsgx_PercentageOfReimbursementExpenses', window );">Percentage of reimbursement expenses</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hsgx_PercentageOfReimbursementExpensesSubjectToAcceptance', window );">Percentage of reimbursement expenses subject to acceptance</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Research and development expense from transaction with Intrexon</a></td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="nump">3,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=hsgx_PurposeCoMember', window );">Purpose, Co. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hsgx_DevelopmentCostReimbursementCommitment', window );">Reimbursement for development cost, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Reimbursement for development cost, paid</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hsgx_CollaborationAgreementTerminationNoticePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement Termination Notice Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hsgx_CollaborationAgreementTerminationNoticePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hsgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hsgx_CollaborationAgreementTerminationNoticePeriodOnUnremediedMaterialBreach">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement Termination Notice Period On Unremedied Material Breach</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hsgx_CollaborationAgreementTerminationNoticePeriodOnUnremediedMaterialBreach</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hsgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hsgx_CommercializationMilestonesObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commercialization milestones obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hsgx_CommercializationMilestonesObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hsgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hsgx_DevelopmentCostReimbursementCommitment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount committed for reimbursement of development costs of new technology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hsgx_DevelopmentCostReimbursementCommitment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hsgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hsgx_PercentageOfReimbursementExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of reimbursement expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hsgx_PercentageOfReimbursementExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hsgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hsgx_PercentageOfReimbursementExpensesSubjectToAcceptance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of reimbursement expenses subject to acceptance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hsgx_PercentageOfReimbursementExpensesSubjectToAcceptance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hsgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hsgx_SalesMilestonesPaymentsObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sales milestones payments obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hsgx_SalesMilestonesPaymentsObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hsgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transactions with related party during the financial reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39622-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAmountsOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=hsgx_IntrexonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=hsgx_IntrexonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=hsgx_CommercialMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=hsgx_CommercialMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=hsgx_SalesMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=hsgx_SalesMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=hsgx_PurposeCoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=hsgx_PurposeCoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.6.0.2</span><table class="report" border="0" cellspacing="2" id="idp6927512544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events - Additional Information (Detail) - Collagen Supply Agreement [Member] - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 22, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hsgx_OriginalAgreementDate', window );">Original agreement date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Sep. 15,  2015<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementScenarioAxis=us-gaap_ScenarioForecastMember', window );">Scenario, Forecast [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hsgx_RepaymentPeriod', window );">Repayment period</a></td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Payment in exchange of eliminating minimum annual order of material and/or services and any other amounts due supplier</a></td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hsgx_OriginalAgreementDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Original agreement date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hsgx_OriginalAgreementDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hsgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hsgx_RepaymentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Repayment period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">hsgx_RepaymentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>hsgx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transactions with related party during the financial reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39622-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAmountsOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=hsgx_CollagenSupplyAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=hsgx_CollagenSupplyAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementScenarioAxis=us-gaap_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementScenarioAxis=us-gaap_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>86
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
M-(X'P"J8%EQV^3O8:W7..7AKQ%/25V^9"CGIYFHQ*/B76_..7+8\#?NW_+""
MWTG] E!+ P04    "  (@7!*#X<@T^X    K @  $0   &1O8U!R;W!S+V-O
M<F4N>&ULS9+!:L,P#(9?9?B>*&X@'2;U9:6G#08K;.QF;+4UBV-C:R1]^R5>
MFS*V!]C1TN]/GT"M#D+[B,_1!XQD,=V-KNN3T&'#3D1! "1]0J=2.27ZJ7GP
MT2F:GO$(0>D/=418554##DD910IF8!$6(I.MT4)'5.3C!6_T@@^?L<LPHP$[
M=-A3 EYR8'*>&,YCU\(-,,,(HTO?!30+,5?_Q.8.L$MR3'9)#<-0#G7.33MP
M>'MZ?,GK%K9/I'J-TZ]D!9T#;MAU\FO]L-WOF%Q5?%U4=<&;/6]$M1;\_GUV
M_>%W$W;>V(/]Q\970=G"K[N07U!+ P04    "  (@7!*F5R<(Q &  "<)P
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MZBA[X04APGNMJX:O_4*(]@D ?BA(C?F"MJ21=TZ4U5C(+CL#WC*"C]I45R"
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MIIY5:>4=B<VQU67;_WK;<VMT-8YB4:K\9;@6=7^]#/\DKV%\ (X!> V ^,,
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M=S[R]HO4?C/7?I$:*X0RS<"=WPVGY*F"R3=WI9I#?SQIO:T^UZ;[O)WT7H]
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M*3+)'D&Y='HL" 0Z0.D [TY"R0QB7"JR\H,@_4"D?]V![M-H%>B^HF4# .X
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MHC9V1/^+'>M@TMWM)C/[NKF,['5Y_2A[O:F+<_?!V;M]]5[\!U!+ P04
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M:LYMJ[4+R=K^&D'#75;\!5!+ P04    "  (@7!*?,_FWQH$   ]$P  &
M 'AL+W=O<FMS:&5E=',O<VAE970W+GAM;'V866_C-A2%_XJ@]XS$2U*R MM
M[,&@!5H@F&+:9\6F%XP65Y+CZ;\OM<0C\Q[.2RPIAY?G<OFX+&]U\[T]&=,%
M/\JB:E?AJ>LNSU'4[DZFS-M/]<54]C^'NBGSSKXVQZB]-";?#X7*(J(X3J(R
M/U?A>CE\>VW6R_K:%>?*O#9!>RW+O/EO8XKZM@I%^/'AZ_EXZOH/T7IYR8_F
M+]-]N[PV]BVZ1]F?2U.UY[H*&G-8A2_B>2MU7V!0_'TVMW;V'/2IO-7U]_[E
M]_TJC'M'IC"[K@^1VY]WLS5%T4>R/OZ=@H;W.ON"\^>/Z%^&Y&TR;WEKMG7Q
MSWG?G5;A(@SVYI!?B^YK??O-3 GI,)BR_\.\F\+*>R>VCEU=M,/?8'=MN[J<
MHE@K9?YC_#U7P^]MBO]1#!>@J0#="XCDEP7D5$#^+*"&Y$=G0ZJ?\RY?+YOZ
M%C1C;UWR?E"(9VD;<]=_'-IN^)_-MK5?W]>"]#)Z[P--FLVHH;GFKHAL]'L5
MA*K8$"M.CQ5LN4(2KD'").107CXDD>  "@900P U"[#(G$88)>D@J0;)DT@H
M7CBI )FDF!1VHZ$;#=))<8 $!DA8.H(<HYM1HV=&19)*)QLD$IY<4F@E!5;<
MIDU9+4]:NE: 2))GE"R@E07OY-AQLF"56" Z1KA&BAC[R*"/C#>)=(UDO.&U
M<L<:$-&LGQ^LB!A/_QB8$>[\CWG;BU3'GC$I/*01H"IRJQ*H==TN "KA09*
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MS%()!=H)HXF%.J=WV\,Q#?$QX(> P2W.)%1R-N8U&%^JG&Z"()!0^L# <;O
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ML-F04/MPO,&S'<=L-+SIIA_$YF]<? !02P,$%     @ "(%P2@ZT9F"U 0
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M 8T+QQM_-M.838;3_?R#R/*-RS]02P,$%     @ "(%P2CYF+*"S 0  T@,
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M/-MIS";#FW[^06SYQL5O4$L#!!0    (  B!<$I]N.A M0$  -(#   9
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M3R!QR.B&OCF>VKIQP<'RM!,U_ 3WJSL;;[%9I6P5:-NB)@:JC-YMCJ==P$?
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M\65C_QMC/*"4Y 9'J,,/MA@2&A^.'_!LIS&;#&_Z^0>QY1N7?P!02P,$%
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MAO/ZT#"R&^\BR?5"M/X+4$L#!!0    (  B!<$KNORT ZP$  &8%   9
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M72LI#=A4H@?;U<:^1[/!H3)NF]B]&J=R-(SLIP>'S*]>_@=02P,$%     @
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MY_/%,A>2C<N=B=>+N_P#4$L#!!0    (  B!<$J )Q%[(@(   ('   9
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MO_(KKPW<*C$<>U$K]QOL+TJ+9LABI#3LN7]6K7O>AOPO87  '@+P&- 79S&
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M'<2/_LCD#,TN5=-"QQO:.0S.N?OL[PZITFO!SP8&OA@[*LF)TC<U^5+EKJ>
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M>]D=:[J!%FU_9(NNY\;57U!+ P04    "  (@7!*OB1S#-H!  !D!   &0
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MZNY.]?ET!4P#R8;Y=D/+%5O\ 5!+ P04    "  (@7!*2_YG1*X$  "3&@
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MK>1<@38,GG3"E7Y-IP&#4IENHOMB>%.&@>+=^%RBZ<TN_@-02P,$%     @
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M"X[<PO9@#FJ-ONL>*NP4_)9:@W]6;$R9L%5P9!729I+WC!XV%.Y6"D+9.PL
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MM;/O=%JI9R]%F,4YN!BA ?/28] $@VX1FWL$_@<!VL#H CE=(,O'4Q=)X!;
M3@%L!<*;&,DL1H^)+*:Q&!@A"+,DFJ5Q '$6XOB!H]#I*+QSA">%O1&(G +1
M\IK$3H%X04UB1]08XV"R4E\3!S".PP"[#25.0\F=(1A MT#J%$B7ER1S"F0+
M2I+=)TW3;%:.>U $LP=68.#>>8'#3/I XL'FA<L+ MT[#Z(%)1E MULG20(8
MS\\!!Q AE,3)S!28G$_FPOA&Q*EJI+?C2A]U]D Z<JZH%@V>M%RI[ZAQP.A1
MF6ZB^Z(_J/N!XNUP"8'Q)BS^ E!+ P04    "  (@7!*O:A@IN,#  "9$P
M&0   'AL+W=O<FMS:&5E=',O<VAE970U,BYX;6R56%USHS@0_"L4[V>0A/A(
MV:XZ)^LXF[NJU%[=[C.)Y9A:0#X@\=Z_/P&*#Z29M=8/-N#N'HTT/0B69]E\
M;X]"=-Z/JJS;E7_LNM--$+0O1U'E[4*>1*W^.<BFRCMUVKP&[:D1^7X@565
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M.JW4U4L1AV&&+D9HPCR-F'"!62'V]PC\%X*T@=E%Z'016CZ^<8'= M@I@*U
M=",0K6*,F-1B.HOY$&_Q*LE_0#=6(J>5R&$E7ED9,?%BER#=KIS<8](D<!N)
MG49BAY'$+9 X!9+W?Y74*9 Z'*2K5J1W#5_&'%MQCPEP%*V<H,61-U?0-R).
M;2>](U?Z[[%GO.9<@1;</.C>-/K6FQ<4:F6FJ9Z+\=\?%XKWT[6&YKNU^ -0
M2P,$%     @ "(%P2G_<!KY7 @  E@<  !D   !X;"]W;W)K<VAE971S+W-H
M965T-30N>&ULC57;CILP$/T5Q >L,7<B@I2+JE9JI6BK;I\=X@2T@*GMA.W?
MUS:$L&02-0_!-N<R,]B>M&/\71242NNCKAJQM LIVP5"(B]H3<0+:VFCWAP9
MKXE44WY"HN64' RIKI#K."&J2=G866K6=CQ+V5E694-WW!+GNB;\[YI6K%O:
MV+XNO):G0NH%E*4M.=&?5/YJ=US-T*AR*&O:B)(U%J?'I;W"BRUV-<$@WDK:
MB<G8TJGL&7O7DV^'I>WHB&A%<ZDEB'I<Z(96E592<?P91.W14Q.GXZOZ%Y.\
M2F9/!-VPZG=YD,72CFWK0(_D7,E7UGVE0T*!;0W9?Z<76BFXCD1YY*P2YM_*
MST*R>E!1H=3DHW^6C7EV@_Z5!A/<@>".!.7]C. -!.]&\)\2_('@SPBH3\74
M9DLDR5+..HOWG[<E>A?AA:^JG^M%4VSS3I5'J-5+%KAQBBY::,"L>XP[P?CX
MAD%*?S1Q(9.U>R<0N,EGD\T]QOV,V-XC/!>.P@-3]0S?FT;A!+" #PKX1L"?
M"GC.K%8])C*8QF!P[.@?;!2 1@%@A&=&$.9!.4+0) 0$O)D)A/%ADP@TB0"!
M8&;28X))R<(@#&&7&'2) 9=PYM)CXHE+])(DL$L"NB2 2S3;Q<G=YY]]_7XK
MW\.P]V278 <^NPX0T8.#B1\<?_S_AP*#AWN%72"*9'Z% "!_GBV:7%HUY2?3
M$(25LW-CNM%D=6PZ*]-ST W>=ZP?A)_*1EA[)M75:2ZX(V.2JEB<%[75"M4D
MQTE%CU(/(S7F?:?H)Y*U0Q=$8RO._@%02P,$%     @ "(%P2KK@ ',G!
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M'C\^CB=M=30?5L/SU]WUOU!+ P04    "  (@7!*/I/Z:C #  "B#   &0
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MH)T[^Y_N5NK1RRK+\T5\,8F<9MUK\$B#!D6LLP\(#"'6>!*.[P&;J8)@F$#
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M-%%S/G6D:2'9,#=;M'3\_"]02P,$%     @ "(%P2FI3M&@. @  _04  !D
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M, .W2DR-2C#EOD%U45KPB<5(X?1U'-O.C</$?TOS)^ I <\)<?IN ID2R)R
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M%VK,AVXQ3"3KQD[H3>VX^ ]02P,$%     @ "(%P2DB'L0:C @  BPD  !D
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M8"J#^3!3-:@^5L0N$"$Z!HXD):"D!)!D7=RZQ21#3V&(($TN,D[1'4T$U$0
M39&EB3B>$H)=02Z,T-2!;8ESEQ2A2=4IJ#H%5,>6ZM218PN^AQB)H* ("HA(
M+!'TGR+N(48B9J"(&2""6")FSHU/N$ AW'1"P$EJ=QT(1"?\3#0W!%#,)BC
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MM3?:&P-UUPEPBW7^,VH:>WOT_Z1AMIBM5P]57?PSGZ?)>)KNCP]'^T?3?9J
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MDNNK2@J\6G[9<::C1L**L&LK1@<C]YFCU^<@RY9$4S</2K&9874=^WD[08E
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M?1_K4O2AO)4U)G[:6?#*H(V"1I$BK1)23)3)@?%ZN<^?4(N-H?>MI4Y6K-3
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ML+E,4HF8K4@R:UAHW6XO:VTT;6/-MBTPLX7 S7G;=UT:OFAFWPA\C MTY;U
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M)5V%;Q\!/GKY(%E+O//4BO<>-O@>S[V%7LC;/S,<JY48SKP $5ZV< .M@.\
M0C$>KP7A[;H6.AJ)E0;(2XA!@Q[BR/U\=+"/?P%UX1A_,ME+#D[H+^/D<.\
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MT?S^\>@(R0+^^]I=8EH),(@3G=/%IM.U[.2M7APYMCKR1)"" SRTJM$%:C?
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M+KAC *'<HW*ZR\JI2LK@Z.+2*TN# </-J[=^#ZU8]=0>0(QBNO>EC+E>7A?
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M>N[B4N9N#<&)2CA&]4K.(4&8I$TP+C_95+4:BKMDTO%R'BE,?V,_ /+\@.1
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MJR$FL*P!!;S*JH0S#]RY:@#9Q>3=RI]O8"XHDIZ;<5+&/3%<3,%/G/UB1 2
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MC1,9D_CHP,CWUR>R<&"M64@(;O,&>N*H$S1$)W0QR8Z@]%TN+P<)$IC!YRY
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M<J M1G'"NQH2(0N8H@+QW3+<+81:9C:?@\/Q1WO&N1%>)49]MQ=ADLI_;^7
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M NJO6)N/MT'($H*PUQR+HN;M-)ZK+\_W<!>4J_+I'I1Y[0#T#[O-PUJJ) 2
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M^Y3<*;^<W8OHWZCSK:8[I<Y,3MS'KH.4S75*P"-!_M)WF\H_-L>IJ%YZ2&)
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MAFJJ[LP2;3""@_W9" ]6_:QU3Q'!P?Z"4U*S2UMP>%/'/P!02P,$%     @
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M3^'\]D)6Q=2*\+%ZF2G-PBL)\ZZJ;ORV!^.+R+"]'V/]?O+5_U!+ P04
M"  (@7!*4?TPDT0"  "$*0  &@   'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR
M96QSQ=K!;MI $,;Q5T%^@"P[NS,D5<BIEUS3OH %"T8!V_)NE>3MZW*I*R7^
M>D"?+R $FOF??EAK/[ZD<UU.79N;4Y]7[Y=SF[=54TK_S;F\:]*ESG==G]KQ
MFT,W7.HR?AR.KJ]WK_4Q.5FOS0W3&=73XW3FZGF_K8;GO:]6/^OAF,JV<N]G
M]]8-K[E)J61W??-WXX+Q)Q]]^I_UW>%PVJ7OW>[7);7EDXJ_"RKW>9#,!PD]
M*,P'!7I0G ^*]""=#U)ZD,T'&3UH,Q^TH0?=SP?=TX,>YH,>Z$%^#61<\Y,0
MUGRM/>#:\[WV &S/%]L#LCW?; _0]GRU/6#;\]WV &[/E]L#NCW?;@_P]GR]
M!>@M?+T%Z"T+7&NCBVV^W@+T%K[> O06OMX"]!:^W@+T%K[> O06OMX"]!:^
MW@+T%K[> >@=^'H'H'?@ZQV WF&!LQ)T6,+7.P"] U_O /0.?+T#T#OP]0Y
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M+GAM;%!+ 0(4 Q0    (  B!<$H/AR#3[@   "L"   1              "
M 9D!  !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    (  B!<$J97)PC$ 8
M )PG   3              "  ;8"  !X;"]T:&5M92]T:&5M93$N>&UL4$L!
M A0#%     @ "(%P2C4M!K&F @   PH  !@              ( !]P@  'AL
M+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    (  B!<$JR=U=\Y ,
M )D2   8              "  =,+  !X;"]W;W)K<VAE971S+W-H965T,BYX
M;6Q02P$"% ,4    "  (@7!*\50_,U("   O"   &               @ 'M
M#P  >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @ "(%P2LHZ
M4+1D P  / X  !@              ( !=1(  'AL+W=O<FMS:&5E=',O<VAE
M970T+GAM;%!+ 0(4 Q0    (  B!<$H'M?AUF 0   $7   8
M  "  0\6  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4    "  (
M@7!*MP69TBL"  #7!@  &               @ '=&@  >&PO=V]R:W-H965T
M<R]S:&5E=#8N>&UL4$L! A0#%     @ "(%P2GS/YM\:!   /1,  !@
M         ( !/AT  'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0
M   (  B!<$J))"3ZNP$  -0#   8              "  8XA  !X;"]W;W)K
M<VAE971S+W-H965T."YX;6Q02P$"% ,4    "  (@7!*_ZU+$[$!  #2 P
M&               @ %_(P  >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L!
M A0#%     @ "(%P2GXHIN"U 0  T@,  !D              ( !9B4  'AL
M+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4    "  (@7!*"G.9^K,!
M  #2 P  &0              @ %2)P  >&PO=V]R:W-H965T<R]S:&5E=#$Q
M+GAM;%!+ 0(4 Q0    (  B!<$J2!?5(M0$  -(#   9              "
M 3PI  !X;"]W;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#%     @ "(%P
M2@ZT9F"U 0  T@,  !D              ( !*"L  'AL+W=O<FMS:&5E=',O
M<VAE970Q,RYX;6Q02P$"% ,4    "  (@7!*/F8LH+,!  #2 P  &0
M        @ $4+0  >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0
M   (  B!<$I]N.A M0$  -(#   9              "  ?XN  !X;"]W;W)K
M<VAE971S+W-H965T,34N>&UL4$L! A0#%     @ "(%P2N#?RI6T 0  T@,
M !D              ( !ZC   'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q0
M2P$"% ,4    "  (@7!*+.!M#;,!  #2 P  &0              @ '5,@
M>&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    (  B!<$JS%'JK
MM $  -(#   9              "  ;\T  !X;"]W;W)K<VAE971S+W-H965T
M,3@N>&UL4$L! A0#%     @ "(%P2M$8R/JT 0  T@,  !D
M ( !JC8  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4    "  (
M@7!*5YM"9K8!  #2 P  &0              @ &5.   >&PO=V]R:W-H965T
M<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    (  B!<$K!AK9FLP$  -(#   9
M          "  8(Z  !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#
M%     @ "(%P2L7_K!VU 0  T@,  !D              ( !;#P  'AL+W=O
M<FMS:&5E=',O<VAE970R,BYX;6Q02P$"% ,4    "  (@7!*GE]"4;0!  #2
M P  &0              @ %8/@  >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM
M;%!+ 0(4 Q0    (  B!<$KM66WOZ (  !P-   9              "  4-
M  !X;"]W;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @ "(%P2NZ_
M+0#K 0  9@4  !D              ( !8D,  'AL+W=O<FMS:&5E=',O<VAE
M970R-2YX;6Q02P$"% ,4    "  (@7!*#:.W!<,!   W!   &0
M    @ &$10  >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    (
M  B!<$I37]^QMP$  -(#   9              "  7Y'  !X;"]W;W)K<VAE
M971S+W-H965T,C<N>&UL4$L! A0#%     @ "(%P2JY+"0&X 0  T@,  !D
M             ( !;$D  'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"
M% ,4    "  (@7!*BC0Q6;@!  #2 P  &0              @ %;2P  >&PO
M=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    (  B!<$JHM7X=LP$
M -(#   9              "  4I-  !X;"]W;W)K<VAE971S+W-H965T,S N
M>&UL4$L! A0#%     @ "(%P2J_P[@NW 0  T@,  !D              ( !
M-$\  'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"% ,4    "  (@7!*
M39'F5[@!  #2 P  &0              @ $B40  >&PO=V]R:W-H965T<R]S
M:&5E=#,R+GAM;%!+ 0(4 Q0    (  B!<$H6-"Q7]0$  ,L%   9
M      "  1%3  !X;"]W;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#%
M  @ "(%P2J G=+/? 0   04  !D              ( !/54  'AL+W=O<FMS
M:&5E=',O<VAE970S-"YX;6Q02P$"% ,4    "  (@7!*D&'"*;P"  #Q"@
M&0              @ %35P  >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+
M 0(4 Q0    (  B!<$J18/SJD0,  *D1   9              "  49:  !X
M;"]W;W)K<VAE971S+W-H965T,S8N>&UL4$L! A0#%     @ "(%P2D'T18SQ
M 0  Q 4  !D              ( !#EX  'AL+W=O<FMS:&5E=',O<VAE970S
M-RYX;6Q02P$"% ,4    "  (@7!*@"<1>R("   "!P  &0
M@ $V8   >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    (  B!
M<$K1^GA! 0(  (P%   9              "  8]B  !X;"]W;W)K<VAE971S
M+W-H965T,SDN>&UL4$L! A0#%     @ "(%P2NJGRU0P @  PP<  !D
M         ( !QV0  'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q02P$"% ,4
M    "  (@7!*>"IS9QH"  #B!@  &0              @ $N9P  >&PO=V]R
M:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    (  B!<$I"3[%VP0(  -<)
M   9              "  7]I  !X;"]W;W)K<VAE971S+W-H965T-#(N>&UL
M4$L! A0#%     @ "(%P2GD7PC,O @  K@8  !D              ( !=VP
M 'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6Q02P$"% ,4    "  (@7!*U/"K
M: $"  #)!0  &0              @ '=;@  >&PO=V]R:W-H965T<R]S:&5E
M=#0T+GAM;%!+ 0(4 Q0    (  B!<$H6S<L>FP(  $,*   9
M  "  15Q  !X;"]W;W)K<VAE971S+W-H965T-#4N>&UL4$L! A0#%     @
M"(%P2KXD<PS: 0  9 0  !D              ( !YW,  'AL+W=O<FMS:&5E
M=',O<VAE970T-BYX;6Q02P$"% ,4    "  (@7!*]4YG7/,!  !N!0  &0
M            @ 'X=0  >&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+ 0(4
M Q0    (  B!<$I+_F=$K@0  ),:   9              "  2)X  !X;"]W
M;W)K<VAE971S+W-H965T-#@N>&UL4$L! A0#%     @ "(%P2MIW_$G\ 0
MOP4  !D              ( !!WT  'AL+W=O<FMS:&5E=',O<VAE970T.2YX
M;6Q02P$"% ,4    "  (@7!*LEQ.82L$  #0%   &0              @ $Z
M?P  >&PO=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+ 0(4 Q0    (  B!<$KF
MKW)*,@(  !4'   9              "  9R#  !X;"]W;W)K<VAE971S+W-H
M965T-3$N>&UL4$L! A0#%     @ "(%P2KVH8*;C P  F1,  !D
M     ( !!88  'AL+W=O<FMS:&5E=',O<VAE970U,BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    (  B!<$K.V+[U\@$  .H$   9              "
M 9B6  !X;"]W;W)K<VAE971S+W-H965T-3<N>&UL4$L! A0#%     @ "(%P
M2DA#]_L2 @  T04  !D              ( !P9@  'AL+W=O<FMS:&5E=',O
M<VAE970U."YX;6Q02P$"% ,4    "  (@7!*)/EJ_BP"  " !@  &0
M        @ $*FP  >&PO=V]R:W-H965T<R]S:&5E=#4Y+GAM;%!+ 0(4 Q0
M   (  B!<$I86+;6"0(  /T%   9              "  6V=  !X;"]W;W)K
M<VAE971S+W-H965T-C N>&UL4$L! A0#%     @ "(%P2FI3M&@. @  _04
M !D              ( !K9\  'AL+W=O<FMS:&5E=',O<VAE970V,2YX;6Q0
M2P$"% ,4    "  (@7!*=@S^;Q("  "!!0  &0              @ 'RH0
M>&PO=V]R:W-H965T<R]S:&5E=#8R+GAM;%!+ 0(4 Q0    (  B!<$I=BT5M
M0P(  )H'   9              "  3ND  !X;"]W;W)K<VAE971S+W-H965T
M-C,N>&UL4$L! A0#%     @ "(%P2DB'L0:C @  BPD  !D
M ( !M:8  'AL+W=O<FMS:&5E=',O<VAE970V-"YX;6Q02P$"% ,4    "  (
M@7!*!!VA)/D"   (#   &0              @ &/J0  >&PO=V]R:W-H965T
M<R]S:&5E=#8U+GAM;%!+ 0(4 Q0    (  B!<$JIA#N+'0(  /L%   9
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M%&<! 'AL+W-T>6QE<RYX;6Q02P$"% ,4    "  (@7!*9;Z4$<$$   .+0
M#P              @ &+:0$ >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @
M"(%P2E'],)-$ @  A"D  !H              ( !>6X! 'AL+U]R96QS+W=O
M<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ "(%P2@4-5&,! @  LR@  !,
M             ( !]7 ! %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     $X
,3@!4%0  )W,!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='UTF-8'?>
<FilingSummary>
  <Version>3.6.0.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>173</ContextCount>
  <ElementCount>352</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>60</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="hsgx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>101 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.histogenics.com/taxonomy/role/DocumentandEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="hsgx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>103 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.histogenics.com/taxonomy/role/StatementOfFinancialPositionClassified</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="hsgx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>104 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.histogenics.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="hsgx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>105 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.histogenics.com/taxonomy/role/StatementOfIncomeAlternative</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="hsgx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>106 - Statement - Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.histogenics.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome</Role>
      <ShortName>Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="hsgx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>107 - Statement - Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.histogenics.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncomeParenthetical</Role>
      <ShortName>Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="hsgx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>108 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.histogenics.com/taxonomy/role/StatementOfCashFlowsIndirect</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="hsgx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>109 - Statement - Consolidated Statements of Cash Flows (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.histogenics.com/taxonomy/role/StatementOfCashFlowsIndirectParenthetical</Role>
      <ShortName>Consolidated Statements of Cash Flows (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="hsgx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>110 - Disclosure - Nature of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsNatureOfOperations</Role>
      <ShortName>Nature of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="hsgx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>111 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="hsgx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>112 - Disclosure - Loss Per Common Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock</Role>
      <ShortName>Loss Per Common Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="hsgx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>113 - Disclosure - Prepaid Expenses and Other Current Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsPrepaidExpensesAndOtherCurrentAssetsTextBlock</Role>
      <ShortName>Prepaid Expenses and Other Current Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="hsgx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>114 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="hsgx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>115 - Disclosure - Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</Role>
      <ShortName>Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="hsgx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>116 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="hsgx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>117 - Disclosure - Capital Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock</Role>
      <ShortName>Capital Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="hsgx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>118 - Disclosure - Warrants</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsWarrantDisclosureTextBlock</Role>
      <ShortName>Warrants</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="hsgx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>119 - Disclosure - Equipment Loan Payable</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlock</Role>
      <ShortName>Equipment Loan Payable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="hsgx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>120 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="hsgx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>121 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="hsgx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>122 - Disclosure - Employee Benefits</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsPensionAndOtherPostretirementBenefitsDisclosureTextBlock</Role>
      <ShortName>Employee Benefits</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="hsgx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>123 - Disclosure - Related Parties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock</Role>
      <ShortName>Related Parties</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="hsgx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>124 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="hsgx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>125 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="hsgx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>126 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="hsgx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>127 - Disclosure - Loss Per Common Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlockTables</Role>
      <ShortName>Loss Per Common Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="hsgx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>128 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsPrepaidExpensesAndOtherCurrentAssetsTextBlockTables</Role>
      <ShortName>Prepaid Expenses and Other Current Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsPrepaidExpensesAndOtherCurrentAssetsTextBlock</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="hsgx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>129 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlockTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="hsgx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>130 - Disclosure - Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlockTables</Role>
      <ShortName>Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="hsgx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>131 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlockTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="hsgx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>132 - Disclosure - Capital Stock (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlockTables</Role>
      <ShortName>Capital Stock (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="hsgx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>133 - Disclosure - Equipment Loan Payable (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlockTables</Role>
      <ShortName>Equipment Loan Payable (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsDebtDisclosureTextBlock</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="hsgx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>134 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="hsgx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>135 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlockTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.histogenics.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="hsgx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>136 - Disclosure - Nature of Business - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.histogenics.com/taxonomy/role/DisclosureNatureOfBusinessAdditionalInformation</Role>
      <ShortName>Nature of Business - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="hsgx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>137 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.histogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="hsgx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>138 - Disclosure - Summary of Significant Accounting Policies - Summary of Operations in Different Geographic Regions (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.histogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfOperationsInDifferentGeographicRegions</Role>
      <ShortName>Summary of Significant Accounting Policies - Summary of Operations in Different Geographic Regions (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="hsgx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>139 - Disclosure - Summary of Significant Accounting Policies - Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.histogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasis</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="hsgx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>140 - Disclosure - Summary of Significant Accounting Policies - Schedule of Reconciliation of Liabilities Measured at Fair Value (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.histogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfReconciliationOfLiabilitiesMeasuredAtFairValue</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Reconciliation of Liabilities Measured at Fair Value (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="hsgx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>141 - Disclosure - Summary of Significant Accounting Policies - Schedule of Depreciation and Amortization using Straight-line Method over Estimated Useful Lives of Assets (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.histogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfDepreciationAndAmortizationUsingStraightlineMethodOverEstimatedUsefulLivesOfAssets</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Depreciation and Amortization using Straight-line Method over Estimated Useful Lives of Assets (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="hsgx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>142 - Disclosure - Summary of Significant Accounting Policies - Summary of Intangible Assets, Net of Accumulated Impairment Charges (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.histogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfIntangibleAssetsNetOfAccumulatedImpairmentCharges</Role>
      <ShortName>Summary of Significant Accounting Policies - Summary of Intangible Assets, Net of Accumulated Impairment Charges (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="hsgx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>143 - Disclosure - Loss Per Common Share - Schedule of Basic and Diluted Loss Per Common Share (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.histogenics.com/taxonomy/role/DisclosureLossPerCommonShareScheduleOfBasicAndDilutedLossPerCommonShare</Role>
      <ShortName>Loss Per Common Share - Schedule of Basic and Diluted Loss Per Common Share (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="hsgx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>144 - Disclosure - Loss Per Common Share - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.histogenics.com/taxonomy/role/DisclosureLossPerCommonShareScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShare</Role>
      <ShortName>Loss Per Common Share - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="hsgx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>145 - Disclosure - Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.histogenics.com/taxonomy/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpensesAndOtherCurrentAssets</Role>
      <ShortName>Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="hsgx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>146 - Disclosure - Property and Equipment - Schedule of Property and Equipment (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.histogenics.com/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipment</Role>
      <ShortName>Property and Equipment - Schedule of Property and Equipment (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="hsgx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>147 - Disclosure - Property and Equipment - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.histogenics.com/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformation</Role>
      <ShortName>Property and Equipment - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="hsgx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>148 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.histogenics.com/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpenses</Role>
      <ShortName>Accrued Expenses - Schedule of Accrued Expenses (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="hsgx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>149 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.histogenics.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="hsgx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>150 - Disclosure - Commitments and Contingencies - Schedule of Minimum Annual Lease Commitments Under Non-Cancellable Operating Leases (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.histogenics.com/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMinimumAnnualLeaseCommitmentsUnderNonCancellableOperatingLeases</Role>
      <ShortName>Commitments and Contingencies - Schedule of Minimum Annual Lease Commitments Under Non-Cancellable Operating Leases (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="hsgx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>151 - Disclosure - Capital Stock - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.histogenics.com/taxonomy/role/DisclosureCapitalStockAdditionalInformation</Role>
      <ShortName>Capital Stock - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="hsgx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>152 - Disclosure - Capital Stock - Schedule of Common Stock Reserved for Future Issuance (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.histogenics.com/taxonomy/role/DisclosureCapitalStockScheduleOfCommonStockReservedForFutureIssuance</Role>
      <ShortName>Capital Stock - Schedule of Common Stock Reserved for Future Issuance (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="hsgx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>153 - Disclosure - Warrants - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.histogenics.com/taxonomy/role/DisclosureWarrantsAdditionalInformation</Role>
      <ShortName>Warrants - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="hsgx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>154 - Disclosure - Equipment Loan Payable - Schedule of Outstanding Borrowing Obligations (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.histogenics.com/taxonomy/role/DisclosureEquipmentLoanPayableScheduleOfOutstandingBorrowingObligations</Role>
      <ShortName>Equipment Loan Payable - Schedule of Outstanding Borrowing Obligations (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="hsgx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>155 - Disclosure - Equipment Loan Payable - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.histogenics.com/taxonomy/role/DisclosureEquipmentLoanPayableAdditionalInformation</Role>
      <ShortName>Equipment Loan Payable - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="hsgx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>156 - Disclosure - Stock-Based Compensation - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.histogenics.com/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformation</Role>
      <ShortName>Stock-Based Compensation - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="hsgx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>157 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity Under the 2012 and 2013 Plans (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.histogenics.com/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityUnderThe2012And2013Plans</Role>
      <ShortName>Stock-Based Compensation - Summary of Stock Option Activity Under the 2012 and 2013 Plans (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="hsgx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>158 - Disclosure - Stock-Based Compensation - Additional Information about Stock Option Activity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.histogenics.com/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationAboutStockOptionActivity</Role>
      <ShortName>Stock-Based Compensation - Additional Information about Stock Option Activity (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="hsgx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>159 - Disclosure - Stock-Based Compensation - Schedule of Restricted Stock Awards Under the 2012 and 2013 Plans (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.histogenics.com/taxonomy/role/DisclosureStockBasedCompensationScheduleOfRestrictedStockAwardsUnderThe2012And2013Plans</Role>
      <ShortName>Stock-Based Compensation - Schedule of Restricted Stock Awards Under the 2012 and 2013 Plans (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="hsgx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>160 - Disclosure - Stock-Based Compensation - Summary of Stock-Based Compensation (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.histogenics.com/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation - Summary of Stock-Based Compensation (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="hsgx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>161 - Disclosure - Stock-Based Compensation - Summary of Weighted-Average Assumptions Used in the Black-Scholes Option Pricing Model to Determine the Fair Value of the Employee Stock Option Grants (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.histogenics.com/taxonomy/role/DisclosureStockBasedCompensationSummaryOfWeightedAverageAssumptionsUsedInTheBlackScholesOptionPricingModelToDetermineTheFairValueOfTheEmployeeStockOptionGrants</Role>
      <ShortName>Stock-Based Compensation - Summary of Weighted-Average Assumptions Used in the Black-Scholes Option Pricing Model to Determine the Fair Value of the Employee Stock Option Grants (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="hsgx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>162 - Disclosure - Stock-Based Compensation - Summary of Weighted-Average Assumptions Used in the Black-Scholes Option Pricing Model to Determine the Fair Value of the Non-Employee Stock Option Grants (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.histogenics.com/taxonomy/role/DisclosureStockBasedCompensationSummaryOfWeightedAverageAssumptionsUsedInTheBlackScholesOptionPricingModelToDetermineTheFairValueOfTheNonEmployeeStockOptionGrants</Role>
      <ShortName>Stock-Based Compensation - Summary of Weighted-Average Assumptions Used in the Black-Scholes Option Pricing Model to Determine the Fair Value of the Non-Employee Stock Option Grants (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="hsgx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>163 - Disclosure - Income Taxes - Components of Loss Before Income Taxes (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.histogenics.com/taxonomy/role/DisclosureIncomeTaxesComponentsOfLossBeforeIncomeTaxes</Role>
      <ShortName>Income Taxes - Components of Loss Before Income Taxes (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="hsgx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>164 - Disclosure - Income Taxes - Schedule of Reconciliation of Income Tax Expense (Benefit) Computed at Statutory Federal Income Tax Rate (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.histogenics.com/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseBenefitComputedAtStatutoryFederalIncomeTaxRate</Role>
      <ShortName>Income Taxes - Schedule of Reconciliation of Income Tax Expense (Benefit) Computed at Statutory Federal Income Tax Rate (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="hsgx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>165 - Disclosure - Income Taxes - Components of Deferred Tax Assets and Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.histogenics.com/taxonomy/role/DisclosureIncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilities</Role>
      <ShortName>Income Taxes - Components of Deferred Tax Assets and Liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="hsgx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>166 - Disclosure - Income Taxes - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.histogenics.com/taxonomy/role/DisclosureIncomeTaxesAdditionalInformation</Role>
      <ShortName>Income Taxes - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="hsgx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>167 - Disclosure - Income Taxes - Summary of Changes In Unrecognized Tax Benefits (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.histogenics.com/taxonomy/role/DisclosureIncomeTaxesSummaryOfChangesInUnrecognizedTaxBenefits</Role>
      <ShortName>Income Taxes - Summary of Changes In Unrecognized Tax Benefits (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="hsgx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>168 - Disclosure - Employee Benefits - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.histogenics.com/taxonomy/role/DisclosureEmployeeBenefitsAdditionalInformation</Role>
      <ShortName>Employee Benefits - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="hsgx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>169 - Disclosure - Related Parties - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.histogenics.com/taxonomy/role/DisclosureRelatedPartiesAdditionalInformation</Role>
      <ShortName>Related Parties - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="hsgx-20161231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>170 - Disclosure - Subsequent Events - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.histogenics.com/taxonomy/role/DisclosureSubsequentEventsAdditionalInformation</Role>
      <ShortName>Subsequent Events - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>hsgx-20161231.xml</File>
    <File>hsgx-20161231.xsd</File>
    <File>hsgx-20161231_cal.xml</File>
    <File>hsgx-20161231_def.xml</File>
    <File>hsgx-20161231_lab.xml</File>
    <File>hsgx-20161231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies/>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>92
<FILENAME>0001193125-17-085372-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-17-085372-xbrl.zip
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M@IDO-"D 2;GW_7GQYIV?WK+WL@_@?4D51$D@4O[*)"B_B,TH#<:7]_'C:_@
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M=!3%%13% @E0/%LP;=,1%-.09%.U"%5$;MXE8E"P[ZT4=Z-I)9E6/2$Z79.
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M )H00E/;- 7=L"V!RL2P)45WB.H6IS\2::QFE8HA>G(CS0JE.K->5.J"L7#
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M>$5#Q4C\I294]S&9O6U?RK)D44U3!=MQ&'8Y\%8798&HFD0TS79L@Q1U5M)
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MT^+=C\DU[J?:,6TY</9INF<)3,DS"O];!_^\B_NI&A#T6L0":V*!1!F89=-
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M5"-[,$;=DS'%\:(L5AG3B=@CXG<B!\ /HE]AP12JXSRI*/%P0U9JE;9=+\U
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M">9QBE=LBSX?>!4<KRL5?7C@P701+I;LHCJ[CSW%*K;$QUNX,$31! 4>34'
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M:^L>&AXPON(EU;620SU3NVII/= "_O2/P$\\^,L!..I[VEK";6W=RC8F51<
MSP\3YC:\"WG0!SK\/>P9S'U]!(\#XS)0SB!-8?I;%-^FX'I@NO!M-%\NZIP[
MPA5% KZ6:ZL>. ^>!B:(.H))'$.PB:YKMD&(*CF#7[>NH/RAX2OO0_%+,T4.
M&,%4J_QAZ']@":<EIV&(6<9LM"LK<*;O$ 1S1$8(<AV"0?/9C>%R%5BX"@MQ
M0M" 7=AY.#:@JA]X!T?;_0Z.K)SD/9CO!?.C]79']@7LEH"9EG.([\J?!X=Q
M.R_CWI=TSN@ESX9>8@7W81153L<N1O_E1TL_>2J9FN6Q!JTQ^O:Z;SYOE]L3
M$SL,S/A9[%U^3)9>#%[$=FBE,A$O-/'9KMI\QUJ+AVN8VJ[#@.<GKKFS_?3B
M1.HG2;M01&U?F?INZ]_/'=7/MF:-LG!KU3^#:X1]*Z7)A63LK0>^=S5P>A6K
M+Z11XS$R@V7&U)P%T81E)Z?^_>!Y4NG5KW?^- UXHK0VEW**-B])*=.GO9^@
M[G+$05[]*E3/4-?-;J4#'G_NFG4@A/7ZM/ 7?6:F=Z%!>?7K'T%:ZX#7.KMZ
MBOKO0835,&8T,2>S, K3!18^/0;/<CYCND2A(I$%R=(E@8HRDDLU@;B2I7FB
M+6I2EHC7%3S\K9S/;*&C<3#C)QB+X^%P?IP3COLE]?,\2#[SRL(JU?+>1$LJ
MR*AX:51/7-K(6#G:'K,^B*S$(4S_M%D%"_[4GY0:CJ:KBF8)IN(J I5=2]"I
M(0JZ(^FR8BK$E8<_2&CKVUKC!@8RG!LC9$<C'39P$U>OUH U66;%=%GA>[S
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MC[#GDX"=P[()1$NF:7"R[=FF$F&TEF=J)P($G(B@TD4Q'P[W6_4KV[YP)3,
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M 3/PUH"W>1ORUNZ35>@%U+%Y(T'L!7ON#OC-=@?<LU_9N3D@^MS9 +J\>W-
M]?G:Y!W]J\]M\G;J9Z6V];/*ON,6?_X#_,5R(B[ZC>6OK3X$F^SMGBF\\WH>
MLS]9<932V_*\")J5P47R?.ZW\=ROZ'FX)K;(@H$Y!,>\?SEV]\_[CQ=N8H%"
M7D"98G"[5[;J&4Y?I$OYA;2PV)- >BD>Y?SL7#R[:^^(%*$0QT'(, P0 *4
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M-P:=7J77:C7-03,7J=D2(( &PDO]8GG8R59(.Q29-DEZZ]@!RH._C+!()GK
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MU @<VAEN(_!U--MDX6M2 @B_V0H(912GK%UYVO_$8#1CUE=IJ=27,G)Y6R.
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M0\8SS)R)@V@3)M,K,:78]T3YIT<6GXV@']HN[!9K/1F+$+0\'2U<FH>)[PJ
MF8.\IF5M[<Z&;\!QL0C\$=Z2>6%"#0A7/\U$(WKEB\!K "OG/A6<:O8,42W[
M=D_C#54EKN*QDCF=<$Z\ERC<<M+RJB*Q(OEWDD!9H75C UU^8_?,B]D7%AU
M9CNA7ZV8C1_?;WJJZ-;7R.YVWZI5#:NBFYVFJ5>-2E?O]*H-W>J;G<; Z!H-
M4\KN])!+.\X>)Q'/_9\V-;F%F^JQ<!0XG/X.*'U;O4Z]UM*;G4I#K[8M0V^U
M6UW=JG7-7JW>1.T#MFZ]_X0\)F$R3@AL;O@OG*8 2$",<,(UC!+',]&F8$3$
M2'T+(OLG&-W):4)MN-#H0SL&3B#*IY'=+Y@-G+D"1P#L"OSX;HH)^2$QNJX=
M! OXTH,=C).Y=\3K@"RU!P;$PMEXE Q4<1W@/8#M#G*;@,V0>I2]*UN2^ R
M1>RFGW$SN-##U!E-1?DUOH4FML!F'QP0CT/Q.U\]1.+RZ"C*XF6-N#0>F!^0
MK[A]0P"B90C!EZ_"P&8 :"1(I;)0L\R2AG==0I!C[7D"2M-*0,E%+@=GBHR/
MX%L6.47RIW?WF=DAXK 7];DWY;B45UM%WUZE5;/,9ENOU'I(>1U+;_:;-;TU
M:%8[G4ZUWFX...69W+!)C[SU%-D#?_$]7WZ;0TI\,Y=LQJS ::M&JY4Y[L8S
M+-TMBNKS.F_K_2>]4FUF+W?K,99$QVC*QK&+PD;*G78(BD$(%J=B:OX!: (Z
MV_BK]PW;/:!&V[%#)[Q%X_0(F<R==J/?KE2J>K<^L) S=_1FHUW56ZWZH%FI
MU:N5BG$$NVBG0HZBI\-3&XADE%KDP7(Z"_P0JLID')+J!9HUX!'*.Q>UR]"9
MQ2Z7"3-4N<NII^5V"L*8/B1)&\Q]+OU"ALU$7#[QE9>)HF$3@4P$N</-$5P/
M=30A,##A60@(9Y3L=(.9E5&+A8)+:\%CR>HE^AAV&('\0F7@WL=C<&5Q(NR;
M1]^6>1=?DLM-V#"W/:/ 'D4QK(]P7 (QM[_""#A-E)I<<\4NHIW8V@3,.ALU
M3%P'G@QM;M#Z(T'O93#IF?8%+ BM68*[F3OXU1N^*Y#W:'S& 1D[8R<<Q6$H
M&KV(4]XC>.:N/2(U?%43+EJQY(AL'TW4+UJQK*M+:%6>UXJEND<E0>OE*@F*
M5Y^T?N(%6IFLJT1\(K_><ZM QK>__ZI9K7)-Z1RZK?/'YMZATHFM&'5;G,WG
MUKB$0OM+YWG9<H03'/K_ I:(A@3)J94YL<GW2+U"Q\'C7[4ID)0>;68'?S$Q
M07#K@Y>?0=MT-?/ F?CYOX0;^(LS =76BQZ'4IH&N?UKPY %]Q0?3<[G>//X
M"1=1*2YB&Y1B3X'QH]]^(NRM8Y>CO-JV7ANOWJQNO?M+"D&>K!RHZ-WQQ-X=
MBO:QIJ936U-+^,;&,!=[?K-[+IIT[<E+N(_^UX)Q%'M^DWLNU)(55F(]C97\
MX7MLH7$;EYS_9U,,8!DE:_^94V=1#7 N1USW]MV.G-=>A05\<F4/YH_-[JNQ
M*<D4A=I6[/EM[KE0VYZKMHE.L&G:\>DYR-/DRVJEHU4R]Y]T_;*R^WDKY$:(
M%X ZWR["1Z.>0K,[M%]_N6%>H><5>WX;>R[TO%?@GGNNJ*K42HWZ^IX6KTXL
MG\M9"UVM -2AYB2_QO(97EQP'HGXJZ7#!RWF6JG)#;!4$)1=^O>5M]2AY!MS
ML?+F&N=VLT-,^'A"K=R@9C;:5K^A=WM&2Z\V*WV]7:TU]4:S6^M7K7ZO5;.P
M-M!Z_\FTS$RMW!//M0-0EIJTY!,2U?>?ZC7K<4@L'29[_&MJ7A$MKEW 7D"Q
M_K]C9X[%/4<=<M*J]>LUL]_4^[5F7Z\.ZE6]V6HV=*O1JW2:QJ#::O0?+0U4
MV@29S<,-UTALPEI9N_[V];K_[?9_M?:7GM;_O]^OKO\ OK'%)#SRX ]Y6[PB
M3%Y5,?[CV>,_ZK6G%^V8E9>K7S'-8@#(@93$P\]9V#CX0\FY?H/C)W8$2S&B
MXID7MGV8]XE3S8MVXJK\_CJ98*5X(KE/[@_:MW=KO;[VP=?2N;5FM8YQOJ)[
ML8+[G^TA-G;P@\4+XO]S?8354K6Z?OQG[DCA^4>UK*/T:RYDQ'8Z0<-]ZKMC
MS9G- _^>]W\\.TIIE.K--T(I1SMJ(3\4NNCZU$"1=[1Q/.Q_<Q>P\ PIHW84
M92-_!ZU5"_EQ>CJY\2?1@QVPLZ.+UIG8&/D\YUN:$5',Q2GN)']W<M;:FG64
M647SM?&JLY-,IE6J'$>7R>=9CS-AMM#;'K'[P_!7'(\04Z=4-M;&;!ZPD?,R
M\XF?BT>7K9*U_VS6#^=%-)>-4JNYMU6W];"%7O>6=(CB3O)W)X5>]V@&4DGS
MV-D$,ZU2LVZ<AS*W;SBS5#%/ZI!^C<*H&'E8W$H^;V77Y'\U0;9RN"34GF*6
MR"G$6L!3K''^SWJC7PSCDM/&?C'+#0W>XN(B^$7XH)Y\@*.'Y/"B4&,>#N]:
MFSYVP3/I: 7,'2MI./Z+CY-T%[N,ZGI* O2&$5='397NM.%OO49+;^%$S6JO
MT]*;E7I3-QH-HU/MULUVH[DI5;IH\[\Y_]@TC+]M;.R?I#@^J>@YF0"0#A!
M'2R1>$/RKU0X5@X?E8.TY,9UKKYTO_[1UV[;_Z]_LVW!HE)H<Z50/6>%0H-=
MV=XRTU/FSL R8P<5/3GW4+,U+!"BL8F!-F83!K^,LT/M. ^'/P^9QR9.A(O$
M#)FY?!3?I4S!P=&-U)*=_CZF.6_I'IXQ&.8UHEGN"M)N:93G; Z'QP%._H2/
MXAPRD+M,P0R -LT*M$-141)NJ2<I1OZ\_,5N43(WZ0+[CO9X1:H E2(MU3@\
M9>)/8TLQSJ8"GL;+U0YMF4]TF,_?3K__@XR%V%ZOT<Z,2,UH 3OJD<_T[12W
MMO;6M@_SR%UYUVG.?*+:K=>'DN=1S%5T 'IB?S&<*[Z7*_(%@@:78$@VK;T;
M5I\X8K_O(4%L6LWUZ2W//631?.]IQ#$ 8Q/V?'+Z>':RAU5?G^J1/RIY]E'K
M+?/%: 4LN,</> (@[D)*0J\BK,\H53\?FVMYV)#52^WMM.I1GDZ>Y[T5"MZQ
M95@ZM_4L-+QZJ6*\>@VO4C(:Z[-?"JFU$P^RDB2&'#+(PV[NK.16<2]%5/L<
MPXUMBD1[(\<524/^9%WX^5($GS]0;#+&5"$[PK R+!%&\%;J'3)A8Q;8KKI
M8$<4J\X$+NT0WCIQV2BB8#>YR9@V<3P;-@+/XXJ\M8+FA$6$\Q5'.(MLIP.$
M.%M/#W$>/<ZX^=5;NCD>YO.W$YDX7HA3O$-$.=-M^)/TYR+NF;>KS%W<\^5.
M>OIH9^&-V1Y16-4-4Z42=,E4BT25\>1NF^=ZXZUJ>7W=T@Y^C;\=>[NY/F 1
MFGL:(5W*1O(?L%<]_:02E: IK+6(W0A436T2^+-5R^GH!/52W\OA3@OI\=QQ
M3=<,C##,B-;&SF3" N:-V/EUEZNT]N>AYR C+LURD;Z1!W+YPB+MZQST+1(
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M$"P(82-(C.0[F!4A[IK$1<A63L;!1,>CY>T9IL#@RP38895' +\$=@X(,)H
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M?K-*4AS65X&) @9;6 =H;P+E<#(@.K63$XDWAH1A4>!PO"EQ7X$0V+$7A\(
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MU#"$852SW0.?=]!US1:I3<>U[8QAZ5P"PJH (&K9F-;JUA]K@]>+V:W_C:=
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M:V83FP0 [IGUBM%<4QU_$J@LM6&@#O=?)X=HK;!2.-^VNH9E]O5NVP*693:
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MH.DAO,'(G(0!C=Y=@; B/."*RG>;.X))'H?"0\I0(X(?.7M,XF.#7EO*VB1
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M_0$H^$Q()>YF3J64PL3G]\:QA\XH0NAH#1[44-MY5J9*&LDQ0M(#UAU?6/#
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M;GCQR"'L ;'4HR7L[9[9:C?:7;U1;S7U:K57U3OM2E.O-RVCVQH,FCVKBL;
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M7*8W<#QJ;' _C@7."<)YINC%D0J]H<!XU[*FM1P,(&MO)=JO35*IR=5:[ -
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M#"E$%RRD61W %]KL->N#9KNC=XU>7;?;O9;>L6Q3MYI6O=DQK%[+KE=8ER6
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M&,?UHSV3L+J'Y[^/5G>QV^H,>LU&1V_W3-C%KE77.]U.7[<:?6/0:+;KP_I
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M$U"I&/= EZ]EFEFKMY^G6]K1EVK4C+;U B[-"Q1$?6?AQC!M]*='L1/&>K(
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ML*".')64+864S9T>DZ='[%=M^Z[ 86.'T3/@QQ%O%4D6#4>5%DT)4'3<H8F
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MQ7_'7FATS=5.:N+.(_ 3<J6UW>4T0E_RD!6'#F+NP!# $U(.AW"6$_T*^]<
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MXHG4LCCW8G^CZIG3>+/^$7FP*(GOAU!>?H+F.#(S#K'.NS;"7-A"-+^0DUK
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MIK<AWTQ%]0O":U"(HR68H:#GWNX+<%M)JUP;2$%MR0$51_<YF"H94 [%X(N
M0_Z2Z=R5("^'(#_G[(8#7%(WA=NL@XC$N29TT[F#T(FI6]USQZCPHP"4?IFH
MQCU%U*F.NUB0BPK 9W2_YX4K.<)%[X4HQ=0FR4^:1)"D/<@X<!X9'HBG">LA
M;@>2X3V,<FHH^7+ K:($K#D0 0QM)8[OB:S8SZ;*\7(CW(%34WD8VSZ#Y7*G
MH#T3PCBNY!?4+WCWYXBP1-$81%N51K&440CFE7F>4 7&!*C*S37JQ<S%@4,A
M6&ZQGMK*X[B)(',EIR3GEA,%/AE6B%49BF[/67C'G2"LK;JAHIV60#]7<$:C
M!^%23SB =^6V+Q4+5J#_!PHX;16R+1$W_K*I@4/64UYQO$B?B]I=GMMF$1-/
MB A?3;M*N"Z*X->>.W>YS_N]9.-@9K TXGHB4?.7VU.XOBZ^G[+UZ(/&Y@LO
MN&-,SQX7,XM44%_@_[!R_.P*Q,O4%1#Z<>C ,C^DC_"P)"U&V$Z9?.'Z)RB,
M\- XSMI=!.&UXXMF]M('Z/HW",0KFDW!&B3@+P8O4!Y),&>8 :CX4E8Q!>,Y
MBF'F#%:8:X)(*-NPH%JN$P,\#(2?(%8Z@5ZCAIQ[@89] .A-'Q3G8FVI3:*,
MA.?V\';FDE5+1RECY/A5D)+!V)&-AGSI=I3=N-!TPMX$S">=&B:?O?@#&CY)
M2'_(XN_8+LNCOU*_,B0ABJ=$ <Z03?@!*+ND8%_3(R&[1L2A($3A7G5A+ O(
M,0D)HAW1SV(#OGF-.UB X2S='C1*ESIPI>U,0.\2+@TEX0'8!USK*.+A19EW
MP=,ST#4,MO%8BYWH1R00P\$^=-*W+V LTN+\$'0E#OFO7ER7W!\QN0* _&JH
M=KD^@IKS20@W^G)D$MN0<)\]J$T3['E ]"Z<U5DK$;SD:>),RGJU"^E Y\T#
M8^+#Z@4)6;[)"^J!BF-G E^<)+0")PS1PA=:-6< J(#S (C2S<;!D"OM:GXV
M-:'$\4.9>MR'LRZG8YT/#/88HP8AHQ2. %<\#A.*RFP04((!51>]^/JBBS_W
M54--ZRKD1B?H5KIBT77%ODB2<^=722CZ33F* 8Y>3OCG-@A_I.U01&>'K,M!
MYJY[Z&9'(J,O>^-<-"0;\V8.I)PL%!;(7YTVDR F[&#V&>AE<&#\*\39G"Q$
M29W#1'.2I5=QVSF;6#H2.>%GV-.!BZLE-VC%L\JMG)S[VB5&6"CXDJ8_9N$G
MQ-?CK9;R%X#K$YG+AV3Y.=@.[">PO'X0+B3[RS?Q$]_(AR92D9[7C$A+EJWI
MA 5"5@)HYNA% R4&X?+YHZ&S8$GLCM,\ R7P0VH[0G!2BS=G[J"-1SU&0)_&
M5\_N'$I4&..''G8H V$^2X"R0$'@@1Q4DU9GC\Y]'DUAL4-ZN=+IYA1GH:Y^
M22[(S<MMQIGVC0PS'@C(*3$;'L^?&#FT,'00N;R/G]P.KL)D/>XV[W&-GV84
MS-D);W#$V[=@:A@J2$ *OP>@! *QY*L37.XLD8;J!>XF4V5>^FU^XE-L6L3(
M:>>X'H5GT#=)BZYEB7"1:'DGY\'W@QI]Y0BRXC7%UX_(3_91^$52$JY\:*72
MBY9]%L)OQ2^FTKE2Y("22\O).9^D]:0FR3^L).U.&[NVD"DR;92HL\^KOL.%
M.R?)AB^<N IBE)(!*[G_4]>3/O(%6',)A47YP5(_O[&3;[V7F6XBSXKSX@EF
M@F'6+GGTUP0_M A^DIE0.,P-/)SKH3SCCX'.1BE5;I1U\*TTLY)H9I0GJO?(
MCXH6!5"!4V6<E(<]J'D+:=$A6H#7H>-S\X_GSP6+S+(*TX(?BLOAGU5/NBN>
MYKWKU90X>E;FF) UEE%,5@\@DM7Q,0P:(G]BH1M,EM-5LG[>J^F'2Y/.:A9$
M_U*:((R1=0+N>0Y0\N5X%F"B*'^2\D7P"W-*E\ROG;_C9*E5_&J#48J;>M0V
M.)>12 JNDHUX=8=!2^>:21?$2@?>--]%1DPPKD!..X9[)MLKA\R9N-Y=+K6E
M8JC%=JMQ/LHI:>VM4$H(U0 X_BQI>?FZ89V'R ;(W0=YMY7PH+QS)/%YED%*
M;N+VR;<YMTXXB;33).*=T8E*<_?T'08.-Q3UI U;Y>6EENM3QG4 ?L/%DD^H
ME7G:3'@:I*$^Y0FLEI3]FL_47=S$791%WQM_(\Z61N"PTB:-H/(-2!.*$X^O
M!/9"*6"DL&549<T6_-YA^OFZN\%3*WBT!-,RQ-5,HQR1K/J7=.5&F:Z<EEME
MM?Y+=XDZ8XL1%H&+_G!,M.19/EGP1%RY+$KC1J+3ML>TM#I.F6;F Z6<R"NL
MR1,#3LXV+1:%""[W*GA@S2*QAEIN9\[6VD.[0&4 *"\W[ '? 1)EF_?@GGFI
MNX*L)UQ^X/Y=^9ISAF-E3'Y/Q>O$M1<("CR'"_.W^ ?-ZJ(7^Z)O5'3O4V^E
MID9'SQ/QL)9=2M5(41]5-1?K98"^A#Q2QR;YNG;TU;%1MD3)U7]$L@N_->Z8
MAE R>%:U90J'5/18$@OZW <]A6E?G9^L<JJ5W6IV^6'&>)@B839?:,6KYU*[
MC6O;(8M2+YE2)9_"1,%P&$)A:4F]6J(FP[6I[LFK1^@A5&T) &C,8RU8@!!S
MU16#V,X-X\)0C:H0,UM;B2GCS&AGILO8,,G<%)?*[H2ES(O\"<(ICR80I7 "
MF^;"<Y7AA<H8&][-.33S':Z7PS,AN0Q@I0Q>.(X5F $R). /_&B6)[6,4(+E
M'&'$A,U"8_&,24=4!-)NIB\,_$?M%46I\T:*("IQ-D)[XDE$_-PX]= :<7N$
M*5A)@/)H)$KE%=K'ZPA%),?";*B"DU_A7+HL\U"CC62JJZ O+,Q"KY#G_F!D
MKCL^Z:V$L4.T1D!"H B?^Z#<_R!KA3)[,P<23_)0O%-*(3;ETS@WCNN154)P
M1A@20,+VF<CXE[5?:@D"YU-<G8&1,.L?6126@I$6X_RD >'*8VI0>*=>QAHJ
M_/]AP@69<3R!E8;WI8:_ZPO/\;D!AJ$*=DUITT+) \-=\ [8?C(ULA1Y[7RJ
MKC?E7L+N5_?]-D@\G,45K)DF',@]%470JV?I+M7Y^92L$D4G*2 >4D$6>Z%Z
MWMP!T$OQN-A*:6^:&;7\7BW3&C$CZM:A ^',CH]'2'A,FI7H9(SPV\N2K>(L
MY>(L:%ZDH36B!WY+*34J+XPI^S.^#6!>;,%!$"/"?PC9U5V^M'/]]8"O4HJ6
M&W/_W7K>(^]0?BZWKN?A-8J F!VA*@AJ3N?',_7',U[O, =AF $2R9'H@N<J
M267"8! MOY.F,F>,SV?M;!6UC :!PY@%WB1W'Q4&3@H?EH5%L0+K0]H*+[6B
M09PXW1UZ4:..DIW8D'R_ $'C[%E+$!13^AI/) )"EDO)%4@1YL4KG\!R87?N
MSC9(&DJOP6S-B*?U+4"!\$@'4:+%B:_H(LH:N(?,%;B5@C.D.;Q:ERO&(8<9
M6?L2-9M'>* $6U17D6K.%<\IB3T[=$*?0&-./P91] ZI.@45FL&A5S9N.6S<
M[!R]]!QE_')&EQ?!+#W,B,;+FGG"4'H0HLJ)!(M)BR8)AX3)@47!I- PYC 0
MYXN9-$'/\III\/=+PQ=Y,6JB:=+S6G A=>JBO)02NEVL7B,'_3@)R00#[@5B
M*&*ARXWF12@TJ338C36O*$F5$6!HZLE#NAT' 2"55T !7]TM@03+?,8)YK-*
MP,O-,Y*'D5.U>;%>&E"6^["Z-I@O:-BQR.^&E<!+N;(NEY;N"TPIJV/%JF8$
MG>/[37*5#&U=#,CK"EV*K[N49B\/(3VU:>:-1ZMUYG!-&>&D,'L(,:ZE#W[3
MZM-R%H>.D9<;8Q@PN"*Z%K"H@BA]@M=AR^0@-_SDS8JS0Q*Q\+J@YDT(/1FE
MY2SO2(IO<I\XZ?<K 55LI7C@>@D59TO25,Z7L*(629Z/D6XVP:?0@B4[\=19
MPA5)>5W*Z8#>3Z^6ON5.E1O#OWBV[$44ERY2KHX;1MSSG]U2Y9ZKB2<ILQ$\
MB-QC%$Q+680HJ,]S,LDRTH&"6Q]^G[F+5&L3,?E;@4"F.YC&=XWW* -@R_/6
ME?M%6YO>KPD_AS6L_=I%[X7PRF'Y$/ 3!?4K.PO^/ASAOXD+1BWJP/SEJG\A
M2&*"0^;6OQ*( 7%$%;TQA2X5YKB!-?(H#=_2;$(4*W1XBF.:<$1*ND@J0*>&
M4F.]">=+X<Q@;""S[ZM90BM+%'Y(L<>R]EBD.ZSN\ST"U)V*P)'8<G(]PK:X
M<J,KEE82G?M/3L]:-P49K+3L<FC9W8AN/3%+JI'KY*OS4FC"*&5:)!*2<#SC
M2,""*ZSK"D*H@RK(WPK$'PD1!>1/\ 3Y+M+8@<<PIJ>L=#V2H_"C.'<RHI5;
M!?JN8;QH2C8$=QW+DE!BF>PG%A2BYV"("J=\O:C;T^*[!4EIEW?"\>X4WRBZ
M4]2D-S^?XZD(]$]P&# G)_1 6W3G4N>CW,Z3-\)A32^5K)W70'*'L;O43R-D
M^IPY!/]%:?4P!<SYXAD L5"<TP>6MIGB,UI_'7 D%R?*(43+6!YTK,CMX<((
M4$CN<B-'#*HIP@_SCF?;K<MSVX I2<)>,5/((X<ZMXO 9=1-!3W-2T%-@BK)
MKR7="F1'GK0)/)>E('+RR%%C@OFZH8I(@@XAL?I*")5$"'VA( K<C.XD( C>
M3!HAF*T?H NZ*MXLD7 Z1YETDY;Z-VI:!CJN'.XEB@;*8>H%\)]\ 3^_S*/N
M92]?PB\PJ-<,HWU;$ ?/#=.]_)9['L;\/3C+S"R<GFZT:IJ:3J.=?@T6[EAK
MV?5W[[6>X,"7R(&1QPG1.DX93]KN@)[FAH\/5!3)F2G9&B1W'A/07\$7!E*2
MS5#(?^ZH?\_QY2SU0<8KEDL@%F&00?<#<^87CV3F=0*L'M<K@XT!%L]K_TV<
M4/2%H2-5,E$P()J9;2&;!S>.QP4I^D,>F8XBP9 >QC5>T[^*<8$%3XYY"ZN_
M6!ADMA=U.1.NI%O:2HZR&2]M T\9KR1'L3TR2^Q%((D@JTBYP^6WE6MNZT:S
M!E=50HM'0G7[)YM<(QL1=[YM-.#.#Q3,^C]%9!)?\D\LG^A+Z$)TV<(H_[R[
M"MV)MJZQ@G8N(?/Y'&$=/-.'0AKP5U NR;G8_>&2UV7 KG@-3Z -"4W_C'=G
M2UF)*.%1[BE%[AG"0?K(_KB.))(A)BYY$Q!_%HN2$,:,WVP%5I['.&=\$0\
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MULII!^L[59T0?#TM)F0B-3B-:TLWTF9K@.<:;+?XY1YT2E!$<,F-)<(3ZCE
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M!/X%MTF WV&Y7+ [WH5G-T0-U#>9>LF>B:<U'EKS?&*+EB7XF@;*'?$EP91
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MGS&=.1A6GF6WJ_PXP[R2ZD]V!2W&750"?-B0I3;&C: N0P_@0WS#U07B*BY
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ML]JWD=T?FM5V:%8/B^:^Q>A)(;)O,7H"..Q;C)X$/ONV:2>$R[Y5SQE@N2]
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M?GX^E#)(F1SZ8CXD@T%:P:^Q*!_(N\/CD\-WN3=W(N+!!_(V]^A<4D]#:1*
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M/<K.I>YBC\+=NKY7[;!797<54+S>:"$X;HV.)YA[>D9A49(O4$9Z(UHW^JQ
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M S87[=H2/9$X=]1AO5J5A3JJ4'H<:UF!M.H"WQ%R'X?Q);;P\[]02P,$%
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M8?\;G- __>/\X?;D[,/IR<DB35<_??SX[=NW#Q@'FQ4_^,GRX\G[]YNO_5K
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ML0Q?T"4]M--9[9=3=81DBT#B267Y<QCGQ_@BH9<$E>3Y/_*W?0L'4A>62DM
MX'AS/Y4&.ZO?C00X6[(R#LX]$E*UX!XC0F6Z5\IJ;NB@UQ)[A)L70M">#L$%
MK'A@LBD>*-(^I5PA'@_SH%WB(Q20:ZJR;6R$&W;K4U,B>XY"?TH%"Y8];:<Z
MWP@O*7_N#NWVN]&?;\M^Y)Q>?^8I_Q>BOQ3V0!R4I1JB"W#@HJ9V[F*1Q.=A
MDB)_<9L&XGP,T5 ;.F!/?#];9OD;]9=4/_9#45LEA8D@(5LO0J4=R;S[TUE^
MBWH^$T/R5(?NB<#XW..B\$(6RQ4.MZA?&61O4S-X9<]42PL]O*Z16Y:((1P/
MYX13MIBV(5*A@(.O U:+GG08576'C0)UP-UP:C$4DTC;&4D98CMLF5M+AS_
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M[PZELGH[JG1G44%X$U^&L[RY4/H+2N;86RU"_P'-<R'9.R.)(/_#/'GYF .
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MC&&SN*I9:S;W1=TC/3AY-?:U,>U)C]%\43:W).U)JTY?-GAST,YD%,6 @MS
M<RV3I!YPWV1*%,Q.A-P.'8O>9%ILX+$G(,V09^DGK 7Q<Y8GD$1>W!TOZ[&
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M&&*_9P2M/@R'X$0"<?];S9;39H!.4$+,".0-4\PJ*7;DI P"5L6[.G!3U-\
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M)I28P=FR&LA&MJ6VA;01@%M:>E/]Q=3EI$_8OS\=C]YK%F^_8+KDWCIXMKX
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MM7\7CU$<VDXL_]T;:)@!N;I@$I5=4VLA ,+"C9CH]Y0+V'+?>)9H!.M 2QB
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M'4-!MY9@0&KPQDXT56T##"F66/9_5_X8#'08;W$_6JXWTR:X,#+&C#-#E&H
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MM9G-T\M0,YJ%H_MI?U!.5O?Y2:5*SB"5[#M*J513JU=3 PY4BJ&P<*Q2P$1
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MA9D9*M:[OF0$HW=WFYJ1E.<AIJ!H1&F].QV1TZ:HUBFC*'!KLT<A.T&.X)F
M;$VR9S"I/ PP:I<ED+E@<#%KA=@H"[(IG$178L_2;%72C"Z^VCQX/.)]$&)V
M'T#2'-SS@F_0MY%V.U_3^-Q@'7-0TWL6L/,E<!3)GZ"SENM>-!EP3%"ALE8+
MP'XQ#T;=!P9[;6($K I;+E^Q,*XJ;T$"JRR*S-K%LCJO+"*+T#)DE#I+039<
MD=?*^X6V,3OY/7[8B:@&PQ@!*0D<08-'RJ%6UJ):,U=!#%VK^"U+@"ZZ$B
M(,DKVY;L39#?'![ X".*&:. <G/$M*6W_W1-AL9+.PQ?20K]S0YWPK.C#@J0
ML&H72V*VL5PN.]"6L4"4!RHQ,20+5&8%*QW$@DQICRKM]"D-!L=^S^Y$:8_E
MS  OK8H3=@7V,"@DJ012N\35$M,2^B@U4V V0#/>@;=-"3C8%'VJ&R&9TD:
MX3:DH2E^O276IS4L61L/T8_83@ 2-*U2";O;?#E?=B6-*0?R$^7!JI@R+H8
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MXD\'VR=\/[KDZ1 3TU3Q>QXM$Q.B)D&%F[_.-[/IMIH*]8SQ&4-4X&A>!J3
M+G*YCSZ[G)_S*# ."VZYSKMNG8W)<KIBA%1^TVI";>'NCM[B>4EFIVY\_C2P
MF9B) :]14JE4?2DY^;OC%^LBAS$U>^*GPCIR<2^U#F=J_GQ/A85XNW1^O;"8
MXL8$P,ZH(14!VPVI)@2ZQPL2+'8T8#2V0&A[2GO0JHD@Y4VS)!I=W:*,C.[
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MZ&6R2!QT7HL.PHRP<1@=HBZ_LC2(3!U*2UXHB*[<#H9!ZKKOA)3(JV9 ZWK
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M<F=KQ!#U,5TY\[!-)KMN2G6"/(HN(L8!%%7M#E8"38LQ@# 1'/!U$+%%NLN
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MBSL2F85FBW.<1+I,#[<J?Y8JBY(NR7K[!/FPU]RW.% 9 76](7V][TA<^2D
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MR]/@)K2*5+0&JJ@/3WTN6$92IUF,P-!#YX9.X\.0V'F0VR28SN:+=MPP8J9
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M9'QX-(,X.#2B(;)%ML9\4,8(>LX-#<%]?G)(VI PR<NW"\>A-Z62U/,V#/R
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MS22Z7](-BU9))#QJN;**$$D.S=/IC3G=)53J6D!/M?4[;)L)(7^L@:G;+&#
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M] Q!4G22%NN*M),5>5,O@/O$$??Z]6:^R@#-SE@D= N5[$8TH56OM574.BO
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MT=L@D;##;.?KZ:H9RODMPT%&%Q3>Y^O9A/4HG=E&**<+COOS=;6:OJDAV.\
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M#).V-:14$$30FHG"9DPFKB_IMVF]>*K'CB3ER\W>8%4S IY"Y#8'.E5?"CC
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MV1M,[M-7&#^]^B$+[O^"=SN2%*Z_[-MV$HS)'\-,3M8HJ9G)0AE-4C5!24]
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M0;FZQWG(9[-CI"K@.)[T40M_J*'CWCTY2J+F)/2U0=6R:HR)K"5MDZJQ,M=
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MN(VVG"R.0(Q$@$(&#O[!4LX EL,*$Q:2[()9BS<(IHFQI!XACE/\87'A-VR
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M4+RDT12)P+=Y =%M!**O.5B4\0-Z]?/M)CHNT@/0;^]^O<>"UQ(^QZ BY0M
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M_C,F)4%\&JZP;1>SN^@AK"36 32+"A\:?'Z-A(G_/%T34D(D"L!B0V[[IQ>
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M#?<F.6QGQ?&8W+[X>*8)VJY<@.EMK3N[.>M\V"2'%^\&>EL7"E *R*8V'M.
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MZP3/T4_TV>!T8&YK@Z,A1O0*P%]7ZJXBR H/X>,FX=4(P?$,+4E]FN]A^;W
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MF$)F3"&C2>^80L9^F)WB:R[;>PRY\TZR'4/NCAMRYZLKKB.14KX[AH^14@*
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M2O<WLI>D/W>8[4:]OROK<6)1U\R5NWY)DRN8%B!\>2@B=L4Z5E,[\=(%8K=
M=!MD"=H6Z/$/RU5)7*]OP *&D!U!+>QH15@*8E +"[B:RW1!WG/T1J%KB%]
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MS8SM#BITNZ9<'RNSX)EC&8V,\!OUF#5WT# X- Z#V7902B9YF^TBEI+*4'+
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MFKY>\>6GBM:!H#M0DC4__3P,0:J2;<U/&ZH\D'K)<#RUBQJ&C9-[R5.')$4
MM<Q=9Y*S4^$25$Z1XW>.3@7DY%4-9Y*?LR=V+#74F:3A-(1>I9#LE7'3*\RT
MC19GDF:S%X0T:ZE>:LV?*MP2L,39QOQ'CFZS.9/TFH;W7-OR?28I-SD62:&$
M>R8._ :0>C@GSW1%.XH0O#/S6\4NOFLL1CVD03(+-GCVC4-O*P_U59IEZ3?T
MP_0YALLJ:X,-O]8;\%Q(F\D8C6W8^S I]PDBH"1H"YR#6*WM4\YS(Z&UU*<X
M!^'WR_3U?00@)O9'_ .F\<<6C>A7O]'2AM2$'?QY>&H>$"L85]^D^,[26MA8
M4WS:\_JX,Q:ST\0VC==$Q&$=<UI+.Q0G2RS(2J%+:6K$+^(1QC!,DU^P165S
M%23TK W<IC;?<_[]WGZ^J?>2[ZX"@F>DC4]W%_:SHZ5%$'L)S.YBT3./G9+\
MKX00[2+K90H[B637'%8'PT-]W[V72 6@"+>7OS(HB_O<:8*8;[&O1E$.![P]
M0+>6TAZZ)V<[$RMZ<I%18]2.;U$[IQ[W,NJV=D__59##_!%=JT$T14]?!C&>
MV";.NC*DN]N?6]M!HJHPQ(Q?U!C _OPX<4&4AJ-NSTG='GJ-IHMKQ$1!IL*L
MW<0VC7=!2-QFZA(X.T/#=;!&?RDV$G,0#F%CCHC969&+BYL$<;^5<SK (R+6
MONTYB2<.FMFFE9MF@M+0.?LR7QFD=%9'?WV^8H3''8TN^GSL^-S7Z*DOL)#L
MN5CZI7ER(D1)PSO_)/3B%H*4--SU/86RR\^?I5/^:(G1\ T\Y*:]3^<[.D\.
MY6SAAJ_DZ9GW_(K]<=B\9^< L306K'OX'''A%L_M:LB.%_]EUQI<)4H^R/?M
MBCUX$I/!043/2XYC]I*<9>^0[&Q#9T>2I=_PE8O=-E:IY*H5]UM9H]3YXG[-
ML2-E$G<[D12?Q)LS+W*R5Y];R?5SD?6UWZ!&M/RW<#U!PT;MNN.'"GY**ZOE
M^ZK0?/KE\"4EV:U 5=8@?\)NI^V_8UB_I,5_@V(.PG29P#^("A"F..B__A5N
MQ[(T'YD(KW!N1JHZ38L7D#V]!$E51X)U_NW1XQ?Z3<6.XR/=_O98^E.5^D\@
M 5D03Y)H$JU@ O$34,!74'-"W)G(];4QJ_L$,;A@5U7E 7\)\[!L3H#7PZ$9
M<+DN?A\K7@9UT1\.\)TF-FGD0NM "=&]ZE-\.8?1V &Z3Z9,+T@"Q#8AK@F$
M0<ZO%<IH;)/NKTF^!B%<0!#Q*^PRVULNCJQ==$RRE'+/\9TLO,RMPX:SH\!D
M60D#+!G$Z">L8?0LGL S;P*5Q5?H/#O,MTX*-4&5(//CG]2Y.["<FSIM#U9C
M.K3)WOJM-+KDJI+RI"Q>T@Q+<Z:!DOCB22)X+-Q.&ZWI-HU?Y=F3;Y-;$<7"
M?8)8S22'(:UJWU$_;<:KNB>EK6PZOP+\)H%H\HK$^R4@F4NQ,G^7(I'JJGW,
M[Y_4&UE/L,I.IXKML;]^4N>[X9HZV: JV;%R C=]KF4^Z22&/8HTJV*G\RF'
M,"-$HLD@67&:\#6@*B-8F>%6%[@5\SF*.'I;(V_3T[?TZ24M<W16T,H_O<"L
M "#I*,)G91:^("#QMF";"_4&&G(.I CU?8+O!/BJ1SUSB"'H_@;B5]"':L$
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M;!>G4X4HM'VNMZ0RU8?J WF63\N\9J-7[."ZPK\(LL)MP[A[2T%5 ?L>.SC
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M,;'8'(3^\?\!4$L! A0#%     @ "(%P2H3+C?_\< $ 'I<. !$
M     ( !     &AS9W@M,C Q-C$R,S$N>&UL4$L! A0#%     @ "(%P2H'S
M$O4D%P  K?D  !$              ( !*W$! &AS9W@M,C Q-C$R,S$N>'-D
M4$L! A0#%     @ "(%P2A4_D;5:%@  M3X! !4              ( !?H@!
M &AS9W@M,C Q-C$R,S%?8V%L+GAM;%!+ 0(4 Q0    (  B!<$K"%9U!8S4
M $6E P 5              "  0N? 0!H<V=X+3(P,38Q,C,Q7V1E9BYX;6Q0
M2P$"% ,4    "  (@7!*I&JUVP68   CLP@ %0              @ &AU $
M:'-G>"TR,#$V,3(S,5]L86(N>&UL4$L! A0#%     @ "(%P2@+.0H[P40
M7E$& !4              ( !V6P" &AS9W@M,C Q-C$R,S%?<')E+GAM;%!+
4!08     !@ & (H!  #\O@(    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
